PT J
AU Xu, D
   Yu, Z
   Cai, X
   Lin, J
   Lin, T
   Sun, J
   Liu, Z
   Cao, Y
   He, Y
AF Xu, Danghan
   Yu, Zhanbo
   Cai, Ximin
   Lin, Jietao
   Lin, Tengjiao
   Sun, Jian
   Liu, Zhaoxi
   Cao, Yang
   He, Yihan
TI Effect of Fu's subcutaneous needling for cancer pain management: protocol for a
SO BMJ open
LA English
DT Journal Article
DE COMPLEMENTARY MEDICINE; Cancer pain; PAIN MANAGEMENT
AB INTRODUCTION: Pain is a common symptom in patients with cancer, and pain  management is crucial for these patients. Fu's subcutaneous needling (FSN) is a  modern acupuncture therapy based on basic medicine commonly used in patients with  pain. However, evidence of its effectiveness in treating cancer pain has not been  systematically proven. Therefore, this pragmatic randomised controlled trial aims  to evaluate the effectiveness and safety of FSN for cancer pain management.  METHODS AND ANALYSIS: Overall, 120 eligible patients will be recruited and  randomly assigned into two groups using block randomisation. Both groups will be  administered analgesic drugs according to the National Comprehensive Cancer  Network guidelines. The treatment group will receive FSN therapy one time a day  for 6 days. Additionally, we will assess analgesic consumption as the primary  outcome and the Numerical Rating Scale, outbreak pain, symptom assessment and  adverse events as secondary outcomes to evaluate the effect and safety of FSN in  treating cancer pain. The incidence of adverse events will be monitored to assess  the safety of FSN. ETHICS AND DISSEMINATION: Ethics approval was obtained from  the Ethics Committee of the First Affiliated Hospital of Guangzhou University of  Chinese Medicine (approval No: K(2021)096). The results will be published in a  peer-reviewed journal, and trial participants will be informed via email and/or  phone calls. TRIAL REGISTRATION NUMBER: ChiCTR2200056348.
C1 Rehabilitation Center, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China.
   Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China.
   Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China.
   Oncology Center, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China.
   Radiotherapy Department, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China.
   Acupuncture Department, Guangdong Provincial Hospital of Chinese Medicine (The Second Affiliated Hospital of Guangzhou University of Chinese Medicine),Guangdong Provincial Academy of Chinese Medical Science, Guangzhou, Guangdong,China.
   Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China.
   Oncology Center, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China.
   Oncology Department, Guangdong Provincial Hospital of Chinese Medicine (The Second Affiliated Hospital of Guangzhou University of Chinese Medicine),Guangdong Provincial Academy of Chinese Medical Science, Guangzhou, Chinayihanhe@gzucm.edu.cn.
NR 0
TC 0
SN 2044-605
EI 
J9 BMJ Open
PD APR 28
PY 2023
VL 13
IS 4
BP e068232
EP e068232
DI 10.1136/bmjopen-2022-068232
PG 1
WC Humans; Acupuncture Therapy; methods; Cancer Pain; therapy; Neoplasms; complications; Pain Management; methods; Subcutaneous Tissue; Treatment Outcome; Vascular Surgical Procedures; Pragmatic Clinical Trials as Topic
UT PubMed:37105691
PM 37105691
DA 2023-04-28
ER

PT J
AU Hou, Y
   Lu, J
   Xie, J
   Zhu, R
   Wu, M
   Wang, K
   Zhou, J
   Li, J
AF Hou, Yuchao
   Lu, Jiajing
   Xie, Jing
   Zhu, Runjia
   Wu, Mengdie
   Wang, Ke
   Zhou, Jia
   Li, Jing
TI Effects of electroacupuncture on perioperative anxiety and stress response in
SO Frontiers in psychiatry
LA English
DT Journal Article
DE electroacupuncture; perioperative anxiety; randomized controlled clinical trial (RCT); stress response; surgery
AB BACKGROUND: Perioperative anxiety is one of the main psychological stresses  experienced by patients who undergo cancer surgery. The surgery itself inevitably  causes a stress response characterized by activation of the sympathetic nervous  system and the hypothalamic-pituitary-adrenal axis. Both the perioperative  anxiety and surgical stress response lead to increased levels of catecholamines  and prostaglandins, which may be related to perioperative suppression of  antimetastatic immunity and tumor-promoting alterations in the microenvironment.  Hence, we designed this clinical trial to investigate the effect of  electroacupuncture in reducing perioperative anxiety and surgical stress  response. METHODS: This is a randomized, single-center, parallel, and controlled  clinical trial. Seventy-eight participants between the ages of 35 and 85 with  gastric or colorectal cancer who plan to undergo tumorectomy will be randomly  divided into an electroacupuncture group and a control group. The primary outcome  will be the six-item short form of the State-Trait Anxiety Inventory score. The  secondary outcomes will be the Amsterdam Preoperative Anxiety and Information  Scale score; levels of plasma cortisol, adrenocorticotropic hormone,  interleukin-6, and tumor necrosis factor-α; first exhaust time after surgery;  postoperative quality of the recovery-15 score, numeric rating scale for pain  score; and dosage of postoperative analgesics. DISCUSSION: Cumulative studies  revealed the efficacy of various types of acupuncture therapy with regard to  reducing the anxiety and stress response caused by surgery. We expect that the  results of this trial will provide high-quality clinical evidence for the choice  of perioperative acupuncture for patients undergoing cancer surgery. CLINICAL  TRIAL REGISTRATION: https://www.chictr.org.cn, identifier ChiCTR200003 7127.
C1 Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
   Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
   Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
   Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
   Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
   Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
   Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
   Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
NR 0
TC 0
SN 1664-064
EI 1664-064
J9 Front Psychiatry
PD MAR 14
PY 2023
VL 14
IS 
BP 1095650
EP 1095650
DI 10.3389/fpsyt.2023.1095650
PG 0
UT PubMed:36911113
PM 36911113
DA 2023-03-14
ER

PT J
AU D'Souza, RS
   Alvarez, GAM
   Dombovy-Johnson, M
   Eller, J
   Abd-Elsayed, A
AF D'Souza, Ryan S.
   Alvarez, Gabriel A. Martinez
   Dombovy-Johnson, Marissa
   Eller, Jennifer
   Abd-Elsayed, Alaa
TI Evidence-Based Treatment of Pain in Chemotherapy-Induced Peripheral Neuropathy
SO CURRENT PAIN AND HEADACHE REPORTS
LA English
DT Review
DE Peripheral neuropathy; Chemotherapy; Cancer; Chronic pain; Systematic review; Neuromodulation
ID advanced cancer-patients; double-blind; scrambler therapy; adjunctive therapy; nerve-stimulation; american society; oromucosal spray; pilot trial; acupuncture; neurotoxicity
AB Purpose of ReviewChemotherapy-induced peripheral neuropathy (CIPN) is a debilitating and often painful condition that occurs after administration of chemotherapeutic agents. The primary objective of this systematic review was to appraise the literature on conservative, pharmacological, and interventional treatment options for CIPN pain.Recent FindingsThere is level I evidence supporting modest to moderate improvement in CIPN pain from duloxetine treatment, as well as short-term modest improvement from physical therapy and acupuncture. Although opioid and cannabis administration may provide short-term modest improvement, administration is commonly limited by side effects. Generally, most studies reported no clinical benefit from yoga, topical neuropathic agents, gabapentinoids, and tricyclic antidepressants. Evidence is currently equivocal for scrambler therapy and transcutaneous electrical nerve stimulation. Finally, evidence on neuromodulation options is limited to mostly case reports/series and one observational study highlighting moderate improvement with auricular nerve stimulation.This systematic review provides an overview of conservative, pharmacologic, and interventional treatment modalities for CIPN pain. Furthermore, it provides a level of evidence and degree of recommendation based on the United States Preventive Services Task Force (USPSTF) criteria for each specific treatment modality.
C1 [D'Souza, Ryan S.; Eller, Jennifer] Mayo Clin Hosp, Dept Anesthesiol & Perioperat Med, Rochester, MN USA.
   [Alvarez, Gabriel A. Martinez; Dombovy-Johnson, Marissa] Mayo Clin Hosp, Dept Phys Med & Rehabil, Rochester, MN USA.
   [Abd-Elsayed, Alaa] Univ Wisconsin, Dept Anesthesiol, Madison, WI 53715 USA.
C3 Mayo Clinic; Mayo Clinic; University of Wisconsin System; University of Wisconsin Madison
RP Abd-Elsayed, A (corresponding author), Univ Wisconsin, Dept Anesthesiol, Madison, WI 53715 USA.
EM abdelsayed@wisc.edu
CR Anand P, 2019, J PAIN RES, V12, P2039, DOI 10.2147/JPR.S213912
   Argyriou AA, 2012, CRIT REV ONCOL HEMAT, V82, P51, DOI 10.1016/j.critrevonc.2011.04.012
   Avan R, 2018, J RES MED SCI, V23, P0, DOI 10.4103/jrms.JRMS_1068_17
   Bao T, 2020, JNCI CANCER SPECT, V4, P0, DOI 10.1093/jncics/pkaa048
   Bao T, 2020, JAMA NETW OPEN, V3, P0, DOI 10.1001/jamanetworkopen.2020.0681
   Bao T, 2014, INTEGR CANCER THER, V13, P396, DOI 10.1177/1534735414534729
   Barton DL, 2011, SUPPORT CARE CANCER, V19, P833, DOI 10.1007/s00520-010-0911-0
   Ben-Arye E, 2022, CANCER-AM CANCER SOC, V128, P3641, DOI 10.1002/cncr.34422
   Ben-Horin I, 2017, INTEGR CANCER THER, V16, P258, DOI 10.1177/1534735417690254
   Burgess J, 2021, ONCOL THER, V9, P385, DOI 10.1007/s40487-021-00168-y
   Cartoni C, 2012, SUPPORT CARE CANCER, V20, P2621, DOI 10.1007/s00520-012-1511-y
   Chen HP, 2014, NEUROCHEM RES, V39, P76, DOI 10.1007/s11064-013-1192-z
   Chien A, 2021, PM&R, V13, P55, DOI 10.1002/pmrj.12361
   Childs DS, 2021, J PAIN SYMPTOM MANAG, V61, P1247, DOI 10.1016/j.jpainsymman.2020.11.025
   Cioroiu C, 2017, CURR NEUROL NEUROSCI, V17, P0, DOI 10.1007/s11910-017-0757-7
   Clark PG, 2012, J EVID-BASED INTEGR, V17, P161, DOI 10.1177/2156587212450175
   Coyne Patrick J, 2013, J PAIN PALLIAT CARE PHARMACOTHER, V27, P359, DOI 10.3109/15360288.2013.847519
   DAlessandro EG, 2022, BMJ SUPPORT PALLIAT, V12, P64, DOI 10.1136/bmjspcare-2018-001542
   DSouza RS, 2022, BIOMEDICINES, V10, P0, DOI 10.3390/biomedicines10081909
   de Moor JS, 2013, CANCER EPIDEM BIOMAR, V22, P561, DOI 10.1158/1055-9965.EPI-12-1356
   Dhawan S, 2020, CANCER NURS, V43, P269, DOI 10.1097/NCC.0000000000000693
   Fallon MT, 2017, BRIT J PAIN, V11, P119, DOI 10.1177/2049463717710042
   Farshchian N, 2018, CANCER CHEMOTH PHARM, V82, P787, DOI 10.1007/s00280-018-3664-y
   Fernandes J, 2016, INT J REHABIL RES, V39, P368, DOI 10.1097/MRR.0000000000000196
   Filipczak-Bryniarska I, 2017, MED ONCOL, V34, P0, DOI 10.1007/s12032-017-1015-1
   Friedemann T, 2022, PHYTOMEDICINE, V104, P0, DOI 10.1016/j.phymed.2022.154294
   Galantino Mary Lou, 2020, INT J YOGA THERAP, V30, P49, DOI 10.17761/2020-d-18-00030
   Galantino ML, 2019, INTEGR CANCER THER, V18, P0, DOI 10.1177/1534735419850627
   Garcia MK, 2014, J HEMATOL ONCOL, V7, P0, DOI 10.1186/1756-8722-7-41
   Gewandter JS, 2019, SUPPORT CARE CANCER, V27, P1765, DOI 10.1007/s00520-018-4424-6
   Gewandter JS, 2014, SUPPORT CARE CANCER, V22, P1807, DOI 10.1007/s00520-014-2158-7
   Hagedorn JM, 2020, J PAIN RES, V13, P3295, DOI 10.2147/JPR.S263857
   Hammack JE, 2002, PAIN, V98, P195, DOI 10.1016/S0304-3959(02)00047-7
   Han XY, 2017, BMC CANCER, V17, P0, DOI 10.1186/s12885-016-3037-z
   Hershman DL, 2014, J CLIN ONCOL, V32, P1941, DOI 10.1200/JCO.2013.54.0914
   Hershman DL, 2011, BREAST CANCER RES TR, V125, P767, DOI 10.1007/s10549-010-1278-0
   Hill KP, 2017, POL ARCH INTERN MED, V127, P785, DOI 10.20452/pamw.4123
   Hincker A, 2019, PAIN, V160, P1835, DOI 10.1097/j.pain.0000000000001577
   Hsieh YL, 2016, ACUPUNCT MED, V34, P398, DOI 10.1136/acupmed-2016-011112
   Huang CC, 2021, J CLIN MED, V10, P0, DOI 10.3390/jcm10163694
   Iravani S, 2020, PAIN RES MANAG, V2020, P0, DOI 10.1155/2020/2504674
   Jeong YJ, 2018, EVID-BASED COMPL ALT, V2018, P0, DOI 10.1155/2018/5367014
   Kautio AL, 2008, J PAIN SYMPTOM MANAG, V35, P31, DOI 10.1016/j.jpainsymman.2007.02.043
   Kautio AL, 2009, ANTICANCER RES, V29, P2601
   Kneis S, 2019, BMC CANCER, V19, P0, DOI 10.1186/s12885-019-5522-7
   Knoerl R, 2022, J CANCER SURVIV, V16, P882, DOI 10.1007/s11764-021-01081-z
   Lichtman AH, 2018, J PAIN SYMPTOM MANAG, V55, P179, DOI 10.1016/j.jpainsymman.2017.09.001
   Loprinzi C, 2020, SUPPORT CARE CANCER, V28, P1183, DOI 10.1007/s00520-019-04881-3
   Loprinzi CL, 2020, J CLIN ONCOL, V38, P0, DOI 10.1200/JCO.20.01399
   Lu WD, 2020, ONCOLOGIST, V25, P310, DOI 10.1634/theoncologist.2019-0489
   Lynch ME, 2014, J PAIN SYMPTOM MANAG, V47, P166, DOI 10.1016/j.jpainsymman.2013.02.018
   Magnowska M, 2018, GINEKOL POL, V89, P200, DOI 10.5603/GP.a2018.0034
   Matsuoka H, 2019, J PAIN SYMPTOM MANAG, V58, P645, DOI 10.1016/j.jpainsymman.2019.06.020
   McCrary JM, 2019, SUPPORT CARE CANCER, V27, P3849, DOI 10.1007/s00520-019-04680-w
   Miaskowski C, 2017, J PAIN SYMPTOM MANAG, V54, P204, DOI 10.1016/j.jpainsymman.2016.12.342
   Nagashima M, 2014, SUPPORT CARE CANCER, V22, P1579, DOI 10.1007/s00520-014-2132-4
   Otake A, 2015, ANTICANCER RES, V35, P359
   Pachman DR, 2015, SUPPORT CARE CANCER, V23, P943, DOI 10.1007/s00520-014-2424-8
   Park SB, 2013, CA-CANCER J CLIN, V63, P419, DOI 10.3322/caac.21204
   Pike Crystal T, 2012, CHEMOTHER RES PRACT, V2012, P913848, DOI 10.1155/2012/913848
   Portenoy RK, 2012, J PAIN, V13, P438, DOI 10.1016/j.jpain.2012.01.003
   Rao RD, 2007, CANCER-AM CANCER SOC, V110, P2110, DOI 10.1002/cncr.23008
   Rostock M, 2013, EVID-BASED COMPL ALT, V2013, P0, DOI 10.1155/2013/349653
   Sacco J, 2016, MED ACUPUNCT, V28, P131, DOI 10.1089/acu.2016.1170
   Schroeder S, 2012, ACUPUNCT MED, V30, P4, DOI 10.1136/acupmed-2011-010034
   Schwenk M, 2016, GERONTOLOGY, V62, P553, DOI 10.1159/000442253
   Seretny M, 2014, PAIN, V155, P2461, DOI 10.1016/j.pain.2014.09.020
   Smith EML, 2013, JAMA-J AM MED ASSOC, V309, P1359, DOI 10.1001/jama.2013.2813
   Smith TJ, 2020, J PALLIAT CARE, V35, P53, DOI 10.1177/0825859719827589
   Smith TJ, 2010, J PAIN SYMPTOM MANAG, V40, P883, DOI 10.1016/j.jpainsymman.2010.03.022
   Strand N, 2022, J PAIN RES, V15, P2483, DOI 10.2147/JPR.S362204
   Streckmann F, 2019, SUPPORT CARE CANCER, V27, P2471, DOI 10.1007/s00520-018-4531-4
   Stringer J, 2022, EUR J ONCOL NURS, V60, P0, DOI 10.1016/j.ejon.2022.102171
   Tonello R, 2019, J PAIN, V20, P515, DOI 10.1016/j.jpain.2018.11.003
   Tonezzer Tania, 2017, J PHYS THER SCI, V29, P685, DOI 10.1589/jpts.29.685
   Tsavaris N, 2008, PAIN MED, V9, P1209, DOI 10.1111/j.1526-4637.2007.00325.x
   Velasco R, 2021, ANTI-CANCER DRUG, V32, P88, DOI 10.1097/CAD.0000000000001005
   Waissengrin B, 2021, THER ADV MED ONCOL, V13, P0, DOI 10.1177/1758835921990203
   Whiting PF, 2015, JAMA-J AM MED ASSOC, V313, P2456, DOI 10.1001/jama.2015.6358
   Wonders KY, 2013, HEALTH PSYCHOL RES, V1, P149, DOI 10.4082/hpr.2013.e28
   Wong R, 2016, INTEGR CANCER THER, V15, P153, DOI 10.1177/1534735415627926
   Yang YH, 2012, SUPPORT CARE CANCER, V20, P1491, DOI 10.1007/s00520-011-1237-2
   Zajaczkowska R, 2019, INT J MOL SCI, V20, P0, DOI 10.3390/ijms20061451
   Zhang SQ, 2017, J TRADIT CHIN MED, V37, P179
NR 84
TC 32
Z9 34
U1 5
U2 22
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 1531-3433
EI 1534-3081
J9 CURR PAIN HEADACHE R
JI Curr. Pain Headache Rep.
PD MAY 15
PY 2023
VL 27
IS 5
BP 99
EP 116
DI 10.1007/s11916-023-01107-4
EA APR 2023
PG 18
WC Clinical Neurology
SC Neurosciences & Neurology
GA AK8R1
UT WOS:000968770900001
PM 37058254
DA 2026-01-16
ER

PT J
AU Bas-Cutrina, F
   Loras, C
   Pardo, A
   Ballester-Clau, R
   Huertas, C
   Guarner-Argente, C
   Colan-Hernandez, J
   Consiglieri, CF
   Andujar, X
   Vilanova-Serra, M
   González-Huix, F
   Pardo-Grau, L
   Maisterra, S
   Ruiz-Ramírez, P
   Garcia-Sumalla, A
   Tebé, C
   Videla, S
   Gornals, JB
AF Bas-Cutrina, Francesc
   Loras, Carme
   Pardo, Albert
   Ballester-Clau, Raquel
   Huertas, Carlos
   Guarner-Argente, Carlos
   Colan-Hernandez, Juan
   Consiglieri, Claudia F
   Andujar, Xavi
   Vilanova-Serra, Magdalena
   González-Huix, Ferran
   Pardo-Grau, Laura
   Maisterra, Sandra
   Ruiz-Ramírez, Pablo
   Garcia-Sumalla, Albert
   Tebé, Cristian
   Videla, Sebastià
   Gornals, Joan B
TI Management of small subepithelial tumors by endoscopic banding without resection
SO Gastrointestinal endoscopy
LA English
DT Journal Article
AB BACKGROUND AND AIMS: Endoscopic band ligation (EBL) without resection combined  with single-incision needle-knife (SINK) biopsy sampling may have a positive  impact on small GI subepithelial tumor (SET) management, but the method needs to  be tested. The aim was to evaluate the feasibility of this strategy in  small-sized SETs. METHODS: This prospective multicenter observational cohort  study in 7 centers included patients with SETs ≤15 mm (confirmed by EUS) between  March 2017 and March 2020. The primary outcome was clinical success at 4 weeks,  defined as complete SET disappearance on EUS. Secondary outcomes were long-term  (1-year) clinical success, technical difficulty level, clinical impact, yield  pathology, and safety. RESULTS: Of 273 patients screened, 122 (62.3% women; mean  age, 60.9 ± 13.2 years) were included with SETs (mean size, 9 ± 2.8 mm; gastric  location, 77%; superficial layer dependence, 63%). The primary endpoint was  achieved in 73.6% of patients (95% confidence interval [CI], 64.8-81.2). At the  1-year follow-up, the success rate was 68.4% (95% CI, 59.1-76.8). A favorable  clinical impact was observed in 97 cases (79.5%; 95% CI, 71.3-86.3). Pathology  diagnosis was known in 70%. Potentially malignant lesions were present in 24.7%.  The related adverse events rate was 4.1% (95% CI, 1.3-9.3; all mild: 2 bleeding,  2 abdominal pain). On multivariable analysis, the ≤10-mm SET group was associated  with a greater success rate (1 year, 87%; relative risk, 5.07; 95% CI, 2.63-9.8)  and clinical impact rate (92.7%; relative risk, 6.15; 95% CI, 2.72-13.93).  CONCLUSIONS: EBL plus SINK biopsy sampling seems to be feasible and safe, and it  may offer a favorable clinical impact in small-sized SETs. In particular,  SETs ≤10 mm are the best candidates. (Clinical trial registration number:  NCT03247231.).
C1 Endoscopy Unit, Department of Digestive Diseases, Hospital Universitari de Bellvitge, Barcelona, Spain
   Bellvitge Biomedical Research Institute (IDIBELL),Barcelona, Spain
   Department of Clinical Sciences, School of Medicine and HealthSciences, University of Barcelona, Barcelona, Spain
   Digestive Diseases Unit,Hospital General de Granollers, Barcelona, Spain.
   Endoscopy Unit, Department of Digestive Diseases, Hospital Universitari Mútua de Terrassa, Barcelona, Spain
   Centro de Investigación Biomédica en Red deEnfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III,Madrid, Spain
   Faculty of Health Sciences, Universitat Oberta de Catalunya,Barcelona, Spain.
   Department of Digestive Diseases, Hospital Universitari Joan XXIII, Tarragona, Spain.
   Endoscopy Unit, Department of Digestive Diseases, Hospital Universitari Arnau de Vilanova, Lleida, Spain.
   Endoscopy Unit, Department of Digestive Diseases, Hospital Universitari Doctor Josep Trueta, Girona, Spain.
   Endoscopy Unit, Digestive Pathology Service, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain.
   Endoscopy Unit, Department of Digestive Diseases, Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain.
   Endoscopy Unit, Department of Digestive Diseases, Hospital Universitari de Bellvitge, Barcelona, Spain
   Bellvitge Biomedical Research Institute (IDIBELL),Barcelona, Spain
   Department of Clinical Sciences, School of Medicine and HealthSciences, University of Barcelona, Barcelona, Spain.
   Endoscopy Unit, Department of Digestive Diseases, Hospital Universitari Mútua de Terrassa, Barcelona, Spain
   Centro de Investigación Biomédica en Red deEnfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III,Madrid, Spain.
   Department of Digestive Diseases, Hospital Universitari Joan XXIII, Tarragona, Spain.
   Endoscopy Unit, Department of Digestive Diseases, Hospital Universitari Arnau de Vilanova, Lleida, Spain.
   Endoscopy Unit, Department of Digestive Diseases, Hospital Universitari Doctor Josep Trueta, Girona, Spain.
   Endoscopy Unit, Department of Digestive Diseases, Hospital Universitari de Bellvitge, Barcelona, Spain
   Bellvitge Biomedical Research Institute (IDIBELL),Barcelona, Spain
   Department of Clinical Sciences, School of Medicine and HealthSciences, University of Barcelona, Barcelona, Spain.
   Endoscopy Unit, Department of Digestive Diseases, Hospital Universitari Mútua de Terrassa, Barcelona, Spain
   Centro de Investigación Biomédica en Red deEnfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III,Madrid, Spain.
   Endoscopy Unit, Department of Digestive Diseases, Hospital Universitari de Bellvitge, Barcelona, Spain
   Bellvitge Biomedical Research Institute (IDIBELL),Barcelona, Spain
   Department of Clinical Sciences, School of Medicine and HealthSciences, University of Barcelona, Barcelona, Spain.
   Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain
   Statistics Advisory Service, Bellvitge Biomedical Research Institute (IDIBELL), Barcelona,Spain.
   Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain
   Department of Clinical Sciences, School of Medicine and Health Sciences, University ofBarcelona, Barcelona, Spain
   Clinical Research and Clinical Trial Unit(UICEC-IDIBELL), Hospital Universitari de Bellvitge, Barcelona, Spain.
   Endoscopy Unit, Department of Digestive Diseases, Hospital Universitari de Bellvitge, Barcelona, Spain
   Bellvitge Biomedical Research Institute (IDIBELL),Barcelona, Spain
   Department of Clinical Sciences, School of Medicine and HealthSciences, University of Barcelona, Barcelona, Spain
   Faculty of Health Sciences,Universitat Oberta de Catalunya, Barcelona, Spain.
NR 0
TC 0
SN 1097-677
EI 
J9 Gastrointest Endosc
PD JUN 2
PY 2023
VL 98
IS 6
BP 911
EP 921.e8
DI 10.1016/j.gie.2023.05.057
PG 1
WC Humans; Female; Middle Aged; Aged; Male; Stomach Neoplasms; pathology; Prospective Studies; Biopsy; methods; Gastrointestinal Neoplasms; surgery; Endoscopy
UT PubMed:37263361
PM 37263361
DA 2023-06-02
ER

PT J
AU Zou, X
   Chen, ZY
   Yang, YH
   Qiao, Y
   He, SJ
   Li, Q
   Chen, WL
   Zhang, XY
   Li, SY
   Sha, SY
   Hu, MH
   Zhang, XY
   Yang, MJ
   Wang, RP
   Wu, HG
   Shi, Y
   Xue, XH
   Ji, YJ
AF Zou, Xuan
   Chen, Zi-Yi
   Yang, Yu-Han
   Qiao, Yu
   He, Shu-Jin
   Li, Qiong
   Chen, Wei-Li
   Zhang, Xin-Yue
   Li, Si-Yu
   Sha, Shan-Yan
   Hu, Min-Hao
   Zhang, Xi-Yin
   Yang, Ming-Ju
   Wang, Rui-Ping
   Wu, Huan-Gan
   Shi, Yin
   Xue, Xiao-Hong
   Ji, Ya-Jie
TI Acupoint Thread Embedding Combined With Wenshen Bugu Decoction for the Treatment of Aromatase Inhibitor-Associated Musculoskeletal Symptom Among Postmenopausal Breast Cancer Patients: Study Protocol of a Randomized Controlled Trial
SO INTEGRATIVE CANCER THERAPIES
LA English
DT Article
DE aromatase inhibitor-associated musculoskeletal symptom (AIMSS); acupoint thread embedding (ATE); Wenshen Bugu Decoction; breast cancer; endocrine therapy
ID quality-of-life; acupuncture; therapy; women; validity; osteoporosis; management; tamoxifen; adherence
AB Background:Aromatase inhibitors (AIs) are recommended as the preferred therapy for postmenopausal women with hormone receptor-positive (HR+) breast cancer. As a result, aromatase inhibitor-associated musculoskeletal symptom (AIMSS) have become a major problem leading to therapy discontinuation and decreased quality of life in patients receiving adjuvant AIs treatment. Multiple therapies have been attempted, but have yielded limited clinical results. This study will be performed to determine whether acupoint thread embedding (ATE) combined with Wenshen Bugu Decoction can effectively treat AIMSS, so as to improve the AIs medication compliance of postmenopausal breast cancer patients. Methods:This study will utilize a randomized, 2 parallel groups controlled trial design. A total of 128 eligible postmenopausal breast cancer women with AIMSS will be randomized to receive a 12-week treatment with Wenshen Bugu Decoction alone (control group) or in combination with ATE (treatment group) in a 1:1 ratio. The primary outcome will be the 12 week Brief Pain Inventory Worst Pain (BPI-WP) score. The secondary outcome measures will include response rate, Brief Pain Inventory-Short Form (BFI-SF), Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), Functional Assessment of Cancer Therapy-Endocrine Symptom (FACT-ES), Functional Assessment of Cancer Therapy-Breast (FACT-B), bone marrow density (BMD), blood markers of bone metabolite, Morisky medication adherence scale-8 (MMAS-8), credibility and expectancy, and survival outcomes. Discussion:This trial may provide clinical evidence that ATE combined with Wenshen Bugu Decoction can be beneficial for treating AIMSS among postmenopausal breast cancer survivors. Our findings will be helpful to enhance the quality of life and reduce the occurrence of AIs withdrawal.
C1 [Zou, Xuan; Chen, Zi-Yi; Yang, Yu-Han; Qiao, Yu; He, Shu-Jin; Li, Qiong; Chen, Wei-Li; Zhang, Xin-Yue; Li, Si-Yu; Sha, Shan-Yan; Hu, Min-Hao; Zhang, Xi-Yin; Yang, Ming-Ju; Xue, Xiao-Hong; Ji, Ya-Jie] Shanghai Univ Tradit Chinese Med, Shanghai, Peoples R China.
   [Zou, Xuan; Chen, Zi-Yi; Qiao, Yu; He, Shu-Jin; Zhang, Xi-Yin; Wu, Huan-Gan; Shi, Yin; Ji, Ya-Jie] Shanghai Res Inst Acupuncture & Meridian, Shanghai, Peoples R China.
   [Wang, Rui-Ping] Tongji Univ, Shanghai, Peoples R China.
   [Xue, Xiao-Hong; Ji, Ya-Jie] Shanghai Univ Tradit Chinese Med, Yueyang Hosp Integrat Chinese & Western Med, 110,Ganhe Rd, Shanghai 200437, Peoples R China.
C3 Shanghai University of Traditional Chinese Medicine; Tongji University; Shanghai University of Traditional Chinese Medicine
RP Xue, XH; Ji, YJ (corresponding author), Shanghai Univ Tradit Chinese Med, Yueyang Hosp Integrat Chinese & Western Med, 110,Ganhe Rd, Shanghai 200437, Peoples R China.
EM 195641459@qq.com; 2373602874@qq.com
CR Unknown -, 1994, WORLD HEALTH ORGAN TECH REP SER, V843, P1
   BELLAMY N, 1988, J RHEUMATOL, V15, P1833
   Bian ZX, 2011, ANN INTERN MED, V154, P290, DOI 10.7326/0003-4819-154-4-201102150-00016
   Brady MJ, 1997, J CLIN ONCOL, V15, P974, DOI 10.1200/JCO.1997.15.3.974
   Butani D, 2021, BREAST CANCER-TARGET, V13, P625, DOI 10.2147/BCTT.S331831
   Chai C, 2016, EFFECTS RUAI SHUHOU, V0, P0
   Chen T, 2020, AM J CHINESE MED, V48, P793, DOI 10.1142/S0192415X20500408
   Chim K, 2013, BMC CANCER, V13, P0, DOI 10.1186/1471-2407-13-401
   Coombes RC, 2004, NEW ENGL J MED, V350, P1081, DOI 10.1056/NEJMoa040331
   Crew KD, 2010, J CLIN ONCOL, V28, P1154, DOI 10.1200/JCO.2009.23.4708
   Devilly GJ, 2000, J BEHAV THER EXP PSY, V31, P73, DOI 10.1016/S0005-7916(00)00012-4
   Farrar JT, 2001, PAIN, V94, P149, DOI 10.1016/S0304-3959(01)00349-9
   G-Tsadik D, 2020, INT J HYPERTENS, V2020, P0, DOI 10.1155/2020/9540810
   Ge L, 2022, CHIN MED-UK, V17, P0, DOI 10.1186/s13020-021-00558-4
   Goldhirsch A, 2007, ANN ONCOL, V18, P1133, DOI 10.1093/annonc/mdm271
   Gradishar W J, 2021, JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, V0, P0, DOI DOI 10.6004/JNCCN.2021.0023
   Gradishar WJ, 2020, J NATL COMPR CANC NE, V18, P452, DOI 10.6004/jnccn.2020.0016
   He SJ, 2023, ACAD J SHANGHAI U TR, V37, P76
   Hershman DL, 2018, JAMA-J AM MED ASSOC, V320, P167, DOI 10.1001/jama.2018.8907
   Huang F, 2019, EVID-BASED COMPL ALT, V2019, P0, DOI 10.1155/2019/2673763
   Huo Jin, 2017, ZHONGGUO ZHEN JIU, V37, P1251, DOI 10.13703/j.0255-2930.2017.11.031
   Hyder T, 2021, FRONT ENDOCRINOL, V12, P0, DOI 10.3389/fendo.2021.713700
   Jung Y, 2018, J BREAST CANCER, V21, P182, DOI 10.4048/jbc.2018.21.2.182
   Kiyomi A, 2015, J CANCER, V6, P367, DOI 10.7150/jca.10695
   Korde LA, 2021, J CLIN ONCOL, V39, P1485, DOI 10.1200/JCO.20.03399
   Li Q, 2017, J HUBEI U TRADIT CHI, V19, P13
   MacPherson H, 2010, PLOS MED, V7, P0, DOI 10.1371/journal.pmed.1000261
   Manyanga T, 2014, BMC COMPLEM ALTERN M, V14, P0, DOI 10.1186/1472-6882-14-312
   Mendoza TR, 2004, CLIN J PAIN, V20, P357, DOI 10.1097/00002508-200409000-00011
   Morisky DE, 2008, J CLIN HYPERTENS, V10, P348, DOI 10.1111/j.1751-7176.2008.07572.x
   Niravath P, 2013, ANN ONCOL, V24, P1443, DOI 10.1093/annonc/mdt037
   Pan H, 2018, AM J CHINESE MED, V46, P489, DOI 10.1142/S0192415X18500258
   Qi QL, 2022, BIOMED RES INT, V2022, P0, DOI 10.1155/2022/1164355
   Roberts KE, 2022, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD013167.pub2
   Shi N, 2021, AM J TRANSL RES, V13, P1789
   Soerjomataram I, 2021, NAT REV CLIN ONCOL, V18, P663, DOI 10.1038/s41571-021-00514-z
   Sung H, 2021, CA-CANCER J CLIN, V71, P209, DOI 10.3322/caac.21660
   Unger JM, 2022, J CLIN ONCOL, V40, P1474, DOI 10.1200/JCO.21.02377
   Wang B, 2016, SHANGHAI J ACUPUNCT, V35, P1429
   Wang X, 2020, THER ADV MED ONCOL, V12, P0, DOI 10.1177/1758835920925991
   Winer EP, 2005, J CLIN ONCOL, V23, P619, DOI 10.1200/JCO.2005.09.121
   Yang JW, 2020, J TRADIT CHIN MED, V42, P1897
   Zhang X, 2015, SCI REP-UK, V5, P0, DOI 10.1038/srep07835
   Zhang Y, 2021, HEART SURG FORUM, V24, P0
NR 44
TC 0
Z9 0
U1 4
U2 15
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1534-7354
EI 1552-695X
J9 INTEGR CANCER THER
JI Integr. Cancer Ther.
PD JUN 15
PY 2023
VL 22
IS 
BP 
EP 
DI 10.1177/15347354231188679
PG 12
WC Oncology; Integrative & Complementary Medicine
SC Oncology; Integrative & Complementary Medicine
GA O8KC9
UT WOS:001046233500001
PM 37565358
DA 2026-01-16
ER

PT J
AU Ben-Arye, E
   Hirsh, I
   Segev, Y
   Grach, M
   Master, V
   Eden, A
   Samuels, N
   Stein, N
   Gressel, O
   Ostrovsky, L
   Galil, G
   Schmidt, M
   Schiff, E
   Lavie, O
AF Ben-Arye, Eran
   Hirsh, Irena
   Segev, Yakir
   Grach, Michael
   Master, Viraj
   Eden, Arie
   Samuels, Noah
   Stein, Nili
   Gressel, Orit
   Ostrovsky, Ludmila
   Galil, Galit
   Schmidt, Meirav
   Schiff, Elad
   Lavie, Ofer
TI A randomized-controlled trial assessing the effect of intraoperative acupuncture
SO Journal of cancer research and clinical oncology
LA English
DT Journal Article
DE Acupuncture; Gynecological oncology; Integrative medicine; Integrative oncology; Intraoperative; Pain
AB CONTEXT AND OBJECTIVES: The present study examined the impact of intraoperative  acupuncture on anesthesia-related parameters in patients undergoing gynecological  oncology surgery. METHODS: Participants underwent preoperative integrative  oncology (IO) touch/relaxation treatments, followed by intraoperative acupuncture  (Group A); preoperative IO treatments without acupuncture (Group B); or standard  care only (Group C). Mean arterial pressure (MAP), heart rate (HR), MAP  variability (mean of MAP standard deviation), bispectral index (BIS), and  calculated blood pressure Average Real Variability (ARV) were measured  intraoperatively. RESULTS: A total of 91 patients participated: Group A, 41;  Group B, 24; Group C, 26. Among patients undergoing open laparotomy, Group A  showed lower and more stable MAP and HR compared to Group B, (MAP, p = 0.026; HR,  p = 0.029) and Group C (MAP, p = 0.025). Mean BIS, from incision to suture  closing, was lower in Group A (vs. controls, p = 0.024). In patients undergoing  laparoscopic surgery, MAP was elevated within Group A (p = 0.026) throughout  surgery, with MAP variability significantly higher in Group A (P = 0.023) and  Group B (P = 0.013) 10 min post-incision (vs. pre-incision). All groups showed  similar intraoperative and post-anesthesia use of analgesic medication.  CONCLUSION: Intraoperative acupuncture was shown to reduce and stabilize MAP and  HR, and reduce BIS in gynecology oncology patients undergoing laparotomy, with no  impact on perioperative analgesic medication use. In the laparoscopic setting,  intraoperative acupuncture was associated with elevated MAP. Further research is  needed to explore the hemodynamic and BIS-associated benefits and risks of  intraoperative acupuncture, and the impact on the use of analgesic drugs in  response to these changes.
C1 Integrative Oncology Program, The Oncology Service, Lin, Zebulun, and Carmel Medical Centers, Clalit Health Services, 35 Rothschild St, Haifa, Israel.eranben@netvision.net.il.
   Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, 
   Department of Anesthesiology, Critical Care and Pain Medicine, Carmel Medical Center, Haifa, Israel.
   Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel.
   Department of Obstetrics and Gynecology, Carmel Medical Center, Haifa, Israel.
   Department of Anesthesiology, Critical Care and Pain Medicine, Carmel Medical Center, Haifa, Israel.
   Department of Urology and Winship Cancer Institute of Emory University, Atlanta, GA, USA.
   Department of Anesthesiology, Critical Care and Pain Medicine, Carmel Medical Center, Haifa, Israel.
   Center for Integrative Complementary Medicine, Faculty of Medicine, Shaarei Zedek Medical Center, Hebrew University of Jerusalem, Jerusalem, Israel.
   Department of Community Medicine and Epidemiology, Carmel Medical Center, Haifa, Israel.
   Integrative Oncology Program, The Oncology Service, Lin, Zebulun, and Carmel Medical Centers, Clalit Health Services, 35 Rothschild St, Haifa, Israel.
   Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, 
   Department of Obstetrics and Gynecology, Carmel Medical Center, Haifa, Israel.
   Integrative Oncology Program, The Oncology Service, Lin, Zebulun, and Carmel Medical Centers, Clalit Health Services, 35 Rothschild St, Haifa, Israel.
   Department of Anesthesiology, Critical Care and Pain Medicine, Carmel Medical Center, Haifa, Israel.
   Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel.
   Department of Internal Medicine & Integrative Medicine Service, Bnai-Zion, 
   Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel.
   Department of Obstetrics and Gynecology, Carmel Medical Center, Haifa, Israel.
NR 0
TC 0
SN 1432-133
EI 0171-521
J9 J Cancer Res Clin Oncol
PD APR 16
PY 2023
VL 149
IS 11
BP 8177
EP 8189
DI 10.1007/s00432-023-04758-3
PG 12
WC Female; Humans; Acupuncture Analgesia; Anesthesia; Acupuncture Therapy; Analgesics; Neoplasms
UT PubMed:37061627
PM 37061627
DA 2023-04-16
ER

PT J
AU Zhang, Q
   Yuan, Y
   Zhang, M
   Qiao, B
   Cui, Y
   Wang, Y
   Feng, L
AF Zhang, Qinglin
   Yuan, Yuntong
   Zhang, Meiling
   Qiao, Baohua
   Cui, Yiyuan
   Wang, Ying
   Feng, Li
TI Efficacy and safety of acupuncture-point stimulation combined with opioids for
SO Frontiers in oncology
LA English
DT Journal Article
DE acupuncture-point stimulation; cancer pain; network meta-analysis; opioid; supplementary alternative therapy
AB BACKGROUND: Pain is one of the most common and troublesome symptoms of cancer.  Although potential positive effects of acupuncture-point stimulation (APS) on  cancer pain have been observed, knowledge regarding the selection of the optimal  APS remains unclear because of a lack of evidence from head-to-head randomized  controlled trials (RCTs). OBJECTIVE: This study aimed to carry out a network  meta-analysis to compare the efficacy and safety of different APS combined with  opioids in treating moderate to severe cancer pain and rank these methods for  practical consideration. METHODS: A comprehensive search of eight electronic  databases was conducted to obtain RCTs involving different APS combined with  opioids for moderate to severe cancer pain. Data were screened and extracted  independently using predesigned forms. The quality of RCTs was appraised with the  Cochrane Collaboration risk-of-bias tool. The primary outcome was the total pain  relief rate. Secondary outcomes were the total incidence of adverse reactions,  the incidence of nausea and vomiting, and the incidence of constipation. We  applied a frequentist, fixed-effect network meta-analysis model to pool effect  sizes across trials using rate ratios (RR) with their 95% confidence intervals  (CI). Network meta-analysis was performed using Stata/SE 16.0. RESULTS: We  included 48 RCTs, which consisted of 4,026 patients, and investigated nine  interventions. A network meta-analysis showed that a combination of APS and  opioids was superior in relieving moderate to severe cancer pain and reducing the  incidence of adverse reactions such as nausea, vomiting, and constipation  compared to opioids alone. The ranking of total pain relief rates was as follows:  fire needle (surface under the cumulative ranking curve (SUCRA) = 91.1%), body  acupuncture (SUCRA = 85.0%), point embedding (SUCRA = 67.7%), auricular  acupuncture (SUCRA = 53.8%), moxibustion (SUCRA = 41.9%), transcutaneous  electrical acupoint stimulation (TEAS) (SUCRA = 39.0%), electroacupuncture (SUCRA  = 37.4%), and wrist-ankle acupuncture (SUCRA = 34.1%). The ranking of total  incidence of adverse reactions was as follows: auricular acupuncture (SUCRA =  23.3%), electroacupuncture (SUCRA = 25.1%), fire needle (SUCRA = 27.2%), point  embedding (SUCRA = 42.6%), moxibustion (SUCRA = 48.2%), body acupuncture (SUCRA =  49.8%), wrist-ankle acupuncture (SUCRA = 57.8%), TEAS (SUCRA = 76.3%), and  opioids alone (SUCRA = 99.7%). CONCLUSIONS: APS seemed to be effective in  relieving cancer pain and reducing opioid-related adverse reactions. Fire needle  combined with opioids may be a promising intervention to reduce moderate to  severe cancer pain as well as reduce opioid-related adverse reactions. However,  the evidence was not conclusive. More high-quality trials investigating the  stability of evidence levels of different interventions on cancer pain must be  conducted. SYSTEMATIC REVIEW REGISTRATION:  https://www.crd.york.ac.uk/PROSPERO/#searchadvanced, identifier CRD42022362054.
C1 Department of Oncology, The Third Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, China.
   Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China.
   National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing, China.
   Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China.
   Department of Oncology, The Third Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, China.
   Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China.
   National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing, China.
   Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China.
   National Cancer Center/National Clinical Research Center for Cancer/Cancer 
   National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing, China.
NR 0
TC 0
SN 2234-943
EI 2234-943
J9 Front Oncol
PD JUN 19
PY 2023
VL 13
IS 
BP 1166580
EP 1166580
DI 10.3389/fonc.2023.1166580
PG 0
UT PubMed:37333815
PM 37333815
DA 2023-06-19
ER

PT J
AU Mao, JJ
   Witt, CM
AF Mao, Jun J
   Witt, Claudia M
TI Acupuncture as an Evidence-Based Treatment for Cancer Pain Management: The Joint
SO Journal of integrative and complementary medicine
LA English
DT Journal Article
C1 Integrative Medicine Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
   Institute for Complementary and Integrative Medicine, University Hospital Zurich and University of Zurich, Zurich, Switzerland.
NR 0
TC 0
SN 2768-361
EI 
J9 J Integr Complement Med
PD FEB 28
PY 2023
VL 29
IS 4
BP 209
EP 211
DI 10.1089/jicm.2023.0018
PG 2
WC Humans; United States; Integrative Oncology; Cancer Pain; therapy; Medical Oncology; Radiation Oncology; Acupuncture Therapy; Neoplasms; complications
UT PubMed:36847338
PM 36847338
DA 2023-02-28
ER

PT J
AU Christensen, Holz S
AF Christensen Holz, Sara
TI Aromatase Inhibitor Musculoskeletal Syndrome and Bone Loss: a Review of the
SO Current oncology reports
LA English
DT Review
DE Aromatase inhibitor; Cancer rehabilitation; Cancer treatment side effects; Musculoskeletal complications
AB PURPOSE OF REVIEW: The study aims to review the literature regarding  musculoskeletal complications of aromatase inhibitors and treatment options for  these complications. RECENT FINDINGS: Aromatase inhibitors are common medications  to treat hormone receptor-positive breast cancer in postmenopausal women and have  been shown to improve survival and prevent disease recurrence. However, 20-60%  patients stop treatment prematurely due to side effects. Side effects include  joint stiffness and pain, tendonitis, tendon tears, muscle pain, and carpal  tunnel syndrome known as aromatase inhibitor musculoskeletal syndrome (AIMSS) as  well as bone loss. Proposed mechanisms of AIMSS include decreased estrogen  levels, inflammation, and genetic factors. Switching aromatase inhibitors,  exercise, non-steroidal anti-inflammatory medications, duloxetine, acupuncture,  prednisone, and bisphosphonates are some treatment options for this syndrome and  will be discussed in more detail in this review. Aromatase inhibitors are  important in the treatment of hormone receptor-positive breast cancer in  postmenopausal women. As we study the incidence of side effects of these  medications including bone loss and AIMSS and determine the mechanisms of these  symptoms and possible treatment options, we will decrease the incidence of  patients discontinuing treatment prematurely and improve symptoms, quality of  life, and survival in this patient population.
C1 School of Medicine and Public Health, University of Wisconsin, Madison, WI, USA. christensenholz@rehab.wisc.edu.
NR 0
TC 0
SN 1534-626
EI 
J9 Curr Oncol Rep
PD APR 14
PY 2023
VL 25
IS 7
BP 825
EP 831
DI 10.1007/s11912-023-01413-5
PG 6
WC Humans; Female; Aromatase Inhibitors; adverse effects; Quality of Life; Neoplasm Recurrence, Local; drug therapy; Breast Neoplasms; drug therapy; Diphosphonates; therapeutic use
UT PubMed:37052869
PM 37052869
DA 2023-04-14
ER

PT J
AU Mao, JJ
   Romero, SAD
   Baser, RE
   Wong, GT
   Xiao, H
   Deng, GRY
   Mo, ZL
   Walker, D
   Macleod, JE
   Li, QS
   Barton-Burke, M
   Panageas, K
   Farrar, JT
   Epstein, AS
AF Mao, Jun J.
   Romero, Sally A. D.
   Baser, Raymond E.
   Wong, Greta
   Xiao, Han
   Deng, Gary
   Mo, Zunli
   Walker, Desiree
   Macleod, Jodi Elizabeth
   Li, Qing Susan
   Barton-Burke, Margaret
   Panageas, Katherine
   Farrar, John T.
   Epstein, Andrew S.
TI Acupuncture versus massage for pain in patients living with advanced cancer: The IMPACT randomized clinical trial.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY USA.
   Mem Sloan Kettering Canc Ctr, New York, NY USA.
   Univ Calif San Diego, La Jolla, CA USA.
   Mem Sloan Kettering Canc Ctr, Basking Ridge New Jersey, Basking Ridge, NJ USA.
   Miami Canc Inst, Miami, FL USA.
   Univ Penn, Philadelphia, PA USA.
C3 Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; University of California System; University of California San Diego; Memorial Sloan Kettering Cancer Center; University of Pennsylvania
FU Patient-Centered Outcomes Research Institute (PCORI); U.S. National Institutes of Health
NR 0
TC 0
Z9 0
U1 1
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD JUN 1
PY 2023
VL 41
IS 16_SUPPL
BP 
EP 
DI 10.1200/JCO.2023.41.16_suppl.12101
PG 1
WC Oncology
SC Oncology
GA 6KK9C
UT WOS:001555475400019
DA 2026-01-16
ER

PT J
AU Carvalho, V
   Rangrej, SB
   Rathore, R
AF Carvalho, Victoria
   Rangrej, Shahid B
   Rathore, Rajni
TI The Benefits of Integrative Medicine for Pain Management in Oncology: A Narrative
SO Cureus
LA English
DT Review
DE cancer pain management; chronic pain; integrative medicine; oncologic pain; pain
AB The aim of this evidence-based study is to narrate and evaluate the current  evidence on recommendations for practicing physicians and other healthcare  providers regarding integrative approaches to managing pain in patients with  cancer. This review will assess the guideline recommendations and analyze the  role of integrative medicine in addressing cancer pain in patients. The  literature search highlights relevant studies that will inform evidence-based  recommendations for practicing physicians, highlighting their relevance and  weaknesses. Acupuncture, massage, and hypnosis have intermediate-strength  evidence quality and are moderately recommended for various types of cancer pain.  Most of the evidence points to acupuncture being recommended for aromatase  inhibitor-related joint pain, hypnosis for procedural pain, and massage for  palliative care pain. Other practices with lower-quality evidence include yoga  and guided imagery with progressive muscle relaxation, mostly recommended for  general cancer pain or musculoskeletal pain. Additionally, music therapy is  recommended for procedural or surgical pain. Low-quality or inconclusive evidence  was found for other mind-body interventions or natural products. Similarly, there  is insufficient evidence to provide recommendations for pediatric patients.  Further research is required to enhance our understanding of the role of  integrative medicine interventions in caring for cancer patients.
C1 Medical School, Saint James School of Medicine, Arnos Vale, VCT.
   Anatomy/Research, Saint James School of Medicine, Arnos Vale, VCT.
   Pharmacology and Therapeutics, Saint James School of Medicine, Arnos Vale, VCT.
NR 0
TC 0
SN 2168-818
EI 2168-818
J9 Cureus
PD AUG 1
PY 2023
VL 15
IS 6
BP e41203
EP e41203
DI 10.7759/cureus.41203
PG 1
UT PubMed:37525791
PM 37525791
DA 2023-08-01
ER

PT J
AU Liu, SF
   Chen, QD
   Zhang, QG
   Tao, K
   Li, CH
   Chang, BL
   Wang, WF
   Wu, Z
AF Liu, Shengfu
   Chen, Qiudan
   Zhang, Qinggang
   Tao, Kun
   Li, Changhong
   Chang, Baolei
   Wang, Weifeng
   Wu, Zhong
TI Electroacupuncture combined with extracorporeal shock wave therapy improves pain symptoms and inflammatory factor levels in knee osteoarthritis patients
SO HELIYON
LA English
DT Article
DE Electroacupuncture; Extracorporeal shock wave therapy; Knee osteoarthritis; Synovial fluid
ID plantar fasciitis; subchondral bone; acupuncture; cartilage; model
AB Objective: To compare the clinical efficacy and safety of electroacupuncture combined with extracorporeal shock wave therapy (EESWT) and extracorporeal shock wave therapy (ESWT) in the treatment of knee osteoarthritis (KOA).Methods: A total of 135 KOA patients who received EESWT treatment were selected as the EESWT group, and 135 KOA patients who received extracorporeal shock wave therapy (ESWT) were selected as the ESWT group. The clinical efficacy, inflammatory factors in joint synovial fluid and adverse events during treatment were compared before and after treatment.Results: The clinical effective rate of patients in the EESWT group (89.63 %) after treatment was significantly higher than that of the ESWT group (74.81 %) (p < 0.01). The lysholm kness (LKSS) score and range of motion (ROM) of the patients in the EESWT group after treatment were higher than those of the ESWT group, while Lequesne index score, visual analogue scale (VAS) score and Western Ontario and McMaster Universities Arthritis Index (WOMAC) were lower than those of the ESWT group (p < 0.01). Compared with ESWT group, the changes in the expression levels of nitric oxide (NO), superoxide dismutase (SOD), interleukin 1 beta (IL-1 beta), tumor necrosis factor-alpha (TNF-alpha), matrix metalloproteinase-3 (MMP-3), and transforming growth factor beta 1 (TGF-beta 1) in the synovial fluid of the EESWT group after treatment were significantly greater than those of the ESWT group (p < 0.01). No significant difference in the incidence of adverse events between the EESWT group and the ESWT group (p > 0.05).Conclusion: EESWT significantly improves pain symptoms and inflammatory factor levels in KOA patients and is an optional KOA treatment option worthy of clinical attention.
C1 [Liu, Shengfu; Zhang, Qinggang; Tao, Kun; Wang, Weifeng; Wu, Zhong] Tongji Univ, Shanghai Peoples Hosp 10, Sch Med, Dept Orthoped, Shanghai 200072, Peoples R China.
   [Chen, Qiudan] Fudan Univ, Jingan Dist Ctr Hosp Shanghai, Dept Cent Lab, Clin Lab, Shanghai 200040, Peoples R China.
   [Li, Changhong] Peoples Hosp Gengma Dai & Va Autonomous Cty, Dept Surg 2, Lincang 677599, Yunnan, Peoples R China.
   [Chang, Baolei] Ma Anshan 17 Met Hosp, Maanshan 243000, Anhui, Peoples R China.
   [Wang, Weifeng] Shanghai Univ Tradit Chinese Med, Longhua Hosp, Dept Lab Med, Shanghai 200032, Peoples R China.
   [Wang, Weifeng] 301 Yanchang Zhong Rd, Shanghai 200072, Peoples R China.
C3 Tongji University; Fudan University; Shanghai University of Traditional Chinese Medicine
RP Wang, WF; Wu, Z (corresponding author), Tongji Univ, Shanghai Peoples Hosp 10, Sch Med, Dept Orthoped, Shanghai 200072, Peoples R China.; Chang, BL (corresponding author), Ma Anshan 17 Met Hosp, Maanshan 243000, Anhui, Peoples R China.; Wang, WF (corresponding author), 301 Yanchang Zhong Rd, Shanghai 200072, Peoples R China.
EM baozi19820607403@sina.com; weifengdangdao@163.com; wuzhong0515@126.com
FU National Natural Science Foundation of China of the Shanghai Tenth people's hospital [04.03.19.162]; Clinical Research Project of Shanghai Municipal Health Commission [202140240]
CR AABAKKEN L, 1990, SCAND J GASTROENTERO, V25, P443, DOI 10.3109/00365529009095513
   Abe Y, 2014, CIRC J, V78, P2915, DOI 10.1253/circj.CJ-14-0230
   Aringer M, 2022, ANN RHEUM DIS, V81, P0, DOI 10.1136/annrheumdis-2020-217105
   Avendaño-Coy J, 2020, INT J SURG, V82, P64, DOI 10.1016/j.ijsu.2020.07.055
   Bacchetti P, 2002, ANESTHESIOLOGY, V97, P1028, DOI 10.1097/00000542-200210000-00050
   Bao Fei, 2011, ZHONGGUO ZHEN JIU, V31, P241
   Chen JW, 2020, EQUINE VET J, V52, P449, DOI 10.1111/evj.13183
   Chen LX, 2021, JAMA NETW OPEN, V4, P0, DOI 10.1001/jamanetworkopen.2021.10715
   Cheng L, 2019, J SPORT MED PHYS FIT, V59, P822, DOI 10.23736/S0022-4707.18.09023-0
   Cheng Xiangjuan, 2015, ZHONGHUA XIN XUE GUAN BING ZA ZHI, V43, P259
   Deyle GD, 2020, NEW ENGL J MED, V382, P1420, DOI 10.1056/NEJMoa1905877
   Du C, 2019, NUTRIENTS, V11, P0, DOI 10.3390/nu11020290
   Gollwitzer H, 2015, J BONE JOINT SURG AM, V97A, P701, DOI 10.2106/JBJS.M.01331
   Hashimoto S, 2019, AM J SPORT MED, V47, P2937, DOI 10.1177/0363546519871059
   Hawker GA, 2011, OSTEOARTHR CARTILAGE, V19, P366, DOI 10.1016/j.joca.2011.01.021
   Hsiao CC, 2019, INT J MOL SCI, V20, P0, DOI 10.3390/ijms20194934
   Imamura M, 2015, INT J INFLAMM, V2015, P0, DOI 10.1155/2015/329792
   Jenei-Lanzl Z, 2019, CELL SIGNAL, V53, P212, DOI 10.1016/j.cellsig.2018.10.005
   Ju ZY, 2015, INT J CLIN EXP MED, V8, P18981
   Kan HS, 2019, HONG KONG MED J, V25, P0, DOI 10.12809/hkmj187600
   Karan A, 2003, CLIN RHEUMATOL, V22, P397, DOI 10.1007/s10067-003-0761-y
   Kasemsuk T, 2016, CLIN RHEUMATOL, V35, P2531, DOI 10.1007/s10067-016-3363-1
   Kawcak CE, 2011, AM J VET RES, V72, P772, DOI 10.2460/ajvr.72.6.772
   Kolasinski SL, 2020, ARTHRITIS RHEUMATOL, V72, P220, DOI 10.1002/art.41142
   LEA RD, 1995, J BONE JOINT SURG AM, V77A, P784, DOI 10.2106/00004623-199505000-00017
   Lecorney J, 2018, JOINT BONE SPINE, V85, P605, DOI 10.1016/j.jbspin.2017.10.002
   Min SC, 2017, CLIN RHEUMATOL, V36, P2351, DOI 10.1007/s10067-017-3690-x
   Ng MML, 2003, J ALTERN COMPLEM MED, V9, P641, DOI 10.1089/107555303322524490
   Okur SÇ, 2019, J MUSCULOSKEL NEURON, V19, P178
   Pengas Ioannis, 2018, J EXP ORTHOP, V5, P21, DOI 10.1186/s40634-018-0132-x
   Qin D, 2019, J ETHNOPHARMACOL, V244, P0, DOI 10.1016/j.jep.2019.112045
   Roos EM, 2016, NAT REV RHEUMATOL, V12, P92, DOI 10.1038/nrrheum.2015.135
   Santangelo KS, 2012, OSTEOARTHR CARTILAGE, V20, P1610, DOI 10.1016/j.joca.2012.08.011
   Schepens SL, 2012, J GERONTOL A-BIOL, V67, P1114, DOI 10.1093/gerona/gls076
   Sharma L, 2021, NEW ENGL J MED, V384, P51, DOI 10.1056/NEJMcp1903768
   Shi GX, 2020, J PAIN RES, V13, P2171, DOI 10.2147/JPR.S256950
   Shi XW, 2020, BIOMED PHARMACOTHER, V123, P0, DOI 10.1016/j.biopha.2019.109724
   Suther KR, 2018, PEDIATR RADIOL, V48, P1567, DOI 10.1007/s00247-018-4187-8
   Tang HY, 2019, MEDICINE, V98, P0, DOI 10.1097/MD.0000000000015119
   Tao R, 2015, INFLAMMATION, V38, P1546, DOI 10.1007/s10753-015-0129-x
   TEGNER Y, 1985, CLIN ORTHOP RELAT R, V0, P43
   Vitali M, 2019, J DRUG ASSESS, V8, P77, DOI 10.1080/21556660.2019.1605370
   Wang CJ, 2017, INT J MED SCI, V14, P213, DOI 10.7150/ijms.17469
   Wang CJ, 2012, J SURG RES, V178, P196, DOI 10.1016/j.jss.2012.01.010
   Wang CJ, 2011, ARCH ORTHOP TRAUM SU, V131, P1153, DOI 10.1007/s00402-011-1289-2
   Wang HJ, 2017, INT J UROL, V24, P573, DOI 10.1111/iju.13403
   Wang TT, 2013, ANAL CHEM, V85, P9486, DOI 10.1021/ac400987u
   Witt C, 2005, LANCET, V366, P136, DOI 10.1016/S0140-6736(05)66871-7
   Wu GW, 2019, CHIN J INTEGR MED, V25, P677, DOI 10.1007/s11655-018-2916-8
   Yu H, 2019, AM J PHYSIOL-LUNG C, V317, PL569, DOI 10.1152/ajplung.00080.2018
   Yuan PH, 2019, NEUROUROL URODYNAM, V38, P1457, DOI 10.1002/nau.24017
   Yuan XC, 2018, J PAIN RES, V11, P2797, DOI 10.2147/JPR.S171664
   Yue Ping, 2016, ZHEN CI YAN JIU, V41, P235
   Zhang RX, 2014, ANESTHESIOLOGY, V120, P482, DOI 10.1097/ALN.0000000000000101
NR 54
TC 3
Z9 3
U1 1
U2 12
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 
EI 2405-8440
J9 HELIYON
JI Heliyon
PD OCT 15
PY 2023
VL 9
IS 10
BP 
EP 
DI 10.1016/j.heliyon.2023.e20771
EA OCT 2023
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA Z2MC3
UT WOS:001110459900001
PM 37842584
DA 2026-01-16
ER

PT J
AU Desai, VM
   Priya, S
   Gorantla, S
   Singhvi, G
AF Desai, Vaibhavi Meghraj
   Priya, Sakshi
   Gorantla, Srividya
   Singhvi, Gautam
TI Revolutionizing Therapeutic Delivery with Microneedle Technology for Tumor Treatment
SO PHARMACEUTICS
LA English
DT Review
DE microneedles; tumor therapy; tumor diagnosis; theranostic; chemotherapy
ID transdermal drug-delivery; patch; nanoparticles; platform; gene; pain
AB The tumor is an uncontrolled growth of tissue that can be localized (benign) or possesses the capability of metastasis (malignant). The conventional methods of tumor diagnosis, such as acupuncture, endoscopy, and histopathology, and treatment methods, such as injections, chemotherapy, surgery, and radiotherapy, are invasive, expensive, and pose severe safety and management issues for the patients. Microneedle technology is a recently developed approach for active transdermal drug delivery. It is minimally invasive, self-administrable, bypasses the first-pass effect, and effectively delivers chemotherapeutics and drugs at low doses, thus, overcoming the drawbacks of conventional delivery systems. This review provides an idea of the types, materials utilized in the fabrication, and techniques used for the preparation of microneedles (MNs), as well as their application in tumor diagnosis and treatment. Additionally, emphasis is given to the case studies related to MNs-assisted tumor therapy, such as photothermal therapy, gene therapy, photodynamic therapy, chemotherapy, immunotherapy, and various combination therapies. MNs also serve as a tool for diagnosis by the bio-sampling of blood and interstitial skin fluid, as well as biosensing various cancer biomarkers. The combined therapy and diagnostics provide theranostic MNs for enhanced and personalized tumor therapy. The limitations and prospects of MNs development are also discussed.
C1 [Desai, Vaibhavi Meghraj; Priya, Sakshi; Gorantla, Srividya; Singhvi, Gautam] Birla Inst Technol & Sci BITS Pilani, Dept Pharm, Ind Res Lab, Pilani Campus, Pilani 333031, India.
C3 Birla Institute of Technology & Science Pilani (BITS Pilani)
RP Singhvi, G (corresponding author), Birla Inst Technol & Sci BITS Pilani, Dept Pharm, Ind Res Lab, Pilani Campus, Pilani 333031, India.
EM gautam.singhvi@pilani.bits-pilani.ac.in
CR Akilov OE, 2021, MICRONEEDLE ARRAY DO, V0, P0
   Al Sulaiman D, 2019, ACS NANO, V13, P9620, DOI 10.1021/acsnano.9b04783
   Aldawood FK, 2021, POLYMERS-BASEL, V13, P0, DOI 10.3390/polym13162815
   Alimardani V, 2021, DRUG DELIV TRANSL RE, V11, P788, DOI 10.1007/s13346-020-00819-z
   Amarnani R, 2022, BIOMED MICRODEVICES, V24, P0, DOI 10.1007/s10544-021-00604-w
   Beale JM, 2010, WILSON GISVOLDS TXB, V12th, P355
   Bhatnagar S, 2019, J CHEM SCI, V131, P0, DOI 10.1007/s12039-019-1666-x
   Burton K, 2019, U.S. PATENT, V0, Patent No. 20191398271
   Chang H, 2017, ADV MATER, V29, P0, DOI 10.1002/adma.201702243
   Chen SX, 2020, J CONTROL RELEASE, V324, P218, DOI 10.1016/j.jconrel.2020.05.006
   Ciui B, 2018, ADV HEALTHC MATER, V7, P0, DOI 10.1002/adhm.201701264
   Cole G, 2018, EUR J PHARM BIOPHARM, V127, P288, DOI 10.1016/j.ejpb.2018.02.029
   Dabholkar N, 2021, INT J BIOL MACROMOL, V170, P602, DOI 10.1016/j.ijbiomac.2020.12.177
   Donnelly RF, 2018, DELIVERY PHOTOSENSIT, V0, P235
   Donnelly RF, 2012, ADV FUNCT MATER, V22, P4879, DOI 10.1002/adfm.201200864
   Duong HTT, 2020, J MATER CHEM B, V8, P1171, DOI 10.1039/c9tb02175b
   DUSA Pharmaceuticals Inc, 2018, MICR LES PREP PRIOR, V0, P0
   Falo LD, 2015, U.S. PATENT, V0, Patent No. 201601364071
   Foye WO, 2008, FOYES PRINCIPLES MED, V7th, P1199
   Fu JJ, 2020, J NANOBIOTECHNOL, V18, P0, DOI 10.1186/s12951-020-00697-0
   Gill HS, 2008, CLIN J PAIN, V24, P585, DOI 10.1097/AJP.0b013e31816778f9
   Gittard SD, 2011, FARADAY DISCUSS, V149, P171, DOI 10.1039/c005374k
   Gorantla S, 2022, EXPERT OPIN DRUG DEL, V19, P395, DOI 10.1080/17425247.2022.2053674
   Gorantla S, 2021, INT J BIOL MACROMOL, V184, P438, DOI 10.1016/j.ijbiomac.2021.06.059
   Guo QY, 2021, APPL MATER TODAY, V24, P0, DOI 10.1016/j.apmt.2021.101110
   Hao Y, 2017, J BIOMED NANOTECHNOL, V13, P1581, DOI 10.1166/jbn.2017.2474
   Haq MI, 2009, BIOMED MICRODEVICES, V11, P35, DOI 10.1007/s10544-008-9208-1
   Hejmady S, 2020, DRUG DISCOV TODAY, V25, P2227, DOI 10.1016/j.drudis.2020.09.031
   Jain R, 2022, DRUG DISCOV TODAY, V27, P1176, DOI 10.1016/j.drudis.2021.12.005
   Jain R, 2020, CURR PHARM DESIGN, V26, P4615, DOI 10.2174/1381612826666200826140448
   Kathryn M, 2020, U.S. PATENT, V0, Patent No. 20210723131
   Keum DH, 2015, ADV HEALTHC MATER, V4, P1153, DOI 10.1002/adhm.201570048
   Kim H, 2019, ACS BIOMATER SCI ENG, V5, P5150, DOI 10.1021/acsbiomaterials.9b00961
   Kim H, 2020, ACS NANO, V14, P7227, DOI 10.1021/acsnano.0c02343
   Lan XM, 2020, NANOSCALE, V12, P18885, DOI 10.1039/d0nr04213g
   Lan XM, 2018, ACS APPL MATER INTER, V10, P33060, DOI 10.1021/acsami.8b12926
   Lee Y, 2021, ADV MATER, V33, P0, DOI 10.1002/adma.202100425
   Lin SY, 2021, APPL MATER TODAY, V23, P0, DOI 10.1016/j.apmt.2021.101036
   Lin SY, 2020, NANOSCALE, V12, P10265, DOI 10.1039/d0nr01444c
   Mahmood A, 2022, DRUG DELIV TRANSL RE, V12, P1118, DOI 10.1007/s13346-021-00986-7
   Mahmoud TA, 2015, CHINESE PATENT, V0, Patent No. 104853802
   Miskawaan Integrative Cancer Care, 2021, GLOBAL CANC FACTS FI, V0, P0
   Mohan AMV, 2017, BIOSENS BIOELECTRON, V91, P574, DOI 10.1016/j.bios.2017.01.016
   Moreira AF, 2020, INT J PHARMACEUT, V576, P0, DOI 10.1016/j.ijpharm.2019.118907
   Moreira AF, 2019, PHARMACOL RES, V148, P0, DOI 10.1016/j.phrs.2019.104438
   Neuberger W, 2007, U.S. PATENT, V0, Patent No. 79765712
   Pan JT, 2018, SCI REP-UK, V8, P0, DOI 10.1038/s41598-018-19463-2
   Park W, 2021, RSC ADV, V11, P10393, DOI 10.1039/d1ra00747e
   Priya S, 2022, BIOMED PHARMACOTHER, V155, P0, DOI 10.1016/j.biopha.2022.113717
   Qinying MX, 2019, PATENT NO. 109701152A 109701152, V0, P0
   Queiroz MLB, 2020, EXPERT OPIN THER PAT, V30, P433, DOI 10.1080/13543776.2020.1742324
   Rapalli VK, 2021, EXPERT OPIN DRUG DEL, V18, P1829, DOI 10.1080/17425247.2021.2010702
   Ruan WY, 2018, INT J PHARMACEUT, V553, P298, DOI 10.1016/j.ijpharm.2018.10.043
   Seetharam AA, 2020, PHARMACEUTICS, V12, P0, DOI 10.3390/pharmaceutics12111101
   SkinJect Inc, 2021, OP LAB DOS ESC TRIAL, V0, P0
   SkinJect Inc, 2021, PLACEBO MICRONEEDLES IN HEALTHY VOLUNTEERS (PART I) AND EFFICACY/SAFETY OF DOXORUBICIN MICRONEEDLES IN BASAL CELL CANCER SUBJECTS, V0, P0
   Song G, 2021, CHEM ENG J, V426, P0, DOI 10.1016/j.cej.2021.130790
   Song S, 2019, IEEE T BIOMED CIRC S, V13, P1288, DOI 10.1109/TBCAS.2019.2954846
   Tian ZF, 2019, J NANOSCI NANOTECHNO, V19, P2453, DOI 10.1166/jnn.2019.15884
   Turner JG, 2021, MACROMOL BIOSCI, V21, P0, DOI 10.1002/mabi.202000307
   University of California, 2018, US MICR EXP TREATM T, V0, P0
   University of California, 2017, US MICR PHOT THER, V0, P0
   Waghule T, 2019, BIOMED PHARMACOTHER, V109, P1249, DOI 10.1016/j.biopha.2018.10.078
   Wei SH, 2020, BIOMATER SCI-UK, V8, P5739, DOI 10.1039/d0bm00914h
   whoint, 2022, WHO CANC, V0, P0
   Xu QN, 2020, J MATER CHEM B, V8, P4331, DOI 10.1039/d0tb00105h
   Yuan W, 2020, SCI ADV, V6, P0, DOI 10.1126/sciadv.aaz9664
   Yufang Z, 2021, CHINA, V0, Patent No. [108578355B, 108578355]
   Zahn JD, 2004, BIOMED MICRODEVICES, V6, P183, DOI 10.1023/B:BMMD.0000042047.83433.96
   Zhao X, 2018, J CONTROL RELEASE, V286, P201, DOI 10.1016/j.jconrel.2018.07.038
   Zhen G, 2021, U.S. PATENT, V0, Patent No. 38046201
   Zhi DF, 2020, J CONTROL RELEASE, V325, P52, DOI 10.1016/j.jconrel.2020.06.032
   Zhu JX, 2020, SMALL, V16, P0, DOI 10.1002/smll.201905910
NR 73
TC 23
Z9 23
U1 8
U2 61
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
SN 
EI 1999-4923
J9 PHARMACEUTICS
JI Pharmaceutics
PD JAN 15
PY 2023
VL 15
IS 1
BP 
EP 
DI 10.3390/pharmaceutics15010014
PG 27
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 7Z6XY
UT WOS:000915701200001
PM 36678643
DA 2026-01-16
ER

PT J
AU Li, H
   Schlaeger, JM
   Patil, CL
   Danciu, O
   Chen, Z
   Lif, N
   Gao, S
   Doorenbos, AZ
AF Li, Hongjin
   Schlaeger, Judith M
   Patil, Crystal L
   Danciu, Oana
   Chen, Zhengjia
   Lif, Natalie
   Gao, Shuang
   Doorenbos, Ardith Z
TI Feasibility of implementing acupuncture in medically underserved breast cancer
SO Contemporary clinical trials
LA English
DT Journal Article
DE Acupuncture; Barriers; Breast cancer; Facilitators; Multiple symptoms; Underserved
AB Nearly 94% of breast cancer survivors experience one or more symptoms or side  effects during or after endocrine therapy. Joint pain, hot flashes, sleep  disturbance, fatigue, depression, and anxiety are the most common concurrent  symptoms, some of which can persist for 5 to 10 years. Acupuncture is a holistic  modality that addresses multiple symptoms and side effects in a single therapy.  Acupuncture has not yet been investigated for its effectiveness in treating the  multiple symptoms experienced by breast cancer survivors receiving endocrine  therapy. Medically underserved breast cancer survivors typically have limited  access to acupuncture. The barriers limiting access to acupuncture need to be  removed to enable equal access to breast cancer survivors for this evidence-based  treatment. Thus, we developed a randomized controlled trial with a 5-week  acupuncture intervention versus usual care for medically underserved breast  cancer survivors. Mixed methods (semi-structured interviews, surveys, study  notes) will be used to obtain in-depth understanding of barriers and facilitators  for eventual implementation of the acupuncture intervention. This study will  facilitate the widespread implementation, dissemination, and sustained  utilization of acupuncture for symptom management among medically underserved  breast cancer survivors receiving endocrine therapy.
C1 University of Illinois, Chicago College of Nursing, Department of Human Development Nursing Science, 845 S. Damen Avenue (M/C 802), Chicago, IL 60612,USA
   University of Illinois Cancer Center, 818 South Wolcott Ave, Chicago, IL60612, USA. 
   University of Illinois, Chicago College of Nursing, Department of Human Development Nursing Science, 845 S. Damen Avenue (M/C 802), Chicago, IL 60612,USA.
   University of Illinois, Chicago College of Nursing, Department of Human Development Nursing Science, 845 S. Damen Avenue (M/C 802), Chicago, IL 60612,USA.
   University of Illinois, Chicago College of Medicine, Department of Hematology/Oncology, 820 S. Wood Street Suite 172 CSN (M/C 712), Chicago, IL60612, USA.
   University of Illinois Cancer Center, 818 South Wolcott Ave, Chicago, IL 60612, USA.
   University of Illinois, Chicago College of Nursing, Department of Human Development Nursing Science, 845 S. Damen Avenue (M/C 802), Chicago, IL 60612,USA.
   University of Illinois, Chicago College of Medicine, 1853 W Polk St, Chicago, IL 60612, USA.
   University of Illinois Cancer Center, 818 South Wolcott Ave, Chicago, IL 60612, USA
   University of Illinois, Chicago College of Nursing, Department ofBiobehavioral Nursing Science, 845 S. Damen Avenue (M/C 802), Chicago, IL 60612,USA.
EM hongjin@uic.edu
NR 0
TC 0
SN 1559-203
EI 1551-714
J9 Contemp Clin Trials
PD NOV 17
PY 2023
VL 136
IS 
BP 107387
EP 107387
DI 10.1016/j.cct.2023.107387
PG 0
WC Humans; Female; Breast Neoplasms; drug therapy; Cancer Survivors; Feasibility Studies; Medically Underserved Area; Treatment Outcome; Acupuncture Therapy; Randomized Controlled Trials as Topic
UT PubMed:37972754
PM 37972754
DA 2023-11-17
ER

PT J
AU Guan, QX
   Yang, H
   Liu, YM
   Li, Y
   Luo, YT
   Zou, SJ
AF Guan, Qing-Xia
   Yang, Han
   Liu, Yu-Meng
   Li, Ying
   Luo, Yu-Ting
   Zou, Shu-Jun
TI [Research progress on traditional Chinese medicine compounds combined with
SO Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese
LA chi
DT Review
DE combined therapy; external therapy; hyperplasia of mammary glands; research progress; traditional Chinese medicine compounds
AB Hyperplasia of mammary glands is a benign breast disease with disordered breast  structure. Nowadays, the incidence rate of breast hyperplasia in women is  increasing year by year, and the etiology is related to the imbalance of estrogen  and progesterone in the body. The symptoms include breast pain, breast nodules,  or nipple discharge, which can develop into breast cancer in the context of  psychological pressure. Therefore, it is timely and effectively necessary for  people to treat the symptoms. At present, traditional Chinese medicine(TCM) often  treats breast hyperplasia by oral drug, external application, acupuncture,  moxibustion, and massage, while western medicine often uses hormone therapy or  surgery. TCM can regulate hormone levels to treat breast hyperplasia.  Acupuncture, moxibustion, and other methods can stimulate acupoints to reduce  breast lumps. However, since TCM is easy to produce hepatorenal toxicity after  long-term use and simple external treatment is slow to take effect, rapid and  effective treatment is difficult to be achieved. Although western medicine can  inhibit the disease, it is easy to produce toxic and side effects if taken for a  long time. In addition, surgery can only remove the focus and the recurrence rate  is high. Some studies have found that the combination of oral and external use of  TCM compounds has a significant effect, with mild toxic and side effects, few  adverse reactions, and a low recurrence rate. Based on the relevant literature in  recent years, this article reviewed the combination of oral and external  treatment of TCM in the treatment of hyperplasia of mammary glands, discussed the  effectiveness, clinical evaluation indexes, and mechanism, and pointed out the  existing shortcomings to explore a comprehensive therapy worthy of clinical  application.
C1 School of Pharmacy, Heilongjiang University of Chinese Medicine Harbin 150006,China.
   School of Pharmacy, Heilongjiang University of Chinese Medicine Harbin 150006,China.
   School of Pharmacy, Heilongjiang University of Chinese Medicine Harbin 150006,China.
   School of Pharmacy, Heilongjiang University of Chinese Medicine Harbin 150006,China.
   School of Pharmacy, Heilongjiang University of Chinese Medicine Harbin 150006,China.
   School of Pharmacy, Heilongjiang University of Chinese Medicine Harbin 150006,China.
NR 0
TC 0
SN 
EI 1001-530
J9 Zhongguo Zhong Yao Za Zhi
PD JUN 29
PY 2023
VL 48
IS 11
BP 2856
EP 2867
DI 10.19540/j.cnki.cjcmm.20230315.601
PG 11
WC Female; Humans; Mammary Glands, Human; Medicine, Chinese Traditional; Hyperplasia; Acupuncture Therapy; Breast Neoplasms; Drug-Related Side Effects and Adverse Reactions; Estrogens
UT PubMed:37381948
PM 37381948
DA 2023-06-29
ER

PT J
AU Chang, XS
   Zhu, YJ
   Zhao, WJ
   Liu, YH
   He, YH
   Chen, YD
   Xu, DH
   Mao, JJ
   Zhang, HB
AF Chang, Xuesong
   Zhu, Yanjuan
   Zhao, Wenjie
   Liu, Yihong
   He, Yihan
   Chen, Yadong
   Xu, Danghan
   Mao, Jun J.
   Zhang, Hai-bo
TI Electro-acupuncture for health-related quality of life and symptoms in patients with gastric cancer undergoing adjuvant chemotherapy (EAGER): a protocol for a multicenter randomized controlled trial
SO HEALTH AND QUALITY OF LIFE OUTCOMES
LA English
DT Article
DE Acupuncture; Gastric cancer; Adjuvant chemotherapy; Health-related quality of life; Symptoms
ID under-the-curve; enhance interpretation; clinical-trial; acupuncture; gastrectomy; therapy; fatigue; system; safety; pain
AB BackgroundPatients with local gastric cancer experience a decline of Health-related quality of life (HRQOL) during adjuvant chemotherapy following gastrectomy. Our previous pilot study has indicated the potential of acupuncture to improve HRQOL and control cancer-related symptoms burden. This full-scale trial will focus on confirming the effect of acupuncture for patients with gastric cancer.MethodsA multicenter, open-label, three-arm randomized controlled trial with 249 patients will be conducted in China. Patients will be randomly assigned, in a ratio of 1:1:1, to receive high-dose acupuncture (HA, 7 times each chemo-cycle for 3 cycles), low-dose acupuncture (LA, 3 times each chemo-cycle for 3 cycles), or no acupuncture. The acupoints prescription consisted of bilateral ST36, PC6, SP4, DU20, EX-HN3, and selected Back-shu points. Patients-reported Functional Assessment of Cancer Therapy-Gastric (FACT-Ga) and modified Edmonton Symptom Assessment Scale (mESAS) during the therapy will be recorded. Area under curve (AUC, 21 days/cycle x 3 cycles) and average trajectory of FACT-Ga and mESAS will be calculated. The primary outcome will be the differences in AUC of the FACT-Ga Trial Outcome Index (TOI) between HA and LA versus control groups. Secondary outcomes include AUCs and average trajectory of other FACT-Ga subscales and mESAS scores.DiscussionThis study aims to assess the effect of acupuncture and to compare the difference between LA and HA groups on HRQOL and symptom burden controlling in gastric cancer patients by an adequately powered trial.
C1 [Chang, Xuesong; Zhu, Yanjuan; Liu, Yihong; He, Yihan; Chen, Yadong; Zhang, Hai-bo] Guangzhou Univ Chinese Med, Guangdong Prov Hosp Tradit Chinese Med, Dept Oncol, Affiliated Hosp 2, Guangzhou, Peoples R China.
   [Zhu, Yanjuan; Zhang, Hai-bo] Guangdong Prov Key Lab Clin Res Tradit Chinese Med, Guangzhou, Peoples R China.
   [Zhu, Yanjuan; Zhang, Hai-bo] Guangzhou Univ Chinese Med, Guangdong Hong Kong Macau Joint Lab Chinese Med &, Hong Kong, Guangdong, Peoples R China.
   [Zhao, Wenjie] Guangzhou Univ Chinese Med, Clin Med Sch 2, Guangzhou, Peoples R China.
   [Xu, Danghan] Guangzhou Univ Chinese Med, Rehabil Ctr, Affiliated Hosp 1, Guangzhou, Peoples R China.
   [Mao, Jun J.] Mem Sloan Kettering Canc Ctr, Bendheim Integrat Med Ctr, New York, NY 10065 USA.
   [Zhang, Hai-bo] Guangzhou Univ Chinese Med, State Key Lab Dampness Syndrome Chinese Med, Affiliated Hosp 2, Guangzhou, Peoples R China.
C3 Guangzhou University of Chinese Medicine; Guangzhou University of Chinese Medicine; Guangzhou University of Chinese Medicine; Guangzhou University of Chinese Medicine; Memorial Sloan Kettering Cancer Center; Guangzhou University of Chinese Medicine
RP Zhang, HB (corresponding author), Guangzhou Univ Chinese Med, Guangdong Prov Hosp Tradit Chinese Med, Dept Oncol, Affiliated Hosp 2, Guangzhou, Peoples R China.; Zhang, HB (corresponding author), Guangdong Prov Key Lab Clin Res Tradit Chinese Med, Guangzhou, Peoples R China.; Zhang, HB (corresponding author), Guangzhou Univ Chinese Med, Guangdong Hong Kong Macau Joint Lab Chinese Med &, Hong Kong, Guangdong, Peoples R China.; Mao, JJ (corresponding author), Mem Sloan Kettering Canc Ctr, Bendheim Integrat Med Ctr, New York, NY 10065 USA.; Zhang, HB (corresponding author), Guangzhou Univ Chinese Med, State Key Lab Dampness Syndrome Chinese Med, Affiliated Hosp 2, Guangzhou, Peoples R China.
EM maoj@mskcc.org; haibozh@gzucm.edu.cn
FU National Cancer Institute [P30CA008748] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA008748] Funding Source: Medline
CR Bang YJ, 2012, LANCET, V379, P315, DOI 10.1016/S0140-6736(11)61873-4
   Bao T, 2018, J CLIN ONCOL, V0, P36
   Benson AB III, 2022, J NATL COMPR CANC NE, V20, P1139, DOI 10.6004/jnccn.2022.0051
   Bushmakin AG, 2011, QUAL LIFE RES, V20, P491, DOI 10.1007/s11136-010-9776-4
   Cappelleri JC, 2009, PAIN PRACT, V9, P348, DOI 10.1111/j.1533-2500.2009.00293.x
   Chae HD, 2016, J ALTERN COMPLEM MED, V22, P465, DOI 10.1089/acm.2015.0161
   Chan AW, 2013, BMJ-BRIT MED J, V346, P0, DOI 10.1136/bmj.e7586
   Chang S, 2013, TAIWAN J OBSTET GYNE, V52, P171, DOI 10.1016/j.tjog.2013.04.005
   Cheng CS, 2017, SUPPORT CARE CANCER, V25, P3807, DOI 10.1007/s00520-017-3812-7
   Etemadi A, 2020, LANCET GASTROENTEROL, V5, P42, DOI 10.1016/S2468-1253(19)30328-0
   Fairclough DL, 1997, STAT MED, V16, P1197, DOI 10.1002/(SICI)1097-0258(19970615)16:11<1197::AID-SIM531>3.3.CO;2-0
   Garcia MK, 2013, J CLIN ONCOL, V31, P952, DOI 10.1200/JCO.2012.43.5818
   Garland SN, 2019, JNCI-J NATL CANCER I, V111, P1323, DOI 10.1093/jnci/djz050
   Garland SN, 2011, CANCER-AM CANCER SOC, V117, P1302, DOI 10.1002/cncr.25556
   Ge L, 2022, CHIN MED-UK, V17, P0, DOI 10.1186/s13020-021-00558-4
   Graham J, 2018, CURR ONCOL, V25, PE319, DOI 10.3747/co.25.3935
   He YH, 2020, JAMA ONCOL, V6, P271, DOI 10.1001/jamaoncol.2019.5233
   Hu YN, 2021, ANN SURG ONCOL, V28, P48, DOI 10.1245/s10434-020-09274-z
   Hwang M-S, 2016, STUDY TREATMENT MECH, V0, P0
   Jin HE, 2019, EJSO-EUR J SURG ONC, V45, P2231, DOI 10.1016/j.ejso.2019.06.030
   Johnstone PAS, 2017, CANCER MED-US, V6, P2034, DOI 10.1002/cam4.1125
   Lee SS, 2016, ANN SURG, V263, P738, DOI 10.1097/SLA.0000000000001481
   Liu ZS, 2017, JAMA-J AM MED ASSOC, V317, P2493, DOI 10.1001/jama.2017.7220
   Lundeberg T, 2008, ACUPUNCT MED, V26, P239, DOI 10.1136/aim.26.4.239
   LYDICK E, 1995, QUAL LIFE RES, V4, P41, DOI 10.1007/BF00434382
   MacPherson H, 2013, PLOS ONE, V8, P0, DOI 10.1371/journal.pone.0077438
   Mao JJ, 2022, J CLIN ONCOL, V40, P3998, DOI 10.1200/JCO.22.01357
   Mao JJ, 2021, JAMA ONCOL, V7, P720, DOI 10.1001/jamaoncol.2021.0310
   McGee SF, 2018, CLIN LUNG CANCER, V19, PE91, DOI 10.1016/j.cllc.2017.05.018
   Milton L, 2021, SUPPORT CARE CANCER, V29, P595, DOI 10.1007/s00520-020-05755-9
   Molassiotis A, 2013, J CLIN ONCOL, V31, P2058, DOI 10.1200/JCO.2013.49.2470
   Molassiotis A, 2012, J CLIN ONCOL, V30, P4470, DOI 10.1200/JCO.2012.41.6222
   Munene G, 2012, J SURG ONCOL, V105, P337, DOI 10.1002/jso.22139
   Network NCC, 2020, NCCN CLINICAL PRACTICE GUIDELINES IN ONCOLOGY: BREAST CANCER VERSION 6.2020, V0, P0
   Ouyang A, 2007, WORLD J GASTROENTERO, V13, P5360, DOI 10.3748/wjg.v13.i40.5360
   Park SH, 2021, ANN ONCOL, V32, P368, DOI 10.1016/j.annonc.2020.11.017
   Paterson C, 2005, BMJ-BRIT MED J, V330, P1202, DOI 10.1136/bmj.330.7501.1202
   Raskin P, 2003, DIABETES CARE, V26, P2063, DOI 10.2337/diacare.26.7.2063
   Shan B, 2015, J GASTROINTEST ONCOL, V6, P544, DOI 10.3978/j.issn.2078-6891.2015.046
   Sox HC, 2016, JAMA-J AM MED ASSOC, V316, P1205, DOI 10.1001/jama.2016.11409
   Sprangers MAG, 2002, MAYO CLIN PROC, V77, P561, DOI 10.4065/77.6.561
   Sun N, 2019, ACUPUNCT MED, V37, P261, DOI 10.1136/acupmed-2017-011608
   Sung H, 2021, CA-CANCER J CLIN, V71, P209, DOI 10.3322/caac.21660
   Takahashi M, 2017, WORLD J GASTROENTERO, V23, P2068, DOI 10.3748/wjg.v23.i11.2068
   Tas D, 2014, ASIAN PAC J CANCER P, V15, P3139, DOI 10.7314/APJCP.2014.15.7.3139
   Wang Wenjie, 2016, ZHONGGUO ZHEN JIU, V36, P641, DOI 10.13703/j.0255-2930.2016.06.023
   White A, 2008, ACUPUNCT MED, V26, P111, DOI 10.1136/aim.26.2.111
   Witt CM, 2009, FORSCH KOMPLEMENTMED, V16, P91, DOI 10.1159/000209315
   Woo A, 2016, ANN PALLIAT MED, V5, P13, DOI 10.3978/j.issn.2224-5820.2016.01.02
   World Health O, 2019, WHO GLOB REP TRAD CO, V0, P0
   Zhang XY, 2021, BIOSCI TRENDS, V15, P283, DOI 10.5582/bst.2021.01318
   Zhou J, 2017, CURR ONCOL, V24, PE1, DOI 10.3747/co.24.3296
   Zhu LP, 2018, EVID-BASED COMPL ALT, V2018, P0, DOI 10.1155/2018/2890465
   Zhu Y, 2021, J PAIN SYMPTOM MANAG, V0, P0
NR 54
TC 3
Z9 4
U1 7
U2 22
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 
EI 1477-7525
J9 HEALTH QUAL LIFE OUT
JI Health Qual. Life Outcomes
PD JUL 11
PY 2023
VL 21
IS 1
BP 
EP 
DI 10.1186/s12955-023-02135-9
PG 9
WC Health Care Sciences & Services; Health Policy & Services
SC Health Care Sciences & Services
GA L9MY3
UT WOS:001026447200001
PM 37434165
DA 2026-01-16
ER

PT J
AU Rosenscheg, M
   Pedron, J
   Pedroso, L
AF Rosenscheg, Marcelen
   Pedron, Julia
   Pedroso, Lorena
TI Treatment of Cancer Pain: A Systematic Review.
SO American journal of clinical oncology
LA English
DT Journal Article
AB CONTEXTUALIZATION: One of the biggest problems regarding the treatment of cancer  patients is pain, whether due to the cancer or the treatment itself. Therefore,  there is a search for treatments that aims to promote an effective treatment in  this sense. PURPOSE: This article aims to verify which are the recent methods  used to treat pain in cancer patients in a multidisciplinary sense, and to  evaluate their effectiveness. METHODOLOGY: Systematic reviews, meta-analyses and  randomized clinical trials utilizing the LILACS, NCBI, and MEDLINE platforms of  the last 5 years were included. The descriptors were pain treatment in oncology,  pain management, complementary therapies, and other synonyms, in Portuguese,  English and Spanish. This included any technique that was effective in the  treatment of cancer pain. RESULTS: The initial search found 2246 articles, of  which 22 were included in the systematic review. Most of these are acupuncture  treatments, opioids versus anti-inflammatories versus analgesics, radiotherapy,  behavioral therapies, among others. Most articles suggest benefits with these  therapies, improved quality of life for patients and tolerable side effects.  CONCLUSION: This study demonstrates the effectiveness of the current methods used  in the treatment of pain in cancer patients so that professionals in the area can  have more options for treating cancer pain. Despite the important limitations,  the guideline for further research and the situations in which treatments have  shown effectiveness are present in it.
C1 Bonding Institution, Centro Universitário Campo Real, Guarapuava-PR, Brazil.
NR 0
TC 0
SN 1537-453
EI 
J9 Am J Clin Oncol
PD JUL 24
PY 2023
VL 46
IS 10
BP 450
EP 458
DI 10.1097/COC.0000000000001029
PG 8
WC Humans; Cancer Pain; therapy; Quality of Life; Pain; drug therapy; Pain Management; Analgesics, Opioid; therapeutic use; Neoplasms; therapy
UT PubMed:37482642
PM 37482642
DA 2023-07-24
ER

PT J
AU Zhang, T
   Zhang, Q
   Zhu, PY
   Sun, WD
   Ding, ZQ
   Hu, L
AF Zhang, Teng
   Zhang, Qiang
   Zhu, Peiye
   Sun, Weidong
   Ding, Zaiqiao
   Hu, Lu
TI The Efficacy of Acupuncture in the Treatment of Chemotherapy-Induced Peripheral Neuropathy: A Network Meta-Analysis
SO ALTERNATIVE THERAPIES IN HEALTH AND MEDICINE
LA English
DT Article
ID clinical-practice guidelines; electroacupuncture; interventions; mechanisms; prevention; analgesia; pain
AB Background center dot Chemotherapy-induced peripheral neuropathy (CIPN), one of the most common adverse events associated with chemotherapy, may affect efficacy because of the interruption of chemotherapy or change of regimen in severe cases, and may even increase cancer mortality. Relevant data supports the evidence that acupuncture can treat pain and sensory abnormalities. However, choosing the most effective acupuncture therapy is difficult because of the lack of evidence-based medicine and comparisons between different acupuncture therapies for treating CIPN. The aim of this study was to use a network meta-analysis (NMA) to evaluate the efficacy of different acupuncture therapies for CIPN. Methods center dot We searched Embase, PubMed, Web of Science, The Cochrane Library, The Chinese Journal Full Text Database, Chinese Biomedical Literature Database, and WanFang Database for randomized controlled trials (RCTs) of acupuncture for CIPN. The search period was from the creation of the relevant library to August 10, 2023. A total of 2 investigators independently performed literature screening, data extraction, and risk for bias evaluation. Stata 14.0 software (StataCorp LLC, College Station, Texas USA), was used for the NMA. Results center dot A total of 13 eligible RCTs involving 746 patients and 6 acupuncture therapies were included in the study. The NMA results showed that electroacupuncture was superior to moxibustion, manual acupuncture, acupoint injection and Western medicine in improving the total effective rate of treatment of CIPN; electroacupuncture + moxibustion was better than manual acupuncture, acupoint injection, and Western medicine. Manual acupuncture's total effective rate was better than Western medicine. However, electroacupuncture was the most effective treatment for CIPN according to the surface under the cumulative ranking curve (SUCRA) ranking. Conclusion center dot After a comprehensive evaluation of 6 acupuncture therapies for treating CIPN based on NMA, electroacupuncture may be the best option for treating CIPN. However, would be more convincing to get evidence from more RCTs.
C1 [Zhang, Teng; Sun, Weidong] Dazhou Vocat & Tech Coll, Dept Clin Med, Dazhou, Sichuan, Peoples R China.
   [Zhang, Qiang; Ding, Zaiqiao; Hu, Lu] Army Med Ctr PLA, Dept Oncol, Chongqing, Peoples R China.
   [Zhu, Peiye] Chongqing Univ Technol, Coll Pharm & Bioengn, Chongqing, Peoples R China.
C3 Army Medical University; Chongqing University of Technology
RP Ding, ZQ; Hu, L (corresponding author), Army Med Ctr PLA, Dept Oncol, Chongqing, Peoples R China.
EM dingzaiqiao@163.com; hulumeier2023@163.com
CR Brown TJ, 2019, JAMA ONCOL, V5, P750, DOI 10.1001/jamaoncol.2018.6771
   Butturini E, 2013, FREE RADICAL BIO MED, V65, P1322, DOI 10.1016/j.freeradbiomed.2013.09.015
   Cao SC, 2015, J PRACT ONCOL, V30, P374
   Cassileth BR, 2007, CHEST, V132, P340S, DOI 10.1378/chest.07-1389
   Chen W, 2018, WORLD LATEST MEDICINE INFORMATION, V05, P150
   Chen ZY, 2022, EVID-BASED COMPL ALT, V2022, P0, DOI 10.1155/2022/6875253
   Chien TJ, 2019, INTEGR CANCER THER, V18, P0, DOI 10.1177/1534735419886662
   Choi JW, 2015, AM J CHINESE MED, V43, P57, DOI 10.1142/S0192415X15500044
   Chung G, 2022, PHARMACEUTICS, V14, P0, DOI 10.3390/pharmaceutics14071407
   Desai N, 2022, JAMA INTERN MED, V182, P766, DOI 10.1001/jamainternmed.2022.1812
   Friedemann T, 2022, PHYTOMEDICINE, V104, P0, DOI 10.1016/j.phymed.2022.154294
   Higgins JPT, 2011, BMJ-BRIT MED J, V343, P0, DOI 10.1136/bmj.d5928
   Hou S, 2018, PAIN PHYSICIAN, V21, P571, DOI 10.36076/ppj.2018.6.571
   Hutton B, 2015, ANN INTERN MED, V162, P777, DOI 10.7326/M14-2385
   Hwang MS, 2020, MEDICINE, V99, P0, DOI 10.1097/MD.0000000000019837
   Iravani S, 2020, PAIN RES MANAG, V2020, P0, DOI 10.1155/2020/2504674
   Jin YX, 2020, EVID-BASED COMPL ALT, V2020, P0, DOI 10.1155/2020/8875433
   Jordan B, 2020, ANN ONCOL, V31, P1306, DOI 10.1016/j.annonc.2020.07.003
   Lau WK, 2008, NEUROSCIENCE, V155, P463, DOI 10.1016/j.neuroscience.2008.06.016
   Li J, 2021, ASIA-PACIFIC TRADITIONAL MEDICINE, V17, P196, DOI 10.11954/ytctyy.202101060
   Li SS, 2022, FRONT ONCOL, V12, P0, DOI 10.3389/fonc.2022.864046
   Lin JG, 2008, AM J CHINESE MED, V36, P635, DOI 10.1142/S0192415X08006107
   Liu B, 2009, HEBEI J TRADIT CHIN, V31, P1040
   Liu LL, 2021, INNER MONG J TCM, V40, P106
   Loprinzi CL, 2020, J CLIN ONCOL, V38, P0, DOI 10.1200/JCO.20.01399
   Ma X, 2023, ACUPUNCTURE AND HERBAL MEDICINE, V0, P0, DOI DOI 10.1097/HM1099.0000000000000069
   Mai ZF, 2008, MODERN PREVENTIVE MEDICINE, V35, P122
   Mei Jun-hua, 2015, ZHONGGUO ZHONG XI YI JIE HE ZA ZHI, V35, P1463
   Meng XZ, 2011, BRAIN RES, V1414, P58, DOI 10.1016/j.brainres.2011.08.004
   Ni X, 2022, MEDICAL JOURNAL OF LIAONING, V36, P92
   Oh PJ, 2018, J KOREAN ACAD NURS, V48, P123, DOI 10.4040/jkan.2018.48.2.123
   Pachman DR, 2011, CLIN PHARMACOL THER, V90, P377, DOI 10.1038/clpt.2011.115
   Podratz JL, 2011, NEUROBIOL DIS, V41, P661, DOI 10.1016/j.nbd.2010.11.017
   Rostock M, 2013, EVID-BASED COMPL ALT, V2013, P0, DOI 10.1155/2013/349653
   Salanti G, 2011, J CLIN EPIDEMIOL, V64, P163, DOI 10.1016/j.jclinepi.2010.03.016
   Salat K, 2020, PHARMACOL REP, V72, P486, DOI 10.1007/s43440-020-00109-y
   Salat K, 2020, PHARMACOL REP, V72, P508, DOI 10.1007/s43440-020-00106-1
   Seretny M, 2014, PAIN, V155, P2461, DOI 10.1016/j.pain.2014.09.020
   Shiflett SC, 2011, EXPLORE-NY, V7, P148, DOI 10.1016/j.explore.2011.02.004
   Shin GJE, 2022, FRONT PAIN RES, V3, P0, DOI 10.3389/fpain.2022.912977
   Shlay JC, 1998, JAMA-J AM MED ASSOC, V280, P1590, DOI 10.1001/jama.280.18.1590
   Sisignano M, 2014, NAT REV NEUROL, V10, P694, DOI 10.1038/nrneurol.2014.211
   Staff NP, 2017, ANN NEUROL, V81, P772, DOI 10.1002/ana.24951
   Stubblefield MD, 2009, J NATL COMPR CANC NE, V7, PS1, DOI 10.6004/jnccn.2009.0078
   Sui MH, 2018, CEREBROVASC DIS, V16, P1331, DOI 10.12102/j.issn.1672-1349.2018.10.06
   Sui Minghong, 2016, ZHONGGUO ZHEN JIU, V36, P512
   Tian YP, 2011, TIANJIN J TCM, V28, P212
   Wang M, 2022, EUR J ONCOL NURS, V58, P0, DOI 10.1016/j.ejon.2022.102134
   Wang SM, 2008, ANESTH ANALG, V106, P602, DOI 10.1213/01.ane.0000277493.42335.7b
   Was H, 2022, FRONT PHARMACOL, V13, P0, DOI 10.3389/fphar.2022.750507
   Wei H, 2014, YUNNAN JOURNAL OF TRADITIONAL CHINESE MEDICINE AND MATERIA MEDICA, V35, P19
   Xiong Q, 2015, EUR NEUROL, V74, P323, DOI 10.1159/000441449
   Xiong ZF, 2016, WORLD J ACUPUNCT-MOX, V26, P20, DOI 10.1016/S1003-5257(17)30005-3
   Xu Wei-Ru, 2010, ZHONGGUO ZHEN JIU, V30, P457
   Yan Q, 2011, EXP TOXICOL PATHOL, V63, P151, DOI 10.1016/j.etp.2009.11.002
   Yan YJ, 2012, J LIAONING UNIV TCM, V14, P230
   Yang J, 2017, BIOMED RES INT, V2017, P0, DOI 10.1155/2017/5068347
   Zhai YK, 2022, MED SCI MONITOR, V28, P0, DOI 10.12659/MSM.935979
   Zhang HJ, 2014, ANESTHESIOLOGY, V120, P1463, DOI 10.1097/ALN.0000000000000176
   Zhang SQ, 2017, J TRADIT CHIN MED, V37, P179
   Zhao ZQ, 2008, PROG NEUROBIOL, V85, P355, DOI 10.1016/j.pneurobio.2008.05.004
NR 61
TC 6
Z9 7
U1 1
U2 9
PU InnoVision Professional Media
PI Eagan
PA 3470 Washington Drive Suite 102, Eagan, MN 55122, UNITED STATES
SN 1078-6791
EI 
J9 ALTERN THER HEALTH M
JI Altern. Ther. Health Med.
PD NOV-DEC 15
PY 2023
VL 29
IS 8
BP 898
EP 906
DI 
PG 9
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA EG1E0
UT WOS:001137669200149
PM 37708563
DA 2026-01-16
ER

PT J
AU Lee, RP
AF Lee, Ru-Ping
TI [Storing Complementary Therapy Knowledge to Expand Nursing Roles].
SO Hu li za zhi The journal of nursing
LA chi
DT Journal Article
AB Incorporating complementary therapy into nursing care is common in clinical  practice. Complementary therapy is a non-pharmacological approach used to help  address symptoms that cannot be alleviated entirely by medication. These  complementary therapies often serve specific purposes, and nurses are the ideal  candidates to administer them due to their patient care expertise. However,  before applying any complementary therapy, it is essential to understand the  potential medical safety, ethical, and legal considerations involved in the  therapeutic process. Furthermore, administrators should strengthen their  knowledge and implementation of these therapies to ensure safety during use.  Complementary therapy facilitates the management of symptoms that are not  manageable by medication alone. For example, aromatherapy and light therapy are  employed in clinical settings to alleviate anxiety, depression, insomnia, and  pain (Farrar & Farrar, 2020; Fong et al., 2023), while acupuncture, acupressure,  and qigong are utilized to relieve pain in cancer patients (Behzadmehr et al.,  2020). Although complementary therapy is gradually gaining acceptance in clinical  practice for mitigating patient discomfort, it has yet to achieve widespread  adoption, with the culture within healthcare institutions and the attitudes of  healthcare professionals being significant factors influencing adoption  willingness. Research findings indicate that the primary factor influencing the  use of complementary therapy by nurses is lack of relevant knowledge (Siedlecki,  2021). Elements of complementary therapy have been incorporated into the  blueprint of the National Council Licensure Examination - Registered Nurse in  Western countries. Thus, nursing education programs in the United States are now  required to integrate complementary therapy into their curricula (Helms, 2006).  The above emphasizes the importance of equipping nursing professionals with  crucial knowledge and skills related to complementary therapy. When integrated  appropriately and safely into patient care, complementary therapy not only  enhances the quality and status of nursing but also demonstrates the  irreplaceable role of nurses in assisting patients manage symptoms that are not  fully manageable by medication alone. As modern medical technology and treatment  modalities continue to grow in complexity, nursing professionals must maintain an  open-minded perspective and be willing to adapt to and learn the diverse  knowledge and skills required in today's era of interdisciplinary. Implementing  complementary therapy requires relevant healthcare knowledge for symptom relief  as well as familiarity with the related principles and skills. Complementary  therapy often involves more extended contact with the recipients of care, making  it safer and more appropriate when administered by nursing professionals who have  received medical training. In this column, three articles discuss common  complementary therapeutic practices such as aromatherapy, the non-invasive  Chinese medicine meridian-and-acupoint intervention, and light therapy. Each  article introduces the principles of these therapies and their application in  nursing. It is hoped that the information provided on these three complementary  therapies will help nursing professionals find reference points for expanding and  strengthening their interdisciplinary nursing practices. Thus, the inherent  advantages of the nursing profession may be leveraged to further enhance and  implement the professional nursing process and to maximize the roles and  capabilities of the nursing profession.
C1 PhD, RN, Professor, Institute of Medical Sciences, Tzu Chi University, Taiwan, ROC. fish@gms.tcu.edu.tw.
NR 0
TC 0
SN 
EI 0047-262
J9 Hu Li Za Zhi
PD NOV 20
PY 2023
VL 70
IS 6
BP 4
EP 5
DI 10.6224/JN.202312_70(6).01
PG 1
WC Humans; Complementary Therapies; Aromatherapy; Psychotherapy; Acupuncture Points; Anxiety
UT PubMed:37981877
PM 37981877
DA 2023-11-20
ER

PT J
AU Bao, T
   Zhi, WI
   Baser, RE
   Li, QS
   Weitzman, M
   Gillespie, EF
   Robson, M
   Mao, JJ
AF Bao, Ting
   Zhi, W Iris
   Baser, Raymond E
   Li, Q Susan
   Weitzman, Matthew
   Gillespie, Erin F
   Robson, Mark
   Mao, Jun J
TI Electro-acupuncture versus battle field auricular acupuncture in breast cancer
SO Breast cancer research and treatment
LA English
DT Journal Article
DE Acupuncture; Breast cancer; Pain; Quality of life
AB PURPOSE: Chronic musculoskeletal pain is common and debilitating among breast  cancer survivors. The PEACE trial demonstrated that electro-acupuncture (EA) and  battle field auricular acupuncture (BFAA) both reduced pain more than usual care  (UC) in cancer survivors. However, the comparative effectiveness between EA and  BFAA among breast cancer survivors is unknown. METHODS: EA and BFAA received ten  weekly treatments. UC was offered ten EA treatments after week 12. The primary  endpoint was change in mean Brief Pain Inventory (BPI) pain severity from  baseline to week 12. We analyzed the subset of 165 (46%) trial participants with  a breast cancer primary diagnosis. We conducted constrained linear mixed model  analyses, which constrained all arms to a common pre-randomization baseline mean.  Model-based mean estimates at weeks 12 and 24 were compared between arms using  model contrasts. RESULTS: Among 165 breast cancer survivors, common  pre-randomization mean pain severity was 5.35 [95% Confidence Interval (CI) 5.04,  5.66]. At week 12, BPI pain severity score was 2.69 (2.26. 3.13) in EA, 3.60  (3.17, 4.02) in BFAA, and 5.06 (4.47, 5.65) in UC. EA reduced pain severity  significantly more than BFAA at weeks 12 [- 0.90 (- 1.45, - 0.36), p = 0.001] and  24 [- 0.82, (- 1.38, - 0.27), p = 0.004]. EA and BFAA significantly improved both  Patient-Reported Outcomes Measurement Information System (PROMIS) - Global Health  physical health and mental health component scores at week 12 compared to UC.  Mild toxicities were reported. CONCLUSION: EA was more effective than BFAA at  reducing pain severity, but both similarly improved physical and mental health  scores. Breast cancer survivors with chronic musculoskeletal pain may consider EA  before BFAA. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02979574.  https://clinicaltrials.gov/ct2/show/NCT02979574.
C1 Integrative Medicine Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. tingbao@gmail.com.
   Breast Medicine Service, Solid Tumor Division, Department of Medicine, Memorial 
   Integrative Medicine Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 321 E. 61st Street, 4th Floor, New York, NY, 10065, USA.tingbao@gmail.com.
   Breast Medicine Service, Solid Tumor Division, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
   Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
   Integrative Medicine Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
   Integrative Medicine Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
   Department of Radiation Oncology, University of Washington School of Medicine, Seattle, WA, USA.
   Breast Medicine Service, Solid Tumor Division, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
   Integrative Medicine Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
NR 0
TC 0
SN 1573-721
EI 0167-680
J9 Breast Cancer Res Treat
PD AUG 24
PY 2023
VL 202
IS 2
BP 287
EP 295
DI 10.1007/s10549-023-07072-1
PG 8
WC Humans; Female; Breast Neoplasms; complications; Cancer Survivors; Musculoskeletal Pain; therapy; Acupuncture, Ear; Acupuncture Therapy
UT PubMed:37612534
PM 37612534
DA 2023-08-24
ER

PT J
AU Tian, SX
   Xu, T
   Shi, RY
   Cai, YQ
   Wu, MH
   Zhen, SJ
   Wang, W
   Zhou, Y
   Du, JY
   Fang, JF
   Shao, XM
   Liu, BY
   Jiang, YL
   He, XF
   Fang, JQ
   Liang, Y
AF Tian, Shu-Xin
   Xu, Ting
   Shi, Ren-Yi
   Cai, Yang-Qian
   Wu, Ming-Hui
   Zhen, Si-Jia
   Wang, Wen
   Zhou, You
   Du, Jun-Ying
   Fang, Jun-Fan
   Shao, Xiao-Mei
   Liu, Bo-Yi
   Jiang, Yong-Liang
   He, Xiao-Fen
   Fang, Jian-Qiao
   Liang, Yi
TI Analgesic effect of electroacupuncture on bone cancer pain in rat model: the role of peripheral P2X3 receptor
SO PURINERGIC SIGNALLING
LA English
DT Article
DE Electroacupuncture; Bone cancer-induced pain; P2X3 receptor; DRG
ID dorsal-root ganglion; p2x(3) receptor; acupuncture; trafficking; hypersensitivity; sensitization; contributes; activation; expression; blockade
AB Upregulation of P2X3 receptor (P2X3R) has been strongly implicated in nociceptive signaling including bone cancer pain (BCP). The present study, using rat bone cancer model, aimed to explore the role of P2X3R in regulating rat pain behavior under the intervention of electroacupuncture (EA). The BCP model was successfully established by injection with MRMT-1 breast cancer cell into the medullary cavity of left tibia for 3 x 10(4) cells/3 mu L PBS in rats as revealed by obvious bone destruction, decreased paw withdrawal thresholds (PWTs), and reduced paw withdrawal latencies (PWLs). Western blot analyses showed that P2X3R expression was significantly upregulated in ipsilateral lumbar 4-6 (L4-6) dorsal root ganglia (DRG), but the difference not seen in spinal cord dorsal horn (SCDH). With the in-depth study of P2X3R activation, we observed that intrathecal injection of P2X3R agonist alpha,beta-meATP aggravated MRMT-1 induced BCP, while injection of P2X3R inhibitor A-317491 alleviated pain. Subsequently, we demonstrated that BCP induced mechanical allodynia and thermal hyperalgesia were attenuated after EA treatment. Under EA treatment, total P2X3R protein expression in ipsilateral DRGs was decreased, and it is worth mentioning that decreased expression of P2X3R membrane protein, which indicated that both the expression and membrane trafficking of P2X3R were inhibited by EA. The immunofluorescence assay showed that EA stimulation exerted functions by reducing the expression of P2X3R-positive cells in ipsilateral DRGs of BCP rats. Ca2+ imaging analysis revealed that the EA stimulation decreased the percentage of alpha,beta-meATP responsive neurons in DRGs and inhibited calcium influx. Notably, the inhibitory effect of EA on mechanical allodynia and nociceptive flinches was abolished by intrathecal injection of alpha,beta-meATP. These findings demonstrated EA stimulation ameliorated mechanical allodynia and thermal hyperalgesia in rat model of MRMT-1-induced BCP. EA exerts analgesic effect on BCP by reducing the overexpression and functional activity of P2X3R in ipsilateral DRGs of BCP rats. Our work first demonstrates the critical and overall role of P2X3R in EA's analgesia against peripheral sensitization of MRMT-1-induced BCP and further supports EA as a potential therapeutic option for cancer pain in clinic.
C1 [Tian, Shu-Xin; Xu, Ting; Cai, Yang-Qian; Wu, Ming-Hui; Zhen, Si-Jia; Wang, Wen; Zhou, You; Du, Jun-Ying; Fang, Jun-Fan; Shao, Xiao-Mei; Liu, Bo-Yi; Jiang, Yong-Liang; He, Xiao-Fen; Fang, Jian-Qiao; Liang, Yi] Zhejiang Chinese Med Univ, Sch Clin Med 3, Dept Neurobiol & Acupuncture Res, Key Lab Acupuncture & Neurol Zhejiang Prov, 548 Binwen Rd, Hangzhou 310053, Zhejiang, Peoples R China.
   [Shi, Ren-Yi] Sanya Tradit Chinese Med Hosp, Dept Acupuncture & Moxibust, Sanya 572000, Peoples R China.
   [Fang, Jian-Qiao; Liang, Yi] Chinese Med Univ, Affiliated Hosp Zhejiang 3, Dept Acupuncture & Moxibust, Hangzhou 310005, Peoples R China.
C3 Zhejiang Chinese Medical University; China Medical University
RP Liang, Y (corresponding author), Zhejiang Chinese Med Univ, Sch Clin Med 3, Dept Neurobiol & Acupuncture Res, Key Lab Acupuncture & Neurol Zhejiang Prov, 548 Binwen Rd, Hangzhou 310053, Zhejiang, Peoples R China.; Liang, Y (corresponding author), Chinese Med Univ, Affiliated Hosp Zhejiang 3, Dept Acupuncture & Moxibust, Hangzhou 310005, Peoples R China.
EM liangyiwww@126.com
FU National Natural Science Foundation of China [82174510, 81674061]; Zhejiang Provincial Natural Science Funds [LGF21H270006]; Key Foundation of the Zhejiang Health Committee [2021ZZ017]
CR Burnstock G, 1996, LANCET, V347, P1604, DOI 10.1016/S0140-6736(96)91082-X
   Chen XQ, 2014, J MOL CELL BIOL, V6, P140, DOI 10.1093/jmcb/mju011
   Cheng RD, 2013, CHIN J INTEGR MED, V19, P374, DOI 10.1007/s11655-013-1447-1
   Crockett SD, 2019, GASTROENTEROLOGY, V156, P218, DOI 10.1053/j.gastro.2018.07.016
   Dai WL, 2021, J ADV RES, V28, P139, DOI 10.1016/j.jare.2020.08.005
   Du Junying, 2015, ZHONGGUO ZHEN JIU, V35, P161
   Edwards CM, 2021, FRONT ONCOL, V11, P0, DOI 10.3389/fonc.2021.644303
   Fei XY, 2020, PURINERG SIGNAL, V16, P491, DOI 10.1007/s11302-020-09728-9
   Gilchrist LS, 2005, BRAIN RES, V1044, P197, DOI 10.1016/j.brainres.2005.02.081
   Guedon JMG, 2016, PAIN, V157, P1239, DOI 10.1097/j.pain.0000000000000514
   Han JS, 2004, NEUROSCI LETT, V361, P258, DOI 10.1016/j.neulet.2003.12.019
   Han JS, 2003, TRENDS NEUROSCI, V26, P17, DOI 10.1016/S0166-2236(02)00006-1
   Hansen RR, 2012, EUR J PHARMACOL, V688, P27, DOI 10.1016/j.ejphar.2012.05.008
   He JJ, 2020, EXP NEUROL, V334, P0, DOI 10.1016/j.expneurol.2020.113482
   He YH, 2020, JAMA ONCOL, V6, P271, DOI 10.1001/jamaoncol.2019.5233
   Huang LYM, 2013, GLIA, V61, P1571, DOI 10.1002/glia.22541
   Kaan TKY, 2010, BRAIN, V133, P2549, DOI 10.1093/brain/awq194
   Köles L, 2007, CURR PHARM DESIGN, V13, P2368
   Kwakwa KA, 2017, CANCERS, V9, P0, DOI 10.3390/cancers9070084
   Lee HJ, 2009, J EXP CLIN CANC RES, V28, P0, DOI 10.1186/1756-9966-28-102
   Liang Y, 2019, MOL PAIN, V15, P0, DOI 10.1177/1744806919847810
   Liang Y, 2018, INTEGR CANCER THER, V17, P401, DOI 10.1177/1534735417728335
   Lin JG, 2008, AM J CHINESE MED, V36, P635, DOI 10.1142/S0192415X08006107
   Ma WY, 2014, EXPERT OPIN THER TAR, V18, P459, DOI 10.1517/14728222.2014.887683
   Medhurst SJ, 2002, PAIN, V96, P129, DOI 10.1016/S0304-3959(01)00437-7
   Meng FF, 2015, CANCER SCI, V106, P430, DOI 10.1111/cas.12609
   Nakatsuka T, 2006, PFLUG ARCH EUR J PHY, V452, P598, DOI 10.1007/s00424-006-0057-6
   Paley CA, 2011, EVID-BASED COMPL ALT, V2011, P1, DOI 10.1093/ecam/neq020
   Pan HL, 2016, NEUROSCI BULL, V32, P445, DOI 10.1007/s12264-016-0060-7
   Robinson LE, 2013, FRONT CELL NEUROSCI, V7, P0, DOI 10.3389/fncel.2013.00233
   Storkson RV, 1996, J NEUROSCI METH, V65, P167, DOI 10.1016/0165-0270(95)00164-6
   Sun S, 2006, EXP NEUROL, V198, P294, DOI 10.1016/j.expneurol.2005.11.011
   Sung H, 2021, CA-CANCER J CLIN, V71, P209, DOI 10.3322/caac.21660
   Tang Y, 2019, BRAIN RES BULL, V151, P144, DOI 10.1016/j.brainresbull.2018.10.015
   Tian XY, 2006, BRAIN RES, V1088, P101, DOI 10.1016/j.brainres.2006.03.014
   Wang SY, 2016, PURINERG SIGNAL, V12, P139, DOI 10.1007/s11302-015-9488-x
   Wang WS, 2014, J NEUROSCI RES, V92, P1703, DOI 10.1002/jnr.23451
   Wang W, 2021, FRONT PHARMACOL, V12, P0, DOI 10.3389/fphar.2021.593043
   Weng ZJ, 2015, PURINERG SIGNAL, V11, P321, DOI 10.1007/s11302-015-9447-6
   Wu JX, 2012, EUR J PAIN, V16, P1378, DOI 10.1002/j.1532-2149.2012.00149.x
   Wu JX, 2016, MOL PAIN, V12, P0, DOI 10.1177/1744806916644929
   Xiang XN, 2019, INT J MOL SCI, V20, P0, DOI 10.3390/ijms20133248
   Xiao Z, 2010, BRAIN RES, V1330, P31, DOI 10.1016/j.brainres.2010.03.030
   Xu M, 2021, ACS CHEM NEUROSCI, V12, P3323, DOI 10.1021/acschemneuro.1c00224
   Yang H, 2018, FRONT CELL NEUROSCI, V12, P0, DOI 10.3389/fncel.2018.00129
   Yin CY, 2020, THERANOSTICS, V10, P12189, DOI 10.7150/thno.48028
   Zhang EJ, 2017, MOL MED REP, V16, P2009, DOI 10.3892/mmr.2017.6853
   Zhang Q, 2006, BRAIN RES, V1102, P78, DOI 10.1016/j.brainres.2006.05.040
   Zhang RX, 2008, EUR J PAIN, V12, P870, DOI 10.1016/j.ejpain.2007.12.006
   Zhang RX, 2007, ANESTH ANALG, V105, P1482, DOI 10.1213/01.ane.0000284705.34629.c5
   Zhou YF, 2018, PURINERG SIGNAL, V14, P359, DOI 10.1007/s11302-018-9617-4
   Zhou YL, 2015, PAIN, V156, P1892, DOI 10.1097/j.pain.0000000000000248
NR 52
TC 15
Z9 20
U1 2
U2 21
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 1573-9538
EI 1573-9546
J9 PURINERG SIGNAL
JI Purinergic Signal.
PD MAR 15
PY 2023
VL 19
IS 1
BP 13
EP 27
DI 10.1007/s11302-022-09861-7
EA APR 2022
PG 15
WC Biochemistry & Molecular Biology; Neurosciences
SC Biochemistry & Molecular Biology; Neurosciences & Neurology
GA 9O3UP
UT WOS:000794879900002
PM 35478452
DA 2026-01-16
ER

PT J
AU Giralt, I
   Carvajal, GD
   Fabregas, R
   Baulies, S
AF Giralt, Isabel
   Carvajal, Gilda Delmira
   Fabregas, Rafael
   Baulies, Sonia
TI [Scientific letter evaluating acupuncture and auriculotherapy action in
SO Atencion primaria
LA spa
DT Letter
C1 Unidad de Acupuntura Clínica Mujer Dexeus, Barcelona, Sociedad Médica Profesional ENERGIMED-2007, Barcelona, España. 
   Unidad de Acupuntura Clínica Mujer Dexeus, Barcelona, Sociedad Médica Profesional ENERGIMED-2007, Barcelona, España.
   Clínica Mujer Dexeus, Barcelona, España.
   Clínica Mujer Dexeus, Barcelona, España.
EM isagiralt@gmail.com
NR 0
TC 0
SN 1578-127
EI 0212-656
J9 Aten Primaria
PD SEP 11
PY 2023
VL 55
IS 12
BP 102740
EP 102740
DI 10.1016/j.aprim.2023.102740
PG 0
WC Humans; Female; Breast Neoplasms; drug therapy; Acupuncture Therapy; adverse effects; Auriculotherapy; Arthralgia; therapy; Hormones
UT PubMed:37690338
PM 37690338
DA 2023-09-11
ER

PT J
AU Lu, SS
   Wang, B
   Wang, JQ
   Guo, Y
   Li, SS
   Zhao, SH
   Yang, YZ
   Feng, YT
   Xu, ZF
AF Lu, Shanshan
   Wang, Bin
   Wang, Jiaqi
   Guo, Yi
   Li, Shanshan
   Zhao, Suhong
   Yang, Yuanzhen
   Feng, Yiting
   Xu, Zhifang
TI Moxibustion for the Treatment of Cancer and its Complications: Efficacies and Mechanisms
SO INTEGRATIVE CANCER THERAPIES
LA English
DT Review
DE moxibustion; cancer; complications of cancer; chemotherapy; side-effect
ID natural-killer-cells; quality-of-life; metastatic cancer; lymphocyte ratio; breast-cancer; growth-factor; lung-cancer; fatigue; chemotherapy; hyperthermia
AB Cancer treatment remains a significant challenge for the medical community, and improved therapies are necessary to treat cancer and its associated complications. Current anticancer therapies often have significant side effects, underscoring the need for new treatment options. Moxibustion is a representative external therapy used in traditional Chinese medicine. This review examines clinical studies demonstrating moxibustion's ability to improve the efficacy of radiotherapy and chemotherapy and control tumor progression. Moxibustion can prevent and treat various complications of cancer, including cancer-related or therapy-induced gastrointestinal symptoms, myelosuppression, fatigue, pain, and postoperative lymphedema. has also been shown to enhance the quality of life for cancer patients. However, very few studies have investigated the underlying mechanisms for these effects, a topic that requires systematic elucidation. Evidence has shown that moxibustion alone or combined with chemotherapy can improve survival and inhibit tumor growth in cancer-bearing animal models. The anticancer effect of moxibustion is associated with alleviating the tumor immunosuppressive and vascular microenvironments. Additionally, the therapeutic effects of moxibustion may originate from the heat and radiation produced during the combustion process on acupoints or lesions. This evidence provides a scientific basis for the clinical application of moxibustion in anticancer treatment and reducing the side effects of cancer therapies and helps promote the precise application of moxibustion in cancer treatment.
C1 [Lu, Shanshan; Wang, Bin] Tianjin Med Univ, Canc Inst & Hosp, Natl Clin Res Ctr Canc, Tianjin, Peoples R China.
   [Lu, Shanshan; Wang, Jiaqi; Guo, Yi; Li, Shanshan; Zhao, Suhong; Yang, Yuanzhen; Feng, Yiting; Xu, Zhifang] Tianjin Univ Tradit Chinese Med, Tianjin, Peoples R China.
   [Guo, Yi; Xu, Zhifang] Natl Clin Res Ctr Chinese Med Acupuncture & Moxibu, Tianjin, Peoples R China.
   [Xu, Zhifang] Tianjin Univ Tradit Chinese Med, Res Ctr Expt Acupuncture Sci, 10 Poyang Lake Rd, Tianjin 301617, Peoples R China.
   [Wang, Jiaqi] Tianjin Univ Tradit Chinese Med, Res Ctr Expt Acupuncture Sci, 10 Poyang Lake Rd, Tianjin 301617, Peoples R China.
C3 Tianjin Medical University; Tianjin University of Traditional Chinese Medicine; Tianjin University of Traditional Chinese Medicine; Tianjin University of Traditional Chinese Medicine
RP Xu, ZF (corresponding author), Tianjin Univ Tradit Chinese Med, Res Ctr Expt Acupuncture Sci, 10 Poyang Lake Rd, Tianjin 301617, Peoples R China.; Wang, JQ (corresponding author), Tianjin Univ Tradit Chinese Med, Res Ctr Expt Acupuncture Sci, 10 Poyang Lake Rd, Tianjin 301617, Peoples R China.
EM wangjiaqi557@163.com; xuzhifangmsn@hotmail.com
FU Tianjin Innovation and Entrepreneurship Training Plan for College Students [202210063035]; National Innovation and Entrepreneurship Training Plan for College Students [20210063010]; National Natural Science Foundation of China (NSFC) [82074534]; Research Project of Tianjin Municipal Health Commission on Traditional Chinese Medicine and Integrative Medicine [2019140]
CR Allen BM, 2020, NAT MED, V26, P1125, DOI 10.1038/s41591-020-0892-6
   Bower JE, 2014, NAT REV CLIN ONCOL, V11, P597, DOI 10.1038/nrclinonc.2014.127
   Chen K, 2000, ZHONGGUO ZHONG XI YI JIE HE ZA ZHI, V20, P733
   Chen YF, 2002, ZHONGGUO ZHEN JIU, V22, P261
   Cheng CT, 2014, ANZ J SURG, V84, P510, DOI 10.1111/ans.12474
   Cheng L, 2019, FRONT NEUROSCI-SWITZ, V12, P0, DOI 10.3389/fnins.2018.01057
   Chiba A, 1997, AM J CHINESE MED, V25, P281, DOI 10.1142/S0192415X97000317
   Chiu JH, 2013, EVID BASED COMPLEMENT ALTERNAT MED, V2013, P1
   Choi TY, 2015, SUPPORT CARE CANCER, V23, P1819, DOI 10.1007/s00520-014-2530-7
   Cornelissen AJM, 2017, BREAST CANCER RES TR, V163, P281, DOI 10.1007/s10549-017-4180-1
   [崔瑾 Cui J], 2007, 中国组织工程研究与临床康复 JOURNAL OF CLINICAL REHABILITATIVE TISSUE ENGINEERING RESEARCH, V11, P5473
   Dale David C, 2009, CURR OPIN SUPPORT PALLIAT CARE, V3, P207, DOI 10.1097/SPC.0b013e32832ea6ae
   Detmar M, 2000, J INVEST DERM SYMP P, V5, P20, DOI 10.1046/j.1087-0024.2000.00003.x
   Elming PB, 2019, CANCERS, V11, P0, DOI 10.3390/cancers11010060
   Evans TS, 2017, CANCER SYMPTOMS AND SIDE EFFECTS: A RESEARCH AGENDA TO ADVANCE CANCER CARE OPTIONS, V0, P0
   Ganesan AP, 2013, J IMMUNOL, V191, P2009, DOI 10.4049/jimmunol.1301317
   Ge AX, 2015, CHIN J PATHOG BIOL, V10, P491
   Glasner A, 2018, IMMUNITY, V48, P396, DOI 10.1016/j.immuni.2018.01.010
   Guo Qi, 2020, ZHONGGUO ZHEN JIU, V40, P8, DOI 10.13703/j.0255-2930.20190116-k0003
   Han K, 2021, CANCER MED-US, V10, P4721, DOI 10.1002/cam4.4020
   Han K, 2020, INTEGR CANCER THER, V19, P0, DOI 10.1177/1534735420962854
   Hau DM, 1999, AM J CHINESE MED, V27, P157, DOI 10.1142/S0192415X99000203
   He XR, 2013, ASIAN PAC J CANCER P, V14, P3067, DOI 10.7314/APJCP.2013.14.5.3067
   Hesketh PJ, 2003, EUR J CANCER, V39, P1074, DOI 10.1016/S0959-8049(02)00674-3
   Hiam-Galvez KJ, 2021, NAT REV CANCER, V21, P345, DOI 10.1038/s41568-021-00347-z
   Hinshaw DC, 2019, CANCER RES, V79, P4557, DOI 10.1158/0008-5472.CAN-18-3962
   Hu D, 2021, J CELL MOL MED, V25, P2900, DOI 10.3233/jifs-202844
   Huang Kai-yu, 2015, ZHEN CI YAN JIU, V40, P504
   Huang Wen-juan, 2014, ZHEN CI YAN JIU, V39, P477
   Huang YH, 2012, P NATL ACAD SCI USA, V109, P17561, DOI 10.1073/pnas.1215397109
   Hwang M, 2022, J IMMUNOTHER CANCER, V10, P0, DOI 10.1136/jitc-2022-004688
   Jeon JH, 2017, INTEGR CANCER THER, V16, P118, DOI 10.1177/1534735416654762
   Jia Wen-Rui, 2014, ZHEN CI YAN JIU, V39, P211
   Jin HM, 2020, EVID-BASED COMPL ALT, V2020, P0, DOI 10.1155/2020/5691468
   Kato T, 2021, CANCERS, V13, P0, DOI 10.3390/cancers13112535
   Kim J, 2016, MEDIAT INFLAMM, V2016, P0, DOI 10.1155/2016/6058147
   Kobayashi H, 2019, ACCOUNTS CHEM RES, V52, P2332, DOI 10.1021/acs.accounts.9b00273
   Kotsakis A, 2016, SCI REP-UK, V6, P0, DOI 10.1038/srep39247
   Kupper TS, 2004, NAT REV IMMUNOL, V4, P211, DOI 10.1038/nri1310
   Kurita GP, 2008, CANCER NURS, V31, P49, DOI 10.1097/01.NCC.0000305673.06211.cd
   Langers I, 2012, BIOL-TARGETS THER, V6, P73, DOI 10.2147/BTT.S23976
   Lawrence D, 2004, J NATL CANC INSTITUE, V32, P40, DOI 10.1093/JNCIMONOGRAPHS/LGH027
   Lee J, 2014, INTEGR CANCER THER, V13, P211, DOI 10.1177/1534735413510025
   Li JX, 2019, INTEGR CANCER THER, V18, P0, DOI 10.1177/1534735419890020
   Li LJ, 2021, J INTEGR MED-JIM, V19, P251, DOI 10.1016/j.joim.2021.02.001
   Li Ling, 2018, ZHEN CI YAN JIU, V43, P657, DOI 10.13702/j.1000-0607.170853
   Li Wanying, 2018, ZHONGGUO ZHEN JIU, V38, P695, DOI 10.13703/j.0255-2930.2018.07.003
   Li Zhiping, 2015, ZHONGGUO ZHEN JIU, V35, P1010
   Liang YL, 2019, PHYS MED REHAB KUROR, V29, P39, DOI 10.1055/s-0044-102011
   Liu WYC, 2017, CURR ONCOL REP, V19, P0, DOI 10.1007/s11912-017-0570-0
   Liu XL, 2020, THERANOSTICS, V10, P3793, DOI 10.7150/thno.40805
   Liu Zhi-Dan, 2009, ZHEN CI YAN JIU, V34, P219
   Lu L, 2016, J MED RES COMBAT TRAUMA CARE, V29, P75
   Lu Lu, 2018, ZHEN CI YAN JIU, V43, P110, DOI 10.13702/j.1000-0607.107698
   Lu Mei, 2015, ZHONGGUO ZHEN JIU, V35, P1145
   Lu Mei, 2015, ZHEN CI YAN JIU, V40, P396
   Lu Mei, 2015, ZHONGGUO ZHEN JIU, V35, P264
   Mao HJ, 2016, CANCER-AM CANCER SOC, V122, P3667, DOI 10.1002/cncr.30189
   McQuade RM, 2016, FRONT PHARMACOL, V7, P0, DOI 10.3389/fphar.2016.00414
   Mei L, 2011, ZHONGGUO ZHONG XI YI JIE HE ZA ZHI, V31, P0
   Mercadante S, 2010, INTERN EMERG MED, V5, PS31, DOI 10.1007/s11739-010-0448-8
   Minton O, 2010, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD006704.pub3
   OKAZAKI M, 1990, AM J CHINESE MED, V18, P121, DOI 10.1142/S0192415X90000162
   Oun R, 2018, DALTON T, V47, P6645, DOI 10.1039/c8dt00838h
   Pei Jian, 2010, ZHEN CI YAN JIU, V35, P243
   Pergolizzi Joseph, 2008, PAIN PRACT, V8, P287, DOI 10.1111/j.1533-2500.2008.00204.x
   Pillay B, 2016, CANCER TREAT REV, V42, P56, DOI 10.1016/j.ctrv.2015.11.007
   Qing FH, 2001, ZHONGGUO ZHEN JIU, V9, P29
   Qiu Xingsheng, 2004, J TRADIT CHIN MED, V24, P56
   Rashid M, 2021, GENE, V798, P0, DOI 10.1016/j.gene.2021.145796
   Saligan LN, 2015, SUPPORT CARE CANCER, V23, P2461, DOI 10.1007/s00520-015-2763-0
   Sawaji Y, 2002, BRIT J CANCER, V86, P1597, DOI 10.1038/sj.bjc.6600268
   SJODIN B, 1990, SPORTS MED, V10, P236
   Staff NP, 2017, ANN NEUROL, V81, P772, DOI 10.1002/ana.24951
   Sung H, 2021, CA-CANCER J CLIN, V71, P209, DOI 10.3322/caac.21660
   Szor DJ, 2018, J SURG ONCOL, V117, P851, DOI 10.1002/jso.25036
   Takayama S, 2011, EVID-BASED COMPL ALT, V2011, P0, DOI 10.1093/ecam/nep110
   Valdés-Ferrada J, 2020, FRONT IMMUNOL, V11, P0, DOI 10.3389/fimmu.2020.01413
   van den Beuken-van Everdingen MHJ, 2016, J PAIN SYMPTOM MANAG, V51, P1070, DOI 10.1016/j.jpainsymman.2015.12.340
   Wang B, 2020, EVID-BASED COMPL ALT, V2020, P0, DOI 10.1155/2020/3170803
   Wang CH, 2019, INTEGR CANCER THER, V18, P0, DOI 10.1177/1534735419866919
   Wang Li-Li, 2019, ZHONGGUO ZHEN JIU, V39, P1169, DOI 10.13703/j.0255-2930.2019.11.009
   Wang P, 2016, CHIN J INTEGR MED, V22, P532, DOI 10.1007/s11655-015-2157-7
   Wu SY, 2020, MOL CANCER, V19, P0, DOI 10.1186/s12943-020-01238-x
   Wu WC, 2014, P NATL ACAD SCI USA, V111, P4221, DOI 10.1073/pnas.1320753111
   Xia DQ, 2020, J ONCOL CHIN MED, V2, P82
   Xue N, 2020, CANCER MANAG RES, V12, P8015, DOI 10.2147/CMAR.S249797
   Yamamoto Tetsuya, 2011, NIHON EISEIGAKU ZASSHI, V66, P71, DOI 10.1265/jjh.66.71
   Yan Ya-Nan, 2016, ZHEN CI YAN JIU, V41, P321
   Yi T, 2016, NEURAL REGEN RES, V11, P610, DOI 10.4103/1673-5374.180746
   Zawawi WFAWM, 2021, SCI REP-UK, V11, P0, DOI 10.1038/s41598-021-89740-0
   Zhai D, 1995, ZHEN CI YAN JIU, V20, P36
   Zhai DD, 1996, ZHEN CI YAN JIU, V2, P77
   Zhai DD, 1994, ZHEN CI YAN JIU, V0, P63
   Zhang C, 2016, J CHENGDU UNIV TRADIT CHIN MED, V39, P1
   Zhang FR, 2020, WORLD JOURNAL OF INTEGRATED TRADITIONAL AND WEST- ERN MEDICINE, V15, P1934, DOI 10.13935/J.CNKI.SJZX.201038
   Zhang HW, 2018, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD010559.pub2
   Zhang Lei, 2020, ZHONGGUO ZHEN JIU, V40, P1164, DOI 10.13703/j.0255-2930.20191119-k0005
   Zhang Lei, 2020, ZHEN CI YAN JIU, V45, P574, DOI 10.13702/j.1000-0607.190568
   Zhang MX, 2018, J TRADIT CHIN MED, V38, P439
   Zhang MX, 2016, CHIN J CLIN, V44, P42
   Zhang Qu-Fei, 2013, ZHONGGUO ZHEN JIU, V33, P207
   Zhang T, 1994, ZHEN CI YAN JIU, V19, P69
   Zhang Xue, 2017, ZHEN CI YAN JIU, V42, P235
   Zhang Y, 2021, FRONT IMMUNOL, V11, P0, DOI 10.3389/fimmu.2020.609705
   Zhao X, 2011, J. ACUPUNCT. TUINA SCI., V9, P331, DOI 10.1007/s11726-011-0545-x
   Zhao Xi-Xin, 2007, ZHONGGUO ZHEN JIU, V27, P715
   Zhou LG, 2017, WORLD J ACUPUNCT-MOX, V27, P35, DOI 10.1016/S1003-5257(18)30009-6
   Zhou Ting, 2019, ZHONGGUO ZHEN JIU, V39, P133, DOI 10.13703/j.0255-2930.2019.02.005
   Zhu B, 2015, ZHONGGUO ZHEN JIU, V35, P1048
NR 110
TC 23
Z9 24
U1 9
U2 39
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1534-7354
EI 1552-695X
J9 INTEGR CANCER THER
JI Integr. Cancer Ther.
PD JUN 15
PY 2023
VL 22
IS 
BP 
EP 
DI 10.1177/15347354231198089
PG 18
WC Oncology; Integrative & Complementary Medicine
SC Oncology; Integrative & Complementary Medicine
GA S3SU5
UT WOS:001070409400001
PM 37746720
DA 2026-01-16
ER

PT J
AU Chiaramonte, R
   Bonfiglio, M
   Caramma, S
   Condorelli, R
AF Chiaramonte, Rita
   Bonfiglio, Marco
   Caramma, Salvatore
   Condorelli, Rosaria
TI The Role of Rehabilitation in the Treatment of Constipation in Oncological Patients
SO JOURNAL OF CLINICAL MEDICINE
LA English
DT Review
DE neoplasms; constipation; rehabilitation; osteopathy
ID opioid-induced constipation; quality-of-life; cancer-patients; chemotherapy; prevalence; impact; electroacupuncture; acupressure; therapy
AB Background: Chemotherapy, as well as opioid and antiemetic drugs, can contribute to constipation in oncological patients. This systematic review aims to analyse the potential of specific rehabilitation strategies and alternative strategies for improving constipation symptoms, with the goal of incorporating these strategies into a dedicated protocol for managing cancer-related constipation. This could potentially reduce the dosages of or eliminate the need for constipation medications. Methods: A systematic search was conducted on PubMed, Scopus and Web of Science. The review included studies analysing constipation complaints in cancer patients treated with rehabilitation, acupuncture and osteopathy. Results: The review included 16 studies in line with PRISMA and PICOS criteria. Most studies showed that physical exercise, abdominal massage, TENS, acupuncture and education on the correct defecation position positively impacted the management of constipation and quality of life in oncological patients. A physiotherapy program involving massages as well as aerobic and resistance training improved constipation in oncological women, regardless of age, sex and frailty. A combination of abdominal massage, abdominal muscle stretching and education on proper defecation position alleviated the severity of constipation and related depression. However, the outcomes regarding TENS were yet inconsistent. Another technique, becoming increasingly common for constipation, and demonstrating positive results, involved stimulating trigger points through acupressure and acupuncture. Conversely, osteopathic and superficial manipulations more frequently required constipation medications than did the other alternative approaches. However, no existing studies have proposed a specific protocol to manage cancer-related constipation. Conclusions: The results of the studies confirm the positive influences of rehabilitation, osteopathy and acupuncture on constipation and pain in oncological patients. Nevertheless, further studies are required to establish the best type, timing and duration of treatment, as well as how the stage and location of the cancer and the cause of constipation (drug-induced or functional) impact the results.
C1 [Chiaramonte, Rita] Univ Catania, Dept Biomed & Biotechnol Sci, I-95123 Catania, Italy.
   [Bonfiglio, Marco] Prov Hlth Dept Siracusa, I-96014 Sicily, Italy.
   [Caramma, Salvatore] Policlin San Marco Hosp, Dept Pain Management, I-95123 Catania, Italy.
   [Condorelli, Rosaria] Ist Oncol Svizzera Italiana, Dept Med Oncol, EOC, CH-6500 Bellinzona, Switzerland.
C3 University of Catania; Institute of Oncology Research (IOR)
RP Chiaramonte, R (corresponding author), Univ Catania, Dept Biomed & Biotechnol Sci, I-95123 Catania, Italy.; Bonfiglio, M (corresponding author), Prov Hlth Dept Siracusa, I-96014 Sicily, Italy.
EM ritachiaramd@gmail.com; mrc.bnf@hotmail.it; salvacaramma@tiscali.it; rosaria.condorelli@eoc.ch
CR Azmanova M, 2022, CHEMBIOCHEM, V23, P0, DOI 10.1002/cbic.202100641
   Belsey J, 2010, ALIMENT PHARM THER, V31, P938, DOI 10.1111/j.1365-2036.2010.04273.x
   Bouhassira D, 2017, PAIN, V158, P1118, DOI 10.1097/j.pain.0000000000000895
   Cai H, 2019, J INT MED RES, V47, P6337, DOI 10.1177/0300060519874539
   Calabrese V, 2010, NEUROCHEM RES, V35, P2208, DOI 10.1007/s11064-010-0304-2
   Drossman DA, 2016, GASTROENTEROLOGY, V150, P1257, DOI 10.1053/j.gastro.2016.03.035
   Dzierzanowski T, 2015, SUPPORT CARE CANCER, V23, P1787, DOI 10.1007/s00520-014-2495-6
   Feng R, 2015, DIAGN PATHOL, V10, P0, DOI 10.1186/s13000-015-0382-1
   Friedrichsen Maria, 2004, INT J PALLIAT NURS, V10, P321
   Gálvez R, 2014, ATEN PRIM, V46, P32, DOI 10.1016/j.aprim.2013.08.007
   Gibson RJ, 2006, SUPPORT CARE CANCER, V14, P890, DOI 10.1007/s00520-006-0040-y
   Guyatt G, 2011, J CLIN EPIDEMIOL, V64, P383, DOI 10.1016/j.jclinepi.2010.04.026
   Guyatt GH, 2011, J CLIN EPIDEMIOL, V64, P1303, DOI 10.1016/j.jclinepi.2011.04.014
   Guyatt GH, 2011, J CLIN EPIDEMIOL, V64, P1277, DOI 10.1016/j.jclinepi.2011.01.011
   Guyatt GH, 2011, J CLIN EPIDEMIOL, V64, P1283, DOI 10.1016/j.jclinepi.2011.01.012
   Guyatt GH, 2011, J CLIN EPIDEMIOL, V64, P407, DOI 10.1016/j.jclinepi.2010.07.017
   Hanai A, 2016, BREAST CANCER RES TR, V155, P99, DOI 10.1007/s10549-015-3652-4
   He LH, 2021, MEDICINE, V100, P0, DOI 10.1097/MD.0000000000023748
   Higgins JPT, 2008, COCHRANE HDB SYSTEMA, V0, P0
   Higgins JPT, 2011, BMJ-BRIT MED J, V343, P0, DOI 10.1136/bmj.d5928
   Jani Bhairvi, 2018, MO MED, V115, P236
   Jensen BT, 2014, J MULTIDISCIP HEALTH, V7, P301, DOI 10.2147/JMDH.S62172
   López-Armada MJ, 2022, ANTIOXIDANTS-BASEL, V11, P0, DOI 10.3390/antiox11061151
   Kimura S, 2021, SUPPORT CARE CANCER, V29, P4723, DOI 10.1007/s00520-021-06023-0
   Lagrange A, 2019, EUR J OBSTET GYN R B, V241, P49, DOI 10.1016/j.ejogrb.2019.08.003
   Lai T K T, 2011, COMPLEMENT THER CLIN PRACT, V17, P37, DOI 10.1016/j.ctcp.2010.02.004
   Lehmann J, 2023, CANCERS, V15, P0, DOI 10.3390/cancers15061637
   Li DN, 2020, J NEUROSCI NURS, V52, P257, DOI 10.1097/JNN.0000000000000531
   McQuade RM, 2016, FRONT PHARMACOL, V7, P0, DOI 10.3389/fphar.2016.00414
   Nakano J, 2020, INT J REHABIL RES, V43, P62, DOI 10.1097/MRR.0000000000000386
   Pizzino G, 2017, OXID MED CELL LONGEV, V2017, P0, DOI 10.1155/2017/8416763
   Potter J, 2003, PALLIATIVE MED, V17, P310, DOI 10.1191/0269216303pm760oa
   Shamseer L, 2015, BMJ-BRIT MED J, V349, P0, DOI 10.1136/bmj.g7647
   Shekelle PG, 2019, ONE-TO-ONE OBSERVATION: A SYSTEMATIC REVIEW, V0, P0
   Shin J, 2018, WESTERN J NURS RES, V40, P67, DOI 10.1177/0193945916680362
   Simioni Carolina, 2018, ONCOTARGET, V9, P17181, DOI 10.18632/oncotarget.24729
   Sondergaard J, 2017, SCAND J PAIN, V15, P83, DOI 10.1016/j.sjpain.2017.01.006
   Song N, 2020, WORLD J ACUPUNCT-MOX, V30, P13, DOI 10.1016/j.wjam.2020.01.002
   Tantawy SA, 2017, DIABET METAB SYND OB, V10, P513, DOI 10.2147/DMSO.S140250
   Vecchio M, 2021, J FUNCT MORPHOL KIN, V6, P0, DOI 10.3390/jfmk6040093
   Wang PM, 2019, SUPPORT CARE CANCER, V27, P3473, DOI 10.1007/s00520-019-4655-1
   Wang WM, 2023, JAMA NETW OPEN, V6, P0, DOI 10.1001/jamanetworkopen.2023.0310
   Wang WM, 2022, FRONT MED-LAUSANNE, V9, P0, DOI 10.3389/fmed.2022.818258
   Wójcik M, 2022, ANTIOXIDANTS-BASEL, V11, P0, DOI 10.3390/antiox11061118
   Yang YP, 2020, CHIN CLIN ONCOL, V9, P0, DOI 10.21037/cco.2019.11.02
   Yildirim D, 2022, SUPPORT CARE CANCER, V30, P5201, DOI 10.1007/s00520-022-06947-1
   Yildirim D, 2019, EUR J ONCOL NURS, V41, P110, DOI 10.1016/j.ejon.2019.05.013
NR 47
TC 9
Z9 9
U1 0
U2 17
PU MDPI
PI BASEL
PA MDPI AG, Grosspeteranlage 5, CH-4052 BASEL, SWITZERLAND
SN 
EI 2077-0383
J9 J CLIN MED
JI J. Clin. Med.
PD AUG 15
PY 2023
VL 12
IS 15
BP 
EP 
DI 10.3390/jcm12155083
PG 18
WC Medicine, General & Internal
SC General & Internal Medicine
GA O7IZ9
UT WOS:001045516400001
PM 37568485
DA 2026-01-16
ER

PT J
AU Zhou, DF
   Rong, JC
   Zheng, SZ
   Zhang, K
   Yang, HZ
   Yang, LS
   Tang, CZ
AF Zhou, Dan-feng
   Rong, Jian-cheng
   Zheng, Shu-zhen
   Zhang, Kun
   Yang, Hong-zhi
   Yang, Lian-sheng
   Tang, Chun-zhi
TI Enhanced acupuncture therapy for radiotherapy-related neuropathic pain in patients with gynecologic cancer: a report of two cases and brief review
SO FRONTIERS IN NEUROLOGY
LA English
DT Review
DE neuropathic pain; radiotherapy; acupuncture; cancer; case report
ID prevalence; management; opioids; drugs
AB As radiation therapy is increasingly utilized in the treatment of cancer, neuropathic pain (NP) is a common radiotherapy-related adverse effect and has a significant impact on clinical outcomes negatively. However, despite an improved understanding of neuropathic pain management, pain is often undertreated in patients with cancer. Herein, we reported two cases with radiotherapy-related neuropathic pain (RRNP) who presented a positive reaction to acupuncture. Patient 1 (a 73-year-old woman) with gynecologic cancer complained of burning and electric shock-like pain in the lower limb after radiotherapy. With the accepted combination of acupuncture and drugs, the pain was alleviated completely in 8 weeks. Patient 2 (a 64-year-old woman) accepted acupuncture in the absence of medication because of her inability to tolerate the adverse events of anticonvulsant drugs. She achieved remission of pain 4 weeks later. The results of this study showed that acupuncture might be promising for controlling the RRNP in patients with cancer, especially who were intolerant or unresponsive to medications.
C1 [Zhou, Dan-feng; Zheng, Shu-zhen; Zhang, Kun; Yang, Lian-sheng] Sun Yat Sen Univ, Affiliated Hosp 3, Dept Acupuncture & Moxibust, Guangzhou, Peoples R China.
   [Rong, Jian-cheng] Jiangmen Cent Hosp, Dept Rehabil, Jiangmen, Peoples R China.
   [Yang, Hong-zhi] Sun Yat Sen Univ, Affiliated Hosp 3, Dept Tradit Chinese Med, Guangzhou, Peoples R China.
   [Yang, Lian-sheng] Guangzhou Univ Chinese Med, Med Coll Acu Moxi & Rehabil, Guangzhou, Peoples R China.
   [Tang, Chun-zhi] Guangzhou Univ Chinese Med, Med Coll Acu Moxi & Rehabil, South China Res Ctr Acupuncture & Moxibust, Guangzhou, Peoples R China.
C3 Sun Yat Sen University; Sun Yat Sen University; Guangzhou University of Chinese Medicine; Guangzhou University of Chinese Medicine
RP Yang, LS (corresponding author), Sun Yat Sen Univ, Affiliated Hosp 3, Dept Acupuncture & Moxibust, Guangzhou, Peoples R China.; Yang, LS (corresponding author), Guangzhou Univ Chinese Med, Med Coll Acu Moxi & Rehabil, Guangzhou, Peoples R China.; Tang, CZ (corresponding author), Guangzhou Univ Chinese Med, Med Coll Acu Moxi & Rehabil, South China Res Ctr Acupuncture & Moxibust, Guangzhou, Peoples R China.
EM yanglsh5@mail.sysu.edu.cn; jordan664@gzucm.edu.cn
FU Construction Project of Inheritance Studio of National Famous and Old Traditional Chinese Medicine Experts in 2022
CR Ben-Arye E, 2022, CANCER-AM CANCER SOC, V128, P3641, DOI 10.1002/cncr.34422
   Bennett MI, 2012, PAIN, V153, P359, DOI 10.1016/j.pain.2011.10.028
   Bennett MI, 2011, PALLIATIVE MED, V25, P553, DOI 10.1177/0269216310378546
   Chan KY, 2023, ACUPUNCT MED, V41, P268, DOI 10.1177/09645284221125421
   Delanian S, 2012, RADIOTHER ONCOL, V105, P273, DOI 10.1016/j.radonc.2012.10.012
   Dupoiron D, 2022, J PAIN RES, V15, P241, DOI 10.2147/JPR.S341378
   Edwards HL, 2019, CANCERS, V11, P0, DOI 10.3390/cancers11030373
   Fallon M, 2018, ANN ONCOL, V29, P166, DOI 10.1093/annonc/mdy152
   Friedemann T, 2022, PHYTOMEDICINE, V104, P0, DOI 10.1016/j.phymed.2022.154294
   Gagnier JJ, 2014, J CLIN EPIDEMIOL, V67, P46, DOI 10.1016/j.jclinepi.2013.08.003
   Greco MT, 2014, J CLIN ONCOL, V32, P4149, DOI 10.1200/JCO.2014.56.0383
   He GH, 2015, NEURAL REGEN RES, V10, P128, DOI 10.4103/1673-5374.150720
   Jensen TS, 2011, PAIN, V152, P2204, DOI 10.1016/j.pain.2011.06.017
   Jiang JR, 2019, J CLIN ONCOL, V37, P135, DOI 10.1200/JCO.18.00896
   Kane CM, 2018, PALLIATIVE MED, V32, P276, DOI 10.1177/0269216317711826
   Karri J, 2021, ADV THER, V38, P1425, DOI 10.1007/s12325-021-01640-x
   Kouri M, 2022, J CLIN MED, V11, P0, DOI 10.3390/jcm11164877
   Lee S, 2020, J ALTERN COMPLEM MED, V26, P1136, DOI 10.1089/acm.2020.0307
   Mañas A, 2011, INT J RADIAT ONCOL, V81, P511, DOI 10.1016/j.ijrobp.2010.05.047
   Rayment C, 2013, PALLIATIVE MED, V27, P714, DOI 10.1177/0269216312464408
   Scarborough BM, 2018, CA-CANCER J CLIN, V68, P182, DOI 10.3322/caac.21453
   Schroeder S, 2012, ACUPUNCT MED, V30, P4, DOI 10.1136/acupmed-2011-010034
   van den Beuken-van Everdingen MHJ, 2018, CANCERS, V10, P0, DOI 10.3390/cancers10120502
   Xu ZH, 2022, FRONT NEUROL, V13, P0, DOI 10.3389/fneur.2022.963358
   Yoon SY, 2018, KOREAN J INTERN MED, V33, P1058, DOI 10.3904/kjim.2018.162
   Zhang XW, 2022, PHYTOMEDICINE, V106, P0, DOI 10.1016/j.phymed.2022.154430
NR 26
TC 0
Z9 1
U1 2
U2 8
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-2295
EI 
J9 FRONT NEUROL
JI Front. Neurol.
PD JUN 7
PY 2023
VL 14
IS 
BP 
EP 
DI 10.3389/fneur.2023.1163990
PG 6
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA J8UB9
UT WOS:001012310200001
PM 37351267
DA 2026-01-16
ER

PT J
AU Lagerstedt, K
   Efverman, A
AF Lagerstedt, Kristina
   Efverman, Anna
TI A Randomized Sham-Controlled Mixed Methods Pilot Study of the Feasibility of
SO Integrative cancer therapies
LA English
DT Journal Article
DE acupuncture; cancer rehabilitation; complementary and alternative therapies; integrative oncology; neuropathy; neurotoxicity; nursing; pain; physiotherapy
AB OBJECTIVE: Since there is a lack of effective pharmacological therapies for  chemotherapy-induced neuropathy and many patients ask for integrative cancer  therapies such as acupuncture, the objective of this pilot study was to describe  patients' experiences, and to study the feasibility and short-term effects of  genuine acupuncture for chemotherapy-induced neuropathic pain and unpleasant  sensations compared to sham acupuncture. METHODS: The pilot study used mixed  methods, collecting quantitative and qualitative data. Patients (n = 12) with  chemotherapy-induced neuropathy after colorectal cancer were blindly randomized  to genuine acupuncture or telescopic sham acupuncture. Individual interviews were  conducted, and were analyzed using qualitative content analysis. The patients  registered pain and unpleasant sensations (100 mm Visual Analog Scales) before  and after n = 120 sessions, n = 60 genuine and n = 60 sham acupuncture sessions.  RESULTS: Five categories of patient experiences were described. The neuropathy  negatively affected life. Physical activity was perceived to be important for  health, but neuropathy was a barrier. The neuropathy required symptom-managing  strategies. Acupuncture was pleasant and valuable, but some patients presented  doubts regarding its effect mechanisms. After the genuine acupuncture sessions,  pain (mean -2.0 steps relief during each session) and unpleasant sensations  (-2.4) in the face was reduced more than after sham acupuncture (+0.1 steps worse  pain, P = .018, +0.1 steps worse unpleasant sensations, P = .036). After genuine  acupuncture, unpleasant sensations in the hands were reduced less (-0.23)  compared to after sham acupuncture (-5.5, P = .002). Pain or unpleasant  sensations in the feet did not change. CONCLUSIONS: Patients experienced that the  neuropathy negatively changed their life and that acupuncture was pleasant and  valuable. Patients receiving genuine acupuncture had short-term effects regarding  pain and unpleasant sensations in the face compared to patients receiving sham  acupuncture, while hands and feet did not improve. The patients were successfully  blinded and complied with the acupuncture. We welcome future full-scaled  randomized sham-controlled acupuncture studies.
C1 Region of Kronoberg, Växjö, Sweden.
   University of Gävle, Gävle, Sweden.
NR 0
TC 0
SN 1552-695
EI 1534-735
J9 Integr Cancer Ther
PD JUN 9
PY 2023
VL 22
IS 
BP 15347354231178877
EP 15347354231178877
DI 10.1177/15347354231178877
PG 1
WC Humans; Pilot Projects; Feasibility Studies; Acupuncture Therapy; methods; Peripheral Nervous System Diseases; therapy; Pain; chemically induced; Antineoplastic Agents; adverse effects; Patient Outcome Assessment; Neoplasms; drug therapy
UT PubMed:37294052
PM 37294052
DA 2023-06-09
ER

PT J
AU Huang, HY
   Wang, BQ
   Chen, SJ
   Fang, JY
   Wang, XH
   Chen, LC
   Jiang, Y
   Zhang, HZ
   Chen, JC
   Lin, ZG
AF Huang, Hongye
   Wang, Bingqian
   Chen, Shuijin
   Fang, Jiayu
   Wang, Xiaohua
   Chen, Lechun
   Jiang, Yu
   Zhang, Huanzhen
   Chen, Jincheng
   Lin, Zhigang
TI Chinese Tuina remodels the synaptic structure in neuropathic pain rats by downregulating the expression of N-methyl D- aspartate receptor subtype 2B and postsynaptic density protein-95 in the spinal cord dorsal horn
SO JOURNAL OF TRADITIONAL CHINESE MEDICINE
LA English
DT Article
DE neuralgia; spinal cord dorsal horn; receptors; N-Methyl-D-aspartate; disks large homolog 4 protein; neuronal plasticity; Chinese Tuina
ID glutamate release; plasticity; injury; nr2b; electroacupuncture; interleukin-1-beta; hypersensitivity; mechanisms; sensation; increase
AB OBJECTIVE: To investigate whether the Chinese massage system, Tuina, exerts analgesic effects in a rat model of chronic constriction injury (CCI) by remodeling the synaptic structure in the spinal cord dorsal horn (SCDH). METHODS: Sixty-nine male Sprague-Dawley rats were randomly and evenly divided into the normal group, sham group, CCI group, CCI + Tuina group, CCI + MK-801 [an N-methyl D-aspartate receptor subtype 2B (NR2B) antagonist] group, and CCI + MK-801 + Tuina group. The neuropathic pain model was established using CCI with right sciatic nerve ligation. Tuina was administered 4 d after CCI surgery, using pressing manipulation for 10 min, once daily. Motor function was observed with the inclined plate test, and pain behaviors were observed by the Von Frey test and acetone spray test. At 19 d after surgery, the L3-L5 spinal cord segments were removed. Glutamate, interleukin 1 & beta; (IL-1 & beta;), and tumor necrosis factor-& alpha; (TNF-& alpha;) levels were detected by enzyme-linked immunosorbent assay. The protein expression levels of NR2B and postsynaptic density protein-95 (PSD-95) were detected by Western blot, and the synaptic structure was observed by transmission electron microscopy (TEM). RESULTS: CCI reduced motor function and caused mechanical and cold allodynia in rats, increased glutamate concentration and TNF-& alpha; and IL-1 & beta; levels, and increased expression of synapse-related proteins NR2B and PSD-95 in the SCDH. TEM revealed that the synaptic structure of SCDH neurons was altered. Most of these disease-induced changes were reversed by Tuina and intrathecal injection of MK-801 (P < 0.05 or < 0.01). For the majority of experiments, no significant differences were found between the CCI + MK-801 and CCI + MK 801 + Tuina groups. CONCLUSIONS: Chinese Tuina can alleviate pain by remodeling the synaptic structure, and NR2B and PSD95 receptors in the SCDH may be among its targets. & COPY; 2023 JTCM. All rights reserved.
C1 [Huang, Hongye; Fang, Jiayu; Wang, Xiaohua] Fujian Univ Tradit Chinese Med, Coll Rehabil Med, Fuzhou 350122, Peoples R China.
   [Chen, Shuijin; Chen, Lechun; Jiang, Yu; Zhang, Huanzhen; Chen, Jincheng; Lin, Zhigang] Fujian Univ Tradit Chinese Med, Subsidiary Rehabil Hosp, Fuzhou 350003, Peoples R China.
   [Chen, Shuijin; Chen, Lechun; Jiang, Yu; Zhang, Huanzhen; Chen, Jincheng; Lin, Zhigang] Fujian Prov Key Lab Rehabil Technol, Fuzhou 350003, Peoples R China.
   [Wang, Bingqian] Peking Univ, Int Hosp, Beijing 102206, Peoples R China.
C3 Fujian University of Traditional Chinese Medicine; Fujian University of Traditional Chinese Medicine; Peking University
RP Lin, ZG (corresponding author), Fujian Univ Tradit Chinese Med, Subsidiary Rehabil Hosp, Fuzhou 350003, Peoples R China.
EM linzhigang@fjtcm.edu.cn
FU Effects of Tuina Point Press on AMPA/NMDA Receptor Scaffold Protein and Synaptic Plasticity in Spinal Dorsal Horn of Rats with Neuropathic Pain [2020CXA052] Funding Source: Medline; Study on Analgesic Mechanism of Tuina on Neuropathic Pain in Spinal Dorsal Horn/ACC Brain Region based on PKA-NMDA-NR2B Pathway [2020J01758] Funding Source: Medline; Natural Science Foundation-funded Project: Study on the Mechanism of Tuina and Tuina in Regulating the Synaptic Plasticity of Spinal Dorsal Horn in Lumbar Disc Herniation Based on LncRNA-HOTAIR/miR-219 Mediated NMDAR Pathway [82174523] Funding Source: Medline; Natural Science Foundation of Fujian Province: Study on the Mechanism of Tuina Regulating the Synaptic Plasticity of Spinal Dorsal Horn in Lumbar Disc Herniation based on NMDAR-CAMK2-CREB Pathway [2020J01757] Funding Source: Medline; Fujian Health Science and Technology Program: Study on the Analgesic Mechanism of Tuina Manipulation On Lumbar Disc Herniation from the Efficacy of miR-219/NR2B Mediated Synaptic Transmission [2020GGA070] Funding Source: Medline
CR Ai J, 2020, MEDICINE, V99, P0, DOI 10.1097/MD.0000000000019332
   Alomar SY, 2021, PHARMACEUTICALS-BASE, V14, P0, DOI 10.3390/ph14040307
   BENNETT GJ, 1988, PAIN, V33, P87, DOI 10.1016/0304-3959(88)90209-6
   Berger JV, 2011, BRAIN RES REV, V67, P282, DOI 10.1016/j.brainresrev.2011.03.003
   Bittar A, 2017, PAIN, V158, P2137, DOI 10.1097/j.pain.0000000000001014
   Borja GB, 2021, METHODS MOL BIOL, V2191, P109, DOI 10.1007/978-1-0716-0830-2_8
   CHAPLAN SR, 1994, J NEUROSCI METH, V53, P55, DOI 10.1016/0165-0270(94)90144-9
   Chen J, 2011, PAIN, V152, P1165, DOI 10.1016/j.pain.2011.01.049
   Chen LC, 2020, FU JIAN YI KE XUE XU, V54, P291
   DMello R, 2011, MOL THER, V19, P1780, DOI 10.1038/mt.2011.42
   Deng MC, 2019, CELL MOL LIFE SCI, V76, P1889, DOI 10.1007/s00018-019-03047-y
   Duarte RV, 2020, PAIN, V161, P24, DOI 10.1097/j.pain.0000000000001689
   Gao Yong-Hui, 2009, ZHEN CI YAN JIU, V34, P376
   Gui XW, 2020, CELL BIOSCI, V10, P0, DOI 10.1186/s13578-020-00405-3
   GULDNER FH, 1980, NEUROSCI LETT, V17, P27, DOI 10.1016/0304-3940(80)90056-7
   Guo W, 2007, J NEUROSCI, V27, P6006, DOI 10.1523/JNEUROSCI.0176-07.2007
   Huang LE, 2018, SCI REP-UK, V8, P0, DOI 10.1038/s41598-018-26209-7
   Jiang HL, 2016, J TRADIT CHIN MED, V36, P85
   JONES DG, 1978, BRAIN RES, V147, P47, DOI 10.1016/0006-8993(78)90771-0
   Kawasaki Y, 2008, J NEUROSCI, V28, P5189, DOI 10.1523/JNEUROSCI.3338-07.2008
   Kuner R, 2017, NAT REV NEUROSCI, V18, P20, DOI 10.1038/nrn.2016.162
   Li MJ, 2017, PAIN, V158, P717, DOI 10.1097/j.pain.0000000000000827
   Li S, 2011, J NEUROSCI RES, V89, P1869, DOI 10.1002/jnr.22719
   Liang F, 2017, SAUDI PHARM J, V25, P649, DOI 10.1016/j.jsps.2017.04.039
   Liao WT, 2020, BRAIN RES BULL, V164, P307, DOI 10.1016/j.brainresbull.2020.09.005
   Lin TB, 2015, ANESTHESIOLOGY, V123, P909, DOI 10.1097/ALN.0000000000000809
   [林志刚 Lin Zhigang], 2020, 中华中医药杂志 CHINA JOURNAL OF TRADITIONAL CHINESE MEDICINE AND PHARMACY, V35, P927
   Loftis JM, 2003, PHARMACOL THERAPEUT, V97, P55, DOI 10.1016/S0163-7258(02)00302-9
   Lu LJ, 2017, J MOL CELL BIOL, V9, P132, DOI 10.1093/jmcb/mjw043
   Luo HB, 2019, CHIN HERB MED, V11, P438, DOI 10.1016/j.chmed.2019.03.005
   Osikowicz M, 2013, EXP PHYSIOL, V98, P372, DOI 10.1113/expphysiol.2012.069922
   Park Chang Hyun, 2016, APPLIED MICROSCOPY 한국현미경학회지, V46, P188, DOI 10.9729/am.2016.46.4.188
   Peng B, 2010, NEUROSCI LETT, V486, P24, DOI 10.1016/j.neulet.2010.09.037
   Peterson CD, 2021, MOL PAIN, V17, P0, DOI 10.1177/17448069211029171
   Qu XX, 2009, EXP NEUROL, V215, P298, DOI 10.1016/j.expneurol.2008.10.018
   RIVLIN AS, 1977, J NEUROSURG, V47, P577, DOI 10.3171/jns.1977.47.4.0577
   Roh DH, 2010, EXP NEUROL, V224, P123, DOI 10.1016/j.expneurol.2010.03.002
   Smith BH, 2020, PAIN, V161, PS127, DOI 10.1097/j.pain.0000000000001824
   Sung BK, 2003, J NEUROSCI, V23, P2899
   Vissers K, 2005, ANESTH ANALG, V101, P457, DOI 10.1213/01.ANE.0000158471.41575.F0
   Wang J, 2017, MOL PAIN, V13, P0, DOI 10.1177/1744806917746564
   Wang XY, 2018, J HEADACHE PAIN, V19, P0, DOI 10.1186/s10194-018-0935-2
   Wang ZF, 2019, J CEREBR BLOOD F MET, V39, P1588, DOI 10.1177/0271678X18762637
   Wu QY, 2021, MOL PAIN, V17, P0, DOI 10.1177/1744806921997654
   Wu ZW, 2019, TRIALS, V20, P0, DOI 10.1186/s13063-018-3096-3
   Xu FX, 2017, NEUROREPORT, V28, P856, DOI 10.1097/WNR.0000000000000849
   Xu QL, 2012, NEURAL REGEN RES, V7, P1378, DOI 10.3969/j.issn.1673-5374.2012.18.003
   Yan XS, 2013, J BIOL CHEM, V288, P30544, DOI 10.1074/jbc.M113.495465
   Yu TY, 2012, ANMO TUINA XUE, V3rd, P3
   Zhang SP, 2020, TRIALS, V21, P0, DOI 10.1186/s13063-020-4198-2
NR 50
TC 8
Z9 13
U1 3
U2 20
PU JOURNAL TRADITIONAL CHINESE MED
PI BEIJING
PA 16 NANXIAOJIE, DONGZHIMEN NEI, BEIJING, 100700, PEOPLES R CHINA
SN 0255-2922
EI 1577-7014
J9 J TRADIT CHIN MED
JI J. Tradit. Chin. Med.
PD AUG 15
PY 2023
VL 43
IS 4
BP 715
EP 724
DI 10.19852/j.cnki.jtcm.20221214.002
PG 10
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA M8DJ6
UT WOS:001032463500001
PM 37454256
DA 2026-01-16
ER

PT J
AU Zhang, X
   Wang, A
   Wang, MW
   Li, G
   Wei, Q
AF Zhang, Xia
   Wang, Ao
   Wang, Miaowei
   Li, Guo
   Wei, Quan
TI Non-pharmacological therapy for chemotherapy-induced peripheral neurotoxicity: a network meta-analysis of randomized controlled trials
SO BMC NEUROLOGY
LA English
DT Article
DE Chemotherapy; Adjuvant; Peripheral nervous system diseases; Randomized controlled trial
ID colorectal-cancer; neuropathy; prevention; massage
AB BackgroundChemotherapy-induced peripheral neurotoxicity (CIPN) is the most common adverse effect in patients undergoing chemotherapy, and no effective interventions are currently available for its prevention and treatment. Non-pharmacological therapies appear to be beneficial for the prevention and treatment of CIPN, but it remains unclear which therapy is most effective. The aim of this study was to identify the most effective non-pharmacological therapy for CIPN patients.MethodsPubMed, Web of Science, Embase, and Cochrane Library were searched for randomized controlled trials on non-pharmacological therapies for CIPN. The primary outcomes included pain and peripheral neuropathological symptoms, and the secondary outcomes included quality of life, sensory and motor symptoms. The pairwise analysis and a network meta-analysis were performed using a random effects model.ResultsA total of 46 articles were included in this study, involving 2,878 participants. Our study showed that massage was more effective in pain-alleviating compared with acupuncture [SMD = 0.81, 95%CI (0.04, 1.57)], vitamin and gabapentin [SMD = 2.56, 95%CI (1.39, 3.74)], and usual care and placebo [SMD = 0.9, 95%CI (0.31, 1.49)]. As for attenuating peripheral neuropathological symptoms, massage was more effective than usual care and placebo [SMD = 0.75, 95%CI (0.33, 1.17)], sensorimotor training [SMD = 1.17, 95%CI (0.24, 2.10)], electrostimulation [SMD=-1.18, 95%CI (-2.14, -0.21)], multimodal exercise [SMD=-0.82, 95%CI (-1.57, -0.08)], and resistance training [SMD = 1.03, 95%CI (0.11, 1.95)]. Massage was also more effective than other non-pharmacological therapies in improving quality of life, sensory and motor symptoms.ConclusionsAccording to our study, massage has advantages in alleviating pain, improving quality of life, and improving peripheral neuropathological symptoms and has better effect than other non-pharmacological interventions, representing certain clinical significance. However, the results of this study should be interpreted with caution due to the limitations of the included studies. In the future, more high-quality multi arm randomized controlled trials can be attempted to provide direct comparisons of the relative effects of non-pharmacological interventions.
C1 [Zhang, Xia; Wang, Ao; Wang, Miaowei; Li, Guo; Wei, Quan] Sichuan Univ, West China Hosp, Inst Rehabil Med, Rehabil Med Ctr, Chengdu, Sichuan, Peoples R China.
   [Zhang, Xia; Wang, Ao; Wang, Miaowei; Li, Guo; Wei, Quan] Key Lab Rehabil Med Sichuan Prov, Chengdu, Sichuan, Peoples R China.
C3 Sichuan University
RP Wei, Q (corresponding author), Sichuan Univ, West China Hosp, Inst Rehabil Med, Rehabil Med Ctr, Chengdu, Sichuan, Peoples R China.; Wei, Q (corresponding author), Key Lab Rehabil Med Sichuan Prov, Chengdu, Sichuan, Peoples R China.
EM weiquan@scu.edu.cn
CR Al Onazi MM, 2021, J PAIN SYMPTOM MANAG, V61, P1127, DOI 10.1016/j.jpainsymman.2020.10.028
   Bao T, 2021, ONCOLOGIST, V26, PE2070, DOI 10.1002/onco.13933
   Bao T, 2020, JNCI CANCER SPECT, V4, P0, DOI 10.1093/jncics/pkaa048
   Bao T, 2020, JAMA NETW OPEN, V3, P0, DOI 10.1001/jamanetworkopen.2020.0681
   Bland KA, 2019, CLIN BREAST CANCER, V19, P411, DOI 10.1016/j.clbc.2019.05.013
   Cao A, 2023, JAMA NETW OPEN, V6, P0, DOI 10.1001/jamanetworkopen.2023.26463
   Chan KY, 2023, ACUPUNCT MED, V41, P268, DOI 10.1177/09645284221125421
   Chien TJ, 2019, INTEGR CANCER THER, V18, P0, DOI 10.1177/1534735419886662
   Chitkumarn P, 2022, SUPPORT CARE CANCER, V30, P4835, DOI 10.1007/s00520-022-06890-1
   Cornell JE, 2015, ANN INTERN MED, V162, P797, DOI 10.7326/M15-0930
   Cumpston M, 2019, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.ED000142
   Cunningham JE, 2011, SUPPORT CARE CANCER, V19, P1473, DOI 10.1007/s00520-011-1231-8
   DAlessandro EG, 2022, BMJ SUPPORT PALLIAT, V12, P64, DOI 10.1136/bmjspcare-2018-001542
   Dalal K, 2014, EVID-BASED COMPL ALT, V2014, P0, DOI 10.1155/2014/843036
   Flatters SJL, 2017, BRIT J ANAESTH, V119, P737, DOI 10.1093/bja/aex229
   Friedemann T, 2022, PHYTOMEDICINE, V104, P0, DOI 10.1016/j.phymed.2022.154294
   GHOLAMZADEH H, 2023, TURKISH J ONCOL, V38, P0
   Greenlee H, 2016, BREAST CANCER RES TR, V156, P453, DOI 10.1007/s10549-016-3759-2
   Hammond EA, 2020, NEUROREHAB NEURAL RE, V34, P235, DOI 10.1177/1545968319899918
   Huang CC, 2021, J CLIN MED, V10, P0
   Huang MC, 2023, ONCOLOGIST, V28, PE436, DOI 10.1093/oncolo/oyad065
   Ikio Y, 2022, SUPPORT CARE CANCER, V30, P4981, DOI 10.1007/s00520-022-06846-5
   Iravani S, 2020, PAIN RES MANAG, V2020, P0, DOI 10.1155/2020/2504674
   Izgu N, 2019, EUR J ONCOL NURS, V40, P36, DOI 10.1016/j.ejon.2019.03.002
   Izgu N, 2019, CANCER NURS, V42, P139, DOI 10.1097/NCC.0000000000000577
   Joy L, 2022, SUPPORT CARE CANCER, V30, P5509, DOI 10.1007/s00520-022-06975-x
   Jung MS, 2023, CANCER NURSING, V0, P0
   Kanda K, 2023, ASIA-PAC J ONCOL NUR, V10, P0, DOI 10.1016/j.apjon.2023.100198
   Kanzawa-Lee GA, 2022, CANCER NURS, V45, PE531, DOI 10.1097/NCC.0000000000001003
   Kim SY, 2021, ASIAN ONCOL NURS, V21, P129, DOI 10.5388/aon.2021.21.3.129
   Kneis S, 2019, BMC CANCER, V19, P0, DOI 10.1186/s12885-019-5522-7
   Knoerl R, 2022, J CANCER SURVIV, V16, P882, DOI 10.1007/s11764-021-01081-z
   Knoerl R, 2018, BMC CANCER, V18, P0, DOI 10.1186/s12885-018-5093-z
   Knoerl R, 2018, J PAIN, V19, P382, DOI 10.1016/j.jpain.2017.11.009
   Kurt S, 2018, EUR J ONCOL NURS, V32, P12, DOI 10.1016/j.ejon.2017.11.001
   Lai XB, 2019, CANCER NURS, V42, P20, DOI 10.1097/NCC.0000000000000539
   Loprinzi CL, 2020, J CLIN ONCOL, V38, P0, DOI 10.1200/JCO.20.01399
   Lu WD, 2020, ONCOLOGIST, V25, P310, DOI 10.1634/theoncologist.2019-0489
   Molassiotis A, 2019, INTEGR CANCER THER, V18, P0, DOI 10.1177/1534735419836501
   Moyer CA, 2004, PSYCHOL BULL, V130, P3, DOI 10.1037/0033-2909.130.1.3
   Müller J, 2021, BRIT J CANCER, V125, P955, DOI 10.1038/s41416-021-01471-1
   Noh GO, 2019, EUR J ONCOL NURS, V42, P82, DOI 10.1016/j.ejon.2019.08.007
   Oh PJ, 2018, J KOREAN ACAD NURS, V48, P123, DOI 10.4040/jkan.2018.48.2.123
   Park SB, 2013, CA-CANCER J CLIN, V63, P419, DOI 10.3322/caac.21204
   Prinsloo S, 2018, J PAIN SYMPTOM MANAG, V55, P1276, DOI 10.1016/j.jpainsymman.2018.01.010
   Rahmati M, 2023, J MED VIROL, V95, P0, DOI 10.1002/jmv.28325
   Rahmati M, 2023, J MED VIROL, V95, P0, DOI 10.1002/jmv.28298
   Rostock M, 2013, EVID-BASED COMPL ALT, V2013, P0, DOI 10.1155/2013/349653
   Saraboon C, 2021, J BODYW MOV THER, V28, P164, DOI 10.1016/j.jbmt.2021.07.013
   Schönsteiner SS, 2017, EXP HEMATOL ONCOL, V5, P0, DOI 10.1186/s40164-017-0065-6
   Seretny M, 2014, PAIN, V155, P2461, DOI 10.1016/j.pain.2014.09.020
   Shigematsu H, 2020, SUPPORT CARE CANCER, V28, P5005, DOI 10.1007/s00520-020-05345-9
   Smith TJ, 2020, J PALLIAT CARE, V35, P53, DOI 10.1177/0825859719827589
   Song SY, 2020, INTEGR CANCER THER, V19, P0, DOI 10.1177/1534735420925519
   Staff NP, 2017, ANN NEUROL, V81, P772, DOI 10.1002/ana.24951
   Streckmann F, 2022, SPORTS MED, V52, P1043, DOI 10.1007/s40279-021-01596-6
   Streckmann F, 2019, SUPPORT CARE CANCER, V27, P2471, DOI 10.1007/s00520-018-4531-4
   Stringer J, 2022, EUR J ONCOL NURS, V60, P0, DOI 10.1016/j.ejon.2022.102171
   Teng C, 2023, SUPPORT CARE CANCER, V31, P0, DOI 10.1007/s00520-022-07463-y
   Waibel S, 2021, ANN CLIN TRANSL NEUR, V8, P1680, DOI 10.1002/acn3.51426
   Zajaczkowska R, 2019, INT J MOL SCI, V20, P0, DOI 10.3390/ijms20061451
   Zimmer P, 2018, SUPPORT CARE CANCER, V26, P615, DOI 10.1007/s00520-017-3875-5
NR 62
TC 8
Z9 8
U1 2
U2 22
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 
EI 1471-2377
J9 BMC NEUROL
JI BMC Neurol.
PD DEC 11
PY 2023
VL 23
IS 1
BP 
EP 
DI 10.1186/s12883-023-03485-z
PG 14
WC Clinical Neurology
SC Neurosciences & Neurology
GA CF1W0
UT WOS:001123754100006
PM 38082216
DA 2026-01-16
ER

PT J
AU Mao, Q
   Huang, B
   Zhu, D
   Wang, Y
   Xu, S
   Wu, D
   Huang, G
   Li, Z
   Chi, Z
   Chen, R
AF Mao, Qiangjian
   Huang, Biao
   Zhu, Daocheng
   Wang, Yuqing
   Xu, Shiqi
   Wu, Desheng
   Huang, Guomin
   Li, Ziru
   Chi, Zhenhai
   Chen, Rixin
TI A Bibliometric Analysis of Acupuncture Therapy in the Treatment of
SO Journal of pain research
LA English
DT Review
DE CiteSpace; acupuncture therapy; bibliometrics; musculoskeletal pain
AB BACKGROUND: Acupuncture therapy has been widely used in the treatment of  musculoskeletal pain (MP) in many countries around the world. However, there are  no bibliometric studies on acupuncture therapy for MP. Therefore, the aim of this  study was to analyze the current status, frontiers and hot spots in the use of  acupuncture therapy for the treatment of MP. METHODS: Literature on acupuncture  therapy for MP was extracted from the Web of Science Core Collection database  from 2003 to 2022. CiteSpace 6.2.R4 (64-bit) software was used to analyze the  number and centrality of journals, countries, institutions, authors, references  and keywords, and the functions of co-occurrence and clustering were applied to  draw a visual knowledge map. RESULTS: Over the past 20 years, the annual journal  publications have been on a steady upward trend, with 438 articles published in  143 journals, including Acupuncture in Medicine Journal published the most (28,  6.39%), JAMA-Journal of the American Medical Association was the journal with the  highest impact factor (IF = 120.7003), USA dominated with the most publications  (140, 31.96%) among 44 countries, and among 196 research organizations Kyung Hee  University was the most prolific (19, 4.34%) and Ha, In-Hyuk was the most  published author (9, 2.05%). "Acupuncture" is the most popular and highly sought  after keywords. "Low back pain" is the keyword with the highest centrality.  CONCLUSION: This article provides the current situation of the use of acupuncture  therapy in the treatment of MP in the past 20 years, and statistical analysis  reveals that "low back pain", "knit osteoporosis" and "break cancer" are new  research diseases related to acupuncture therapy for MP, and "myobasic trigger  point" is a new research direction of acupuncture therapy for MP. Therefore, this  study helps researchers grasp the research hotspots and provide certain  references for in-depth research and future topic selection.
C1 The Affiliated Hospital of Jiangxi University of Chinese Medicine, Nanchang, Jiangxi, People's Republic of China.
   The Affiliated Hospital of Jiangxi University of Chinese Medicine, Nanchang, Jiangxi, People's Republic of China.
   The Affiliated Hospital of Jiangxi University of Chinese Medicine, Nanchang, Jiangxi, People's Republic of China.
   Jiangxi University of Chinese Medicine, Nanchang, Jiangxi, People's Republic of China.
   Jiangxi University of Chinese Medicine, Nanchang, Jiangxi, People's Republic of China.
   The Affiliated Hospital of Jiangxi University of Chinese Medicine, Nanchang, Jiangxi, People's Republic of China.
   The Affiliated Hospital of Jiangxi University of Chinese Medicine, Nanchang, Jiangxi, People's Republic of China.
   The Affiliated Hospital of Jiangxi University of Chinese Medicine, Nanchang, Jiangxi, People's Republic of China.
   The Affiliated Hospital of Jiangxi University of Chinese Medicine, Nanchang, Jiangxi, People's Republic of China.
   The Affiliated Hospital of Jiangxi University of Chinese Medicine, Nanchang, Jiangxi, People's Republic of China.
NR 0
TC 0
SN 1178-709
EI 1178-709
J9 J Pain Res
PD NOV 29
PY 2023
VL 16
IS 
BP 3853
EP 3870
DI 10.2147/JPR.S431689
PG 17
UT PubMed:38026461
PM 38026461
DA 2023-11-29
ER

PT J
AU Hou, YC
   Lu, JJ
   Xie, J
   Zhu, RJ
   Wu, MD
   Wang, K
   Zhou, J
   Li, J
AF Hou, Yuchao
   Lu, Jiajing
   Xie, Jing
   Zhu, Runjia
   Wu, Mengdie
   Wang, Ke
   Zhou, Jia
   Li, Jing
TI Effects of electroacupuncture on perioperative anxiety and stress response in patients undergoing surgery for gastric or colorectal cancer: Study protocol for a randomized controlled trial
SO FRONTIERS IN PSYCHIATRY
LA English
DT Article
DE perioperative anxiety; stress response; electroacupuncture; surgery; randomized controlled clinical trial (RCT)
ID preoperative anxiety; enhanced recovery; gastrointestinal surgery; state anxiety; yintang point; short-form; acupuncture; scale; acupressure; analgesia
AB Background Perioperative anxiety is one of the main psychological stresses experienced by patients who undergo cancer surgery. The surgery itself inevitably causes a stress response characterized by activation of the sympathetic nervous system and the hypothalamic-pituitary-adrenal axis. Both the perioperative anxiety and surgical stress response lead to increased levels of catecholamines and prostaglandins, which may be related to perioperative suppression of antimetastatic immunity and tumor-promoting alterations in the microenvironment. Hence, we designed this clinical trial to investigate the effect of electroacupuncture in reducing perioperative anxiety and surgical stress response.Methods This is a randomized, single-center, parallel, and controlled clinical trial. Seventy-eight participants between the ages of 35 and 85 with gastric or colorectal cancer who plan to undergo tumorectomy will be randomly divided into an electroacupuncture group and a control group. The primary outcome will be the six-item short form of the State-Trait Anxiety Inventory score. The secondary outcomes will be the Amsterdam Preoperative Anxiety and Information Scale score; levels of plasma cortisol, adrenocorticotropic hormone, interleukin-6, and tumor necrosis factor-alpha; first exhaust time after surgery; postoperative quality of the recovery-15 score, numeric rating scale for pain score; and dosage of postoperative analgesics.Discussion Cumulative studies revealed the efficacy of various types of acupuncture therapy with regard to reducing the anxiety and stress response caused by surgery. We expect that the results of this trial will provide high-quality clinical evidence for the choice of perioperative acupuncture for patients undergoing cancer surgery.
C1 [Hou, Yuchao; Lu, Jiajing; Xie, Jing; Zhu, Runjia; Wu, Mengdie; Wang, Ke; Zhou, Jia; Li, Jing] Shanghai Univ Tradit Chinese Med, Yueyang Hosp Integrated Tradit Chinese & Western M, Shanghai, Peoples R China.
C3 Shanghai University of Traditional Chinese Medicine
RP Zhou, J; Li, J (corresponding author), Shanghai Univ Tradit Chinese Med, Yueyang Hosp Integrated Tradit Chinese & Western M, Shanghai, Peoples R China.
EM pdzhoujia@163.com; lj0806@hotmail.com
FU BEBPC-TCM [2019XZZX-ZJ0011]; Accelerating the Development of Chinese Medicine Three-Year Action Plan of Shanghai [ZY(2018-2020)-CCCX-2004-04]; Clinical Key Specialty Construction Foundation of Shanghai [shslczdzk04701]; Shanghai Clinical Research Center for Acupuncture and Moxibustion [20MC1920500]; Three-year Action Plan of Shanghai Municipality to Further Accelerate the Inheritance, Innovation and Development of Traditional Chinese Medicine [ZY(2021-2023)-0302]
CR Abraham J, 2020, AM J GERIAT PSYCHIAT, V28, P1107, DOI 10.1016/j.jagp.2020.02.010
   Acar HV, 2013, J ALTERN COMPLEM MED, V19, P420, DOI 10.1089/acm.2012.0494
   Agarwal A, 2005, ANAESTHESIA, V60, P978, DOI 10.1111/j.1365-2044.2005.04332.x
   Aust H, 2018, J PSYCHOSOM RES, V111, P133, DOI 10.1016/j.jpsychores.2018.05.012
   Bae H, 2014, EVID-BASED COMPL ALT, V2014, P0, DOI 10.1155/2014/850367
   Chan AW, 2013, ANN INTERN MED, V158, P200, DOI 10.7326/0003-4819-158-3-201302050-00583
   Chan AW, 2013, BMJ-BRIT MED J, V346, P0, DOI 10.1136/bmj.e7586
   Dalamagka M, 2015, ACUPUNCT MED, V33, P360, DOI 10.1136/acupmed-2014-010689
   Desborough JP, 2000, BRIT J ANAESTH, V85, P109, DOI 10.1093/bja/85.1.109
   Dunn AJ, 2000, ANN NY ACAD SCI, V917, P608, DOI 10.1111/j.1749-6632.2000.tb05426.x
   Eddy JL, 2014, CELL IMMUNOL, V290, P120, DOI 10.1016/j.cellimm.2014.05.013
   Feldheiser A, 2016, ACTA ANAESTH SCAND, V60, P289, DOI 10.1111/aas.12651
   Gioia L, 2006, J CATARACT REFR SURG, V32, P1951, DOI 10.1016/j.jcrs.2006.06.027
   Gustafsson UO, 2019, WORLD J SURG, V43, P659, DOI 10.1007/s00268-018-4844-y
   Hawker GA, 2011, ARTHRIT CARE RES, V63, PS240, DOI 10.1002/acr.20543
   Hiller JG, 2018, NAT REV CLIN ONCOL, V15, P205, DOI 10.1038/nrclinonc.2017.194
   Hole J, 2015, LANCET, V386, P1659, DOI 10.1016/S0140-6736(15)60169-6
   Horowitz M, 2015, NAT REV CLIN ONCOL, V12, P213, DOI 10.1038/nrclinonc.2014.224
   Huang HM, 2022, FRONT NEUROL, V13, P0, DOI 10.3389/fneur.2022.930753
   Jung WM, 2015, SCI REP-UK, V5, P0, DOI 10.1038/srep12455
   Kim-Fuchs C, 2014, BRAIN BEHAV IMMUN, V40, P40, DOI 10.1016/j.bbi.2014.02.019
   Kleif J, 2018, BRIT J ANAESTH, V120, P28, DOI 10.1016/j.bja.2017.11.013
   Klopfenstein CE, 2000, CAN J ANAESTH, V47, P511, DOI 10.1007/BF03018941
   Kotani N, 2001, ANESTHESIOLOGY, V95, P349, DOI 10.1097/00000542-200108000-00015
   Le CP, 2016, NAT COMMUN, V7, P0, DOI 10.1038/ncomms10634
   MacPherson H, 2002, J ALTERN COMPLEM MED, V8, P85, DOI 10.1089/107555302753507212
   MALIZIA E, 1979, LANCET, V2, P535
   MARTEAU TM, 1992, BRIT J CLIN PSYCHOL, V31, P301, DOI 10.1111/j.2044-8260.1992.tb00997.x
   Michalek-Sauberer A, 2012, CLIN ORAL INVEST, V16, P1517, DOI 10.1007/s00784-011-0662-4
   Moerman N, 1996, ANESTH ANALG, V82, P445, DOI 10.1097/00000539-199603000-00002
   Mortensen K, 2014, BRIT J SURG, V101, P1209, DOI 10.1002/bjs.9582
   Neeman E, 2013, BRAIN BEHAV IMMUN, V30, PS32, DOI 10.1016/j.bbi.2012.03.006
   Ni CY, 2018, INT J SURG, V54, P254, DOI 10.1016/j.ijsu.2018.04.060
   Paraskeva A, 2004, AM J CHINESE MED, V32, P789, DOI 10.1142/S0192415X04002363
   Powell R, 2016, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD008646.pub2
   Scott MJ, 2015, ACTA ANAESTH SCAND, V59, P1212, DOI 10.1111/aas.12601
   Singleton N, 2017, J ORTHOP SURG-HONG K, V25, P0, DOI 10.1177/2309499017718902
   Stamenkovic DM, 2018, MINERVA ANESTESIOL, V84, P1307, DOI 10.23736/S0375-9393.18.12520-X
   Stark PA, 2013, ANESTHESIOLOGY, V118, P1332, DOI 10.1097/ALN.0b013e318289b84b
   Tluczek A, 2009, J NURS MEAS, V17, P19, DOI 10.1891/1061-3749.17.1.19
   Wang SZ, 2010, WORLD J UROL, V28, P451, DOI 10.1007/s00345-010-0571-1
   Wang SM, 2005, ANESTH ANALG, V101, P666, DOI 10.1213/01.ANE.0000175212.17642.45
   Wiles MD, 2017, ANAESTHESIA, V72, P335, DOI 10.1111/anae.13785
   Wong LP, 2020, TRANSBOUND EMERG DIS, V67, P2892, DOI 10.1111/tbed.13662
   Wu H, 2020, HEALTH QUAL LIFE OUT, V18, P0, DOI 10.1186/s12955-020-01294-3
   Wunsch JK, 2018, ACUPUNCT MED, V36, P222, DOI 10.1136/acupmed-2017-011456
   Xu YJ, 2020, BJS-BRIT J SURG, V107, PE133, DOI 10.1002/bjs.11403
   Yuan W, 2019, CHINESE MED J-PEKING, V132, P707, DOI 10.1097/CM9.0000000000000123
   Zhang BH, 2018, FRONT PHARMACOL, V8, P0, DOI 10.3389/fphar.2017.00940
NR 49
TC 9
Z9 11
U1 2
U2 24
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-0640
EI 
J9 FRONT PSYCHIATRY
JI Front. Psychiatry
PD FEB 23
PY 2023
VL 14
IS 
BP 
EP 
DI 10.3389/fpsyt.2023.1095650
PG 7
WC Psychiatry
SC Psychiatry
GA 9S2ZL
UT WOS:000946214500001
PM 36911113
DA 2026-01-16
ER

PT J
AU Nguyen, MD
   Tran, TV
   Nguyen, QV
   Ha, CD
   Dang, LVP
AF Nguyen, Minh Duc
   Tran, Thanh Van
   Nguyen, Quoc Vinh
   Ha, Cay Doan
   Dang, Linh Vu Phuong
TI Effectiveness of bee venom acupuncture for patients suffering from periarthritis humeroscapularis
SO JOURNAL OF TRADITIONAL CHINESE MEDICINE
LA English
DT Article
DE periarthritis humeroscapularis; bee venom acupuncture; visual analogue scale; range of motion; articular; shoulder function score; inflammatory cytokines
ID shoulder pain; disorders
AB OBJECTIVE: To evaluate the efficacy of bee venom acupuncture in humeroscapularis (PHS) patients. METHODS: One hundred and twenty patients diagnosed with PHS were assigned into four groups: BV1 (0.01 mg/kg), BV2 (0.005 mg/kg), BV3 (0.0025 mg/kg), and control group (vitamin B1 plus novocain 3% injection) with 15 d of treatment. The outcomes of the study including visual analogue scale (VAS) score and [3-endorphin, inflammatory cytokines including interleukin-10 (IL-10), IL-1[3 and tumor necrosis factor & alpha; (TNF-& alpha;) and shoulder function score were assessed at baseline, after 10 and 15 d of treatment. RESULTS: All four groups reported statistically significant improvement in VAS score, motion range, and shoulder function score (P < 0.01), only the BV3 group showed significant increase of anti-inflammatory (IL-10) and decrease of pro-inflammatory (IL-1[3, TNF-& alpha;) cytokines after treatment (P < 0.05). The BV3 group presented a significant difference between all outcomes compared to the control and other groups. CONCLUSION: BV3 groups showed better recovery including reduced pain, improved motor function and normalized inflammatory cytokines than current therapy used in Vietnam and other groups. & COPY; 2023 JTCM. All rights reserved.
C1 [Nguyen, Minh Duc] Natl Hosp Acupuncture, Specialist Clin, Hanoi 1000, Vietnam.
   [Tran, Thanh Van] Natl Hosp Acupuncture, Dept Sr Specialist, Hanoi 1000, Vietnam.
   [Nguyen, Quoc Vinh] Mil Inst Tradit Med, Dept Sr Specialist, Hanoi 1000, Vietnam.
   [Ha, Cay Doan] Natl Hosp Acupuncture, Dept Minimally Invas Spine, Hanoi 1000, Vietnam.
   [Dang, Linh Vu Phuong] Dai Nam Univ, Dept Med, Hanoi 1000, Vietnam.
RP Dang, LVP (corresponding author), Dai Nam Univ, Dept Med, Hanoi 1000, Vietnam.
EM phuonglinh.j@gmail.com
CR Asheghan Mahsa, 2016, MATER SOCIOMED, V28, P253, DOI 10.5455/msm.2016.28.253-257
   Ben-Arie E, 2020, EVID-BASED COMPL ALT, V2020, P0, DOI 10.1155/2020/9790470
   Brien S, 2004, EVID-BASED COMPL ALT, V1, P251, DOI 10.1093/ecam/neh035
   Chen Jun, 2008, SHENGLI XUEBAO, V60, P645
   Chung HJ, 2016, PLOS ONE, V11, P0, DOI 10.1371/journal.pone.0168120
   CONSTANT CR, 1987, CLIN ORTHOP RELAT R, V0, P160
   Cyriax J, 1982, TXB ORTHOPAEDICS MED, V2nd, P191
   DUELTGEN C, 1960, ARCH PHYS THER (LEIPZ), V12, P123
   Gu SM, 2015, J NEUROINFLAMM, V12, P0, DOI 10.1186/s12974-015-0344-2
   Ham HJ, 2019, TRANSL NEURODEGENER, V8, P0, DOI 10.1186/s40035-019-0167-7
   Hand GCR, 2007, J BONE JOINT SURG BR, V89B, P928, DOI 10.1302/0301-620X.89B7.19097
   Kim YS, 2005, EVID-BASED COMPL ALT, V2, P325, DOI 10.1093/ecam/neh102
   KOBUROVA K L, 1985, ACTA PHYSIOLOGICA ET PHARMACOLOGICA BULGARICA, V11, P50
   Koh PS, 2013, J SHOULDER ELB SURG, V22, P1053, DOI 10.1016/j.jse.2012.10.045
   Kwon YB, 2001, PAIN, V90, P271, DOI 10.1016/S0304-3959(00)00412-7
   Lee JD, 2005, EVID-BASED COMPL ALT, V2, P79, DOI 10.1093/ecam/neh070
   Lee JA, 2014, BMJ OPEN, V4, P0, DOI 10.1136/bmjopen-2014-006140
   Lee MS, 2008, J PAIN, V9, P289, DOI 10.1016/j.jpain.2007.11.012
   Lee SH, 2016, EVID-BASED COMPL ALT, V2016, P0, DOI 10.1155/2016/3549878
   Lee WR, 2015, TOXINS, V7, P4758, DOI 10.3390/toxins7114758
   Li D, 2016, TOXINS BASEL, V0, P8
   Lim SM, 2015, J INTEGR MED-JIM, V13, P241, DOI 10.1016/S2095-4964(15)60178-9
   Niewald M, 2007, RADIAT ONCOL, V2, P0, DOI 10.1186/1748-717X-2-34
   OLDBERG S, 1972, UPSALA J MED SCI, V77, P143, DOI 10.1517/03009734000000022
   Park HJ, 2007, BIOCHEM PHARMACOL, V73, P237, DOI 10.1016/j.bcp.2006.09.023
   Park JH, 2010, INT J TOXICOL, V29, P49, DOI 10.1177/1091581809353948
   PENG CHL, 1978, COMP MED EAST WEST, V6, P57, DOI 10.1142/S0147291778000083
   Shen L, 2020, J PHARMACOPUNCT, V23, P44, DOI 10.3831/KPI.2020.23.008
   Sung SH, 2021, TOXINS BASEL, V0, P13
   Szczudlik A, 1983, NEUROL NEUROCHIR POL, V17, P535
   Urwin M, 1998, ANN RHEUM DIS, V57, P649, DOI 10.1136/ard.57.11.649
   vanderWindt DAWM, 1996, BRIT J GEN PRACT, V46, P519
   WAGENHAUFJ, 1969, DEUT MED WOCHENSCHR, V94, P1579, DOI 10.1055/s-0028-1110306
   Wang J, 1993, J TRADIT CHIN MED, V13, P262
NR 34
TC 6
Z9 7
U1 1
U2 4
PU JOURNAL TRADITIONAL CHINESE MED
PI BEIJING
PA 16 NANXIAOJIE, DONGZHIMEN NEI, BEIJING, 100700, PEOPLES R CHINA
SN 0255-2922
EI 1577-7014
J9 J TRADIT CHIN MED
JI J. Tradit. Chin. Med.
PD AUG 15
PY 2023
VL 43
IS 4
BP 795
EP 800
DI 10.19852/j.cnki.jtcm.2023.04.002
PG 6
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA M5HJ8
UT WOS:001030523300001
PM 37454265
DA 2026-01-16
ER

PT J
AU Van, de Castle B
   Lukkahatai, N
   Billing, BL
   Huang, X
   Wu, H
   Zhang, J
   Abdi, S
   Kameoka, J
   Smith, TJ
AF Van de Castle, Barb
   Lukkahatai, Nada
   Billing, Bsn Lynn
   Huang, Xinran
   Wu, Hulin
   Zhang, Jingyu
   Abdi, Salahadin
   Kameoka, Jun
   Smith, Thomas J
TI Nurse-Administered Auricular Point Acupressure for Cancer-Related Pain.
SO Integrative cancer therapies
LA English
DT Journal Article
DE auricular acupressure; cancer; cancer-related-pain; nursing; pain
AB PURPOSE: The study aimed to (1) examine the feasibility of providing a training  course on auricular point acupressure (APA) for clinical oncology nurses to  integrate APA into real-world nursing care settings, and (2) examine the  effectiveness of APA on cancer-related pain (CRP) under usual inpatient oncology  ward conditions. METHODS: This was a 2-phase feasibility study. Phase 1, an  in-person, 8 hour training program was provided to oncology nurses. Phase 2, a  prospective and feasibility study was conducted to evaluate the integration of  APA into nursing care activities to manage CRP. Oncology patients were included  if their pain was rated at ≥4 on a 0 to 10 numeric rating scale in the past  24 hours. Patients received 1 APA treatment administered by the nurses and were  instructed to stimulate the points for 3 days. Study outcomes (pain intensity,  fatigue, and sleep disturbance), pain medication use, and APA practice were  measured by a phone survey daily. RESULTS: Ten oncology nurses received APA  training in phase 1. APA had been added to the hospital's electronic health  records (EHRs) as a pain treatment. In phase 2, 33 oncology patients received APA  treatment with a 100% adherence rate (pressing the seeds 3 times per day,  3 minutes per time based on the suggestion). The side effects of APA were minimal  (~8%-12% felt tenderness on the ear). After 3 days of APA, patients reported 38%  pain relief, 39% less fatigue, and 45% improvement in sleep disturbance; 24%  reduced any type of pain medication use and 19% reduced opioid use (10 mg opioids  using milligram morphine equivalent). The major barrier to integrating APA into  routine nursing practice was time management (how to include APA in a daily  workflow). CONCLUSION: It is feasible to provide 8-hour training to oncology  nurses for mastering APA skill and then integrating APA into their daily nursing  care for patients with CRP. Based on the promising findings (decreased pain,  improved fatigue and sleep disturbance, and less opioid use), the next step is to  conduct a randomized clinical trial with a larger sample to confirm the efficacy  of APA for oncology nurses to treat CRP in real-world practice.ClinicalTrial.gov  identifier number: NCT04040140.
C1 University of Maryland School of Nursing, Baltimore, MD, USA.
   Johns Hopkins University School of Nursing, Baltimore, MD, USA.
   Johns Hopkins Hospital, Baltimore, MD, USA.
   The University of Texas Health Science Center at Houston School of Public Health, Houston, TX, USA.
   The University of Texas Health Science Center at Houston School of Public Health, Houston, TX, USA.
   Johns Hopkins University School of Nursing, Baltimore, MD, USA.
   The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
   Waseda University, Tokyo, Japan.
   Johns Hopkins University School of Medicine, Baltimore, MD, USA.
NR 0
TC 0
SN 1552-695
EI 1534-735
J9 Integr Cancer Ther
PD SEP 14
PY 2023
VL 22
IS 
BP 15347354231198086
EP 15347354231198086
DI 10.1177/15347354231198086
PG 1
WC Humans; Acupressure; Analgesics, Opioid; Cancer Pain; therapy; Fatigue; Feasibility Studies; Neoplasms; complications; Prospective Studies; Treatment Outcome
UT PubMed:37706457
PM 37706457
DA 2023-09-14
ER

PT J
AU Yang, X
   Liang, B
   Xue, D
   Liang, J
   Zaslawski, C
   Chen, J
AF Yang, Xia
   Liang, Bing
   Xue, Demin
   Liang, Jing
   Zaslawski, Chris
   Chen, Ji
TI Global research trends in acupuncture for cancer pain: A bibliometric analysis.
SO Medicine
LA English
DT Journal Article
AB BACKGROUND: In recent years, acupuncture has gained popularity in the management  of cancer-related pain (CRP). This study aims to use bibliometric analysis to  investigate the historical development, recent hotspots and research trends in  this field. METHODS: The Web of Science Core Collection database was selected as  the data source for this study to retrieve and obtain literature related to  acupuncture and CRP. Data analyses were performed with CiteSpace and VOSviewer to  conduct the bibliometric analysis. RESULTS: This bibliometric analysis was  conducted from 2000 to 2022. A total of 664 publications were included in this  work. The number of publications has steadily increased over the last 2 decades.  The United States has the largest number of published articles (244 papers),  while the People's Republic of China has the highest centrality (0.48). The  primary research institutions were Memorial Sloan-Kettering Cancer Center, Kyung  Hee University and Beijing University of Chinese Medicine. Mao Jun J. was the  most prolific author, while Heather Greenlee was the most cited one. The most  productive journal was Integrative Cancer Therapies. The most frequent keywords  excluding the search subject were "electroacupuncture," "management," "quality of  life," "breast cancer," "Aromatase inhibitor," "neuropathic pain," "mechanisms,"  and "protocol." CONCLUSION: This study explored the application value of  acupuncture in the management of CRP with bibliometric analysis, offering an  intuitive understanding of this topic and revealing the hotspots and research  trends.
C1 Basic Medical College, Chengdu University of Traditional Chinese Medicine, Chengdu, China.
   Basic Medical College, Chengdu University of Traditional Chinese Medicine, Chengdu, China.
   School of Chinese Classics, Chengdu University of Traditional Chinese Medicine, Chengdu, China.
   School of Foreign Languages, Chengdu University of Traditional Chinese Medicine, Chengdu, China.
   Faculty of Science, University of Technology, Sydney, New South Wales, Australia.
   School of Foreign Languages, Chengdu University of Traditional Chinese Medicine, Chengdu, China.
NR 0
TC 0
SN 1536-596
EI 0025-797
J9 Medicine (Baltimore)
PD OCT 13
PY 2023
VL 102
IS 41
BP e34739
EP e34739
DI 10.1097/MD.0000000000034739
PG 1
WC Humans; Cancer Pain; therapy; Quality of Life; Acupuncture Therapy; Electroacupuncture; Bibliometrics; Neoplasms; complications
UT PubMed:37832094
PM 37832094
DA 2023-10-13
ER

PT J
AU Wang, H
   Qu, S
   Zhou, T
   Hu, Q
   Zhao, X
   Yang, Q
   Chi, H
   Luo, S
   Li, X
   Ke, H
   He, X
   Zhao, H
AF Wang, Hanzhi
   Qu, Siying
   Zhou, Tianshu
   Hu, Qunqi
   Zhao, Xiaoxuan
   Yang, Qujia
   Chi, Hengyu
   Luo, Shiling
   Li, Xinyue
   Ke, Huanxiao
   He, Xiaofen
   Zhao, Hongli
TI Current Perspectives and Trend of Acupuncture in Breast Cancer-Related Symptoms:
SO Journal of pain research
LA English
DT Review
DE CiteSpace; VOSviewer; acupuncture; bibliometric study; breast cancer-related symptoms; cancer pain
AB PURPOSE: This bibliometric research aims to delineate global publication trends  and emerging research interests in the use of acupuncture for breast cancer  (BC)-related symptoms treatment over the past three decades. Furthermore, it  identifies influential institutions, potential collaborative partners, and future  research trends, thereby providing guidance for relevant, novel research  directions. METHODS: Scientific publications related to acupuncture for  BC-related symptoms were gathered from the Web of Science Core Collection (WoSCC)  from 1993 to 2023. Four software applications were principally used to analyze  the resulting data: the "bibliometrix" package in the R environment (version  4.2.3), VOSviewer, CiteSpace6.1.R6, and the bibliometrics website. These  applications were employed to evaluate different parameters. RESULTS: A total of  621 papers on acupuncture in BC-related symptoms treatment were analyzed. The  United States, China, and South Korea contributed the most, with Memorial Sloan  Kettering Cancer Center, and Columbia University leading institutions. It is  interesting to mention that Mao, Jun J. and Molassiotis, A. feature among the top  10 authors and co-cited authors. JAMA is the leading journal, with an ongoing  focus on acupuncture's effectiveness. Keywords show that the initial research  focus was mainly on "vasomotor symptoms", but in recent years there has been a  gradual shift towards "pain", "chemotherapy-induced peripheral neuropathy  (CIPN)", "electroacupuncture", and "non-specific effects". CONCLUSION:  Acupuncture has demonstrated a unique value in the process of adjuvant treatment  of BC-related symptoms, and has been shown to be effective in reducing pain,  eliminating fatigue, and improving quality of life. The study of the mechanisms  of acupuncture and the application of electroacupuncture are possible future  research priorities in this field. This study offers a deep perspective on  acupuncture for BC research, highlighting key points and future trends.
C1 Department of Traditional Chinese Medicine (TCM) Gynecology, Hangzhou Hospital of Traditional Chinese Medicine Affiliated to Zhejiang Chinese Medical University,Hangzhou City, Zhejiang Province, People's Republic of China.
   Zhejiang Chinese Medical University, Hangzhou City, Zhejiang Province, People's 
   Zhejiang Chinese Medical University, Hangzhou City, Zhejiang Province, People's Republic of China.
   Wenzhou Medical University, Wenzhou City, Zhejiang Province, People's Republic of China.
   Zhejiang Chinese Medical University, Hangzhou City, Zhejiang Province, People's Republic of China.
   Department of Traditional Chinese Medicine (TCM) Gynecology, Hangzhou Hospital of Traditional Chinese Medicine Affiliated to Zhejiang Chinese Medical University,Hangzhou City, Zhejiang Province, People's Republic of China.
   Department of Traditional Chinese Medicine (TCM) Gynecology, Hangzhou Hospital of Traditional Chinese Medicine Affiliated to Zhejiang Chinese Medical University,Hangzhou City, Zhejiang Province, People's Republic of China.
   Zhejiang Chinese Medical University, Hangzhou City, Zhejiang Province, People's 
   Zhejiang Chinese Medical University, Hangzhou City, Zhejiang Province, People's Republic of China.
   Department of Traditional Chinese Medicine (TCM) Gynecology, Hangzhou Hospital of Traditional Chinese Medicine Affiliated to Zhejiang Chinese Medical University,Hangzhou City, Zhejiang Province, People's Republic of China.
   Women's Hospital, School of Medicine, Zhejiang University, Hangzhou City, Zhejiang Province, People's Republic of China.
   Department of Traditional Chinese Medicine (TCM) Gynecology, Hangzhou Hospital of Traditional Chinese Medicine Affiliated to Zhejiang Chinese Medical University,Hangzhou City, Zhejiang Province, People's Republic of China.
   Zhejiang Chinese Medical University, Hangzhou City, Zhejiang Province, People's 
   Department of Neurobiology and Acupuncture Research, The Third Clinical Medical College, Zhejiang Chinese Medical University, Key Laboratory of Acupuncture andNeurology of Zhejiang Province, Hangzhou City, Zhejiang Province, People'sRepublic of China.
   Department of Traditional Chinese Medicine (TCM) Gynecology, Hangzhou Hospital of Traditional Chinese Medicine Affiliated to Zhejiang Chinese Medical University,Hangzhou City, Zhejiang Province, People's Republic of China.
NR 0
TC 0
SN 1178-709
EI 1178-709
J9 J Pain Res
PD DEC 11
PY 2023
VL 16
IS 
BP 4165
EP 4180
DI 10.2147/JPR.S442151
PG 15
UT PubMed:38078016
PM 38078016
DA 2023-12-11
ER

PT J
AU Shi, YM
   Nguyen, T
   Farrell, M
   Rodgers-Melnick, S
   Moss, G
   Kaiser, C
   Dusek, JA
   Mendiratta, P
   Adan, F
   Lee, RT
AF Shi, Yuming
   Nguyen, Thuy
   Farrell, Megan
   Rodgers-Melnick, Samuel
   Moss, Gabriel
   Kaiser, Christine
   Dusek, Jeffery A. A.
   Mendiratta, Prateek
   Adan, Francoise
   Lee, Richard T. T.
TI Retrospective Outcomes of a New Acupuncture Service at a Comprehensive Cancer Center
SO JOURNAL OF INTEGRATIVE AND COMPLEMENTARY MEDICINE
LA English
DT Article
DE acupuncture; cancer; symptom management; integrative oncology
ID emergency-department; integrative medicine; pain management; care; implementation; survivors; protocol
AB Introduction: Among cancer centers, patients' interest in acupuncture is growing, in addition to clinical research in the intervention. Their National Cancer Institute-designated comprehensive cancer center piloted an acupuncture service. Their aim was to assess whether acupuncture impacted patient self-reported symptoms as delivered clinically and discuss their implementation strategy.Methods: Patients undergoing acupuncture at a comprehensive cancer center from June 2019 to March 2020 were asked to complete a modified Edmonton Symptom Assessment Scale (ESAS) before and after each session. The authors evaluated symptom changes after acupuncture in both outpatient and inpatient settings. A change of >= 1 U, on the 0-10 scale, was considered clinically significant.Results: Three hundred and nine outpatient and 394 inpatient acupuncture sessions were provided to patients at the comprehensive cancer center during this period, of which surveys from 186 outpatient (34 patients) and 124 inpatient (57 patients) sessions were available for analysis. The highest pretreatment symptoms reported by outpatients were neuropathy (5.78), pain (5.58), and tiredness (5.59). Outpatients receiving acupuncture reported clinically significant improvements in pain (ESAS score change of -2.97), neuropathy (-2.68), decreased lack of well-being (-2.60), tiredness (-1.85), nausea (-1.83), anxiety (-1.56), activities of daily living issues (-1.32), depression (-1.23), anorexia (-1.19), insomnia (-1.14), and shortness of breath (-1.14). The most severe pretreatment symptoms reported by inpatients were pain (6.90), insomnia (6.16), and constipation (5.44). Inpatients receiving acupuncture reported clinically significant improvements in anxiety (-3.69), nausea (-3.61), insomnia (-3.26), depression (-2.98), pain (-2.77), neuropathy (-2.68), anorexia (-2.20), constipation (-1.95), and diarrhea (-1.26).Conclusion: Both outpatient and inpatient participants in this pilot acupuncture program reported clinically significant improvements in symptoms after a single acupuncture treatment. Some differences between the outpatient and inpatient settings warrant further investigation.
C1 [Shi, Yuming; Farrell, Megan; Rodgers-Melnick, Samuel; Moss, Gabriel; Dusek, Jeffery A. A.; Mendiratta, Prateek; Adan, Francoise; Lee, Richard T. T.] Case Western Reserve Univ, Cleveland, OH USA.
   [Nguyen, Thuy; Rodgers-Melnick, Samuel; Kaiser, Christine; Dusek, Jeffery A. A.; Adan, Francoise] Univ Hosp Connor Whole Hlth, Cleveland, OH USA.
   [Nguyen, Thuy] Cleveland Clin, Cleveland, OH USA.
   [Mendiratta, Prateek; Lee, Richard T. T.] Univ Hosp Cleveland Med Ctr, Cleveland, OH USA.
   [Lee, Richard T. T.] City Hope Comprehens Canc Ctr, Dept Support Care Med, Integrat Med Program, Duarte, CA USA.
   [Lee, Richard T. T.] City Hope Comprehens Canc Ctr, Dept Med Oncol, Integrat Med Program, Duarte, CA USA.
   [Lee, Richard T. T.] City Hope Comprehens Canc Ctr, Dept Support Care Med, Integrat Med Program, Duarte, CA 91010 USA.
   [Lee, Richard T. T.] City Hope Comprehens Canc Ctr, Dept Med Oncol, Integrat Med Program, Duarte, CA 91010 USA.
C3 University System of Ohio; Case Western Reserve University; Cleveland Clinic Foundation; University Hospitals of Cleveland; City of Hope; City of Hope; City of Hope; City of Hope
RP Lee, RT (corresponding author), Case Western Reserve Univ, Cleveland, OH USA.; Lee, RT (corresponding author), Univ Hosp Cleveland Med Ctr, Cleveland, OH USA.; Lee, RT (corresponding author), City Hope Comprehens Canc Ctr, Dept Support Care Med, Integrat Med Program, Duarte, CA 91010 USA.; Lee, RT (corresponding author), City Hope Comprehens Canc Ctr, Dept Med Oncol, Integrat Med Program, Duarte, CA 91010 USA.
EM richlee@coh.org
CR Bao T, 2018, ACUPUNCT MED, V36, P80, DOI 10.1136/acupmed-2017-011435
   Chang VT, 2000, CANCER, V88, P2164, DOI 10.1002/(SICI)1097-0142(20000501)88:9<2164::AID-CNCR24>3.0.CO;2-5
   Chao MT, 2016, J INTEGR MED-JIM, V14, P228, DOI 10.1016/S2095-4964(16)60252-2
   Chia KL, 2018, ACUPUNCT MED, V36, P183, DOI 10.1136/acupmed-2017-011547
   Choi TY, 2012, SUPPORT CARE CANCER, V20, P1147, DOI 10.1007/s00520-012-1432-9
   Cohen MM, 2017, MED J AUSTRALIA, V206, P494, DOI 10.5694/mja16.00771
   Dans M, 2021, J NATL COMPR CANC NE, V19, P780, DOI 10.6004/jnccn.2021.0033
   Desai K, 2021, J ALTERN COMPLEM MED, V27, P1011, DOI 10.1089/acm.2021.0102
   Dusek JA, 2018, J ALTERN COMPLEM MED, V24, P557, DOI 10.1089/acm.2017.0203
   Garcia MK, 2018, INTEGR CANCER THER, V17, P148, DOI 10.1177/1534735416685403
   Garcia MK, 2013, J CLIN ONCOL, V31, P952, DOI 10.1200/JCO.2012.43.5818
   Grant SJ, 2021, INTEGR CANCER THER, V20, P0, DOI 10.1177/15347354211002253
   Highfield ES, 2012, J IMMIGR MINOR HEALT, V14, P433, DOI 10.1007/s10903-011-9538-6
   Hu CQ, 2016, EVID-BASED COMPL ALT, V2016, P0, DOI 10.1155/2016/1720239
   Hui D, 2015, CANCER-AM CANCER SOC, V121, P3027, DOI 10.1002/cncr.29437
   Jiang C, 2021, SUPPORT CARE CANCER, V29, P5777, DOI 10.1007/s00520-021-06081-4
   LaPaglia D, 2016, J ALTERN COMPLEM MED, V22, P729, DOI 10.1089/acm.2015.0283
   Larbi OM, 2021, JCO ONCOL PRACT, V17, P672, DOI 10.1200/OP.20.00471
   Li HJ, 2021, ACUPUNCT MED, V39, P612, DOI 10.1177/09645284211017303
   Liou KT, 2020, J ALTERN COMPLEM MED, V26, P85, DOI 10.1089/acm.2020.0022
   Lopez G, 2018, J CANCER, V9, P3613, DOI 10.7150/jca.26527
   Lu K, 2014, CLIN J PAIN, V30, P825, DOI 10.1097/AJP.0000000000000036
   Lyman GH, 2018, J CLIN ONCOL, V36, P2647, DOI 10.1200/JCO.2018.79.2721
   Mao JJ, 2022, J CLIN ONCOL, V40, P3998, DOI 10.1200/JCO.22.01357
   Mao JJ, 2011, J CANCER SURVIV, V5, P8, DOI 10.1007/s11764-010-0153-7
   Reece-Stremtan S, 2021, J PAIN SYMPTOM MANAG, V62, P1239, DOI 10.1016/j.jpainsymman.2021.06.003
   Reinstein AS, 2017, PAIN MED, V18, P169, DOI 10.1093/pm/pnv114
   Shen JN, 2000, JAMA-J AM MED ASSOC, V284, P2755, DOI 10.1001/jama.284.21.2755
   Swarm RA, 2019, J NATL COMPR CANC NE, V17, P977, DOI 10.6004/jnccn.2019.0038
   Thompson LMA, 2015, J ACUPUNCT MERIDIAN, V8, P127, DOI 10.1016/j.jams.2015.04.002
   USCensus Bureau, 2021, QUICKFACTS CLEV CIT, V0, P0
   Yaguda S, 2019, J ALTERN COMPLEM MED, V25, P675, DOI 10.1089/acm.2019.0071
   Yun Hyeongjun, 2017, JOURNAL OF THE NATIONAL CANCER INSTITUTE MONOGRAPHS, V0, PP29, DOI 10.1093/jncimonographs/lgx004
NR 34
TC 4
Z9 4
U1 0
U2 3
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 2768-3605
EI 2768-3613
J9 J INTEGR COMPLEMENT
JI J. Integr. Complement. Med.
PD OCT 1
PY 2023
VL 29
IS 10
BP 674
EP 682
DI 10.1089/jicm.2022.0709
EA MAY 2023
PG 9
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA T6SY3
UT WOS:000996906300001
PM 37252748
DA 2026-01-16
ER

PT J
AU Yang, MX
   Baser, RE
   Khanin, R
   Autuori, I
   Li, QS
   Panageas, KS
   Orlow, I
   Mao, JJ
AF Yang, Mingxiao
   Baser, Raymond E.
   Khanin, Raya
   Autuori, Isidora
   Li, Qing S.
   Panageas, Katherine S.
   Orlow, Irene
   Mao, Jun J.
TI COMT Val158Met Affects the Analgesic Response to Acupuncture Among Cancer Survivors With Chronic Pain
SO JOURNAL OF PAIN
LA English
DT Article
DE COMT Val158Met; chronic pain; acupuncture; cancer survivors; treatment response
ID catechol-o-methyltransferase; morphine; polymorphism; biomarkers; symptoms; genetics; reward
AB Catechol-O-methyltransferase (COMT) is the major enzyme involved in the catabolism of dopamine, a neurotransmitter in the brain's reward system. The common COMT polymorphism Val158Met (rs4680 G > A) modulates pain response to opioids through a reward-motivated me-chanism; however, its role in nonpharmacological pain medicine has not been clinically characterized. We genotyped 325 participants from a randomized controlled trial of cancer survivors with chronic musculoskeletal pain. We found that carrying methionine at position 158 (158Met) of COMT, encoded by the A allele, significantly increased the analgesic response to electroacupuncture (74% vs 50%; odds ratio [OR]: 2.79; 95% confidence interval [CI]: 1.31, 6.05; P < .01), but not to auricular acupuncture (68% vs 60%; OR: 1.43; 95% CI: .65, 3.12; P = .37) or usual care (24% vs 18%; OR: 1.46; 95% CI: .38, 7.24; P = .61) compared to Val/Val. These findings raise the possibility that COMT Val158Met might be an important predictor of analgesic response to electroacupuncture, providing novel in-sights into precision nonpharmacologic pain management tailored to individual genetic back-grounds.
C1 [Yang, Mingxiao; Li, Qing S.; Mao, Jun J.] Mem Sloan Kettering Canc Ctr, Dept Med, Integrat Med Serv, 321 East 61st St,Room 456, New York, NY 10065 USA.
   [Baser, Raymond E.; Autuori, Isidora; Panageas, Katherine S.; Orlow, Irene] Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, New York, NY 10065 USA.
   [Khanin, Raya] Mem Sloan Kettering Canc Ctr, Bioinformat Core Computat Biol Program, New York, NY 10065 USA.
C3 Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center
RP Mao, JJ (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Med, Integrat Med Serv, 321 East 61st St,Room 456, New York, NY 10065 USA.
EM maoj@mskcc.org
FU Department of Defense Office of the Congressionally Directed Medical Research Programs through the Peer Reviewed Medical Research Program Clinical Trial Award [W81XWH-15-1-0245]; National Institutes of Health/National Cancer Institute (NIH/NCI) Cancer Center Support Grant [P30 CA008748]; NCI [R01 CA240417]; National Cancer Institute [R01CA240417, P30CA008748] Funding Source: NIH RePORTER
CR Aslaksen PM, 2018, PAIN, V159, P2585, DOI 10.1097/j.pain.0000000000001370
   Bilder RM, 2004, NEUROPSYCHOPHARMACOL, V29, P1943, DOI 10.1038/sj.npp.1300542
   Bjorland S, 2016, BMC MUSCULOSKEL DIS, V17, P1, DOI 10.1186/s12891-016-1356-5
   Cargnin S, 2013, J PAIN, V14, P1097, DOI 10.1016/j.jpain.2013.04.006
   Cleeland CS, 1994, ANNALS ACADEMY OF MEDICINE SINGAPORE, V23, P129
   Collins FS, 2015, NEW ENGL J MED, V372, P793, DOI 10.1056/NEJMp1500523
   Cornett EM, 2020, CURR ONCOL REP, V22, P0, DOI 10.1007/s11912-020-0865-4
   Correa DD, 2016, NEURO-ONCOLOGY, V18, P1425, DOI 10.1093/neuonc/now057
   Crew KD, 2007, J CLIN ONCOL, V25, P3877, DOI 10.1200/JCO.2007.10.7573
   Deandrea S, 2008, ANN ONCOL, V19, P1985, DOI 10.1093/annonc/mdn419
   Diatchenko L, 2005, HUM MOL GENET, V14, P135, DOI 10.1093/hmg/ddi013
   Diatchenko L, 2007, TRENDS GENET, V23, P605, DOI 10.1016/j.tig.2007.09.004
   Edwards RR, 2016, PAIN, V157, P1851, DOI 10.1097/j.pain.0000000000000602
   Eisenhofer G, 2004, PHARMACOL REV, V56, P331, DOI 10.1124/pr.56.3.1
   Farrar JT, 2000, PAIN, V88, P287, DOI 10.1016/S0304-3959(00)00339-0
   Fernández-de-las-Peñas C, 2012, BREAST CANCER RES TR, V133, P405, DOI 10.1007/s10549-011-1757-y
   Fields HL, 2006, PROCEEDINGS OF THE 11TH WORLD CONGRESS ON PAIN, V0, P449
   Fields HL, 2007, REGION ANESTH PAIN M, V32, P242, DOI 10.1016/j.rapm.2007.01.001
   Fillingim RB, 2016, J PAIN, V17, PT10, DOI 10.1016/j.jpain.2015.08.010
   Genovese TJ, 2021, J PAIN SYMPTOM MANAG, V62, PE192, DOI 10.1016/j.jpainsymman.2021.03.002
   Genovese TJ, 2019, PAIN MED, V20, P191, DOI 10.1093/pm/pny067
   Giske L, 2010, EUR J PAIN, V14, P959, DOI 10.1016/j.ejpain.2010.02.011
   Goldman D, 2005, NAT REV GENET, V6, P521, DOI 10.1038/nrg1635
   Gosain R, 2013, CANCER J, V19, P405, DOI 10.1097/01.PPO.0000434391.11187.c3
   Hall KT, 2012, PLOS ONE, V7, P0, DOI 10.1371/journal.pone.0048135
   He YH, 2020, JAMA ONCOL, V6, P271, DOI 10.1001/jamaoncol.2019.5233
   Hershman DL, 2015, ADV EXP MED BIOL, V862, P89, DOI 10.1007/978-3-319-16366-6_7
   Howlader N, 2020, NEW ENGL J MED, V383, P640, DOI 10.1056/NEJMoa1916623
   Knisely MR, 2019, J PAIN, V20, P1100, DOI 10.1016/j.jpain.2019.03.008
   Kolesnikov Y, 2011, ANESTH ANALG, V112, P448, DOI 10.1213/ANE.0b013e318202cc8d
   Kumar S, 2019, ANAESTHESIA, V74, P1456, DOI 10.1111/anae.14813
   Liou KT, 2020, MEDICINE, V99, P0, DOI 10.1097/MD.0000000000020085
   Mao JJ, 2021, JAMA ONCOL, V7, P720, DOI 10.1001/jamaoncol.2021.0310
   Matsuoka H, 2012, ONCOL REP, V27, P1393, DOI 10.3892/or.2012.1660
   Miller KD, 2019, CA-CANCER J CLIN, V69, P363, DOI 10.3322/caac.21565
   Niculescu AB, 2019, MOL PSYCHIATR, V24, P501, DOI 10.1038/s41380-018-0345-5
   Niemtzow RC, 2018, MED ACUPUNCT, V30, P57, DOI 10.1089/acu.2018.29077.rcn
   Orlow I, 2012, INT J CANCER, V130, P405, DOI 10.1002/ijc.26023
   Ozberk D, 2022, PHARMACOGENOMICS, V23, P281, DOI 10.2217/pgs-2021-0139
   Parkin GM, 2018, J HUM GENET, V63, P1251, DOI 10.1038/s10038-018-0511-2
   Raats MM, 1992, FOOD QUALITY AND PREFERENCE, V3, P89, DOI 10.1016/0950-3293(91)90028-D
   Rakvåg TT, 2005, PAIN, V116, P73, DOI 10.1016/j.pain.2005.03.032
   Reyes-Gibby CC, 2007, PAIN, V130, P25, DOI 10.1016/j.pain.2006.10.023
   Robson ME, 2015, J CLIN ONCOL, V33, P3660, DOI 10.1200/JCO.2015.63.0996
   Scott DJ, 2007, NEURON, V55, P325, DOI 10.1016/j.neuron.2007.06.028
   Sexton JE, 2018, ANNU REV PHARMACOL, V58, P123, DOI 10.1146/annurev-pharmtox-010617-052554
   Singh A, 2020, J PSYCHOPHARMACOL, V34, P1200, DOI 10.1177/0269881120944162
   Tammimäki A, 2012, PHARMACOGENET GENOM, V22, P673, DOI 10.1097/FPC.0b013e3283560c46
   Tchivileva IE, 2010, PHARMACOGENET GENOM, V20, P239, DOI 10.1097/FPC.0b013e328337f9ab
   van Beers EH, 2006, BRIT J CANCER, V94, P333, DOI 10.1038/sj.bjc.6602889
   van den Beuken-van Everdingen MHJ, 2016, J PAIN SYMPTOM MANAG, V51, P1070, DOI 10.1016/j.jpainsymman.2015.12.340
   Vickers AJ, 2018, J PAIN, V19, P455, DOI 10.1016/j.jpain.2017.11.005
   Yang GS, 2019, SEMIN ONCOL NURS, V35, P291, DOI 10.1016/j.soncn.2019.04.011
   Yang MX, 2021, NPJ BREAST CANCER, V7, P0, DOI 10.1038/s41523-021-00355-0
   Yang XJ, 2018, BRAIN IMAGING BEHAV, V12, P798, DOI 10.1007/s11682-017-9735-6
   Yaple ZA, 2020, HUM BRAIN MAPP, V41, P3993, DOI 10.1002/hbm.25103
   Zhang RX, 2014, ANESTHESIOLOGY, V120, P482, DOI 10.1097/ALN.0000000000000101
   Zubieta JK, 2003, SCIENCE, V299, P1240, DOI 10.1126/science.1078546
   Zylla D, 2017, SUPPORT CARE CANCER, V25, P1687, DOI 10.1007/s00520-017-3614-y
NR 61
TC 8
Z9 9
U1 1
U2 9
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 1526-5900
EI 1528-8447
J9 J PAIN
JI J. Pain
PD SEP 15
PY 2023
VL 24
IS 9
BP 1721
EP 1730
DI 10.1016/j.jpain.2023.05.005
EA SEP 2023
PG 10
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA T6LN1
UT WOS:001079082300001
PM 37187218
DA 2026-01-16
ER

PT J
AU Li, C
   Zhao, C
   Zhao, J
   Wang, M
   Luo, F
   Zhou, J
AF Li, Chunyu
   Zhao, Can
   Zhao, Jingjing
   Wang, Min
   Luo, Furong
   Zhou, Jianwei
TI Global research trends of acupuncture therapy on cancer pain: A bibliometric and
SO Frontiers in oncology
LA English
DT Journal Article
DE VOSviewer; acupuncture; bibliometric analysis; cancer pain; web of science
AB BACKGROUND: The number of publications on acupuncture for cancer pain is  increasing rapidly with an upward tendency. Considering that no bibliometric  articles related to this topic have been published yet. It is necessary to  evaluate the global scientific output of research in this field, and shed light  on the direction of clinical cancer pain management in the future. METHODS:  Research publications regarding acupuncture on cancer pain from inception to 2022  were downloaded from the Web of Science Core Collection. Bibliometric analyses  were performed using CiteSpace software, the bibliometrix R package, and  VOSviewer software. Network maps were generated to assess the collaborations  between different countries, institutions, authors, and keywords. And clusters  map was generated to evaluate reference. RESULTS: A total of 790 articles related  to acupuncture therapy for cancer pain were identified. We observe that the  number of publications is gradually increasing over time. China and the United  States were the main contributors. Mem Sloan Kettering Canc Ctr (38 papers) and  Beijing Univ Chinese Med (28 papers) contributed the most publications, becoming  the leading contributors in this field. Although J Clin Oncol (28 articles)  ranked ninth in terms of publication volume, it was the journal with the most  citations and the highest number of IF (50.717) and H-index (494) at the same  time. MAO J from Mem Sloan Kettering Canc Ctr was the most prolific author (23  articles). The main hot topics included matters related to acupuncture (239  times), pain (199 times), management (139 times), quality of life (107 times),  electroacupuncture (100 times), and breast cancer (82 times). CONCLUSION: Our  bibliometric analysis provides a comprehensive overview of the development of  acupuncture for cancer pain, enabling relevant authors and research teams to  identify the current research status in this field. At the same time, acupuncture  for breast cancer (BC) pain, aromatase inhibitor-induced arthralgia (AIA), and  chemotherapy-induced peripheral neuropathy (CIPN) may soon become prospective  focus.
C1 Acupuncture and Tuina School/The 3rd Teaching Hospital, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China.
   College of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China.
   Department of Acupuncture, Sichuan Second Hospital of Traditional Chinese Medicine, Chengdu, Sichuan, China.
   Department of Acupuncture, Sichuan Second Hospital of Traditional Chinese Medicine, Chengdu, Sichuan, China.
   Department of Traditional Chinese Medicine, Xi'an No. 3 Hospital, the Affiliated Hospital of Northwest University, Xi'an, Shanxi, China.
   Sichuan Academy of Chinese Medicine Sciences, Chengdu, Sichuan, China.
NR 0
TC 0
SN 2234-943
EI 2234-943
J9 Front Oncol
PD MAR 24
PY 2023
VL 13
IS 
BP 1077961
EP 1077961
DI 10.3389/fonc.2023.1077961
PG 0
UT PubMed:36950556
PM 36950556
DA 2023-03-24
ER

PT J
AU Wang, Z
   Xu, H
   Wang, Z
   Zhou, H
   Diao, JY
   Zhang, LJ
   Wang, Y
   Li, MX
   Zhou, YF
AF Wang, Zhen
   Xu, Hui
   Wang, Zheng
   Zhou, Hang
   Diao, Jieyao
   Zhang, Lijuan
   Wang, Yu
   Li, Miaoxiu
   Zhou, Yunfeng
TI Effects of externally-applied, non-pharmacological Interventions on short- and long-term symptoms and inflammatory cytokine levels in patients with knee osteoarthritis: a systematic review and network meta-analysis
SO FRONTIERS IN IMMUNOLOGY
LA English
DT Review
DE knee osteoarthritis; externally-applied; non-pharmacological interventions; short- and long-term; efficacy; inflammatory cytokine; network meta-analysis
ID platelet-rich plasma; double-blind; laser acupuncture; hyaluronic-acid; intraarticular injection; synovial-fluid; pain; efficacy; management; therapy
AB Background: With the continuous development of clinical medicine, an increasing number of non-pharmacological interventions have been applied for the treatment of knee osteoarthritis (KOA), with the results of several recent randomized controlled trials (RCTs) showing that a variety of externally-applied, non-pharmacological interventions (EANPI) can improve symptoms and inflammation in patients with KOA. However, the relative benefits and disadvantages of non-drug therapies remain uncertain, and an optimal treatment strategy has not yet been determined.Objective: This study applied network meta-analysis (NMA) to compare and rank the effectiveness of EANPI on the short- and long-term clinical symptoms and inflammatory cytokine levels in patients with KOA.Methods Two independent researchers searched online databases and performed manual retrieval of related citations to identify RCTs that met the selection criteria for the network meta-analysis. These researchers retrieved studies indexed from database inception to August 2023 and performed data extraction and assessment of the risk of bias.Results: The analysis included 80 RCTs involving 8440 participants and nine externally-applied, non-pharmacological therapies, namely extracorporeal shock wave, radiofrequency, acupotomy, laser therapy, Tuina therapy, kinesio taping, electroacupuncture, platelet-rich plasma injection, and ozone therapy. The treatment courses ranged from 1 to 12 weeks, with follow-up periods ranging from 4 to 24 weeks. The results of the NMA indicated that each non-drug therapy was superior to sham intervention in improving all outcome indicators. Except for the visual analog scale (VAS) and Western Ontario MacMaster (WOMAC) pain outcomes, all non-drug therapies had better efficacy than pharmacological treatments. For short-term VAS and tumor necrosis factor-alpha (TNF-alpha), extracorporeal shock wave performed better than other therapies (90.2% and 85.2% respectively). Radiofrequency therapy may be the most promising method to reduce long-term VAS, short- and long-term WOMAC pain, and interleukin (IL)-1 beta level (84.8%, 97.8%, 90.1%, 94.8% respectively). Tuina therapy may be a significant choice for short- and long-term outcomes of WOMAC function and range of motion (ROM).Conclusions: The results of the comprehensive comparison of the outcome indicators in 9 different EANPI indicated that radiofrequency and Tuina therapy were more effective and consistently ranked high in improving clinical symptoms in the short and long term. Radiofrequency is effective at relieving pain, and Tuina therapy can be given priority for treatment when hypofunction is the main symptom. EANPI to improve pain symptoms may be related to the regulation of inflammatory cytokine levels, which may be a potential mechanism of action.Systematic review registration https://www.crd.york.ac.uk/prospero/display_record.php?, identifier CRD42023464177.
C1 [Wang, Zhen; Xu, Hui; Wang, Zheng; Zhou, Hang; Diao, Jieyao; Zhou, Yunfeng] Henan Univ Chinese Med, Coll Acupuncture & Massage, Zhengzhou, Peoples R China.
   [Xu, Hui] Henan Univ Chinese Med, Affiliated Hosp 3, Tuina Dept, Zhengzhou, Peoples R China.
   [Zhang, Lijuan] Jiaozuo Coal Ind Grp Co Ltd, Rehabil Dept, Cent Hosp, Jiaozuo, Peoples R China.
   [Wang, Yu] Xidian Univ, Coll Comp Sci, Xian, Peoples R China.
   [Li, Miaoxiu] Shanghai Univ Chinese Med, Coll Acupuncture & Massage, Shanghai, Peoples R China.
C3 Henan University of Traditional Chinese Medicine; Henan University of Traditional Chinese Medicine; Xidian University; Shanghai University of Traditional Chinese Medicine
RP Zhou, YF (corresponding author), Henan Univ Chinese Med, Coll Acupuncture & Massage, Zhengzhou, Peoples R China.
EM zyf5680198@126.com
FU Henan Province Chinese Medicine Scientific Research Special project [2022ZY1108]; Central Plains Thousand Talents Program-Central Plains Famous Doctors [ZYQR201912120]; 2022 Central Plains Talent Plan (Talent Education Series)-Central Plains Youth Top Talent Project [2022, 5]; Henan Province Science and Technology Research-Social Development Project [222102310214]; Henan Provincial Science and Technology R&D Program Joint Fund (superior discipline cultivation category) [222301420061]; Henan Province key research and development and promotion special project (science and technology research) [232102311203]; Henan Province Traditional Chinese Medicine "Double First-Class" Scientific Research Project [HSRP-DFCTCM-2023-7-09]
CR Acosta-Olivo C, 2014, CIR CIR, V82, P137
   Adatia A, 2012, J PHARM PHARMACOL, V64, P617, DOI 10.1111/j.2042-7158.2012.01458.x
   Ahmad MA, 2022, PHYSIOTHERAPY, V114, P85, DOI 10.1016/j.physio.2021.03.011
   Alghadir A, 2014, LASER MED SCI, V29, P749, DOI 10.1007/s10103-013-1393-3
   Anandkumar S, 2014, PHYSIOTHER THEOR PR, V30, P375, DOI 10.3109/09593985.2014.896963
   Unknown -, 2017, J NECK LOW BACK PAIN, V0, P0
   Unknown -, 2017, CHIN J BONE JOINT INJURY, V0, P0
   Arai T, 2022, BMC MUSCULOSKEL DIS, V23, P0, DOI 10.1186/s12891-022-05937-y
   Babaei-Ghazani A, 2018, CLIN RHEUMATOL, V37, P2517, DOI 10.1007/s10067-018-4147-6
   Bannuru RR, 2019, OSTEOARTHR CARTILAGE, V27, P1578, DOI 10.1016/j.joca.2019.06.011
   Bennell KL, 2021, JAMA-J AM MED ASSOC, V326, P2021, DOI 10.1001/jama.2021.19415
   BERTAZZOLO N, 1994, AGENTS ACTIONS, V41, P90, DOI 10.1007/BF01986402
   Bijlsma JWJ, 2011, LANCET, V377, P2115, DOI 10.1016/S0140-6736(11)60243-2
   Bowden J, 2011, BMC MED RES METHODOL, V11, P0, DOI 10.1186/1471-2288-11-41
   Cai LX, 2022, CHIN SCI TECHNOL J DATABASE MED HEALTH, V12), P0001
   Chen AF, 2020, BMC MUSCULOSKEL DIS, V21, P0, DOI 10.1186/s12891-020-03380-5
   Chen G, 2018, NEURON, V100, P1292, DOI 10.1016/j.neuron.2018.11.009
   Chu JB, 2022, KNEE SURG SPORT TR A, V30, P4063, DOI 10.1007/s00167-022-06887-7
   Cole BJ, 2017, AM J SPORT MED, V45, P339, DOI 10.1177/0363546516665809
   Culvenor AG, 2017, ARTHRIT CARE RES, V69, P649, DOI 10.1002/acr.23005
   Dainese P, 2022, OSTEOARTHR CARTILAGE, V30, P516, DOI 10.1016/j.joca.2021.12.003
   Dantas LO, 2021, BRAZ J PHYS THER, V25, P688, DOI 10.1016/j.bjpt.2021.07.003
   Dogan N, 2022, JCPSP-J COLL PHYSICI, V32, P1441, DOI 10.29271/jcpsp.2022.11.1441
   Donec V, 2020, CLIN REHABIL, V34, P877, DOI 10.1177/0269215520916859
   Dong B, 2022, MODERN CHIN MED, V42, P108, DOI 10.13424/j.cnki.mtcm.2022.01.021
   Duymus TM, 2017, KNEE SURG SPORT TR A, V25, P485, DOI 10.1007/s00167-016-4110-5
   El-Hakeim EH, 2018, PAIN PHYSICIAN, V21, P169, DOI 10.36076/ppj.2018.2.169
   Elawamy A, 2021, PAIN PHYSICIAN, V24, P127, DOI 10.36076/ppj.2021.24.127-134
   Fang GG, 2022, J MODERN TRADITIONAL CHIN MED, V02), P122
   Feng WH, 2019, SICHUAN J PHYSIOL SCI, V44, P457
   Ferreira RM, 2019, ACTA REUMATOL PORT, V44, P173
   Görmeli G, 2017, KNEE SURG SPORT TR A, V25, P958, DOI 10.1007/s00167-015-3705-6
   Güler T, 2022, RHEUMATOL INT, V42, P591, DOI 10.1007/s00296-022-05101-8
   Günaydin OE, 2022, PHYSIOTHER THEOR PR, V38, P661, DOI 10.1080/09593985.2020.1780657
   Hei G, 2019, CHIN J PAIN MED, V26, P150
   Helianthi DR, 2016, ACTA MED INDONES, V48, P114
   Higgins JPT, 2003, BMJ-BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Higgins JPT, 2011, BMJ-BRIT MED J, V343, P0, DOI 10.1136/bmj.d5928
   Huang XH, 2022, CHIN J CLIN PHARMACOL, V12), P1316, DOI 10.13699/j.carolcarrollnki.1001-6821.2022.12.005
   Hussain SM, 2016, SCOT MED J, V61, P7, DOI 10.1177/0036933015619588
   Hutton B, 2015, ANN INTERN MED, V162, P777, DOI 10.7326/M14-2385
   Ji JJ, 2020, CHIN J GERIATRIC MULTI-ORGAN DIS, V20, P410
   Jiang F, 2018, CHIN J MODERN MED, V28, P48
   Ju ZY, 2017, J SHANGHAI ACUPUNCTU, V4, P1111, DOI 10.13460/JISSN.1005-0957.2017.09.1111
   Kolasinski SL, 2020, ARTHRITIS RHEUMATOL, V72, P220, DOI 10.1002/art.41142
   Kong LL, 2020, JIANGSU MED, V46-48, P1000, DOI 10.19460/j.carolcarrollnki.0253-3685.2020.10.008
   Levinger I, 2011, ARTHRITIS RHEUM-US, V63, P1343, DOI 10.1002/art.30287
   Li HT, 2017, J TRADITIONAL CHIN MED, V01), P110, DOI 10.19664/j.carolcarrollnki.1002-2392.2017.01.033
   Li JF, 2018, CHIN ELDERLY MED J, V10), P1126, DOI 10.3760/cma.J.iSSN.0254-9026.2018.10.016
   Li MX, 2019, J TRADITIONAL CHINES, V35, P35
   Li SM, 2021, TRIALS, V22, P0, DOI 10.1186/s13063-021-05786-5
   Li WW, 2021, MED J CHIN PEOPLES HEALTH, V9, P0005
   Li YJ, 2002, LAB MED CLINIC, V19, P240
   [李忠龙 Li Zhonglong], 2015, 中国康复医学杂志 CHINESE JOURNAL OF REHABILITATION MEDICINE, V30, P580
   Lin L, 2021, SHANGHAI UNIV TRADITIONAL CHIN MED, V0, P0, DOI DOI 10.27320/
   Lin X, 2018, J CHIN MED, V4, P23, DOI 10.13193/j.iSSN.1673-7717.2018.01.005
   Liu WF, 2019, CHINA MED EQUIP INF, V25, P61
   Liu Y, 2022, WORLD J ACUPUNCT-MOX, V32, P329, DOI 10.1016/j.wjam.2022.07.009
   de Jesus CCL, 2017, PLOS ONE, V12, P0, DOI 10.1371/journal.pone.0179185
   Lv ZT, 2019, ARTHRITIS RES THER, V21, P0, DOI 10.1186/s13075-019-1899-6
   Ma JY, 2017, HAINAN MED, V28, P3553
   Mabey T, 2016, BIOMARKERS, V21, P639, DOI 10.3109/1354750X.2016.1171907
   Meng F, 2017, HEBEI MED, V39, P168
   Meng T, 2018, CHONGQING MED J, V47, P3184
   Moffett John, 2012, J PAIN RES, V5, P347, DOI 10.2147/JPR.S35076
   Mostafa MSEM, 2022, PHOTOBIOMOD PHOTOMED, V40, P198, DOI 10.1089/photob.2021.0136
   Mutlu EK, 2017, AM J PHYS MED REHAB, V96, P25, DOI 10.1097/PHM.0000000000000520
   Page MJ, 2018, BMJ OPEN, V8, P0, DOI 10.1136/bmjopen-2017-019703
   Pan JK, 2023, TRADITIONAL CHINESE, V35, P1
   Pan Q, 2023, J LIAONING TRADIT CHIN MED, V50, P174, DOI 10.13192/j.iSSN.1000-1719.2023.03.049
   Park YB, 2021, AM J SPORT MED, V49, P487, DOI 10.1177/0363546520986867
   Patel S, 2013, AM J SPORT MED, V41, P356, DOI 10.1177/0363546512471299
   Perlman A, 2019, J GEN INTERN MED, V34, P379, DOI 10.1007/s11606-018-4763-5
   Raeissadat SA, 2021, BMC MUSCULOSKEL DIS, V22, P0, DOI 10.1186/s12891-021-04017-x
   Rahimzadeh Poupak, 2022, ANESTH PAIN MED, V12, Pe127121, DOI 10.5812/aapm-127121
   Reyes-Sosa R, 2020, J APPL BIOMED, V18, P41, DOI 10.32725/jab.2020.012
   Rouse B, 2017, INTERN EMERG MED, V12, P103, DOI 10.1007/s11739-016-1583-7
   Sari Z, 2019, PAIN RES MANAG, V2019, P0, DOI 10.1155/2019/8514808
   Seitidis G, 2022, PREV SCI, V23, P415, DOI 10.1007/s11121-021-01289-6
   Shen XY, 2009, LASER MED SCI, V24, P129, DOI 10.1007/s10103-007-0536-9
   Shi BH, 2019, CLIN REV, V35, P1111
   Shim S, 2017, EPIDEMIOL HEALTH, V39, P0, DOI 10.4178/epih.e2017047
   Sluijter Menno E, 2008, PAIN PRACT, V8, P57, DOI 10.1111/j.1533-2500.2007.00172.x
   Su Wenzhen, 2019, ZHONGGUO XIU FU CHONG JIAN WAI KE ZA ZHI, V33, P1527, DOI 10.7507/1002-1892.201905007
   Tu JF, 2021, ARTHRITIS RHEUMATOL, V73, P448, DOI 10.1002/art.41584
   Uematsu H, 2021, PAIN PHYSICIAN, V24, PE761, DOI 10.36076/ppj.2021.24.e761
   Uhlmann L, 2018, BMC MED RES METHODOL, V18, P0, DOI 10.1186/s12874-018-0574-y
   Uysal A, 2020, INT ORTHOP, V44, P1311, DOI 10.1007/s00264-020-04541-w
   Vina ER, 2018, CURR OPIN RHEUMATOL, V30, P160, DOI 10.1097/BOR.0000000000000479
   Wang C, 2019, CHINESE J BONE INJUR, V35, P848
   Wang HL, 2019, J CLIN MEDICAL LIT E, V7, P74
   Wang Q, 2022, J SHANGHAI ACUPUNCTURE MAGAZINE, V9, P713, DOI 10.13460/j.iSSN.1005-0957.2021.13.0048
   Wang SQ, 2020, J REHABILITATION, V30, P177
   Wang XB, 2020, J TRADITIONAL CHINES, V13, P55, DOI 10.19664/J.CAROLCARROLLNKI.1002-2392.200145
   Wang XC, 2016, CHIN J PAIN MED, V27, P785
   Wang YC, 2022, MEDICINA-LITHUANIA, V58, P0, DOI 10.3390/medicina58081028
   Wang Z, 2023, EUR J MED RES, V28, P0, DOI 10.1186/s40001-022-00968-6
   Watt Jennifer, 2022, METHODS MOL BIOL, V2345, P187, DOI 10.1007/978-1-0716-1566-9_12
   Wu MX, 2010, CHIN J INTEGR MED, V16, P291, DOI 10.1007/s11655-010-0513-1
   Wu YL, 2022, CLIN J PRACT HOSPITAL, V19, P62, DOI 10.3969/j.issn.1672-6170.2022.02.017
   Xie JW, 2021, AGEING RES REV, V70, P0, DOI 10.1016/j.arr.2021.101413
   Xin R, 2021, J CLIN MED RES PRACT, V6, P35, DOI 10.19347/j.carolcarrollnki.2096-1413.202109013
   Xiong YZ, 2020, CHINESE J ORTHOPAEDI, V28, P19
   Xu Dang-Han, 2022, ZHONGGUO ZHEN JIU, V42, P1351, DOI 10.13703/j.0255-2930.20220126-k0002
   Xu H, 2023, WORLD CHIN MED, V18, P929
   Xu H, 2023, PAIN MED, V24, P244, DOI 10.1093/pm/pnac127
   Yang S, 2022, CHINESE J ACUTE CHIN, V31, P1177
   Yu SP, 2015, AUST PRESCR, V38, P115, DOI 10.18773/austprescr.2015.039
   Yurtkuran M, 2007, PHOTOMED LASER SURG, V25, P14, DOI 10.1089/pho.2006.1093
   Zhang W, 2008, OSTEOARTHR CARTILAGE, V16, P137, DOI 10.1016/j.joca.2007.12.013
   Zhang WJ, 2020, WEST J TRAD CHIN MED, V33, P107, DOI 10.12174/j.issn.1004-6852.2020.09.31
   Zhao L, 2021, J RHEUMATOL, V48, P924, DOI 10.3899/jrheum.200217
   Zhao Q, 2021, J LOGISTICS COLL ARMED POLICE FORCE (MEDICAL EDITION), V30, P20, DOI 10.16548/J.2095-3720.2021.11.072
   Zhao Z, 2013, J SURG RES, V185, P661, DOI 10.1016/j.jss.2013.07.004
   Zheng LL, 2019, J TISSUE ENG, V27, P5681
   Zheng YL, 2011, CHIN J CLIN, V49, P717
   Zhong ZY, 2019, ARCH PHYS MED REHAB, V100, P1695, DOI 10.1016/j.apmr.2019.04.020
   Zhu DY, 2019, FUJIAN UNIV TRADITIONAL CHIN MED, V0, P0
   Zhuo ZM, 2021, MODERN BIOMED PROG, V21, P2551
   Zuo XT, 2022, NANJING UNIV CHIN MED, V0, P0, DOI DOI 10.27253/dcnki.Gnjzu.2021.000208
NR 120
TC 20
Z9 22
U1 8
U2 38
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-3224
EI 
J9 FRONT IMMUNOL
JI Front. Immunol.
PD DEC 14
PY 2023
VL 14
IS 
BP 
EP 
DI 10.3389/fimmu.2023.1309751
PG 20
WC Immunology
SC Immunology
GA DP1H5
UT WOS:001133163400001
PM 38155966
DA 2026-01-16
ER

PT J
AU Han, XR
   Yue, W
   Chen, HC
   He, W
   Luo, JH
   Chen, SX
   Liu, N
   Yang, M
AF Han, Xin-Rui
   Yue, Wei
   Chen, Hui-Chao
   He, Wei
   Luo, Jiang-He
   Chen, Shan-Xia
   Liu, Na
   Yang, Ming
TI Treatment duration of wrist-ankle acupuncture for relieving post-thyroidectomy
SO Journal of integrative medicine
LA English
DT Journal Article
DE Post-operative pain; Randomized controlled trial; Thyroid tumor; Thyroidectomy; Wrist-ankle acupuncture
AB BACKGROUND: Treatment duration of wrist-ankle acupuncture (WAA) is uncertain for  post-thyroidectomy pain relief. OBJECTIVE: This study evaluated the effect of  different WAA treatment duration on post-operative pain relief and other  discomforts associated with thyroidectomy. DESIGN, SETTING, PARTICIPANTS AND  INTERVENTION: This randomized controlled trial was conducted at a single research  site in Guangzhou, China. A total of 132 patients receiving thyroidectomy were  randomly divided into the control group (sham WAA, 30 min) and three intervention  groups (group 1: WAA, 30 min; group 2: WAA, 45 min; group 3: WAA, 60 min), with  group allocation ratio of 1:1:1:1. Acupuncture was administered within 1 hour of  leaving the operating room. OUTCOMES AND MEASURES: Primary outcome was patients'  pain at the surgical site assessed by visual analogue scale (VAS) at the moment  after acupuncture treatment (post-intervention). Secondary outcomes included the  patients' pain VAS scores at 6, 12, 24, 48 and 72 h after the thyroidectomy, the  40-item Quality of Recovery (QoR-40) score, the grade of post-operative nausea  and vomiting (PONV), and the use of additional analgesic therapy. RESULTS: The  adjusted mean difference (AMD) in VAS scores from baseline to post-intervention  in group 1 was -0.89 (95% confidence interval [CI], -1.02 to -0.76). The decrease  in VAS score at post-intervention was statistically significant in group 1  compared to the control group (AMD, -0.43; 95% CI, -0.58 to -0.28; P < 0.001),  and in groups 2 and 3 compared to group 1 (group 2 vs group 1: AMD, -0.65; 95%  CI, -0.81 to -0.48; P < 0.001; group 3 vs group 1: AMD, -0.66; 95% CI, -0.86 to  -0.47; P < 0.001). The VAS scores in the four groups converged beyond 24 h after  the operation. Fewer patients in group 2 and group 3 experienced PONV in the  first 24 h after operation. No statistical differences were measured in QoR-40  score and the number of patients with additional analgesic therapy. CONCLUSION:  Compared with the 30 min intervention, WAA treatment with longer needle retention  time (45 or 60 min) had an advantage in pain relief within 6 h after surgery.  WAA's analgesic effect lasted for 6-12 h post-operatively. Please cite this  article as: Han XR, Yue W, Chen HC, He W, Luo JH, Chen SX, Liu N, Yang M.  Treatment duration of wrist-ankle acupuncture for relieving post-thyroidectomy  pain: A randomized controlled trial. J Integr Med. 2023; 21(2): 168-175.
C1 Department of Nursing, Chengdu Integrated TCM & Western Medicine Hospital, Sichuan 610041, Sichuan Province, China.
   School of Nursing, Guangzhou University of Chinese Medicine, Guangzhou 510006, Guangdong Province, China.
   Department of Nursing, Guangdong Provincial Hospital of Traditional Chinese Medicine, Guangzhou 510120, Guangdong Province, China.
   Department of General Surgery, Guangdong Provincial Hospital of Traditional Chinese Medicine, Guangzhou 510120, Guangdong Province, China.
   Department of Gynecology and Obstetrics, Guangzhou Women and Children's Medical Center, Guangzhou 510120, Guangdong Province, China.
   School of Nursing, Guangzhou University of Chinese Medicine, Guangzhou 510006, Guangdong Province, China.
   School of Nursing, Guangzhou University of Chinese Medicine, Guangzhou 510006, Guangdong Province, China.
   School of Nursing, Guangzhou University of Chinese Medicine, Guangzhou 510006, Guangdong Province, China.
EM hlym@gzucm.edu.cn
NR 0
TC 0
SN 
EI 2095-496
J9 J Integr Med
PD FEB 26
PY 2023
VL 21
IS 2
BP 168
EP 175
DI 10.1016/j.joim.2023.02.001
PG 7
WC Male; Humans; Ankle; Wrist; Duration of Therapy; Thyroidectomy; Postoperative Nausea and Vomiting; drug therapy; Acupuncture Therapy; Analgesics; therapeutic use; Pain; drug therapy
UT PubMed:36841749
PM 36841749
DA 2023-02-26
ER

PT J
AU Zhang, YL
   Mao, JJ
   Li, QS
   Weitzman, M
   Liou, KT
AF Zhang, Yi Lily
   Mao, Jun J
   Li, Q Susan
   Weitzman, Matthew
   Liou, Kevin T
TI Battlefield acupuncture for chronic musculoskeletal pain in cancer survivors: a
SO Frontiers in pain research (Lausanne, Switzerland)
LA English
DT Journal Article
DE auricular acupuncture; battlefield acupuncture; cancer; care delivery; clinical trial; pain
AB INTRODUCTION: Battlefield Acupuncture (BFA), a standardized auricular acupuncture  protocol, is widely used for pain in the military but is not well-studied in  oncology. This study examined cancer survivors who received BFA for pain.  METHODS: This is a secondary analysis of a randomized trial that compared the  effectiveness of BFA and electroacupuncture vs. usual care for chronic  musculoskeletal pain in cancer survivors. This study focused on participants  randomized to BFA. Participants received 10 weekly treatments. Needles were  placed until one of these stop conditions were satisfied: ten needles were  administered; pain severity decreased to ≤1 out of 10; patient declined further  needling, or vasovagal reaction was observed. Pain severity was assessed using  Brief Pain Inventory. Responders were those with ≥30% pain severity reduction. We  examined pain location, BFA stop reason, and pain reduction of participants  during the first session. We also examined which factors predicted responder  status after the first session (week 1) or the full treatment (week 12). RESULTS:  Among 143 randomized to BFA, most common pain locations were lower back (30.8%)  and knee/leg (18.2%). Of 138 who initiated treatment, 41 (30.0%) received ten  needles; 81 (59.1%) achieved pain ≤1; 14 (10.2%) declined further needling; and 1  (0.7%) had vasovagal reaction. BFA reduced pain severity by 2.9 points (95% CI  2.6 to 3.2) after the first session (P < 0.001). After adjusting for baseline  pain severity, responders at week 1 were 2.5 times more likely to be responders  at week 12, compared to those who were non-responders at week 1 (AOR 2.5, 95% CI  1.02 to 6.11, P = 0.04). Among those who achieved pain ≤1, 74% were responders at  week 12, a higher proportion compared to the proportion of responders among those  who received ten needles (39.5%), those who declined further needling (50%), and  those with vasovagal reaction (0.0%) (P = 0.001). Those with pain in proximal  joints had a higher proportion of responders at week 12, compared to those with  pain in distal joints (64.2% vs. 20%, P = 0.008). CONCLUSION: Specific factors  may predict the likelihood of achieving meaningful pain reduction from BFA.  Understanding these predictors could inform precision pain management and  acupuncture delivery models.
C1 Integrative Medicine Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, United States.
   Integrative Medicine Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, United States.
   Integrative Medicine Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, United States.
   Integrative Medicine Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, United States.
   Integrative Medicine Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, United States.
NR 0
TC 0
SN 2673-561
EI 2673-561
J9 Front Pain Res (Lausanne)
PD DEC 20
PY 2023
VL 4
IS 
BP 1279420
EP 1279420
DI 10.3389/fpain.2023.1279420
PG 0
UT PubMed:38116187
PM 38116187
DA 2023-12-20
ER

PT J
AU Zhang, RY
   Zhu, BF
   Zhao, JG
   Zhao, L
   Wang, LK
AF Zhang, R Y
   Zhu, B F
   Zhao, J G
   Zhao, L
   Wang, L K
TI Electroacupuncture Stimulation Alleviates Inflammatory Pain in Male Rats by
SO Physiological research
LA English
DT Journal Article
AB In the present study, we focused on whether the analgesic effect of  Electroacupuncture (EA) is related to the regulation of oxidative stress. We  established a chronic inflammatory pain model in male rats by a single injection  of complete Freund's adjuvant (CFA) and then treated the animals with daily EA  stimulation at the site of "zusanli". The analgesic effect of EA was evaluated by  measuring the paw withdrawal threshold (PWT) when rats received mechanical and  thermal pain stimulation. The levels of inflammation-related molecules and  oxidative stress-related markers in the spinal cord were measured by western  blotting or ELISA kits. EA stimulation and antioxidants effectively increased the  PWT in CFA rats. Co-treatment of CFA rats with the ROS donor t-butyl  hydroperoxide (t-BOOH) further decreased the PWT and weakened the analgesic  effect of EA. EA treatment inhibited inflammation and oxidative stress, as shown  by decreased levels of tumor necrosis factor-alpha (TNF-alpha), interleukin-1beta  (IL-1beta), IL-6, and MDA and increased activity of SOD and catalase. Moreover,  EA reduced the expression of p-p38, p-ERK, and p-p65 and simultaneously  downregulated the expression of TRPV1 and TRPV4 in CFA rats. In an in vitro  study, direct stimulation with t-BOOH to the C6 cells increased the production of  TNF-alpha, IL-1beta, IL-6, activated p38, ERK, and p65 and up-regulated the  expression of TRPV1 and TRPV4, and these effects could be prevented by the ROS  scavenger PBN. Taken together, our data indicate that the inhibition of oxidative  stress and the generation of ROS contribute to the analgesic effect of EA in male  CFA rats.
C1 Department of Pain Management, Anhui Medical University, Hospital of Hefei, Hefei, People's Republic of China. wlk9560@163.com.
NR 0
TC 0
SN 1802-997
EI 0862-840
J9 Physiol Res
PD NOV 28
PY 2023
VL 72
IS 5
BP 657
EP 667
DI 10.33549/physiolres.934965
PG 10
WC Rats; Male; Animals; TRPV Cation Channels; Electroacupuncture; Tumor Necrosis Factor-alpha; Interleukin-6; Reactive Oxygen Species; Rats, Sprague-Dawley; Chronic Pain; Inflammation; chemically induced; Analgesics; Oxidative Stress
UT PubMed:38015764
PM 38015764
DA 2023-11-28
ER

PT J
AU Yang, M
   Baser, RE
   Khanin, R
   Autuori, I
   Li, QS
   Panageas, KS
   Orlow, I
   Mao, JJ
AF Yang, Mingxiao
   Baser, Raymond E
   Khanin, Raya
   Autuori, Isidora
   Li, Qing S
   Panageas, Katherine S
   Orlow, Irene
   Mao, Jun J
TI COMT Val158Met Affects the Analgesic Response to Acupuncture Among Cancer
SO The journal of pain
LA English
DT Journal Article
DE COMT Val158Met; acupuncture; cancer survivors; chronic pain; treatment response
AB Catechol-O-methyltransferase (COMT) is the major enzyme involved in the  catabolism of dopamine, a neurotransmitter in the brain's reward system. The  common COMT polymorphism Val158Met (rs4680 G>A) modulates pain response to  opioids through a reward-motivated mechanism; however, its role in  nonpharmacological pain medicine has not been clinically characterized. We  genotyped 325 participants from a randomized controlled trial of cancer survivors  with chronic musculoskeletal pain. We found that carrying methionine at position  158 (158Met) of COMT, encoded by the A allele, significantly increased the  analgesic response to electroacupuncture (74% vs 50%; odds ratio [OR]: 2.79; 95%  confidence interval [CI]: 1.31, 6.05; P < .01), but not to auricular acupuncture  (68% vs 60%; OR: 1.43; 95% CI: .65, 3.12; P = .37) or usual care (24% vs 18%; OR:  1.46; 95% CI: .38, 7.24; P = .61) compared to Val/Val. These findings raise the  possibility that COMT Val158Met might be an important predictor of analgesic  response to electroacupuncture, providing novel insights into precision  nonpharmacologic pain management tailored to individual genetic backgrounds.  PERSPECTIVE: This work suggests the modulating effects of the polymorphism in  COMT Val158Met on the response to acupuncture. Further research needs to validate  these findings, increase the mechanistic understanding of acupuncture, and guide  further development of acupuncture as a precision pain management strategy.
C1 Integrative Medicine Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
   Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York.
   Bioinformatics Core Computational Biology Program, Memorial Sloan Kettering Cancer Center, New York, New York.
   Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York.
   Integrative Medicine Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
   Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York.
   Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York.
   Integrative Medicine Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
EM maoj@mskcc.org
NR 0
TC 0
SN 1528-844
EI 1526-590
J9 J Pain
PD MAY 16
PY 2023
VL 24
IS 9
BP 1721
EP 1730
DI 10.1016/j.jpain.2023.05.005
PG 9
WC Humans; Catechol O-Methyltransferase; genetics; Chronic Pain; genetics; Cancer Survivors; Genotype; Acupuncture Therapy; Analgesics, Opioid; Polymorphism, Single Nucleotide; genetics; Neoplasms
UT PubMed:37187218
PM 37187218
DA 2023-05-16
ER

PT J
AU Liou, KT
   Ashare, R
   Worster, B
   Jones, KF
   Yeager, KA
   Acevedo, AM
   Ferrer, R
   Meghani, SH
AF Liou, Kevin T
   Ashare, Rebecca
   Worster, Brooke
   Jones, Katie F
   Yeager, Katherine A
   Acevedo, Amanda M
   Ferrer, Rebecca
   Meghani, Salimah H
TI SIO-ASCO guideline on integrative medicine for cancer pain management:
SO JNCI cancer spectrum
LA English
DT Journal Article
AB Racial and ethnic disparities in pain management pose major challenges to  equitable cancer care delivery. These disparities are driven by complex  interactions between patient-, provider-, and system-related factors that resist  reductionistic solutions and require innovative, holistic approaches. On  September 19, 2022, the Society for Integrative Oncology and the American Society  of Clinical Oncology published a joint guideline to provide evidence-based  recommendations on integrative medicine for cancer pain management. Integrative  medicine, which combines conventional treatments with complementary modalities  from cultures and traditions around the world, are uniquely equipped to resonate  with diverse cancer populations and fill existing gaps in pain management.  Although some complementary modalities, such as music therapy and yoga, lack  sufficient evidence to make a specific recommendation, other modalities, such as  acupuncture, massage, and hypnosis, demonstrated an intermediate level of  evidence, resulting in moderate strength recommendations for their use in cancer  pain management. However, several factors may hinder real-world implementation of  the Society for Integrative Oncology and the American Society of Clinical  Oncology guideline and must be addressed to ensure equitable pain management for  all communities. These barriers include, but are not limited to, the lack of  insurance coverage for many complementary therapies, the limited diversity and  availability of complementary therapy providers, the negative social norms  surrounding complementary therapies, the underrepresentation of racial and ethnic  subgroups in the clinical research of complementary therapies, and the paucity of  culturally attuned interventions tailored to diverse individuals. This commentary  examines both the challenges and the opportunities for addressing racial and  ethnic disparities in cancer pain management through integrative medicine.
C1 Integrative Medicine Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
   Department of Psychology, State University of New York at Buffalo, Buffalo, NY, USA.
   Department of Medical Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, USA.
   Center for Aging and Serious Illness, Massachusetts General Hospital, Boston, MA, USA.
   Nell Hodgson Woodruff School of Nursing, Emory University, Atlanta, GA, USA.
   Behavioral Research Program, Division of Cancer Control and Population Sciences, National Cancer Institute, Rockville, MD, USA.
   Behavioral Research Program, Division of Cancer Control and Population Sciences, National Cancer Institute, Rockville, MD, USA.
   Department of Biobehavioral Health Science, School of Nursing, University of Pennsylvania, Philadelphia, PA, USA.
NR 0
TC 0
SN 2515-509
EI 
J9 JNCI Cancer Spectr
PD JUN 12
PY 2023
VL 7
IS 4
BP 
EP 
DI 10.1093/jncics/pkad042
PG 0
WC Humans; Cancer Pain; therapy; Complementary Therapies; Ethnic and Racial Minorities; Healthcare Disparities; Integrative Medicine; Integrative Oncology; Neoplasms; complications; Pain Management; methods; Practice Guidelines as Topic; Socioeconomic Disparities in Health; American Cancer Society
UT PubMed:37307074
PM 37307074
DA 2023-06-12
ER

PT J
AU Kim, WK
   Shin, JS
   Lee, J
   Koh, W
   Ha, IH
   Park, HJ
   Lee, SK
   Hong, JY
AF Kim, Won Kyung
   Shin, Joon-Shik
   Lee, Jinho
   Koh, Wonil
   Ha, In-Hyuk
   Park, Hyen Joo
   Lee, Sang Kook
   Hong, Jin Young
TI Effects of the administration of Shinbaro 2 in a rat lumbar disk herniation model
SO FRONTIERS IN NEUROLOGY
LA English
DT Article
DE lumbar disc herniation; Shinbaro 2; pro-inflammatory cytokines; inflammation; disk degeneration-related factors
ID intervertebral disc; pain; centipede; gcsb-5
AB The current standard for the pharmacological management of lumbar disk herniation (LDH), involving non-steroidal anti-inflammatory drugs, muscle relaxants, and opioid analgesics, often carries a risk of adverse events. The search for alternative therapeutic options remains a vital objective, given the high prevalence of LDH and the critical impact on the quality of life. Shinbaro 2 is a clinically effective herbal acupuncture against inflammation and various musculoskeletal disorders. Therefore, we explored whether Shinbaro 2 exerts protective effects in an LDH rat model. The results showed that Shinbaro 2 suppressed pro-inflammatory cytokines, interleukin-1 beta, tumor necrosis factor-alpha, disk degeneration-related factors, matrix metalloproteinase-1,-3,-9, and ADAMTS-5 in LDH rats. Shinbaro 2 administration reinstated a behavioral activity to a normal level in the windmill test. The results indicated that Shinbaro 2 administration restored spinal cord morphology and functions in the LDH model. Therefore, Shinbaro 2 exerted a protective effect in LDH via actions on inflammatory responses and disk degeneration, indicating that future research is warranted to assess the action mechanisms further and validate its effects.
C1 [Kim, Won Kyung; Park, Hyen Joo; Lee, Sang Kook] Seoul Natl Univ, Nat Prod Res Inst, Coll Pharm, Seoul, South Korea.
   [Shin, Joon-Shik; Lee, Jinho; Koh, Wonil] Jaseng Hosp Korean Med, Seoul, South Korea.
   [Ha, In-Hyuk; Hong, Jin Young] Jaseng Med Fdn, Jaseng Spine & Joint Res Inst, Seoul, South Korea.
C3 Seoul National University (SNU)
RP Lee, SK (corresponding author), Seoul Natl Univ, Nat Prod Res Inst, Coll Pharm, Seoul, South Korea.; Hong, JY (corresponding author), Jaseng Med Fdn, Jaseng Spine & Joint Res Inst, Seoul, South Korea.
EM sklee61@snu.ac.kr; vrt23@jaseng.org
CR Ali SM, 2019, AMB EXPRESS, V9, P0, DOI 10.1186/s13568-019-0816-3
   Alini M, 2008, EUR SPINE J, V17, P2, DOI 10.1007/s00586-007-0414-y
   Amin RM, 2017, CURR REV MUSCULOSKE, V10, P507, DOI 10.1007/s12178-017-9441-4
   Bachmeier BE, 2009, EUR SPINE J, V18, P1573, DOI 10.1007/s00586-009-1031-8
   Chao WW, 2011, CHIN MED-UK, V6, P0, DOI 10.1186/1749-8546-6-29
   Cho G, 2015, J PHARMACOPUNCT, V18, P44, DOI 10.3831/KPI.2015.18.005
   Cho HK, 2016, J KOREAN NEUROSURG S, V59, P98, DOI 10.3340/jkns.2016.59.2.98
   Choi HS, 2019, EVID-BASED COMPL ALT, V2019, P0, DOI 10.1155/2019/2345640
   Cunha C, 2018, ARTHRITIS RES THER, V20, P0, DOI 10.1186/s13075-018-1743-4
   Daly C, 2016, BIOMED RES INT, V2016, P0, DOI 10.1155/2016/5952165
   Ducati LG, 2013, EUR SPINE J, V22, PS404, DOI 10.1007/s00586-012-2516-4
   Freynhagen R, 2009, CURR PAIN HEADACHE R, V13, P185, DOI 10.1007/s11916-009-0032-y
   Gao WD, 2020, BIOMED RES INT, V2020, P0, DOI 10.1155/2020/1860637
   García-Cosamalón J, 2010, J ANAT, V217, P1, DOI 10.1111/j.1469-7580.2010.01227.x
   He JB, 2019, FRONT PHARMACOL, V10, P0, DOI 10.3389/fphar.2019.01344
   HOLM S, 1993, ACTA ORTHOP SCAND, V64, P13, DOI 10.3109/17453679309160105
   Nasab NH, 2021, NAT PROD COMMUN, V16, P0, DOI 10.1177/1934578X211050790
   Hwang L, 2018, EVID-BASED COMPL ALT, V2018, P0, DOI 10.1155/2018/5057372
   Ito T, 2007, SPINE, V32, P159, DOI 10.1097/01.brs.0000251437.10545.e9
   Jung HW, 2010, INT IMMUNOPHARMACOL, V10, P155, DOI 10.1016/j.intimp.2009.10.010
   Kanemoto M, 1996, SPINE, V21, P1, DOI 10.1097/00007632-199601010-00001
   Kang JD, 1997, SPINE, V22, P1065, DOI 10.1097/00007632-199705150-00003
   Karbwang J, 1997, EUR J CLIN PHARMACOL, V52, P307, DOI 10.1007/s002280050295
   Kim MJ, 2020, EVID-BASED COMPL ALT, V2020, P0, DOI 10.1155/2020/6749425
   Kim TH, 2011, J ETHNOPHARMACOL, V136, P297, DOI 10.1016/j.jep.2011.04.037
   Kim WK, 2016, CHIN MED-UK, V11, P0, DOI 10.1186/s13020-016-0089-6
   Lee H, 2017, BIOCHEM J, V474, P635, DOI 10.1042/BCJ20161039
   Lee SG, 2012, J ETHNOPHARMACOL, V142, P634, DOI 10.1016/j.jep.2012.05.020
   Lee YJ, 2017, BMC COMPLEM ALTERN M, V17, P0, DOI 10.1186/s12906-017-1942-6
   Lee YJ, 2016, BMC COMPLEM ALTERN M, V16, P0, DOI 10.1186/s12906-016-1288-5
   Löffek S, 2011, EUR RESPIR J, V38, P191, DOI 10.1183/09031936.00146510
   Lu PF, 2011, CSH PERSPECT BIOL, V3, P0, DOI 10.1101/cshperspect.a005058
   Oliveira CB, 2018, EUR SPINE J, V27, P2791, DOI 10.1007/s00586-018-5673-2
   Park JH, 2021, J CLIN MED, V10, P0, DOI 10.3390/jcm10081703
   Park SH, 2019, MEDIAT INFLAMM, V2019, P0, DOI 10.1155/2019/7651470
   Risbud MV, 2014, NAT REV RHEUMATOL, V10, P44, DOI 10.1038/nrrheum.2013.160
   Ruan WF, 2016, INT J SURG, V31, P86, DOI 10.1016/j.ijsu.2016.05.061
   Taher F, 2012, ADV ORTHOP, V2012, P0, DOI 10.1155/2012/970752
   Zhang XX, 2022, FRONT PLANT SCI, V13, P0, DOI 10.3389/fpls.2022.980854
   Zhao DD, 2016, MOLECULES, V21, P0, DOI 10.3390/molecules21101362
NR 40
TC 8
Z9 12
U1 0
U2 9
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-2295
EI 
J9 FRONT NEUROL
JI Front. Neurol.
PD MAR 10
PY 2023
VL 14
IS 
BP 
EP 
DI 10.3389/fneur.2023.1044724
PG 9
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 0A4SA
UT WOS:000951812800001
PM 36970511
DA 2026-01-16
ER

PT J
AU Yin, Y
   Wang, L
   Zhao, L
   Lin, L
   Shen, X
AF Yin, Yue
   Wang, Lina
   Zhao, Ling
   Lin, Lin
   Shen, Xueyong
TI Effect of 10.6 μm laser moxibustion on inflammation in diabetic peripheral
SO Frontiers in endocrinology
LA English
DT Journal Article
DE NF- kappa B; diabetes mellitus; diabetic peripheral neuropathy; inflammation; laser moxibustion
AB Diabetic peripheral neuropathy (DPN) is the main cause of disability in diabetes  patients but the efficacy of available drugs is poor. Moxibustion is an  adjunctive treatment for DPN that can reduce symptoms. The peak value of the far  infrared wavelength of 10.6 μm laser moxibustion is close to the infrared  radiation spectrum of traditional moxibustion. Its effect is similar to that of  moxibustion and does not cause pain, infection or produce irritating smoke.  Twenty-four male SD rats were divided into control (Con), DPN, laser moxibustion  (LM), and pyrrolidine dithiocarbamate (PDTC) groups (n=6/group). The DPN, LM and  PDTC group rats were intraperitoneally injected with 1% streptozotocin (STZ) to  induce a model of DPN. LM group rats were irradiated with a laser at bilateral  ST36 acupoints for 15 min, once every other day, for 14 days. PDTC group rats  were intraperitoneally injected with PDTC once a day. Body weight, blood glucose,  and paw withdrawal mechanical threshold (PWMT) were measured and laser speckle  imaging (LSI) performed before and after modeling and at 1 and 2 weeks after  intervention. Two weeks after intervention, changes in serum interleukin 1β  (IL1β), interleukin 6 (IL6), tumor necrosis factor α (TNFα) and nerve growth  factor (NGF) were analyzed, and the abundance of NF-κB and IκB-α proteins and  levels of NF-κB and IκB-α mRNAs in the sciatic nerve were observed. The results  showed that 10.6 μm laser moxibustion can relieve pain, improve microcirculation,  and alleviate inflammation in DPN rats, possibly via the NF-κB inflammatory  pathway.
C1 School of Acupuncture-Moxibustion and Tuina, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
   School of Acupuncture-Moxibustion and Tuina, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
   School of Acupuncture-Moxibustion and Tuina, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
   School of Nursing, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
   School of Acupuncture-Moxibustion and Tuina, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
   Laboratory of Systemic Physiology for Acupuncture and Meridian, Shanghai Research
NR 0
TC 0
SN 1664-239
EI 1664-239
J9 Front Endocrinol (Lausanne)
PD AUG 18
PY 2023
VL 14
IS 
BP 1203677
EP 1203677
DI 10.3389/fendo.2023.1203677
PG 0
WC Male; Animals; Rats; Rats, Sprague-Dawley; NF-kappa B; Diabetic Neuropathies; therapy; Moxibustion; NF-KappaB Inhibitor alpha; Inflammation; therapy; Lasers; Diabetes Mellitus
UT PubMed:37593350
PM 37593350
DA 2023-08-18
ER

PT J
AU Li, CY
   Zhao, C
   Zhao, JJ
   Wang, M
   Luo, FR
   Zhou, JW
AF Li, Chunyu
   Zhao, Can
   Zhao, Jingjing
   Wang, Min
   Luo, Furong
   Zhou, Jianwei
TI Global research trends of acupuncture therapy on cancer pain: A bibliometric and visualized study
SO FRONTIERS IN ONCOLOGY
LA English
DT Review
DE acupuncture; cancer pain; bibliometric analysis; VOSviewer; web of science
ID induced peripheral neuropathy; inhibitor-related arthralgia; early breast-cancer; electroacupuncture; chemotherapy; trial; women; mechanisms; symptoms; management
AB Background The number of publications on acupuncture for cancer pain is increasing rapidly with an upward tendency. Considering that no bibliometric articles related to this topic have been published yet. It is necessary to evaluate the global scientific output of research in this field, and shed light on the direction of clinical cancer pain management in the future.Methods Research publications regarding acupuncture on cancer pain from inception to 2022 were downloaded from the Web of Science Core Collection. Bibliometric analyses were performed using CiteSpace software, the bibliometrix R package, and VOSviewer software. Network maps were generated to assess the collaborations between different countries, institutions, authors, and keywords. And clusters map was generated to evaluate reference.Results A total of 790 articles related to acupuncture therapy for cancer pain were identified. We observe that the number of publications is gradually increasing over time. China and the United States were the main contributors. Mem Sloan Kettering Canc Ctr (38 papers) and Beijing Univ Chinese Med (28 papers) contributed the most publications, becoming the leading contributors in this field. Although J Clin Oncol (28 articles) ranked ninth in terms of publication volume, it was the journal with the most citations and the highest number of IF (50.717) and H-index (494) at the same time. MAO J from Mem Sloan Kettering Canc Ctr was the most prolific author (23 articles). The main hot topics included matters related to acupuncture (239 times), pain (199 times), management (139 times), quality of life (107 times), electroacupuncture (100 times), and breast cancer (82 times).Conclusion Our bibliometric analysis provides a comprehensive overview of the development of acupuncture for cancer pain, enabling relevant authors and research teams to identify the current research status in this field. At the same time, acupuncture for breast cancer (BC) pain, aromatase inhibitor-induced arthralgia (AIA), and chemotherapy-induced peripheral neuropathy (CIPN) may soon become prospective focus.
C1 [Li, Chunyu] Chengdu Univ Tradit Chinese Med, Teaching Hosp 3, Acupuncture & Tuina Sch, Chengdu, Sichuan, Peoples R China.
   [Zhao, Can] Chengdu Univ Tradit Chinese Med, Coll Pharm, Chengdu, Sichuan, Peoples R China.
   [Zhao, Jingjing; Wang, Min] Sichuan Second Hosp Tradit Chinese Med, Dept Acupuncture, Chengdu, Sichuan, Peoples R China.
   [Luo, Furong] Northwest Univ, Xian Hosp 3, Dept Tradit Chinese Med, Affiliated Hosp, Xian, Shanxi, Peoples R China.
   [Zhou, Jianwei] Sichuan Acad Chinese Med Sci, Chengdu, Sichuan, Peoples R China.
C3 Chengdu University of Traditional Chinese Medicine; Chengdu University of Traditional Chinese Medicine; Northwest University Xi'an
RP Zhou, JW (corresponding author), Sichuan Acad Chinese Med Sci, Chengdu, Sichuan, Peoples R China.
EM Jianweizhou126@126.com
FU project of Sichuan Provincial Administration of traditional Chinese Medicine [2021ZD02]
CR Bae K, 2015, INTEGR CANCER THER, V14, P496, DOI 10.1177/1534735415596573
   Bao T, 2018, EUR J CANCER, V101, P12, DOI 10.1016/j.ejca.2018.06.008
   Behzadmehr R, 2020, COMPLEMENT THER MED, V49, P0, DOI 10.1016/j.ctim.2020.102318
   Ben-Arye E, 2022, CANCER-AM CANCER SOC, V128, P3641, DOI 10.1002/cncr.34422
   Burstein HJ, 2010, J CLIN ONCOL, V28, P3784, DOI 10.1200/JOP.000082
   Cai DB, 2020, JAMA ONCOL, V6, P939, DOI 10.1001/jamaoncol.2020.0622
   Chang PJ, 2021, CANCERS, V13, P0, DOI 10.3390/cancers13205191
   Chavooshi B, 2017, PSYCHOSOMATICS, V58, P506, DOI 10.1016/j.psym.2017.01.003
   Chien TJ, 2020, CLIMACTERIC, V23, P130, DOI 10.1080/13697137.2019.1664460
   Chien TJ, 2017, PLOS ONE, V12, P0, DOI 10.1371/journal.pone.0180918
   Chien TJ, 2015, J ALTERN COMPLEM MED, V21, P251, DOI 10.1089/acm.2014.0083
   Choi JW, 2015, AM J CHINESE MED, V43, P57, DOI 10.1142/S0192415X15500044
   Crew KD, 2010, J CLIN ONCOL, V28, P1154, DOI 10.1200/JCO.2009.23.4708
   de la Rosa-Díaz I, 2022, LIFE-BASEL, V12, P0, DOI 10.3390/life12091328
   Gorin SS, 2012, J CLIN ONCOL, V30, P539, DOI 10.1200/JCO.2011.37.0437
   Greenlee H, 2016, BREAST CANCER RES TR, V156, P453, DOI 10.1007/s10549-016-3759-2
   He YH, 2020, JAMA ONCOL, V6, P271, DOI 10.1001/jamaoncol.2019.5233
   Huang CC, 2021, J CLIN MED, V10, P0, DOI 10.3390/jcm10163694
   Jones KF, 2022, J PALLIAT MED, V25, P964, DOI 10.1089/jpm.2021.0512
   Kutcher AM, 2022, WESTERN J NURS RES, V44, P169, DOI 10.1177/0193945921992538
   Lau CHY, 2016, MEDICINE, V95, P0, DOI 10.1097/MD.0000000000002901
   Lee HJ, 2009, ACUPUNCTURE ELECTRO, V34, P27, DOI 10.3727/036012909803861095
   Li HJ, 2021, J ALTERN COMPLEM MED, V27, P1084, DOI 10.1089/acm.2021.0133
   Li X, 2020, NEURAL PLAST, V2020, P0, DOI 10.1155/2020/8850653
   Liu L, 2022, FRONT NEUROSCI-SWITZ, V16, P0, DOI 10.3389/fnins.2022.992577
   Liu XM, 2021, INTEGR CANCER THER, V20, P0, DOI 10.1177/1534735420980811
   Lyman GH, 2018, J CLIN ONCOL, V36, P2647, DOI 10.1200/JCO.2018.79.2721
   Magee D, 2019, PAIN MANAG, V9, P63, DOI 10.2217/pmt-2018-0031
   Maindet C, 2019, SUPPORT CARE CANCER, V27, P3119, DOI 10.1007/s00520-019-04829-7
   Mao JJ, 2009, INTEGR CANCER THER, V8, P123, DOI 10.1177/1534735409332903
   Mao JJ, 2022, CA-CANCER J CLIN, V72, P144, DOI 10.3322/caac.21706
   Mao JJ, 2021, JAMA ONCOL, V7, P720, DOI 10.1001/jamaoncol.2021.0310
   McGuire Deborah B, 2004, J NATL CANCER INST MONOGR, V0, P51
   Molassiotis A, 2002, SUPPORT CARE CANCER, V10, P237, DOI 10.1007/s00520-001-0329-9
   Oh B, 2013, ACUPUNCT MED, V31, P264, DOI 10.1136/acupmed-2012-010309
   Peng SL, 2021, J PERS MED, V11, P0, DOI 10.3390/jpm11121244
   Pfister DG, 2010, J CLIN ONCOL, V28, P2565, DOI 10.1200/JCO.2009.26.9860
   Price S, 2006, INTEGR CANCER THER, V5, P308, DOI 10.1177/1534735406294899
   Roberts K, 2017, CRIT REV ONCOL HEMAT, V111, P66, DOI 10.1016/j.critrevonc.2017.01.010
   Roberts KE, 2020, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD012988.pub2
   Rostock M, 2013, EVID-BASED COMPL ALT, V2013, P0, DOI 10.1155/2013/349653
   Ruano A, 2022, J PAIN SYMPTOM MANAG, V63, PE505, DOI 10.1016/j.jpainsymman.2021.12.021
   Santen RJ, 2017, J CLIN ENDOCR METAB, V102, P3647, DOI 10.1210/jc.2017-01138
   Staff NP, 2017, ANN NEUROL, V81, P772, DOI 10.1002/ana.24951
   Sung H, 2021, CA-CANCER J CLIN, V71, P209, DOI 10.3322/caac.21660
   Swarm RA, 2019, J NATL COMPR CANC NE, V17, P977, DOI 10.6004/jnccn.2019.0038
   Tait RC, 2018, J PAIN, V19, P1367, DOI 10.1016/j.jpain.2018.06.002
   Tang QL, 2020, JAMA ONCOL, V6, P938, DOI 10.1001/jamaoncol.2020.0616
   Tsaras Konstantinos, 2018, ASIAN PAC J CANCER PREV, V19, P1661
   van den Beuken-van Everdingen MHJ, 2016, J PAIN SYMPTOM MANAG, V51, P1070, DOI 10.1016/j.jpainsymman.2015.12.340
   Wang BL, 2020, JAMA ONCOL, V6, P938, DOI 10.1001/jamaoncol.2020.0619
   Wang FJ, 2022, CHIN J INTEGR MED, V28, P833, DOI 10.1007/s11655-022-2896-1
   Wang M, 2022, EUR J ONCOL NURS, V58, P0, DOI 10.1016/j.ejon.2022.102134
   Wang Y, 2022, COMPUT MATH METHOD M, V2022, P0, DOI 10.1155/2022/3921021
   Yang J, 2021, BMJ SUPPORT PALLIAT, V11, P264, DOI 10.1136/bmjspcare-2020-002638
   Yang NN, 2022, CURR NEUROPHARMACOL, V20, P738, DOI 10.2174/1570159X19666210609162809
   Yoon SY, 2018, KOREAN J INTERN MED, V33, P1058, DOI 10.3904/kjim.2018.162
   Zhang F, 2017, GASTROENT RES PRACT, V2017, P0, DOI 10.1155/2017/5687496
   Zhang RX, 2014, ANESTHESIOLOGY, V120, P482, DOI 10.1097/ALN.0000000000000101
   Zhang YZ, 2021, FRONT ONCOL, V11, P0, DOI 10.3389/fonc.2021.646315
   Zhou Jincao, 2022, EVID BASED COMPLEMENT ALTERNAT MED, V2022, P8734207, DOI 10.1155/2022/8734207
   Zhu XY, 2021, FRONT ONCOL, V11, P0, DOI 10.3389/fonc.2021.745280
NR 62
TC 4
Z9 5
U1 2
U2 49
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 2234-943X
EI 
J9 FRONT ONCOL
JI Front. Oncol.
PD MAR 6
PY 2023
VL 13
IS 
BP 
EP 
DI 10.3389/fonc.2023.1077961
PG 13
WC Oncology
SC Oncology
GA A6IU8
UT WOS:000956146400001
PM 36950556
DA 2026-01-16
ER

PT J
AU Zhang, D
   Ji, Y
   Lv, L
   Zhou, QY
   Liu, ZJ
   Zhang, CL
   Chen, SS
AF Zhang, Di
   Ji, Yue
   Lv, Liu
   Zhou, Qiongyang
   Liu, Zhijiang
   Zhang, Chenlin
   Chen, Shanshan
TI An Overview of Systematic Reviews and Meta-Analyses of Clinical Studies of Acupuncture for Cancer Pain
SO INTEGRATIVE CANCER THERAPIES
LA English
DT Article
DE pain; cancer; acupuncture; overview; evidence
ID management; quality; risk
AB Background:Systematic reviews (SRs) and meta-analyses (MAs) for the use of acupuncture for cancer pain have been increasing, but the evidence has not been systematically and comprehensively assessed. We aimed to perform an overview of the evidence quality of SRs/MAs of acupuncture for improving cancer pain.Methods:8 databases were systematically searched to identify SRs/MAs of acupuncture for improving cancer pain. The A Measurement Tool to Assess Systematic Reviews 2 (AMSTAR-2), Risk of Bias in Systematic Reviews (ROBIS), Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA), and Grades of Recommendations, Assessment, Development, and Evaluation (GRADE), respectively, were applied by 2 independent reviewers to evaluate the methodological quality, risk of bias, reporting quality, and evidence quality.Results:A total of 14 SRs/MAs were included in the present study. By AMSTAR-2, two reviews were rated as having high methodological quality, while 12 were given a critically low rating. All SRs/MAs in Phase 1, Domain 1, and Domain 4, according to ROBIS, were at low risk. Furthermore, 4 reviews in Domain 2, twelve reviews in Domain 3, and ten SRs/MAs in Phase 3, were rated as having low risk of bias. With reporting quality, some reporting flaws were identified in the topic of protocol and registration, additional analyses, and search strategy. According to GRADE, the level of evidence quality was "critically low" to "moderate," and risk of bias was the most common downgraded factor.Conclusion:Acupuncture may be beneficial in improving cancer pain. However, due to the identified limitations and inconsistent findings, we recommend further rigorous, and more standardized SRs/MAs to provide strong evidence for definitive conclusions.
C1 [Zhang, Di] Shandong Univ Tradit Chinese Med, Affiliated Hosp, Jinan, Peoples R China.
   [Ji, Yue; Zhang, Chenlin] Tianjin Univ Tradit Chinese Med, Tianjin, Peoples R China.
   [Lv, Liu] Beijing Univ Chinese Med, Dongzhimen Hosp, Beijing, Peoples R China.
   [Zhou, Qiongyang] First Peoples Hosp Wenling, Wenling, Peoples R China.
   [Liu, Zhijiang] Gushi Cty Hosp TCM, Gushi, Peoples R China.
   [Chen, Shanshan] Gansu Prov Hosp TCM, Lanzhou, Peoples R China.
   [Chen, Shanshan] Gansu Prov Hosp TCM, 418 Guazhou Rd, Lanzhou City 730050, Gansu Province, Peoples R China.
C3 Shandong University of Traditional Chinese Medicine; Tianjin University of Traditional Chinese Medicine; Beijing University of Chinese Medicine
RP Chen, SS (corresponding author), Gansu Prov Hosp TCM, 418 Guazhou Rd, Lanzhou City 730050, Gansu Province, Peoples R China.
EM csstcm@163.com
FU Not Applicable.
CR [边双林 Bian Shuanglin], 2020, 中国中医基础医学杂志 CHINESE JOURNAL OF BASIC MEDICINE IN TRADITIONAL CHINESE MEDICINE, V26, P1143
   CAMPBELL A, 1999, ACUPUNCT MED, V17, P124, DOI 10.1136/AIM.17.2.124
   Chiu HY, 2017, EUR J CANCER CARE, V26, P0, DOI 10.1111/ecc.12457
   Choi TY, 2012, SUPPORT CARE CANCER, V20, P1147, DOI 10.1007/s00520-012-1432-9
   Chua IS, 2019, JAMA ONCOL, V5, P734, DOI 10.1001/jamaoncol.2019.0042
   Dong B, 2021, BMC COMPLEMENT MED, V21, P0, DOI 10.1186/s12906-020-03193-y
   Fletcher J, 2013, CAN MED ASSOC J, V185, P459, DOI 10.1503/cmaj.130319
   Guyatt GH, 2008, BRIT MED J, V336, P924, DOI 10.1136/bmj.39489.470347.AD
   He YH, 2020, JAMA ONCOL, V6, P271, DOI 10.1001/jamaoncol.2019.5233
   Hu CQ, 2016, EVID-BASED COMPL ALT, V2016, P0, DOI 10.1155/2016/1720239
   Huang JK, 2022, FRONT PUBLIC HEALTH, V10, P0, DOI 10.3389/fpubh.2022.842096
   Huang JK, 2022, GASTROENT RES PRACT, V2022, P0, DOI 10.1155/2022/7942845
   Huang JK, 2021, PAIN RES MANAG, V2021, P0, DOI 10.1155/2021/2752246
   Huang JK, 2020, J PAIN SYMPTOM MANAG, V61, P1052, DOI 10.1016/j.jpainsymman.2020.10.007
   Huang JK, 2021, FRONT CARDIOVASC MED, V8, P0, DOI 10.3389/fcvm.2021.589267
   Huang JK, 2021, CARDIOVASC THER, V2021, P0, DOI 10.1155/2021/8816590
   Huang JK, 2020, FRONT AGING NEUROSCI, V12, P0, DOI 10.3389/fnagi.2020.574023
   Huang JK, 2020, EVID-BASED COMPL ALT, V2020, P0, DOI 10.1155/2020/2032575
   Huang JK, 2020, EVID-BASED COMPL ALT, V2020, P0, DOI 10.1155/2020/1560978
   Huang JK, 2020, FRONT NEUROL, V11, P0, DOI 10.3389/fneur.2020.00917
   Huang JK, 2020, EUR J INTEGR MED, V37, P0, DOI 10.1016/j.eujim.2020.101133
   Huang JK, 2020, EVID-BASED COMPL ALT, V2020, P0, DOI 10.1155/2020/6920902
   Huang JK, 2020, EVID-BASED COMPL ALT, V2020, P0, DOI 10.1155/2020/4262910
   Kim TH, 2017, MATURITAS, V100, P82, DOI 10.1016/j.maturitas.2017.02.002
   Kim YC, 2015, CANCER MED-US, V4, P1196, DOI 10.1002/cam4.471
   Kwon JH, 2014, J CLIN ONCOL, V32, P1727, DOI 10.1200/JCO.2013.52.4827
   Li DH, 2021, EVID-BASED COMPL ALT, V2021, P0, DOI 10.1155/2021/5558590
   Linde K, 2010, BMC MED, V8, P0, DOI 10.1186/1741-7015-8-75
   Liu BY, 2021, ACUPUNCT HERB MED, V1, P65, DOI 10.1097/HM9.0000000000000017
   McAuley L, 2000, LANCET, V356, P1228, DOI 10.1016/S0140-6736(00)02786-0
   Miller M, 2015, JAMA INTERN MED, V175, P608, DOI 10.1001/jamainternmed.2014.8071
   Moffet HH, 2009, J ALTERN COMPLEM MED, V15, P213, DOI 10.1089/acm.2008.0356
   Neufeld NJ, 2017, FUTURE ONCOL, V13, P833, DOI 10.2217/fon-2016-0423
   Page MJ, 2021, BMJ-BRIT MED J, V372, P0, DOI 10.1136/bmj.n160
   Paley CA, 2011, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD007753.pub2
   Peng Hao, 2010, ZHONG XI YI JIE HE XUE BAO, V8, P501
   Sharfstein JM, 2019, JAMA-J AM MED ASSOC, V322, P809, DOI 10.1001/jama.2019.9794
   Shea BJ, 2017, BMJ-BRIT MED J, V358, P0, DOI 10.1136/bmj.j4008
   司尚坤, 2023, 上海针灸杂志 SHANGHAI JOURNAL OF ACUPUNCTURE AND MOXIBUSTION, V42, P318
   Simone CB II, 2012, CLIN J PAIN, V28, P157, DOI 10.1097/AJP.0b013e318223be30
   Swarm RA, 2019, J NATL COMPR CANC NE, V17, P977, DOI 10.6004/jnccn.2019.0038
   Tawfik GM, 2020, BMC MED RES METHODOL, V20, P0, DOI 10.1186/s12874-020-01094-9
   van den Beuken-van Everdingen MHJ, 2016, J PAIN SYMPTOM MANAG, V51, P1070, DOI 10.1016/j.jpainsymman.2015.12.340
   Vowles KE, 2015, PAIN, V156, P569, DOI 10.1097/01.j.pain.0000460357.01998.f1
   Wang JF, 2020, J EMERG TRADIT CHIN -MED, V29, P1140, DOI 10.3969/j.issn.1004-745X.2020.07.005
   Wang LF, 2023, ACUPUNCT HERB MED, V3, P83, DOI 10.1097/HM9.0000000000000062
   Whiting P, 2016, J CLIN EPIDEMIOL, V69, P225, DOI 10.1016/j.jclinepi.2015.06.005
   Yan ZB, 2022, FRONT PAIN RES, V3, P0, DOI 10.3389/fpain.2022.925013
   Zhang L, 2022, NURS REHABIL J, V21, P58, DOI 10.3969/j.issn.1671-9875.2022.12.015
   Zhang XW, 2022, WORLD J TRAD CHINESE, V8, P402, DOI 10.4103/2311-8571.351510
NR 50
TC 4
Z9 4
U1 2
U2 8
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1534-7354
EI 1552-695X
J9 INTEGR CANCER THER
JI Integr. Cancer Ther.
PD JUN 15
PY 2023
VL 22
IS 
BP 
EP 
DI 10.1177/15347354231210288
PG 11
WC Oncology; Integrative & Complementary Medicine
SC Oncology; Integrative & Complementary Medicine
GA X5YH9
UT WOS:001099201600001
PM 37942632
DA 2026-01-16
ER

PT J
AU Sun, DP
   Fu, J
   Teng, J
   Huang, Q
   Zhang, CD
   Gao, XZ
AF Sun, Dun-Po
   Fu, Jie
   Teng, Juan
   Huang, Qian
   Zhang, Chuan-Dong
   Gao, Xu-Zhu
TI [Cervical spondylosis of nerve root type with qi stagnation and blood stasis
SO Zhongguo zhen jiu = Chinese acupuncture & moxibustion
LA chi
DT Journal Article
DE acupuncture; inflammatory factors; nerve root type cervical spondylosis, qi stagnation and blood stasis; neurological function; warming needle
AB OBJECTIVE: To compare the clinical efficacy on cervical spondylosis of nerve root  type with qi stagnation and blood stasis treated with warming needle with  different lengths of moxa stick. METHODS: Six hundred patients with cervical  spondylosis of nerve root type with qi stagnation and blood stasis were randomly  divided into 4 groups: a 4 cm length group (150 cases, 5 cases dropped off, 2  cases suspended), a 3 cm length group (150 cases, 6 cases dropped off, 2 cases  suspended), a 2 cm length group (150 cases, 6 cases dropped off), and a routine  acupuncture group (150 cases, 6 cases dropped off). Warming needle with moxa  stick in the length of 4 cm, 3 cm and 2 cm was delivered in the 4 cm length  group, the 3 cm length group and the 2 cm length group, respectively. In the  routine acupuncture group, simple acupuncture was applied. The acupoints selected  in the above groups included Dazhui (GV 14) and bilateral Jiaji (EX-B 2) of C(5)  and C(7), Fengchi (GB 20), Jianzhen (SI 9), Quchi (LI 11), Zhongzhu (TE 3), etc.  In each group, the intervention was delivered once daily and 5 times a week. One  course of intervention was composed of 2 weeks and 2 courses were required. The  TCM syndrome score, the score of clinical assessment scale for cervical  spondylosis (CASCS), the score of the brachial plexus traction test of the  affected upper limb, F wave occurrence rate and conduction velocity of the ulnar  nerve, the median nerve and the radial nerve of the affected upper limb were  compared before and after treatment in the patients of each group. The levels of  serum inflammatory factors, i.e. interleukin-1β (IL-1β), interleukin-6 (IL-6),  tumor necrosis factor α (TNF-α) and hypersensitive C-reactive protein (hs-CRP),  were measured before and after treatment in the patients of each group. The  clinical cfficacy was evaluated in the 4 groups. RESULTS: After treatment, the  results of TCM syndrome evaluation, i.e. the scores of neck pain, activity  limitation and upper limb numbness and pain, as well as the total scores; and the  scores of brachial plexus traction test were reduced when compared with those  before treatment in each group (P<0.01, P<0.05). The scores of subjective  symptoms and adaptability, and the total scores of CASCS were elevated in  comparison with those before treatment in each group (P<0.01, P<0.05). In the 4  cm length group, compared with the other 3 groups, the scores of neck pain and  activity limitation for TCM syndrome evaluation, and its total score were lower  (P<0.05, P<0.01); and the scores of subjective symptoms and adaptability, and the  total score of CASCS were higher (P<0.05, P<0.01). The score of the brachial  plexus traction test in the 4 cm length group was lower than that of the routine  acupuncture group (P<0.05). After treatment, F wave occurrence rates and  conduction velocity of median nerve and radial nerve were increased when compared  with those before treatment in each group (P<0.05, P<0.01). F wave occurrence  rate and conduction velocity of the radial nerve in the 4 cm length group were  higher than those of the other 3 groups (P<0.05), and those of the median nerve  were higher when compared with the routine acupuncture group (P<0.05). After  treatment, the levels of serum IL-1β, IL-6 and TNF-α were all reduced when  compared with those before treatment in each group (P<0.01, P<0.05); the level of  serum IL-6 in the 4 cm length group was lower than those of the other 3 groups  and serum level of TNF-α was lower compared with that in the routine acupuncture  group (P<0.05). The total effective rate of the 4 cm length group was 78.3%  (112/143), which was higher when compared with the 3 cm length group (67.6%,  96/142), the 2 cm length group (65.3%, 94/144) and the routine acupuncture group  (53.5%, 77/144), respectively (P<0.05). CONCLUSION: Warming needle with moxa  stick of 4 cm in length effectively relieves the clinical symptoms of cervical  spondylosis of nerve root type with qi stagnation and blood stasis, improves the  nerve function of the upper limbs, and reduces the inflammatory responses caused  by nerve compression. The clinical efficacy of this therapy with moxa stick of 4  cm in length is superior to the warming needle with moxa sticks of 3 cm and 2 cm,  as well as the routine acupuncture.
C1 Lianyungang Affiliated Hospital of Nanjing University of Chinese Medicine/Lianyungang Hospital of TCM Affiliated to Kangda College of NanjingMedical University, Lianyungang 222004, Jiangsu Province, China.
   Lianyungang Affiliated Hospital of Nanjing University of Chinese Medicine/Lianyungang Hospital of TCM Affiliated to Kangda College of NanjingMedical University, Lianyungang 222004, Jiangsu Province, China.
   Lianyungang Affiliated Hospital of Nanjing University of Chinese Medicine/Lianyungang Hospital of TCM Affiliated to Kangda College of NanjingMedical University, Lianyungang 222004, Jiangsu Province, China.
   Lianyungang Affiliated Hospital of Nanjing University of Chinese Medicine/Lianyungang Hospital of TCM Affiliated to Kangda College of NanjingMedical University, Lianyungang 222004, Jiangsu Province, China.
   Lianyungang Affiliated Hospital of Nanjing University of Chinese Medicine/Lianyungang Hospital of TCM Affiliated to Kangda College of NanjingMedical University, Lianyungang 222004, Jiangsu Province, China.
   Central Laboratory of Lianyungang Second People's Hospital.
NR 0
TC 0
SN 
EI 0255-293
J9 Zhongguo Zhen Jiu
PD JUN 14
PY 2023
VL 43
IS 6
BP 647
EP 53
DI 10.13703/j.0255-2930.20220810-k0003
PG -594
WC Humans; Interleukin-6; Neck Pain; Qi; Tumor Necrosis Factor-alpha; Spondylosis; therapy
UT PubMed:37313558
PM 37313558
DA 2023-06-14
ER

PT J
AU Zhang, J
   Wu, W
   Ren, Y
   Yuan, Y
   Jia, L
AF Zhang, Junning
   Wu, Weizhen
   Ren, Yuehan
   Yuan, Yi
   Jia, Liqun
TI Electroacupuncture for the treatment of cancer pain: a systematic review and
SO Frontiers in pain research (Lausanne, Switzerland)
LA English
DT Review
DE cancer pain; complementary and alternative medicine; electroacupuncture; meta-analysis; rct; systematic review
AB OBJECTIVE: This paper aims to review the current evidence on electroacupuncture  as an effective and safe therapy for cancer pain management. METHODS: Five  databases were searched from their inception through November 11, 2022. Only the  randomized controlled trials that meet the eligibility criteria were finally  included in the study. Literature screening and data extraction were performed  independently by two reviewers, and RevMan 5.3 used for meta-analysis. RESULTS: A  total of 17 RCTs met our inclusion criteria. We used 8 indicators to estimate the  meta-analysis results, most of which proved statistically significant, including  VAS scores, NRS scores, and KPS scores. To be specific, VAS scores (MD = -1.41,  95% CI: -2.42 to -0.41, P = 0.006) and NRS scores (MD = -1.19, 95% CI: -1.72 to  -0.66, P < 0.0001) were significantly lower in the treatment group compared to  the control group. The treatment group's KPS scores (MD = 5.48, 95% CI: 3.27 to  7.69, P < 0.00001) were higher than those of the control group. Also, in the  treatment group, the number of burst pain (MD = -2.66, 95% CI: -3.32 to -1.99,  P < 0.00001) and side effect rates (RR = 0.51, 95% CI: 0.39 to 0.67, P < 0.00001)  greatly reduced, while the response rate (RR = 1.17, 95% CI: 1.09 to 1.26,  P < 0.0001) significantly increased compared to the control group. CONCLUSION:  This study demonstrates the advantages of electroacupuncture in the treatment of  cancer pain. Meanwhile, rigorous RCTs should be designed and conducted in the  future to further demonstrate the exact efficacy of electroacupuncture.  SYSTEMATIC REVIEW REGISTRATION: https://www.crd.york.ac.uk/PROSPERO/, identifier  CRD42022376148.
C1 Graduate School, Beijing University of Chinese Medicine, Beijing, China.
   Department of Oncology of Integrative Chinese and Western Medicine, China-Japan 
   Graduate School, Beijing University of Chinese Medicine, Beijing, China.
   Graduate School, Beijing University of Chinese Medicine, Beijing, China.
   Graduate School, Beijing University of Chinese Medicine, Beijing, China.
   Department of Oncology of Integrative Chinese and Western Medicine, China-Japan Friendship Hospital, Beijing, China.
NR 0
TC 0
SN 2673-561
EI 2673-561
J9 Front Pain Res (Lausanne)
PD MAY 31
PY 2023
VL 4
IS 
BP 1186506
EP 1186506
DI 10.3389/fpain.2023.1186506
PG 0
UT PubMed:37255718
PM 37255718
DA 2023-05-31
ER

PT J
AU Epstein, AS
   Liou, KT
   Romero, SAD
   Baser, RE
   Wong, G
   Xiao, H
   Mo, Z
   Walker, D
   MacLeod, J
   Li, Q
   Barton-Burke, M
   Deng, GE
   Panageas, KS
   Farrar, JT
   Mao, JJ
AF Epstein, Andrew S
   Liou, Kevin T
   Romero, Sally A D
   Baser, Raymond E
   Wong, Greta
   Xiao, Han
   Mo, Zunli
   Walker, Desiree
   MacLeod, Jodi
   Li, Qing
   Barton-Burke, Margaret
   Deng, Gary E
   Panageas, Katherine S
   Farrar, John T
   Mao, Jun J
TI Acupuncture vs Massage for Pain in Patients Living With Advanced Cancer: The
SO JAMA network open
LA English
DT Journal Article
AB IMPORTANCE: Pain is challenging for patients with advanced cancer. While recent  guidelines recommend acupuncture and massage for cancer pain, their comparative  effectiveness is unknown. OBJECTIVE: To compare the effects of acupuncture and  massage on musculoskeletal pain among patients with advanced cancer. DESIGN,  SETTING, AND PARTICIPANTS: A multicenter pragmatic randomized clinical trial was  conducted at US cancer care centers consisting of a northeastern comprehensive  cancer center and a southeastern cancer institute from September 19, 2019,  through February 23, 2022. The principal investigator and study statisticians  were blinded to treatment assignments. The duration of follow-up was 26 weeks.  Intention-to-treat analyses were performed (linear mixed models). Participants  included patients with advanced cancer with moderate to severe pain and  clinician-estimated life expectancy of 6 months or more. Patient recruitment  strategy was multipronged (eg, patient database queries, mailings, referrals,  community outreach). Eligible patients had English or Spanish as their first  language, were older than 18 years, and had a Karnofsky score greater than or  equal to 60 (range, 0-100; higher scores indicating less functional impairment).  INTERVENTIONS: Weekly acupuncture or massage for 10 weeks with monthly booster  sessions up to 26 weeks. MAIN OUTCOMES AND MEASURES: The primary end point was  the change in worst pain intensity score from baseline to 26 weeks. The secondary  outcomes included fatigue, insomnia, and quality of life. The Brief Pain  Inventory (range, 0-10; higher numbers indicate worse pain intensity or  interference) was used to measure the primary outcome. The secondary outcomes  included fatigue, insomnia, and quality of life. RESULTS: A total of 298  participants were enrolled (mean [SD] age, 58.7 [14.1] years, 200 [67.1%] were  women, 33 [11.1%] Black, 220 [74.1%] White, 46 [15.4%] Hispanic, and 78.5% with  solid tumors). The mean (SD) baseline worst pain score was 6.9 (1.5). During 26  weeks, acupuncture reduced the worst pain score, with a mean change of -2.53 (95%  CI, -2.92 to -2.15) points, and massage reduced the Brief Pain Inventory worst  pain score, with a mean change of -3.01 (95% CI, -3.38 to -2.63) points; the  between-group difference was not significant (-0.48; 95% CI, -0.98 to 0.03;  P = .07). Both treatments also improved fatigue, insomnia, and quality of life  without significant between-group differences. Adverse events were mild and  included bruising (6.5% of patients receiving acupuncture) and transient soreness  (15.1% patients receiving massage). CONCLUSIONS AND RELEVANCE: In this randomized  clinical trial among patients with advanced cancer, both acupuncture and massage  were associated with pain reduction and improved fatigue, insomnia, and quality  of life over 26 weeks; however, there was no significant different between the  treatments. More research is needed to evaluate how best to integrate these  approaches into pain treatment to optimize symptom management for the growing  population of people living with advanced cancer. TRIAL REGISTRATION:  ClinicalTrials.gov Identifier: NCT04095234.
C1 Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
   Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
   Department of Obstetrics, Gynecology, and Reproductive Sciences, University of California, San Diego.
   Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York.
   Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
   Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
   Cancer Patient Support Center, Baptist Health Miami Cancer Institute, Miami, Florida.
   Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
   Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
   Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
   Office of Nursing Research, Memorial Sloan Kettering Cancer Center, New York, New York.
   Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
   Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York.
   Department of Biostatistics and Epidemiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia.
   Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
NR 0
TC 0
SN 2574-380
EI 
J9 JAMA Netw Open
PD NOV 14
PY 2023
VL 6
IS 11
BP e2342482
EP e2342482
DI 10.1001/jamanetworkopen.2023.42482
PG 1
WC Female; Humans; Male; Middle Aged; Acupuncture Therapy; Fatigue; Massage; Musculoskeletal Pain; Neoplasms; complications; Quality of Life; Sleep Initiation and Maintenance Disorders; Adult; Aged
UT PubMed:37962891
PM 37962891
DA 2023-11-14
ER

PT J
AU Rosenscheg, M
   Pedron, J
   Pedroso, L
AF Rosenscheg, Marcelen
   Pedron, Julia
   Pedroso, Lorena
TI Treatment of Cancer Pain
SO AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
LA English
DT Review
DE cancer pain; pain management; complementary therapies; medical oncology; interdisciplinary research
ID breast-cancer; buprenorphine; therapy; impact; scale
AB Contextualization:One of the biggest problems regarding the treatment of cancer patients is pain, whether due to the cancer or the treatment itself. Therefore, there is a search for treatments that aims to promote an effective treatment in this sense.Purpose:This article aims to verify which are the recent methods used to treat pain in cancer patients in a multidisciplinary sense, and to evaluate their effectiveness.Methodology:Systematic reviews, meta-analyses and randomized clinical trials utilizing the LILACS, NCBI, and MEDLINE platforms of the last 5 years were included. The descriptors were pain treatment in oncology, pain management, complementary therapies, and other synonyms, in Portuguese, English and Spanish. This included any technique that was effective in the treatment of cancer pain.Results:The initial search found 2246 articles, of which 22 were included in the systematic review. Most of these are acupuncture treatments, opioids versus anti-inflammatories versus analgesics, radiotherapy, behavioral therapies, among others. Most articles suggest benefits with these therapies, improved quality of life for patients and tolerable side effects.Conclusion:This study demonstrates the effectiveness of the current methods used in the treatment of pain in cancer patients so that professionals in the area can have more options for treating cancer pain. Despite the important limitations, the guideline for further research and the situations in which treatments have shown effectiveness are present in it.
C1 [Rosenscheg, Marcelen; Pedron, Julia; Pedroso, Lorena] Ctr Univ Campo Real, Bonding Inst, Guarapuava, PR, Brazil.
RP Rosenscheg, M (corresponding author), Ctr Univ Campo Real, Bonding inst, St Afonso Botelho 348, BR-85012030 Guarapuava, PR, Brazil.
EM med-marcelenrosenscheg@camporea.edu.br; med-juliapedron@camporeal.edu.br; med-lorenapedroso@camporeal.edu.br
CR Ahn JS, 2017, J PAIN RES, V10, P1963, DOI 10.2147/JPR.S140320
   Bang JY, 2019, GASTROINTEST ENDOSC, V89, P58, DOI 10.1016/j.gie.2018.08.005
   Bell T, 2016, CURR MED RES OPIN, V32, P959, DOI 10.1185/03007995.2016.1157060
   Boyd C, 2016, PAIN MED, V17, P1553, DOI 10.1093/pm/pnw100
   Breivik H, 2008, BRIT J ANAESTH, V101, P17, DOI 10.1093/bja/aen103
   Carvalho A PV, 2013, DIAGN TRAT, V18, P38
   Castro Augusto Everton Dias, 2015, REVISTA INTELLECTUS. USE OF COMPLEMENTARY THERAPIES IN PAIN MANAGEMENT: AN INTEGRATIVE REVIEW, V01, P0
   CELLA DF, 1993, J CLIN ONCOL, V11, P570, DOI 10.1200/JCO.1993.11.3.570
   Crichton N, 2001, J CLIN NURS, V10, P706
   Delgado DA, 2018, JAAOS GLOB RES REV, V2, P0, DOI 10.5435/JAAOSGlobal-D-17-00088
   Dou Z, 2017, ASIA-PAC J CLIN ONCO, V13, PE57, DOI 10.1111/ajco.12311
   Eyigor S, 2018, COMPLEMENT THER CLIN, V32, P40, DOI 10.1016/j.ctcp.2018.04.010
   Gandini RC, 2001, FACTORIAL VALIDATION OF THE DEPRESSION INVENTORY BY BECK AND OTHER PSYCHOLOGISTS IN WOMEN WITH CANCER IN GENERAL (CNPQ PIBIC/UFU N 106/2000), V0, P0
   Gennaro N, 2019, SKELETAL RADIOL, V48, P1161, DOI 10.1007/s00256-018-3140-0
   Graner KM, 2010, TEMAS EM PSICOLOGIA, V18, P345
   Guo YM, 2015, EVID-BASED COMPL ALT, V2015, P0, DOI 10.1155/2015/840742
   He YH, 2020, JAMA ONCOL, V6, P271, DOI 10.1001/jamaoncol.2019.5233
   Jara C, 2018, CLIN TRANSL ONCOL, V20, P97, DOI 10.1007/s12094-017-1791-2
   Lam TY, 2017, BMC COMPLEM ALTERN M, V17, P0, DOI 10.1186/s12906-017-1838-5
   Lee KH, 2017, CHIN J CANCER, V36, P0, DOI 10.1186/s40880-017-0241-4
   LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.2307/2336267
   Liu Q, 2018, EUR J PAIN, V22, P492, DOI 10.1002/ejp.1144
   Magee DJ, 2019, BRIT J ANAESTH, V123, PE412, DOI 10.1016/j.bja.2019.02.028
   Majidinejad S, 2019, ADV J EMERG MED, V3, P0, DOI 10.22114/ajem.v0i0.129
   Nia HS, 2017, INT J NURS PRACT, V23, P0, DOI 10.1111/ijn.12513
   Oldenmenger WH, 2018, CANCER TREAT REV, V63, P96, DOI 10.1016/j.ctrv.2017.12.005
   Pan HM, 2019, MEDICINE, V98, P0, DOI 10.1097/MD.0000000000015505
   Péus D, 2013, BMC MED INFORM DECIS, V13, P0, DOI 10.1186/1472-6947-13-72
   Ritter PL, 2006, J RHEUMATOL, V33, P574
   Saritas S, 2019, COMPLEMENT MED RES, V26, P231, DOI 10.1159/000497234
   Schmidt-Hansen M, 2016, BMJ SUPPORT PALLIAT, V6, P292, DOI 10.1136/bmjspcare-2015-000939
   Siemens W, 2020, SUPPORT CARE CANCER, V28, P5323, DOI 10.1007/s00520-020-05370-8
   Souza V, 2016, REVISTA CIENTIFICA SENA AIRES, V5, P70
   Spencer K, 2019, INT J RADIAT ONCOL, V105, P559, DOI 10.1016/j.ijrobp.2019.07.009
   Stewart BW, 2014, WORLD CANCER REPORT 2014, V0, P1
   Xu LP, 2020, COMPLEMENT THER CLIN, V39, P0, DOI 10.1016/j.ctcp.2020.101170
NR 36
TC 4
Z9 4
U1 2
U2 12
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0277-3732
EI 1537-453X
J9 AM J CLIN ONCOL-CANC
JI Am. J. Clin. Oncol.-Cancer Clin. Trials
PD OCT 15
PY 2023
VL 46
IS 10
BP 450
EP 458
DI 10.1097/COC.0000000000001029
PG 9
WC Oncology
SC Oncology
GA S6GP7
UT WOS:001072129900005
PM 37482642
DA 2026-01-16
ER

PT J
AU Wu, ZH
   Liu, QH
AF Wu, Zanhua
   Liu, Qinghua
TI Effects of repetitive transcranial magnetic stimulation combined with acupuncture on NLRP3 inflammasome and protease levels in patients with neuropathic pain
SO AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH
LA English
DT Article
DE Repetitive transcranial magnetic stimulation; acupuncture; neuropathic pain; IGF-1; NLRP3; inflammatory factor
ID mechanisms
AB Purpose: This study aimed to investigate whether repetitive transcranial magnetic stimulation (rTMS) combined with acupuncture could alleviate pain in patients suffering from postherpetic neuralgia (PHN) by inhibiting NOD-like receptor 3 (NLRP3) inflammasome activation. Methods: Data of 92 PHN patients were retrospectively collected. The patients were grouped as control (nerve block), rTMS, and rTMS + acupuncture groups according to treatment methods. The visual analogue scale (VAS) score, as well as tumor necrosis factor (TNF)-alpha, interleukin (IL)-1 beta, IL-6, NLRP3, and Caspase-1 levels of patients in each group prior and post-treatment were analyzed. Results: The rTMS + acupuncture group showed higher efficacy than the rTMS group and the control group, contributing to markedly lower VAS score, as well as TNF-alpha, IL-1 beta, IL-6, NLRP3 and Caspase-1 levels than the other two groups (P < 0.05). Conclusion: rTMS plus acupuncture can reduce the inflammatory immune response and ease the pain in patients by inhibiting NLRP3 inflammasome and its resulting inflammatory factors, Caspase-1 and IL-1 beta.
C1 [Wu, Zanhua; Liu, Qinghua] Peoples Hosp Guangxi Zhuang Autonomous Reg, Dept Rehabil Med, Nanning 530000, Guangxi, Peoples R China.
   [Liu, Qinghua] Hanzhong 3201 Hosp, Dept Orthopaed, Hanzhong 723000, Shaanxi, Peoples R China.
RP Liu, QH (corresponding author), Hanzhong 3201 Hosp, Dept Orthopaed, Hanzhong 723000, Shaanxi, Peoples R China.
EM 2792-286459@qq.com
CR Baron R, 2010, LANCET NEUROL, V9, P807, DOI 10.1016/S1474-4422(10)70143-5
   Bouhassira D, 2019, REV NEUROL-FRANCE, V175, P16, DOI 10.1016/j.neurol.2018.09.016
   Cavalli E, 2019, INT J IMMUNOPATH PH, V33, P0, DOI 10.1177/2058738419838383
   Chen X, 2021, ACS CHEM NEUROSCI, V12, P2917, DOI 10.1021/acschemneuro.1c00271
   Dimitrova A, 2017, J ALTERN COMPLEM MED, V23, P164, DOI 10.1089/acm.2016.0155
   Dyson-Hudson TA, 2007, ARCH PHYS MED REHAB, V88, P1276, DOI 10.1016/j.apmr.2007.06.014
   Gierthmühlen J, 2016, SEMIN NEUROL, V36, P462, DOI 10.1055/s-0036-1584950
   He Y, 2016, TRENDS BIOCHEM SCI, V41, P1012, DOI 10.1016/j.tibs.2016.09.002
   Ju ZY, 2017, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD012057.pub2
   Klein MM, 2015, PAIN, V156, P1601, DOI 10.1097/j.pain.0000000000000210
   Lefaucheur JP, 2020, CLIN NEUROPHYSIOL, V131, P474, DOI 10.1016/j.clinph.2019.11.002
   Leung A, 2020, NEUROMODULATION, V23, P267, DOI 10.1111/ner.13094
   Li Qiu-Yue, 2017, ZHONGGUO ZHONG YAO ZA ZHI, V42, P3709, DOI 10.19540/j.cnki.cjcmm.20170907.004
   Liu P, 2020, INFLAMMOPHARMACOLOGY, V28, P1495, DOI 10.1007/s10787-020-00737-z
   OConnor AB, 2009, PHARMACOECONOMICS, V27, P95, DOI 10.2165/00019053-200927020-00002
   Qin ZS, 2015, EVID-BASED COMPL ALT, V2015, P0, DOI 10.1155/2015/425108
   Rachid F, 2018, PSYCHIAT RES, V269, P145, DOI 10.1016/j.psychres.2018.08.013
   Saleh C, 2022, NEUROL SCI, V43, P3007, DOI 10.1007/s10072-022-05978-0
   Schmader K, 2016, CLIN GERIATR MED, V32, P539, DOI 10.1016/j.cger.2016.02.011
   Scholz J, 2019, PAIN, V160, P53, DOI 10.1097/j.pain.0000000000001365
   Smith ES, 2018, J NEUROL, V265, P231, DOI 10.1007/s00415-017-8641-6
   Soligo M, 2013, INT REV NEUROBIOL, V111, P91, DOI 10.1016/B978-0-12-411545-3.00005-5
   Taylor R, 2018, AUSTRALAS PSYCHIATRY, V26, P189, DOI 10.1177/1039856217748249
   Yao L, 2021, J NEUROIMMUNOL, V351, P0, DOI 10.1016/j.jneuroim.2020.577458
   Zhan XY, 2023, FRONT IMMUNOL, V13, P0, DOI 10.3389/fimmu.2022.1109938
   Zhang RX, 2014, ANESTHESIOLOGY, V120, P482, DOI 10.1097/ALN.0000000000000101
   Zhao WX, 2017, NEUROSCI LETT, V637, P108, DOI 10.1016/j.neulet.2016.11.041
   Zhu SM, 2009, J ZHEJIANG UNIV-SC B, V10, P625, DOI 10.1631/jzus.B0920049
NR 28
TC 5
Z9 8
U1 0
U2 9
PU E-CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 1943-8141
EI 
J9 AM J TRANSL RES
JI Am. J. Transl. Res.
PD JUN 15
PY 2023
VL 15
IS 7
BP 4699
EP 4708
DI 
PG 10
WC Oncology; Medicine, Research & Experimental
SC Oncology; Research & Experimental Medicine
GA P1YS5
UT WOS:001048673500011
PM 37560225
DA 2026-01-16
ER

PT J
AU Zhou, XL
   Wang, H
   Wu, S
   Li, J
   Wu, F
   Lu, W
   Zhao, JW
   Li, YH
AF Zhou, Xu-Liu
   Wang, Hua
   Wu, Song
   Li, Jia
   Wu, Fan
   Lu, Wei
   Zhao, Jia-Wei
   Li, Yi-Hong
TI Comparison of the effects of moxibustion and acupuncture of combined "Biao-Ben"
SO Zhen ci yan jiu = Acupuncture research
LA chi
DT Journal Article
DE Acupuncture; Combined “Biao-Ben” acupoints; Diarrhea-predominant irritable bowel syndrome; Heart rate variability; Inflammatory cytokines; Moxibustion
AB OBJECTIVES: To compare the effects of moxibustion and acupuncture of combined  "Biao-Ben" acupoints (Biao indicates pathogenic factors of disease, Ben refers to  body constitution) on a rat model of irritable bowel syndrome with diarrhea  (IBS-D). METHODS: Forty female SD rats were randomly divided into 4 groups：normal  group, model group, moxibustion group, and acupuncture group, with 10 rats in  each group. The IBS-D rat model was established by administering acute-chronic  stress combined with folium sennae gavage for 28 days. Rats in the moxibustion  group received moxibustion at bilateral "Zusanli"(ST36), "Guanyuan"(CV4), and  "Neiguan"(PC6), while those in the acupuncture group received acupuncture at the  same acupoints, both for 15 min every time, once a day. The treatments were  administered for 21 days. The loose stool rate was observed. Colonic pain  threshold and colonic distension threshold were measured by a self-made balloon  catheter. Total distance traveled and grid crossing numbers were observed by open  field test. Heart rate variability(HRV) time domain indexes SDANN and PNN50 were  acguired by using electrophysiological recorder. Histopathological changes in the  colon tissue were observed after HE staining. Contents of interleukin-6(IL-6),  IL-8, and tumor necrosis factor-alpha(TNF-α) in serum were detected by ELISA.  RESULTS: Compared with the normal group, rats in the model group showed increased  loose stool rate(P<0.05), decreased pain threshold and distension  threshold(P<0.05), reduced total distance traveled and grid crossing numbers in  the open field test(P<0.05), decreased HRV time domain indexes SDANN and  PNN50(P<0.01, P<0.05), and elevated levels of serum IL-6, IL-8, and TNF-α  contents(P<0.05). Compared with the model group, the moxibustion group and  acupuncture group showed decreased loose stool rate(P<0.05), increased total  distance traveled and grid crossing numbers in the open field test(P<0.05),  increased pain threshold and distension threshold(P<0.05), increased SDANN and  PNN50 (P<0.05), and decreased levels of serum IL-6, IL-8, and TNF-α  contents(P<0.05). Compared with the acupuncture group, the moxibustion group  showed further decreased loose stool rate(P<0.05), increased total distance  traveled and grid crossing numbers in the open field test(P<0.05), increased pain  threshold and distension threshold(P<0.05), increased SDANN and PNN50(P<0.05),  and decreased levels of serum IL-6, IL-8, and TNF-α contents(P<0.05). No  significant pathological changes were observed in the colon tissue of rats in  each group. CONCLUSIONS: Moxibustion of combined "Biao-Ben" acupoints is more  effective in regulating HRV and serum IL-6, IL-8, and TNF-α contents in the IBS-D  rat model. Based on the combined "Biao-Ben" acupoints method, moxibustion has  better therapeutic effects on IBS-D than acupuncture.
C1 College of Acupuncture and Orthopedics, Hubei University of Chinese Medicine, Wuhan 430061, China. 2814416550@qq.com.
   College of Acupuncture and Orthopedics, Hubei University of Chinese Medicine, Wuhan 430061, China. hwang.tcm@china.com.
   College of Acupuncture and Orthopedics, Hubei University of Chinese Medicine, Wuhan 430061, China.
   College of Acupuncture and Orthopedics, Hubei University of Chinese Medicine, Wuhan 430061, China.
   College of Acupuncture and Orthopedics, Hubei University of Chinese Medicine, Wuhan 430061, China.
   College of Acupuncture and Orthopedics, Hubei University of Chinese Medicine, Wuhan 430061, China.
   College of Acupuncture and Orthopedics, Hubei University of Chinese Medicine, Wuhan 430061, China.
   College of Acupuncture and Orthopedics, Hubei University of Chinese Medicine, Wuhan 430061, China.
NR 0
TC 0
SN 
EI 1000-060
J9 Zhen Ci Yan Jiu
PD NOV 21
PY 2023
VL 48
IS 11
BP 1134
EP 1141
DI 10.13702/j.1000-0607.20230147
PG 7
WC Rats; Female; Animals; Irritable Bowel Syndrome; therapy; Moxibustion; Rats, Sprague-Dawley; Tumor Necrosis Factor-alpha; genetics; Interleukin-8; Interleukin-6; genetics; Acupuncture Points; Acupuncture Therapy; Diarrhea; therapy; Autonomic Nervous System
UT PubMed:37984911
PM 37984911
DA 2023-11-21
ER

PT J
AU Huang, MC
   Chang, SC
   Liao, WL
   Ke, TW
   Lee, AL
   Wang, HM
   Chang, CP
   Yen, HR
   Chang, HH
   Chen, WT
AF Huang, Ming-Cheng
   Chang, Sheng-Chi
   Liao, Wen-Ling
   Ke, Tao-Wei
   Lee, Ai-Lin
   Wang, Hwei-Ming
   Chang, Che-Pin
   Yen, Hung-Rong
   Chang, Hen-Hong
   Chen, William Tzu-Liang
TI Acupuncture May Help to Prevent Chemotherapy-Induced Peripheral Neuropathy: A
SO The oncologist
LA English
DT Journal Article
DE acupuncture; chemotherapy; colorectal cancer; oxaliplatin; peripheral neuropathy; prevention
AB OBJECTIVE: This study investigated the efficacy of acupuncture in preventing  chemotherapy-induced peripheral neuropathy (CIPN) in patients with colorectal  cancer (CRC). METHODS: This single center, randomized, controlled, single-blind  clinical trial randomly assigned patients with stage 3 CRC attending outpatient  clinics in China Medical University Hospital to either verum or sham acupuncture  treatment concurrently with chemotherapy. Primary outcomes were nerve conduction  velocity (NCV) and touch thresholds of limb terminals. Secondary outcomes were  total and subdomain scores on the Functional Assessment of Cancer Therapy-General  (FACT-G), and scores on the FACT/GOG-Ntx subscale and the Brief Pain  Inventory-Short Form (BPI-SF), at baseline, weeks 12, 36, and follow-up (week  48). RESULTS: Thirty-two patients met the inclusion criteria and received verum  acupuncture (N = 16) or sham acupuncture (N = 16). Under the -intent-to-treat  principle, 26 participants were analyzed. Significant changes from baseline for  questionnaire scores and sensory NCV were observed in both study groups. Sham  acupuncture was associated with significant reductions from baseline in motor NCV  and sensory touch thresholds; no such changes were observed with verum  acupuncture. No serious adverse events were reported. CONCLUSION: Prophylactic  acupuncture may exert neuroprotective effects on mechanical or tactile touch  thresholds during chemotherapy regimens in patients with CRC, with evidence of  this protectiveness persisting at 6 months' follow-up. The lack of change in  motor NCV values with verum acupuncture indicates neuroprotective effects.  Sensory NCV values and patient-reported outcomes did not differ significantly  between the study groups.
C1 Graduate Institute of Chinese Medicine, School of Chinese Medicine, College of Chinese Medicine, China Medical University, Taichung, Taiwan.
   Department of Chinese Medicine, China Medical University Hospital, Taichung, 
   Division of Colorectal Surgery, Department of Surgery, China.
   Medical University Hospital, Taichung, Taiwan.
   Graduate Institute of Integrated Medicine, College of Chinese Medicine, China Medical University, Taichung, Taiwan.
   Center for Personalized Medicine, Department of Medical Research, China Medical 
   Division of Colorectal Surgery, Department of Surgery, China.
   Medical University Hospital, Taichung, Taiwan.
   College of Chinese Medicine, China Medical University, Taichung, Taiwan.
   All Ease Traditional Chinese Medicine Clinic, Taichung, Taiwan.
   Department of Surgery, China Medical University Hospital, Taichung, Taiwan.
   Department of Chinese Medicine, China Medical University Hospital, Taichung, Taiwan.
   Department of Chinese Medicine, China Medical University Hospital, Taichung, Taiwan.
   School of Chinese Medicine, College of Chinese Medicine, China Medical 
   Chinese Medicine Research Center, China Medical University, Taichung, Taiwan.
   Department of Biotechnology, Asia University, Taichung, Taiwan.
   Department of Chinese Medicine, China Medical University Hospital, Taichung, Taiwan.
   Graduate Institute of Integrated Medicine, College of Chinese Medicine, China 
   Chinese Medicine Research Center, China Medical University, Taichung, Taiwan.
   Division of Colorectal Surgery, Department of Surgery, China.
   Medical University Hospital, Taichung, Taiwan.
   School of Medicine, Department of Surgery, China Medical University, Taichung, Taiwan.
   Division of Colorectal Surgery, Department of Surgery, China Medical University
NR 0
TC 0
SN 1549-490
EI 1083-715
J9 Oncologist
PD MAR 28
PY 2023
VL 28
IS 6
BP e436
EP e447
DI 10.1093/oncolo/oyad065
PG 1
WC Humans; Single-Blind Method; Neuroprotective Agents; adverse effects; Acupuncture Therapy; adverse effects; Peripheral Nervous System Diseases; chemically induced; Antineoplastic Agents; adverse effects
UT PubMed:36971468
PM 36971468
DA 2023-03-28
ER

PT J
AU Brozović, G
   Lesar, N
   Janev, D
   Bošnjak, T
   Muhaxhiri, B
AF Brozović, Gordana
   Lesar, Nikola
   Janev, Dimitar
   Bošnjak, Tomislav
   Muhaxhiri, Burim
TI CANCER PAIN AND THERAPY.
SO Acta clinica Croatica
LA English
DT Review
DE adjuvant drugs; cancer pain; integrative medicine; non-opioids; opioids; regional nerve block
AB Cancer pain is not a homogenous and clearly understood pathological process. The  best treatment is a combination of drug and non-drug measures. Pain is divided  into visceral, bone or neuropathic pain and has characteristics of continuous or  intermittent pain. Cancer bone pain therapy remains centered on strong opioid,  radiotherapy and bisphosphonates. Invasive procedures are aimed to improve  neurological function, ambulation and pain relief. Solid tumors often demand  surgery. Treatment of acute postoperative pain is crucial for the prevention of  chronic pain. Chemotherapy and radiation sometimes also cause pain. The  management of cancer pain has improved because of rapid diagnosis and treatment,  understanding of analgesics and the cooperation of patients and their family. The  presence of special pain centers in hospitals also raise standard of cancer pain  management. Drug therapy with non-opioid, opioid and adjuvant drugs is the base  of such management. The side effects must be monitored and timely treated.  Methods of regional nerve blockade in pain control are numerous. Placement of  epidural, intrathecal and subcutaneous catheters, conductive nerve blocks with  continuous delivery of mixed local anesthetics are very successful for selected  patients. Conventional physical therapy involving lymphatic drainage is useful.  Acupuncture, psychotherapy and similar methods are also applicable.
C1 Division of Anaesthesiology, Reanimatology and Intensive Care Medicine, University Hospital for Tumors, Sestre milosrdnice University Hospital Center,Zagreb, Croatia.
   Faculty of Dental Medicine and Health, Josip Juraj Strossmayer University of 
   Division of Anaesthesiology, Reanimatology and Intensive Care Medicine, University Hospital for Tumors, Sestre milosrdnice University Hospital Center,Zagreb, Croatia.
   Division of Anaesthesiology, Reanimatology and Intensive Care Medicine, University Hospital for Tumors, Sestre milosrdnice University Hospital Center,Zagreb, Croatia.
   Division of Anaesthesiology, Reanimatology and Intensive Care Medicine, University Hospital for Tumors, Sestre milosrdnice University Hospital Center,Zagreb, Croatia.
   Division of Anaesthesiology, Reanimatology and Intensive Care Medicine, University Hospital for Tumors, Sestre milosrdnice University Hospital Center,Zagreb, Croatia.
NR 0
TC 0
SN 1333-945
EI 0353-946
J9 Acta Clin Croat
PD FEB 25
PY 2023
VL 61
IS Suppl 2
BP 103
EP 108
DI 10.20471/acc.2022.61.s2.13
PG 5
WC Humans; Cancer Pain; drug therapy; Pain Management; Analgesics, Opioid; Pain, Postoperative; drug therapy; Analgesics; therapeutic use; Chronic Pain; drug therapy; Anesthetics, Local; Neoplasms
UT PubMed:36824638
PM 36824638
DA 2023-02-25
ER

PT J
AU Semeniuk, G
   Bahadini, B
   Ahn, E
   Zain, J
   Cheng, J
   Govindarajan, A
   Rose, J
   Lee, RT
AF Semeniuk, George
   Bahadini, Bahareh
   Ahn, Eugene
   Zain, Jasmine
   Cheng, Jessica
   Govindarajan, Ameish
   Rose, Judy
   Lee, Richard T.
TI Integrative Oncology and the Clinical Care Network: Challenges and Opportunities
SO JOURNAL OF CLINICAL MEDICINE
LA English
DT Article
DE integrative oncology; clinical care network; implementation
ID quality-of-life; breast-cancer patients; stress reduction; massage therapy; alternative medicine; palliative care; acupuncture; survivors; pain; health
AB Integrative oncology is a new and growing field of cancer care. Integrative oncology is a patient-centered, evidence-based field of comprehensive cancer care that utilizes integrative therapies such as mind-body practices, acupuncture, massage, music therapy, nutrition, and exercise in collaboration with conventional cancer treatments. Patient interest and utilization has been growing over the past two decades. Clinical research has shown the benefits of these approaches to improving symptom management and quality of life, and is now being incorporated into national guidelines from the National Comprehensive Cancer Network (NCCN) and American Society for Clinical Oncology (ASCO). The availability of these services at cancer centers is growing, although the structure and implementation of integrative oncology remains highly variable. This article discusses the benefits of integrative oncology and provides an overview of the current state of integrative oncology programs nationwide. Current challenges and opportunities for cancer centers to provide integrative services is reviewed in the areas of programmatic structure, clinical service, education, and research.
C1 [Semeniuk, George; Bahadini, Bahareh; Ahn, Eugene; Zain, Jasmine; Cheng, Jessica; Govindarajan, Ameish; Rose, Judy; Lee, Richard T.] City Hope Comprehens Canc Ctr, Duarte, CA 91010 USA.
   [Ahn, Eugene] City Hope Chicago, Zion, IL 60099 USA.
C3 City of Hope
RP Lee, RT (corresponding author), City Hope Comprehens Canc Ctr, Duarte, CA 91010 USA.
EM gsemeniuk@coh.org; bbahadini@coh.org; eugene.ahn@ctca-hope.com; jazain@coh.org; jescheng@coh.org; agovindarajan@coh.org; jrose@coh.org; richlee@coh.org
CR [Adler N.E. Institute of Medicine (IOM) Institute of Medicine (IOM)], 2008, CANCER CARE FOR THE WHOLE PATIENT: MEETING PSYCHOSOCIAL HEALTH NEEDS, V0, P0, DOI DOI 10.17226/11993
   Andersen BL, 2008, CANCER-AM CANCER SOC, V113, P3450, DOI 10.1002/cncr.23969
   Unknown -, 2021, MEDITATION: IN DEPTH, V0, P0
   Antoni MH, 2006, NAT REV CANCER, V6, P240, DOI 10.1038/nrc1820
   Barnes Patricia M, 2004, ADV DATA, V0, P1
   Bower JE, 2015, CANCER-AM CANCER SOC, V121, P1231, DOI 10.1002/cncr.29194
   Brauer JA, 2010, J ALTERN COMPLEM MED, V16, P183, DOI 10.1089/acm.2009.0354
   Campbell KL, 2019, MED SCI SPORT EXER, V51, P2375, DOI 10.1249/MSS.0000000000002116
   Cassileth BR, 2004, J PAIN SYMPTOM MANAG, V28, P244, DOI 10.1016/j.jpainsymman.2003.12.016
   Chiu HY, 2017, EUR J CANCER CARE, V26, P0, DOI 10.1111/ecc.12457
   Chlebowski RT, 2020, J CLIN ONCOL, V38, P1419, DOI 10.1200/JCO.19.00435
   Choi TY, 2012, SUPPORT CARE CANCER, V20, P1147, DOI 10.1007/s00520-012-1432-9
   Clarke Tainya C, 2018, NCHS DATA BRIEF, V0, P1
   Cramer H, 2012, CURR ONCOL, V19, PE343, DOI 10.3747/co.19.1016
   Cramer H, 2017, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD010802.pub2
   Danhauer SC, 2017, SUPPORT CARE CANCER, V25, P1357, DOI 10.1007/s00520-016-3556-9
   Dans M, 2021, J NATL COMPR CANC NE, V19, P780, DOI 10.6004/jnccn.2021.0033
   Dong B, 2021, BMC COMPLEMENT MED, V21, P0, DOI 10.1186/s12906-020-03193-y
   Dusek JA, 2018, J ALTERN COMPLEM MED, V24, P557, DOI 10.1089/acm.2017.0203
   Finley DJ, 2021, SURG ONCOL, V37, P0, DOI 10.1016/j.suronc.2021.101525
   Fu WW, 2016, ANN PALLIAT MED, V5, P93, DOI 10.21037/apm.2016.03.06
   Greenlee H, 2017, CA-CANCER J CLIN, V67, P195, DOI 10.3322/caac.21397
   Gu J, 2015, CLIN PSYCHOL REV, V37, P1, DOI 10.1016/j.cpr.2015.01.006
   He YH, 2020, JAMA ONCOL, V6, P271, DOI 10.1001/jamaoncol.2019.5233
   Hershman DL, 2018, JAMA-J AM MED ASSOC, V320, P167, DOI 10.1001/jama.2018.8907
   Hoffman CJ, 2012, J CLIN ONCOL, V30, P1335, DOI 10.1200/JCO.2010.34.0331
   International Agency for Research on Cancer Latest, 2020, GLOB CANC DAT CANC B, V0, P0
   Jiang C, 2021, SUPPORT CARE CANCER, V29, P5777, DOI 10.1007/s00520-021-06081-4
   Kinkead B, 2018, CANCER-AM CANCER SOC, V124, P546, DOI 10.1002/cncr.31064
   Kutner JS, 2008, ANN INTERN MED, V149, P369, DOI 10.7326/0003-4819-149-6-200809160-00003
   Larbi OM, 2021, JCO ONCOL PRACT, V17, P672, DOI 10.1200/OP.20.00471
   Latte-Naor S, 2019, J ONCOL PRACT, V15, P7, DOI 10.1200/JOP.18.00554
   Lee K, 2023, BMC CANCER, V23, P0, DOI 10.1186/s12885-023-10884-5
   Lee RT, 2021, CANCER-AM CANCER SOC, V127, P1827, DOI 10.1002/cncr.33324
   Lee RT, 2014, J CLIN ONCOL, V32, P4095, DOI 10.1200/JCO.2014.55.8676
   Lee SH, 2015, INTEGR CANCER THER, V14, P297, DOI 10.1177/1534735415572885
   Lengacher CA, 2009, PSYCHO-ONCOLOGY, V18, P1261, DOI 10.1002/pon.1529
   Ligibel JA, 2022, J CLIN ONCOL, V40, P2491, DOI 10.1200/JCO.22.00687
   Lin KY, 2011, EVID-BASED COMPL ALT, V2011, P1, DOI 10.1155/2011/659876
   Lyman GH, 2018, J ONCOL PRACT, V14, P495, DOI 10.1200/JOP.18.00283
   Lyman GH, 2018, J CLIN ONCOL, V36, P2647, DOI 10.1200/JCO.2018.79.2721
   Mao JJ, 2022, J CLIN ONCOL, V40, P3998, DOI 10.1200/JCO.22.01357
   Mao JJ, 2011, J CANCER SURVIV, V5, P8, DOI 10.1007/s11764-010-0153-7
   Metin ZG, 2019, EUR J ONCOL NURS, V42, P116, DOI 10.1016/j.ejon.2019.09.003
   Mishra Suruchi, 2021, NCHS DATA BRIEF, V0, P1
   Musial F, 2011, FORSCH KOMPLEMENTMED, V18, P192, DOI 10.1159/000330714
   Nahin Richard L, 2016, NATL HEALTH STAT REPORT, V0, P1
   Narayanan S, 2021, INTEGR CANCER THER, V20, P0, DOI 10.1177/1534735421999101
   Newmaster SG, 2013, BMC MED, V11, P0, DOI 10.1186/1741-7015-11-222
   Niazi AK, 2011, N AM J MED SCI, V3, P20, DOI 10.4297/najms.2011.320
   Paley CA, 2015, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD007753.pub3
   Pan YQ, 2014, INT J CLIN ONCOL, V19, P829, DOI 10.1007/s10147-013-0635-5
   Pierce JP, 2007, JAMA-J AM MED ASSOC, V298, P289, DOI 10.1001/jama.298.3.289
   Piet J, 2012, J CONSULT CLIN PSYCH, V80, P1007, DOI 10.1037/a0028329
   Reeves MM, 2021, NUTRIENTS, V13, P0, DOI 10.3390/nu13114091
   Rock CL, 2022, CA-CANCER J CLIN, V72, P230, DOI 10.3322/caac.21719
   Sanford NN, 2019, JAMA ONCOL, V5, P735, DOI 10.1001/jamaoncol.2019.0349
   Shen JN, 2000, JAMA-J AM MED ASSOC, V284, P2755, DOI 10.1001/jama.284.21.2755
   Sung H, 2021, CA-CANCER J CLIN, V71, P209, DOI 10.3322/caac.21660
   Tao WW, 2016, J PAIN SYMPTOM MANAG, V51, P728, DOI 10.1016/j.jpainsymman.2015.11.027
   Thompson-Lastad A, 2019, J ALTERN COMPLEM MED, V25, P733, DOI 10.1089/acm.2019.0073
   Valle CG, 2023, CANCER-AM CANCER SOC, V129, P461, DOI 10.1002/cncr.34556
   Van Blarigan EL, 2018, JAMA ONCOL, V4, P783, DOI 10.1001/jamaoncol.2018.0126
   Witt Claudia M, 2017, JOURNAL OF THE NATIONAL CANCER INSTITUTE MONOGRAPHS, V0, PP3, DOI 10.1093/jncimonographs/lgx012
   Wu XY, 2015, SCI REP-UK, V5, P0, DOI 10.1038/srep16776
   Yeung KS, 2018, ONCOLOGY-NY, V32, P516
   Yun Hyeongjun, 2017, JOURNAL OF THE NATIONAL CANCER INSTITUTE MONOGRAPHS, V0, PP29, DOI 10.1093/jncimonographs/lgx004
   Zainal NZ, 2013, PSYCHO-ONCOLOGY, V22, P1457, DOI 10.1002/pon.3171
NR 68
TC 12
Z9 13
U1 1
U2 12
PU MDPI
PI BASEL
PA MDPI AG, Grosspeteranlage 5, CH-4052 BASEL, SWITZERLAND
SN 
EI 2077-0383
J9 J CLIN MED
JI J. Clin. Med.
PD JUN 15
PY 2023
VL 12
IS 12
BP 
EP 
DI 10.3390/jcm12123946
PG 12
WC Medicine, General & Internal
SC General & Internal Medicine
GA K3GO4
UT WOS:001015357600001
PM 37373639
DA 2026-01-16
ER

PT J
AU Bae, K
   Lamoury, G
   Carroll, S
   Morgia, M
   Lim, S
   Baron-Hay, S
   Shin, IS
   Park, SJ
   Oh, B
AF Bae, Kyeore
   Lamoury, Gillian
   Carroll, Susan
   Morgia, Marita
   Lim, Stephanie
   Baron-Hay, Sally
   Shin, In-Soo
   Park, So-Jung
   Oh, Byeongsang
TI Comparison of the clinical effectiveness of treatments for aromatase inhibitor-induced arthralgia in breast cancer patients: A systematic review with network meta-analysis
SO CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
LA English
DT Review
DE Breast cancer; Aromatase inhibitor; Pain; Quality of life; Network meta-analysis
ID musculoskeletal symptoms; postmenopausal women; comparative efficacy; controlled trial; double-blind; vitamin-d; phase-ii; acupuncture; pain; therapy
AB Aromatase inhibitor-induced arthralgia (AIA) contributes to poor adherence of aromatase inhibitor therapies in patients with breast cancer. A systematic review using network meta-analysis (NMA) was conducted to examine the clinical effectiveness of multiple therapies and rank probabilities for the management of AIA. Randomized controlled trials (RCTs) assessing treatments for AIA in postmenopausal women with stage 0-III hormone receptor-positive breast cancer were searched from inception to October 2021. The main NMA involved 1516 participants from 17 RCTs. Acupuncture was the highest ranked intervention to improve pain intensity followed by sham acupuncture, multicomponent herbal medicine, exercise, duloxetine, vitamin D, omega-3 fatty acids, physical therapy, testosterone, and inactive controls. Single natural products were inferior to controls. The current review provides new insights into the management of AIA in breast cancer survivors for increased survival and can be utilized to make evidence-based decisions regarding treatment.
C1 [Bae, Kyeore] Doban Hosp, Integrat Canc Ctr, Seoul 03170, South Korea.
   [Bae, Kyeore; Lamoury, Gillian; Carroll, Susan; Morgia, Marita; Baron-Hay, Sally; Oh, Byeongsang] Royal North Shore Hosp, Northern Sydney Canc Ctr, Sydney, NSW 2065, Australia.
   [Lamoury, Gillian; Carroll, Susan; Baron-Hay, Sally; Oh, Byeongsang] Univ Sydney, Fac Med & Hlth, Sydney, NSW 2006, Australia.
   [Lim, Stephanie] Macarthur Canc Therapy Ctr, Med Oncol Dept, Campbelltown, NSW 2560, Australia.
   [Lim, Stephanie] Western Sydney Univ, Campbelltown, NSW 2560, Australia.
   [Shin, In-Soo] Dongguk Univ, Dept Grad Sch Educ, Seoul 04620, South Korea.
   [Park, So-Jung] Pusan Natl Univ, Korean Med Hosp, Dept Internal Med, Yangsan 50612, Gyeongnam, South Korea.
   [Oh, Byeongsang] Royal North Shore Hosp, Northern Sydney Canc Ctr, Sydney, NSW, Australia.
   [Oh, Byeongsang] Univ Sydney, Sydney Med Sch, Sydney, NSW, Australia.
C3 Royal North Shore Hospital; University of Sydney; University of Sydney; University of Sydney; Western Sydney University; Dongguk University; Pusan National University; University of Sydney; Royal North Shore Hospital; University of Sydney
RP Oh, B (corresponding author), Royal North Shore Hosp, Northern Sydney Canc Ctr, Sydney, NSW, Australia.; Oh, B (corresponding author), Univ Sydney, Sydney Med Sch, Sydney, NSW, Australia.
EM kyeorebae@gmail.com; Gillian.Lamoury@health.nsw.gov.au; Susan.Carroll@health.nsw.gov.au; Marita.Morgia@health.nsw.gov.au; Stephanie.Lim@health.nsw.gov.au; sbaronha@med.usyd.edu.au; 9065031@daum.net; vivies@hanmail.net; byeong.oh@sydney.edu.au
FU [MIMIC2019-RS07]
CR Amandusson Å, 1999, PAIN, V83, P243, DOI 10.1016/S0304-3959(99)00109-8
   Bae K, 2020, BMJ OPEN, V10, P0, DOI 10.1136/bmjopen-2019-033461
   Baglia ML, 2019, CANCER-AM CANCER SOC, V125, P2262, DOI 10.1002/cncr.32051
   Bao T, 2013, BREAST CANCER RES TR, V138, P167, DOI 10.1007/s10549-013-2427-z
   Beckwée D, 2017, SUPPORT CARE CANCER, V25, P1673, DOI 10.1007/s00520-017-3613-z
   Blok EJ, 2018, JNCI-J NATL CANCER I, V110, P0, DOI 10.1093/jnci/djx134
   Borenstein M, 2009, INTRODUCTION TO META-ANALYSIS, V0, PP217, DOI 10.1002/9780470743386.CH23
   Burstein HJ, 2019, THE J, V0, P0
   Calder PC, 2017, BIOCHEM SOC T, V45, P1105, DOI 10.1042/BST20160474
   Cathcart-Rake E, 2021, SUPPORT CARE CANCER, V29, P387, DOI 10.1007/s00520-020-05473-2
   Chan A, 2017, SUPPORT CARE CANCER, V25, P3785, DOI 10.1007/s00520-017-3810-9
   Chim K, 2013, BMC CANCER, V13, P0, DOI 10.1186/1471-2407-13-401
   Coleman RE, 2008, CANCER TREAT REV, V34, P275, DOI 10.1016/j.ctrv.2007.10.004
   Conejo I, 2018, BMC COMPLEM ALTERN M, V18, P0, DOI 10.1186/s12906-018-2236-3
   Crew KD, 2010, J CLIN ONCOL OFF J A, V28, P0
   Crew KD, 2010, J CLIN ONCOL, V28, P1154, DOI 10.1200/JCO.2009.23.4708
   Donovitz G, 2021, EUR J BREAST HEALTH, V17, P150, DOI 10.4274/ejbh.galenos.2021.6213
   Ernst A, 2021, CLIN BREAST CANCER, V21, PE38, DOI 10.1016/j.clbc.2020.07.008
   Fields J, 2016, J PAIN SYMPTOM MANAG, V52, P548, DOI 10.1016/j.jpainsymman.2016.03.010
   FOLLMANN D, 1992, J CLIN EPIDEMIOL, V45, P769, DOI 10.1016/0895-4356(92)90054-Q
   Geneen LJ, 2017, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD011279.pub3
   Glaser R, 2015, MATURITAS, V82, P291, DOI 10.1016/j.maturitas.2015.06.002
   Glaser R, 2021, ANDROGENS CLINICAL RESEARCH AND THERAPEUTICS, V2, P94, DOI 10.1089/andro.2021.0003
   Glaser RL, 2019, BMC CANCER, V19, P0, DOI 10.1186/s12885-019-6457-8
   Gnant M, 2021, NEW ENGL J MED, V385, P395, DOI 10.1056/NEJMoa2104162
   Goss PE, 2016, NEW ENGL J MED, V375, P209, DOI 10.1056/NEJMoa1604700
   Gregori D, 2018, JAMA-J AM MED ASSOC, V320, P2564, DOI 10.1001/jama.2018.19319
   Gupta A, 2020, JCO ONCOL PRACT, V16, P733, DOI 10.1200/OP.20.00113
   Guyatt GH, 2008, BRIT MED J, V336, P924, DOI 10.1136/bmj.39489.470347.AD
   Henry NL, 2008, BREAST CANCER RES TR, V111, P365, DOI 10.1007/s10549-007-9774-6
   Henry NL, 2019, CANCER-AM CANCER SOC, V125, P2123, DOI 10.1002/cncr.32024
   Henry NL, 2018, J CLIN ONCOL, V36, P326, DOI 10.1200/JCO.2017.74.6651
   Hershman DL, 2015, J CLIN ONCOL, V33, P1910, DOI 10.1200/JCO.2014.59.5595
   Hershman DL, 2011, BREAST CANCER RES TR, V126, P529, DOI 10.1007/s10549-010-1132-4
   Hozo S, 2005, BMC MED RES METHODOL, V5, P13, DOI 10.1186/1471-2288-5-13
   Hróbjartsson A, 2010, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD003974.pub3
   Hutton B, 2015, ANN INTERN MED, V162, P777, DOI 10.7326/M14-2385
   Jonat W, 2006, LANCET ONCOL, V7, P991, DOI 10.1016/S1470-2045(06)70948-2
   Key TJ, 2013, LANCET ONCOL, V14, P1009, DOI 10.1016/S1470-2045(13)70301-2
   Kim TH, 2018, MATURITAS, V118, P29, DOI 10.1016/j.maturitas.2018.09.005
   Lee YH, 2016, RHEUMATOL INT, V36, P663, DOI 10.1007/s00296-016-3468-5
   Li F, 2015, THE J, V0, P0
   Li FS, 2017, NAT PLANTS, V3, P0, DOI 10.1038/nplants.2017.109
   Li XX, 2017, PAIN PHYSICIAN, V20, P0
   Lim Tiaw-Kee, 2018, MEDICINES (BASEL), V5, P0, DOI 10.3390/medicines5030063
   Liu SB, 2021, NATURE, V598, P641, DOI 10.1038/s41586-021-04001-4
   López-López JAL, 2018, RES SYNTH METHODS, V9, P336, DOI 10.1002/jrsm.1310
   Lu G, 2004, STAT MED, V23, P3105, DOI 10.1002/sim.1875
   Lund Irene, 2006, ACUPUNCT MED, V24, P13
   Mao JJ, 2014, EUR J CANCER, V50, P267, DOI 10.1016/j.ejca.2013.09.022
   Nasser Mona, 2020, AM J PUBLIC HEALTH, V110, P753, DOI 10.2105/AJPH.2020.305609
   Nekovarova T, 2014, FRONT BEHAV NEUROSCI, V8, P0, DOI 10.3389/fnbeh.2014.00099
   Niravath P, 2013, ANN ONCOL, V24, P1443, DOI 10.1093/annonc/mdt037
   Oh B, 2013, ACUPUNCT MED, V31, P264, DOI 10.1136/acupmed-2012-010309
   Peng N, 2018, BREAST, V37, P18, DOI 10.1016/j.breast.2017.08.003
   Pfeilschifter J, 2002, ENDOCR REV, V23, P90, DOI 10.1210/er.23.1.90
   Prieto-Alhambra D, 2012, BREAST CANCER RES TR, V133, P1159, DOI 10.1007/s10549-012-2013-9
   Puhan MA, 2014, BMJ-BRIT MED J, V349, P0, DOI 10.1136/bmj.g5630
   Rastelli AL, 2011, BREAST CANCER RES TR, V129, P107, DOI 10.1007/s10549-011-1644-6
   Romero SAD, 2020, BREAST, V49, P48, DOI 10.1016/j.breast.2019.10.008
   Rudroju N, 2013, PAIN PHYSICIAN, V16, P0
   Rücker G, 2015, BMC MED RES METHODOL, V15, P0, DOI 10.1186/s12874-015-0060-8
   Schwarzer Guido, 2024, CRAN, V0, P0
   Shapiro AC, 2016, BREAST CANCER RES TR, V155, P501, DOI 10.1007/s10549-016-3710-6
   Shenouda M, 2021, CLIN BREAST CANCER, V0, P0, DOI DOI 10.1016/j.clbc.2021
   Sordi R, 2019, J NAT REM, V0, P0
   Stagg NJ, 2011, ANESTHESIOLOGY, V114, P940, DOI 10.1097/ALN.0b013e318210f880
   Sterne JAC, 2019, BMJ-BRIT MED J, V366, P0, DOI 10.1136/bmj.l4898
   Sung H, 2021, CA-CANCER J CLIN, V71, P209, DOI 10.3322/caac.21660
   Tenti S, 2020, INT J MOL SCI, V21, P0, DOI 10.3390/ijms21165625
   Tin ST, 2021, BRIT J CANCER, V125, P126, DOI 10.1038/s41416-021-01392-z
   Traish A, 2018, J CLIN MED, V7, P0, DOI 10.3390/jcm7120549
   Tripkovic L, 2012, AM J CLIN NUTR, V95, P1357, DOI 10.3945/ajcn.111.031070
   Tsai CL, 2021, SCI REP-UK, V11, P0, DOI 10.1038/s41598-021-94466-0
   Tufanaru C, 2015, INT J EVID-BASED HEA, V13, P196, DOI 10.1097/XEB.0000000000000065
   Villaggio B, 2012, CLIN EXP RHEUMATOL, V30, P934
   Xu ZJ, 2020, BRIT J NUTR, V123, P84, DOI 10.1017/S0007114519002290
   Younus J, 2010, CURR ONCOL, V17, P87
   Zhao ZQ, 2008, PROG NEUROBIOL, V85, P355, DOI 10.1016/j.pneurobio.2008.05.004
NR 79
TC 9
Z9 14
U1 0
U2 11
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1040-8428
EI 1879-0461
J9 CRIT REV ONCOL HEMAT
JI Crit. Rev. Oncol./Hematol.
PD JAN 15
PY 2023
VL 181
IS 
BP 
EP 
DI 10.1016/j.critrevonc.2022.103898
EA DEC 2022
PG 10
WC Oncology; Hematology
SC Oncology; Hematology
GA G6AL6
UT WOS:000989961200001
PM 36535489
DA 2026-01-16
ER

PT J
AU Ben-Arye, E
   Segev, Y
   Galil, G
   Marom, I
   Gressel, O
   Stein, N
   Hirsh, I
   Samuels, N
   Schmidt, M
   Schiff, E
   Lurie, I
   Lavie, O
AF Ben-Arye, Eran
   Segev, Yakir
   Galil, Galit
   Marom, Inbal
   Gressel, Orit
   Stein, Nili
   Hirsh, Irena
   Samuels, Noah
   Schmidt, Meirav
   Schiff, Elad
   Lurie, Irina
   Lavie, Ofer
TI Acupuncture during gynecological oncology surgery: A randomized controlled trial assessing the impact of integrative therapies on perioperative pain and anxiety
SO CANCER
LA English
DT Article
DE acupuncture; anxiety; gynecological oncology; integrative medicine; integrative oncology; pain; peri-operative
ID quality-of-life; low-frequency electroacupuncture; electrical acupoint stimulation; complementary medicine; postoperative pain; general-anesthesia; recovery score; cancer; patient; nausea
AB BackgroundIn this study, the impact of a multimodal integrative oncology pre- and intraoperative intervention on pain and anxiety among patients undergoing gynecological oncology surgery was explored. MethodsStudy participants were randomized to three groups: Group A received preoperative touch/relaxation techniques, followed by intraoperative acupuncture; Group B received preoperative touch/relaxation only; and a control group (Group C) received standard care. Pain and anxiety were scored before and after surgery using the Measure Yourself Concerns and Wellbeing (MYCAW) and Quality of Recovery (QOR-15) questionnaires, using Part B of the QOR to assess pain, anxiety, and other quality-of-life parameters. ResultsA total of 99 patients participated in the study: 45 in Group A, 25 in Group B, and 29 in Group C. The three groups had similar baseline demographic and surgery-related characteristics. Postoperative QOR-Part B scores were significantly higher in the treatment groups (A and B) when compared with controls (p = .005), including for severe pain (p = .011) and anxiety (p = .007). Between-group improvement for severe pain was observed in Group A compared with controls (p = .011). Within-group improvement for QOR depression subscales was observed in only the intervention groups (p <0.0001). Compared with Group B, Group A had better improvement of MYCAW-reported concerns (p = .025). ConclusionsA preoperative touch/relaxation intervention may significantly reduce postoperative anxiety, possibly depression, in patients undergoing gynecological oncology surgery. The addition of intraoperative acupuncture significantly reduced severe pain when compared with controls. Further research is needed to confirm these findings and better understand the impact of intraoperative acupuncture on postoperative pain. Plain language summary Integrative oncology programs are increasingly becoming part of supportive/palliative care, with many working within the Society for Integrative Oncology.This study examined the impact of a multimodal integrative oncology program on pain and anxiety among 99 patients undergoing gynecological oncology surgery. Participants were randomized to three groups: preoperative touch/relaxation treatments, followed by intraoperative acupuncture; preoperative touch/relaxation without acupuncture; and a control group receiving standard care only.The preoperative touch/relaxation intervention significantly reduced perioperative anxiety, with the addition of intraoperative acupuncture significantly reducing severe pain as well, when compared with controls. Further research is needed to confirm these findings.
C1 [Ben-Arye, Eran; Galil, Galit; Gressel, Orit] Clalit Hlth Serv, Lin Med Ctr, Integrat Oncol Program, Oncol Serv, Haifa, Israel.
   [Ben-Arye, Eran; Galil, Galit; Gressel, Orit] Clalit Hlth Serv, Zebulun Med Ctr, Oncol Serv, Integrat Oncol Program, Haifa, Israel.
   [Ben-Arye, Eran; Galil, Galit; Gressel, Orit] Clalit Hlth Serv, Carmel Med Ctr, Haifa, Israel.
   [Ben-Arye, Eran; Segev, Yakir; Gressel, Orit; Schiff, Elad; Lavie, Ofer] Technion Israel Inst Technol, Rappaport Fac Med, Haifa, Israel.
   [Segev, Yakir; Marom, Inbal; Schmidt, Meirav; Lurie, Irina; Lavie, Ofer] Carmel Hosp, Dept Obstet & Gynecol, Haifa, Israel.
   [Stein, Nili] Carmel Hosp, Dept Community Med & Epidemiol, Haifa, Israel.
   [Hirsh, Irena] Carmel Hosp, Dept Anesthesiol Crit Care & Pain Med, Haifa, Israel.
   [Samuels, Noah] Hebrew Univ Jerusalem, Fac Med, Ctr Integrat Complementary Med, Shaarei Zedek Med Ctr, Jerusalem, Israel.
   [Schiff, Elad] Bnai Zion Hosp, Dept Internal Med & Integrat Med Serv, Haifa, Israel.
   [Ben-Arye, Eran] Lin Med Ctr, Oncol Serv, 35 Rothschild St, Haifa, Israel.
C3 Clalit Health Services; Clalit Health Services; Clalit Health Services; Carmel Medical Center; Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Clalit Health Services; Carmel Medical Center; Clalit Health Services; Carmel Medical Center; Clalit Health Services; Carmel Medical Center; Hebrew University of Jerusalem; Shaare Zedek Medical Center; Bnai Zion Medical Center
RP Ben-Arye, E (corresponding author), Lin Med Ctr, Oncol Serv, 35 Rothschild St, Haifa, Israel.
EM eranben@netvision.net.il
FU Israel Cancer Association [20180006]
CR Attias S, 2016, J CLIN ANESTH, V29, P54, DOI 10.1016/j.jclinane.2015.10.017
   Ben-Arye E, 2022, PSYCHO-ONCOLOGY, V31, P207, DOI 10.1002/pon.5794
   Ben-Arye E, 2021, J CANCER RES CLIN, V147, P2361, DOI 10.1007/s00432-020-03506-1
   Ben-Arye E, 2016, SUPPORT CARE CANCER, V24, P1457, DOI 10.1007/s00520-016-3093-6
   Ben-Arye E, 2015, SUPPORT CARE CANCER, V23, P3411, DOI 10.1007/s00520-015-2690-0
   Ben-Arye E, 2012, PATIENT EDUC COUNS, V89, P423, DOI 10.1016/j.pec.2012.02.011
   Ben-Arye E, 2012, INT J GYNECOL CANCER, V22, P146, DOI 10.1097/IGC.0b013e318226c614
   Bisseling KCHM, 2009, AUST NZ J OBSTET GYN, V49, P660, DOI 10.1111/j.1479-828X.2009.01074.x
   Cheng SI, 2021, MED ACUPUNCT, V33, P286, DOI 10.1089/acu.2021.0003
   Dalamagka M, 2015, ACUPUNCT MED, V33, P360, DOI 10.1136/acupmed-2014-010689
   Dessole M, 2018, INT J GYNECOL CANCER, V28, P267, DOI 10.1097/IGC.0000000000000612
   Doll KM, 2016, GYNECOL ONCOL, V141, P329, DOI 10.1016/j.ygyno.2016.03.003
   Felix MMD, 2018, REV LAT-AM ENFERM, V26, P0, DOI 10.1590/1518-8345.2850.3101
   El-Rakshy M, 2009, ACUPUNCT MED, V27, P9, DOI 10.1136/aim.2008.000075
   Elkins Gary, 2004, CLIN NURS RES, V13, P237, DOI 10.1177/1054773803262222
   Ferrandina G, 2014, GYNECOL ONCOL, V133, P518, DOI 10.1016/j.ygyno.2014.03.015
   Grech D, 2016, J ACUPUNCT MERIDIAN, V9, P234
   Grimm D, 2021, ARCH GYNECOL OBSTET, V303, P967, DOI 10.1007/s00404-020-05869-9
   Gul DK, 2020, HOLIST NURS PRACT, V34, P356, DOI 10.1097/HNP.0000000000000413
   Honerlaw KR, 2016, GYNECOL ONCOL, V140, P301, DOI 10.1016/j.ygyno.2015.09.005
   Huang S, 2017, J ANESTH, V31, P58, DOI 10.1007/s00540-015-2057-1
   Jeffers L, 2019, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD012894.pub2
   Liu X, 2015, ACUPUNCT MED, V33, P270, DOI 10.1136/acupmed-2014-010749
   Minig L, 2013, SUPPORT CARE CANCER, V21, P715, DOI 10.1007/s00520-012-1571-z
   Myles PS, 1999, ANESTH ANALG, V88, P83, DOI 10.1097/00000539-199901000-00016
   Navaee Maryam, 2020, J COMPLEMENT INTEGR MED, V17, P0, DOI 10.1515/jcim-2019-0229
   Ozhanli Y, 2022, J PERIANESTH NURS, V37, P238, DOI 10.1016/j.jopan.2021.08.008
   Paraskeva A, 2004, AM J CHINESE MED, V32, P789, DOI 10.1142/S0192415X04002363
   Paterson C, 2007, COMPLEMENT THER MED, V15, P38, DOI 10.1016/j.ctim.2006.03.006
   Petersen RW, 2002, BJOG-INT J OBSTET GY, V109, P386, DOI 10.1016/S1470-0328(02)01271-5
   Quinlan-Woodward J, 2016, ONCOL NURS FORUM, V43, P725, DOI 10.1188/16.ONF.725-732
   Reynaud D, 2021, TRIALS, V22, P0, DOI 10.1186/s13063-021-05511-2
   Rithirangsriroj K, 2015, GYNECOL ONCOL, V136, P82, DOI 10.1016/j.ygyno.2014.10.025
   Samuels N, 2009, INT J CLIN PRACT, V63, P1554, DOI 10.1111/j.1742-1241.2009.02222.x
   Shalom-Sharabi I, 2017, J CANCER RES CLIN, V143, P2535, DOI 10.1007/s00432-017-2509-0
   Shalom-Sharabi I, 2017, SUPPORT CARE CANCER, V25, P3181, DOI 10.1007/s00520-017-3726-4
   Shalom-Sharabi I, 2017, J CANCER RES CLIN, V143, P1243, DOI 10.1007/s00432-017-2368-8
   Sharp DM, 2010, EUR J CANCER, V46, P312, DOI 10.1016/j.ejca.2009.10.006
   Stark PA, 2013, ANESTHESIOLOGY, V118, P1332, DOI 10.1097/ALN.0b013e318289b84b
   Streitberger K, 2004, ANAESTHESIA, V59, P142, DOI 10.1111/j.1365-2044.2004.03577.x
   Sun K, 2017, CLIN J PAIN, V33, P340, DOI 10.1097/AJP.0000000000000400
   Tychman J, 1979, SHEELON LEHAARACHAT, V0, P0
   Unsal N, 2020, J ALTERN COMPLEM MED, V26, P67, DOI 10.1089/acm.2019.0181
   Wetzel B, 2011, CLIN J PAIN, V27, P262, DOI 10.1097/AJP.0b013e3181fd516c
   Wiles MD, 2017, ANAESTHESIA, V72, P335, DOI 10.1111/anae.13785
NR 45
TC 18
Z9 26
U1 2
U2 28
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0008-543X
EI 1097-0142
J9 CANCER-AM CANCER SOC
JI Cancer
PD MAR 15
PY 2023
VL 129
IS 6
BP 908
EP 919
DI 10.1002/cncr.34542
EA JAN 2023
PG 12
WC Oncology
SC Oncology
GA 9I9PV
UT WOS:000913589500001
PM 36647622
DA 2026-01-16
ER

PT J
AU Huang, MC
   Chang, SC
   Liao, WL
   Ke, TW
   Lee, AL
   Wang, HM
   Chang, CP
   Yen, HR
   Chang, HH
   Chen, WTL
AF Huang, Ming-Cheng
   Chang, Sheng-Chi
   Liao, Wen-Ling
   Ke, Tao-Wei
   Lee, Ai-Lin
   Wang, Hwei-Ming
   Chang, Che-Pin
   Yen, Hung-Rong
   Chang, Hen-Hong
   Chen, William Tzu-Liang
TI Acupuncture May Help to Prevent Chemotherapy-Induced Peripheral Neuropathy: A Randomized, Sham-Controlled, Single-Blind Study
SO ONCOLOGIST
LA English
DT Article
DE acupuncture; chemotherapy; peripheral neuropathy; prevention; colorectal cancer; oxaliplatin
ID quality-of-life; oxaliplatin-induced-neuropathy; colorectal-cancer; adjuvant treatment; trial; electroacupuncture; neurotoxicity; fluorouracil; association; disturbance
AB Objective This study investigated the efficacy of acupuncture in preventing chemotherapy-induced peripheral neuropathy (CIPN) in patients with colorectal cancer (CRC). Methods This single center, randomized, controlled, single-blind clinical trial randomly assigned patients with stage 3 CRC attending outpatient clinics in China Medical University Hospital to either verum or sham acupuncture treatment concurrently with chemotherapy. Primary outcomes were nerve conduction velocity (NCV) and touch thresholds of limb terminals. Secondary outcomes were total and subdomain scores on the Functional Assessment of Cancer Therapy-General (FACT-G), and scores on the FACT/GOG-Ntx subscale and the Brief Pain Inventory-Short Form (BPI-SF), at baseline, weeks 12, 36, and follow-up (week 48). Results Thirty-two patients met the inclusion criteria and received verum acupuncture (N = 16) or sham acupuncture (N = 16). Under the intent-to-treat principle, 26 participants were analyzed. Significant changes from baseline for questionnaire scores and sensory NCV were observed in both study groups. Sham acupuncture was associated with significant reductions from baseline in motor NCV and sensory touch thresholds; no such changes were observed with verum acupuncture. No serious adverse events were reported. Conclusion Prophylactic acupuncture may exert neuroprotective effects on mechanical or tactile touch thresholds during chemotherapy regimens in patients with CRC, with evidence of this protectiveness persisting at 6 months' follow-up. The lack of change in motor NCV values with verum acupuncture indicates neuroprotective effects. Sensory NCV values and patient-reported outcomes did not differ significantly between the study groups.
C1 [Huang, Ming-Cheng] China Med Univ, Grad Inst Chinese Med, Sch Chinese Med, Coll Chinese Med, Taichung, Taiwan.
   [Huang, Ming-Cheng; Chang, Che-Pin; Yen, Hung-Rong; Chang, Hen-Hong] China Med Univ Hosp, Dept Chinese Med, Taichung, Taiwan.
   [Chang, Sheng-Chi; Ke, Tao-Wei; Chen, William Tzu-Liang] China Med Univ Hosp, Div Colorectal Surg, Dept Surg, Taichung, Taiwan.
   [Liao, Wen-Ling; Chang, Hen-Hong] China Med Univ, Grad Inst Integrated Med, Coll Chinese Med, 91 Xueshi Rd, Taichung 40402, Taiwan.
   [Liao, Wen-Ling] China Med Univ Hosp, Dept Med Res, Ctr Personalized Med, Taichung, Taiwan.
   [Lee, Ai-Lin] All Ease Tradit Chinese Med Clin, Taichung, Taiwan.
   [Yen, Hung-Rong] China Med Univ, Sch Chinese Med, Coll Chinese Med, Taichung, Taiwan.
   [Yen, Hung-Rong; Chang, Hen-Hong] China Med Univ, Chinese Med Res Ctr, Taichung, Taiwan.
   [Yen, Hung-Rong] Asia Univ, Dept Biotechnol, Taichung, Taiwan.
   [Chen, William Tzu-Liang] China Med Univ, Dept Surg, Sch Med, Taichung, Taiwan.
   [Chen, William Tzu-Liang] China Med Univ, Dept Surg, Div Colorectal Surg, Hsinchu Hosp, Zhu Bei, Taiwan.
   [Ke, Tao-Wei] China Med Univ, Coll Chinese Med, Taichung, Taiwan.
   [Wang, Hwei-Ming] China Med Univ Hosp, Dept Surg, Taichung, Taiwan.
C3 China Medical University Taiwan; China Medical University Taiwan; China Medical University Hospital - Taiwan; China Medical University Taiwan; China Medical University Hospital - Taiwan; China Medical University Taiwan; China Medical University Taiwan; China Medical University Hospital - Taiwan; China Medical University Taiwan; China Medical University Taiwan; Asia University Taiwan; China Medical University Taiwan; China Medical University Taiwan; China Medical University Taiwan; China Medical University Taiwan; China Medical University Hospital - Taiwan
RP Chang, HH (corresponding author), China Med Univ, Grad Inst Integrated Med, Coll Chinese Med, 91 Xueshi Rd, Taichung 40402, Taiwan.; Chen, WTL (corresponding author), China Med Univ Hosp, 2 Yude Rd, Taichung 404332, Taiwan.
EM tcmchh55@gmail.com; golfoma22@gmail.com
FU China Medical University Hospital [DMR-111-194]; "Chinese Medicine Research Center, China Medical University" from The Featured Areas Research Center Program by the Ministry of Education (MOE) in Taiwan [CMRC-CMA-6]
CR Alberti P, 2020, EXPERT OPIN DRUG MET, V16, P1147, DOI 10.1080/17425255.2021.1842873
   Andre T, 2004, NEW ENGL J MED, V350, P2343, DOI 10.1056/NEJMoa032709
   André T, 2009, J CLIN ONCOL, V27, P3109, DOI 10.1200/JCO.2008.20.6771
   Argyriou AA, 2019, J NEUROL NEUROSUR PS, V90, P1361, DOI 10.1136/jnnp-2019-320969
   Argyriou AA, 2015, TOXICS, V3, P187, DOI 10.3390/toxics3020187
   Argyriou AA, 2014, CANCER MANAG RES, V6, P135, DOI 10.2147/CMAR.S44261
   Bao T, 2020, JAMA NETW OPEN, V3, P0, DOI 10.1001/jamanetworkopen.2020.0681
   Bao T, 2018, EUR J CANCER, V101, P12, DOI 10.1016/j.ejca.2018.06.008
   Bao T, 2014, INTEGR CANCER THER, V13, P396, DOI 10.1177/1534735414534729
   Beijers AJM, 2020, ANN ONCOL, V31, P131, DOI 10.1016/j.annonc.2019.09.006
   CAMPBELL A, 1999, ACUPUNCT MED, V17, P124, DOI 10.1136/AIM.17.2.124
   DAlessandro EG, 2022, BMJ SUPPORT PALLIAT, V12, P64, DOI 10.1136/bmjspcare-2018-001542
   Donald GK, 2011, ACUPUNCT MED, V29, P230, DOI 10.1136/acupmed.2011.010025
   Dougherty PM, 2004, PAIN, V109, P132, DOI 10.1016/j.pain.2004.01.021
   Franconi G, 2013, EVID-BASED COMPL ALT, V2013, P0, DOI 10.1155/2013/516916
   Garcia MK, 2014, J HEMATOL ONCOL, V7, P0, DOI 10.1186/1756-8722-7-41
   Greenlee H, 2016, BREAST CANCER RES TR, V156, P453, DOI 10.1007/s10549-016-3759-2
   Han XY, 2017, BMC CANCER, V17, P0, DOI 10.1186/s12885-016-3037-z
   Hong JS, 2014, CURR ONCOL, V21, P174, DOI 10.3747/co.21.1984
   Hsieh YL, 2016, ACUPUNCT MED, V34, P398, DOI 10.1136/acupmed-2016-011112
   Iravani S, 2020, PAIN RES MANAG, V2020, P0, DOI 10.1155/2020/2504674
   Kosturakis AK, 2014, J CLIN ONCOL, V32, P3156, DOI 10.1200/JCO.2013.54.5418
   Linde K, 2007, PAIN, V128, P264, DOI 10.1016/j.pain.2006.12.006
   Litscher G, 2002, LASER MED SCI, V17, P19, DOI 10.1007/s10103-002-8262-9
   Loprinzi CL, 2020, J CLIN ONCOL, V38, P0, DOI 10.1200/JCO.20.01399
   Lu WD, 2020, ONCOLOGIST, V25, P310, DOI 10.1634/theoncologist.2019-0489
   Moharic M, 2012, J DIABETES COMPLICAT, V26, P319, DOI 10.1016/j.jdiacomp.2012.04.008
   Molassiotis A, 2019, INTEGR CANCER THER, V18, P0, DOI 10.1177/1534735419836501
   Mols F, 2014, SUPPORT CARE CANCER, V22, P2261, DOI 10.1007/s00520-014-2255-7
   Mols F, 2013, J CLIN ONCOL, V31, P2699, DOI 10.1200/JCO.2013.49.1514
   Pachman DR, 2014, SUPPORT CARE CANCER, V22, P2281, DOI 10.1007/s00520-014-2289-x
   Roldan CJ, 2018, PAIN PHYSICIAN, V21, PE419, DOI 10.36076/ppj.2018.4.e419
   Rostock M, 2013, EVID-BASED COMPL ALT, V2013, P0, DOI 10.1155/2013/349653
   Sereno M, 2014, CRIT REV ONCOL HEMAT, V89, P166, DOI 10.1016/j.critrevonc.2013.08.009
   Smith EML, 2013, JAMA-J AM MED ASSOC, V309, P1359, DOI 10.1001/jama.2013.2813
   Staff NP, 2017, ANN NEUROL, V81, P772, DOI 10.1002/ana.24951
   Tofthagen C, 2013, SUPPORT CARE CANCER, V21, P3307, DOI 10.1007/s00520-013-1905-5
   Wong Raimond, 2006, ACUPUNCT MED, V24, P87
   Yang YH, 2012, SUPPORT CARE CANCER, V20, P1491, DOI 10.1007/s00520-011-1237-2
   Zedan AH, 2014, CLIN COLORECTAL CANC, V13, P73, DOI 10.1016/j.clcc.2013.11.004
   Zhang SQ, 2017, J TRADIT CHIN MED, V37, P179
   Zhi WI, 2018, INTEGR CANCER THER, V17, P1079, DOI 10.1177/1534735418788667
   Zhou W, 2014, J ACUPUNCT MERIDIAN, V7, P186
NR 43
TC 14
Z9 16
U1 7
U2 22
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1083-7159
EI 1549-490X
J9 ONCOLOGIST
JI Oncologist
PD JUN 15
PY 2023
VL 28
IS 6
BP E436
EP E447
DI 10.1093/oncolo/oyad065
EA MAR 2023
PG 12
WC Oncology
SC Oncology
GA P0ZN0
UT WOS:000952698500001
PM 36971468
DA 2026-01-16
ER

PT J
AU Yang, M
   Baser, RE
   Liou, KT
   Li, SQ
   Piulson, L
   Panageas, KS
   Mao, JJ
AF Yang, Mingxiao
   Baser, Raymond E
   Liou, Kevin T
   Li, Susan Q
   Piulson, Lauren
   Panageas, Katherine S
   Mao, Jun J
TI Effect of acupuncture versus usual care on sleep quality in cancer survivors with
SO Cancer
LA English
DT Journal Article
DE cancer survivor; chronic pain; clinical trial; integrative care; sleep disturbance
AB BACKGROUND: Chronic pain negatively affects sleep; it is unclear whether pain  relief from acupuncture contributes to sleep quality improvements in cancer  survivors. This study aimed to evaluate the effect of acupuncture versus usual  care on sleep quality among cancer survivors with comorbid sleep disturbance and  chronic musculoskeletal pain. METHODS: Sleep outcome data from the Personalized  Electroacupuncture Versus Auricular Acupuncture Comparative Effectiveness (PEACE)  randomized clinical trial were analyzed. Electroacupuncture or auricular  acupuncture was compared with usual care for sleep quality improvement over 10  weeks of treatment among cancer survivors with clinically significant sleep  disturbance and chronic musculoskeletal pain at baseline. Sleep quality was  measured with the Pittsburgh Sleep Quality Index (PSQI) global score. RESULTS:  Among 268 participants (mean [standard deviation (SD)] age, 61.4 [12.6] years;  191 women [71.3%]; mean [SD] baseline PSQI global score, 10.3 [3.3] points),  electroacupuncture and auricular acupuncture resulted in greater reductions in  the PSQI global score from baseline to 10 weeks in comparison with usual care:  1.42 points (95% confidence interval [CI], 0.45-2.38; p = .004) and 1.59 points  (95% CI, 0.62-2.55; p = .001), respectively. The improvement in sleep quality for  the acupuncture groups was sustained for 24 weeks from randomization.  Furthermore, a greater proportion of patients in the electroacupuncture and  auricular acupuncture groups had clinically meaningful improvement in sleep  quality compared to the usual care group (41.0% and 42.9% vs. 21.4%; p = .044).  CONCLUSIONS: Among cancer survivors with comorbid sleep disturbance and chronic  pain, electroacupuncture and auricular acupuncture produced a clinically relevant  and persistent improvement in sleep quality. These findings suggest that  acupuncture may be an evidence-based nonpharmacologic intervention to improve  sleep health for cancer survivors with pain. PLAIN LANGUAGE SUMMARY: This study  analyzed the sleep quality data from a published randomized clinical trial that  evaluated the effect of electroacupuncture or auricular acupuncture versus usual  care on pain relief among people who survived cancer. This analysis included a  prespecified subgroup of 268 participants with co-occurring sleep disturbance and  chronic musculoskeletal pain at baseline and found that patients who used  acupuncture for pain relief demonstrated greater improvements in sleep quality  compared with patients who received usual care. Sleep quality improvement by  acupuncture was sustained after the treatment ended.
C1 Integrative Medicine Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
   Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
   Integrative Medicine Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
   Integrative Medicine Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
   Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
   Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
   Integrative Medicine Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
NR 0
TC 0
SN 1097-014
EI 0008-543
J9 Cancer
PD MAR 30
PY 2023
VL 129
IS 13
BP 2084
EP 2094
DI 10.1002/cncr.34766
PG 10
WC Humans; Female; Middle Aged; Chronic Pain; complications; Musculoskeletal Pain; Sleep Quality; Cancer Survivors; Acupuncture Therapy; methods; Treatment Outcome; Neoplasms; complications
UT PubMed:36989257
PM 36989257
DA 2023-03-30
ER

PT J
AU Mao, JJ
   Liou, K
   Romero, SAD
   Baser, RE
   Wong, G
   Xiao, H
   Deng, G
   Mo, ZL
   Walker, D
   MacLeod, JE
   Li, QS
   Barton-Burke, M
   Panageas, K
   Farrar, JT
   Epstein, AS
AF Mao, Jun J.
   Liou, Kevin
   Romero, Sally A. D.
   Baser, Raymond E.
   Wong, Greta
   Xiao, Han
   Deng, Gary
   Mo, Zunli
   Walker, Desiree
   MacLeod, Jodi Elizabeth
   Li, Qing Susan
   Barton-Burke, Margaret
   Panageas, Katherine
   Farrar, John T.
   Epstein, Andrew S.
TI Acupuncture versus massage for pain in patients living with advanced cancer: The IMPACT randomized clinical trial
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY USA.
   Mem Sloan Kettering Canc Ctr, New York, NY USA.
   Univ Calif San Diego, La Jolla, CA USA.
   Mem Sloan Kettering Canc Ctr Basking Ridge New Je, Basking Ridge, NJ USA.
   Miami Canc Inst, Miami, FL USA.
   Univ Penn, Philadelphia, PA USA.
C3 Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; University of California System; University of California San Diego; University of Pennsylvania
FU Patient-Centered Outcomes Research Institute (PCORI); U.S. National Institutes of Health
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD JUN 1
PY 2023
VL 41
IS 16
BP 
EP 
DI 
PG 1
WC Oncology
SC Oncology
GA P9JR8
UT WOS:001053772002978
DA 2026-01-16
ER

PT J
AU Li, MY
   Kwok, SWH
   Tan, JY
   Bressington, D
   Liu, XL
   Wang, T
   Chen, SL
AF Li, Meng -Yuan
   Kwok, Stephen Wai Hang
   Tan, Jing-Yu (Benjamin)
   Bressington, Daniel
   Liu, Xian-Liang
   Wang, Tao
   Chen, Shun-Li
TI Somatic acupressure for the fatigue-sleep disturbance-depression symptom cluster in breast cancer survivors: A phase II randomized controlled trial
SO EUROPEAN JOURNAL OF ONCOLOGY NURSING
LA English
DT Article
DE Breast neoplasms; Acupressure; Fatigue; Sleep disorder; Depression; Symptom cluster; Randomized controlled trial
ID quality-of-life; chinese version; sample-size; acupuncture; reliability; validation; program; manage; women; pain
AB Objective: To evaluate the feasibility of the somatic acupressure (SA) for managing the fatigue-sleep disturbance-depression symptom cluster (FSDSC) among breast cancer (BC) survivors and its preliminary effects.Methods: In this Phase II randomized controlled trial (RCT), 51 participants were randomised evenly into the true SA group, sham SA group, and usual care group. All the participants received usual care. The two SA groups performed additional true or sham self-acupressure daily for seven weeks. The primary outcomes related to the assessment of participants' recruitment and compliance with study questionnaires and interventions. Clinical outcomes assessed the preliminary effects of SA on fatigue, sleep disturbance, depression, and quality of life. Semi-structured interviews were undertaken to capture participants' experiences of participating in this study. The statistical effects of the intervention on the outcomes were modelled in repeated measures ANOVA and adjusted generalized estimating equations.Results: Forty-five participants completed the SA intervention. No adverse events were reported. Over 85% of the participants could sustain for 25 days or more and 15 min or more per session, but the adherence to the intervention requirement was yet to improve. The group by time effect of the FSDSC and depression were significant (p < 0.05). Qualitative findings showed that participants positively viewed SA as a beneficial strategy for symptom management. Conclusions: The SA intervention protocol and the trial procedures were feasible. The results demonstrated signs of improvements in targeted outcomes, and a full-scale RCT is warranted to validate the effects of SA on the FSDSC.
C1 [Li, Meng -Yuan; Liu, Xian-Liang; Wang, Tao] Charles Darwin Univ, Fac Hlth, Brisbane Ctr, Sch Nursing, Brisbane, Qld, Australia.
   [Kwok, Stephen Wai Hang] Murdoch Univ, Harry Butler Inst, Perth, WA, Australia.
   [Kwok, Stephen Wai Hang; Tan, Jing-Yu (Benjamin); Bressington, Daniel] Charles Darwin Univ, Fac Hlth, Sch Nursing, Ellengowan Dr, Casuarina, NT, Australia.
   [Chen, Shun-Li] Southwest Med Univ, Affiliated Hosp, 25 Taiping St, Luzhou 646000, Sichuan, Peoples R China.
   [Wang, Tao] Charles Darwin Univ, Fac Hlth, Brisbane Ctr, Sch Nursing, 410 Ann St, Brisbane, Qld, Australia.
   [Chen, Shun-Li] Southwest Med Univ, Affiliated Hosp, Luzhou 25 Taiping St, Jiangyang Dist Luzhou, Sichuan, Peoples R China.
C3 Charles Darwin University; Murdoch University; Charles Darwin University; Southwest Medical University; Charles Darwin University; Southwest Medical University
RP Wang, T (corresponding author), Charles Darwin Univ, Fac Hlth, Brisbane Ctr, Sch Nursing, 410 Ann St, Brisbane, Qld, Australia.; Chen, SL (corresponding author), Southwest Med Univ, Affiliated Hosp, Luzhou 25 Taiping St, Jiangyang Dist Luzhou, Sichuan, Peoples R China.
EM mengyuanli@students.cdu.edu.au; stephen.kwok@murdoch.edu.au; benjamin.tan@cdu.edu.au; daniel.bressington@cdu.edu.au; daniel.liu@cdu.edu.au; alison.wang@cdu.edu.au; chen1054633477@163.com
FU Charles Darwin University Rainmaker Readiness Grant
CR Berger AM, 2015, J NATL COMPR CANC NE, V13, P1012, DOI 10.6004/jnccn.2015.0122
   Bower JE, 2014, NAT REV CLIN ONCOL, V11, P597, DOI 10.1038/nrclinonc.2014.127
   Bower JE, 2011, J CLIN ONCOL, V29, P3517, DOI 10.1200/JCO.2011.36.1154
   Brady MJ, 1997, J CLIN ONCOL, V15, P974, DOI 10.1200/JCO.1997.15.3.974
   Braun V, 2006, QUAL RES PSYCHOL, V3, P77, DOI 10.1191/1478088706QP063OA
   Brown BT, 2009, CHIROPR. J. AUST., V39, P18, DOI 10.3316/informit.381529701096924
   Button KS, 2013, NAT REV NEUROSCI, V14, P365, DOI 10.1038/nrn3475
   Chan CWH, 2020, INT J ENV RES PUB HE, V17, P0, DOI 10.3390/ijerph17082950
   Cheung DST, 2022, EUR J CANCER CARE, V31, P0, DOI 10.1111/ecc.13314
   Cleeland CS, 2003, CANCER-AM CANCER SOC, V97, P2919, DOI 10.1002/cncr.11382
   Cohen J, 1992, CURR DIR PSYCHOL SCI, V1, P98, DOI 10.1111/1467-8721.EP10768783
   Efird J, 2011, INT J ENV RES PUB HE, V8, P15, DOI 10.3390/ijerph8010015
   Faul F, 2007, BEHAV RES METHODS, V39, P175, DOI 10.3758/BF03193146
   Fiorentino Lavinia, 2011, DRUG DISCOV TODAY DIS MODELS, V8, P167
   He XL, 2022, ONCOL NURS FORUM, V49, P243, DOI 10.1188/22.ONF.243-254
   He XL, 2021, ASIA-PAC J ONCOL NUR, V8, P337, DOI 10.4103/2347-5625.308677
   Ho RTH, 2014, SLEEP MED, V15, P565, DOI 10.1016/j.sleep.2013.10.019
   Ho SY, 2015, J PAIN SYMPTOM MANAG, V49, P707, DOI 10.1016/j.jpainsymman.2014.09.009
   Huong HTX, 2022, SLEEP BREATH, V26, P445, DOI 10.1007/s11325-021-02370-8
   Jain S, 2015, BREAST CANCER-TARGET, V7, P267, DOI 10.2147/BCTT.S25014
   Jiao J, 2015, J NURSES TRAIN (CHINESE), V30, P2221, DOI 10.16821/J.CNKI.HSJX.2015.24.005
   Julious SA, 2005, PHARM STAT, V4, P287, DOI 10.1002/pst.185
   Kawi J, 2022, EVID-BASED COMPL ALT, V2022, P0, DOI 10.1155/2022/8079691
   Khanghah AG, 2019, J ACUPUNCT MERIDIAN, V12, P103
   Koper N, 2009, J APPL ECOL, V46, P590, DOI 10.1111/j.1365-2664.2009.01642.x
   Leyrat C, 2018, INT J EPIDEMIOL, V47, P321, DOI 10.1093/ije/dyx169
   Li F, 2019, STAT MED, V38, P636, DOI 10.1002/sim.7995
   Li M, 2012, J CLIN ONCOL, V30, P1187, DOI 10.1200/JCO.2011.39.7372
   Li P, 2015, STAT MED, V34, P281, DOI 10.1002/sim.6344
   Li QP, 2016, EUR J ONCOL NURS, V25, P16, DOI 10.1016/j.ejon.2016.09.004
   Ling WM, 2014, ONCOL NURS FORUM, V41, P581, DOI 10.1188/14.ONF.581-592
   Liu XL, 2020, EVID-BASED COMPL ALT, V2020, P0, DOI 10.1155/2020/2591320
   [毛婷 Mao Ting], 2018, 护理学杂志 JOURNAL OF NURSING SCIENCE, V33, P38
   Mendoza TR, 1999, CANCER-AM CANCER SOC, V85, P1186, DOI 10.1002/(SICI)1097-0142(19990301)85:5<1186::AID-CNCR24>3.0.CO;2-N
   Molassiotis A, 2012, J CLIN ONCOL, V30, P4470, DOI 10.1200/JCO.2012.41.6222
   Qiao SN, 2019, PATIENT PREFER ADHER, V13, P923, DOI 10.2147/PPA.S203900
   Schober P, 2018, ANESTH ANALG, V126, P1763, DOI 10.1213/ANE.0000000000002864
   Serdar CC, 2021, BIOCHEM MEDICA, V31, P0, DOI 10.11613/BM.2021.010502
   Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI 10.3322/caac.21708
   Skivington K, 2021, BMJ-BRIT MED J, V374, P0, DOI 10.1136/bmj.n2061
   So WKW, 2021, CANCER MED-US, V10, P2531, DOI 10.1002/cam4.3794
   So WKW, 2020, CANCER NURS, V43, PE304, DOI 10.1097/NCC.0000000000000730
   Soerjomataram I, 2021, NAT REV CLIN ONCOL, V18, P663, DOI 10.1038/s41571-021-00514-z
   Sui YL, 2020, EUR J ONCOL NURS, V45, P0, DOI 10.1016/j.ejon.2019.101707
   Suresh Kp, 2011, J HUM REPROD SCI, V4, P8, DOI 10.4103/0974-1208.82352
   Tan J, 2017, EFFECTS OF AURICULAR ACUPRESSURE ON CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING IN BREAST CANCER PATIENTS: A PRELIMINARY RANDOMIZED CONTROLLED TRIAL, V0, P0, DOI DOI 10.25236/IJFM.2024.061010
   Tan JY, 2022, BMC COMPLEMENT MED, V22, P0, DOI 10.1186/s12906-022-03543-y
   Tan JY, 2015, PLOS ONE, V10, P0, DOI 10.1371/journal.pone.0132989
   Tan JY, 2022, INT J ENV RES PUB HE, V19, P0, DOI 10.3390/ijerph191911934
   Tan JY, 2021, COMPLEMENT THER CLIN, V45, P0, DOI 10.1016/j.ctcp.2021.101490
   Teerenstra S, 2010, BIOMETRICS, V66, P1230, DOI 10.1111/j.1541-0420.2009.01374.x
   Tian J, 2012, SUPPORT CARE CANCER, V20, P2379, DOI 10.1007/s00520-011-1357-8
   Wan CH, 2007, BREAST CANCER RES TR, V106, P413, DOI 10.1007/s10549-007-9511-1
   Wang M, 2014, ADV STAT, V2014, P1, DOI 10.1155/2014/303728
   Wang T, 2023, COMPLEMENT THER CLIN, V51, P0, DOI 10.1016/j.ctcp.2023.101735
   Wang T, 2022, BMJ OPEN, V12, P0, DOI 10.1136/bmjopen-2021-054597
   Wang XS, 2004, J PAIN SYMPTOM MANAG, V27, P322, DOI 10.1016/j.jpainsymman.2003.09.008
   Weaver M T, 1985, NURSE PRACT, V10, P38
   White A, 2004, RHEUMATOLOGY, V43, P662, DOI 10.1093/rheumatology/keg005
   Wong WM, 2023, CANCER NURS, V46, PE70, DOI 10.1097/NCC.0000000000001048
   Xu SF, 2013, EVID-BASED COMPL ALT, V2013, P0, DOI 10.1155/2013/581203
   Yeh CH, 2016, CANCER NURS, V39, P402, DOI 10.1097/NCC.0000000000000303
   Zick SM, 2016, JAMA ONCOL, V2, P1470, DOI 10.1001/jamaoncol.2016.1867
NR 63
TC 11
Z9 11
U1 6
U2 43
PU ELSEVIER SCI LTD
PI London
PA 125 London Wall, London, ENGLAND
SN 1462-3889
EI 1532-2122
J9 EUR J ONCOL NURS
JI Eur. J. Oncol. Nurs.
PD OCT 15
PY 2023
VL 66
IS 
BP 
EP 
DI 10.1016/j.ejon.2023.102380
EA AUG 2023
PG 12
WC Oncology; Nursing
SC Oncology; Nursing
GA R3YC7
UT WOS:001063729300001
PM 37607468
DA 2026-01-16
ER

PT J
AU Gao, XY
   Zhang, N
   Liu, K
   Xi, HQ
   Liu, Y
   He, X
   Han, S
   Zhu, B
AF Gao, Xin-Yan
   Zhang, Nan
   Liu, Kun
   Xi, Han-Qing
   Liu, Yun
   He, Xun
   Han, Shu
   Zhu, Bing
TI Peripheral neural mechanism of visceral pain and acupoint sensitization in 2, 4,
SO Zhen ci yan jiu = Acupuncture research
LA chi
DT Journal Article
DE Acupoint sensitization; Colitis; Dorsal root ganglion; In vivo calcium imaging; Neuron
AB OBJECTIVES: To explore the neural mechanism of visceral pain and related somatic  (acupoints) sensitization by using in vivo calcium imaging of dorsal root ganglia  (DRG) neurons. METHODS: Eight BALB/c mice were randomly divided into control and  model groups, with 4 mice in each group. The colitis model was induced by  colorectal perfusion of 2, 4, 6-trinitrobenzene sulfonic acid (TNBS) once daily  for 7 days. Mice of the control group received colorectal perfusion of normal  saline once daily for 7 days. The location and area of the somatic neurogenic  inflammation (cutaneous exudation of Evans blue ［EB］) of the 2 groups of mice  were observed after intravenous injection of EB. For pain behavioral tests,  sixteen C57BL/6J mice were randomly divided into control and model groups, with 8  mice in each group, and a Von Frey filament was used to stimulate the referred  somatic reactive regions in colitis mice, and the number of avoidance and paw  withdraw reaction within 10 tests was recorded. For in vivo DRG calcium imaging  tests, 24 Pirt-GCaMP6s transgenic mice were randomly and equally divided into  control group and colitis model group. The responses of the neurons in L6 or L4  DRG to colorectal distension (CRD), lower back brushing, or mechanical  stimulation at the hindpaw were observed using confocal fluorescence microscope.  RESULTS: Compared with the control group, the area of EB exudation spot in the  hindpaw and lower back regions was increased in the colitis model group (P<0.05),  and the avoidance or paw withdraw numbers induced by Von Frey stimulation at the  lower back and hindpaw were increased (P<0.01, P<0.05), indicating that colitis  induced regional skin (acupoints) sensitization in the lower back and hindpaw  regions. Compared with the control group, the percentage of L6 DRG neurons  activated by 60 mm Hg CRD in the colitis model mice were apparently increased  (P<0.01), the activated neurons mainly involved the medium-sized DRG neurons  (P<0.01). In Pirt-GCaMP6s transgenic mice, following brushing the skin of the  receptive field (lower back) of L6 DRG neurons, the fluorescence intensity of the  brushing-activated DRG neurons and small, medium and large-sized neurons were  significantly higher in the colitis model group than those in the control group  (P<0.001, P<0.01, P<0.05). After brushing and clamping the skin of the right  hindpaw (receptive field of L4 DRG neurons), the percentages of the activated L4  DRG neurons were obviously higher in the colitis model group than those in the  control group (P<0.01, P<0.05), while there were no significant changes in the  proportion of small, medium and large-sized neurons between the control and  colitis model groups. CONCLUSIONS: Colitis may lead to body surface sensitization  at the same and adjacent neuro-segments as well as to an increase of the number  and activity of the responsive lumbar DRG neurons, among which the L6 DRG neurons  at the same neuro-segment as the rectum colon showed an increase in the number of  responders and intensity of calcium fluorescence signal while L4 DRG neurons at  the level adjacent to the rectum colon showed an increase in the number of  responders, suggesting that there may be different mechanisms of peripheral  neural sensitization.
C1 Institute of Acupuncture and Moxibustion, China Academy of Chinese Medical Sciences, Beijing 100700, China. gaoxy@mail.cintcm.ac.cn.
   Institute of Acupuncture and Moxibustion, China Academy of Chinese Medical Sciences, Beijing 100700, China.
   Institute of Acupuncture and Moxibustion, China Academy of Chinese Medical Sciences, Beijing 100700, China.
   Institute of Acupuncture and Moxibustion, China Academy of Chinese Medical Sciences, Beijing 100700, China.
   Institute of Acupuncture and Moxibustion, China Academy of Chinese Medical Sciences, Beijing 100700, China.
   Institute of Acupuncture and Moxibustion, China Academy of Chinese Medical Sciences, Beijing 100700, China.
   School of Engineering Medicine, Beihang University, Beijing 100191.
   Institute of Acupuncture and Moxibustion, China Academy of Chinese Medical Sciences, Beijing 100700, China. zhubing@mail.cintcm.ac.cn.
NR 0
TC 0
SN 
EI 1000-060
J9 Zhen Ci Yan Jiu
PD DEC 26
PY 2023
VL 48
IS 12
BP 1183
EP 1192
DI 10.13702/j.1000-0607.20221141
PG 9
WC Mice; Animals; Visceral Pain; genetics; Calcium; Acupuncture Points; Mice, Inbred C57BL; Colitis; chemically induced; Trinitrobenzenes; Mice, Transgenic; Colorectal Neoplasms
UT PubMed:38146240
PM 38146240
DA 2023-12-26
ER

PT J
AU Wang, N
   Zhao, L
   Zhang, D
   Kong, FM
AF Wang, Na
   Zhao, Lu
   Zhang, Dou
   Kong, Fanming
TI Research progress on the immunomodulatory mechanism of acupuncture in tumor immune microenvironment
SO FRONTIERS IN IMMUNOLOGY
LA English
DT Review
DE acupuncture; tumor immune microenvironment; traditional Chinese medicine; immunotherapy; cancer immunity
ID cancer-patients; m2 macrophages; electroacupuncture; cells; innate; pain; immunosuppression; activation; acupoint; efficacy
AB With the constantly deeper understanding of individualized precision therapy, immunotherapy is increasingly developed and personalized. The tumor immune microenvironment (TIME) mainly consists of infiltrating immune cells, neuroendocrine cells, extracellular matrix, lymphatic vessel network, etc. It is the internal environment basis for the survival and development of tumor cells. As a characteristic treatment of traditional Chinese medicine, acupuncture has shown potentially beneficial impacts on TIME. The currently available information demonstrated that acupuncture could regulate the state of immunosuppression through a range of pathways. An effective way to understand the mechanisms of action of acupuncture was to analyze the response following treatment of the immune system. This research reviewed the mechanisms of acupuncture regulating tumor immunological status based on innate and adaptive immunity.
C1 [Wang, Na; Zhao, Lu; Zhang, Dou; Kong, Fanming] Tianjin Univ Tradit Chinese Med, Teaching Hosp 1, Dept Oncol, Tianjin, Peoples R China.
   [Wang, Na; Zhao, Lu; Zhang, Dou; Kong, Fanming] Natl Clin Res Ctr Chinese Med Acupuncture & Moxibu, Tianjin, Peoples R China.
C3 Tianjin University of Traditional Chinese Medicine
RP Kong, FM (corresponding author), Tianjin Univ Tradit Chinese Med, Teaching Hosp 1, Dept Oncol, Tianjin, Peoples R China.; Kong, FM (corresponding author), Natl Clin Res Ctr Chinese Med Acupuncture & Moxibu, Tianjin, Peoples R China.
EM kongfanming08@163.com
FU National Natural Science Foundation of China [81403220]; National Key Research and Development (RD) Plan [2018YFC1707400]; Tianjin Health and Family Planning-high Level Talent Selection and Training Project
CR Albini A, 2018, FRONT IMMUNOL, V9, P0, DOI 10.3389/fimmu.2018.00527
   Ali U, 2020, BIOMED PHARMACOTHER, V125, P0, DOI 10.1016/j.biopha.2020.109898
   Arranz L, 2007, AM J CHINESE MED, V35, P35, DOI 10.1142/S0192415X07004606
   Borst K, 2021, IMMUNITY, V54, P2194, DOI 10.1016/j.immuni.2021.09.014
   Cabioglu MT, 2007, AM J CHINESE MED, V35, P955, DOI 10.1142/S0192415X07005429
   Cai Yujia, 2012, J EVID BASED MED, V5, P12, DOI 10.1111/j.1756-5391.2012.01163.x
   Cao BQ, 2021, NEURAL REGEN RES, V16, P944, DOI 10.4103/1673-5374.297061
   Chen HY, 2013, BMC COMPLEM ALTERN M, V13, P0, DOI 10.1186/1472-6882-13-362
   Cheng CS, 2017, SUPPORT CARE CANCER, V25, P3807, DOI 10.1007/s00520-017-3812-7
   Church SE, 2017, ADV EXP MED BIOL, V1036, P33, DOI 10.1007/978-3-319-67577-0_3
   Colonna M, 2017, ANNU REV IMMUNOL, V35, P441, DOI 10.1146/annurev-immunol-051116-052358
   da Silva MD, 2015, MOL NEUROBIOL, V51, P19, DOI 10.1007/s12035-014-8790-x
   Darvin P, 2018, EXP MOL MED, V50, P0, DOI 10.1038/s12276-018-0191-1
   Deets KA, 2021, NAT IMMUNOL, V22, P412, DOI 10.1038/s41590-021-00869-6
   Demaria O, 2019, NATURE, V574, P45, DOI 10.1038/s41586-019-1593-5
   Ding N, 2018, PLOS ONE, V13, P0, DOI 10.1371/journal.pone.0194022
   Ding SS, 2014, QJM-INT J MED, V107, P341, DOI 10.1093/qjmed/hct196
   Dong HX, 2017, EVID-BASED COMPL ALT, V2017, P0, DOI 10.1155/2017/3647080
   Dou BM, 2021, FRONT NEUROSCI-SWITZ, V15, P0, DOI 10.3389/fnins.2021.695670
   Duan QQ, 2020, TRENDS CANCER, V6, P605, DOI 10.1016/j.trecan.2020.02.022
   Gajewski TF, 2013, NAT IMMUNOL, V14, P1014, DOI 10.1038/ni.2703
   Gardner A, 2020, FRONT IMMUNOL, V11, P0, DOI 10.3389/fimmu.2020.00924
   Giese MA, 2019, BLOOD, V133, P2159, DOI 10.1182/blood-2018-11-844548
   Guo QJ, 2015, BIOMED RES INT, V2015, P0, DOI 10.1155/2015/261620
   Hajizadeh F, 2021, LIFE SCI, V264, P0, DOI 10.1016/j.lfs.2020.118699
   Han JS, 2011, NEUROSCI BIOBEHAV R, V35, P680, DOI 10.1016/j.neubiorev.2010.08.006
   Han QQ, 2021, J CANCER, V12, P7003, DOI 10.7150/jca.55803
   Hinshaw DC, 2019, CANCER RES, V79, P4557, DOI 10.1158/0008-5472.CAN-18-3962
   Hu LY, 2018, BRAIN BEHAV IMMUN, V68, P132, DOI 10.1016/j.bbi.2017.10.011
   Huang ZH, 2019, ACUPUNCT MED, V37, P292, DOI 10.1136/acupmed-2017-011593
   Hwang JH, 2018, EXP THER MED, V16, P310, DOI 10.3892/etm.2018.6190
   Jin LL, 2021, AM J TRANSL RES, V13, P8118
   Johnston MF, 2011, EVID-BASED COMPL ALT, V2011, P1, DOI 10.1093/ecam/nep236
   Kan BH, 2018, NEURAL REGEN RES, V13, P1390, DOI 10.4103/1673-5374.235292
   Kim DJ, 2014, J TRADIT CHIN MED, V34, P550, DOI 10.1016/S0254-6272(15)30061-3
   Komi DEA, 2020, CLIN REV ALLERG IMMU, V58, P313, DOI 10.1007/s12016-019-08753-w
   Lee SWH, 2014, COMPLEMENT THER MED, V22, P965, DOI 10.1016/j.ctim.2014.10.010
   Lee YS, 2016, JOVE-J VIS EXP, V0, P0, DOI DOI 10.3791/54213
   Lee YS, 2019, INT REV CEL MOL BIO, V348, P123, DOI 10.1016/bs.ircmb.2019.07.006
   Li GY, 2013, EXP THER MED, V6, P699, DOI 10.3892/etm.2013.1225
   Li GY, 2013, ACUPUNCT MED, V31, P51, DOI 10.1136/acupmed-2012-010254
   Li LJ, 2021, J INTEGR MED-JIM, V19, P251, DOI 10.1016/j.joim.2021.02.001
   Li L, 2020, NEURAL PLAST, V2020, P0, DOI 10.1155/2020/8836173
   Li NC, 2021, J INFLAMM RES, V14, P7191, DOI 10.2147/JIR.S341581
   Li S, 2019, J EXP CLIN CANC RES, V38, P0, DOI 10.1186/s13046-018-1003-0
   Li SS, 2022, FRONT ONCOL, V12, P0, DOI 10.3389/fonc.2022.864046
   Li YY, 2019, INT J MOL SCI, V20, P0, DOI 10.3390/ijms20235917
   Liang Y, 2018, INTEGR CANCER THER, V17, P401, DOI 10.1177/1534735417728335
   Lichterman JN, 2021, CELLS-BASEL, V10, P0, DOI 10.3390/cells10061270
   Liu AQ, 2022, CONTRAST MEDIA MOL I, V2022, P0, DOI 10.1155/2022/3444360
   Liu X, 1993, J TRADIT CHIN MED, V13, P174
   Liu ZF, 2022, EVID-BASED COMPL ALT, V2022, P0, DOI 10.1155/2022/8528938
   Locati M, 2020, ANNU REV PATHOL-MECH, V15, P123, DOI 10.1146/annurev-pathmechdis-012418-012718
   Locy H, 2018, FRONT IMMUNOL, V9, P0, DOI 10.3389/fimmu.2018.02909
   Lu WD, 2009, J ALTERN COMPLEM MED, V15, P745, DOI 10.1089/acm.2008.0589
   Mori H, 2013, J INTEGR MED-JIM, V11, P101, DOI 10.3736/jintegrmed2013012
   Ngambenjawong C, 2017, ADV DRUG DELIVER REV, V114, P206, DOI 10.1016/j.addr.2017.04.010
   Ocana A, 2017, MOL CANCER, V16, P0, DOI 10.1186/s12943-017-0707-7
   Oura M, 2021, JAMA ONCOL, V7, P1399, DOI 10.1001/jamaoncol.2021.2517
   Pan P, 2021, FRONT AGING NEUROSCI, V13, P0, DOI 10.3389/fnagi.2021.706834
   Patente TA, 2019, FRONT IMMUNOL, V9, P0, DOI 10.3389/fimmu.2018.03176
   Pei LX, 2020, MAYO CLIN PROC, V95, P1671, DOI 10.1016/j.mayocp.2020.01.042
   Prager I, 2019, J LEUKOCYTE BIOL, V105, P1319, DOI 10.1002/JLB.MR0718-269R
   Prinz M, 2019, CELL, V179, P292, DOI 10.1016/j.cell.2019.08.053
   Rodríguez-Gómez JA, 2020, CELLS-BASEL, V9, P0, DOI 10.3390/cells9071717
   Saraswati W, 2019, MED ACUPUNCT, V31, P29, DOI 10.1089/acu.2018.1316
   Schreiber RD, 2011, SCIENCE, V331, P1565, DOI 10.1126/science.1203486
   Shaul ME, 2019, NAT REV CLIN ONCOL, V16, P601, DOI 10.1038/s41571-019-0222-4
   Tang WF, 2021, BIOMED PHARMACOTHER, V134, P0, DOI 10.1016/j.biopha.2020.111001
   Vesely MD, 2011, ANNU REV IMMUNOL, V29, P235, DOI 10.1146/annurev-immunol-031210-101324
   Viola A, 2019, FRONT IMMUNOL, V10, P0, DOI 10.3389/fimmu.2019.01462
   Wang NK, 2018, ONCOL LETT, V15, P189, DOI 10.3892/ol.2017.7262
   Wang ZG, 2018, INFLAMMATION, V41, P859, DOI 10.1007/s10753-018-0740-8
   Wei Y, 2015, EVID-BASED COMPL ALT, V2015, P0, DOI 10.1155/2015/340126
   Witt CM, 2011, CHIN J INTEGR MED, V17, P166, DOI 10.1007/s11655-011-0662-x
   Wu DJ, 2017, ADV EXP MED BIOL, V1011, P211, DOI 10.1007/978-94-024-1170-6_7
   Wu KY, 2020, FRONT IMMUNOL, V11, P0, DOI 10.3389/fimmu.2020.01731
   Wu SY, 2020, MOL CANCER, V19, P0, DOI 10.1186/s12943-020-01238-x
   Xu JP, 2022, FRONT SURG, V9, P0, DOI 10.3389/fsurg.2022.901638
   Xu Y, 2018, AM J CHINESE MED, V46, P997, DOI 10.1142/S0192415X18500520
   Yang G, 2022, BIOMED RES INT, V2022, P0, DOI 10.1155/2022/7037497
   Yang G, 2016, CHIN J INTEGR MED, V22, P219, DOI 10.1007/s11655-016-2462-9
   Yang YQ, 2013, CLIN REV ALLERG IMMU, V44, P254, DOI 10.1007/s12016-012-8321-3
   Yim YK, 2007, EVID-BASED COMPL ALT, V4, P51, DOI 10.1093/ecam/nel054
   Zeng BY, 2013, INT REV NEUROBIOL, V111, PXV, DOI 10.1016/B978-0-12-411545-3.09989-2
   Zhang D, 2008, EXPLORE-NY, V4, P170, DOI 10.1016/j.explore.2008.02.002
   Zhang Y, 2021, FRONT IMMUNOL, V11, P0, DOI 10.3389/fimmu.2020.609705
   Zhang ZY, 2021, LIFE SCI, V272, P0, DOI 10.1016/j.lfs.2021.119259
   Zhao JG, 2017, ACUPUNCT MED, V35, P224, DOI 10.1136/acupmed-2016-011107
   Zhao YX, 2020, J PAIN RES, V13, P239, DOI 10.2147/JPR.S241101
NR 90
TC 14
Z9 18
U1 10
U2 76
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-3224
EI 
J9 FRONT IMMUNOL
JI Front. Immunol.
PD FEB 14
PY 2023
VL 14
IS 
BP 
EP 
DI 10.3389/fimmu.2023.1092402
PG 7
WC Immunology
SC Immunology
GA 9I8BF
UT WOS:000939728000001
PM 36865562
DA 2026-01-16
ER

PT J
AU Bahçecioğlu, Turan G
   Özer, Z
   Yanmış, S
   Aksoy, A
AF Bahçecioğlu Turan, Gülcan
   Özer, Zülfünaz
   Yanmış, Safiye
   Aksoy, Asude
TI The Effects of Self-Acupressure on Pain, Fatigue, and Sleep Quality in Colon and
SO Cancer nursing
LA English
DT Journal Article
AB BACKGROUND: Pancreatic and colon cancer are among important gastrointestinal  cancer diseases. Pain, fatigue, and insomnia are among the most common symptoms  in cancer patients receiving chemotherapy. Self-acupressure may improve patients'  pain, fatigue, sleep quality, quality of life, and functional well-being.  OBJECTIVE: The aim of this study was to examine the effects of self-acupressure  application on pain, fatigue, and sleep quality in colon and pancreatic cancer  patients receiving chemotherapy. METHODS: This randomized controlled study was  conducted with 60 patients in treatment for pancreatic or colon cancer, 30 in the  intervention and 30 in the control group, between June and October 2021.  Participants in the intervention group were asked to complete 16 acupressure  sessions for 4 weeks, 2 days a week in the morning and afternoon for a total of  18 minutes, depending on the preparation and pressure time on 4 pressure points.  Control group participants did not receive any interventions during the study.  The data were collected by using a personal information form, the Pittsburgh  Sleep Quality Index, the Piper Fatigue Scale, and the visual analog scale.  RESULTS: After self-acupressure, the visual analog scale, Piper Fatigue Scale,  and Pittsburgh Sleep Quality Index scores of the intervention group decreased  when compared with the control group scores; the difference between the 2 groups  was statistically significant. CONCLUSION: Self-acupressure was effective in  reducing the pain, fatigue, and sleep disorder scores of patients with colon or  pancreatic cancer receiving chemotherapy. IMPLICATIONS FOR PRACTICE: In nursing  practice, self-acupressure, an applicable, accessible, and inexpensive method in  the management of cancer-related symptoms, can be supported and maintained during  a 4-week period.
C1 Author Affiliations: Faculty of Health Sciences, Department of Nursing, Fırat University (Dr Bahçecioğlu Turan), Elaziğ
   Faculty of Health Sciences, IstanbulSabahattin Zaim University (Dr Özer)
   Faculty of Health Sciences, Department ofNursing, Erzican Binali Yıldırım University (Dr Yanmış)
   and Department ofInternal Medicine, Medical School Fırat University (Dr Aksoy), Elaziğ, Turkey.
NR 0
TC 0
SN 1538-980
EI 
J9 Cancer Nurs
PD FEB 3
PY 2023
VL 46
IS 6
BP 457
EP 466
DI 10.1097/NCC.0000000000001193
PG 9
UT PubMed:36728147
PM 36728147
DA 2023-02-03
ER

PT J
AU Chiaramonte, R
   Bonfiglio, M
   Caramma, S
   Condorelli, R
AF Chiaramonte, Rita
   Bonfiglio, Marco
   Caramma, Salvatore
   Condorelli, Rosaria
TI The Role of Rehabilitation in the Treatment of Constipation in Oncological
SO Journal of clinical medicine
LA English
DT Review
DE constipation; neoplasms; osteopathy; rehabilitation
AB BACKGROUND: Chemotherapy, as well as opioid and antiemetic drugs, can contribute  to constipation in oncological patients. This systematic review aims to analyse  the potential of specific rehabilitation strategies and alternative strategies  for improving constipation symptoms, with the goal of incorporating these  strategies into a dedicated protocol for managing cancer-related constipation.  This could potentially reduce the dosages of or eliminate the need for  constipation medications. METHODS: A systematic search was conducted on PubMed,  Scopus and Web of Science. The review included studies analysing constipation  complaints in cancer patients treated with rehabilitation, acupuncture and  osteopathy. RESULTS: The review included 16 studies in line with PRISMA and PICOS  criteria. Most studies showed that physical exercise, abdominal massage, TENS,  acupuncture and education on the correct defecation position positively impacted  the management of constipation and quality of life in oncological patients. A  physiotherapy program involving massages as well as aerobic and resistance  training improved constipation in oncological women, regardless of age, sex and  frailty. A combination of abdominal massage, abdominal muscle stretching and  education on proper defecation position alleviated the severity of constipation  and related depression. However, the outcomes regarding TENS were yet  inconsistent. Another technique, becoming increasingly common for constipation,  and demonstrating positive results, involved stimulating trigger points through  acupressure and acupuncture. Conversely, osteopathic and superficial  manipulations more frequently required constipation medications than did the  other alternative approaches. However, no existing studies have proposed a  specific protocol to manage cancer-related constipation. CONCLUSIONS: The results  of the studies confirm the positive influences of rehabilitation, osteopathy and  acupuncture on constipation and pain in oncological patients. Nevertheless,  further studies are required to establish the best type, timing and duration of  treatment, as well as how the stage and location of the cancer and the cause of  constipation (drug-induced or functional) impact the results.
C1 Department of Biomedical and Biotechnological Sciences, University of Catania, 95123 Catania, Italy.
   Provincial Health Department of Siracusa, 96014 Sicily, Italy.
   Department of Pain Management, Policlinico-San Marco Hospital, 95123 Catania, Italy.
   Department of Medical Oncology, EOC-Istituto Oncologico della Svizzera Italiana, 6500 Bellinzona, Switzerland.
NR 0
TC 0
SN 2077-038
EI 2077-038
J9 J Clin Med
PD AUG 12
PY 2023
VL 12
IS 15
BP 
EP 
DI 10.3390/jcm12155083
PG 0
UT PubMed:37568485
PM 37568485
DA 2023-08-12
ER

PT J
AU Lopez, AM
AF Lopez, Ana Maria
TI Integrative oncology in cancer care: Reaching a tipping point.
SO Cancer
LA English
DT Editorial
DE acupuncture; anxiety; gyn oncology; integrative oncology; pain
C1 Sidney Kimmel Medical College and Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
NR 0
TC 0
SN 1097-014
EI 
J9 Cancer
PD JAN 18
PY 2023
VL 129
IS 6
BP 834
EP 835
DI 10.1002/cncr.34539
PG 1
WC Humans; Integrative Oncology; Medical Oncology; Neoplasms; therapy
UT PubMed:36647627
PM 36647627
DA 2023-01-18
ER

PT J
AU Li, HJ
   Schlaeger, JM
   Patil, CL
   Danciu, OC
   Xia, YL
   Sun, J
   Doorenbos, AZ
AF Li, Hongjin
   Schlaeger, Judith M.
   Patil, Crystal L.
   Danciu, Oana C.
   Xia, Yinglin
   Sun, Jun
   Doorenbos, Ardith Z.
TI Feasibility of Acupuncture and Exploration of Metabolomic Alterations for Psychoneurological Symptoms Among Breast Cancer Survivors
SO BIOLOGICAL RESEARCH FOR NURSING
LA English
DT Article
DE acupuncture; psychoneurological symptoms; metabolites; breast cancer
ID bioelectrical-impedance analysis; vector analysis biva; brain natriuretic peptide; acute heart-failure; body-composition; phase-angle; bioimpedance analysis; scientific statement; prognostic value; diagnosis
AB Objective Approximately 24-68% of breast cancer survivors report co-occurring psychoneurological symptoms of pain, fatigue, sleep disturbance, depression, and anxiety during and after cancer treatment. This study aimed to assess the feasibility and acceptability of acupuncture for the treatment of multiple psychoneurological symptoms among breast cancer survivors and explore metabolomic changes before and after acupuncture. Methods We conducted a single-arm, prospective pilot study of breast cancer survivors with at least two moderate to severe psychoneurological symptoms (>3 on a 0-10 scale). Acupuncture was administered twice weekly for 5 weeks, for 30 minutes per session. Along with Patient-Reported Outcomes Measurement Information System (PROMIS) questionnaires, a fasting serum comprehensive hydrophilic metabolites panel was analyzed at baseline and after acupuncture. Results Eight participants (mean age 52.5 +/- 10.9 years; 62.5% Black) were enrolled. Feasibility was supported, with 67% recruitment, 87.5% retention, and 98% acceptability. Post intervention, PROMIS T-scores were reduced for all psychoneurological symptoms. Significant differences in serum metabolites before and after acupuncture were F-1,6/2,6-DP, glutathione disulfide, phosphorylcholine, 6-methylnicotinamide, glutathione, and putrescine (variable importance of projection values larger than 1.5 and p values <0.05). Pathway analysis indicated that glutathione metabolism (p = 0.002, q = 0.071), and arginine and proline metabolisms (p = 0.009, q = 0.166) were potentially involved in mechanisms of acupuncture. Conclusions Acupuncture to reduce multiple psychoneurological symptoms among breast cancer survivors was feasible and acceptable. Study findings also shed light on the metabolic pathways involved in the acupuncture response and will be tested in future studies.
C1 [Li, Hongjin; Schlaeger, Judith M.; Patil, Crystal L.] Univ Illinois, Coll Nursing, Dept Human Dev Nursing Sci, Chicago, IL 60612 USA.
   [Li, Hongjin; Danciu, Oana C.; Sun, Jun; Doorenbos, Ardith Z.] Univ Illinois, Canc Ctr, Chicago, IL 60612 USA.
   [Danciu, Oana C.; Xia, Yinglin; Sun, Jun] Univ Illinois, Coll Med, Chicago, IL 60612 USA.
   [Doorenbos, Ardith Z.] Univ Illinois, Coll Nursing, Dept Biobehav Nursing Sci, Chicago, IL 60612 USA.
C3 University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital
RP Li, HJ (corresponding author), Univ Illinois, 845 S Damen Ave,MC 802, Chicago, IL 60612 USA.
EM hongjin@uic.edu
FU National Center for Complementary and Integrative Health of the National Institutes of Health [K24AT011995-01]
CR Agus A, 2018, CELL HOST MICROBE, V23, P716, DOI 10.1016/j.chom.2018.05.003
   Al-Bashaireh AM, 2021, CUREUS J MED SCIENCE, V13, P0, DOI 10.7759/cureus.19953
   Amtmann D, 2010, PAIN, V150, P173, DOI 10.1016/j.pain.2010.04.025
   Bahrami Taghanaki HR, 2021, J. NUTR. FASTING HEALTH, V9, P196, DOI 10.22038/JNFH.2021.54314.1310
   Beger RD, 2016, METABOLOMICS, V12, P0, DOI 10.1007/s11306-016-1094-6
   Bellg AJ, 2004, HEALTH PSYCHOL, V23, P443, DOI 10.1037/0278-6133.23.5.443
   BENJAMINI Y, 1995, J ROY STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x
   Bjerkeset E, 2020, BREAST CANCER RES TR, V180, P63, DOI 10.1007/s10549-020-05522-8
   Borrelli B, 2005, J CONSULT CLIN PSYCH, V73, P852, DOI 10.1037/0022-006X.73.5.852
   Brauer JA, 2010, J ALTERN COMPLEM MED, V16, P183, DOI 10.1089/acm.2009.0354
   Cella D, 2010, J CLIN EPIDEMIOL, V63, P1179, DOI 10.1016/j.jclinepi.2010.04.011
   Cessna JM, 2016, J PSYCHOSOM RES, V81, P9, DOI 10.1016/j.jpsychores.2015.12.002
   Chou YJ, 2021, BIOL RES NURS, V23, P42, DOI 10.1177/1099800420942586
   Doong SH, 2015, BIOL RES NURS, V17, P237, DOI 10.1177/1099800414550394
   Dorland HF, 2018, J CANCER SURVIV, V12, P371, DOI 10.1007/s11764-018-0676-x
   Eaton LH, 2011, NURS RES, V60, P430, DOI 10.1097/NNR.0b013e31823386aa
   Garland SN, 2017, MENOPAUSE, V24, P517, DOI 10.1097/GME.0000000000000779
   Giovanni M, 1989, THE FOUNDATIONS OF CHINESE MEDICINE: A COMPREHENSIVE TEXT FOR ACUPUNCTURISTS AND HERBALISTS, V0, P219
   Hershman DL, 2018, JAMA-J AM MED ASSOC, V320, P167, DOI 10.1001/jama.2018.8907
   Kim HJ, 2012, CANCER NURS, V35, PE1, DOI 10.1097/NCC.0b013e318233a811
   Kornilov V, 2022, EUR J PSYCHIAT, V36, P288, DOI 10.17116/jnevro2022122081136
   Kwekkeboom KL, 2020, ONCOL NURS FORUM, V47, P498, DOI 10.1188/20.ONF.498-511
   Kwekkeboom KL, 2018, J PAIN SYMPTOM MANAG, V55, P1286, DOI 10.1016/j.jpainsymman.2018.01.008
   Langford DJ, 2016, SUPPORT CARE CANCER, V24, P605, DOI 10.1007/s00520-015-2819-1
   Li HJ, 2021, J ALTERN COMPLEM MED, V27, P1084, DOI 10.1089/acm.2021.0133
   Li W, 2020, MEDICINE, V99, P0, DOI 10.1097/MD.0000000000022752
   Lozano F, 2014, ACUPUNCTURE FOR PAIN MANAGEMENT, V0, PP13, DOI 10.1007/978-1-4614-5275-12
   MacPherson H, 2010, J ALTERN COMPLEM MED, V16, PST1, DOI 10.1089/acm.2010.1610
   Mannes ZL, 2022, J GEN INTERN MED, V37, P3937, DOI 10.1007/s11606-021-07370-8
   Mardinoglu A, 2015, MOL SYST BIOL, V11, P0, DOI 10.15252/msb.20156487
   Morris G, 2014, MOL NEUROBIOL, V50, P1059, DOI 10.1007/s12035-014-8705-x
   Paice JA, 2016, J CLIN ONCOL, V34, P3325, DOI 10.1200/JCO.2016.68.5206
   Pilkonis PA, 2011, ASSESSMENT, V18, P263, DOI 10.1177/1073191111411667
   Quach CW, 2016, QUAL LIFE RES, V25, P2811, DOI 10.1007/s11136-016-1325-3
   Schumacher r, 2021, AM SOC BREAST SURGEO, V0, P0
   Smith C, 2013, ACUPUNCT MED, V31, P9, DOI 10.1136/acupmed-2012-010228
   Starkweather A, 2017, SUPPORT CARE CANCER, V25, P167, DOI 10.1007/s00520-016-3400-2
   Su XT, 2020, OXID MED CELL LONGEV, V2020, P0, DOI 10.1155/2020/7875396
   Weljie AM, 2011, J BIOMOL NMR, V49, P185, DOI 10.1007/s10858-011-9486-4
   Wilkie DJ, 2003, J PAIN SYMPTOM MANAG, V25, P213, DOI 10.1016/S0885-3924(02)00638-3
   Wilkie DJ, 2001, FAM COMMUNITY HEALTH, V24, P48, DOI 10.1097/00003727-200110000-00007
   Wu YY, 2017, EXP THER MED, V14, P107, DOI 10.3892/etm.2017.4479
   Xia Y, 2022, AM CHEM SOC, V0, P0, DOI DOI 10.1021/acsinfocus.7e5035
   Xiao Bin, 2014, ZHONGGUO ZHEN JIU, V34, P956
   Yu L, 2012, BEHAV SLEEP MED, V10, P6, DOI 10.1080/15402002.2012.636266
   Zhang AH, 2016, SCI REP-UK, V6, P0, DOI 10.1038/srep19942
   Zhang CJ, 2023, HEALTH COMMUN, V38, P275, DOI 10.1080/10410236.2021.1950292
   Zhou W, 2014, J ACUPUNCT MERIDIAN, V7, P190
NR 48
TC 5
Z9 5
U1 0
U2 11
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1099-8004
EI 1552-4175
J9 BIOL RES NURS
JI Biol. Res. Nurs.
PD APR 15
PY 2023
VL 25
IS 2
BP 326
EP 335
DI 10.1177/10998004221136567
EA OCT 2022
PG 10
WC Nursing
SC Nursing
GA 9Y2EK
UT WOS:000875969600001
PM 36306737
DA 2026-01-16
ER

PT J
AU Zhang, JL
   Qin, ZS
   So, TH
   Chang, TY
   Yang, SC
   Chen, HY
   Yeung, WF
   Chung, KF
   Chan, PY
   Huang, Y
   Xu, SF
   Chiang, CY
   Lao, LX
   Zhang, ZJ
AF Zhang, Jialing
   Qin, Zongshi
   So, Tsz Him
   Chang, Tien Yee
   Yang, Sichang
   Chen, Haiyong
   Yeung, Wing Fai
   Chung, Ka Fai
   Chan, Pui Yan
   Huang, Yong
   Xu, Shifen
   Chiang, Chun Yuan
   Lao, Lixing
   Zhang, Zhang-Jin
TI Acupuncture for chemotherapy-associated insomnia in breast cancer patients: an assessor-participant blinded, randomized, sham-controlled trial
SO BREAST CANCER RESEARCH
LA English
DT Article
DE Chemotherapy-associated insomnia; Breast cancer; Acupuncture; Cessation rate of sleeping medications
ID cognitive-behavioral therapy; sleep quality index; chinese version; integrative medicine; benzodiazepine use; hospital anxiety; severity index; fact-b; validation; depression
AB Background Insomnia is a highly prevalent symptom occurred during and post-chemotherapy. Acupuncture may have beneficial effects in the management of chemotherapy-associated insomnia. This study was conducted to determine the efficacy and safety of acupuncture in improving chemotherapy-associated insomnia in breast cancer patients.Methods This assessor-participant blinded, randomized, sham-controlled trial was conducted from November 2019 to January 2022 (follow-up completed July 2022). Participants were referred by oncologists from two Hong Kong hospitals. Assessments and interventions were conducted at the outpatient clinic of School of Chinese Medicine, the University of Hong Kong. The 138 breast cancer patients with chemotherapy-associated insomnia were randomly assigned to receive either 15 sessions of active acupuncture regimen by combining needling into body acupoints and acupressure on auricular acupoints or sham acupuncture control (69 each) for 18 weeks, followed by 24 weeks of follow-up. The primary outcome was measured using Insomnia Severity Index (ISI). Secondary outcomes included the Pittsburgh Sleep Quality Index, Actiwatch and sleep diary for sleep parameters, depression and anxiety, fatigue and pain, and quality of life.Results There were 87.7% (121/138) participants who completed the primary endpoint (week-6). The active acupuncture regimen was not superior to the sham control in reducing ISI score from baseline to 6 weeks (mean difference: - 0.4, 95% CI - 1.8-1.1; P = 0.609), but produced short-term treatment and long-term follow-up better outcomes in improving sleep onset latency, total sleep time, sleep efficiency, anxiety, depression, and quality of life. Participants of the active acupuncture group had a pronouncedly higher cessation rate of sleeping medications than the sham control (56.5% vs. 14.3%, P = 0.011). All treatment-related adverse events were mild. No participants discontinued treatments due to adverse events.Conclusion The active acupuncture regimen could be considered as an effective option for the management of chemotherapy-associated insomnia. It also could serve as a tapering approach to reduce and even replace the use of sleeping medications in breast cancer patients.
C1 [Zhang, Jialing; Qin, Zongshi; Yang, Sichang; Chen, Haiyong; Chan, Pui Yan; Lao, Lixing; Zhang, Zhang-Jin] Univ Hong Kong, LKS Fac Med, Sch Chinese Med, Pokfulam, 10 Sassoon Rd, Hong Kong, Peoples R China.
   [Zhang, Jialing] Hong Kong Baptist Univ, Sch Chinese Med, Kowloon Tong, Hong Kong, Peoples R China.
   [So, Tsz Him] Univ Hong Kong, LKS Fac Med, Dept Clin Oncol, Pokfulam, Hong Kong, Peoples R China.
   [Chang, Tien Yee] Hong Kong Sanat & Hosp, Comprehens Oncol Ctr, Hong Kong, Peoples R China.
   [Yeung, Wing Fai] Hong Kong Polytech Univ, Sch Nursing, Hung Hom, Hong Kong, Peoples R China.
   [Chung, Ka Fai] Univ Hong Kong, Dept Psychiat, Pokfulam, Hong Kong, Peoples R China.
   [Huang, Yong] Southern Med Univ, Sch Tradit Chinese Med, Guangzhou 510515, Guangdong, Peoples R China.
   [Xu, Shifen] Shanghai Univ Tradit Chinese Med, Shanghai Municipal Hosp Tradit Chinese Med, Shanghai 200071, Peoples R China.
   [Chiang, Chun Yuan] Hong Kong Inst Cell & Mol Med, Hong Kong, Peoples R China.
   [Chiang, Chun Yuan] Digital Ctr, State Key Lab Qual Appraisal TCM, Hong Kong, Peoples R China.
   [Lao, Lixing] Virginia Univ Integrat Med, Fairfax, VA 22031 USA.
   [Zhang, Zhang-Jin] Univ Hong Kong, Dept Chinese Med, Shenzhen Hosp HKU SZH, Shenzhen 518053, Guangdong, Peoples R China.
C3 University of Hong Kong; Hong Kong Baptist University; University of Hong Kong; Hong Kong Polytechnic University; University of Hong Kong; Southern Medical University - China; Shanghai University of Traditional Chinese Medicine; University of Hong Kong
RP Lao, LX; Zhang, ZJ (corresponding author), Univ Hong Kong, LKS Fac Med, Sch Chinese Med, Pokfulam, 10 Sassoon Rd, Hong Kong, Peoples R China.; Lao, LX (corresponding author), Virginia Univ Integrat Med, Fairfax, VA 22031 USA.; Zhang, ZJ (corresponding author), Univ Hong Kong, Dept Chinese Med, Shenzhen Hosp HKU SZH, Shenzhen 518053, Guangdong, Peoples R China.
EM llao@vuim.edu; zhangzj@hku.hk
FU Health and Medical Research Fund, Government of the Hong Kong Special Administrative Region of China [16172761]
CR Ball LJ, 2016, ENDOCR REV, V37, P450, DOI 10.1210/er.2015-1133
   Bang H, 2016, CONT CLIN TRIAL COMM, V3, P117, DOI 10.1016/j.conctc.2016.05.003
   Bergdahl L, 2017, COMPLEMENT THER CLIN, V28, P220, DOI 10.1016/j.ctcp.2017.06.006
   Bjelland I, 2002, J PSYCHOSOM RES, V52, P69, DOI 10.1016/S0022-3999(01)00296-3
   Bower JE, 2011, J CLIN ONCOL, V29, P3517, DOI 10.1200/JCO.2011.36.1154
   BUYSSE DJ, 1989, PSYCHIAT RES, V28, P193, DOI 10.1002/smll.202408771
   Carney CE, 2012, SLEEP, V35, P287, DOI 10.5665/sleep.1642
   Davidson JR, 2002, SOC SCI MED, V54, P1309, DOI 10.1016/S0277-9536(01)00043-0
   de Zambotti M, 2011, J SLEEP RES, V20, P318, DOI 10.1111/j.1365-2869.2010.00871.x
   Deng GE, 2013, CHEST, V143, PE420, DOI 10.1378/chest.12-2364
   Dhingra L, 2011, ONCOLOGIST, V16, P523, DOI 10.1634/theoncologist.2010-0330
   Dhond RP, 2007, J ALTERN COMPLEM MED, V13, P603, DOI 10.1089/acm.2007.7040
   Edinger JD, 2003, SLEEP, V26, P177, DOI 10.1093/sleep/26.2.177
   Franco-Santana LE, 2013, NEUROCHEM INT, V63, P275, DOI 10.1016/j.neuint.2013.05.004
   Fleming L, 2019, SLEEP, V42, P0, DOI 10.1093/sleep/zsy245
   Fleming L, 2010, PSYCHO-ONCOLOGY, V19, P991, DOI 10.1002/pon.1652
   Garland SN, 2019, JNCI-J NATL CANCER I, V111, P1323, DOI 10.1093/jnci/djz050
   Greenlee H, 2017, CA-CANCER J CLIN, V67, P195, DOI 10.3322/caac.21397
   Haque R, 2021, J WOMENS HEALTH, V30, P1604, DOI 10.1089/jwh.2019.8135
   Health NI, 2018, DATA SAFETY MONITORI, V0, P0
   Ho RTH, 2014, SLEEP MED, V15, P565, DOI 10.1016/j.sleep.2013.10.019
   Höxtermann MD, 2021, CANCERS, V13, P0, DOI 10.3390/cancers13164082
   Hoang HTX, 2020, SLEEP BREATH, V24, P241, DOI 10.1007/s11325-019-01839-x
   Koffel E, 2018, J GEN INTERN MED, V33, P955, DOI 10.1007/s11606-018-4390-1
   Lao LX, 1999, ARCH OTOLARYNGOL, V125, P567, DOI 10.1001/archotol.125.5.567
   Leung CM, 1999, ACTA PSYCHIAT SCAND, V100, P456, DOI 10.1111/j.1600-0447.1999.tb10897.x
   Linde K, 2007, PAIN, V128, P264, DOI 10.1016/j.pain.2006.12.006
   Liou KT, 2020, CANCER-AM CANCER SOC, V126, P3042, DOI 10.1002/cncr.32847
   Little RJ, 2012, NEW ENGL J MED, V367, P1355, DOI 10.1056/NEJMsr1203730
   Lyman GH, 2018, J CLIN ONCOL, V36, P2647, DOI 10.1200/JCO.2018.79.2721
   Ma Y, 2021, SLEEP MED REV, V55, P0, DOI 10.1016/j.smrv.2020.101376
   MacPherson H, 2010, J ALTERN COMPLEM MED, V16, PST1, DOI 10.1089/acm.2010.1610
   Mao JJ, 2007, EXPLORE-NY, V3, P372, DOI 10.1016/j.explore.2006.12.003
   Mao JJ, 2022, J CLIN ONCOL, V40, P3998, DOI 10.1200/JCO.22.01357
   Mao JJ, 2022, CA-CANCER J CLIN, V72, P144, DOI 10.3322/caac.21706
   Mendoza T, 2006, EUR J PAIN, V10, P353, DOI 10.1016/j.ejpain.2005.06.002
   Moher D, 2001, JAMA-J AM MED ASSOC, V285, P1987, DOI 10.1001/jama.285.15.1987
   Morin CM, 2011, SLEEP, V34, P601, DOI 10.1093/sleep/34.5.601
   Palesh O, 2020, SLEEP, V43, P0, DOI 10.1093/sleep/zsaa070
   Palesh O, 2012, NAT SCI SLEEP, V4, P151, DOI 10.2147/NSS.S18895
   Palesh OG, 2010, J CLIN ONCOL, V28, P292, DOI 10.1200/JCO.2009.22.5011
   Ng R, 2012, BREAST CANCER RES TR, V131, P619, DOI 10.1007/s10549-011-1764-z
   Riley KE, 2021, INT J BEHAV MED, V28, P683, DOI 10.1007/s12529-021-09962-4
   Savard J, 2001, SLEEP, V24, P583, DOI 10.1093/sleep/24.5.583
   Savard J, 2001, J CLIN ONCOL, V19, P895, DOI 10.1200/JCO.2001.19.3.895
   Savard J, 2018, BEHAV SLEEP MED, V16, P294, DOI 10.1080/15402002.2016.1210148
   Savard J, 2015, CANCER-AM CANCER SOC, V121, P1703, DOI 10.1002/cncr.29244
   Savard MH, 2005, PSYCHO-ONCOLOGY, V14, P429, DOI 10.1002/pon.860
   Si LG, 2015, EUR J INTEGR MED, V7, P492, DOI 10.1016/j.eujim.2015.05.008
   Souza RCD, 2020, NURS OPEN, V7, P1274, DOI 10.1002/nop2.516
   Streitberger K, 1998, LANCET, V352, P364, DOI 10.1016/S0140-6736(97)10471-8
   Suen LKP, 2002, AM J CHINESE MED, V30, P429, DOI 10.1142/S0192415X0200051X
   Vincent C, 1990, COMPLEMENTARY MEDICAL RESEARCH, V4, P8
   Wan CH, 2007, BREAST CANCER RES TR, V106, P413, DOI 10.1007/s10549-007-9511-1
   Wang XY, 2008, ACUPUNCTURE ELECTRO, V33, P33, DOI 10.3727/036012908803861203
   Wang XS, 2004, J PAIN SYMPTOM MANAG, V27, P322, DOI 10.1016/j.jpainsymman.2003.09.008
   Weiss AR, 2010, J CLIN SLEEP MED, V6, P336
   Yang MX, 2021, NPJ BREAST CANCER, V7, P0, DOI 10.1038/s41523-021-00355-0
   Yang XY, 2021, ANN GEN PSYCHIATR, V20, P0, DOI 10.1186/s12991-021-00327-5
   Yang XG, 2010, J TRADIT CHIN MED, V30, P309, DOI 10.1016/S0254-6272(10)60063-5
   Yeung WF, 2019, J PSYCHIATR RES, V109, P59, DOI 10.1016/j.jpsychires.2018.11.015
   Yeung WF, 2009, SLEEP, V32, P1039, DOI 10.1093/sleep/32.8.1039
   Yeung WF, 2009, SLEEP MED, V10, P694, DOI 10.1016/j.sleep.2008.08.012
   Yin X, 2017, SLEEP MED, V37, P193, DOI 10.1016/j.sleep.2017.02.012
   Zhang JL, 2021, INTEGR CANCER THER, V20, P0, DOI 10.1177/15347354211058695
   Zhang JL, 2022, PHYTOMEDICINE, V102, P0, DOI 10.1016/j.phymed.2022.154160
   Zhang JL, 2021, INTEGR CANCER THER, V20, P0, DOI 10.1177/15347354211019103
   Zhang ZJ, 2020, BRAIN BEHAV IMMUN, V88, P88, DOI 10.1016/j.bbi.2020.04.035
   Zhang ZJ, 2020, PSYCHIAT CLIN NEUROS, V74, P183, DOI 10.1111/pcn.12959
   Zhang ZJ, 2012, EVID-BASED COMPL ALT, V2012, P0, DOI 10.1155/2012/429412
   Zhang ZJ, 2012, PLOS ONE, V7, P0, DOI 10.1371/journal.pone.0029651
   Zhang ZJ, 2010, J AFFECT DISORDERS, V124, P9, DOI 10.1016/j.jad.2009.07.005
   Zhao FY, 2021, SLEEP MED, V80, P244, DOI 10.1016/j.sleep.2021.01.053
   Zitman FG, 2001, BRIT J PSYCHIAT, V178, P317, DOI 10.1192/bjp.178.4.317
   Zou C, 2015, PLOS ONE, V10, P0, DOI 10.1371/journal.pone.0122724
NR 75
TC 48
Z9 56
U1 11
U2 62
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1465-5411
EI 1465-542X
J9 BREAST CANCER RES
JI Breast Cancer Res.
PD APR 26
PY 2023
VL 25
IS 1
BP 
EP 
DI 10.1186/s13058-023-01645-0
PG 15
WC Oncology
SC Oncology
GA I4TP5
UT WOS:001002724400002
PM 37101228
DA 2026-01-16
ER

PT J
AU Wang, WM
   Liu, Y
   Yang, XF
   Sun, JH
   Yue, ZH
   Lu, DR
   Zhou, KH
   Sun, YJ
   Hou, AH
   Zang, ZW
   Jin, XQ
   Liu, C
   Wang, YH
   Yu, JN
   Zhu, LL
   Liu, ZS
AF Wang, Weiming
   Liu, Yan
   Yang, Xiaofang
   Sun, Jianhua
   Yue, Zenghui
   Lu, Dianrong
   Zhou, Kehua
   Sun, Yuanjie
   Hou, Aihua
   Zang, Zhiwei
   Jin, Xiaoqing
   Liu, Chao
   Wang, Yuhang
   Yu, Jinna
   Zhu, Lili
   Liu, Zhishun
TI Effects of Electroacupuncture for Opioid-Induced Constipation in Patients With Cancer in China: A Randomized Clinical Trial
SO JAMA NETWORK OPEN
LA English
DT Article
ID double-blind; placebo; pain; prucalopride; multicenter; prevalence; challenges; management; naloxegol
AB IMPORTANCE Opioid-induced constipation (OIC) is prevalent among patients treated with opioids for cancer pain. Safe and effective therapies for OIC in patients with cancer remain an unmet need. OBJECTIVE To determine the efficacy of electroacupuncture (EA) for OIC in patients with cancer. DESIGN, SETTING, AND PARTICIPANTS This randomized clinical trial was conducted at 6 tertiary hospitals in China among 100 adult patients with cancer who were screened for OIC and enrolled between May 1, 2019, and December 11, 2021. INTERVENTIONS Patients were randomized to receive 24 sessions of EA or sham electroacupuncture (SA) over 8 weeks and then were followed up for 8 weeks after treatment. MAIN OUTCOMES AND MEASURES The primary outcome was the proportion of overall responders, defined as patients who had at least 3 spontaneous bowel movements (SBMs) per week and an increase of at least 1 SBM from baseline in the same week for at least 6 of the 8 weeks of the treatment period. All statistical analyses were based on the intention-to-treat principle. RESULTS A total of 100 patients (mean [SD] age, 64.4 [10.5] years; 56 men [56.0%]) underwent randomization; 50 were randomly assigned to each group. Among them, 44 of 50 patients (88.0%) in the EA group and 42 of 50 patients (84.0%) in the SA group received at least 20 (>= 83.3%) sessions of treatment. The proportion of overall responders at week 8 was 40.1%(95% CI, 26.1%-54.1%) in the EA group and 9.0% (95% CI, 0.5%-17.4%) in the SA group (difference between groups, 31.1 percentage points [95% CI, 14.8-47.6 percentage points]; P < .001). Compared with SA, EA provided greater relief for most OIC symptoms and improved quality of life among patients with OIC. Electroacupuncture had no effects on cancer pain and its opioid treatment dosage. Electroacupuncture-related adverse events were rare, and, if any, all were mild and transient. CONCLUSIONS AND RELEVANCE This randomized clinical trial found that 8-week EA treatment could increase weekly SBMs with a good safety profile and improve quality of life for the treatment of OIC. Electroacupuncture thus provided an alternative option for OIC in adult patients with cancer.
C1 [Wang, Weiming; Sun, Yuanjie; Yu, Jinna; Zhu, Lili; Liu, Zhishun] China Acad Chinese Med Sci, Guanganmen Hosp, Dept Acupuncture & Moxibust, Beijing, Peoples R China.
   [Liu, Yan] Beijing Univ Chinese Med, Dongzhimen Hosp, Key Lab Chinese Internal Med, Minist Educ, Beijing, Peoples R China.
   [Yang, Xiaofang; Liu, Chao] Guizhou Univ Tradit Chinese Med, Coll Acumox & Tuina, Guiyang, Peoples R China.
   [Sun, Jianhua; Wang, Yuhang] Nanjing Univ Chinese Med, Dept Acupuncture Rehabil, Affiliated Hosp, Nanjing, Peoples R China.
   [Yue, Zenghui] Hunan Univ Chinese Med, Coll Acupuncture & Tuina, Changsha, Hunan, Peoples R China.
   [Lu, Dianrong] China Acad Chinese Med Sci, Wang Jing Hosp, Dept Oncol, Beijing, Peoples R China.
   [Zhou, Kehua] ThedaCare Reg Med Ctr Appleton, Dept Hosp Med, Appleton, WI USA.
   [Hou, Aihua] Yantai Hosp Tradit Chinese Med, Dept Oncol, Yantai, Peoples R China.
   [Zang, Zhiwei] Yantai Hosp Tradit Chinese Med, Dept Acupuncture, Yantai, Peoples R China.
   [Jin, Xiaoqing] Zhejiang Hosp, Dept Acupuncture, Hangzhou, Peoples R China.
C3 Guang'anmen Hospital, CACMS; China Academy of Chinese Medical Sciences; Beijing University of Chinese Medicine; Guizhou University of Traditional Chinese Medicine; Nanjing University of Chinese Medicine; Hunan University of Chinese Medicine; China Academy of Chinese Medical Sciences
RP Liu, ZS (corresponding author), China Acad Chinese Med Sci, Guanganmen Hosp, Dept Acupuncture & Moxibust, 5 Beixiange St, Beijing, Peoples R China.
EM zhishunjournal@163.com
FU National Administration of Traditional Chinese Medicine "Project of building evidence-based practice capacity for TCM-Project BEBPC-TCM" [2019XZZX-ZJ]
CR Bell TJ, 2009, PAIN MED, V10, P35, DOI 10.1111/j.1526-4637.2008.00495.x
   Bennett MI, 2019, PAIN, V160, P38, DOI 10.1097/j.pain.0000000000001363
   Bouhassira D, 2017, PAIN, V158, P1118, DOI 10.1097/j.pain.0000000000000895
   Bruner HC, 2015, J PAIN RES, V8, P289, DOI 10.2147/JPR.S61326
   Camilleri M, 2008, NEW ENGL J MED, V358, P2344, DOI 10.1056/NEJMoa0800670
   Camilleri M, 2011, AM J GASTROENTEROL, V106, P835, DOI 10.1038/ajg.2011.30
   Chey WD, 2014, NEW ENGL J MED, V370, P2387, DOI 10.1056/NEJMoa1310246
   Cook SF, 2008, ALIMENT PHARM THER, V27, P1224, DOI 10.1111/j.1365-2036.2008.03689.x
   Coyne KS, 2014, CLINICOECONOMIC OUTC, V6, P269, DOI 10.2147/CEOR.S61602
   Crockett SD, 2019, GASTROENTEROLOGY, V156, P218, DOI 10.1053/j.gastro.2018.07.016
   Dalal S, 2006, J PALLIAT MED, V9, P391, DOI 10.1089/jpm.2006.9.391
   De Schepper HU, 2004, NEUROGASTROENT MOTIL, V16, P383, DOI 10.1111/j.1365-2982.2004.00513.x
   Dorn Spencer, 2014, AM J GASTROENTEROL SUPPL, V2, P31, DOI 10.1038/ajgsup.2014.7
   Du F, 2015, AM J PHYSIOL-REG I, V309, PR109, DOI 10.1152/ajpregu.00396.2014
   European Medicines Agency, 2016, GUIDELINE ON THE EVALUATION OF MEDICINAL PRODUCTS FOR THE TREATMENT OF CHRONIC CONSTIPATION (INCLUDING OPIOID INDUCED CONSTIPATION) AND FOR BOWEL CLEANSING, V0, P0
   Ge ZY, 2018, EVID-BASED COMPL ALT, V2018, P0, DOI 10.1155/2018/2086163
   Hale M, 2017, LANCET GASTROENTEROL, V2, P555, DOI 10.1016/S2468-1253(17)30105-X
   Han CH, 2021, CLIN EPIDEMIOL, V13, P907, DOI 10.2147/CLEP.S324193
   Johanson JF, 2007, MEDGENMED, V0, P0
   Johanson JF, 2004, CLIN GASTROENTEROL H, V2, P796, DOI 10.1016/S1542-3565(04)00356-8
   Lacy BE, 2016, GASTROENTEROLOGY, V150, P1393, DOI 10.1053/j.gastro.2016.02.031
   Lewis SJ, 1997, SCAND J GASTROENTERO, V32, P920, DOI 10.3109/00365529709011203
   Liu BY, 2021, AM J GASTROENTEROL, V116, P1024, DOI 10.14309/ajg.0000000000001050
   Liu MW, 2002, J PAIN SYMPTOM MANAG, V23, P48, DOI 10.1016/S0885-3924(01)00369-4
   Liu ZS, 2016, ANN INTERN MED, V165, P761, DOI 10.7326/M15-3118
   Luthra P, 2019, GUT, V68, P434, DOI 10.1136/gutjnl-2018-316001
   McMillan Susan C, 2002, ONCOL NURS FORUM, V29, P1421, DOI 10.1188/02.ONF.1421-1428
   Mercadante S, 2010, LANCET ONCOL, V11, P484, DOI 10.1016/S1470-2045(09)70350-X
   Nelson AD, 2015, THER ADV GASTROENTER, V8, P206, DOI 10.1177/1756283X15578608
   Penning-van Beest Fernie J A, 2010, J MED ECON, V13, P129, DOI 10.3111/13696990903584436
   Pergolizzi JV, 2020, DRUG DES DEV THER, V14, P1009, DOI 10.2147/DDDT.S221278
   Rauck RL, 2017, PAIN PRACT, V17, P329, DOI 10.1111/papr.12445
   Slatkin Neal, 2009, J SUPPORT ONCOL, V7, P39
   Tack J, 2022, CLIN GASTROENTEROL H, V20, P855, DOI 10.1016/j.cgh.2021.05.004
   Thomas J, 2008, NEW ENGL J MED, V358, P2332, DOI 10.1056/NEJMoa0707377
   US Food and Drug Administration, 2018, FDA BRIEF DOC GASTR, V0, P0
   VINCENT C, 1995, J ROY SOC MED, V88, P199
   Wang WM, 2022, FRONT MED-LAUSANNE, V9, P0, DOI 10.3389/fmed.2022.818258
   Wang XJ, 2019, AM J PHYSIOL-GASTR L, V316, PG797, DOI 10.1152/ajpgi.00018.2018
   Wang Y, 2019, THER ADV GASTROENTER, V12, P0, DOI 10.1177/1756284819881859
   World Med Assoc, 2013, JAMA-J AM MED ASSOC, V310, P2191, DOI 10.1001/jama.2013.281053
   Zhou KH, 2011, J ALTERN COMPLEM MED, V17, P1007, DOI 10.1089/acm.2010.0652
NR 42
TC 26
Z9 33
U1 4
U2 27
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2574-3805
EI 
J9 JAMA NETW OPEN
JI JAMA Netw. Open
PD FEB 15
PY 2023
VL 6
IS 2
BP 
EP 
DI 10.1001/jamanetworkopen.2023.0310
PG 14
WC Medicine, General & Internal
SC General & Internal Medicine
GA Q7PS3
UT WOS:001059412800003
PM 36811861
DA 2026-01-16
ER

PT J
AU Shan, YP
   Zhang, J
   Ma, YH
   Zhang, YM
AF Shan, Yunping
   Zhang, Juan
   Ma, Yinhua
   Zhang, Yiming
TI The effects of acupuncture combined with western medicine in the treatment of neck, shoulder, lumbar and leg pain
SO AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH
LA English
DT Article
DE Neck shoulder low back pain; acupuncture treatment; symptom improvement; motor functions; inflammatory factors
ID physical-therapy; herbal medicine; primary-care; scale; back
AB Objective: To investigate the effect of Traditional Chinese Medicine (TCM) acupuncture combined with western medicine in the treatment of neck, shoulder, lumbar and leg pain and its influence on the degree of pain, motor functions and inflammatory factor levels. Methods: In this retrospective study, 86 patients with neck, shoulder, lumbar and leg pain treated in Department of Orthopedics and Traumatology, Hangzhou Fuyang Hospital of TCM from June 2019 to June 2022 were selected as the study subjects. According to different treatment methods, these patients were divided into an observation group (n=43) and a control group (n=43). Patients from the control group were treated with conventional western medicine, while those from the observation group were treated with combination of traditional Chinese medicine acupuncture (Acupuncture + Fumigation with Collaterals-Dredging Decoction) and western medicine. Patients in both groups were treated for 4 weeks continuously. The treatment effect, visual analogue scale (VAS) score, limb motor function scale (Fugl-Meyer) score, cervical function score, daily living ability score, the levels of inflammatory factors including interleukin-6 (IL-6), tumor necrosis factor-a (TNF-a) and C-reactive protein (CRP) were recorded and compared between two groups. Results: The effective rate of patients in the observation group was 93.02%, which was significantly higher than 76.74% in the control group (P<0.05). There was no significant difference in the term of Fugl-Meyer score, VAS score and levels of inflammatory factors before treatment between two groups (all P>0.05). After treatment, the VAS score and the levels of IL-6, TNF-a and CRP in both of groups significantly decreased in contrast to before treatment. The Fugl-Meyer score after treatment in both of groups was significantly increased in contrast to before treatment. Compared with those after treatment in control group, the VAS score and the levels of IL-6, TNF-a and CRP after treatment in the observation group were obviously lower, while the Fugl-Meyer score in the observation group was significantly higher (all P<0.05). Conclusion: TCM acupuncture combined with western medicine has a good therapeutic effect on neck, shoulder, lumbar and leg pains, which can effectively relieve the pain, improve motor function and reduce the inflammatory reactions in patients. The combined treatment has clinical application values and is worth promoting.
C1 [Shan, Yunping; Ma, Yinhua] Hangzhou Fuyang Hosp TCM Orthoped & Traumatol, Dept Pain Treatment, Hangzhou, Zhejiang, Peoples R China.
   [Zhang, Juan] Zhejiang Prov Hosp TCM, Dept Pain Treatment, Hangzhou, Zhejiang, Peoples R China.
   [Zhang, Yiming] Hangzhou Fuyang Hosp TCM Orthoped & Traumatol, Orthoped & Traumatol Dept, Hangzhou, Zhejiang, Peoples R China.
   [Zhang, Yiming] Hangzhou Fuyang Hosp TCM Orthoped & Traumatol, Orthoped & Traumatol Dept, 418 Fengpu Rd,Fuchun St, Hangzhou 311400, Zhejiang, Peoples R China.
C3 Zhejiang Chinese Medical University
RP Zhang, YM (corresponding author), Hangzhou Fuyang Hosp TCM Orthoped & Traumatol, Orthoped & Traumatol Dept, 418 Fengpu Rd,Fuchun St, Hangzhou 311400, Zhejiang, Peoples R China.
EM zhangyiming_doctor@outlook.com
CR Baroncini A, 2022, J ORTHOP SURG RES, V17, P0, DOI 10.1186/s13018-022-03212-3
   Childs JD, 2008, J ORTHOP SPORT PHYS, V38, PA1, DOI 10.2519/jospt.2008.0303
   Dionne CE, 2022, SPINE, V47, PE595, DOI 10.1097/BRS.0000000000004408
   Dong HY, 2020, SCI REP-UK, V10, P0, DOI 10.1038/s41598-020-69382-4
   Haas R, 2023, BMC PRIM CARE, V24, P0, DOI 10.1186/s12875-023-01976-z
   HERCZ G, 1988, AM J KIDNEY DIS, V11, P70, DOI 10.1016/S0272-6386(88)80179-3
   Huang HS, 2022, J REHABIL MED, V54, P0, DOI 10.2340/jrm.v54.2304
   Kang SX, 2021, MEDICINE, V100, P0, DOI 10.1097/MD.0000000000024200
   Trinh K, 2016, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD004870.pub4
   Krebs EE, 2022, JAMA-J AM MED ASSOC, V328, P2307, DOI 10.1001/jama.2022.21833
   Li CX, 2020, EUR J PAIN, V24, P1653, DOI 10.1002/ejp.1617
   Lin GH, 2023, ARCH PHYS MED REHAB, V0, P0
   Ma T, 2006, AM J CHINESE MED, V34, P759, DOI 10.1142/S0192415X06004272
   Moulton CD, 2021, J AFFECT DISORDERS, V282, P280, DOI 10.1016/j.jad.2020.12.185
   Mu JL, 2020, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD013814
   Oshima Y, 2022, GLOB SPINE J, V12, P795, DOI 10.1177/2192568220964167
   Panthi S, 2017, BMC COMPLEM ALTERN M, V17, P0, DOI 10.1186/s12906-017-1927-5
   Sabari JS, 2005, ARCH PHYS MED REHAB, V86, P1609, DOI 10.1016/j.apmr.2004.12.028
   Schäfer AGM, 2018, J MED INTERNET RES, V20, P0, DOI 10.2196/jmir.9465
   Trinh K, 2010, SPINE, V35, P2121, DOI 10.1097/BRS.0b013e3181edfd17
   Wang CN, 2021, J PAIN RES, V14, P1611, DOI 10.2147/JPR.S311311
   [王樟连 WANG Zhanglian], 2007, 中国针灸 CHINESE ACUPUNCTURE AND MOXIBUSTION, V27, P657
   Yang HY, 2021, MEDICINE, V100, P0, DOI 10.1097/MD.0000000000024926
   Yao M, 2017, HEALTH QUAL LIFE OUT, V15, P0, DOI 10.1186/s12955-017-0752-3
   Yuan QL, 2015, PLOS ONE, V10, P0, DOI 10.1371/journal.pone.0117146
   Yuan S, 2020, MEDICINE, V99, P0, DOI 10.1097/MD.0000000000019117
   Zeng WP, 2021, MEDICINE, V100, P0, DOI 10.1097/MD.0000000000025686
   Zheng Zhi-xin, 2011, ZHONG XI YI JIE HE XUE BAO, V9, P153, DOI 10.3736/jcim20110207
NR 28
TC 4
Z9 5
U1 0
U2 7
PU E-CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 1943-8141
EI 
J9 AM J TRANSL RES
JI Am. J. Transl. Res.
PD JUN 15
PY 2023
VL 15
IS 6
BP 4246
EP 4254
DI 
PG 9
WC Oncology; Medicine, Research & Experimental
SC Oncology; Research & Experimental Medicine
GA M7OK9
UT WOS:001032073000024
PM 37434859
DA 2026-01-16
ER

PT J
AU Ling, FY
   Qi, WC
   Li, X
   Zhou, J
   Xiong, J
   Zhao, Y
   Zheng, QH
   Liang, FR
AF Ling, Fayang
   Qi, Wenchuan
   Li, Xiao
   Zhou, Jun
   Xiong, Jian
   Zhao, Yi
   Zheng, Qianhua
   Liang, Fanrong
TI Bibliometric Analysis of Acupuncture Therapy for Cancer Pain Over the Past 10 Years
SO JOURNAL OF PAIN RESEARCH
LA English
DT Review
ID induced peripheral neuropathy; inhibitor-induced arthralgia; breast-cancer; nerve stimulation; multiple-myeloma; american society; double-blind; hot flashes; electroacupuncture; chemotherapy
AB Purpose: Cancer pain is a common symptom of cancer patients and greatly affects quality of life. Acupuncture has certain curative effects on cancer pain. The aim of this study was to analyze and visualize the current status and research trend of acupuncture treatment for cancer pain over the last 10 years and provide directions for future development. Methods: A search of the Web of Science Core Collection from 2012-01-01 to 2022-08-20 was performed to collect studies related to acupuncture therapy for cancer pain. CiteSpace was used to conduct bibliometric analysis and visualization from the perspective of the volume of annual publications, journals, nations, institutions, authors, keywords, and references. Results: A total of 302 studies were included in the analysis. The number of publications increased steadily with some fluctuations over the past decade. Integrative Cancer Therapies was the journal with the most relevant publications, and the Journal of Clinical Oncology was the most frequently cited journal. China had the highest volume of publications, and the USA contributed most to international collaboration. The most prolific institution was Memorial Sloan Kettering Cancer Center. The most productive author was Mao JJ, and the most influential author was Lu WD. "Acupuncture" was the top keyword in frequency and centrality. The references with the highest frequency and centrality were published by HE, Y, and Ting Bao, respectively. Conclusion: A stable development trend has formed in this field. The overall collaborative network needs to be strengthened. Breast cancer and multiple myeloma, electroacupuncture and bee venom acupuncture, postoperative pain, peripheral neuropathic pain syndrome, and aromatase inhibitors-associated arthralgia syndrome are research hotspots in this field. Randomized controlled trials (RCTs), evidence-based evaluations and mechanisms (cancer-induced bone pain) are research trends and frontiers. Keywords: acupuncture analgesia, cancer, pain, bibliometric analysis, CiteSpace
C1 [Ling, Fayang; Qi, Wenchuan; Li, Xiao; Zhou, Jun; Xiong, Jian; Zhao, Yi; Zheng, Qianhua] Chengdu Univ Tradit Chinese Med, Acupuncture & Tuina Sch, Chengdu, Peoples R China.
   [Liang, Fanrong] Chengdu Univ Tradit Chinese Med, Clin Res Ctr Acupuncture & Moxibust Sichuan Prov, Acupuncture & Tuina Sch, Chengdu, Peoples R China.
C3 Chengdu University of Traditional Chinese Medicine; Chengdu University of Traditional Chinese Medicine
RP Zheng, QH (corresponding author), Chengdu Univ Tradit Chinese Med, Acupuncture & Tuina Sch, Chengdu, Peoples R China.; Liang, FR (corresponding author), Chengdu Univ Tradit Chinese Med, Clin Res Ctr Acupuncture & Moxibust Sichuan Prov, Acupuncture & Tuina Sch, Chengdu, Peoples R China.
EM acuresearch@126.com; zhengqianhua@cdutcm.edu.cn
FU National Natural Science Foundation of China [U21A20404]; General Program of the National Natural Science Foundation of China [82074556]
CR Afsharimani B, 2011, CANCER METAST REV, V30, P225, DOI 10.1007/s10555-011-9285-0
   Unknown -, 2018, WHO GUIDELINES FOR THE PHARMACOLOGICAL AND RADIOTHERAPEUTIC MANAGEMENT OF CANCER PAIN IN ADULTS AND ADOLESCENTS, V0, P0
   Bae K, 2015, INTEGR CANCER THER, V14, P496, DOI 10.1177/1534735415596573
   Bao T, 2020, JAMA NETW OPEN, V3, P0, DOI 10.1001/jamanetworkopen.2020.0681
   Bao T, 2018, EUR J CANCER, V101, P12, DOI 10.1016/j.ejca.2018.06.008
   Bao T, 2014, INTEGR CANCER THER, V13, P396, DOI 10.1177/1534735414534729
   Bao T, 2011, PAIN RES TREAT, V2011, P0, DOI 10.1155/2011/920807
   Bao T, 2013, BREAST CANCER RES TR, V138, P167, DOI 10.1007/s10549-013-2427-z
   Boyette-Davis JA, 2011, J PAIN, V12, P1017, DOI 10.1016/j.jpain.2011.04.008
   Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21609
   Bruera Eduardo, 2015, AM SOC CLIN ONCOL EDUC BOOK, V0, PPE593, DOI 10.14694/edbook_am.2015.35.e593
   Cassileth Barrie, 2007, CURR PAIN HEADACHE REP, V11, P265, DOI 10.1007/s11916-007-0202-8
   Chen C, 2005, PROCEEDINGS OF THE 10TH INTERNATIONAL CONFERENCE ON INTELLIGENT USER INTERFACES, V0, PP98, DOI 10.1145/1040830.1040859
   Chen CM, 2006, J AM SOC INF SCI TEC, V57, P359, DOI 10.1002/asi.20317
   Chen JH, 2020, THORAC CANCER, V11, P928, DOI 10.1111/1759-7714.13343
   Chen L, 2017, BREAST, V33, P132, DOI 10.1016/j.breast.2017.03.015
   Cherniack EP, 2018, TOXICON, V154, P74, DOI 10.1016/j.toxicon.2018.09.013
   Chien TJ, 2019, INTEGR CANCER THER, V18, P0, DOI 10.1177/1534735419886662
   Chien TJ, 2015, J ALTERN COMPLEM MED, V21, P251, DOI 10.1089/acm.2014.0083
   Chiu HY, 2017, EUR J CANCER CARE, V26, P0, DOI 10.1111/ecc.12457
   Choi J, 2017, TOXINS, V9, P0, DOI 10.3390/toxins9110351
   Choi TY, 2017, INTEGR CANCER THER, V16, P135, DOI 10.1177/1534735416664172
   Choi TY, 2012, SUPPORT CARE CANCER, V20, P1147, DOI 10.1007/s00520-012-1432-9
   Chung VCH, 2016, MEDICINE, V95, P0, DOI 10.1097/MD.0000000000002793
   Clézardin P, 2021, PHYSIOL REV, V101, P797, DOI 10.1152/physrev.00012.2019
   Cowan AJ, 2022, JAMA-J AM MED ASSOC, V327, P464, DOI 10.1001/jama.2022.0003
   Crew KD, 2010, J CLIN ONCOL, V28, P1154, DOI 10.1200/JCO.2009.23.4708
   Deng G, 2018, ONCOLOGY-NY, V32, P310
   Deng G, 2018, SUPPORT CARE CANCER, V26, P657, DOI 10.1007/s00520-017-3881-7
   Dimitrova A, 2017, J ALTERN COMPLEM MED, V23, P164, DOI 10.1089/acm.2016.0155
   Donald GK, 2011, ACUPUNCT MED, V29, P230, DOI 10.1136/acupmed.2011.010025
   Dougherty PM, 2004, PAIN, V109, P132, DOI 10.1016/j.pain.2004.01.021
   Fallon M, 2018, ANN ONCOL, V29, P166, DOI 10.1093/annonc/mdy152
   Garcia MK, 2015, CANCER-AM CANCER SOC, V121, P3948, DOI 10.1002/cncr.29630
   Garcia MK, 2014, J HEMATOL ONCOL, V7, P0, DOI 10.1186/1756-8722-7-41
   Garcia MK, 2013, J CLIN ONCOL, V31, P952, DOI 10.1200/JCO.2012.43.5818
   Ge L, 2022, CHIN MED-UK, V17, P0, DOI 10.1186/s13020-021-00558-4
   Greenlee H, 2017, CA-CANCER J CLIN, V67, P195, DOI 10.3322/caac.21397
   Greenlee H, 2016, BREAST CANCER RES TR, V156, P453, DOI 10.1007/s10549-016-3759-2
   Greenlee Heather, 2014, JOURNAL OF THE NATIONAL CANCER INSTITUTE MONOGRAPHS, V0, PP346, DOI 10.1093/jncimonographs/lgu041
   Gulland A, 2014, BMJ-BRIT MED J, V348, P0, DOI 10.1136/bmj.g1338
   Han XY, 2017, BMC CANCER, V17, P0, DOI 10.1186/s12885-016-3037-z
   He YH, 2020, JAMA ONCOL, V6, P271, DOI 10.1001/jamaoncol.2019.5233
   Hershman DL, 2018, JAMA-J AM MED ASSOC, V320, P167, DOI 10.1001/jama.2018.8907
   Hershman DL, 2014, J CLIN ONCOL, V32, P1941, DOI 10.1200/JCO.2013.54.0914
   Hu CQ, 2016, EVID-BASED COMPL ALT, V2016, P0, DOI 10.1155/2016/1720239
   Jiang B, 2021, INTEGR CANCER THER, V20, P0, DOI 10.1177/1534735421995237
   Jimenez-Andrade JM, 2010, ANN NY ACAD SCI, V1198, P173, DOI 10.1111/j.1749-6632.2009.05429.x
   Kelly RB, 2019, AM FAM PHYSICIAN, V100, P89
   Kim K, 2018, INTEGR CANCER THER, V17, P1137, DOI 10.1177/1534735418786797
   Kim W, 2016, TOXINS, V8, P0, DOI 10.3390/toxins8020033
   Kim W, 2015, COMPLEMENT THER MED, V23, P626, DOI 10.1016/j.ctim.2015.03.011
   Kwekkeboom KL, 2016, SEMIN ONCOL NURS, V32, P373, DOI 10.1016/j.soncn.2016.08.004
   Lau CHY, 2016, MEDICINE, V95, P0, DOI 10.1097/MD.0000000000002901
   Lee HJ, 2009, ACUPUNCTURE ELECTRO, V34, P27, DOI 10.3727/036012909803861095
   Lee MS, 2008, J PAIN, V9, P289, DOI 10.1016/j.jpain.2007.11.012
   Lesi G, 2016, J CLIN ONCOL, V34, P1795, DOI 10.1200/JCO.2015.63.2893
   Li YY, 2019, INT J MOL SCI, V20, P0, DOI 10.3390/ijms20235917
   Lian WL, 2014, CHIN J INTEGR MED, V20, P136, DOI 10.1007/s11655-013-1439-1
   Ligibel JA, 2017, NPJ BREAST CANCER, V3, P0, DOI 10.1038/s41523-017-0040-8
   Lin T, 2020, PAIN MED, V21, PS6, DOI 10.1093/pm/pnaa164
   Liu XM, 2021, INTEGR CANCER THER, V20, P0, DOI 10.1177/1534735420980811
   Liu YL, 2022, J PAIN RES, V15, P2085, DOI 10.2147/JPR.S371399
   Loibl S, 2021, LANCET, V397, P1750, DOI 10.1016/S0140-6736(20)32381-3
   Loprinzi CL, 2020, J CLIN ONCOL, V38, P0, DOI 10.1200/JCO.20.01399
   Lu WD, 2008, HEMATOL ONCOL CLIN N, V22, P631, DOI 10.1016/j.hoc.2008.04.005
   Lu WD, 2020, ONCOLOGIST, V25, P310, DOI 10.1634/theoncologist.2019-0489
   Lu ZH, 2021, J CLIN ANESTH, V74, P0, DOI 10.1016/j.jclinane.2021.110453
   Lyman GH, 2018, J CLIN ONCOL, V36, P2647, DOI 10.1200/JCO.2018.79.2721
   Ma X, 2022, FRONT NEUROSCI-SWITZ, V16, P0, DOI 10.3389/fnins.2022.940343
   Maindet C, 2019, SUPPORT CARE CANCER, V27, P3119, DOI 10.1007/s00520-019-04829-7
   Mallory MJ, 2015, AM J CHINESE MED, V43, P45, DOI 10.1142/S0192415X15500032
   Mao JJ, 2021, JAMA ONCOL, V7, P720, DOI 10.1001/jamaoncol.2021.0310
   Mao JJ, 2015, J CLIN ONCOL, V33, P3615, DOI 10.1200/JCO.2015.60.9412
   Mao JJ, 2014, CANCER-AM CANCER SOC, V120, P3744, DOI 10.1002/cncr.28917
   Mao JJ, 2014, EUR J CANCER, V50, P267, DOI 10.1016/j.ejca.2013.09.022
   Ng SSM, 2013, GASTROENTEROLOGY, V144, P307, DOI 10.1053/j.gastro.2012.10.050
   Oh B, 2013, ACUPUNCT MED, V31, P264, DOI 10.1136/acupmed-2012-010309
   Ottestad E, 2020, PAIN MED, V21, PS1, DOI 10.1093/pm/pnaa198
   Paice JA, 2016, J CLIN ONCOL, V34, P3325, DOI 10.1200/JCO.2016.68.5206
   Paley CA, 2015, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD007753.pub3
   Patel M, 2020, BEST PRAC RES-CL ANA, V34, P603, DOI 10.1016/j.bpa.2020.08.005
   Rithirangsriroj K, 2015, GYNECOL ONCOL, V136, P82, DOI 10.1016/j.ygyno.2014.10.025
   Ruela LD, 2018, REV ESC ENFERM USP, V52, P0, DOI 10.1590/S1980-220X2017040503402
   Runowicz CD, 2016, CA-CANCER J CLIN, V66, P44, DOI 10.3322/caac.21319
   Ryan C, 2022, BONE, V158, P0, DOI 10.1016/j.bone.2020.115783
   Salat K, 2020, PHARMACOL REP, V72, P508, DOI 10.1007/s43440-020-00106-1
   Schroeder S, 2012, ACUPUNCT MED, V30, P4, DOI 10.1136/acupmed-2011-010034
   Seretny M, 2014, PAIN, V155, P2461, DOI 10.1016/j.pain.2014.09.020
   Staff NP, 2017, ANN NEUROL, V81, P772, DOI 10.1002/ana.24951
   Swarm RA, 2019, J NATL COMPR CANC NE, V17, P977, DOI 10.6004/jnccn.2019.0038
   Tenti S, 2020, INT J MOL SCI, V21, P0, DOI 10.3390/ijms21165625
   van den Beuken-van Everdingen MHJ, 2016, J PAIN SYMPTOM MANAG, V51, P1070, DOI 10.1016/j.jpainsymman.2015.12.340
   Vickers AJ, 2018, J PAIN, V19, P455, DOI 10.1016/j.jpain.2017.11.005
   Walker EM, 2010, J CLIN ONCOL, V28, P634, DOI 10.1200/JCO.2009.23.5150
   Wang W, 2021, FRONT PHARMACOL, V12, P0, DOI 10.3389/fphar.2021.593043
   Witt Claudia M, 2017, JOURNAL OF THE NATIONAL CANCER INSTITUTE MONOGRAPHS, V0, PP3, DOI 10.1093/jncimonographs/lgx012
   Woodbury Anna, 2021, CANCER TREAT RES, V182, P281, DOI 10.1007/978-3-030-81526-4_18
   Xu LP, 2020, COMPLEMENT THER CLIN, V39, P0, DOI 10.1016/j.ctcp.2020.101170
   Xu M, 2021, ACS CHEM NEUROSCI, V12, P3323, DOI 10.1021/acschemneuro.1c00224
   Yao C, 2016, CURR ONCOL, V23, PE27, DOI 10.3747/co.23.2788
   Yun Hyeongjun, 2017, JOURNAL OF THE NATIONAL CANCER INSTITUTE MONOGRAPHS, V0, PP29, DOI 10.1093/jncimonographs/lgx004
   Zeng YC, 2014, INTEGR CANCER THER, V13, P193, DOI 10.1177/1534735413510024
   Zhang CP, 2020, CHIN MED-UK, V15, P0, DOI 10.1186/s13020-020-0289-y
   Zhang RX, 2008, EUR J PAIN, V12, P870, DOI 10.1016/j.ejpain.2007.12.006
   Zhang RX, 2007, ANESTH ANALG, V105, P1482, DOI 10.1213/01.ane.0000284705.34629.c5
   Zhang RX, 2014, ANESTHESIOLOGY, V120, P482, DOI 10.1097/ALN.0000000000000101
   Zhang Y, 2020, ENVIRON SCI POLLUT R, V27, P15515, DOI 10.1007/s11356-020-07646-2
   Zhao WX, 2022, EVID-BASED COMPL ALT, V2022, P0, DOI 10.1155/2022/6886465
   Zia Farah Z, 2017, JOURNAL OF THE NATIONAL CANCER INSTITUTE MONOGRAPHS, V0, PP68, DOI 10.1093/jncimonographs/lgx005
NR 110
TC 14
Z9 17
U1 2
U2 42
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1178-7090
EI 
J9 J PAIN RES
JI J. Pain Res.
PD JUN 15
PY 2023
VL 16
IS 
BP 985
EP 1003
DI 10.2147/JPR.S395421
PG 19
WC Clinical Neurology
SC Neurosciences & Neurology
GA A0BC5
UT WOS:000951854900001
PM 36968762
DA 2026-01-16
ER

PT J
AU Szymoniuk, M
   Chin, JH
   Domagalski, Ł
   Biszewski, M
   Jóźwik, K
   Kamieniak, P
AF Szymoniuk, Michał
   Chin, Jia-Hsuan
   Domagalski, Łukasz
   Biszewski, Mateusz
   Jóźwik, Katarzyna
   Kamieniak, Piotr
TI Brain stimulation for chronic pain management: a narrative review of analgesic
SO Neurosurgical review
LA English
DT Review
DE Chronic pain; Deep brain stimulation; Motor cortex stimulation; Non-invasive brain stimulation; Treatment
AB Chronic pain constitutes one of the most common chronic complaints that people  experience. According to the International Association for the Study of Pain,  chronic pain is defined as pain that persists or recurs longer than 3 months.  Chronic pain has a significant impact on individuals' well-being and psychosocial  health and the economy of healthcare systems as well. Despite the availability of  numerous therapeutic modalities, treatment of chronic pain can be challenging.  Only about 30% of individuals with non-cancer chronic pain achieve improvement  from standard pharmacological treatment. Therefore, numerous therapeutic  approaches were proposed as a potential treatment for chronic pain including  non-opioid pharmacological agents, nerve blocks, acupuncture, cannabidiol, stem  cells, exosomes, and neurostimulation techniques. Although some neurostimulation  methods such as spinal cord stimulation were successfully introduced into  clinical practice as a therapy for chronic pain, the current evidence for brain  stimulation efficacy in the treatment of chronic pain remains unclear. Hence,  this narrative literature review aimed to give an up-to-date overview of brain  stimulation methods, including deep brain stimulation, motor cortex stimulation,  transcranial direct current stimulation, repetitive transcranial magnetic  stimulation, cranial electrotherapy stimulation, and reduced impedance  non-invasive cortical electrostimulation as a potential treatment for chronic  pain.
C1 Student Scientific Association at the Department of Neurosurgery, Medical University of Lublin, Lublin, Poland.
   Student Scientific Association at the Department of Neurosurgery, Medical University of Lublin, Lublin, Poland.
   Student Scientific Association at the Department of Neurosurgery, Medical University of Lublin, Lublin, Poland. lukdom4@gmail.com.
   Student Scientific Association at the Department of Neurosurgery, Medical University of Lublin, Lublin, Poland.
   Student Scientific Association at the Department of Neurosurgery, Medical University of Lublin, Lublin, Poland.
   Department of Neurosurgery, Medical University of Lublin, Lublin, Poland.
NR 0
TC 0
SN 1437-232
EI 0344-560
J9 Neurosurg Rev
PD MAY 29
PY 2023
VL 46
IS 1
BP 127
EP 127
DI 10.1007/s10143-023-02032-1
PG 0
WC Humans; Analgesics; Brain; Chronic Pain; therapy; Electric Stimulation Therapy; methods; Transcranial Direct Current Stimulation; methods; Transcranial Magnetic Stimulation; methods
UT PubMed:37247036
PM 37247036
DA 2023-05-29
ER

PT J
AU Valladales-Restrepo, LF
   Gaviria-Mendoza, A
   Machado-Duque, ME
   Prado-Echeverry, JA
   Cortes-Navarro, JL
   Machado-Alba, JE
AF Valladales-Restrepo, Luis Fernando
   Gaviria-Mendoza, Andres
   Machado-Duque, Manuel Enrique
   Prado-Echeverry, Julio Andres
   Cortes-Navarro, Jorge Luis
   Machado-Alba, Jorge Enrique
TI Chronic pain and continuity of analgesic treatment during the COVID-19 pandemic
SO PAIN PRACTICE
LA English
DT Article
DE analgesics; opioid; chronic pain; COVID-19; pharmacoepidemiology; SARS-CoV-2
ID united-states; impact; individuals; time
AB IntroductionChronic pain can trigger both physical and mental health complications. During the COVID-19 pandemic, patients with chronic diseases have had reduced access to some medications. ObjectiveTo determine the pharmacological management of patients with chronic pain and its continuity during the COVID-19 pandemic. MethodsThis was a retrospective longitudinal study of the continuity of analgesic use in patients with chronic pain between September 1, 2019 and February 28, 2021 based on a drug dispensing database. Survival analysis was performed until the discontinuation of chronic analgesics. ResultsA total of 12,701 patients who were being treated for chronic pain were identified. Their median age was 70.3 years, and 74.4% were women. The pain of rheumatological origin was the most frequent etiology (46.1%); the most used medications were nonopioid analgesics (78.9%), pain modulators (24.8%) and opioid analgesics (23.3%). A total of 76.1% of the patients experienced interruptions in their management during the study period. The median time to the first interruption of treatment was 5.0 months (95% CI: 4.8-5.2). Those who were treated for oncological pain experienced a greater number of interruptions in their management. ConclusionsThe pharmacological management of patients with chronic pain is heterogeneous, and this real-world study showed that a high proportion of patients experienced an interruption of pain management during the 12 months following the onset of the COVID-19 pandemic.
C1 [Valladales-Restrepo, Luis Fernando; Gaviria-Mendoza, Andres; Machado-Duque, Manuel Enrique; Prado-Echeverry, Julio Andres; Cortes-Navarro, Jorge Luis; Machado-Alba, Jorge Enrique] Univ Tecnol Pereira Audifarma SA, Grp Invest Farmacoepidemiol & Farmacovigilancia, Pereira, Colombia.
   [Valladales-Restrepo, Luis Fernando; Gaviria-Mendoza, Andres; Machado-Duque, Manuel Enrique] Fdn Universitaria Autonoma Amer, Fac Med, Grp Invest Biomed, Pereira, Colombia.
   [Machado-Alba, Jorge Enrique] Univ Tecnol Pereira Audifarma SA, Grp Invest Farmacoepidemiol & Farmacovigilancia, Calle 105 14-140, Pereira 660003, Colombia.
C3 Universidad Tecnologica de Pereira; Universidad Tecnologica de Pereira
RP Machado-Alba, JE (corresponding author), Univ Tecnol Pereira Audifarma SA, Grp Invest Farmacoepidemiol & Farmacovigilancia, Calle 105 14-140, Pereira 660003, Colombia.
EM machado@utp.edu.co
CR Akazawa M, 2019, J PAIN RES, V12, P1631, DOI 10.2147/JPR.S203553
   Alonso-Matielo H, 2021, FRONT PHYSIOL, V12, P0, DOI 10.3389/fphys.2021.624154
   Bäckryd E, 2018, INT J WOMENS HEALTH, V10, P55, DOI 10.2147/IJWH.S142052
   Basu Saurav, 2020, INDIAN J MED ETHICS, VV, P103, DOI 10.20529/ijme.2020.041
   Dahlhamer J, 2018, MMWR-MORBID MORTAL W, V67, P1001, DOI 10.15585/mmwr.mm6736a2
   de Moraes ÉB, 2021, PAIN MANAG NURS, V22, P103, DOI 10.1016/j.pmn.2020.11.010
   Díaz Cabezas Ricardo, 2009, ACTA MED COLOMB, V34, P96
   Fallach N, 2021, RHEUMATOL THER, V8, P1129, DOI 10.1007/s40744-021-00329-5
   Valladales-Restrepo LF, 2022, DRUGS-REAL WOR OUTC, V9, P487, DOI 10.1007/s40801-022-00318-2
   Fischer B, 2011, PHARMACOEPIDEM DR S, V20, P1269, DOI 10.1002/pds.2190
   Frazer JS, 2021, FAM MED COMMUNITY HE, V9, P0, DOI 10.1136/fmch-2021-001143
   Galani A, 2021, SCI TOTAL ENVIRON, V798, P0, DOI 10.1016/j.scitotenv.2021.149014
   Hruschak V, 2021, PAIN, V162, P619, DOI 10.1097/j.pain.0000000000002128
   Ingrasciotta Y, 2019, PLOS ONE, V14, P0, DOI 10.1371/journal.pone.0222836
   Javed S, 2020, PAIN MANAG, V10, P275, DOI 10.2217/pmt-2020-0035
   Kleinmann B, 2021, PAIN PHYSICIAN, V24, P165, DOI 10.36076/ppj.2021.24.165-173
   Lacasse A, 2021, PAIN REP, V6, P0, DOI 10.1097/PR9.0000000000000891
   Lassen CL, 2021, MEDICINE, V100, P0, DOI 10.1097/MD.0000000000025153
   Latina R, 2019, PAIN MANAG NURS, V20, P373, DOI 10.1016/j.pmn.2019.01.005
   Mullins CF, 2022, IRISH J MED SCI, V191, P7, DOI 10.1007/s11845-021-02509-2
   Mun CJ, 2021, PAIN MED, V22, P470, DOI 10.1093/pm/pnaa446
   Nieto R, 2020, J CLIN MED, V9, P0, DOI 10.3390/jcm9113558
   Pagé MG, 2021, HEALTH PROMOT CHRON, V41, P141, DOI 10.24095/hpcdp.41.5.01
   Rikin S, 2022, J PRIM CARE COMMUNIT, V13, P0, DOI 10.1177/21501319221076926
   Ruscitto A, 2015, EUR J PAIN, V19, P59, DOI 10.1002/ejp.520
   Serrano-Ibañez ER, 2021, BRIT J HEALTH PSYCH, V26, P544, DOI 10.1111/bjhp.12483
   Smyrnioti ME, 2021, J PAIN RES, V14, P2571, DOI 10.2147/JPR.S323568
   Ushida T, 2019, EXPERT OPIN PHARMACO, V20, P2041, DOI 10.1080/14656566.2019.1651840
   Vaduganathan M, 2020, JAMA-J AM MED ASSOC, V323, P2524, DOI 10.1001/jama.2020.9184
   Zambelli Z, 2022, J HEALTH PSYCHOL, V27, P1099, DOI 10.1177/1359105321995962
   Ziadé N, 2020, INT J RHEUM DIS, V23, P1550, DOI 10.1111/1756-185X.13960
NR 32
TC 3
Z9 5
U1 0
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1530-7085
EI 1533-2500
J9 PAIN PRACT
JI Pain Pract.
PD APR 15
PY 2023
VL 23
IS 4
BP 359
EP 367
DI 10.1111/papr.13197
EA DEC 2022
PG 9
WC Anesthesiology; Clinical Neurology
SC Anesthesiology; Neurosciences & Neurology
GA C9KJ4
UT WOS:000901396300001
PM 36514870
DA 2026-01-16
ER

PT J
AU Liu, S
   Chen, Q
   Zhang, Q
   Tao, K
   Li, C
   Chang, B
   Wang, W
   Wu, Z
AF Liu, Shengfu
   Chen, Qiudan
   Zhang, Qinggang
   Tao, Kun
   Li, Changhong
   Chang, Baolei
   Wang, Weifeng
   Wu, Zhong
TI Electroacupuncture combined with extracorporeal shock wave therapy improves pain
SO Heliyon
LA English
DT Journal Article
DE Electroacupuncture; Extracorporeal shock wave therapy; Knee osteoarthritis; Synovial fluid
AB OBJECTIVE: To compare the clinical efficacy and safety of electroacupuncture  combined with extracorporeal shock wave therapy (EESWT) and extracorporeal shock  wave therapy (ESWT) in the treatment of knee osteoarthritis (KOA). METHODS: A  total of 135 KOA patients who received EESWT treatment were selected as the EESWT  group, and 135 KOA patients who received extracorporeal shock wave therapy (ESWT)  were selected as the ESWT group. The clinical efficacy, inflammatory factors in  joint synovial fluid and adverse events during treatment were compared before and  after treatment. RESULTS: The clinical effective rate of patients in the EESWT  group (89.63 %) after treatment was significantly higher than that of the ESWT  group (74.81 %) (p < 0.01). The lysholm kness (LKSS) score and range of motion  (ROM) of the patients in the EESWT group after treatment were higher than those  of the ESWT group, while Lequesne index score, visual analogue scale (VAS) score  and Western Ontario and McMaster Universities Arthritis Index (WOMAC) were lower  than those of the ESWT group (p < 0.01). Compared with ESWT group, the changes in  the expression levels of nitric oxide (NO), superoxide dismutase (SOD),  interleukin 1β (IL-1β), tumor necrosis factor-α (TNF-α), matrix  metalloproteinase-3 (MMP-3), and transforming growth factor β1 (TGF-β1) in the  synovial fluid of the EESWT group after treatment were significantly greater than  those of the ESWT group (p < 0.01). No significant difference in the incidence of  adverse events between the EESWT group and the ESWT group (p > 0.05). CONCLUSION:  EESWT significantly improves pain symptoms and inflammatory factor levels in KOA  patients and is an optional KOA treatment option worthy of clinical attention.
C1 Department of Orthopedics, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai 200072, China.
   Department of Central Laboratory, Clinical Laboratory, Jing'an District Center Hospital of Shanghai, Fudan University, Shanghai 200040, China.
   Department of Orthopedics, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai 200072, China.
   Department of Orthopedics, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai 200072, China.
   Second Department of Surgery, People's Hospital of Gengma Dai and Va Autonomous County, Lincang, Yunnan 677599, China.
   Ma Anshan No.17 Metallurgical Hospital, Ma Anshan, Anhui 243000, China.
   Department of Orthopedics, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai 200072, China.
   Department of Laboratory Medicine, Longhua Hospital, Shanghai University of 
   Department of Orthopedics, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai 200072, China.
NR 0
TC 0
SN 2405-844
EI 2405-844
J9 Heliyon
PD OCT 16
PY 2023
VL 9
IS 10
BP e20771
EP e20771
DI 10.1016/j.heliyon.2023.e20771
PG 1
UT PubMed:37842584
PM 37842584
DA 2023-10-16
ER

PT J
AU Epstein, AS
   Liou, KT
   Romero, SAD
   Baser, RE
   Wong, G
   Xiao, H
   Mo, ZL
   Walker, D
   MacLeod, J
   Li, Q
   Barton-Burke, M
   Deng, GE
   Panageas, KS
   Farrar, JT
   Mao, JJ
AF Epstein, Andrew S.
   Liou, Kevin T.
   Romero, Sally A. D.
   Baser, Raymond E.
   Wong, Greta
   Xiao, Han
   Mo, Zunli
   Walker, Desiree
   MacLeod, Jodi
   Li, Qing
   Barton-Burke, Margaret
   Deng, Gary E.
   Panageas, Katherine S.
   Farrar, John T.
   Mao, Jun J.
TI Acupuncture vs Massage for Pain in Patients Living With Advanced Cancer: The IMPACT Randomized Clinical Trial
SO JAMA NETWORK OPEN
LA English
DT Article
ID breast-cancer; symptoms; opioids; metaanalysis; severity; outcm; fatigue
AB Importance Pain is challenging for patients with advanced cancer. While recent guidelines recommend acupuncture and massage for cancer pain, their comparative effectiveness is unknown.Objective To compare the effects of acupuncture and massage on musculoskeletal pain among patients with advanced cancer.Design, Setting, and Participants A multicenter pragmatic randomized clinical trial was conducted at US cancer care centers consisting of a northeastern comprehensive cancer center and a southeastern cancer institute from September 19, 2019, through February 23, 2022. The principal investigator and study statisticians were blinded to treatment assignments. The duration of follow-up was 26 weeks. Intention-to-treat analyses were performed (linear mixed models). Participants included patients with advanced cancer with moderate to severe pain and clinician-estimated life expectancy of 6 months or more. Patient recruitment strategy was multipronged (eg, patient database queries, mailings, referrals, community outreach). Eligible patients had English or Spanish as their first language, were older than 18 years, and had a Karnofsky score greater than or equal to 60 (range, 0-100; higher scores indicating less functional impairment).Interventions Weekly acupuncture or massage for 10 weeks with monthly booster sessions up to 26 weeks.Main Outcomes and Measures The primary end point was the change in worst pain intensity score from baseline to 26 weeks. The secondary outcomes included fatigue, insomnia, and quality of life. The Brief Pain Inventory (range, 0-10; higher numbers indicate worse pain intensity or interference) was used to measure the primary outcome. The secondary outcomes included fatigue, insomnia, and quality of life.Results A total of 298 participants were enrolled (mean [SD] age, 58.7 [14.1] years, 200 [67.1%] were women, 33 [11.1%] Black, 220 [74.1%] White, 46 [15.4%] Hispanic, and 78.5% with solid tumors). The mean (SD) baseline worst pain score was 6.9 (1.5). During 26 weeks, acupuncture reduced the worst pain score, with a mean change of -2.53 (95% CI, -2.92 to -2.15) points, and massage reduced the Brief Pain Inventory worst pain score, with a mean change of -3.01 (95% CI, -3.38 to -2.63) points; the between-group difference was not significant (-0.48; 95% CI, -0.98 to 0.03; P = .07). Both treatments also improved fatigue, insomnia, and quality of life without significant between-group differences. Adverse events were mild and included bruising (6.5% of patients receiving acupuncture) and transient soreness (15.1% patients receiving massage).Conclusions and Relevance In this randomized clinical trial among patients with advanced cancer, both acupuncture and massage were associated with pain reduction and improved fatigue, insomnia, and quality of life over 26 weeks; however, there was no significant different between the treatments. More research is needed to evaluate how best to integrate these approaches into pain treatment to optimize symptom management for the growing population of people living with advanced cancer.Trial RegistrationClinicalTrials.gov Identifier: NCT04095234
C1 [Epstein, Andrew S.] Mem Sloan Kettering Canc Ctr, 300 66th St,Room 1013, New York, NY 10065 USA.
   [Mao, Jun J.] Mem Sloan Kettering Canc Ctr, 321 61st St,Room 1013, New York, NY 10065 USA.
   [Epstein, Andrew S.; Liou, Kevin T.; Wong, Greta; Xiao, Han; Walker, Desiree; MacLeod, Jodi; Li, Qing; Deng, Gary E.; Mao, Jun J.] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10065 USA.
   [Romero, Sally A. D.] Univ Calif San Diego, Dept Obstet Gynecol & Reprod Sci, San Diego, CA USA.
   [Baser, Raymond E.; Panageas, Katherine S.] Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, New York, NY 10065 USA.
   [Mo, Zunli] Baptist Hlth Miami Canc Inst, Canc Patient Support Ctr, Miami, FL USA.
   [Barton-Burke, Margaret] Mem Sloan Kettering Canc Ctr, Off Nursing Res, New York, NY USA.
   [Farrar, John T.] Univ Penn, Perelman Sch Med, Dept Biostat & Epidemiol, Philadelphia, PA USA.
C3 Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; University of California System; University of California San Diego; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; University of Pennsylvania
RP Epstein, AS (corresponding author), Mem Sloan Kettering Canc Ctr, 300 66th St,Room 1013, New York, NY 10065 USA.; Mao, JJ (corresponding author), Mem Sloan Kettering Canc Ctr, 321 61st St,Room 1013, New York, NY 10065 USA.
EM epsteina@mskcc.org; maoj@mskcc.org
FU PCORI award [SMPAI-2018C2-12883]; NIH/National Cancer Institute (NCI) Cancer Center [P30 CA008748]; NCI [R01 CA240417]; National Cancer Institute [P30CA008748, K08CA266927] Funding Source: NIH RePORTER
CR Unknown -, 2014, MEDICINE HANDS: MASSAGE THERAPY FOR PEOPLE WITH CANCER, V0, P0
   Unknown -, 2017, COMMON TERMINOLOGY C, V0, P155
   Boyd C, 2016, PAIN MED, V17, P1553, DOI 10.1093/pm/pnw100
   Cleeland CS, 1994, ANNALS ACADEMY OF MEDICINE SINGAPORE, V23, P129
   Desai K, 2021, J ALTERN COMPLEM MED, V27, P1011, DOI 10.1089/acm.2021.0102
   Dodd M J, 2001, ONCOL NURS FORUM, V28, P465
   Dong ST, 2016, SUPPORT CARE CANCER, V24, P1373, DOI 10.1007/s00520-015-2913-4
   Dong ST, 2014, J PAIN SYMPTOM MANAG, V48, P411, DOI 10.1016/j.jpainsymman.2013.10.027
   Dworkin RH, 2008, J PAIN, V9, P105, DOI 10.1016/j.jpain.2007.09.005
   Farrar JT, 2000, PAIN, V88, P287, DOI 10.1016/S0304-3959(00)00339-0
   Gallicchio L, 2022, JNCI-J NATL CANCER I, V114, P1476, DOI 10.1093/jnci/djac158
   Groninger H, 2023, J PAIN SYMPTOM MANAG, V65, P428, DOI 10.1016/j.jpainsymman.2023.01.011
   Hays RD, 2009, QUAL LIFE RES, V18, P873, DOI 10.1007/s11136-009-9496-9
   He YH, 2020, JAMA ONCOL, V6, P271, DOI 10.1001/jamaoncol.2019.5233
   Hershman DL, 2022, JAMA NETW OPEN, V5, P0, DOI 10.1001/jamanetworkopen.2022.41720
   Hershman DL, 2018, JAMA-J AM MED ASSOC, V320, P167, DOI 10.1001/jama.2018.8907
   Johnsen AT, 2009, PALLIATIVE MED, V23, P491, DOI 10.1177/0269216309105400
   Kirkova J, 2011, AM J HOSP PALLIAT ME, V28, P350, DOI 10.1177/1049909110391464
   Kutner JS, 2008, ANN INTERN MED, V149, P369, DOI 10.7326/0003-4819-149-6-200809160-00003
   LeBlanc TW, 2015, LANCET ONCOL, V16, PE333, DOI 10.1016/S1470-2045(15)00080-7
   Liou KT, 2021, SUPPORT CARE CANCER, V29, P427, DOI 10.1007/s00520-020-05504-y
   Liou KT, 2021, J GEN INTERN MED, V36, P527, DOI 10.1007/s11606-020-05871-6
   Liu GHF, 2009, STAT MED, V28, P2509, DOI 10.1002/sim.3639
   MacPherson H, 2017, PAIN, V158, P784, DOI 10.1097/j.pain.0000000000000747
   Mallinckrodt CH, 2008, DRUG INF J, V42, P303, DOI 10.1177/009286150804200402
   Mao Jun J, 2007, ACUPUNCT MED, V25, P158
   Mao JJ, 2022, J CLIN ONCOL, V40, P3998, DOI 10.1200/JCO.22.01357
   Mao JJ, 2021, JAMA ONCOL, V7, P720, DOI 10.1001/jamaoncol.2021.0310
   Mao JJ, 2014, CANCER-AM CANCER SOC, V120, P3744, DOI 10.1002/cncr.28917
   Marinangeli F, 2004, J PAIN SYMPTOM MANAG, V27, P409, DOI 10.1016/j.jpainsymman.2003.10.006
   Mendoza TR, 1999, CANCER-AM CANCER SOC, V85, P1186, DOI 10.1002/(SICI)1097-0142(19990301)85:5<1186::AID-CNCR24>3.0.CO;2-N
   Nabal M, 2012, PALLIATIVE MED, V26, P305, DOI 10.1177/0269216311428528
   Paice JA, 2023, J CLIN ONCOL, V41, P914, DOI 10.1200/JCO.22.02198
   Porta-Sales J, 2015, J PALLIAT MED, V18, P923, DOI 10.1089/jpm.2015.29002.jps
   Ramsdale E, 2022, ONCOLOGIST, V27, PE580, DOI 10.1093/oncolo/oyac053
   Romero SAD, 2022, BMJ OPEN, V12, P0, DOI 10.1136/bmjopen-2021-058281
   Savard MH, 2005, PSYCHO-ONCOLOGY, V14, P429, DOI 10.1002/pon.860
   van den Beuken-van Everdingen MHJ, 2016, J PAIN SYMPTOM MANAG, V51, P1070, DOI 10.1016/j.jpainsymman.2015.12.340
   Vickers AJ, 2018, J PAIN, V19, P455, DOI 10.1016/j.jpain.2017.11.005
   Walsh D, 2000, SUPPORT CARE CANCER, V8, P175, DOI 10.1007/s005200050281
   Walsh D, 2006, SUPPORT CARE CANCER, V14, P831, DOI 10.1007/s00520-005-0899-z
   Walton T, 2010, MEDICAL CONDITIONS AND MASSAGE THERAPY: A DECISION TREE APPROACH, V0, P0
   Yun Hyeongjun, 2017, JOURNAL OF THE NATIONAL CANCER INSTITUTE MONOGRAPHS, V0, PP29, DOI 10.1093/jncimonographs/lgx004
NR 44
TC 37
Z9 45
U1 5
U2 32
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2574-3805
EI 
J9 JAMA NETW OPEN
JI JAMA Netw. Open
PD NOV 14
PY 2023
VL 6
IS 11
BP 
EP 
DI 10.1001/jamanetworkopen.2023.42482
PG 13
WC Medicine, General & Internal
SC General & Internal Medicine
GA Y7MY8
UT WOS:001107078100009
PM 37962891
DA 2026-01-16
ER

PT J
AU Bettini, E
   Idiokitas, R
   Mahmood, L
   Jacobs, S
   Steinhorn, D
AF Bettini, Elizabeth
   Idiokitas, Risi
   Mahmood, Laila
   Jacobs, Shana
   Steinhorn, David
TI Safety and Acceptance of Acupuncture and Acupressure in Children, Adolescents, and Young Adults Undergoing Hematopoietic Stem Cell Transplant
SO CANCER NURSING
LA English
DT Article
DE Acupressure; Acupuncture; Bone marrow transplant; Hematopoietic stem cell transplant; Pediatric Hematology Oncology
ID chemotherapy-induced nausea; pediatric-patients; reduction; medicine; burden; care
AB BackgroundHematopoietic stem cell transplant (HSCT) is associated with significant morbidity and high symptom burden including mucositis pain, nausea, and vomiting. There is little documentation in the literature regarding acupuncture or acupressure for children undergoing HSCT.ObjectiveThe purpose of this study was to determine the safety and acceptance of acupuncture and acupressure in children undergoing HSCT in a large tertiary care children's hospital.MethodsThis is a descriptive retrospective study that evaluated 80 admissions to the HSCT unit over a 24-month period. Every child admitted for HSCT was offered acupuncture or acupressure as part of their care.ResultsOf 80 patients, 46 were male patients (ages range, 0-32 years; mean, 8 years). Diagnoses include leukemia/lymphoma, sickle cell disease, aplastic anemia, neuroblastoma, and other metabolic, other solid tumor, or other hematologic disorders. Both allogenic and autologous were represented. Sixty-six patients (82.5%) agreed to treatment with acupuncture, acupressure, or both. There were no adverse effects or safety concerns noted. Symptoms addressed by acupuncture or acupressure included pain from mucositis, nausea, constipation, diarrhea, anxiety, insomnia, and general wellness or healing.ConclusionThis study demonstrates that acupuncture and acupressure are well accepted by children and their families admitted for HSCT and are safe even when performed in the first 4 weeks following transplant when the patient is likely to have thrombocytopenia.Implications for PracticeThese findings suggest that there may be more therapies for patients undergoing HSCT to help with symptom control.
C1 [Bettini, Elizabeth; Idiokitas, Risi; Mahmood, Laila; Jacobs, Shana] Childrens Natl Hosp, Palliat Care, 111 Michigan Ave NW, Washington, DC 20010 USA.
   [Steinhorn, David] Capital Caring Hosp, Falls Church, VA USA.
C3 Children's National Health System
RP Bettini, E (corresponding author), Childrens Natl Hosp, Palliat Care, 111 Michigan Ave NW, Washington, DC 20010 USA.
EM ebettini@childrensnational.org; Ridiokitas@childrensnational.org; Lmahmood@childrensnational.org; ssjacobs@childrensnational.org; dsteinhorn@capitalcaring.org
CR Chokshi SK, 2017, PEDIATR BLOOD CANCER, V64, P0, DOI 10.1002/pbc.26424
   Deng G, 2018, SUPPORT CARE CANCER, V26, P657, DOI 10.1007/s00520-017-3881-7
   Diorio C, 2017, J GLOB ONCOL, V3, P791, DOI 10.1200/JGO.2016.005587
   Dupuis LL, 2018, CANCER-AM CANCER SOC, V124, P1188, DOI 10.1002/cncr.31198
   Flank J, 2017, BONE MARROW TRANSPL, V52, P1294, DOI 10.1038/bmt.2017.112
   Hu Hiroe, 2019, GLOB ADV HEALTH MED, V8, P2164956119880143, DOI 10.1177/2164956119880143
   Khosravi M, 2017, J NURS MIDWIFERY SCI, V4, P75, DOI 10.4103/jnms.jnms_11_17
   Ladas EJ, 2010, SUPPORT CARE CANCER, V18, P1487, DOI 10.1007/s00520-010-0926-6
   Lown E Anne, 2019, GLOB ADV HEALTH MED, V8, P2164956119870444, DOI 10.1177/2164956119870444
   Majhail NS, 2013, BIOL BLOOD MARROW TR, V19, P1498, DOI 10.1016/j.bbmt.2013.07.020
   Mangurian C, 2018, PALLIAT SUPPORT CARE, V16, P367, DOI 10.1017/S1478951517001018
   Miladinia M, 2017, INT J PEDIATR-MASSHA, V5, P4175, DOI 10.22038/ijp.2016.7324
   Radossi AL, 2018, SUPPORT CARE CANCER, V26, P375, DOI 10.1007/s00520-017-3908-0
   Ralston-Wilson J, 2016, J ALTERN COMPLEM MED, V22, P458, DOI 10.1089/acm.2015.0347
   Tas D, 2016, OALIB, V03, P1, DOI 10.4236/oalib.1102611
   Tomlinson D, 2019, SUPPORT CARE CANCER, V27, P2665, DOI 10.1007/s00520-018-4555-9
   Tsai SL, 2018, MED ACUPUNCT, V30, P61, DOI 10.1089/acu.2018.29075.rtl
   Varejao CD, 2019, J PEDIATR ONCOL NURS, V36, P44, DOI 10.1177/1043454218810140
   Vasquenza K, 2015, PAIN MANAG NURS, V16, P156, DOI 10.1016/j.pmn.2014.05.005
   Yang CS, 2015, PEDIATR RES, V78, P112, DOI 10.1038/pr.2015.91
   Yeh CH, 2012, J ALTERN COMPLEM MED, V18, P334, DOI 10.1089/acm.2011.0102
   Zhang K, 2019, SUPPORT CARE CANCER, V27, P3171, DOI 10.1007/s00520-019-04732-1
   Zia Farah Z, 2017, JOURNAL OF THE NATIONAL CANCER INSTITUTE MONOGRAPHS, V0, PP68, DOI 10.1093/jncimonographs/lgx005
NR 23
TC 3
Z9 4
U1 1
U2 21
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0162-220X
EI 1538-9804
J9 CANCER NURS
JI Cancer Nurs.
PD MAY-JUN 15
PY 2023
VL 46
IS 3
BP E204
EP E207
DI 10.1097/NCC.0000000000001135
PG 4
WC Oncology; Nursing
SC Oncology; Nursing
GA E5MQ6
UT WOS:000975985000013
PM 35679148
DA 2026-01-16
ER

PT J
AU Turan, GB
   Özer, Z
   Yanmis, S
   Aksoy, A
AF Bahcecioglu Turan, Gulcan
   Ozer, Zulfunaz
   Yanmis, Safiye
   Aksoy, Asude
TI The Effects of Self-Acupressure on Pain, Fatigue, and Sleep Quality in Colon and Pancreatic Cancer Patients Receiving Chemotherapy
SO CANCER NURSING
LA English
DT Article
DE Colon cancer; Fatigue; Insomnia; Nurse; Pain; Pancreatic cancer; Self-acupressure
ID auricular point acupressure; randomized controlled-trial; symptom management; clusters
AB BackgroundPancreatic and colon cancer are among important gastrointestinal cancer diseases. Pain, fatigue, and insomnia are among the most common symptoms in cancer patients receiving chemotherapy. Self-acupressure may improve patients' pain, fatigue, sleep quality, quality of life, and functional well-being.ObjectiveThe aim of this study was to examine the effects of self-acupressure application on pain, fatigue, and sleep quality in colon and pancreatic cancer patients receiving chemotherapy.MethodsThis randomized controlled study was conducted with 60 patients in treatment for pancreatic or colon cancer, 30 in the intervention and 30 in the control group, between June and October 2021. Participants in the intervention group were asked to complete 16 acupressure sessions for 4 weeks, 2 days a week in the morning and afternoon for a total of 18 minutes, depending on the preparation and pressure time on 4 pressure points. Control group participants did not receive any interventions during the study. The data were collected by using a personal information form, the Pittsburgh Sleep Quality Index, the Piper Fatigue Scale, and the visual analog scale.ResultsAfter self-acupressure, the visual analog scale, Piper Fatigue Scale, and Pittsburgh Sleep Quality Index scores of the intervention group decreased when compared with the control group scores; the difference between the 2 groups was statistically significant.ConclusionSelf-acupressure was effective in reducing the pain, fatigue, and sleep disorder scores of patients with colon or pancreatic cancer receiving chemotherapy.Implications for PracticeIn nursing practice, self-acupressure, an applicable, accessible, and inexpensive method in the management of cancer-related symptoms, can be supported and maintained during a 4-week period.
C1 [Bahcecioglu Turan, Gulcan] Firat Univ, Fac Hlth Sci, Dept Nursing, Elazig, Turkiye.
   [Ozer, Zulfunaz] Istanbul Sabahattin Zaim Univ, Fac Hlth Sci, Elazig, Turkiye.
   [Yanmis, Safiye] Erzican Binali Yildirim Univ, Fac Hlth Sci, Dept Nursing, Elazig, Turkiye.
   [Aksoy, Asude] Firat Univ, Dept Internal Med, Med Sch, Elazig, Turkiye.
   [Bahcecioglu Turan, Gulcan] Firat Univ, Fac Hlth Sci, Dept Nursing, Rectorate Campus,Exterior Door 2, TR-23200 Center Elazig, Turkiye.
C3 Firat University; Istanbul Sabahattin Zaim University; Firat University; Firat University
RP Turan, GB (corresponding author), Firat Univ, Fac Hlth Sci, Dept Nursing, Rectorate Campus,Exterior Door 2, TR-23200 Center Elazig, Turkiye.
EM glcnbah@hotmail.com; zulfinazozer@gmail.com; safiyeyanmis61@gmail.com; asudeaksoy@hotmail.com
FU The authors are grateful to all participants who agreed to participate voluntarily in this study.
CR Agargun MY, 1996, T RK PSIKIYATRI DERG, V7, P107, DOI 10.5606/ARCHRHEUMATOL.2018.6376
   Unknown -, 2021, HYPERTENSION, V0, P0
   Ayceman N, 1900, HEALTH AND NATURAL THERAPIES ASSOCIATION, V0, P0
   Bahar A, 2019, V6, V0, P42
   Bastani Farideh, 2015, IRAN J NURS MIDWIFERY RES, V20, P545, DOI 10.4103/1735-9066.164508
   Beikmoradi A, 2015, IRAN RED CRESCENT ME, V17, P0, DOI 10.5812/ircmj.25919
   BUYSSE DJ, 1989, PSYCHIAT RES, V28, P193, DOI 10.1002/smll.202408771
   Can G, 2001, MEME KANSERLI HASTALARDA YORGUNLUGUN VE BAKIM GEREKSINIMLERININ DEGERLENDIRILMESI, V0, P0
   Cetin S, 2019, MED J SULEYMAN DEMIREL UNIV, V26, P30
   Çölbay M, 2007, TUBERK TORAK, V55, P167
   Cowmeadow O, 2002, SHIATSU: A PRACTICAL INTRODUCTION, V2nd ed, P0
   Dengso KE, 2020, PANCREATOLOGY, V20, P511, DOI 10.1016/j.pan.2020.01.001
   Ister ED, 2021, HOLIST NURS PRACT, V35, P71, DOI 10.1097/HNP.0000000000000436
   Dong ST, 2014, J PAIN SYMPTOM MANAG, V48, P411, DOI 10.1016/j.jpainsymman.2013.10.027
   Gen?? A, 2018, STANBUL GELIIM U SAL, V0, PP517, DOI 10.38079/igusabder.430828
   Granados-Romero JJ, 2017, INTERNATIONAL JOURNAL OF RESEARCH IN MEDICAL SCIENCES, V5, P4667, DOI 10.18203/2320-6012.ijrms20174914
   Hawker GA, 2011, ARTHRIT CARE RES, V63, PS240, DOI 10.1002/acr.20543
   He YH, 2020, JAMA ONCOL, V6, P271, DOI 10.1001/jamaoncol.2019.5233
   Hmwe NTT, 2016, HOLIST NURS PRACT, V30, P283, DOI 10.1097/HNP.0000000000000165
   Hosseinabadi R, 2015, J INFUS MURS, V38, P397, DOI 10.1097/NAN.0000000000000065
   Huong HTX, 2022, SLEEP BREATH, V26, P445, DOI 10.1007/s11325-021-02370-8
   Huong HTX, 2018, DOCTORAL THESIS, V0, P0
   Ister ED, 2019, SAKARYA ÜNIVERSITESI HOLISTIK SAĞLIK DERGISI, V2, P22
   Karahan Okuroglu G, 2014, CILICIA J PHILOS, V1, P53
   Khanghah AG, 2019, J ACUPUNCT MERIDIAN, V12, P103
   Kim E, 2009, SUPPORT CARE CANCER, V17, P1383, DOI 10.1007/s00520-009-0595-5
   Kruse JL, 2015, CURR PSYCHIAT REP, V17, P0, DOI 10.1007/s11920-015-0555-3
   Kumar JVR, 2015, ASIAN JOURNAL OF NURSING EDUCATION AND RESEARCH, V5, P513, DOI 10.5958/2349-2996.2015.00105.6
   Kuo HC, 2018, RES NURS HEALTH, V41, P469, DOI 10.1002/nur.21885
   Lee EJ, 2011, J PAIN SYMPTOM MANAG, V42, P589, DOI 10.1016/j.jpainsymman.2011.01.007
   Lin L, 2021, BMJ SUPPORT PALLIAT, V11, P32, DOI 10.1136/bmjspcare-2019-001937
   Miladinia M, 2018, EUR J CANCER CARE, V27, P0, DOI 10.1111/ecc.12762
   Molassiotis A, 2007, COMPLEMENT THER MED, V15, P228, DOI 10.1016/j.ctim.2006.09.009
   Neufeld NJ, 2017, FUTURE ONCOL, V13, P833, DOI 10.2217/fon-2016-0423
   Nia HS, 2017, INT J NURS PRACT, V23, P0, DOI 10.1111/ijn.12513
   Ozdemir U, 2017, J HEAL SCI, V26, P253
   Pazarcıkcı F, 2017, MEHMET AKIF ERSOY UN, V5, P11, DOI 10.24998/maeusabed.292260
   Piper B F, 1998, ONCOL NURS FORUM, V25, P677
   Rizi MS, 2017, COMPLEMENT THER CLIN, V29, P136, DOI 10.1016/j.ctcp.2017.09.002
   Serçe S, 2018, INTEGR CANCER THER, V17, P728, DOI 10.1177/1534735418769153
   Shambhavi S, 2021, J COMPLEMENT ALTERN MED RES, V14, P42
   Song HJ, 2015, COMPLEMENT THER MED, V23, P68, DOI 10.1016/j.ctim.2014.11.002
   Tang WR, 2014, COMPLEMENT THER MED, V22, P581, DOI 10.1016/j.ctim.2014.05.006
   Taylor Claire, 2012, NURS TIMES, V108, P22
   Uysal E, 2016, SAKARYA MED J, V6, P217, DOI 10.5505/sakaryamedj.2016.38247
   van den Beuken-van Everdingen MHJ, 2016, J PAIN SYMPTOM MANAG, V51, P1070, DOI 10.1016/j.jpainsymman.2015.12.340
   Wagner J, 2015, AM J NURS, V115, P40, DOI 10.1097/01.NAJ.0000475290.20362.77
   Yang YL, 2020, EVID-BASED COMPL ALT, V2020, P0, DOI 10.1155/2020/1618767
   Yeh CH, 2016, CANCER NURS, V39, P402, DOI 10.1097/NCC.0000000000000303
   Yeh CH, 2015, PAIN MANAG NURS, V16, P285, DOI 10.1016/j.pmn.2014.08.005
   Yoon HG, 2019, APPL NURS RES, V48, P45, DOI 10.1016/j.apnr.2019.05.009
   Zhang B, 2017, MEDICINE, V96, P0, DOI 10.1097/MD.0000000000007750
   Zick SM, 2011, EVID BASED COMPLEMENT, V2011, P142913
   Zick SM, 2021, CONTEMP CLIN TRIALS, V107, P0, DOI 10.1016/j.cct.2021.106477
   Zick SM, 2018, JNCI CANCER SPECT, V2, P0, DOI 10.1093/jncics/pky064
NR 55
TC 7
Z9 8
U1 5
U2 35
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0162-220X
EI 1538-9804
J9 CANCER NURS
JI Cancer Nurs.
PD NOV-DEC 15
PY 2023
VL 46
IS 6
BP 457
EP 466
DI 10.1097/NCC.0000000000001193
PG 10
WC Oncology; Nursing
SC Oncology; Nursing
GA W2IA2
UT WOS:001089906600013
DA 2026-01-16
ER

PT J
AU Su, XJ
   Song, PF
   Meng, FC
   Xu, WS
   Xing, H
   Zhang, H
AF Su, Xiaojie
   Song, Pengfei
   Meng, Fanchao
   Xu, Wenshuai
   Xing, Hua
   Zhang, Hong
TI Tuina Manipulation to Reduce Inflammation and Cartilage Loss in Knee Osteoarthritis Rats
SO JOVE-JOURNAL OF VISUALIZED EXPERIMENTS
LA English
DT Article
ID massage
AB Clinical trials suggest that Tuina manipulation is effective in treating knee osteoarthritis (KOA), while further studies are required to discover its mechanism. Therefore, the manipulation of animal models of knee osteoarthritis is critical. This protocol provides a standard process for Tuina manipulation on KOA rats and a preliminary exploration of the mechanism of Tuina for KOA. The press and kneading manipulation method (a kind of Tuina manipulation that refers to pressing and kneading the specific area of the body surface) is applied on 5 acupoints around the knee joint of rats. The force and frequency of the manipulation were standardized by finger pressure recordings, and the position of the rat during manipulation is described in detail in the protocol. The effect of manipulation can be measured by pain behavior tests and microscopic findings in synovial and cartilage. KOA rats showed significant improvement in pain behavior. The synovial tissue inflammatory infiltration was reduced in the Tuina group, and the expression of tumor necrosis factor (TNF)-alpha was significantly lower. Compared to the control group, chondrocyte apoptosis was less in the Tuina group. This study provides a standardized protocol for Tuina manipulation on KOA rats and preliminary proof that the therapeutic effects of Tuina may be related to reducing synovial inflammation and delayed chondrocyte apoptosis.
C1 [Su, Xiaojie; Song, Pengfei; Meng, Fanchao; Xu, Wenshuai; Xing, Hua; Zhang, Hong] Shanghai Univ Tradit Chinese Med, Yueyang Hosp Integrated Tradit Chinese & Western, Shanghai, Peoples R China.
C3 Shanghai University of Traditional Chinese Medicine
RP Xing, H; Zhang, H (corresponding author), Shanghai Univ Tradit Chinese Med, Yueyang Hosp Integrated Tradit Chinese & Western, Shanghai, Peoples R China.
EM yyyyxinghua@shutcm.edu.cn; zhanghongdoctor@sina.com
FU Shanghai Critical Clinical Specialties Construction Project [Shslczdzk04001]; Sailing program of Shanghai Science and Technology Commission [22YF1444300]; Projects within the budget of Shanghai University of Traditional Chinese Medicine [2021LK091]
CR Callahan LF, 2021, RHEUM DIS CLIN N AM, V47, P1, DOI 10.1016/j.rdc.2020.09.001
   Chen C, 2018, HAINAN MEDICAL JOURNAL, V29, P2617
   Ding X, 2021, SHANGHAI JOURNAL OF TRADITIONAL CHINESE MEDICINE, V55, P54
   Fan C, 2020, INT J DAMAGE MECH, V29, P887, DOI 10.1177/1056789519890064
   Fu Y, 2020, JILIN JOURNAL OF CHINESE MEDICINE, V40, P958
   Gong L, 2016, CHIN J ORTHOPAED TRAUMATOL TRADITION CHIN MED, V24, P16
   [古来撒尔·艾克拜尔 Gulaisaer Aikebaier], 2022, 中国中医药信息杂志 CHINESE JOURNAL OF INFORMATION ON TRADITIONAL CHINESE MEDICINE, V29, P23
   Guo Y, 2011, CHINESE ACUPUNCTURE & MOXIBUSTION, V31, P549
   He Y, 2020, CHINESE IMAGING JOURNAL OF INTEGRATED TRADITIONAL AND WESTERN MEDICINE, V18, P198
   Hua X, 2021, J ACUPUNCT TUINA SCI, V19, P354, DOI 10.1007/s11726-021-1266-4
   HULTH A, 1970, ACTA ORTHOP SCAND, V41, P522, DOI 10.3109/17453677008991540
   Jeong J, 2018, BMC COMPLEM ALTERN M, V18, P0, DOI 10.1186/s12906-018-2149-1
   Jiang J, 2018, JOURNAL OF CHANGCHUN UNIVERSITY OF CHINESE MEDICINE, V34, P129
   Joint Surgery Group Orthopaedic Branch, 2021, CHIN J ORTHOP, V41, P24
   Li C, 2020, JOURNAL OF GUANGZHOU UNIVERSITY OF TRADITIONAL CHINESE MEDICINE, V37, P2157
   [梁玉磊 Liang Yulei], 2014, 时珍国医国药 LISHIZHEN MEDICINE AND MATERIA MEDICA RESEARCH, V25, P2299
   Liu J, 2019, EFFECT OF MASSAGE ON TLR4/MYD88 SIGNAL TRANSDUCTION PATHWAY IN RAT KNEE OSTEOARTHRITIS MODEL, V0, P0
   [刘晶 Liu Jing], 2020, 康复学报 REHABILITATION MEDICINE, V30, P212, DOI 10.3724/sp.j.1329.2020.03009
   Luo R, 2017, THE EFFECTS OF IL-1BIL-6IL-13IL-26TNF-A BY PATELLAR MANIPULATIONS ON RABBIT KNEE OSTEOARTHRITIS MODEL, V0, P0
   Moskowitz RW, 2006, OSTEOARTHR CARTILAGE, V14, P1, DOI 10.1016/j.joca.2005.08.015
   Perlman A, 2019, J GEN INTERN MED, V34, P379, DOI 10.1007/s11606-018-4763-5
   Qian J, 2014, RESEARCH AND EXPLORATION IN LABORATORY, V33, P23
   Qiu F, 2021, ACTA CHINESE MEDICINE, V36, P649
   Seo BR, 2021, SCI TRANSL MED, V13, P0, DOI 10.1126/scitranslmed.abe8868
   Shang P, 2006, ORTHOPAEDIC BIOMECHANICS MATERIALS AND CLINICAL STUDY, V0, P11
   Shen M, 2009, CHINESE MEDICINE MODERN DISTANCE EDUCATION OF CHINA, V7, P130
   Song PF, 2018, J TRADIT CHIN MED, V38, P834
   Spitaels D, 2020, BMJ OPEN, V10, P0, DOI 10.1136/bmjopen-2019-031734
   Tan Q, 2022, CHIN. J. TISSUE ENG. RES, V26, P1714
   Tawonsawatruk T, 2018, BONE JOINT RES, V7, P244, DOI 10.1302/2046-3758.73.BJR-2017-0121.R2
   Wang K, 2017, NATIONAL MEDICAL JOURNAL OF CHINA, V97, P4
   Wu JH, 2018, CHINESE GENERAL PRACTICE, V21, P688
   Yan XH, 2017, ACTA CHIN ME, V32, P875
   Yang B, 2022, ACTA CHINESE MEDICINE, V37, P2571
   Yu S, 2022, JOURNAL OF GUANGXI UNIVERSITY OF CHINESE MEDICINE, V25, P50
   Zeng J, 2016, CHINESE JOURNAL OF CLINICAL RESEARCH, V29, P679
   Zhang Z, 2019, HENAN TRADITIONAL CHINESE MEDICINE, V39, P146
   Zhou Q, 2015, BMC MUSCULOSKEL DIS, V16, P0, DOI 10.1186/s12891-015-0679-y
NR 38
TC 0
Z9 0
U1 2
U2 23
PU JOURNAL OF VISUALIZED EXPERIMENTS
PI CAMBRIDGE
PA 1 ALEWIFE CENTER, STE 200, CAMBRIDGE, MA 02140 USA
SN 1940-087X
EI 
J9 JOVE-J VIS EXP
JI J. Vis. Exp.
PD JUN 15
PY 2023
VL 0
IS 196
BP 
EP 
DI 10.3791/65451
PG 18
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA R8FG9
UT WOS:001066654000042
PM 37458470
DA 2026-01-16
ER

PT J
AU Zhi, WI
   Baser, RE
   Talukder, D
   Mei, YZ
   Harte, SE
   Bao, T
AF Zhi, W. Iris
   Baser, Raymond E.
   Talukder, Dristi
   Mei, Ying Zi
   Harte, Steven E.
   Bao, Ting
TI Mechanistic and thermal characterization of acupuncture for chemotherapy-induced peripheral neuropathy as measured by quantitative sensory testing
SO BREAST CANCER RESEARCH AND TREATMENT
LA English
DT Article
DE Acupuncture; Chemotherapy; Neuropathy; Breast cancer; Sensory loss; Quantitative sensory testing
ID pain sensitivity; pressure pain; risk-factors; prevalence; survivors; domains; women
AB PurposeChemotherapy-induced peripheral neuropathy (CIPN) is a common and debilitating side effect of chemotherapy. Acupuncture is a promising non-pharmacological intervention for CIPN. However, the physiological effects of acupuncture treatment remain poorly understood. We examined the effects of acupuncture on CIPN using semi-objective quantitative sensory testing (QST). MethodsWe conducted a randomized controlled trial of real acupuncture (RA) and sham acupuncture (SA) compared to usual care (UC) in cancer survivors with moderate-to-severe CIPN. Treatment response was assessed with QST measures of tactile and vibration detection thresholds in hands and feet, thermal detection, and pain thresholds at weeks 0, 8, and 12. Constrained linear mixed model (cLMM) regression was used for statistical analysis. Results63 patients completed QST testing. At week 8, vibrational detection thresholds in feet were significantly lower in RA and SA (p = 0.019 and p = 0.046) than in UC, with no difference between RA and SA (p = 0.637). Both RA and SA also showed significantly higher cool thermal detection than UC (p = 0.008 and p = 0.013, respectively), with no difference between RA and SA (p = 0.790). No differences in tactile detection, vibrational detection in hands, warm thermal detection, and thermal pain thresholds were detected among the three arms at weeks 8 and 12. ConclusionQST demonstrated different patterns in RA, SA, and UC. After eight weeks of RA, we observed significant improvements in the vibrational detection threshold in feet and cool thermal detection threshold in hands compared to UC. No significant differences were seen when compared to SA.
C1 [Zhi, W. Iris] Mem Sloan Kettering Canc Ctr, Dept Med, Breast Med Serv, Solid Tumor Div, New York, NY USA.
   [Baser, Raymond E.] Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, Dept Med, New York, NY USA.
   [Talukder, Dristi; Bao, Ting] Mem Sloan Kettering Canc Ctr, Dept Med, Integrat Med Serv, New York, NY 10065 USA.
   [Mei, Ying Zi] Columbia Univ, Barnard Coll, New York, NY USA.
   [Harte, Steven E.] Univ Michigan, Med Sch, Chron Pain & Fatigue Res Ctr, Dept Anesthesiol, Ann Arbor, MI USA.
   [Bao, Ting] Mem Sloan Kettering Canc Ctr, Dept Med, Integrat Med Serv, 321 East 61st St, Room 458, New York, NY 10065 USA.
C3 Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Columbia University; University of Michigan System; University of Michigan; Memorial Sloan Kettering Cancer Center
RP Bao, T (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Med, Integrat Med Serv, New York, NY 10065 USA.; Bao, T (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Med, Integrat Med Serv, 321 East 61st St, Room 458, New York, NY 10065 USA.
EM baot@mskcc.org
FU National Institutes of Health/National Cancer Institute Cancer Center Support Grant; Translational and Integrative Medicine Research Fund at Memorial Sloan Kettering Cancer Center [P30 CA008748]; Frueauff Foundation; National Cancer Institute; Gateway for Cancer Research [R37CA248563, R01CA240417, R01CA251470];  [G-22-1200]; National Cancer Institute [R01CA240417, R01CA251470, P30CA008748, R37CA248563] Funding Source: NIH RePORTER
CR As-Sanie S, 2013, OBSTET GYNECOL, V122, P1047, DOI 10.1097/AOG.0b013e3182a7e1f5
   Backonja M, 2013, PAIN, V154, P1807, DOI 10.1016/j.pain.2013.05.047
   Bao T, 2021, ONCOLOGIST, V26, PE2070, DOI 10.1002/onco.13933
   Bao T, 2020, JAMA NETW OPEN, V3, P0, DOI 10.1001/jamanetworkopen.2020.0681
   Bao T, 2016, BREAST CANCER RES TR, V159, P327, DOI 10.1007/s10549-016-3939-0
   Baron R, 2017, PAIN, V158, P261, DOI 10.1097/j.pain.0000000000000753
   Bates D, 2015, J STAT SOFTW, V67, P1, DOI 10.18637/jss.v067.i01
   Cata JP, 2007, J PAIN, V8, P296, DOI 10.1016/j.jpain.2006.09.014
   DAlessandro EG, 2022, BMJ SUPPORT PALLIAT, V12, P64, DOI 10.1136/bmjspcare-2018-001542
   Drobek W, 2001, CLIN ORAL INVESTIG, V5, P185
   Edwards RR, 2005, PAIN, V114, P315, DOI 10.1016/j.pain.2005.01.007
   Ewertz M, 2015, ACTA ONCOL, V54, P587, DOI 10.3109/0284186X.2014.995775
   Giesbrecht RJS, 2005, PHYS THER, V85, P1085, DOI 10.1093/ptj/85.10.1085
   Giesecke T, 2004, ARTHRITIS RHEUM-US, V50, P613, DOI 10.1002/art.20063
   Greenspan JD, 2011, J PAIN, V12, PT61, DOI 10.1016/j.jpain.2011.08.006
   Hanai A, 2018, JNCI-J NATL CANCER I, V110, P0, DOI 10.1093/jnci/djx178
   Harte SE, 2019, PAIN, V160, P1270, DOI 10.1097/j.pain.0000000000001505
   Hershman DL, 2014, J ONCOL PRACT, V10, PE421, DOI 10.1200/JOP.2014.001776
   Hershman DL, 2011, BREAST CANCER RES TR, V125, P767, DOI 10.1007/s10549-010-1278-0
   Kenward MG, 2010, STAT MED, V29, P1455, DOI 10.1002/sim.3868
   Kleinböhl D, 1999, PAIN, V81, P35, DOI 10.1016/S0304-3959(98)00266-8
   Lenth RV, 2021, R PACKAGE VERSION 1, V0, P0
   Lin D, 2014, INT J MOL SCI, V15, P3234, DOI 10.3390/ijms15023234
   LU GW, 1983, AM J PHYSIOL, V245, PR606, DOI 10.1152/ajpregu.1983.245.4.R606
   Lu WD, 2020, ONCOLOGIST, V25, P310, DOI 10.1634/theoncologist.2019-0489
   Naliboff BD, 1997, GUT, V41, P505, DOI 10.1136/gut.41.4.505
   Petzke F, 2003, PAIN, V105, P403, DOI 10.1016/S0304-3959(03)00204-5
   Pfau DB, 2012, CURR PAIN HEADACHE R, V16, P199, DOI 10.1007/s11916-012-0261-3
   Puta C, 2012, BMC NEUROL, V12, P0, DOI 10.1186/1471-2377-12-98
   Reed BD, 2017, J LOW GENIT TRACT DI, V21, P78, DOI 10.1097/LGT.0000000000000267
   Rolke R, 2006, EUR J PAIN, V10, P77, DOI 10.1016/j.ejpain.2005.02.003
   Rostock M, 2013, EVID-BASED COMPL ALT, V2013, P0, DOI 10.1155/2013/349653
   Schneider BP, 2015, ADV EXP MED BIOL, V862, P77, DOI 10.1007/978-3-319-16366-6_6
   Schroeder S, 2012, ACUPUNCT MED, V30, P4, DOI 10.1136/acupmed-2011-010034
   Seretny M, 2014, PAIN, V155, P2461, DOI 10.1016/j.pain.2014.09.020
   Staff NP, 2017, ANN NEUROL, V81, P772, DOI 10.1002/ana.24951
   Team RC, 2021, R LANG ENV STAT COMP, V0, P0
   Vickers AJ, 2018, J PAIN, V19, P455, DOI 10.1016/j.jpain.2017.11.005
   Wong Raimond, 2006, ACUPUNCT MED, V24, P87
   Zhao ZQ, 2008, PROG NEUROBIOL, V85, P355, DOI 10.1016/j.pneurobio.2008.05.004
   Zhi WI, 2021, BREAST CANCER RES TR, V186, P761, DOI 10.1007/s10549-020-06079-2
   Zhi WI, 2019, BREAST CANCER RES TR, V178, P587, DOI 10.1007/s10549-019-05416-4
NR 42
TC 6
Z9 7
U1 1
U2 4
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0167-6806
EI 1573-7217
J9 BREAST CANCER RES TR
JI Breast Cancer Res. Treat.
PD FEB 15
PY 2023
VL 197
IS 3
BP 535
EP 545
DI 10.1007/s10549-022-06846-3
EA DEC 2022
PG 11
WC Oncology
SC Oncology
GA 8K7DE
UT WOS:000900062800001
PM 36527520
DA 2026-01-16
ER

PT J
AU Alsabri, M
   Carfagnini, C
   Amin, M
   Castilo, F
   Lewis, J
   Ashkar, M
   Hamzah, M
   Mohamed, N
   Saker, M
   Mahgerefteh, J
   Victor, RS
   Peichev, M
   Kupferman, F
   Viswanathan, K
AF Alsabri, Mohammed
   Carfagnini, Christina
   Amin, Mody
   Castilo, Fiorella
   Lewis, Jeremy
   Ashkar, Mohammad
   Hamzah, Mohammed
   Mohamed, Nader
   Saker, Mohammed
   Mahgerefteh, Joseph
   Victor, Rosemarie St.
   Peichev, Mario
   Kupferman, Fernanda
   Viswanathan, Kusum
TI Complementary and alternative medicine for children with sickle cell disease: A systematic review
SO BLOOD REVIEWS
LA English
DT Review
DE Sickle cell disease; Children; Pediatric hematology
ID randomized controlled-trial; pain; management; cancer
AB Background: Complementary and alternative medicine (CAM) is a popular alternative to opioid and other an-algesics in sickle cell disease (SCD). We review the effectiveness, prevalence, and factors associated with CAM use in the pediatric SCD population.Methods: The review protocol was created based on Preferred Reporting Items for Systematic Reviews and Meta -Analyses guidelines. A literature search was conducted in MEDLINE, Embase, Cochrane Library, PubMed, and Web of Science.Results: Twenty-four studies were examined. The prevalence of CAM use in pediatric patients with SCD ranged from 36 to 84.5%. Common inpatient CAM interventions were yoga, virtual reality, and acupuncture, which decreased pain scale scores. Outpatient CAMs were consisted of cognitive behavioral therapy, massage therapy, and guided-imagery, which increased pain tolerability and decreased pain scale scores.Conclusions: CAM modalities can decrease pain scale scores. However, the impact of specific CAM modalities on emergency department visits, hospitalizations, and school absences were inconclusive.
C1 [Alsabri, Mohammed; Castilo, Fiorella; Mahgerefteh, Joseph; Victor, Rosemarie St.; Peichev, Mario; Kupferman, Fernanda; Viswanathan, Kusum] Brookdale Univ, Pediat Dept, Hosp Med Ctr, One Brooklyn Hlth, 1 Brookdale Plaza, Brooklyn, NY 11212 USA.
   [Carfagnini, Christina] Saba Univ, Sch Med, The Bottom, Netherlands.
   [Amin, Mody] Univ Buffalo, Internal Med Dept, 955 Main St, Buffalo, NY 14260 USA.
   [Lewis, Jeremy] St Marys Hosp, Dept Gen Surg, 56 Franklin St, Waterbury, CT 06706 USA.
   [Ashkar, Mohammad] New York Inst Technol, Coll Osteopath Med, Old Westbury, NY USA.
   [Saker, Mohammed] Childrens Hosp Montefiore, Med Ctr, Albert Einstein Coll Med, Bronx, NY USA.
   [Mohamed, Nader] SUNY Downstate, Coll Med, Brooklyn, NY USA.
   [Hamzah, Mohammed] Cleveland Clin Childrens Hosp, Dept Pediat Crit Care, Cleveland, OH USA.
   [Alsabri, Mohammed] Children Hosp Philadelphia, Attending Pediat Emergency Med, 3401 Civ Ctr Blvd, Philadelphia, PA 19104 USA.
C3 State University of New York (SUNY) System; University at Buffalo, SUNY; New York Institute Technology; Montefiore Medical Center; Albert Einstein College of Medicine; Childrens Hospital at Montefiore; Yeshiva University; State University of New York (SUNY) System; SUNY Downstate Health Sciences University; Cleveland Clinic Foundation; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia
RP Alsabri, M (corresponding author), Children Hosp Philadelphia, Attending Pediat Emergency Med, 3401 Civ Ctr Blvd, Philadelphia, PA 19104 USA.
EM alsabri5000@gmail.com; c.carfagnini_037@saba.edu; modyamin@buffalo.edu; mashka01@nyit.edu; hamzahm@ccf.org; nader.mohamed@downstate.edu; msakr@montefiore.org
CR Agrawal AK, 2018, PEDIATR BLOOD CANCER, V66, P0
   Akinsulie AO, 2005, J TROP PEDIATRICS, V51, P200, DOI 10.1093/tropej/fmh097
   Angelopoulou E, 2020, COMPLEMENT THER MED, V0, P49
   Unknown -, 2021, COMPLEMENTARY, V0, P0
   Unknown -, 2022, COVIDENCE SYSTEMATIC REVIEW SOFTWARE, V0, P0
   April KT, 2011, RHEUM DIS CLIN N AM, V37, P85, DOI 10.1016/j.rdc.2010.11.011
   Barakat LP, 2010, J PEDIAT HEMATOL ONC, V32, P540, DOI 10.1097/MPH.0b013e3181e793f9
   Bhushan D, 2015, MED ACUPUNCT, V27, P461, DOI 10.1089/acu.2015.1140
   Bishop FL, 2010, PEDIATRICS, V125, P768, DOI 10.1542/peds.2009-1775
   Bodhise Paul Brown, 2004, HEMATOLOGY, V9, P235, DOI 10.1080/10245330410001701495
   Broome M E, 2001, J NATL BLACK NURSES ASSOC, V12, P6
   Claster S, 2003, BRIT MED J, V327, P1151, DOI 10.1136/bmj.327.7424.1151
   Dampier C, 2004, PEDIATR BLOOD CANCER, V43, P674, DOI 10.1002/pbc.20162
   Dampier C, 2017, J PAIN, V18, P490, DOI 10.1016/j.jpain.2016.12.016
   Darbari DS, 2017, HEMATOL-AM SOC HEMAT, V0, PP534, DOI 10.1182/asheducation-2017.1.534
   Darnall BD, 2021, JAMA NETW OPEN, V4, P0, DOI 10.1001/jamanetworkopen.2021.13401
   Dobson C, 2015, APPL NURS RES, V28, P384, DOI 10.1016/j.apnr.2014.12.005
   Dobson CE, 2014, AM J NURS, V114, P26, DOI 10.1097/01.NAJ.0000445680.06812.6a
   Edwards CL, 2005, INT J BEHAV MED, V12, P171, DOI 10.1207/s15327558ijbm1203_6
   Ehde DM, 2019, TRIALS, V20, P0, DOI 10.1186/s13063-019-3761-1
   Gil KM, 2001, J PEDIATR PSYCHOL, V26, P163, DOI 10.1093/jpepsy/26.3.163
   Green-Murphy A, 2017, PEDIATR BLOOD CANCER, V64, P0
   Heidari Z, 2022, DISABIL REHABIL, V44, P5758, DOI 10.1080/09638288.2021.1949051
   Jang A, 2017, J ALTERN COMPLEM MED, V23, P362, DOI 10.1089/acm.2016.0289
   Jatau AI, 2016, J INTERCULT ETHNOPHA, V5, P191, DOI 10.5455/jice.20160223105521
   Lemanek KL, 2009, J PEDIATR PSYCHOL, V34, P1091, DOI 10.1093/jpepsy/jsp015
   Liberati Alessandro, 2009, PLOS MED, V6, Pe1000100, DOI 10.1371/journal.pmed.1000100
   Mahmood LA, 2021, COMPLEMENT THER MED, V60, P0, DOI 10.1016/j.ctim.2021.102680
   Mahmood LA, 2020, COMPLEMENT THER MED, V49, P0, DOI 10.1016/j.ctim.2019.102287
   Moody K, 2017, J PAIN SYMPTOM MANAG, V53, P1026, DOI 10.1016/j.jpainsymman.2016.12.351
   Murray CB, 2020, PAIN, V161, P439, DOI 10.1097/j.pain.0000000000001732
   Myrvik MP, 2012, J PEDIAT HEMATOL ONC, V34, P340, DOI 10.1097/MPH.0b013e318253f0ba
   Neri Caitlin M, 2016, GLOB ADV HEALTH MED, V5, P44, DOI 10.7453/gahmj.2015.101
   Oshikoya KA, 2008, BMC COMPLEM ALTERN M, V8, P0, DOI 10.1186/1472-6882-8-66
   Palermo TM, 2018, CONTEMP CLIN TRIALS, V74, P88, DOI 10.1016/j.cct.2018.10.006
   Post-White J, 2009, J PEDIATR ONCOL NURS, V26, P7, DOI 10.1177/1043454208323914
   Quinn CT, 2016, EXP BIOL MED, V241, P679, DOI 10.1177/1535370216640385
   Sanchez HC, 2015, J ALTERN COMPLEM MED, V21, P660, DOI 10.1089/acm.2014.0371
   Schardt C, 2007, BMC MED INFORM DECIS, V7, P0, DOI 10.1186/1472-6947-7-16
   Schatz J, 2015, CLIN J PAIN, V31, P536, DOI 10.1097/AJP.0000000000000183
   Shah Nirmish, 2020, J HEALTH ECON OUTCOMES RES, V7, P52, DOI 10.36469/jheor.2020.12852
   Sibinga EMS, 2006, J ALTERN COMPLEM MED, V12, P291, DOI 10.1089/acm.2006.12.291
   Sil S, 2020, COMPLEMENT THER MED, V49, P0, DOI 10.1016/j.ctim.2020.102348
   Sinha CB, 2019, JAMA NETW OPEN, V2, P0
   Sundd P, 2019, ANNU REV PATHOL-MECH, V14, P263, DOI 10.1146/annurev-pathmechdis-012418-012838
   Tang W, 2018, MEDICINE, V97, P1
   Thompson W, 2013, MISSISSIPPI J BEHAV, V2, P151
   Vinson R, 2014, ACAD PEDIATR, V14, P491, DOI 10.1016/j.acap.2014.04.003
   Yawn BP, 2014, JAMA-J AM MED ASSOC, V312, P1033, DOI 10.1001/jama.2014.10517
   Yoon SL, 2006, J ALTERN COMPLEM MED, V12, P995, DOI 10.1089/acm.2006.12.995
   Zebracki K, 2007, J PEDIATR PSYCHOL, V32, P1006, DOI 10.1093/jpepsy/jsm033
NR 51
TC 7
Z9 8
U1 0
U2 9
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 0268-960X
EI 1532-1681
J9 BLOOD REV
JI Blood Rev.
PD MAY 15
PY 2023
VL 59
IS 
BP 
EP 
DI 10.1016/j.blre.2023.101052
EA APR 2023
PG 12
WC Hematology
SC Hematology
GA G2WE7
UT WOS:000987813900001
PM 36775794
DA 2026-01-16
ER

PT J
AU Zou, X
   Chen, ZY
   Yang, YH
   Qiao, Y
   He, SJ
   Li, Q
   Chen, WL
   Zhang, XY
   Li, SY
   Sha, SY
   Hu, MH
   Zhang, XY
   Yang, MJ
   Wang, RP
   Wu, HG
   Shi, Y
   Xue, XH
   Ji, YJ
AF Zou, Xuan
   Chen, Zi-Yi
   Yang, Yu-Han
   Qiao, Yu
   He, Shu-Jin
   Li, Qiong
   Chen, Wei-Li
   Zhang, Xin-Yue
   Li, Si-Yu
   Sha, Shan-Yan
   Hu, Min-Hao
   Zhang, Xi-Yin
   Yang, Ming-Ju
   Wang, Rui-Ping
   Wu, Huan-Gan
   Shi, Yin
   Xue, Xiao-Hong
   Ji, Ya-Jie
TI Acupoint Thread Embedding Combined With Wenshen Bugu Decoction for the Treatment
SO Integrative cancer therapies
LA English
DT Journal Article
DE Wenshen Bugu Decoction; acupoint thread embedding (ATE); aromatase inhibitor-associated musculoskeletal symptom (AIMSS); breast cancer; endocrine therapy
AB BACKGROUND: Aromatase inhibitors (AIs) are recommended as the preferred therapy  for postmenopausal women with hormone receptor-positive (HR+) breast cancer. As a  result, aromatase inhibitor-associated musculoskeletal symptom (AIMSS) have  become a major problem leading to therapy discontinuation and decreased quality  of life in patients receiving adjuvant AIs treatment. Multiple therapies have  been attempted, but have yielded limited clinical results. This study will be  performed to determine whether acupoint thread embedding (ATE) combined with  Wenshen Bugu Decoction can effectively treat AIMSS, so as to improve the AIs  medication compliance of postmenopausal breast cancer patients. METHODS: This  study will utilize a randomized, 2 parallel groups controlled trial design. A  total of 128 eligible postmenopausal breast cancer women with AIMSS will be  randomized to receive a 12-week treatment with Wenshen Bugu Decoction alone  (control group) or in combination with ATE (treatment group) in a 1:1 ratio. The  primary outcome will be the 12 week Brief Pain Inventory Worst Pain (BPI-WP)  score. The secondary outcome measures will include response rate, Brief Pain  Inventory-Short Form (BFI-SF), Western Ontario and McMaster Universities  Osteoarthritis Index (WOMAC), Functional Assessment of Cancer Therapy-Endocrine  Symptom (FACT-ES), Functional Assessment of Cancer Therapy-Breast (FACT-B), bone  marrow density (BMD), blood markers of bone metabolite, Morisky medication  adherence scale-8 (MMAS-8), credibility and expectancy, and survival outcomes.  DISCUSSION: This trial may provide clinical evidence that ATE combined with  Wenshen Bugu Decoction can be beneficial for treating AIMSS among postmenopausal  breast cancer survivors. Our findings will be helpful to enhance the quality of  life and reduce the occurrence of AIs withdrawal.
C1 Shanghai University of Traditional Chinese Medicine, Shanghai, China.
   Shanghai Research Institute of Acupuncture and Meridian, Shanghai, China.
   Shanghai University of Traditional Chinese Medicine, Shanghai, China.
   Shanghai Research Institute of Acupuncture and Meridian, Shanghai, China.
   Shanghai University of Traditional Chinese Medicine, Shanghai, China.
   Shanghai University of Traditional Chinese Medicine, Shanghai, China.
   Shanghai Research Institute of Acupuncture and Meridian, Shanghai, China.
   Shanghai University of Traditional Chinese Medicine, Shanghai, China.
   Shanghai Research Institute of Acupuncture and Meridian, Shanghai, China.
   Shanghai University of Traditional Chinese Medicine, Shanghai, China.
   Shanghai University of Traditional Chinese Medicine, Shanghai, China.
   Shanghai University of Traditional Chinese Medicine, Shanghai, China.
   Shanghai University of Traditional Chinese Medicine, Shanghai, China.
   Shanghai University of Traditional Chinese Medicine, Shanghai, China.
   Shanghai University of Traditional Chinese Medicine, Shanghai, China.
   Shanghai University of Traditional Chinese Medicine, Shanghai, China.
   Shanghai Research Institute of Acupuncture and Meridian, Shanghai, China.
   Shanghai University of Traditional Chinese Medicine, Shanghai, China.
   Tongji University, Shanghai, China.
   Shanghai Research Institute of Acupuncture and Meridian, Shanghai, China.
   Shanghai Research Institute of Acupuncture and Meridian, Shanghai, China.
   Shanghai University of Traditional Chinese Medicine, Shanghai, China.
   Shanghai University of Traditional Chinese Medicine, Shanghai, China.
   Shanghai Research Institute of Acupuncture and Meridian, Shanghai, China.
NR 0
TC 0
SN 1552-695
EI 1534-735
J9 Integr Cancer Ther
PD AUG 11
PY 2023
VL 22
IS 
BP 15347354231188679
EP 15347354231188679
DI 10.1177/15347354231188679
PG 1
WC Humans; Female; Aromatase Inhibitors; adverse effects; Breast Neoplasms; drug therapy; Quality of Life; Acupuncture Points; Postmenopause; Pain; drug therapy; Randomized Controlled Trials as Topic
UT PubMed:37565358
PM 37565358
DA 2023-08-11
ER

PT J
AU de, Sousa TR
   Mattos, S
   Marcon, G
   Furtado, T
   Duarte, da Silva M
AF de Sousa, Tatiane Regina
   Mattos, Suzana
   Marcon, Giovanna
   Furtado, Thayná
   Duarte da Silva, Morgana
TI Acupuncture techniques and acupoints used in individuals under chemotherapy or
SO Journal of clinical nursing
LA English
DT Journal Article
DE acupoints; acupuncture; cancer; pain
AB AIMS AND OBJECTIVES: To describe the main acupuncture techniques and parameters  that have been used in the most varied symptoms of different types of cancer.  BACKGROUND: Clinical evidence about the potential effectiveness of acupuncture  and related therapies to control signs and symptoms associated with cancer or its  treatment has been in several studies. Currently, there is already evidence of  the use of acupuncture for the treatment of nausea and vomiting, fatigue, dry  mouth, anxiety, depression, insomnia and pain. However, many studies lack firm  rights or reproducible guidelines for treatment. DESIGN: This study performs a  systematic review of clinical trials related to the topic, based on the PRISMA  protocol. Thus, a search was carried out in the Scopus, Pubmed and Web of Science  databases, covering studies since January 2007. METHODS: Structured and organised  according to PICO standards, using keywords ("cancer" OR "malignant tumour" OR  "chemotherapy" OR "radiotherapy") AND ("acupuncture" OR "electroacupuncture") AND  ("pain" OR "nausea" OR "vomit" OR "fatigue" OR "xerostomia" OR "insomnia" OR  "depression" OR "neuropathy"). RESULTS: After the selection and evaluation phase,  23 studies were included and analysed. CONCLUSION: Based on this analysis, it is  concluded that acupuncture is safe and there is evidence of the reduction of  gastrointestinal symptoms, chemotherapy-induced peripheral neuropathy, pain, dry  mouth, fatigue, insomnia, and improvement of cognitive capacity. RELEVANCE TO  CLINICAL PRACTICE: Acupuncture treatments could act by minimising the side  effects of conventional treatments and reducing symptoms induced by tumours. NO  PATIENT OR PUBLIC CONTRIBUTION: The patients had no direct involvement with the  study in question.
C1 Program of Post-graduation in Neuroscience, Federal University of Santa Catarina, Florianópolis, Brazil.
   Laboratory of Neurobiology of Pain and Inflammation (LANDI), Department of 
   Department of physiotherapy, Estacio de Santa Catarina University Center, São José, Brazil.
   Department of physiotherapy, Estacio de Santa Catarina University Center, São José, Brazil.
   Department of physiotherapy, Estacio de Santa Catarina University Center, São José, Brazil.
   Program of Post-graduation in Neuroscience, Federal University of Santa Catarina, Florianópolis, Brazil.
   Laboratory of Neurobiology of Pain and Inflammation (LANDI), Department of
NR 0
TC 0
SN 1365-270
EI 
J9 J Clin Nurs
PD JUN 29
PY 2023
VL 32
IS 19-20
BP 6917
EP 6933
DI 10.1111/jocn.16812
PG 16
WC Humans; Acupuncture Points; Acupuncture Therapy; adverse effects; Electroacupuncture; adverse effects; Neoplasms; radiotherapy; Nausea; chemically induced; Xerostomia; etiology; Pain; etiology
UT PubMed:37382085
PM 37382085
DA 2023-06-29
ER

PT J
AU Chu, EC
   Trager, RJ
   Shum, JS
   Ng, KK
AF Chu, Eric C
   Trager, Robert J
   Shum, John S
   Ng, Kenny K
TI Sacral Giant Cell Tumor Presenting as Low Back Pain in the Chiropractic Office: A
SO Cureus
LA English
DT Journal Article
DE chiropractic; giant cell tumors; low back pain; neoplasms; radiculopathy; sacrum
AB Sacral giant cell tumors are a rare cause of low back pain and may be challenging  to identify via routine clinical examination and radiography. A 47-year-old woman  presented to a chiropractor with a one-month history of worsening low back pain  with radiation to the posterior thighs, worsened with ambulation, and used a cane  to walk. She previously saw an orthopedic surgeon and was diagnosed with lumbar  spondylosis, having tried anti-inflammatory medications, exercises, and  acupuncture without success. The chiropractor ordered lumbar magnetic resonance  imaging which revealed an aggressive sacral lesion and referred the patient to an  oncologist. The oncologist performed positron emission tomography/computed  tomography and biopsy, confirming a sacral giant cell tumor. A surgical team  recommended tumor resection, lumbosacral fusion, radiotherapy, and zoledronic  acid infusion. Sacral giant cell tumors are rare and may be challenging to  identify via routine radiography. These tumors are an important differential to  consider for patients with unexplained lumbosacral symptoms unresponsive to care.
C1 New York Chiropractic and Physiotherapy Centre, New York Medical Group, Kowloon, HKG.
   Chiropractic, Connor Whole Health, University Hospitals Cleveland Medical Center, Cleveland, USA.
   College of Chiropractic, Logan University, Chesterfield, USA.
   Radiology, Hong Kong Advanced Imaging, Kowloon, HKG.
   Medical Oncology, reVIVE Oncology and Cancer Centre, Mong Kok, HKG.
NR 0
TC 0
SN 2168-818
EI 2168-818
J9 Cureus
PD FEB 7
PY 2023
VL 15
IS 1
BP e33262
EP e33262
DI 10.7759/cureus.33262
PG 1
UT PubMed:36741639
PM 36741639
DA 2023-02-07
ER

PT J
AU Duc, Nguyen M
   Van, Tran T
   Vinh, Nguyen Q
   Doan, Ha C
   Vu, Phuong Dang L
AF Duc Nguyen, Minh
   Van Tran, Thanh
   Vinh Nguyen, Quoc
   Doan Ha, Cay
   Vu Phuong Dang, Linh
TI Effectiveness of bee venom acupuncture for patients suffering from periarthritis
SO Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan
LA English
DT Journal Article
DE bee venom acupuncture; inflammatory cytokines; periarthritis humeroscapularis; range of motion, articular; shoulder function score; visual analogue scale
AB OBJECTIVE: To evaluate the efficacy of bee venom acupuncture in humeroscapularis  (PHS) patients. METHODS: One hundred and twenty patients diagnosed with PHS were  assigned into four groups: BV1 (0.01 mg/kg), BV2 (0.005 mg/kg), BV3 (0.0025  mg/kg), and control group (vitamin B1 plus novocain 3% injection) with 15 d of  treatment. The outcomes of the study including visual analogue scale (VAS) score  and β-endorphin, inflammatory cytokines including interleukin-10 (IL-10), IL-1β  and tumor necrosis factor α (TNF-α) and shoulder function score were assessed at  baseline, after 10 and 15 d of treatment. RESULTS: All four groups reported  statistically significant improvement in VAS score, motion range, and shoulder  function score ( < 0.01), only the BV3 group showed significant increase of  anti-inflammatory (IL-10) and decrease of pro-inflammatory (IL-1β, TNF-α)  cytokines after treatment ( < 0.05). The BV3 group presented a significant  difference between all outcomes compared to the control and other groups.  CONCLUSION: BV3 groups showed better recovery including reduced pain, improved  motor function and normalized inflammatory cytokines than current therapy used in  Vietnam and other groups.
C1 Senior Specialist Clinic, National Hospital of Acupuncture, Hanoi 1000, Vietnam.
   Department of Senior Specialist National Hospital of Acupuncture, Hanoi 1000, Vietnam.
   Department of Senior Specialist, Military Institute of Traditional Medicine, Hanoi 1000, Vietnam.
   Department of minimally invasive spine, National Hospital of Acupuncture, Hanoi 1000, Vietnam.
   Department of Medicine, Dai Nam University, Hanoi 1000, Vietnam.
NR 0
TC 0
SN 2589-451
EI 0255-292
J9 J Tradit Chin Med
PD JUL 16
PY 2023
VL 43
IS 4
BP 795
EP 800
DI 10.19852/j.cnki.jtcm.2023.04.002
PG 5
WC Humans; Periarthritis; therapy; Interleukin-10; Tumor Necrosis Factor-alpha; Bee Venoms; therapeutic use; Acupuncture Therapy; Cytokines
UT PubMed:37454265
PM 37454265
DA 2023-07-16
ER

PT J
AU Li, QY
   Yang, WX
   Yao, LQ
   Chen, H
   Li, ZR
   Gong, YB
   Shi, J
AF Li, Quan-Yao
   Yang, Wen-Xiao
   Yao, Li-Qiu
   Chen, Hong
   Li, Zhen-Rui
   Gong, Ya-Bin
   Shi, Jun
TI Exploring the Rules of Related Parameters in Transcutaneous Electrical Nerve
SO Pain and therapy
LA English
DT Journal Article
DE Cancer; Cancer pain; Data mining; Parameters; Transcutaneous electrical nerve stimulation
AB INTRODUCTION: This study aims to investigate the regularity of related parameters  in the treatment of cancer pain using transcutaneous electrical nerve stimulation  (TENS). METHODS: A comprehensive literature search was conducted in databases  such as PubMed, Cochrane Library, Embase, Web of Science, OVID, CNKI, CBM, VIP,  and WANNGFANG from inception up to December 2022. A database was established, and  data mining techniques were applied to analyze the relevant TENS parameters.  RESULTS: A total of 27 articles were included, encompassing nine current  frequencies, four retention times, four treatment frequencies, and two wave  types. On the basis of the analysis of parameter association rules, the most  closely related parameter combination for clinical TENS in the treatment of  cancer pain was a current frequency of 2/100 Hz, a treatment frequency of once a  day, a retention time of 30 min, and the dilatational wave. Moreover, the study  involved 22 acupuncture points distributed along 13 meridians. According to the  analysis of acupuncture point association rules, Hegu (LI04), Zusanli (ST36), and  Sanyinjiao (SP06) were the most closely related acupuncture points and could be  used in combination for clinical TENS in cancer pain treatment. Furthermore,  cluster analysis was conducted on acupuncture points with a frequency ≥ 5,  resulting in three categories: the first category included Sanyinjiao (SP06),  Zusanli (ST36), Hegu (LI04), Jiaji point, and Neiguan (PC06); the second category  included Ashi point; and the third category included Back shu point. CONCLUSION:  In the treatment of cancer pain using TENS, it is recommended to use a current  frequency of 2/100 Hz, a treatment frequency of once a day, a retention time of  30 min, and the dilatational wave. The electrode positions were primarily  selected from Ashi point, Back shu point, Sanyinjiao (SP06), Zusanli (ST36), Hegu  (LI04), Jiaji point, and Neiguan (PC06) to achieve the best analgesic effect.
C1 Yueyang Hospital of Integrated Traditional Chinese and Western Medicine Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai,200437, China.
   Yueyang Hospital of Integrated Traditional Chinese and Western Medicine Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai,200437, China.
   Jing'an District Hospital of Traditional Chinese Medicine, Shanghai, 200072, China.
   Yueyang Hospital of Integrated Traditional Chinese and Western Medicine Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai,200437, China.
   Yueyang Hospital of Integrated Traditional Chinese and Western Medicine Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai,200437, China.
   Yueyang Hospital of Integrated Traditional Chinese and Western Medicine Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai,200437, China. gongyabin@hotmail.com.
   Yueyang Hospital of Integrated Traditional Chinese and Western Medicine Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai,200437, China. shijundoctor@163.com.
NR 0
TC 0
SN 2193-651
EI 2193-823
J9 Pain Ther
PD AUG 14
PY 2023
VL 12
IS 6
BP 1355
EP 1374
DI 10.1007/s40122-023-00549-3
PG 19
UT PubMed:37578681
PM 37578681
DA 2023-08-14
ER

PT J
AU Tang, J
   Wu, P
   Yu, ZY
   Wang, X
   Tao, SY
   Jiang, NN
   Chen, GH
   Shuai, RX
AF Tang, Jie
   Wu, Ping
   Yu, Ze-Yun
   Wang, Xue
   Tao, Si-Yu
   Jiang, Nan-Nan
   Chen, Guan-Hua
   Shuai, Rou-Xian
TI [Regulatory effect of moxibustion on LTB4/MMP-9 in serum of patients with
SO Zhen ci yan jiu = Acupuncture research
LA chi
DT Journal Article
DE Interleukin -17; Leukotriene B4; Matrix metalloproteinase-9; Moxibustion; Rheumatoid arthritis; Tumor necrosis factor-α
AB OBJECTIVE: To observe the effects of moxibustion on the contents of leukotriene  B4 (LTB4), interleukin-17 (IL-17), tumor necrosis factor-α (TNF-α) and matrix  metalloproteinase -9 (MMP-9) in serum, and explore the protection mechanisms of  moxibustion in the patients with rheumatoid arthritis (RA). METHODS: A total of  64 patients with RA were randomly divided into treatment group (n=31) and control  group (n=33). The patients in the control group were treated with conventional  medication for consecutive 5 weeks. Based on the treatment in the control group,  the patients in the treatment group were treated with moxibustion at bilateral  Shenshu (BL23), Zusanli (ST36) and Ashi points, 3 times a week, for consecutive 5  weeks. Separately, the visual analogue scale (VAS) score, morning stiffness  score, the number of tender joints, the number of swollen joints, the score of  the disease activity score of 28 joints (DAS28) were observed; the contents of  rheumatoid factor (RF), erythrocyte sedimentation rate (ESR) and C-reative  protein (CRP) in serum were determined by biochemical method; and the contents of  LTB4, IL-17, TNF-α and MMP-9 in serum were detected by using ELISA before and  after treatment in the patients of both groups. RESULTS: After treatment, VAS  score, morning stiffness score, the number of tender joints, the number of  swollen joints, DAS28 score, the contents of serum RF in both groups, and  contents of serum CRP, ESR, LTB4, IL-17, TNF-α and MMP-9 in the treatment group  were significantly reduced when compared with those before treatment (P<0.01,  P<0.05). After treatment, VAS score, morning stiffness score, the number of  tender joints, the number of swollen joints, DAS28 score, and the levels of LTB4,  IL-17 and MMP-9 in serum were obviously lower in the treatment group when  compared with the control group (P<0.01, P<0.05). In the treatment group, the  changes before and after treatment in the levels of LTB4, IL-17 and TNF-α were  positively correlated with that of MMP-9 (P<0.05, r>0). CONCLUSION: Moxibustion  at BL23 and ST36 combined with conventional medication significantly relieves  joint pain and reduce disease activity in RA patients, which may be related to  the modulation of LTB4, IL-17 and MMP-9 by moxibustion.
C1 College of Acupuncture-Moxibustion and Tuina, Chengdu University of Traditional Chinese Medicine, Chengdu 610075, China.
   College of Acupuncture-Moxibustion and Tuina, Chengdu University of Traditional Chinese Medicine, Chengdu 610075, China.
   The First People's Hospital of Yibin City, Yibin 644099, Sichuan Province.
   College of Acupuncture-Moxibustion and Tuina, Chengdu University of Traditional Chinese Medicine, Chengdu 610075, China.
   College of Acupuncture-Moxibustion and Tuina, Chengdu University of Traditional Chinese Medicine, Chengdu 610075, China.
   College of Acupuncture-Moxibustion and Tuina, Chengdu University of Traditional Chinese Medicine, Chengdu 610075, China.
   College of Acupuncture-Moxibustion and Tuina, Chengdu University of Traditional Chinese Medicine, Chengdu 610075, China.
   1College of Acupuncture-Moxibustion and Tuina, Chengdu University of Traditional Chinese Medicine, Chengdu 610075, China
   2The First People's Hospital of YibinCity, Yibin 644099, Sichuan Province.
NR 0
TC 0
SN 
EI 1000-060
J9 Zhen Ci Yan Jiu
PD MAY 30
PY 2023
VL 48
IS 5
BP 488
EP 93
DI 10.13702/j.1000-0607.20220088
PG -395
WC Humans; Leukotriene B4; Moxibustion; Interleukin-17; genetics; Tumor Necrosis Factor-alpha; genetics; Matrix Metalloproteinase 9; genetics; Arthritis, Rheumatoid; genetics
UT PubMed:37247863
PM 37247863
DA 2023-05-30
ER

PT J
AU Li, Y
   Hong, E
   Ye, WG
   You, JY
AF Li, Yan
   Hong, Ensi
   Ye, Wenguo
   You, Jianyu
TI Moxibustion as an Adjuvant Therapy for Cancer Pain: A Systematic Review and Meta-Analysis
SO JOURNAL OF PAIN RESEARCH
LA English
DT Review
DE moxibustion; cancer pain; systematic review; meta-analysis
ID inflammatory visceral pain; pharmacological management; survivors
AB Purpose: Pain is one of the most common and feared symptoms among cancer patients. Unrelieved pain denies patients comfort and greatly affects their overall quality of life. Moxibustion is commonly used to manage chronic pain. However, its efficacy on cancer pain remains inconclusive. This study aimed to evaluate the efficacy of moxibustion for cancer pain.Methods: We searched seven databases to obtain articles about moxibustion combined with pharmacotherapy for cancer pain published before November 2022. All data extraction was carried out independently by two investigators. RevMan 5.4 software was used for data analysis.Results: A total of ten trials involving 999 cases were included. The results of the meta-analysis revealed that moxibustion combined with pharmacotherapy was significantly better than drug therapy alone in improving pain relief rate (RR =1.16, 95% CI = [1.04, 1.30], P = 0.01), reducing pain scores (SMD = -1.43, 95% CI = [-2.09, -0.77], P < 0.0001), Shortening the onset of analgesia (MD = -12.07, 95% CI = [-12.91, -11.22], P < 0.00001), prolonging the duration of analgesia (MD = 3.69, 95% CI = [3.21, 4.18], P < 0.00001), and improving quality of life (SMD = 2.48, 95% CI = [0.67, 4.29], P = 0.007). In addition, moxibustion combined with pharmacotherapy can effectively reduce adverse reactions of drugs (RR =0.35, 95% CI = [0.21, 0.57], P < 0.0001).Conclusion: The evidence in this review supports moxibustion as an effective adjuvant therapy for cancer pain management. However, high-quality RCTs are needed to further confirm these findings. Registration Number: PROSPERO CRD42022370942.
C1 [Li, Yan; Hong, Ensi; You, Jianyu] Jiangxi Univ Chinese Med, Nanchang, Peoples R China.
   [Hong, Ensi; Ye, Wenguo] Jiangxi Univ Chinese Med, Affiliated Hosp, Nanchang, Peoples R China.
   [Ye, Wenguo] Jiangxi Univ Chinese Med, Affiliated Hosp, Nanchang, Jiangxi, Peoples R China.
   [You, Jianyu] Jiangxi Univ Chinese Med, Nanchang, Jiangxi, Peoples R China.
C3 Jiangxi University of Traditional Chinese Medicine; Jiangxi University of Traditional Chinese Medicine; Jiangxi University of Traditional Chinese Medicine; Jiangxi University of Traditional Chinese Medicine
RP Ye, WG (corresponding author), Jiangxi Univ Chinese Med, Affiliated Hosp, Nanchang, Jiangxi, Peoples R China.; You, JY (corresponding author), Jiangxi Univ Chinese Med, Nanchang, Jiangxi, Peoples R China.
EM 648957697@qq.com; youjytcm@163.com
FU National Administration of Traditional Chinese Medicine Cultivation Discipline Construction -Science of Acupuncture [1241800102]
CR Bao GA, 2019, J ACUPUNCT TUINA SCI, V17, P416, DOI 10.1007/s11726-019-1144-5
   Bing L, 2020, J SHANDONG U TRADITI, V44, P539, DOI 10.16294/j.cnki.1007-659x.2020.05.017
   Brown MRD, 2014, BRIT J PAIN, V8, P139, DOI 10.1177/2049463714542605
   Chen FQ, 2020, COMPLEMENT THER CLIN, V39, P0, DOI 10.1016/j.ctcp.2020.101130
   Chen J, 2020, SHAANXI TRADITIONAL CHINESE MEDICINE, V41, P105
   Cherny N, 2001, J CLIN ONCOL, V19, P2542, DOI 10.1200/JCO.2001.19.9.2542
   Choi TY, 2017, MATURITAS, V100, P33, DOI 10.1016/j.maturitas.2017.03.314
   Deng G, 2019, CANCER J, V25, P343, DOI 10.1097/PPO.0000000000000399
   Deng HY, 2013, EVID-BASED COMPL ALT, V2013, P0, DOI 10.1155/2013/379291
   Dong B, 2021, BMC COMPLEMENT MED, V21, P0, DOI 10.1186/s12906-020-03193-y
   Elliott J, 2011, BRIT J CANCER, V105, PS11, DOI 10.1038/bjc.2011.418
   Gutgsell Terence, 2003, AM J HOSP PALLIAT CARE, V20, P140, DOI 10.1177/104990910302000213
   Han K, 2021, CANCER MED-US, V10, P4721, DOI 10.1002/cam4.4020
   He YH, 2020, JAMA ONCOL, V6, P271, DOI 10.1001/jamaoncol.2019.5233
   Higgins JPT, 2011, BMJ-BRIT MED J, V343, P0, DOI 10.1136/bmj.d5928
   Hu D, 2021, J CELL MOL MED, V25, P2900, DOI 10.3233/jifs-202844
   Hu JJ, 2020, ANN PALLIAT MED, V9, P709, DOI 10.21037/apm.2020.02.31
   Huang QT, 2014, GUANGXI TRADIT CHIN MED, V37, P37
   Huang RN, 2020, EVID-BASED COMPL ALT, V2020, P0, DOI 10.1155/2020/5816717
   Huang Xian-Bao, 2020, ZHONGGUO ZHEN JIU, V40, P79, DOI 10.13703/j.0255-2930.20190701-k0003
   Huang Y, 2019, J PAIN RES, V12, P2999, DOI 10.2147/JPR.S218588
   Huang ZL, 2017, EVID-BASED COMPL ALT, V2017, P0, DOI 10.1155/2017/9854893
   Ji YJ, 2021, EVID-BASED COMPL ALT, V2021, P0, DOI 10.1155/2021/1347342
   Jiang Jin-Feng, 2013, ZHONGGUO ZHEN JIU, V33, P860
   Kim SY, 2011, EVID-BASED COMPL ALT, V2011, P0, DOI 10.1093/ecam/nep163
   Kwon JH, 2014, J CLIN ONCOL, V32, P1727, DOI 10.1200/JCO.2013.52.4827
   Lee J, 2014, INTEGR CANCER THER, V13, P211, DOI 10.1177/1534735413510025
   Lee MS, 2010, AM J CHINESE MED, V38, P829, DOI 10.1142/S0192415X10008275
   Li DH, 2021, EVID-BASED COMPL ALT, V2021, P0, DOI 10.1155/2021/5558590
   Li L, 2016, TRADIT CHIN MED RES, V29, P48, DOI 10.3969/j.issn.1001-6910.2016.09.23
   Li Y, 2020, PHOTOBIOMOD PHOTOMED, V38, P237, DOI 10.1089/photob.2019.4744
   Li ZY, 2017, WORLD J GASTROENTERO, V23, P6220, DOI 10.3748/wjg.v23.i34.6220
   Liu L, 2020, SHANG J ACUPUNCT, V39, P692
   Lv L, 2021, RES INTEGR CHIN WEST MED, V13, P284
   Mayer DK, 2011, J CLIN ONCOL, V29, P2683, DOI 10.1200/JCO.2010.34.2816
   Neufeld NJ, 2017, FUTURE ONCOL, V13, P833, DOI 10.2217/fon-2016-0423
   Ngamkham S, 2019, ASIA-PAC J ONCOL NUR, V6, P161, DOI 10.4103/apjon.apjon_67_18
   Paice JA, 2018, CANCER-AM CANCER SOC, V124, P2491, DOI 10.1002/cncr.31303
   Paice JA, 2016, J CLIN ONCOL, V34, P3325, DOI 10.1200/JCO.2016.68.5206
   Pang WSN, 2019, EFFECTIVENESS MOXIBU, V0, P0
   Prommer EE, 2015, CANCER CONTROL, V22, P412, DOI 10.1177/107327481502200407
   Pujol LAM, 2007, J AM OSTEOPATH ASSOC, V107, P0
   STJERNSWARD J, 1988, CANCER SURV, V7, P195
   Swarm RA, 2019, J NATL COMPR CANC NE, V17, P977, DOI 10.6004/jnccn.2019.0038
   Wang LD, 2016, EVID-BASED COMPL ALT, V2016, P0, DOI 10.1155/2016/3174608
   Wang YN, 2021, EVID-BASED COMPL ALT, V2021, P0, DOI 10.1155/2021/6637554
   Wood H, 2018, CLIN MED, V18, P17, DOI 10.7861/clinmedicine.18-1-17
   Xu J, 2014, EVID-BASED COMPL ALT, V2014, P0, DOI 10.1155/2014/783704
   Xu P, 2021, JAMA-J AM MED ASSOC, V18, P2875, DOI 10.3969/j.issn.1672-9455.2021.19.025
   Yao Y, 2022, EVID-BASED COMPL ALT, V2022, P0, DOI 10.1155/2022/6114417
   Zhang CS, 2021, LIFE SCI, V280, P0, DOI 10.1016/j.lfs.2021.119699
   Zhang HW, 2018, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD010559.pub2
   Zhong YM, 2020, EVID-BASED COMPL ALT, V2020, P0, DOI 10.1155/2020/6108619
   Zou M, 2017, JAMA-J AM MED ASSOC, V30, P171
NR 54
TC 11
Z9 12
U1 2
U2 23
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1178-7090
EI 
J9 J PAIN RES
JI J. Pain Res.
PD JUN 15
PY 2023
VL 16
IS 
BP 515
EP 525
DI 10.2147/JPR.S396696
PG 11
WC Clinical Neurology
SC Neurosciences & Neurology
GA 9C1JC
UT WOS:000935181100001
PM 36824500
DA 2026-01-16
ER

PT J
AU Ben-Arye, E
   Hirsh, I
   Segev, Y
   Grach, M
   Master, V
   Eden, A
   Samuels, N
   Stein, N
   Gressel, O
   Ostrovsky, L
   Galil, G
   Schmidt, M
   Schiff, E
   Lavie, O
AF Ben-Arye, Eran
   Hirsh, Irena
   Segev, Yakir
   Grach, Michael
   Master, Viraj
   Eden, Arie
   Samuels, Noah
   Stein, Nili
   Gressel, Orit
   Ostrovsky, Ludmila
   Galil, Galit
   Schmidt, Meirav
   Schiff, Elad
   Lavie, Ofer
TI A randomized-controlled trial assessing the effect of intraoperative acupuncture on anesthesia-related parameters during gynecological oncology surgery
SO JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
LA English
DT Article
DE Integrative oncology; Gynecological oncology; Acupuncture; Pain; Intraoperative; Integrative medicine
ID heart-rate-variability; integrative medicine; nociception level; stimulation; cancer; efficacy
AB Context and objectivesThe present study examined the impact of intraoperative acupuncture on anesthesia-related parameters in patients undergoing gynecological oncology surgery.MethodsParticipants underwent preoperative integrative oncology (IO) touch/relaxation treatments, followed by intraoperative acupuncture (Group A); preoperative IO treatments without acupuncture (Group B); or standard care only (Group C). Mean arterial pressure (MAP), heart rate (HR), MAP variability (mean of MAP standard deviation), bispectral index (BIS), and calculated blood pressure Average Real Variability (ARV) were measured intraoperatively.ResultsA total of 91 patients participated: Group A, 41; Group B, 24; Group C, 26. Among patients undergoing open laparotomy, Group A showed lower and more stable MAP and HR compared to Group B, (MAP, p = 0.026; HR, p = 0.029) and Group C (MAP, p = 0.025). Mean BIS, from incision to suture closing, was lower in Group A (vs. controls, p = 0.024). In patients undergoing laparoscopic surgery, MAP was elevated within Group A (p = 0.026) throughout surgery, with MAP variability significantly higher in Group A (P = 0.023) and Group B (P = 0.013) 10 min post-incision (vs. pre-incision). All groups showed similar intraoperative and post-anesthesia use of analgesic medication.ConclusionIntraoperative acupuncture was shown to reduce and stabilize MAP and HR, and reduce BIS in gynecology oncology patients undergoing laparotomy, with no impact on perioperative analgesic medication use. In the laparoscopic setting, intraoperative acupuncture was associated with elevated MAP. Further research is needed to explore the hemodynamic and BIS-associated benefits and risks of intraoperative acupuncture, and the impact on the use of analgesic drugs in response to these changes.
C1 [Ben-Arye, Eran; Gressel, Orit; Galil, Galit] Clalit Hlth Serv, Lin Med Ctr, Oncol Serv, Integrat Oncol Program, 35 Rothschild St, Haifa, Israel.
   [Ben-Arye, Eran; Gressel, Orit; Galil, Galit] Clalit Hlth Serv, Zebulun Med Ctr, Oncol Serv, Integrat Oncol Program, 35 Rothschild St, Haifa, Israel.
   [Ben-Arye, Eran; Gressel, Orit; Galil, Galit] Clalit Hlth Serv, Carmel Med Ctr, Oncol Serv, Integrat Oncol Program, 35 Rothschild St, Haifa, Israel.
   [Ben-Arye, Eran; Segev, Yakir; Gressel, Orit; Schiff, Elad; Lavie, Ofer] Technion Israel Inst Technol, Rappaport Fac Med, Haifa, Israel.
   [Hirsh, Irena; Grach, Michael; Eden, Arie; Schmidt, Meirav] Carmel Hosp, Dept Anesthesiol Crit Care & Pain Med, Haifa, Israel.
   [Segev, Yakir; Ostrovsky, Ludmila; Lavie, Ofer] Carmel Hosp, Dept Obstet & Gynecol, Haifa, Israel.
   [Master, Viraj] Emory Univ, Dept Urol, Atlanta, GA 30322 USA.
   [Master, Viraj] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA.
   [Samuels, Noah] Hebrew Univ Jerusalem, Shaarei Zedek Med Ctr, Fac Med, Ctr Integrat Complementary Med, Jerusalem, Israel.
   [Stein, Nili] Carmel Hosp, Dept Community Med & Epidemiol, Haifa, Israel.
   [Schiff, Elad] Bnai Zion Hosp, Dept Internal Med, Haifa, Israel.
   [Schiff, Elad] Bnai Zion Hosp, Integrat Med Serv, Haifa, Israel.
C3 Clalit Health Services; Clalit Health Services; Clalit Health Services; Carmel Medical Center; Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Clalit Health Services; Carmel Medical Center; Clalit Health Services; Carmel Medical Center; Emory University; Emory University; Hebrew University of Jerusalem; Shaare Zedek Medical Center; Clalit Health Services; Carmel Medical Center; Bnai Zion Medical Center; Bnai Zion Medical Center
RP Ben-Arye, E (corresponding author), Clalit Hlth Serv, Lin Med Ctr, Oncol Serv, Integrat Oncol Program, 35 Rothschild St, Haifa, Israel.; Ben-Arye, E (corresponding author), Clalit Hlth Serv, Zebulun Med Ctr, Oncol Serv, Integrat Oncol Program, 35 Rothschild St, Haifa, Israel.; Ben-Arye, E (corresponding author), Clalit Hlth Serv, Carmel Med Ctr, Oncol Serv, Integrat Oncol Program, 35 Rothschild St, Haifa, Israel.; Ben-Arye, E (corresponding author), Technion Israel Inst Technol, Rappaport Fac Med, Haifa, Israel.
EM eranben@netvision.net.il
CR Acar HV, 2013, J ALTERN COMPLEM MED, V19, P420, DOI 10.1089/acm.2012.0494
   Baldawi M, 2022, J INTEGR COMPLEMENT, V28, P683, DOI 10.1089/jicm.2021.0429
   Ben-Arye E, 2023, CANCER-AM CANCER SOC, V129, P908, DOI 10.1002/cncr.34542
   Ben-Arye E, 2022, SUPPORT CARE CANCER, V30, P4345, DOI 10.1007/s00520-022-06865-2
   Ben-Arye E, 2021, J CANCER RES CLIN, V147, P2361, DOI 10.1007/s00432-020-03506-1
   Ben-Arye E, 2016, SUPPORT CARE CANCER, V24, P1457, DOI 10.1007/s00520-016-3093-6
   Ben-Arye E, 2013, MED ONCOL, V30, P0, DOI 10.1007/s12032-013-0511-1
   Ben-Arye E, 2012, PATIENT EDUC COUNS, V89, P423, DOI 10.1016/j.pec.2012.02.011
   Ben-Israel N, 2013, J CLIN MONIT COMPUT, V27, P659, DOI 10.1007/s10877-013-9487-9
   Chen JH, 2020, THORAC CANCER, V11, P928, DOI 10.1111/1759-7714.13343
   Cheng Xiang, 2010, ZHONGGUO ZHEN JIU, V30, P305
   Chung JWY, 2014, EVID-BASED COMPL ALT, V2014, P0, DOI 10.1155/2014/819871
   Coulombe MA, 2021, EUR J ANAESTH, V38, P512, DOI 10.1097/EJA.0000000000001431
   Edry R, 2016, ANESTHESIOLOGY, V125, P193, DOI 10.1097/ALN.0000000000001130
   Faiz Seyed Hamid Reza, 2019, ANESTH PAIN MED, V9, Pe96172, DOI 10.5812/aapm.96172
   Hamvas Sz, 2023, COMPLEMENT THER MED, V72, P102905, DOI 10.1016/j.ctim.2022.102905
   Liu X, 2015, ACUPUNCT MED, V33, P270, DOI 10.1136/acupmed-2014-010749
   Mao JJ, 2022, J CLIN ONCOL, V40, P3998, DOI 10.1200/JCO.22.01357
   Mascha EJ, 2015, ANESTHESIOLOGY, V123, P79, DOI 10.1097/ALN.0000000000000686
   Paraskeva A, 2004, AM J CHINESE MED, V32, P789, DOI 10.1142/S0192415X04002363
   Petersen RW, 2002, BJOG-INT J OBSTET GY, V109, P386, DOI 10.1016/S1470-0328(02)01271-5
   Rahimi M, 2019, MED ACUPUNCT, V31, P123, DOI 10.1089/acu.2018.1330
   Rithirangsriroj K, 2015, GYNECOL ONCOL, V136, P82, DOI 10.1016/j.ygyno.2014.10.025
   Sato N, 2000, SURG ENDOSC, V14, P362, DOI 10.1007/s004640000155
   Segev Y, 2021, SUPPORT CARE CANCER, V29, P4055, DOI 10.1007/s00520-020-05961-5
   Shahiri TS, 2022, J CLIN MONIT COMPUT, V36, P623, DOI 10.1007/s10877-021-00772-3
   Shalom-Sharabi I, 2017, J CANCER RES CLIN, V143, P2535, DOI 10.1007/s00432-017-2509-0
   Sharp DM, 2010, EUR J CANCER, V46, P312, DOI 10.1016/j.ejca.2009.10.006
   Stener-Victorin E, 2005, REPROD BIOL ENDOCRIN, V3, P0, DOI 10.1186/1477-7827-3-44
   Stomberg M W, 2001, AANA J, V69, P218
   Vagedes J, 2023, PSYCHOSOM MED, V85, P53, DOI 10.1097/PSY.0000000000001153
   Wang H, 2014, BRIT J ANAESTH, V112, P1075, DOI 10.1093/bja/aeu001
   Witt Claudia M, 2017, JOURNAL OF THE NATIONAL CANCER INSTITUTE MONOGRAPHS, V0, PP3, DOI 10.1093/jncimonographs/lgx012
   Yu JB, 2014, MED SCI MONITOR, V20, P406, DOI 10.12659/MSM.890111
   Zanatta P, 2011, CLIN NEUROPHYSIOL, V122, P2093, DOI 10.1016/j.clinph.2011.03.017
NR 35
TC 6
Z9 7
U1 0
U2 5
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0171-5216
EI 1432-1335
J9 J CANCER RES CLIN
JI J. Cancer Res. Clin. Oncol.
PD SEP 15
PY 2023
VL 149
IS 11
BP 8177
EP 8189
DI 10.1007/s00432-023-04758-3
EA APR 2023
PG 13
WC Oncology
SC Oncology
GA M9VT4
UT WOS:000983706700003
PM 37061627
DA 2026-01-16
ER

PT J
AU Okifuji, A
AF Okifuji, Akiko
TI Editorial: Insights in cancer pain: 2022.
SO Frontiers in pain research (Lausanne, Switzerland)
LA English
DT Editorial
DE acupuncture; bone cancer; breakthrough pain; cancer pain; chemotherapy-induced neuropathic pain
C1 Department of Anesthesiology, School of Medicine, The University of Utah, Salt Lake City, UT, United States.
NR 0
TC 0
SN 2673-561
EI 2673-561
J9 Front Pain Res (Lausanne)
PD JUL 31
PY 2023
VL 4
IS 
BP 1236538
EP 1236538
DI 10.3389/fpain.2023.1236538
PG 0
UT PubMed:37521942
PM 37521942
DA 2023-07-31
ER

PT J
AU Zhou, M
   Pang, F
   Liao, DM
   He, XL
   Yang, YH
   Tang, CL
AF Zhou, Min
   Pang, Fang
   Liao, Dongmei
   He, Xinlu
   Yang, Yunhao
   Tang, Chenglin
TI Electroacupuncture at Fengchi(GB20) and Yanglingquan(GB34) Ameliorates Paralgesia through Microglia-Mediated Neuroinflammation in a Rat Model of Migraine
SO BRAIN SCIENCES
LA English
DT Article
DE migraine; electroacupuncture; paralgesia; microglia; inflammatory response
ID central sensitization; trigeminovascular pathway; inflammatory factors; signaling pathway; pain; hypersensitivity; stimulation; contributes; modulation; allodynia
AB Background: Multiple studies have suggested that paralgesia (hyperalgesia and cutaneous allodynia) in migraine reflects the activation and sensitisation of the trigeminovascular system (TGVS). In particular, it reflects the second-order and higher nerve centre sensitisation, which is caused and maintained by neuroinflammation. Microglia activation leads to the release of proinflammatory cytokines involved in inflammatory responses. Accumulating evidence indicates that electroacupuncture (EA) is effective in ameliorating paralgesia, but the underlying mechanisms of EA in migraine attacks caused by microglia and microglia-mediated inflammatory responses are still unclear. The purpose of this study was to explore whether EA could ameliorate the dysregulation of pain sensation by suppressing microglial activation and the resulting neuroinflammatory response, and to evaluate whether this response was regulated by Toll-like receptor 4 (TLR4)/nuclear factor-kappa B(NF-kappa B) in the trigeminal nucleus caudalis (TNC) in a rat model of migraine. Methods: Repeated Inflammatory Soup (IS) was infused into the dura for seven sessions to establish a recurrent migraine-like rat model, and EA treatment was administered at Fengchi (GB20) and Yanglingquan (GB34) after daily IS infusion. Facial mechanical withdrawal thresholds were measured to evaluate the change in pain perception, and plasma samples and the TNC tissues of rats were collected to examine the changes in calcitonin gene-related peptide (CGRP), the Ibal-1-labelled microglial activation, and the resulting inflammatory response, including interleukin-1 beta (IL-1 beta), tumour necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), and their regulatory molecules TLR4/NF-kappa B, via enzyme-linked immunosorbent assay (ELISA), real-time polymerase chain reaction (RT-PCR), immunohistochemistry (IHC) and Western blot analysis. Results: Repeated IS injections into the dura induced facial mechanical paralgesia, which is the manifestation of migraine attacks, and increased the expression of CGRP, Ibal-1, microglial mediated inflammatory cytokines (IL-1 beta, TNF-alpha, IL-6), and regulatory molecules TLR4/NF-kappa B. EA at GB20/34 significantly attenuated repetitive IS-induced pain hypersensitivity. This effect was consistent with decreased levels of CGRP and inflammatory cytokines in the plasma and the TNC via the inhibition of microglia activation, and this response may be regulated by TLR4/NF-kappa B. Conclusions: EA ameliorated paralgesia in repetitive IS-induced migraine-like rats, which was mainly mediated by a reduction in microglial activation and microglial-mediated inflammatory responses that could be regulated by TLR4/NF-kappa B.
C1 [Zhou, Min; Pang, Fang; Liao, Dongmei; He, Xinlu; Yang, Yunhao; Tang, Chenglin] Chongqing Med Univ, Coll Tradit Chinese Med, Chongqing 400016, Peoples R China.
   [Zhou, Min; Pang, Fang; Liao, Dongmei; He, Xinlu; Yang, Yunhao; Tang, Chenglin] Chongqing Key Lab Tradit Chinese Med Prevent & Cur, Chongqing 400016, Peoples R China.
C3 Chongqing Medical University
RP Tang, CL (corresponding author), Chongqing Med Univ, Coll Tradit Chinese Med, Chongqing 400016, Peoples R China.; Tang, CL (corresponding author), Chongqing Key Lab Tradit Chinese Med Prevent & Cur, Chongqing 400016, Peoples R China.
EM tangchenglin@cqmu.edu.cn
FU Key Discipline Construction Project of Acupuncture Moxibustion and Massage of Chongqing Health Commission [472020320220021]; College of Traditional Chinese Medicine of Chongqing Medical University [2021-ZDXK-D04]; Joint Project of Chongqing Health and Family Planning Commission and Science and Technology Commission [ZY201801007]; Chongqing Yuzhong District Science and Technology Plan Project [20200116]
CR Agalave NM, 2014, PAIN, V155, P1802, DOI 10.1016/j.pain.2014.06.007
   Al-Hassany L, 2022, LANCET NEUROL, V21, P284, DOI 10.1016/S1474-4422(21)00409-9
   Bernstein C, 2012, J CLIN NEUROL, V8, P89
   Bishop J, 2019, PAIN, V160, P2161, DOI 10.1097/j.pain.0000000000001583
   Boyer N, 2017, PAIN, V158, P2025, DOI 10.1097/j.pain.0000000000001007
   Boyer N, 2014, PAIN, V155, P1196, DOI 10.1016/j.pain.2014.03.001
   Bryant CE, 2010, NAT REV MICROBIOL, V8, P8, DOI 10.1038/nrmicro2266
   Burstein R, 1998, J NEUROPHYSIOL, V79, P964, DOI 10.1152/jn.1998.79.2.964
   Buse DC, 2019, HEADACHE, V59, P306, DOI 10.1111/head.13459
   CHAPLAN SR, 1994, J NEUROSCI METH, V53, P55, DOI 10.1016/0165-0270(94)90144-9
   Charles A, 2019, LANCET, V394, P1765, DOI 10.1016/S0140-6736(19)32504-8
   Charles A, 2018, LANCET NEUROL, V17, P174, DOI 10.1016/S1474-4422(17)30435-0
   Chen G, 2018, NEURON, V100, P1292, DOI 10.1016/j.neuron.2018.11.009
   Chen ZY, 2015, EUR J PAIN, V19, P176, DOI 10.1002/ejp.534
   Echeverry S, 2017, PAIN, V158, P1792, DOI 10.1097/j.pain.0000000000000982
   Edvinsson L, 2019, NAT REV NEUROL, V15, P483, DOI 10.1038/s41582-019-0216-y
   Erdener SE, 2021, J HEADACHE PAIN, V22, P0, DOI 10.1186/s10194-021-01353-0
   Fried NT, 2018, CEPHALALGIA, V38, P674, DOI 10.1177/0333102417703764
   GILMORE SA, 1975, ANAT REC, V181, P799, DOI 10.1002/ar.1091810411
   Gong QY, 2020, NEUROSCIENCE, V451, P207, DOI 10.1016/j.neuroscience.2020.10.019
   Han X, 2017, MOL PAIN, V13, P0, DOI 10.1177/1744806917720361
   He W, 2019, J NEUROINFLAMM, V16, P0, DOI 10.1186/s12974-019-1459-7
   Irmak DK, 2019, FRONT CELL NEUROSCI, V13, P0, DOI 10.3389/fncel.2019.00136
   Jack CS, 2005, J IMMUNOL, V175, P4320, DOI 10.4049/jimmunol.175.7.4320
   Ji RR, 2018, ANESTHESIOLOGY, V129, P343, DOI 10.1097/ALN.0000000000002130
   Kawasaki Y, 2008, J NEUROSCI, V28, P5189, DOI 10.1523/JNEUROSCI.3338-07.2008
   Lai HC, 2019, EVID-BASED COMPL ALT, V2019, P0, DOI 10.1155/2019/6173412
   Latremoliere A, 2009, J PAIN, V10, P895, DOI 10.1016/j.jpain.2009.06.012
   Lin JJ, 2015, SCI REP-UK, V5, P0, DOI 10.1038/srep12549
   Liu CY, 2018, MOL PAIN, V14, P0, DOI 10.1177/1744806918795930
   Liu L, 2021, FRONT NEUROSCI-SWITZ, V15, P0, DOI 10.3389/fnins.2021.668616
   Liu L, 2016, EVID-BASED COMPL ALT, V2016, P0, DOI 10.1155/2016/1846296
   Liu SB, 2021, NATURE, V598, P641, DOI 10.1038/s41586-021-04001-4
   Liu SB, 2020, NEURON, V108, P436, DOI 10.1016/j.neuron.2020.07.015
   Long T, 2020, J HEADACHE PAIN, V21, P0, DOI 10.1186/s10194-019-1070-4
   Long T, 2018, J NEUROINFLAMM, V15, P0, DOI 10.1186/s12974-018-1285-3
   Louter MA, 2013, BRAIN, V136, P3489, DOI 10.1093/brain/awt251
   MaassenVandenBrink A, 2018, GENOME MED, V10, P0, DOI 10.1186/s13073-018-0524-7
   Malhotra R, 2016, ANN INDIAN ACAD NEUR, V19, P175, DOI 10.4103/0972-2327.182302
   Martami F, 2018, NEUROL SCI, V39, P1741, DOI 10.1007/s10072-018-3493-0
   McDonald JL, 2015, EVID-BASED COMPL ALT, V2015, P0, DOI 10.1155/2015/975632
   Melo-Carrillo A, 2013, CEPHALALGIA, V33, P1096, DOI 10.1177/0333102413486320
   Noseda R, 2013, PAIN, V154, PS44, DOI 10.1016/j.pain.2013.07.021
   Oliveira AB, 2017, J NEUROIMMUNOL, V313, P138, DOI 10.1016/j.jneuroim.2017.09.008
   Oshinsky ML, 2007, HEADACHE, V47, P1026, DOI 10.1111/j.1526-4610.2007.00871.x
   Pei P, 2019, ACUPUNCT MED, V37, P47, DOI 10.1136/acupmed-2017-011410
   Pei P, 2016, ACUPUNCT MED, V34, P127, DOI 10.1136/acupmed-2015-010840
   Qu ZY, 2020, J PAIN RES, V13, P25, DOI 10.2147/JPR.S226922
   Rahimifard M, 2017, AGEING RES REV, V36, P11, DOI 10.1016/j.arr.2017.02.004
   Riesco N, 2017, CURR PAIN HEADACHE R, V21, P0, DOI 10.1007/s11916-017-0618-8
   Rinne M, 2020, EUR J PHARM SCI, V154, P0, DOI 10.1016/j.ejps.2020.105493
   Rua R, 2018, TRENDS MOL MED, V24, P542, DOI 10.1016/j.molmed.2018.04.003
   Russo AF, 2015, ANNU REV PHARMACOL, V55, P533, DOI 10.1146/annurev-pharmtox-010814-124701
   Strassman AM, 1996, NATURE, V384, P560, DOI 10.1038/384560a0
   Su M, 2018, MOL PAIN, V14, P0, DOI 10.1177/1744806918754612
   Su M, 2016, EUR J NEUROSCI, V44, P2129, DOI 10.1111/ejn.13296
   VOS BP, 1994, J NEUROSCI, V14, P2708
   Wang FZ, 2015, NEUROL SCI, V36, P535, DOI 10.1007/s10072-014-2010-3
   Wang L, 2020, OXID MED CELL LONGEV, V2020, P0, DOI 10.1155/2020/8253904
   Wang Y, 2018, CELL PHYSIOL BIOCHEM, V46, P568, DOI 10.1159/000488624
   Wieseler J, 2017, BRAIN RES, V1664, P87, DOI 10.1016/j.brainres.2017.03.011
   Woolf CJ, 2000, SCIENCE, V288, P1765, DOI 10.1126/science.288.5472.1765
   Wu BX, 2017, J MOL NEUROSCI, V63, P131, DOI 10.1007/s12031-017-0960-7
   Xie LS, 2021, FRONT NEUROSCI-SWITZ, V15, P0, DOI 10.3389/fnins.2021.689629
   Xie LS, 2020, AGING-US, V12, P22538, DOI 10.18632/aging.103663
   Xu XB, 2019, EVID-BASED COMPL ALT, V2019, P0, DOI 10.1155/2019/9512875
   Zhang JW, 2019, MOL IMMUNOL, V116, P29, DOI 10.1016/j.molimm.2019.09.020
   Zhang NS, 2020, HEADACHE, V60, P309, DOI 10.1111/head.13723
   Zhao L, 2017, JAMA INTERN MED, V177, P508, DOI 10.1001/jamainternmed.2016.9378
   Zhao LP, 2020, J PAIN RES, V13, P75, DOI 10.2147/JPR.S225431
   Zhu HT, 2014, J NEUROINFLAMM, V11, P0, DOI 10.1186/1742-2094-11-59
   ZIMMERMANN M, 1983, PAIN, V16, P109, DOI 10.1016/0304-3959(83)90201-4
   Zusso M, 2019, J NEUROINFLAMM, V16, P0, DOI 10.1186/s12974-019-1538-9
NR 73
TC 17
Z9 18
U1 1
U2 20
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
SN 
EI 2076-3425
J9 BRAIN SCI
JI Brain Sci.
PD APR 15
PY 2023
VL 13
IS 4
BP 
EP 
DI 10.3390/brainsci13040541
PG 23
WC Neurosciences
SC Neurosciences & Neurology
GA F0BS5
UT WOS:000979093900001
PM 37190506
DA 2026-01-16
ER

PT J
AU Luna, AL
   González, JA
   Guardo, LL
   Pájaro, Castro N
AF Luna, Alma Luz
   González, Jaime Andrés
   Guardo, Linda Lucía
   Pájaro Castro, Nerlis
TI CyberKnife Radiosurgery for refractory bilateral trigeminal neuralgia. Case
SO Colombia medica (Cali, Colombia)
LA English
DT Journal Article
DE Radiosurgery; intractable pain; microsurgery; microvascular decompression surgery; rhizotomy; robotic surgical procedures; trigeminal neuralgia
AB Case description: A case of a 37-year-old female patient suffering from  refractory bilateral trigeminal neuralgia is presented, who underwent various  interventions such as acupuncture, block therapies and even microvascular  decompression without effective pain relief. CLINICAL FINDINGS: Paresthesias and  shooting-like twinges of pain intensity 10/10 in bilateral maxillary and  mandibular branches of the trigeminal nerve, with nasal and intraoral triggers  that made eating impossible, becoming increasingly severe since refractoriness to  microvascular decompression and carbamazepines, triggering the twinges even  during sleep, generating somnolence, depressive mood and social isolation.  TREATMENT AND RESULTS: The patient was evaluated by an interdisciplinary  neuro-oncology team, where, in accordance with the analysis of the brain magnetic  resonance imaging and the patient's history, it was indicated to perform  Cyberknife® radiosurgery in monofraction on the left trigeminal and subsequently  treat the contralateral trigeminal. When treated with Cyberknife® radiosurgery,  the patient reported absolute improvement in her pain for 2 years. CLINICAL  RELEVANCE: Radiosurgery by CyberKnife is not yet the first line of management in  trigeminal neuralgia, however, it should be considered since several studies have  managed to demonstrate an increase in the quality of life of patients and pain  relief in refractory or severe cases. of said pathology.
C1 Universidad de Sucre, Facultad Ciencias de la Salud, Grupo de Ciencias Médicas y Farmacéuticas. Sincelejo, Colombia.
   Clínica Las Peñitas, Sincelejo, Colombia.
   Universidad de Sucre, Facultad Ciencias de la Salud, Grupo de Ciencias Médicas y Farmacéuticas. Sincelejo, Colombia.
   Clínica Santa María, Sincelejo, Colombia.
   Universidad de Sucre, Facultad Ciencias de la Salud, Grupo de Ciencias Médicas y Farmacéuticas. Sincelejo, Colombia.
   Clínica FOSCAL Internacional, Floridablanca, Colombia.
   Universidad de Sucre, Facultad Ciencias de la Salud, Grupo de Ciencias Médicas y Farmacéuticas. Sincelejo, Colombia.
NR 0
TC 0
SN 1657-953
EI 0120-832
J9 Colomb Med (Cali)
PD JUN 8
PY 2023
VL 53
IS 4
BP e5005283
EP e5005283
DI 10.25100/cm.v53i4.5283
PG 1
WC Female; Humans; Adult; Trigeminal Neuralgia; surgery; Treatment Outcome; Radiosurgery; methods; Quality of Life; Pain
UT PubMed:37287585
PM 37287585
DA 2023-06-08
ER

PT J
AU Jiang, Y
   Wu, L
   Wang, Y
   Tan, J
   Wang, L
   Cai, J
   Zhou, Y
   Sun, G
   Song, Z
   Gu, L
AF Jiang, Yueyi
   Wu, Lei
   Wang, Yue
   Tan, Jing
   Wang, Li
   Cai, Jiaqin
   Zhou, Yihu
   Sun, Guowei
   Song, Zhenghuan
   Gu, Lianbing
TI Effects of Press Needling combined with general anesthesia on postoperative
SO Complementary therapies in medicine
LA English
DT Journal Article
DE Analgesia; Lung surgery; Postoperative pulmonary complications; Press needle acupuncture; Video-assisted thoracoscopic surgery
AB OBJECTIVES: To investigate the effects of press needle therapy on postoperative  analgesia and other relevant complications in patients undergoing thoracoscopic  pulmonary resection. DESIGN: randomized, single-blind, controlled trial SETTING:  Teaching hospitals affiliated with universities. INTERVENTIONS: Eighty-six  patients were randomized into: the Acu group (press-needle group) and the control  group MAIN OUTCOME MEASURES: Pain levels 24, 48, and three months after surgery  were measured using the numeric rating scale (NRS). Perioperative hemodynamics,  total and effective pressing numbers of patient-controlled intravenous analgesia  (PCIA), and incidence of postoperative pulmonary complications were recorded.  Peripheral blood samples were collected to measure the levels of inflammatory  mediators RESULTS: Acu group had significantly lower NRS scores at 24 and 48 h  after operation (NRS scores on movement at 24 h after surgery: Acu vs. Control, 3  (2,3) vs. 3 (3,5), Z = -3.393, P < 0.01 and NRS scores on movement at 48 h after  surgery: 2 (1,3) vs. 3 (2,5), Z = -3.641, P < 0.01), lower number of PCIA  attempts and effective rates (mean total pressing numbers: 4(2,8) vs. 6(3,19),  Z = -1.994, P = 0.046 and mean effective pressing numbers: 3(2,8) vs. 6(3,16),  Z = -2.116, P = 0.034). The Acu group had significantly reduced IL-1  (14.52 ± 3.84 vs. 16.36 ± 3.30, mean difference (MD): - 1.85, 95% confidence  interval (CI): - 3.46, - 0.23, P = 0.026), HIF-1α (10.15 ± 1.71 vs. 10.96 ± 1.73,  MD: -0.81, 95% CI: -1.59, -0.04, P = 0.040) and the incidence of pulmonary  complications after surgery. CONCLUSION: Press needles are a non-invasive and  feasible adjunctive intervention for postoperative analgesic management in  patients undergoing thoracoscopic pulmonary resection.
C1 Nanjing Medical University, Nanjing, People's Republic of China.
   Department of Anesthesiology, Jiangsu Cancer Hospital, Nanjing, People's Republic of China.
   Nanjing Medical University, Nanjing, People's Republic of China.
   Department of Anesthesiology, Jiangsu Cancer Hospital, Nanjing, People's Republic of China.
   Department of Anesthesiology, Jiangsu Cancer Hospital, Nanjing, People's Republic of China.
   Xuzhou Medical University, Xuzhou, People's Republic of China.
   Nanjing Medical University, Nanjing, People's Republic of China.
   Dalian Medical University, Dalian, People's Republic of China.
   Department of Anesthesiology, Jiangsu Cancer Hospital, Nanjing, People's Republic of China. 
   Nanjing Medical University, Nanjing, People's Republic of China
   Department of Anesthesiology, Jiangsu Cancer Hospital, Nanjing, People's Republic of China.
EM 13951947684@163.com
NR 0
TC 0
SN 1873-696
EI 
J9 Complement Ther Med
PD AUG 29
PY 2023
VL 77
IS 
BP 102980
EP 102980
DI 10.1016/j.ctim.2023.102980
PG 0
WC Humans; Single-Blind Method; Lung Neoplasms; surgery; Anesthesia, General; Postoperative Complications; Analgesia
UT PubMed:37640166
PM 37640166
DA 2023-08-29
ER

PT J
AU Chiu, WS
   Lu, YW
   Lien, TH
AF Chiu, Wen-Shan
   Lu, Yu-Wen
   Lien, Ting-Hsuan
TI Iatrogenic Pneumothorax during Acupuncture: Case Report
SO MEDICINA-LITHUANIA
LA English
DT Article
DE acupuncture; iatrogenic pneumothorax; chronic pulmonary diseases; imaging
ID catamenial pneumothorax; safety
AB Acupuncture treatment in local areas is commonly used to treat pain or soreness; however, acupuncture around the neck or shoulder may be a risk factor for pneumothorax. Herein, we report two cases of iatrogenic pneumothorax after acupuncture. These points indicate that physicians should be aware of these risk factors through history-taking before acupuncture. Chronic pulmonary diseases, such as chronic bronchitis, emphysema, tuberculosis, lung cancer, pneumonia, and thoracic surgery, may be associated with a higher risk of iatrogenic pneumothorax after acupuncture. Even if the incidence of pneumothorax should be low under caution and fully evaluated, it is still recommended to arrange further imaging examinations to rule out the possibility of iatrogenic pneumothorax.
C1 [Chiu, Wen-Shan; Lu, Yu-Wen; Lien, Ting-Hsuan] Show Chawn Mem Hosp, Dept Chinese Med, Changhua 500, Taiwan.
RP Lu, YW; Lien, TH (corresponding author), Show Chawn Mem Hosp, Dept Chinese Med, Changhua 500, Taiwan.
EM luffy1964@gmail.com; tiffiny5267@gmail.com
CR Ahiskalioglu EO, 2016, J BACK MUSCULOSKELET, V29, P895, DOI 10.3233/BMR-160666
   Aissa S, 2017, PAN AFR MED J, V27, P0, DOI 10.11604/pamj.2017.27.112.8007
   Chen HN, 2018, J ACUPUNCT MERIDIAN, V11, P355
   Chi LM, 2016, EVID-BASED COMPL ALT, V2016, P0, DOI 10.1155/2016/7358918
   Chou PC, 2015, BMJ OPEN, V5, P0, DOI 10.1136/bmjopen-2015-007819
   Chou PC, 2011, J ALTERN COMPLEM MED, V17, P199, DOI 10.1089/acm.2010.0192
   Chu H, 2018, EVID-BASED COMPL ALT, V2018, P0, DOI 10.1155/2018/2308102
   Furuse N, 2017, MED ACUPUNCT, V29, P155, DOI 10.1089/acu.2017.1230
   Ghisalberti M, 2020, HEART LUNG CIRC, V29, P1648, DOI 10.1016/j.hlc.2020.05.107
   Gilday C, 2021, TOP COMPANION ANIM M, V45, P0, DOI 10.1016/j.tcam.2021.100563
   He WJ, 2012, J ALTERN COMPLEM MED, V18, P892, DOI 10.1089/acm.2011.0825
   Hou XJ, 2021, MEDICINE, V100, P0, DOI 10.1097/MD.0000000000025666
   Kaptchuk TJ, 2002, ANN INTERN MED, V136, P374, DOI 10.7326/0003-4819-136-5-200203050-00010
   Kwon CY, 2018, INTEGR MED RES, V7, P219
   Lin SK, 2019, ACUPUNCT MED, V37, P332, DOI 10.1136/acupmed-2018-011697
   Liu L, 2015, ARCH PHYS MED REHAB, V96, P944, DOI 10.1016/j.apmr.2014.12.015
   Mohammad Nurashikin, 2018, BMJ CASE REP, V2018, P0, DOI 10.1136/bcr-2017-221550
   Quercia R, 2023, FRONT SURG, V10, P0, DOI 10.3389/fsurg.2023.1156465
   Thng F, 2022, INT J EMERG MED, V15, P0, DOI 10.1186/s12245-022-00455-z
   Vickers A, 2002, QUAL SAF HEALTH CARE, V11, P92, DOI 10.1136/qhc.11.1.92
   Vickers AJ, 2018, J PAIN, V19, P455, DOI 10.1016/j.jpain.2017.11.005
   Voláková E, 2017, CES GYNEKOL, V82, P308
   Witt CM, 2009, FORSCH KOMPLEMENTMED, V16, P91, DOI 10.1159/000209315
   Yamashita H, 2008, EVID-BASED COMPL ALT, V5, P391, DOI 10.1093/ecam/nem086
   Yuan QL, 2016, SCI REP-UK, V6, P0, DOI 10.1038/srep30675
   Zuo G, 2019, MEDICINE, V98, P0, DOI 10.1097/MD.0000000000017974
NR 26
TC 6
Z9 7
U1 0
U2 6
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
SN 1010-660X
EI 1648-9144
J9 MEDICINA-LITHUANIA
JI Med. Lith.
PD JUN 15
PY 2023
VL 59
IS 6
BP 
EP 
DI 10.3390/medicina59061100
PG 6
WC Medicine, General & Internal
SC General & Internal Medicine
GA K2EM2
UT WOS:001014624000001
PM 37374304
DA 2026-01-16
ER

PT J
AU Zhou, M
   Pang, F
   Liao, D
   He, X
   Yang, Y
   Tang, C
AF Zhou, Min
   Pang, Fang
   Liao, Dongmei
   He, Xinlu
   Yang, Yunhao
   Tang, Chenglin
TI Electroacupuncture at Fengchi(GB20) and Yanglingquan(GB34) Ameliorates Paralgesia
SO Brain sciences
LA English
DT Journal Article
DE electroacupuncture; inflammatory response; microglia; migraine; paralgesia
AB BACKGROUND: Multiple studies have suggested that paralgesia (hyperalgesia and  cutaneous allodynia) in migraine reflects the activation and sensitisation of the  trigeminovascular system (TGVS). In particular, it reflects the second-order and  higher nerve centre sensitisation, which is caused and maintained by  neuroinflammation. Microglia activation leads to the release of proinflammatory  cytokines involved in inflammatory responses. Accumulating evidence indicates  that electroacupuncture (EA) is effective in ameliorating paralgesia, but the  underlying mechanisms of EA in migraine attacks caused by microglia and  microglia-mediated inflammatory responses are still unclear. The purpose of this  study was to explore whether EA could ameliorate the dysregulation of pain  sensation by suppressing microglial activation and the resulting  neuroinflammatory response, and to evaluate whether this response was regulated  by Toll-like receptor 4 (TLR4)/nuclear factor-kappa B(NF-κB) in the trigeminal  nucleus caudalis (TNC) in a rat model of migraine. METHODS: Repeated Inflammatory  Soup (IS) was infused into the dura for seven sessions to establish a recurrent  migraine-like rat model, and EA treatment was administered at Fengchi (GB20) and  Yanglingquan (GB34) after daily IS infusion. Facial mechanical withdrawal  thresholds were measured to evaluate the change in pain perception, and plasma  samples and the TNC tissues of rats were collected to examine the changes in  calcitonin gene-related peptide (CGRP), the Ibal-1-labelled microglial  activation, and the resulting inflammatory response, including interleukin-1β  (IL-1β), tumour necrosis factor-α (TNF-α), interleukin-6 (IL-6), and their  regulatory molecules TLR4/NF-κB, via enzyme-linked immunosorbent assay (ELISA),  real-time polymerase chain reaction (RT-PCR), immunohistochemistry (IHC) and  Western blot analysis. RESULTS: Repeated IS injections into the dura induced  facial mechanical paralgesia, which is the manifestation of migraine attacks, and  increased the expression of CGRP, Ibal-1, microglial mediated inflammatory  cytokines (IL-1β, TNF-α, IL-6), and regulatory molecules TLR4/NF-κB. EA at  GB20/34 significantly attenuated repetitive IS-induced pain hypersensitivity.  This effect was consistent with decreased levels of CGRP and inflammatory  cytokines in the plasma and the TNC via the inhibition of microglia activation,  and this response may be regulated by TLR4/NF-κB. CONCLUSIONS: EA ameliorated  paralgesia in repetitive IS-induced migraine-like rats, which was mainly mediated  by a reduction in microglial activation and microglial-mediated inflammatory  responses that could be regulated by TLR4/NF-κB.
C1 College of Traditional Chinese Medicine, Chongqing Medical University, Chongqing 400016, China.
   Chongqing Key Laboratory of Traditional Chinese Medicine for Prevention and Cure 
   College of Traditional Chinese Medicine, Chongqing Medical University, Chongqing 400016, China.
   Chongqing Key Laboratory of Traditional Chinese Medicine for Prevention and Cure 
   College of Traditional Chinese Medicine, Chongqing Medical University, Chongqing 400016, China.
   Chongqing Key Laboratory of Traditional Chinese Medicine for Prevention and Cure 
   College of Traditional Chinese Medicine, Chongqing Medical University, Chongqing 400016, China.
   Chongqing Key Laboratory of Traditional Chinese Medicine for Prevention and Cure 
   College of Traditional Chinese Medicine, Chongqing Medical University, Chongqing 400016, China.
   Chongqing Key Laboratory of Traditional Chinese Medicine for Prevention and Cure 
   College of Traditional Chinese Medicine, Chongqing Medical University, Chongqing 400016, China.
   Chongqing Key Laboratory of Traditional Chinese Medicine for Prevention and Cure
NR 0
TC 0
SN 2076-342
EI 2076-342
J9 Brain Sci
PD MAY 16
PY 2023
VL 13
IS 4
BP 
EP 
DI 10.3390/brainsci13040541
PG 0
UT PubMed:37190506
PM 37190506
DA 2023-05-16
ER

PT J
AU Mao, JJ
   Witt, CM
AF Mao, Jun J. J.
   Witt, Claudia M. M.
TI Acupuncture as an Evidence-Based Treatment for Cancer Pain Management: The Joint Society for Integrative Oncology-American Society for Clinical Oncology Guideline
SO JOURNAL OF INTEGRATIVE AND COMPLEMENTARY MEDICINE
LA English
DT Article
ID alternative medicine use; aromatase inhibitors; breast-cancer; united-states; complementary; survivors
C1 [Mao, Jun J. J.] Mem Sloan Kettering Canc Ctr, Dept Med, Integrat Med Serv, New York, NY USA.
   [Witt, Claudia M. M.] Univ Hosp Zurich, Inst Complementary & Integrat Med, Zurich, Switzerland.
   [Witt, Claudia M. M.] Univ Zurich, Zurich, Switzerland.
   [Mao, Jun J. J.] Mem Sloan Kettering Canc Ctr, 321 East 61st St,Room 456, New York, NY 10065 USA.
C3 Memorial Sloan Kettering Cancer Center; University of Zurich; University Zurich Hospital; University of Zurich; Memorial Sloan Kettering Cancer Center
RP Mao, JJ (corresponding author), Mem Sloan Kettering Canc Ctr, 321 East 61st St,Room 456, New York, NY 10065 USA.
EM maoj@mskcc.org
CR Brauer JA, 2010, J ALTERN COMPLEM MED, V16, P183, DOI 10.1089/acm.2009.0354
   Brier MJ, 2017, CANCER-AM CANCER SOC, V123, P169, DOI 10.1002/cncr.30318
   Chim K, 2013, BMC CANCER, V13, P0, DOI 10.1186/1471-2407-13-401
   Dowell Deborah, 2016, JAMA, V315, P1624, DOI 10.15585/mmwr.rr6501e1
   He YH, 2020, JAMA ONCOL, V6, P271, DOI 10.1001/jamaoncol.2019.5233
   Hershman DL, 2018, JAMA-J AM MED ASSOC, V320, P167, DOI 10.1001/jama.2018.8907
   Hershman DL, 2011, BREAST CANCER RES TR, V126, P529, DOI 10.1007/s10549-010-1132-4
   John GM, 2016, J CANCER SURVIV, V10, P850, DOI 10.1007/s11764-016-0530-y
   Li K, 2019, CURR ONCOL, V26, PE147, DOI 10.3747/co.26.4261
   Mao JJ, 2007, COMPLEMENT THER MED, V15, P21, DOI 10.1016/j.ctim.2006.07.006
   Mao JJ, 2022, J CLIN ONCOL, V40, P3998, DOI 10.1200/JCO.22.01357
   Mao JJ, 2021, JAMA ONCOL, V7, P720, DOI 10.1001/jamaoncol.2021.0310
   Mao JJ, 2011, J CANCER SURVIV, V5, P8, DOI 10.1007/s11764-010-0153-7
   Paice JA, 2019, J NATL COMPR CANC NE, V17, P595, DOI 10.6004/jnccn.2019.5010
   Paice JA, 2016, J CLIN ONCOL, V34, P3325, DOI 10.1200/JCO.2016.68.5206
   Rogge AA, 2021, CANCER-AM CANCER SOC, V127, P2683, DOI 10.1002/cncr.33562
   Witt CM, 2022, J CANCER EDUC, V37, P499, DOI 10.1007/s13187-020-01829-8
   Witt CM, 2020, CANCER-AM CANCER SOC, V126, P3031, DOI 10.1002/cncr.32823
   Yun Hyeongjun, 2017, JOURNAL OF THE NATIONAL CANCER INSTITUTE MONOGRAPHS, V0, PP29, DOI 10.1093/jncimonographs/lgx004
NR 20
TC 5
Z9 5
U1 0
U2 13
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 2768-3605
EI 2768-3613
J9 J INTEGR COMPLEMENT
JI J. Integr. Complement. Med.
PD APR 1
PY 2023
VL 29
IS 4
BP 209
EP 211
DI 10.1089/jicm.2023.0018
EA FEB 2023
PG 3
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA D7WA4
UT WOS:000939704300001
PM 36847338
DA 2026-01-16
ER

PT J
AU Wang, Z
   Xu, H
   Wang, Z
   Zhou, H
   Diao, J
   Zhang, L
   Wang, Y
   Li, M
   Zhou, Y
AF Wang, Zhen
   Xu, Hui
   Wang, Zheng
   Zhou, Hang
   Diao, Jieyao
   Zhang, Lijuan
   Wang, Yu
   Li, Miaoxiu
   Zhou, Yunfeng
TI Effects of externally-applied, non-pharmacological Interventions on short- and
SO Frontiers in immunology
LA English
DT Journal Article
DE efficacy; externally-applied; inflammatory cytokine; knee osteoarthritis; network meta-analysis; non-pharmacological interventions; short- and long-term
AB BACKGROUND: With the continuous development of clinical medicine, an increasing  number of non-pharmacological interventions have been applied for the treatment  of knee osteoarthritis (KOA), with the results of several recent randomized  controlled trials (RCTs) showing that a variety of externally-applied,  non-pharmacological interventions (EANPI) can improve symptoms and inflammation  in patients with KOA. However, the relative benefits and disadvantages of  non-drug therapies remain uncertain, and an optimal treatment strategy has not  yet been determined. OBJECTIVE: This study applied network meta-analysis (NMA) to  compare and rank the effectiveness of EANPI on the short- and long-term clinical  symptoms and inflammatory cytokine levels in patients with KOA. METHODS: Two  independent researchers searched online databases and performed manual retrieval  of related citations to identify RCTs that met the selection criteria for the  network meta-analysis. These researchers retrieved studies indexed from database  inception to August 2023 and performed data extraction and assessment of the risk  of bias. RESULTS: The analysis included 80 RCTs involving 8440 participants and  nine externally-applied, non-pharmacological therapies, namely extracorporeal  shock wave, radiofrequency, acupotomy, laser therapy, Tuina therapy, kinesio  taping, electroacupuncture, platelet-rich plasma injection, and ozone therapy.  The treatment courses ranged from 1 to 12 weeks, with follow-up periods ranging  from 4 to 24 weeks. The results of the NMA indicated that each non-drug therapy  was superior to sham intervention in improving all outcome indicators. Except for  the visual analog scale (VAS) and Western Ontario MacMaster (WOMAC) pain  outcomes, all non-drug therapies had better efficacy than pharmacological  treatments. For short-term VAS and tumor necrosis factor-alpha (TNF-α),  extracorporeal shock wave performed better than other therapies (90.2% and 85.2%  respectively). Radiofrequency therapy may be the most promising method to reduce  long-term VAS, short- and long-term WOMAC pain, and interleukin (IL)-1β level  (84.8%, 97.8%, 90.1%, 94.8% respectively). Tuina therapy may be a significant  choice for short- and long-term outcomes of WOMAC function and range of motion  (ROM). CONCLUSIONS: The results of the comprehensive comparison of the outcome  indicators in 9 different EANPI indicated that radiofrequency and Tuina therapy  were more effective and consistently ranked high in improving clinical symptoms  in the short and long term. Radiofrequency is effective at relieving pain, and  Tuina therapy can be given priority for treatment when hypofunction is the main  symptom. EANPI to improve pain symptoms may be related to the regulation of  inflammatory cytokine levels, which may be a potential mechanism of action.  SYSTEMATIC REVIEW REGISTRATION:  https://www.crd.york.ac.uk/prospero/display_record.php?, identifier  CRD42023464177.
C1 College of Acupuncture and Massage, Henan University of Chinese Medicine, Zhengzhou, China.
   College of Acupuncture and Massage, Henan University of Chinese Medicine, Zhengzhou, China.
   Tuina Department, The Third Affiliated Hospital of Henan University of Chinese 
   College of Acupuncture and Massage, Henan University of Chinese Medicine, Zhengzhou, China.
   College of Acupuncture and Massage, Henan University of Chinese Medicine, Zhengzhou, China.
   College of Acupuncture and Massage, Henan University of Chinese Medicine, Zhengzhou, China.
   Rehabilitation Department, Jiaozuo Coal Industry (Group) Co. Ltd., Central Hospital, Jiaozuo, China.
   College of Computer Science, Xidian University, Xian, China.
   College of Acupuncture and Massage, Shanghai University of Chinese Medicine, Shanghai, China.
   College of Acupuncture and Massage, Henan University of Chinese Medicine, Zhengzhou, China.
NR 0
TC 0
SN 1664-322
EI 
J9 Front Immunol
PD DEC 29
PY 2023
VL 14
IS 
BP 1309751
EP 1309751
DI 10.3389/fimmu.2023.1309751
PG 0
WC Humans; Osteoarthritis, Knee; therapy; Cytokines; Pain; Acupuncture Therapy
UT PubMed:38155966
PM 38155966
DA 2023-12-29
ER

PT J
AU Lo, YJ
   Mishra, VK
   Lo, HY
   Dubey, NK
   Lo, WC
AF Lo, Yun-Jo
   Mishra, Viraj Krishna
   Lo, Hung-Yao
   Dubey, Navneet Kumar
   Lo, Wen-Cheng
TI Clinical Spectrum and Trajectory of Innovative Therapeutic Interventions for
SO Aging and disease
LA English
DT Journal Article
AB Increasing incidences of insomnia in adults, as well as the aging population,  have been reported for their negative impact on the quality of life. Insomnia  episodes may be associated with neurocognitive, musculoskeletal, cardiovascular,  gastrointestinal, renal, hepatic, and metabolic disorders. Epidemiological  evidence also revealed the association of insomnia with oncologic and asthmatic  complications, which has been indicated as bidirectional. Two therapeutic  approaches including cognitive behavioral therapy (CBT) and drugs-based therapies  are being practiced for a long time. However, the adverse events associated with  drugs limit their wide and long-term application. Further, Traditional Chinese  medicine, acupressure, and pulsed magnetic field therapy may also provide  therapeutic relief. Notably, the recently introduced cryotherapy has been  demonstrated as a potential candidate for insomnia which could reduce pain, by  suppressing oxidative stress and inflammation. It seems that the synergistic  therapeutic approach of cryotherapy and the above-mentioned approaches might  offer promising prospects to further improve efficacy and safety. Considering  these facts, this perspective presents a comprehensive summary of recent advances  in pathological aetiologies of insomnia including COVID-19, and its therapeutic  management with a greater emphasis on cryotherapy.
C1 EUDA Wellness, Taipei 114, Taiwan.
   Biosource Tech, Ambala 133101, Haryana, India.
   EUDA Wellness, Taipei 114, Taiwan.
   Victory Biotechnology Co., Ltd., Taipei 114757, Taiwan.
   ShiNeo Technology Co., Ltd., New Taipei City 24262, Taiwan.
   Department of Surgery, Division of Neurosurgery, School of Medicine, College of Medicine, Taipei Medical University, Taipei 11031, Taiwan.
   Department of Neurosurgery, Taipei Medical University Hospital, Taipei 11031, 
   Taipei Neuroscience Institute, Taipei Medical University, Taipei 11031, Taiwan.
NR 0
TC 0
SN 2152-525
EI 2152-525
J9 Aging Dis
PD MAY 10
PY 2023
VL 14
IS 4
BP 1038
EP 1069
DI 10.14336/AD.2022.1203
PG 31
UT PubMed:37163444
PM 37163444
DA 2023-05-10
ER

PT J
AU Zhang, Y
   Wang, S
   Ma, X
   Yuan, Y
   Cheng, H
   Lin, L
   Tian, L
AF Zhang, Yueyue
   Wang, Shaotong
   Ma, Xiaomin
   Yuan, Yang
   Cheng, Hui
   Lin, Lu
   Tian, Li
TI Massage therapy can effectively relieve cancer pain: A meta-analysis.
SO Medicine
LA English
DT Journal Article
AB BACKGROUND: To critically evaluate the effects of massage therapy on cancer pain.  METHODS: Nine Chinese and English databases (PubMed, Cochrane Library, Embase,  SCOPUS, Web of Science core, China Biomedical Literature Database, China National  Knowledge Infrastructure, Wanfang, and VIP) were systematically searched from the  inception of databases to November 2022 for randomized controlled trials.  According to Cochrane Collaboration, 2 reviewers independently assessed the risk  of bias and extracted data from the included studies. All analyses were performed  with Review Manager 5.4. RESULTS: Thirteen randomized controlled trials were  included in the meta-analysis, containing 1000 patients (498 in the massage  therapy group and 502 in the control group). Massage therapy could significantly  relieve cancer pain in patients (standardized mean difference = -1.16, 95%  confidence interval [-1.39, -0.93], P < .00001), especially those in the  perioperative period and those with hematological malignancies. Foot reflexology  and hand acupressure had a moderate effect on cancer pain relief, with hand  acupressure being more effective. Massage duration of 10 to 30 minutes and a  program length of ≥1 week had a better effect and could significantly relieve  pain. The occurrence of adverse events was reported in 4 of the 13 studies, all  of which were no adverse events. CONCLUSIONS: Massage therapy can be used as a  complementary alternative therapy to relieve cancer pain in patients with  hematological malignancies, breast cancer, and cancers of the digestive system.  It is suggested that chemotherapy patients use foot reflexology, and  perioperative period patients use hand acupressure. A massage duration of 10 to  30 minutes and a program length of ≥1 week is recommended to achieve better  effects.
C1 School of Nursing, Suzhou Medical College of Soochow University, Suzhou, People's Republic of China.
   The First Affiliated Hospital of Soochow University, Suzhou, People's Republic of 
   School of Nursing, Suzhou Medical College of Soochow University, Suzhou, People's Republic of China.
   The First People's Hospital of Kunshan, Suzhou, People's Republic of China.
   School of Nursing, Suzhou Medical College of Soochow University, Suzhou, People's Republic of China.
   School of Nursing, Suzhou Medical College of Soochow University, Suzhou, People's Republic of China.
   School of Nursing, Suzhou Medical College of Soochow University, Suzhou, People's Republic of China.
   The First Affiliated Hospital of Soochow University, Suzhou, People's Republic of 
   School of Nursing, Suzhou Medical College of Soochow University, Suzhou, People's Republic of China.
   The First Affiliated Hospital of Soochow University, Suzhou, People's Republic of
NR 0
TC 0
SN 1536-596
EI 0025-797
J9 Medicine (Baltimore)
PD JUL 7
PY 2023
VL 102
IS 27
BP e33939
EP e33939
DI 10.1097/MD.0000000000033939
PG 1
WC Humans; Female; Cancer Pain; therapy; Massage; Complementary Therapies; Breast Neoplasms; Hematologic Neoplasms
UT PubMed:37417622
PM 37417622
DA 2023-07-07
ER

PT J
AU van de Castle, B
   Lukkahatai, N
   Billing, BL
   Huang, XR
   Wu, HL
   Zhang, JY
   Abdi, S
   Kameoka, J
   Smith, TJ
AF van de Castle, Barb
   Lukkahatai, Nada
   Billing, B. S. N. Lynn
   Huang, Xinran
   Wu, Hulin
   Zhang, Jingyu
   Abdi, Salahadin
   Kameoka, Jun
   Smith, Thomas J.
TI Nurse-Administered Auricular Point Acupressure for Cancer-Related Pain
SO INTEGRATIVE CANCER THERAPIES
LA English
DT Article
DE cancer-related-pain; pain; cancer; auricular acupressure; nursing
ID low-back-pain; management; acupuncture; diagnosis; survivors
AB Purpose: The study aimed to (1) examine the feasibility of providing a training course on auricular point acupressure (APA) for clinical oncology nurses to integrate APA into real-world nursing care settings, and (2) examine the effectiveness of APA on cancer-related pain (CRP) under usual inpatient oncology ward conditions. Methods: This was a 2-phase feasibility study. Phase 1, an in-person, 8 hour training program was provided to oncology nurses. Phase 2, a prospective and feasibility study was conducted to evaluate the integration of APA into nursing care activities to manage CRP. Oncology patients were included if their pain was rated at >= 4 on a 0 to 10 numeric rating scale in the past 24 hours. Patients received 1 APA treatment administered by the nurses and were instructed to stimulate the points for 3 days. Study outcomes (pain intensity, fatigue, and sleep disturbance), pain medication use, and APA practice were measured by a phone survey daily. Results: Ten oncology nurses received APA training in phase 1. APA had been added to the hospital's electronic health records (EHRs) as a pain treatment. In phase 2, 33 oncology patients received APA treatment with a 100% adherence rate (pressing the seeds 3 times per day, 3 minutes per time based on the suggestion). The side effects of APA were minimal (similar to 8%-12% felt tenderness on the ear). After 3 days of APA, patients reported 38% pain relief, 39% less fatigue, and 45% improvement in sleep disturbance; 24% reduced any type of pain medication use and 19% reduced opioid use (10 mg opioids using milligram morphine equivalent). The major barrier to integrating APA into routine nursing practice was time management (how to include APA in a daily workflow). Conclusion: It is feasible to provide 8-hour training to oncology nurses for mastering APA skill and then integrating APA into their daily nursing care for patients with CRP. Based on the promising findings (decreased pain, improved fatigue and sleep disturbance, and less opioid use), the next step is to conduct a randomized clinical trial with a larger sample to confirm the efficacy of APA for oncology nurses to treat CRP in real-world practice.
C1 [van de Castle, Barb] Univ Maryland, Sch Nursing, Baltimore, MD USA.
   [Lukkahatai, Nada; Zhang, Jingyu] Johns Hopkins Univ, Sch Nursing, Baltimore, MD USA.
   [Billing, B. S. N. Lynn] Johns Hopkins Univ Hosp, Baltimore, MD USA.
   [Huang, Xinran; Wu, Hulin] Univ Texas Hlth Sci Ctr Houston, Sch Publ Hlth, Houston, TX USA.
   [Abdi, Salahadin] Univ Texas MD Anderson Canc Ctr, Houston, TX USA.
   [Kameoka, Jun] Waseda Univ, Tokyo, Japan.
   [Smith, Thomas J.] Johns Hopkins Univ, Sch Med, Baltimore, MD USA.
   [Lukkahatai, Nada] Johns Hopkins Univ, Sch Nursing, 525 North Wolfe St, Baltimore, MD 21205 USA.
C3 University System of Maryland; University of Maryland Baltimore; Johns Hopkins University; Johns Hopkins University; Johns Hopkins Medicine; University of Texas System; University of Texas Health Science Center Houston; University of Texas School Public Health; University of Texas System; UTMD Anderson Cancer Center; Waseda University; Johns Hopkins University; Johns Hopkins University
RP Lukkahatai, N (corresponding author), Johns Hopkins Univ, Sch Nursing, Baltimore, MD USA.; Lukkahatai, N (corresponding author), Johns Hopkins Univ, Sch Nursing, 525 North Wolfe St, Baltimore, MD 21205 USA.
EM nada.lukkahatai@jhu.edu
FU Research reported in this publication was supported by the Brager Humanitarian Award at the Johns Hopkins Kimmel Cancer Center and an Under Armour Women's Health amp;amp; Breast Cancer Innovation Grant, Johns Hopkins Medicine. Funding sources were not inv; Brager Humanitarian Award at the Johns Hopkins Kimmel Cancer Center and an Under Armour Women's Health amp;amp; Breast Cancer Innovation Grant; Johns Hopkins Medicine
CR Unknown -, 2020, NCCN CLINICAL PRACTICE GUIDELINES IN ONCOLOGY: PROSTATE CANCER VERSION 2, V0, P0
   Basch E, 2017, JAMA-J AM MED ASSOC, V318, P197, DOI 10.1001/jama.2017.7156
   Caterino JM, 2019, JAMA NETW OPEN, V2, P0, DOI 10.1001/jamanetworkopen.2019.0979
   Centers for Medicare and Medicaid Services, 2023, CAG-00452N), V0, P0
   Cleeland CS, 1994, ANNALS ACADEMY OF MEDICINE SINGAPORE, V23, P129
   Copenhaver David J, 2021, CANCER TREAT RES, V182, P3, DOI 10.1007/978-3-030-81526-4_1
   Cui J, 2017, ACUPUNCT MED, V35, P200, DOI 10.1136/acupmed-2016-011106
   Deng G, 2019, CANCER J, V25, P343, DOI 10.1097/PPO.0000000000000399
   Dowell D, 2016, JAMA-J AM MED ASSOC, V315, P1624, DOI 10.1001/jama.2016.1464
   Gallaway MS, 2020, PREV CHRONIC DIS, V17, P0, DOI 10.5888/pcd17.190367
   Greenlee H, 2017, CA-CANCER J CLIN, V67, P195, DOI 10.3322/caac.21397
   Grundy S E, 1993, NURSE EDUC, V18, P6, DOI 10.1097/00006223-199301000-00004
   Hamlin AS, 2017, CRIT CARE NURS CLIN, V29, P449, DOI 10.1016/j.cnc.2017.08.005
   Kelleher SA, 2021, CONTEMP CLIN TRIALS, V102, P0, DOI 10.1016/j.cct.2021.106287
   Kim SK, 2021, HOLIST NURS PRACT, V35, P182, DOI 10.1097/HNP.0000000000000457
   Kwekkeboom K, 2018, PSYCHO-ONCOLOGY, V27, P2761, DOI 10.1002/pon.4883
   Ledford CJW, 2018, J AM BOARD FAM MED, V31, P236, DOI 10.3122/jabfm.2018.02.170381
   Lim Y, 2023, INT J ENVIRON RES PUBLIC HEALTH, V20, P1705
   Lin WC, 2015, EVID-BASED COMPL ALT, V2015, P0, DOI 10.1155/2015/103570
   Chien CHYLC, 2015, JOURNAL OF PAIN & RELIEF, V04, P0, DOI 10.4172/2167-0846.1000199
   Maindet C, 2019, SUPPORT CARE CANCER, V27, P3119, DOI 10.1007/s00520-019-04829-7
   Miles M B, 1994, QUALITATIVE DATA ANALYSIS: AN EXPANDED SOURCEBOOK, V0, P0
   Niemtzow R, 2018, MIL MED, V183, PE486, DOI 10.1093/milmed/usy028
   Nogier P, 1981, HDB AURICULOTHERAPY, V0, P0
   Nogier R, 2014, MED ACUPUNCT, V26, P76, DOI 10.1089/acu.2014.1035
   Oleson T, 2014, AURICULOTHERAPY MANUAL: CHINESE AND WESTERN SYSTEMS OF EAR ACUPUNCTURE, V0, P0
   Oliveira CB, 2018, EUR SPINE J, V27, P2791, DOI 10.1007/s00586-018-5673-2
   Paice JA, 2016, J CLIN ONCOL, V34, P3325, DOI 10.1200/JCO.2016.68.5206
   Pandey D, 2021, J IMMIGR MINOR HEALT, V23, P707, DOI 10.1007/s10903-021-01148-0
   Reyes CC, 2019, BMJ SUPPORT PALLIAT, V9, P0, DOI 10.1136/bmjspcare-2018-001533
   Rocque GB, 2013, J ONCOL PRACT, V9, P51, DOI 10.1200/JOP.2012.000698
   Sanford NN, 2019, CANCER-AM CANCER SOC, V125, P4310, DOI 10.1002/cncr.32450
   Scarborough BM, 2018, CA-CANCER J CLIN, V68, P182, DOI 10.3322/caac.21453
   Skelly AC, 2020, NONINVASIVE NONPHARMACOLOGICAL TREATMENT FOR CHRONIC PAIN: A SYSTEMATIC REVIEW UPDATE, V0, P0, DOI DOI 10.23970/ahrqepccer227
   Yang YL, 2020, EVID-BASED COMPL ALT, V2020, P0, DOI 10.1155/2020/1618767
   Yeh CH, 2023, PAIN MANAG NURS, V24, P19, DOI 10.1016/j.pmn.2022.11.004
   Yeh Chao Hsing, 2020, GLOB ADV HEALTH MED, V9, P2164956120906092, DOI 10.1177/2164956120906092
   Yeh CH, 2019, PAIN MANAG NURS, V20, P623, DOI 10.1016/j.pmn.2019.04.004
   Yeh CH, 2017, ONCOL NURS FORUM, V44, P476, DOI 10.1188/17.ONF.476-487
   Yeh CH, 2013, MED ACUPUNCT, V25, P423, DOI 10.1089/acu.2013.1006
   Yeh CH, 2014, MED ACUPUNCT, V26, P148, DOI 10.1089/acu.2014.1026
   Zhong Q, 2019, CHIN J INTEGR MED, V25, P225, DOI 10.1007/s11655-019-3063-1
NR 42
TC 7
Z9 8
U1 1
U2 19
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1534-7354
EI 1552-695X
J9 INTEGR CANCER THER
JI Integr. Cancer Ther.
PD JUN 15
PY 2023
VL 22
IS 
BP 
EP 
DI 10.1177/15347354231198086
PG 10
WC Oncology; Integrative & Complementary Medicine
SC Oncology; Integrative & Complementary Medicine
GA R8ZK1
UT WOS:001067179400001
PM 37706457
DA 2026-01-16
ER

PT J
AU Zhang, RY
   Zhu, BF
   Zhao, JG
   Zhao, L
   Wang, LK
AF Zhang, Rong Yi
   Zhu, Ben Fan
   Zhao, Jia Gui
   Zhao, Long
   Wang, Li Kui
TI Electroacupuncture Stimulation Alleviates Inflammatory Pain in Male Rats by Suppressing Oxidative Stress
SO PHYSIOLOGICAL RESEARCH
LA English
DT Article
DE Electroacupuncture; Inflammatory pain; Oxidative stress; Reactive oxygen species; TRPV1
ID mechanisms; injury; model
AB In the present study, we focused on whether the analgesic effect of Electroacupuncture (EA) is related to the regulation of oxidative stress. We established a chronic inflammatory pain model in male rats by a single injection of complete Freund's adjuvant (CFA) and then treated the animals with daily EA stimulation at the site of "zusanli". The analgesic effect of EA was evaluated by measuring the paw withdrawal threshold (PWT) when rats received mechanical and thermal pain stimulation. The levels of inflammation-related molecules and oxidative stress-related markers in the spinal cord were measured by western blotting or ELISA kits. EA stimulation and antioxidants effectively increased the PWT in CFA rats. Co-treatment of CFA rats with the ROS donor t-butyl hydroperoxide (t-BOOH) further decreased the PWT and weakened the analgesic effect of EA. EA treatment inhibited inflammation and oxidative stress, as shown by decreased levels of tumor necrosis factor-alpha (TNF-alpha), interleukin-10 (IL-10), IL-6, and MDA and increased activity of SOD and catalase. Moreover, EA reduced the expression of p-p38, p-ERK, and p-p65 and simultaneously downregulated the expression of TRPV1 and TRPV4 in CFA rats. In an in vitro study, direct stimulation with t-BOOH to the C6 cells increased the production of TNF-alpha, IL-10, IL-6, activated p38, ERK, and p65 and up-regulated the expression of TRPV1 and TRPV4, and these effects could be prevented by the ROS scavenger PBN. Taken together, our data indicate that the inhibition of oxidative stress and the generation of ROS contribute to the analgesic effect of EA in male CFA rats.
C1 [Zhang, Rong Yi; Zhu, Ben Fan; Zhao, Jia Gui; Zhao, Long; Wang, Li Kui] Anhui Med Univ, Affiliated Hosp 1, Dept Pain Management, Hefei, Anhui, Peoples R China.
   [Wang, Li Kui] Anhui Med Univ, Hosp Hefei, Dept Pain Management, Hefei, Peoples R China.
C3 Anhui Medical University; Anhui Medical University
RP Wang, LK (corresponding author), Anhui Med Univ, Hosp Hefei, Dept Pain Management, Hefei, Peoples R China.
EM wlk9560@163.com
FU National Natural Science Foundation of Anhui Province [1808085MH310]; First Affiliated Hospital of Anhui Medical University [3101005001249]
CR Abbas MA, 2020, CHEM-BIOL INTERACT, V330, P0, DOI 10.1016/j.cbi.2020.109178
   Chen G, 2018, NEURON, V100, P1292, DOI 10.1016/j.neuron.2018.11.009
   Descalzi G, 2015, TRENDS NEUROSCI, V38, P237, DOI 10.1016/j.tins.2015.02.001
   Ebert T J, 1996, ACTA ANAESTHESIOL BELG, V47, P15
   Fan JJ, 2020, CELL DEATH DIS, V11, P0, DOI 10.1038/s41419-020-2317-3
   Gao F, 2018, BRAIN BEHAV IMMUN, V67, P91, DOI 10.1016/j.bbi.2017.08.004
   Hanamoto H, 2015, BMC ANESTHESIOL, V15, P0, DOI 10.1186/s12871-015-0047-3
   Hassler SN, 2014, J NEUROCHEM, V131, P413, DOI 10.1111/jnc.12830
   Hudmon A, 2008, J NEUROSCI, V28, P3190, DOI 10.1523/JNEUROSCI.4403-07.2008
   Kim HY, 2015, NEURAL PLAST, V2015, P0, DOI 10.1155/2015/293423
   Kim HK, 2004, PAIN, V111, P116, DOI 10.1016/j.pain.2004.06.008
   Kozai D, 2014, ANTIOXID REDOX SIGN, V21, P971, DOI 10.1089/ars.2013.5616
   Lawrence T, 2009, CSH PERSPECT BIOL, V1, P0, DOI 10.1101/cshperspect.a001651
   Li YY, 2019, INT J MOL SCI, V20, P0, DOI 10.3390/ijms20235917
   Liang RY, 2021, EVID-BASED COMPL ALT, V2021, P0, DOI 10.1155/2021/3056963
   Lin X, 2014, CURR MED CHEM, V21, P4405, DOI 10.2174/0929867321666140915143040
   Liu PR, 2019, J INT MED RES, V47, P3860, DOI 10.1177/0300060519860026
   Liu YJ, 2021, PHYSIOL RES, V70, P635, DOI 10.33549/physiolres.934649
   Lu QB, 2018, REDOX BIOL, V14, P656, DOI 10.1016/j.redox.2017.11.012
   Lv ZT, 2019, ARTHRITIS RES THER, V21, P0, DOI 10.1186/s13075-019-1899-6
   Ma F, 2009, MOL PAIN, V5, P0, DOI 10.1186/1744-8069-5-31
   Maruta T, 2019, PLOS ONE, V14, P0, DOI 10.1371/journal.pone.0225586
   Moran MM, 2018, BRIT J PHARMACOL, V175, P2185, DOI 10.1111/bph.14044
   Oda M, 2021, BIOCHEM BIOPHYS REP, V28, P0, DOI 10.1016/j.bbrep.2021.101173
   Pinho-Ribeiro FA, 2017, TRENDS IMMUNOL, V38, P5, DOI 10.1016/j.it.2016.10.001
   Ratliff BB, 2016, ANTIOXID REDOX SIGN, V25, P119, DOI 10.1089/ars.2016.6665
   Schäfers M, 2003, PAIN, V104, P579, DOI 10.1016/S0304-3959(03)00115-5
   Sekiguchi M, 2009, EUR SPINE J, V18, P1978, DOI 10.1007/s00586-009-1064-z
   Shakouri SK, 2020, BMC RES NOTES, V13, P0, DOI 10.1186/s13104-020-05352-3
   Sommer C, 1999, NEUROSCI LETT, V270, P25, DOI 10.1016/S0304-3940(99)00450-4
   Sorge RE, 2017, J NEUROSCI RES, V95, P1271, DOI 10.1002/jnr.23841
   Uta D, 2019, NEUROPHARMACOLOGY, V160, P0, DOI 10.1016/j.neuropharm.2019.107753
   Webster Lynn R, 2016, ANESTHESIOL CLIN, V34, P341, DOI 10.1016/j.anclin.2016.01.002
   Xiang XN, 2019, INT J MOL SCI, V20, P0, DOI 10.3390/ijms20133248
   Xue Y, 2020, MOL PAIN, V16, P0, DOI 10.1177/1744806920929246
   Zhang RY, 2020, ARQ NEURO-PSIQUIAT, V78, P617, DOI 10.1590/0004-282X20200078
   Zhao XM, 2019, PHYSIOL RES, V68, P501, DOI 10.33549/physiolres.934084
   Zheng YJ, 2020, LIBYAN J MED, V15, P0, DOI 10.1080/19932820.2020.1730550
NR 38
TC 8
Z9 8
U1 1
U2 8
PU ACAD SCIENCES CZECH REPUBLIC, INST PHYSIOLOGY
PI PRAGUE 4
PA VIDENSKA 1083, PRAGUE 4 142 20, CZECH REPUBLIC
SN 0862-8408
EI 1802-9973
J9 PHYSIOL RES
JI Physiol. Res.
PD OCT 15
PY 2023
VL 72
IS 5
BP 657
EP 667
DI 10.33549/physiolres.934965
PG 11
WC Physiology
SC Physiology
GA CQ1R9
UT WOS:001126623900008
PM 38015764
DA 2026-01-16
ER

PT J
AU Tan, MY
   Mo, CY
   Zhao, Q
AF Tan, Mo-Yao
   Mo, Chao-Yue
   Zhao, Qian
TI Research hotspots and trends on acupuncture therapy on vomiting from 1990 to 2022: A bibliometric analysis
SO COMPLEMENTARY THERAPIES IN MEDICINE
LA English
DT Article
DE Acupuncture; Vomiting; Hotspots and trends; Bibliometric analysis
ID chemotherapy-induced nausea; postoperative nausea; point stimulation; cancer; pain; management
AB Objectives: Acupuncture treatment (AT) is commonly utilized for vomiting; however, limited bibliometric ana-lyses exist in this area. Employing a bibliometric approach, we conducted a comprehensive review spanning three decades to assess the research landscape, advancements, and emerging trends in AT for vomiting.Methods: We collected the related literature data from the Web of Science Core Collection (WOSCC) from 1990 to 2022. VOSviewer and R studio were used to perform the bibliometric analysis of AT on vomiting. The status of authors, countries, affiliations, annual publications, keywords, and journals were analyzed accordingly. Results: The earliest relevant paper was published in 1990. Streitberger, K was the most productive author (7 records) and had significant influence (225 reference times, H-Index = 7). The United States had the highest publication count (224 records) and received the most recognition (9719 reference times, H-Index = 52). MEDICINE had the highest number of outputs (34 records), while ANESTHESIA AND ANALGESIA was the most cited journal (1045 reference times). The institution with the most works was Chengdu University of Traditional Chinese Medicine (CDUTCM) (13 records), and the University of California, Los Angeles received the most ci-tations (1252 reference times). Recent and future research hotspots included AT for postoperative vomiting and post-chemotherapy vomiting. Systematic reviews and meta-analyses were the predominant study types.Conclusions: The current status and development prospects of AT for vomiting are shown in this study. In addition, this article provides valuable ideas and potential directions for future research activities.
C1 [Tan, Mo-Yao; Zhao, Qian] Chengdu First Peoples Hosp, Chengdu, Sichuan, Peoples R China.
   [Mo, Chao-Yue] Chengdu Univ Tradit Chinese Med, Coll Life & Sci, Chengdu, Sichuan, Peoples R China.
C3 Chengdu University of Traditional Chinese Medicine
RP Zhao, Q (corresponding author), Chengdu First Peoples Hosp, Chengdu, Sichuan, Peoples R China.
EM zhaoqian6628@163.com
CR Unknown -, 1997, NIH CONSENS STATEMENT, V15, P1
   Aria M, 2017, J INFORMETR, V11, P959, DOI 10.1016/j.joi.2017.08.007
   Asmussen S, 2017, J NEUROSURG ANESTH, V29, P219, DOI 10.1097/ANA.0000000000000290
   Bartneck C, 2011, SCIENTOMETRICS, V87, P85, DOI 10.1007/s11192-010-0306-5
   Becker Daniel E, 2010, ANESTH PROG, V57, P150, DOI 10.2344/0003-3006-57.4.150
   Bhandari S, 2017, DIGEST DIS SCI, V62, P2035, DOI 10.1007/s10620-016-4432-7
   Boyack KW, 2010, J AM SOC INF SCI TEC, V61, P2389, DOI 10.1002/asi.21419
   Dou BM, 2020, J CLIN ACUPUNCT MOXI, V36, P72, DOI 10.3969/j.issn.1005-0779.2020.10.019
   DUNDEE JW, 1989, LANCET, V1, P1016
   Enblom A, 2017, COMPLEMENT THER MED, V34, P141, DOI 10.1016/j.ctim.2017.08.003
   Enblom A, 2017, ACUPUNCT MED, V35, P251, DOI 10.1136/acupmed-2015-011007
   Enblom A, 2017, EVID-BASED COMPL ALT, V2017, P0, DOI 10.1155/2017/5806351
   Ezzo J, 2005, J CLIN ONCOL, V23, P7188, DOI 10.1200/JCO.2005.06.028
   Ezzo J, 2006, J ALTERN COMPLEM MED, V12, P489, DOI 10.1089/acm.2006.12.489
   Fan SJ, 2018, CLIN J CHIN MED, V10, P122
   Fernández-Ortega P, 2012, SUPPORT CARE CANCER, V20, P3141, DOI 10.1007/s00520-012-1448-1
   Gan TJ, 2020, ANESTH ANALG, V131, P411, DOI 10.1213/ANE.0000000000004833
   Gang Wei-Juan, 2023, ZHONGGUO ZHEN JIU, V43, P3, DOI 10.13703/j.0255-2930.20221205-0001
   Gao W, 2021, SURGERY, V170, P1618, DOI 10.1016/j.surg.2021.08.007
   Hao TY, 2018, SOFT COMPUT, V22, P7875, DOI 10.1007/s00500-018-3511-4
   Jerson B, 2019, CURR OPIN PEDIATR, V31, P630, DOI 10.1097/MOP.0000000000000800
   Kim KH, 2017, BMJ OPEN, V7, P0, DOI 10.1136/bmjopen-2016-013457
   Kim SY, 2015, ACUPUNCT MED, V33, P148, DOI 10.1136/acupmed-2014-010641
   Kotani N, 2001, ANESTHESIOLOGY, V95, P349, DOI 10.1097/00000542-200108000-00015
   Kovac AL, 2021, PEDIATR DRUGS, V23, P11, DOI 10.1007/s40272-020-00424-0
   Kovacic K, 2021, HEADACHE, V61, P231, DOI 10.1111/head.14073
   Lariviere Vincent, 2013, NATURE, V504, P211
   Lee A, 1999, ANESTH ANALG, V88, P1362, DOI 10.1097/00000539-199906000-00031
   Lee A, 2015, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD003281.pub4
   [李旷宇 Li Kuangyu], 2020, 中草药 CHINESE TRADITIONAL AND HERBAL DRUGS, V51, P2046
   Li S, 2019, EUR J INTEGR MED, V30, P0, DOI 10.1016/j.eujim.2019.100951
   Lin WL, 2022, HUNAN J TRADIT CHIN, V38, P111, DOI 10.16808/j.cnki.issn1003-7705.2022.01.033
   Lindley C, 1999, CANCER PRACT, V7, P59, DOI 10.1046/j.1523-5394.1999.07205.x
   Liodden I, 2011, ACUPUNCT MED, V29, P9, DOI 10.1136/aim.2010.002915
   Liu MY, 2021, MEDICINE, V100, P0, DOI 10.1097/MD.0000000000024588
   Lu Jian-Qin, 2013, ZHEN CI YAN JIU, V38, P245
   MALAGELADA JR, 1984, ANN INTERN MED, V101, P211, DOI 10.7326/0003-4819-101-2-211
   Norheim A J, 2001, TIDSSKR NOR LAEGEFOREN, V121, P2712
   Norheim AJ, 2011, ACUPUNCT MED, V29, P3, DOI 10.1136/aim.2011.003988
   Parkman HP, 2011, GASTROENTEROLOGY, V141, P486, DOI 10.1053/j.gastro.2011.04.045
   Parkman HP, 2011, GASTROENTEROLOGY, V140, P101, DOI 10.1053/j.gastro.2010.10.015
   Rithirangsriroj K, 2015, GYNECOL ONCOL, V136, P82, DOI 10.1016/j.ygyno.2014.10.025
   Rosen T, 2003, OBSTET GYNECOL, V102, P129, DOI 10.1016/S0029-7844(03)00375-2
   Shi YZ, 2016, WORLD CHIN MED, V11, P209, DOI 10.3969/j.issn.1673-7202.2016.02.006
   Stoicea N, 2015, FRONT MED, V2, P0, DOI 10.3389/fmed.2015.00087
   Streitberger K, 2006, AUTON NEUROSCI-BASIC, V129, P107, DOI 10.1016/j.autneu.2006.07.015
   Streitberger K, 2011, EUR J ANAESTH, V28, P396, DOI 10.1097/EJA.0b013e3283412529
   Tan MY, 2023, FRONT PUBLIC HEALTH, V11, P0, DOI 10.3389/fpubh.2023.1108756
   van Eck NJ, 2010, SCIENTOMETRICS, V84, P523, DOI 10.1007/s11192-009-0146-3
   Van Eck NJ, 2014, MEASURING SCHOLARLY, V0, PP285, DOI 10.1007/978-3-319-10377-8_13
   Vasigh A, 2018, ANAESTH PAIN INTENSI, V22, P499
   WATCHA MF, 1992, ANESTHESIOLOGY, V77, P162, DOI 10.1097/00000542-199207000-00023
   Xu Mj, 2023, J CLIN ACUPUNCT MOXI, V39, P16, DOI 10.19917/j.cnki.1005-0779.023090
   Yan YQ, 2023, CANCER MED-US, V12, P12504, DOI 10.1002/cam4.5962
   Yao YS, 2015, EVID-BASED COMPL ALT, V2015, P0, DOI 10.1155/2015/324360
   Yin ZH, 2020, EVID-BASED COMPL ALT, V2020, P0, DOI 10.1155/2020/7509481
   Yu Zengfang, 2017, SHANXI J TRAD CHINESE MED, V33, P49
   Zhu J, 2022, ACUPUNCT MED, V40, P415, DOI 10.1177/09645284221076517
NR 58
TC 6
Z9 7
U1 1
U2 49
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 0965-2299
EI 1873-6963
J9 COMPLEMENT THER MED
JI Complement. Ther. Med.
PD SEP 15
PY 2023
VL 76
IS 
BP 
EP 
DI 10.1016/j.ctim.2023.102962
EA JUL 2023
PG 14
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA N5YT0
UT WOS:001037771100001
PM 37406969
DA 2026-01-16
ER

PT J
AU Li, QY
   Yang, WX
   Liu, H
   Jiao, LJ
   Gong, YB
   Shi, J
AF Li, Quan-yao
   Yang, Wen-xiao
   Liu, Hui
   Jiao, Li-Jing
   Gong, Ya-bin
   Shi, Jun
TI Research on Electroacupuncture Parameters for Cancer Pain Based on Data Mining
SO INTEGRATIVE CANCER THERAPIES
LA English
DT Review
DE cancer pain; electroacupuncture; parameter; data mining; traditional Chinese medicine
ID beta-endorphin; electrical-stimulation; acupuncture points; trigger points; management; release; society
AB Background:Cancer pain, a common complication of this disease, has been widely treated by electroacupuncture in recent years. However, there are numerous treatment parameters that are not conducive to clinical translation applications. This study aims to summarize the stimulation parameters commonly used in electroacupuncture treating cancer pain by data mining and visualization techniques to provide a basis for the future acupuncture technology transformation and selection of optimal stimulation parameters. Methods:Nine databases, including Pubmed, Cochrane Library, Embase, Web of Science, OVID, China National Knowledge Infrastructure Database, China Biology Medicine disk, China Science and Technology Journal Database, and Wanfang Database, were searched for clinical studies on electroacupuncture treatment cancer pain published between January 2012 and September 2022. A database was established using Microsoft Excel 2020 and analyzed with SPSS Modeler 18.1 software and SPSS statistics 26.0 software. Results:Twenty-four articles were included according to the established criteria. The most used electroacupuncture stimulation parameters were a dilatational wave, the current frequency of 2/100 Hz, stimulation duration of 30 minutes per treatment, and frequency of treatment once a day. Fifty-eight acupoints were mentioned, and the total frequency of acupoints involved was 156 times. The most used ones include Zusanli (ST36), Sanyinjiao (SP06), Hegu (LI04), Neiguan (PC06), Quchi (LI11), Taichong (LR03), Ashi point, Jiaji point, and those most generally used acupoints that are closely arranged on the Stomach Channel of Foot Yangming and the Spleen Channel of Foot Taiyin. The association analysis of acupoints revealed that the most supported acupoint pair was Sanyinjiao (SP06) and Zusanli (ST36). Cluster analysis demonstrated 3 groups, 1 for obligatory acupoints, 1 for Ashi point, and the third for Jiaji point. Conclusions:A dilatational wave, the current frequency of 2/100 Hz, 30-minute stimulation, and acupoints of the Stomach Channel of Foot Yangming and the Spleen Channel of Foot Taiyin selection are frequently used in electroacupuncture for treating cancer pain. Due to the limitations of this study, further research and more standardized, multi-center, large-sample clinical trials can be carried out to guide optimizing acupuncture treatment schemes and promote the formation of TCM-characteristic technologies for cancer pain.
C1 [Li, Quan-yao; Yang, Wen-xiao; Liu, Hui; Jiao, Li-Jing; Gong, Ya-bin; Shi, Jun] Shanghai Univ Tradit Chinese Med, Yueyang Hosp Integrated Tradit Chinese & Western M, Dept Oncol, Shanghai, Peoples R China.
   [Shi, Jun] Shanghai Univ Tradit Chinese Med, Yueyang Hosp Integrated Tradit Chinese & Western M, Dept Oncol, 110 GanHe Rd HongKou Dist, Shanghai 200437, Peoples R China.
C3 Shanghai University of Traditional Chinese Medicine; Shanghai University of Traditional Chinese Medicine
RP Shi, J (corresponding author), Shanghai Univ Tradit Chinese Med, Yueyang Hosp Integrated Tradit Chinese & Western M, Dept Oncol, 110 GanHe Rd HongKou Dist, Shanghai 200437, Peoples R China.
EM shijundoctor@163.com
CR 林小燕, 2013, 中国疼痛医学杂志 CHINESE JOURNAL OF PAIN MEDICINE, V19, P373
   Cai FH, 2022, EUR J MED RES, V27, P0, DOI 10.1186/s40001-022-00795-9
   Chen A, 2017, SHANGHAI J TRADITION, V51, P16, DOI 10.16305/J.1007-1334.2017.06.005
   Chen H, 2013, PANCREATOLOGY, V13, P594, DOI 10.1016/j.pan.2013.10.007
   Chen LX, 2014, J CERVICODYNIA LUMBO, V35, P76
   Chen ML, 2021, CLIN EFFICACY ELECTR, V0, P0
   Dorsher PT, 2008, J ALTERN COMPLEM MED, V14, P353, DOI 10.1089/acm.2007.0810
   Francesca F, 2003, EUR UROL, V44, P383, DOI 10.1016/S0302-2838(03)00321-X
   Gong J, 2021, J ACUPUNCT TUINA SCI, V19, P129, DOI 10.1007/s11726-021-1236-x
   Gu YJ, 2017, ACTA CHIN MED, V32, P2307, DOI 10.16368/j.issn.1674-8999.2017.12.601
   Han JS, 2003, TRENDS NEUROSCI, V26, P17, DOI 10.1016/S0166-2236(02)00006-1
   Han Xue-Chang, 2020, ZHEN CI YAN JIU, V45, P845, DOI 10.13702/j.1000-0607.200131
   Hu XX, 2020, THERAPEUTIC EFFECT O, V0, P0
   Lee HJ, 2009, ACUPUNCTURE ELECTRO, V34, P27, DOI 10.3727/036012909803861095
   Li DH, 2021, EVID-BASED COMPL ALT, V2021, P0, DOI 10.1155/2021/5558590
   Li YF, 2018, J EXTERN THER TRADIT, V27, P6
   Liang FR, 2016, SUBJECT ACUPUNCTURE, V0, P0
   Liou KT, 2020, MEDICINE, V99, P0, DOI 10.1097/MD.0000000000020085
   Liu Z, 2020, J HUNAN U CHIN MED, V40, P209
   Mao JJ, 2022, J CLIN ONCOL, V40, P3998, DOI 10.1200/JCO.22.01357
   Mao JJ, 2021, JAMA ONCOL, V7, P720, DOI 10.1001/jamaoncol.2021.0310
   MELZACK R, 1977, PAIN, V3, P3, DOI 10.1016/0304-3959(77)90032-X
   National Comprehensive Cancer Network (NCCN), 2023, OVARIAN CANCER VERSION 2.2023. 2023, V0, P0
   Oberoi D, 2022, BMC COMPLEMENT MED, V22, P0, DOI 10.1186/s12906-022-03600-6
   Paice JA, 2016, J CLIN ONCOL, V34, P3325, DOI 10.1200/JCO.2016.68.5206
   Pan P, 2019, PRACT CLIN J INTEGR, V19, P147, DOI 10.13638/j.issn.1671-4040.2019.04.076
   Peng J, 2012, SHANG J ACUPUNCT MOXIBUST, V31, P236
   Ren M, 2016, J LIAONING U TRADIT, V18, P185
   Saraswati W, 2021, J ACUPUNCT MERIDIAN, V14, P5, DOI 10.51507/j.jams.2021.14.1.4
   Scarborough BM, 2018, CA-CANCER J CLIN, V68, P182, DOI 10.3322/caac.21453
   Shen JM, 2013, JOURNAL OF LIAONING UNIVERSITY OF TCM, V15, P189
   Shen L, 2016, J MED RES, V45, P87
   [沈岩金 Shen Yanjin], 2016, 时珍国医国药 LISHIZHEN MEDICINE AND MATERIA MEDICA RESEARCH, V27, P2287
   Wang C, 2019, J NEW CHIN MED, V51, P242, DOI 10.13457/J.CNKI.JNCM.2019.10.069
   Wang H, 2018, HENAN TRADIT. CHIN. MED., V38, P454, DOI 10.16367/J.ISSN.1003-5028.2018.03.0120
   Wang JF, 2020, J EMERG TRADIT CHIN, V29, P608
   Wang L, 2019, GUIDING J TRADIT CHI, V25, P108
   [王文靖 WANG Wenjing], 2006, 针刺研究 ACUPUNCTURE RESEARCH, V31, P131
   Wang XY, 2006, TRADIT. CHIN. MED. RES., V19, P41, DOI 10.3969/j.issn.1001-6910.2006.05.023
   Wang Y, 2017, ZHEJIANG J TRADIT CHIN MED, V52, P684
   [王莹 Wang Ying], 2022, 北京中医药大学学报 JOURNAL OF BEIJING UNIVERSITY OF TRADITIONAL CHINESE MEDICINE, V45, P370
   Wei R, 2018, J CLIN ACUPUNCT MOXI, V34, P10
   Wu J, 2014, CHIN J TRADIT CHIN MED, V32, P1904
   Wu J, 2021, JILIN J CHIN MED, V41, P1401, DOI 10.13463/J.CNKI.JLZYY.2021.11.001
   Wu Z, 2022, ZHEJIANG CLIN MED, V24, P540
   Xu CT, 2020, ZHEJIANG J TRADIT CH, V55, P295, DOI 10.13633/j.cnki.zjtcm.2020.04.035
   Xu LL, 2018, J CANCER RES THER, V14, P99, DOI 10.4103/jcrt.JCRT_736_17
   Yang J, 2021, BMJ SUPPORT PALLIAT, V11, P264, DOI 10.1136/bmjspcare-2020-002638
   Yang Q, 2020, LIAONING J TRADIT CH, V47, P71, DOI 10.13192/j.issn.1000-1719.2020.05.020
   Yang Z, 2021, J TRADIT CHIN MED ONCOL, V3, P30, DOI 10.1007/s12032-021-01474-1
   Ye JH, 2000, J YUNNAN COLL TRADIT, V2, P0, DOI 10.19288/j.cnki.issn.1000-2723.2000.02.008
   Ye JH, 2002, J RADIOIMMUNOL, V15, P14
   Zhang L, 2021, J NEW CHIN MED, V53, P104, DOI 10.13457/j.cnki.jncm.2021.15.026
   Zhang N, 2022, CHINA PRACT MED, V17, P43, DOI 10.14163/j.cnki.11-5547/r.2022.19.010
   [张尧 Zhang Yao], 2012, 中国康复医学杂志 CHINESE JOURNAL OF REHABILITATION MEDICINE, V27, P1097
   Zhang YX, 2020, CHINA MOD DR, V58, P144
   [赵仓焕 Zhao Canghuan], 2006, 暨南大学学报. 自然科学与医学版 JOURNAL OF JINAN UNIVERSITY. NATURAL SCIENCE & MEDICINE EDITION, V27, P812
   Zheng B, 2022, JPN J REHABIL MED, V37, P117
   [郑思懿 Zheng Siyi], 2022, 中医杂志 JOURNAL OF TRADITIONAL CHINESE MEDICINE, V63, P1026
   Zubrzycka M, 2011, BRAIN RES, V1405, P15, DOI 10.1016/j.brainres.2011.06.030
NR 60
TC 6
Z9 6
U1 1
U2 11
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1534-7354
EI 1552-695X
J9 INTEGR CANCER THER
JI Integr. Cancer Ther.
PD JUN 15
PY 2023
VL 22
IS 
BP 
EP 
DI 10.1177/15347354231192017
PG 13
WC Oncology; Integrative & Complementary Medicine
SC Oncology; Integrative & Complementary Medicine
GA O4UH4
UT WOS:001043775500001
PM 37551854
DA 2026-01-16
ER

PT J
AU Frenkel, M
   David, A
   Sapire, K
   Hausner, D
AF Frenkel, Moshe
   David, Adi
   Sapire, Kenneth
   Hausner, David
TI Complementary and Integrative Medicine in Pancreatic Cancer.
SO Current oncology reports
LA English
DT Review
DE Acupuncture; Complementary medicine; Curcumin; Dietary supplements; Homeopathy; Integrative medicine; Mind–body medicine; Nutrition; Nutritional supplements; Pancreatic cancer; Pancreatic ductal adenocarcinoma; Physical activity; Reflexology; Touch therapies
AB PURPOSE OF REVIEW: Pancreatic cancer has high mortality and morbidity rates,  associated with the issues of typically late diagnosis and the limited  effectiveness of current treatments. Patients tend to experience multiple  symptoms that can include anxiety, fear, depression, fatigue, weakness,  peripheral neuropathy, and abdominal pain, which reduce quality of life (QoL) and  may compromise the treatment continuum. Many of those symptoms are amenable to  complementary and integrative medicine (CIM) therapies as a part of supportive  and palliative care. This article reviews research findings on the beneficial  effect of use of CIM modalities in regard to pancreatic cancer, with emphasis on  pancreatic ductal adenocarcinoma (PDAC). RECENT FINDINGS: Given the often-poor  prognosis of the disease, patients with PDAC often seek integrative therapies to  help manage the disease itself, to provide support through cancer treatment and  its symptoms, and to provide emotional stress relief. Data is accumulating in the  past few years on the potential benefits of CIM to the management of pancreatic  cancer symptoms and treatment side effects, in order to augment supportive care.  This data reveal that nutrition counselling; digestive enzyme therapy; microbiome  support; dietary supplements; lifestyle interventions (physical activity and  circadian health/sleep hygiene) appear to improve QoL of these patients through  reduced symptom burden and meeting psychological needs, such as distress and  fatigue. Acupuncture, mindfulness, yoga, reflexology, massage, and homeopathy may  also contribute to symptom reduction, both physical and psychological, in all  stages of the disease. There is supporting evidence that some CIM modalities may  alleviate side effects and symptoms related to pancreatic cancer and its  treatment, suggesting that practitioners might consider integrating these  modalities in certain situations encountered in the treatment of pancreatic  cancer. Further investigation is needed to define the optimal integration of CIM  into the treatment and supportive care of patients affected by pancreatic cancer.
C1 Complementary and Integrative Medicine Service, Oncology Division, Rambam Health Care Campus, Haifa, Israel. frenkelm@netvision.net.il.
   Tal Center for Integrative Medicine, Institute of Oncology, Chaim Sheba Medical Center, Ramat-Gan, Israel.
   Department of Anesthesiology and Perioperative Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
   Tal Center for Integrative Medicine, Institute of Oncology, Chaim Sheba Medical Center, Ramat-Gan, Israel.
   Palliative Care Service, Chaim Sheba Medical Center, Ramat Gan, Israel.
NR 0
TC 0
SN 1534-626
EI 
J9 Curr Oncol Rep
PD FEB 4
PY 2023
VL 25
IS 3
BP 231
EP 242
DI 10.1007/s11912-023-01370-z
PG 11
WC Humans; Quality of Life; psychology; Integrative Medicine; Complementary Therapies; Pancreatic Neoplasms; Fatigue; therapy
UT PubMed:36735141
PM 36735141
DA 2023-02-04
ER

PT J
AU Ribeiro, H
   Alves, R
   Jorge, J
   Gonçalves, AC
   Sarmento-Ribeiro, AB
   Teixeira-Veríssimo, M
   Dourado, M
   Andrade, JP
AF Ribeiro, Hugo
   Alves, Raquel
   Jorge, Joana
   Goncalves, Ana Cristina
   Sarmento-Ribeiro, Ana Bela
   Teixeira-Verissimo, Manuel
   Dourado, Marilia
   Andrade, Jose Paulo
TI Platelet Membrane Proteins as Pain Biomarkers in Patients with Severe Dementia
SO BIOMEDICINES
LA English
DT Article
DE chronic pain; pharmacology; platelets; biomarkers; palliative care
ID rich fibrin; performance; activation; receptors; cd49f
AB Pain is one of the most frequent health problems, and its evaluation and therapeutic approach largely depend on patient self-report. When it is not possible to obtain a self-report, the therapeutic decision becomes more difficult and limited. This study aims to evaluate whether some membrane platelet proteins could be of value in pain characterization. To achieve this goal, we used 53 blood samples obtained from palliative patients, 44 with non-oncological pain and nine without pain. We observed in patients with pain a decrease in the percentage of platelets expressing CD36, CD49f, and CD61 and in the expression levels of CD49f and CD61 when compared with patients without pain. Besides that, an increase in the percentage of platelets expressing CD62p was observed in patients with pain. These results suggest that the levels of these platelet cluster differentiations (CDs) could have some value as pain biomarkers objectively since they are not dependent on the patient's participation. Likewise, CD40 seems to have some importance as a biomarker of moderate and/or severe pain. The identification of pain biomarkers such as CD40, CD49f, CD62p and CD61 can lead to an adjustment of the therapeutic strategy, contributing to a faster and more adequate control of pain and reduction in patient-associated suffering.
C1 [Ribeiro, Hugo] Grp Hlth Ctr Gaia, Community Support Team Palliat Care, P-4430999 Vila Nova De Gaia, Portugal.
   [Ribeiro, Hugo] Univ Porto, Fac Med, P-4200319 Porto, Portugal.
   [Ribeiro, Hugo; Alves, Raquel; Jorge, Joana; Goncalves, Ana Cristina; Sarmento-Ribeiro, Ana Bela; Teixeira-Verissimo, Manuel; Dourado, Marilia] Univ Coimbra, Fac Med, P-3000548 Coimbra, Portugal.
   [Ribeiro, Hugo; Alves, Raquel; Jorge, Joana; Goncalves, Ana Cristina; Sarmento-Ribeiro, Ana Bela; Dourado, Marilia] Univ Coimbra FMUC, Coimbra Inst Clin & Biomed Res iCBR, Grp Environm Genet & Oncobiol CIMAGO, P-3000548 Coimbra, Portugal.
   [Ribeiro, Hugo; Alves, Raquel; Jorge, Joana; Goncalves, Ana Cristina; Sarmento-Ribeiro, Ana Bela] Univ Coimbra FMUC, Univ Clin Hematol & Oncol, Fac Med, P-3000548 Coimbra, Portugal.
   [Ribeiro, Hugo; Alves, Raquel; Jorge, Joana; Goncalves, Ana Cristina; Sarmento-Ribeiro, Ana Bela] Univ Coimbra FMUC, Fac Med, Lab Oncobiol & Hematol LOH, P-3000548 Coimbra, Portugal.
   [Ribeiro, Hugo; Alves, Raquel; Jorge, Joana; Goncalves, Ana Cristina; Sarmento-Ribeiro, Ana Bela; Dourado, Marilia] Ctr Innovat Biomed & Biotechnol CIBB, P-3000548 Coimbra, Portugal.
   [Sarmento-Ribeiro, Ana Bela; Teixeira-Verissimo, Manuel] Ctr Hosp & Univ Coimbra CHUC, Hematol Serv, P-3000548 Coimbra, Portugal.
   [Andrade, Jose Paulo] Univ Porto, Fac Med, CINTESIS RISE, P-4200319 Porto, Portugal.
   [Andrade, Jose Paulo] Univ Porto, Fac Med, Dept Biomed, Unit Anat, P-4200319 Porto, Portugal.
C3 Universidade do Porto; Universidade de Coimbra; Universidade de Coimbra; Universidade de Coimbra; Universidade de Coimbra; Universidade de Coimbra; Universidade de Coimbra; Centro Hospitalar e Universitario de Coimbra (CHUC); Universidade do Porto; Universidade do Porto
RP Ribeiro, H (corresponding author), Grp Hlth Ctr Gaia, Community Support Team Palliat Care, P-4430999 Vila Nova De Gaia, Portugal.; Ribeiro, H (corresponding author), Univ Porto, Fac Med, P-4200319 Porto, Portugal.; Ribeiro, H (corresponding author), Univ Coimbra, Fac Med, P-3000548 Coimbra, Portugal.; Ribeiro, H (corresponding author), Univ Coimbra FMUC, Coimbra Inst Clin & Biomed Res iCBR, Grp Environm Genet & Oncobiol CIMAGO, P-3000548 Coimbra, Portugal.; Ribeiro, H (corresponding author), Univ Coimbra FMUC, Univ Clin Hematol & Oncol, Fac Med, P-3000548 Coimbra, Portugal.; Ribeiro, H (corresponding author), Univ Coimbra FMUC, Fac Med, Lab Oncobiol & Hematol LOH, P-3000548 Coimbra, Portugal.; Ribeiro, H (corresponding author), Ctr Innovat Biomed & Biotechnol CIBB, P-3000548 Coimbra, Portugal.
EM hribeiroff@gmail.com
FU National Funds through FCT-Fundacao para a Ciencia e a Tecnologia within CINTESIS, RD Unit [UIDB/4255/2020]; RISE, Associated Laboratory [LA/P/0053/2020]
CR Akingbade OES, 2018, J ALZHEIMERS DIS, V63, P1235, DOI 10.3233/JAD-180181
   Ali A, 2018, CUREUS J MED SCIENCE, V10, P0, DOI 10.7759/cureus.3293
   Altintoprak F, 2013, WORLD J EMERG SURG, V8, P0, DOI 10.1186/1749-7922-8-49
   Arman M, 2015, NON-THROMBOTIC ROLE OF PLATELETS IN HEALTH AND DISEASE, V0, PP37, DOI 10.5772/60536
   Avcioglu Sumeyra Nergiz, 2014, ISRN OBSTET GYNECOL, V2014, P713542, DOI 10.1155/2014/713542
   Barbar L, 2020, NEURON, V107, P436, DOI 10.1016/j.neuron.2020.05.014
   Barkai O, 2019, PAIN, V160, P1281, DOI 10.1097/j.pain.0000000000001523
   Beko K, 2017, J THROMB HAEMOST, V15, P1223, DOI 10.1111/jth.13684
   Chen YF, 2020, BIOMARK RES, V8, P0, DOI 10.1186/s40364-020-00207-2
   Chignon-Sicard B, 2012, PLAST RECONSTR SURG, V130, P819E, DOI 10.1097/PRS.0b013e31826d1711
   Dostert C, 2019, PHYSIOL REV, V99, P115, DOI 10.1152/physrev.00045.2017
   Farag M, 2016, HEART, V102, PA19, DOI 10.1136/heartjnl-2016-309890.28
   Garcia-Larrea L, 2013, PAIN, V154, PS29, DOI 10.1016/j.pain.2013.09.001
   Gianazza E, 2020, INT J MOL SCI, V21, P0, DOI 10.3390/ijms21124541
   Green SA, 2015, AIDS, V29, P1297, DOI 10.1097/QAD.0000000000000701
   Gruba SM, 2021, ACS MEAS SCI AU, V2, P4, DOI 10.1021/acsmeasuresciau.1c00012
   Jankovic S, 2012, INT J PERIODONT REST, V32, P165
   Kopeikina E, 2021, FRONT CELL NEUROSCI, V15, P0, DOI 10.3389/fncel.2021.680126
   Kumar N, 2015, J ORAL MAXIL SURG, V73, P1042, DOI 10.1016/j.joms.2014.11.013
   Kwon YJ, 2020, THER ADV MUSCULOSKEL, V12, P0, DOI 10.1177/1759720X20912861
   Levi M, 2009, BRIT J HAEMATOL, V145, P24, DOI 10.1111/j.1365-2141.2009.07600.x
   Ludwig N, 2022, CELLS-BASEL, V11, P0, DOI 10.3390/cells11121957
   Marchi A, 2009, CLIN DRUG INVEST, V29, P41, DOI 10.2165/0044011-200929001-00006
   Michels WM, 2010, CLIN J AM SOC NEPHRO, V5, P1003, DOI 10.2215/CJN.06870909
   MOR V, 1984, CANCER-AM CANCER SOC, V53, P2002, DOI 10.1002/1097-0142(19840501)53:9<2002::AID-CNCR2820530933>3.0.CO;2-W
   Niculescu AB, 2019, MOL PSYCHIATR, V24, P501, DOI 10.1038/s41380-018-0345-5
   Orr PM, 2017, CRIT CARE NURS CLIN, V29, P407, DOI 10.1016/j.cnc.2017.08.002
   Osman Y, 2018, J HEMATOP, V11, P37, DOI 10.1007/s12308-018-0322-6
   Ozgul O, 2015, HEAD FACE MED, V11, P0, DOI 10.1186/s13005-015-0094-5
   Raja SN, 2020, PAIN, V161, P1976, DOI 10.1097/j.pain.0000000000001939
   Ramos-Cejudo J, 2022, J AM HEART ASSOC, V11, P0, DOI 10.1161/JAHA.121.023918
   RECHES A, 1980, NATURE, V288, P382, DOI 10.1038/288382a0
   Ribatti D, 2007, LEUKEMIA RES, V31, P1339, DOI 10.1016/j.leukres.2007.02.008
   Ribeiro HACda, 2017, PARTICULARIDADES DA AVALIACAO E TRATAMENTO DA DOR NO IDOSO: CONTRIBUTO PARA A VALIDACAO DA PAIN QUALITY ASSESSMENT SCALE E ABORDAGEM TERAPEUTICA NA POPULACAO IDOSA, V0, P0
   RINGKAMP M, 1994, NEUROSCI LETT, V170, P103, DOI 10.1016/0304-3940(94)90249-6
   Rodriguez C S, 2001, PAIN MANAG NURS, V2, P38, DOI 10.1053/jpmn.2001.23746
   Saboor M, 2013, PAK J MED SCI, V29, P891, DOI 10.12669/pjms.293.3497
   SALEM HH, 1980, JAMA-J AM MED ASSOC, V244, P1122
   Schedel A, 2010, TRANSFUS MED HEMOTH, V37, P293, DOI 10.1159/000319841
   Sevush S, 1998, ARCH NEUROL-CHICAGO, V55, P530, DOI 10.1001/archneur.55.4.530
   Silverstein RL, 2009, SCI SIGNAL, V2, P0, DOI 10.1126/scisignal.272re3
   Soysal P, 2019, J AM MED DIR ASSOC, V20, P183, DOI 10.1016/j.jamda.2018.07.016
   Steel HC, 2021, FRONT IMMUNOL, V11, P0, DOI 10.3389/fimmu.2020.594110
   Valkonen S, 2019, TRANSFUS MED HEMOTH, V46, P267, DOI 10.1159/000499958
   Warden Victoria, 2003, J AM MED DIR ASSOC, V4, P9, DOI 10.1016/S1525-8610(04)70258-3
   Weinstock Christof, 2015, IMMUNOHEMATOLOGY, V31, P145, DOI 10.21307/immunohematology-2019-083
   Weth D, 2015, FRONT NEUROSCI-SWITZ, V9, P0, DOI 10.3389/fnins.2015.00140
   World Health Organization, 2007, NORM GUID PAIN MAN, V0, P0
   World Health Organization, 2009, WHOS PAIN REL LADD, V0, P0
   Yang ZG, 2015, STEM CELLS, V33, P2798, DOI 10.1002/stem.2063
NR 51
TC 3
Z9 3
U1 0
U2 6
PU MDPI
PI BASEL
PA MDPI AG, Grosspeteranlage 5, CH-4052 BASEL, SWITZERLAND
SN 
EI 2227-9059
J9 BIOMEDICINES
JI Biomedicines
PD FEB 15
PY 2023
VL 11
IS 2
BP 
EP 
DI 10.3390/biomedicines11020380
PG 12
WC Biochemistry & Molecular Biology; Medicine, Research & Experimental; Pharmacology & Pharmacy
SC Biochemistry & Molecular Biology; Research & Experimental Medicine; Pharmacology & Pharmacy
GA 9H6QK
UT WOS:000938955000001
PM 36830917
DA 2026-01-16
ER

PT J
AU Lu, S
   Wang, B
   Wang, J
   Guo, Y
   Li, S
   Zhao, S
   Yang, Y
   Feng, Y
   Xu, Z
AF Lu, Shanshan
   Wang, Bin
   Wang, Jiaqi
   Guo, Yi
   Li, Shanshan
   Zhao, Suhong
   Yang, Yuanzhen
   Feng, Yiting
   Xu, Zhifang
TI Moxibustion for the Treatment of Cancer and its Complications: Efficacies and
SO Integrative cancer therapies
LA English
DT Review
DE cancer; chemotherapy; complications of cancer; moxibustion; side-effect
AB Cancer treatment remains a significant challenge for the medical community, and  improved therapies are necessary to treat cancer and its associated  complications. Current anticancer therapies often have significant side effects,  underscoring the need for new treatment options. Moxibustion is a representative  external therapy used in traditional Chinese medicine. This review examines  clinical studies demonstrating moxibustion's ability to improve the efficacy of  radiotherapy and chemotherapy and control tumor progression. Moxibustion can  prevent and treat various complications of cancer, including cancer-related or  therapy-induced gastrointestinal symptoms, myelosuppression, fatigue, pain, and  postoperative lymphedema. has also been shown to enhance the quality of life for  cancer patients. However, very few studies have investigated the underlying  mechanisms for these effects, a topic that requires systematic elucidation.  Evidence has shown that moxibustion alone or combined with chemotherapy can  improve survival and inhibit tumor growth in cancer-bearing animal models. The  anticancer effect of moxibustion is associated with alleviating the tumor  immunosuppressive and vascular microenvironments. Additionally, the therapeutic  effects of moxibustion may originate from the heat and radiation produced during  the combustion process on acupoints or lesions. This evidence provides a  scientific basis for the clinical application of moxibustion in anticancer  treatment and reducing the side effects of cancer therapies and helps promote the  precise application of moxibustion in cancer treatment.
C1 Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, P. R. China.
   Tianjin University of Traditional Chinese Medicine, Tianjin, P. R. China.
   Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, P. R. China.
   Tianjin University of Traditional Chinese Medicine, Tianjin, P. R. China.
   Tianjin University of Traditional Chinese Medicine, Tianjin, P. R. China.
   National Clinical Research Center for Chinese Medicine Acupuncture and 
   Tianjin University of Traditional Chinese Medicine, Tianjin, P. R. China.
   Tianjin University of Traditional Chinese Medicine, Tianjin, P. R. China.
   Tianjin University of Traditional Chinese Medicine, Tianjin, P. R. China.
   Tianjin University of Traditional Chinese Medicine, Tianjin, P. R. China.
   Tianjin University of Traditional Chinese Medicine, Tianjin, P. R. China.
   National Clinical Research Center for Chinese Medicine Acupuncture and
NR 0
TC 0
SN 1552-695
EI 1534-735
J9 Integr Cancer Ther
PD SEP 25
PY 2023
VL 22
IS 
BP 15347354231198089
EP 15347354231198089
DI 10.1177/15347354231198089
PG 1
WC Humans; Moxibustion; adverse effects; Quality of Life; Neoplasms; drug therapy; Fatigue; therapy; Medicine, Chinese Traditional; Tumor Microenvironment
UT PubMed:37746720
PM 37746720
DA 2023-09-25
ER

PT J
AU Zhong, Z
   Jin, K
   Qin, F
   Nie, R
AF Zhong, Zhinian
   Jin, Kang
   Qin, Fengling
   Nie, Rongrong
TI Huoxue Tongluo decoction combined with acupuncture in the treatment of lumbar
SO Journal of back and musculoskeletal rehabilitation
LA English
DT Journal Article
DE Clinical disease; effectiveness; functional recovery
AB BACKGROUND: Lumbar disc herniation (LDH) is a common clinical disease of the  skeletal system, and its prevalence has been on a rise. OBJECTIVE: To evaluate  the efficacy of Huoxue Tongluo decoction plus acupuncture in the treatment of  lumbar disc herniation and its effectiveness in improving the functional recovery  of the patients' affected joints and mitigating their pain. METHODS: In this  prospective study, 110 patients with lumbar disc herniation enrolled in our  Hospital from June 2019 to June 2021 were collected and randomized to receive  either conventional treatment (control group) or Huoxue Tongluo Decoction plus  acupuncture (study group). RESULTS: Huoxue Tongluo Decoction plus acupuncture  resulted in more rapid mitigation of lower extremity symptoms and lumbar symptoms  versus conventional treatment (P< 0.05). Patients receiving traditional Chinese  medicine (TCM) showed milder inflammatory responses than those with conventional  medication, as evidenced by the lower serum concentrations of tumor necrosis  factor-α (TNF-α), interleukin (IL)-6, and high-sensitivity C-reactive protein  (hs-CRP) (P< 0.05). After treatment, the study group had higher Japanese  Orthopedic Association (JOA) scores and lower visual analogue scale (VAS) scores  than the control group (P< 0.05), suggesting that the combination of the herbal  decoction and acupuncture provided better functional recovery of the affected  joints and pain mitigation for the patients. Furthermore, the lower Pittsburgh  sleep quality index (PSQI) scores in patients in the study group indicated better  sleep quality of patients after TCM intervention than after conventional  treatment (P< 0.05). Huoxue Tongluo Decoction plus acupuncture was associated  with a significantly higher efficacy (94.55%) versus conventional treatment (80%)  (P< 0.05). CONCLUSIONS: Huoxue Tongluo Decoction combined with acupuncture  significantly offers a viable treatment alternative for lumbar disc herniation  with promising treatment outcomes, mitigates patients' limb pain, and improves  their lumbar function and sleep quality. Further trials are, however, required  prior to general application in clinical practice.
C1 Department of Rehabilitation Medicine, The Traditional Chinese Medicine Hospital of Qinzhou, Qinzhou, Guangxi, China.
   Department of Rehabilitation Medicine, The Traditional Chinese Medicine Hospital of Qinzhou, Qinzhou, Guangxi, China.
   Department of Rehabilitation Treatment, The Affiliated Hospital of Guilin Medical College, Guilin, Guangxi, China.
   Department of Rehabilitation Treatment, The Affiliated Hospital of Guilin Medical College, Guilin, Guangxi, China.
NR 0
TC 0
SN 1878-632
EI 
J9 J Back Musculoskelet Rehabil
PD SEP 4
PY 2023
VL 37
IS 2
BP 277
EP 283
DI 10.3233/BMR-220347
PG 6
WC Humans; Acupuncture Therapy; Drugs, Chinese Herbal; therapeutic use; Intervertebral Disc Displacement; therapy; Lumbar Vertebrae; Pain; Prospective Studies; Treatment Outcome
UT PubMed:37661864
PM 37661864
DA 2023-09-04
ER

PT J
AU Yeh, CH
   Lukkahatai, N
   Huang, XR
   Wu, HL
   Wang, HY
   Zhang, JY
   Sun, XY
   Smith, TJ
AF Yeh, Chao Hsing
   Lukkahatai, Nada
   Huang, Xinran
   Wu, Hulin
   Wang, Hongyu
   Zhang, Jingyu
   Sun, Xinyi
   Smith, Thomas J.
TI Biological Correlates of the Effects of Auricular Point Acupressure on Pain
SO PAIN MANAGEMENT NURSING
LA English
DT Article
DE Auricular point acupressure; Inflammatory biomarkers; Cytokines; Chemokines; Self-management
ID low-back-pain; cancer survivors; acupuncture; management; il-6; inhibitor; cytokines; society
AB Background: To identify candidate inflammatory biomarkers for the underlying mechanism of auricular point acupressure (APA) on pain relief and examine the correlations among pain intensity, interference, and inflammatory biomarkers.Design: This is a secondary data analysis.Methods: Data on inflammatory biomarkers collected via blood samples and patient self-reported pain intensity and interference from three pilot studies (chronic low back pain, n = 61; arthralgia related to aromatase inhibitors, n = 20; and chemotherapy-induced neuropathy, n = 15) were integrated and analyzed. This paper reports the results based on within-subject treatment effects (change in scores from pre-to post-APA intervention) for each study group (chronic low back pain, cancer pain), between-group differences (changes in scores from pre-to post-intervention between targeted-point APA [T-APA] and non-targeted-point APA [NT-APA]), and correlations among pain intensity, interference, and biomarkers. Results: Within-group analysis (the change score from pre-to post-APA) revealed statistically significant changes in three biomarkers: TNF-alpha (cancer pain in the APA group, p = .03), beta-endorphin (back pain in the APA group, p = .04), and IL-2 (back pain in the NT-APA group, p = .002). Based on between-group analysis in patients with chronic low back pain (T-APA vs NT-APA), IL-4 had the largest effect size (0.35), followed by TNF-alpha (0.29). A strong positive monotonic relationship between IL-1 beta and IL-2 was detected.Conclusions: The current findings further support the potential role of inflammatory biomarkers in the analgesic effects of APA. More work is needed to gain a comprehensive understanding of the underlying mechanisms of APA on chronic pain. Because it is simple, inexpensive, and has no negative side effects, APA can be widely disseminated as an alternative to opioids.(c) 2022 The Authors. Published by Elsevier Inc. on behalf of American Society for Pain Management Nursing.This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ )
C1 [Yeh, Chao Hsing; Wang, Hongyu] Univ Texas Hlth Sci Ctr Houston, Cizik Sch Nursing, Houston, TX USA.
   [Lukkahatai, Nada] Johns Hopkins Univ, Sch Nursing, Baltimore, MD USA.
   [Huang, Xinran; Wu, Hulin] Univ Texas Hlth Sci Ctr Houston, Sch Publ Hlth, Houston, TX USA.
   [Wang, Hongyu] Univ Texas Hlth Sci Ctr Houston, McGovern Med Sch, Houston, TX USA.
   [Zhang, Jingyu; Sun, Xinyi] Johns Hopkins Univ, Krieger Sch Arts & Sci, Baltimore, MD USA.
   [Smith, Thomas J.] Johns Hopkins Univ, Sch Med, Baltimore, MD USA.
   [Yeh, Chao Hsing] 6901 Bertner Ave, Houston, TX 77030 USA.
C3 University of Texas System; University of Texas Health Science Center Houston; Johns Hopkins University; University of Texas System; University of Texas Health Science Center Houston; University of Texas School Public Health; University of Texas System; University of Texas Health Science Center Houston; Johns Hopkins University; Johns Hopkins University
RP Yeh, CH (corresponding author), 6901 Bertner Ave, Houston, TX 77030 USA.
EM chao.hsing.yeh@uth.tmc.edu
FU National Institute on Aging of the National Institutes of Health [R01AG056587]; Under Armour Women's Health & Breast Cancer Innovation Grant, Johns Hopkins Medicine; National Institute on Aging [R01AG056587] Funding Source: NIH RePORTER
CR Abaraogu UO, 2015, J ACUPUNCT MERIDIAN, V8, P220, DOI 10.1016/j.jams.2015.06.010
   Afifi Adel K, 2003, SEMIN PEDIATR NEUROL, V10, P3, DOI 10.1016/S1071-9091(02)00003-7
   Alimi D, 2002, MED ACUPUNCT, V13, P18
   Andrade P, 2013, EUR SPINE J, V22, P714, DOI 10.1007/s00586-012-2502-x
   Unknown -, 2012, PREV TOB UYOUTH YO, V0, P0
   Unknown -, 2005, AURICULAR MEDICINE: A COMPLETE MANUAL OF AURICULAR DIAGNOSIS AND TREATMENT, V0, P0
   Asher GN, 2010, J ALTERN COMPLEM MED, V16, P1097, DOI 10.1089/acm.2009.0451
   Austin PJ, 2010, J NEUROIMMUNOL, V229, P26, DOI 10.1016/j.jneuroim.2010.08.013
   Centers for Medicare and Medicaid Services, 2020, DEC MEM AC CHRON LOW, V0, P0
   Chou RHartung, 2020, COMPARATIVE EFFECTIVENESS REVIEW, V229, P0
   Cleeland CS, 1994, ANNALS ACADEMY OF MEDICINE SINGAPORE, V23, P129
   Cui J, 2017, ACUPUNCT MED, V35, P200, DOI 10.1136/acupmed-2016-011106
   Dalal Shalini, 2019, AM SOC CLIN ONCOL EDUC BOOK, V39, P24, DOI 10.1200/edbk_100020
   Dieleman JL, 2020, JAMA-J AM MED ASSOC, V323, P863, DOI 10.1001/jama.2020.0734
   Finley CR, 2018, CAN FAM PHYSICIAN, V64, P832
   GoldmanRakic PS, 1995, ANN NY ACAD SCI, V769, P71, DOI 10.1111/j.1749-6632.1995.tb38132.x
   Heyward J, 2018, JAMA NETW OPEN, V1, P0, DOI 10.1001/jamanetworkopen.2018.3044
   International Association for the Study of Pain, 2017, IASP TASK FORCE TAXO, V0, P0
   Iyengar S, 2017, PAIN, V158, P543, DOI 10.1097/j.pain.0000000000000831
   Jan AL, 2017, MED ACUPUNCT, V29, P276, DOI 10.1089/acu.2017.1237
   Jones MR, 2018, PAIN THER, V7, P13, DOI 10.1007/s40122-018-0097-6
   Kawi Jennifer, 2021, GLOB ADV HEALTH MED, V10, P2164956120987531, DOI 10.1177/2164956120987531
   Kim TH, 2022, FRONT NEUROSCI-SWITZ, V16, P0, DOI 10.3389/fnins.2022.834112
   Laumet G, 2019, FRONT MOL NEUROSCI, V12, P0, DOI 10.3389/fnmol.2019.00216
   Ledford CJW, 2018, J AM BOARD FAM MED, V31, P236, DOI 10.3122/jabfm.2018.02.170381
   Lin WC, 2015, EVID-BASED COMPL ALT, V2015, P0, DOI 10.1155/2015/103570
   Liu XL, 2015, EVID-BASED COMPL ALT, V2015, P0, DOI 10.1155/2015/657809
   Mizher H, 2020, J PHARM BIOALLIED SC, V12, P663, DOI 10.4103/jpbs.JPBS_13_20
   Moura CD, 2019, REV ESC ENFERM USP, V53, P0, DOI 10.1590/S1980-220X2018021703461
   Nahin RL, 2019, J PAIN, V20, P796, DOI 10.1016/j.jpain.2019.01.003
   National Acupuncture Detoxification Association, 2010, TRAIN RES MAN HDB IN, V4, P0
   Niemtzow R, 2018, MIL MED, V183, PE486, DOI 10.1093/milmed/usy028
   Nogier P, 1987, POINTS REFLEXES AURI, V0, P0
   Nogier P, 1981, HDB AURICULOTHERAPY, V0, P0
   Nogier R, 2014, MED ACUPUNCT, V26, P76, DOI 10.1089/acu.2014.1035
   Oda S, 2005, CYTOKINE, V29, P169, DOI 10.1016/j.cyto.2004.10.010
   Ohtori S, 2012, EUR SPINE J, V21, P2079, DOI 10.1007/s00586-012-2183-5
   Ohtori S, 2012, SPINE, V37, P439, DOI 10.1097/BRS.0b013e318238af83
   Oleson T, 2014, AURICULOTHERAPY MANUAL: CHINESE AND WESTERN SYSTEMS OF EAR ACUPUNCTURE, V0, P0
   Oliveira CB, 2018, EUR SPINE J, V27, P2791, DOI 10.1007/s00586-018-5673-2
   Paice JA, 2018, CANCER-AM CANCER SOC, V124, P2491, DOI 10.1002/cncr.31303
   Paice JA, 2016, J CLIN ONCOL, V34, P3325, DOI 10.1200/JCO.2016.68.5206
   Qaseem A, 2020, ANN INTERN MED, V173, P739, DOI 10.7326/M19-3602
   Qaseem A, 2017, ANN INTERN MED, V166, P514, DOI 10.7326/M16-2367
   Romoli M, 2014, NEUROL SCI, V35, PS189, DOI 10.1007/s10072-014-1768-7
   Schou WS, 2017, J HEADACHE PAIN, V18, P0, DOI 10.1186/s10194-017-0741-2
   Shi GX, 2020, J PAIN RES, V13, P2171, DOI 10.2147/JPR.S256950
   Skelly AC, 2020, NONINVASIVE NONPHARMACOLOGICAL TREATMENT FOR CHRONIC PAIN: A SYSTEMATIC REVIEW UPDATE, V0, P0, DOI DOI 10.23970/ahrqepccer227
   Stein KD, 2016, PSYCHO-ONCOLOGY, V25, P1212, DOI 10.1002/pon.4218
   Substance Abuse and Mental Health Services Administration, 2020, PUBLICATION NO PEP20, V0, P0
   Uddin LQ, 2017, SALIENCE NETWORK OF THE HUMAN BRAIN, V0, P1
   Üceyler N, 2006, ARTHRITIS RHEUM-US, V54, P2656, DOI 10.1002/art.22026
   Xia BJ, 2018, PAIN MED, V19, P193, DOI 10.1093/pm/pnx112
   Yang LH, 2017, EVID-BASED COMPL ALT, V2017, P0, DOI 10.1155/2017/6383649
   Yeh CH, 2021, PAIN MANAG NURS, V24, P0
   Yeh Chao Hsing, 2020, GLOB ADV HEALTH MED, V9, P2164956120906092, DOI 10.1177/2164956120906092
   Yeh CH, 2019, PAIN MANAG NURS, V20, P623, DOI 10.1016/j.pmn.2019.04.004
   Yeh CH, 2017, ONCOL NURS FORUM, V44, P476, DOI 10.1188/17.ONF.476-487
   Yeh CH, 2014, MED ACUPUNCT, V26, P31, DOI 10.1089/acu.2013.1015
   Yeh CH, 2013, MED ACUPUNCT, V25, P423, DOI 10.1089/acu.2013.1006
   Yeh CH, 2014, EVID-BASED COMPL ALT, V2014, P0, DOI 10.1155/2014/934670
   Yeh CH, 2012, EVID-BASED COMPL ALT, V2012, P0, DOI 10.1155/2012/383257
   You E, 2019, PAIN MANAG NURS, V20, P17, DOI 10.1016/j.pmn.2018.07.010
   Zelaya Carla E, 2020, NCHS DATA BRIEF, V0, P1
   Zhong Q, 2019, CHIN J INTEGR MED, V25, P225, DOI 10.1007/s11655-019-3063-1
NR 65
TC 15
Z9 18
U1 5
U2 19
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1524-9042
EI 1532-8635
J9 PAIN MANAG NURS
JI Pain Manag. Nurs.
PD FEB 15
PY 2023
VL 24
IS 1
BP 19
EP 26
DI 10.1016/j.pmn.2022.11.004
EA FEB 2023
PG 8
WC Nursing
SC Nursing
GA 9P5HV
UT WOS:000944317000001
PM 36543665
DA 2026-01-16
ER

PT J
AU Lopez, AM
AF Lopez, Ana Maria
TI Integrative oncology in cancer care: Reaching a tipping point
SO CANCER
LA English
DT Editorial Material
DE acupuncture; anxiety; gyn oncology; integrative oncology; pain
ID acupuncture
AB Preoperativerelaxation techniques decrease anxiety. The addition of intraoperative acupuncture reduced severe perioperative pain associated with gynecological oncology surgery.
C1 [Lopez, Ana Maria] Thomas Jefferson Univ, Sidney Kimmel Canc Ctr, 1025 Walnut St,Coll Bldg,Suite 700, Philadelphia, PA 19107 USA.
   [Lopez, Ana Maria] Thomas Jefferson Univ, Sidney Kimmel Canc Ctr, 1025 Walnut St,Coll Bldg,Suite 700, Philadelphia, PA 19107 USA.
C3 Thomas Jefferson University; Thomas Jefferson University
RP Lopez, AM (corresponding author), Thomas Jefferson Univ, Sidney Kimmel Canc Ctr, 1025 Walnut St,Coll Bldg,Suite 700, Philadelphia, PA 19107 USA.; Lopez, AM (corresponding author), Thomas Jefferson Univ, Sidney Kimmel Canc Ctr, 1025 Walnut St,Coll Bldg,Suite 700, Philadelphia, PA 19107 USA.
EM anamaria.lopez@jefferson.edu
CR Deng GE, 2013, CHEST, V143, PE420, DOI 10.1378/chest.12-2364
   Ernst E, 1998, CANCER-AM CANCER SOC, V83, P777, DOI 10.1002/(SICI)1097-0142(19980815)83:4<777::AID-CNCR22>3.0.CO;2-O
   Greenlee Heather, 2014, JOURNAL OF THE NATIONAL CANCER INSTITUTE MONOGRAPHS, V0, PP346, DOI 10.1093/jncimonographs/lgu041
   Linde K, 2010, BMC MED, V8, P0, DOI 10.1186/1741-7015-8-75
   Lu WD, 2008, HEMATOL ONCOL CLIN N, V22, P631, DOI 10.1016/j.hoc.2008.04.005
   MacPherson H, 2001, COMPLEMENT THER MED, V9, P246, DOI 10.1054/ctim.2001.0488
   Manget Luke, 2022, GINSENG DIGGERS: A HISTORY OF ROOT AND HERB GATHERING IN APPALACHIA, V0, P0
   Meng E, 2021, AM J PUBLIC HEALTH, V111, P896, DOI 10.2105/AJPH.2020.306080
   Ramsay DJ, 1998, JAMA-J AM MED ASSOC, V280, P1518
   Sedhom R, 2021, JCO ONCOL PRACT, V17, P587, DOI 10.1200/OP.21.00361
   Special JR, 1971, NEW YORK TIMES, V0, P0
   Stuyt L, 2018, USING NADA EAR ACUPU, V0, P0
   Venit-Shelton T, 2021, HERBS ROOTS HIST CHI, V0, P0
   Witt Claudia M, 2017, JOURNAL OF THE NATIONAL CANCER INSTITUTE MONOGRAPHS, V0, PP3, DOI 10.1093/jncimonographs/lgx012
NR 15
TC 2
Z9 2
U1 1
U2 8
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0008-543X
EI 1097-0142
J9 CANCER-AM CANCER SOC
JI Cancer
PD MAR 15
PY 2023
VL 129
IS 6
BP 834
EP 835
DI 10.1002/cncr.34539
EA JAN 2023
PG 2
WC Oncology
SC Oncology
GA 9I9PV
UT WOS:000917999900001
PM 36647627
DA 2026-01-16
ER

PT J
AU Xu, DH
   Yu, ZB
   Cai, XM
   Lin, JT
   Lin, TJ
   Sun, J
   Liu, ZX
   Cao, Y
   He, YH
AF Xu, Danghan
   Yu, Zhanbo
   Cai, Ximin
   Lin, Jietao
   Lin, Tengjiao
   Sun, Jian
   Liu, Zhaoxi
   Cao, Yang
   He, Yihan
TI Effect of Fu's subcutaneous needling for cancer pain management: protocol for a pragmatic randomised controlled trial
SO BMJ OPEN
LA English
DT Article
DE Cancer pain; COMPLEMENTARY MEDICINE; PAIN MANAGEMENT
ID acupuncture; sham
AB Introduction Pain is a common symptom in patients with cancer, and pain management is crucial for these patients. Fu's subcutaneous needling (FSN) is a modern acupuncture therapy based on basic medicine commonly used in patients with pain. However, evidence of its effectiveness in treating cancer pain has not been systematically proven. Therefore, this pragmatic randomised controlled trial aims to evaluate the effectiveness and safety of FSN for cancer pain management. Methods and analysis Overall, 120 eligible patients will be recruited and randomly assigned into two groups using block randomisation. Both groups will be administered analgesic drugs according to the National Comprehensive Cancer Network guidelines. The treatment group will receive FSN therapy one time a day for 6 days. Additionally, we will assess analgesic consumption as the primary outcome and the Numerical Rating Scale, outbreak pain, symptom assessment and adverse events as secondary outcomes to evaluate the effect and safety of FSN in treating cancer pain. The incidence of adverse events will be monitored to assess the safety of FSN. Ethics and dissemination Ethics approval was obtained from the Ethics Committee of the First Affiliated Hospital of Guangzhou University of Chinese Medicine (approval No: K(2021)096). The results will be published in a peer-reviewed journal, and trial participants will be informed via email and/or phone calls.
C1 [Xu, Danghan] Guangzhou Univ Chinese Med, Affiliated Hosp 1, Rehabil Ctr, Guangzhou, Guangdong, Peoples R China.
   [Yu, Zhanbo; Cai, Ximin; Liu, Zhaoxi] Guangzhou Univ Chinese Med, Guangzhou, Guangdong, Peoples R China.
   [Lin, Jietao; Cao, Yang] Guangzhou Univ Chinese Med, Affiliated Hosp 1, Ctr Oncol, Guangzhou, Guangdong, Peoples R China.
   [Lin, Tengjiao] Guangzhou Univ Chinese Med, Affiliated Hosp 1, Dept Radiotherapy, Guangzhou, Guangdong, Peoples R China.
   [Sun, Jian] Guangzhou Univ Chinese Med, Affiliated Hosp 2, Guangdong Prov Acad Chinese Med Sci, Acupuncture Dept, Guangzhou, Guangdong, Peoples R China.
   [He, Yihan] Guangzhou Univ Chinese Med, Affiliated Hosp 2, Guangdong Prov Acad Chinese Med Sci, Oncol Dept, Guangzhou, Guangdong, Peoples R China.
C3 Guangzhou University of Chinese Medicine; Guangzhou University of Chinese Medicine; Guangzhou University of Chinese Medicine; Guangzhou University of Chinese Medicine; Guangzhou University of Chinese Medicine; Guangzhou University of Chinese Medicine
RP He, YH (corresponding author), Guangzhou Univ Chinese Med, Affiliated Hosp 2, Guangdong Prov Acad Chinese Med Sci, Oncol Dept, Guangzhou, Guangdong, Peoples R China.
EM yihanhe@gzucm.edu.cn
FU Guangdong Provincial Key Laboratory of Traditional Chinese Medicine and Acupuncture [06]; National Natural Science Foundation of China [82004447]; Guangdong Basic and Applied Basic Research Foundation [2021A1515011597]; Guangdong Provincial Hospital of Chinese Medicine [YN2018QL04]
CR Chiu PE, 2022, J CLIN MED, V11, P0, DOI 10.3390/jcm11237184
   Copenhaver David J, 2021, CANCER TREAT RES, V182, P3, DOI 10.1007/978-3-030-81526-4_1
   Coyne CJ, 2021, SUPPORT CARE CANCER, V29, P4543, DOI 10.1007/s00520-021-05987-3
   Fu ZH, 2012, EVID-BASED COMPL ALT, V2012, P0, DOI 10.1155/2012/353916
   Gerra MC, 2021, GENES-BASEL, V12, P0, DOI 10.3390/genes12081226
   He YH, 2022, ACUPUNCT MED, V40, P133, DOI 10.1177/09645284211056016
   He YH, 2020, JAMA ONCOL, V6, P271, DOI 10.1001/jamaoncol.2019.5233
   Hershman DL, 2018, JAMA-J AM MED ASSOC, V320, P167, DOI 10.1001/jama.2018.8907
   Higdon ML, 2018, AM FAM PHYSICIAN, V97, P741
   Hua Z, 2016, CHINESE ELECT J ACUP, V04, P148
   Huang CH, 2022, PAIN RES MANAG, V2022, P0, DOI 10.1155/2022/7592873
   Huang CH, 2022, EVID-BASED COMPL ALT, V2022, P0, DOI 10.1155/2022/5951327
   Jia Wen, 2019, ZHONGGUO ZHEN JIU, V39, P111, DOI 10.13703/j.0255-2930.2019.01.029
   Kaptchuk TJ, 2010, CHIN J INTEGR MED, V16, P197, DOI 10.1007/s11655-010-0197-x
   Kurita GP, 2021, POL ARCH INTERN MED, V131, P0, DOI 10.20452/pamw.16136
   Lewis MA, 2011, CA-CANCER J CLIN, V61, P287, DOI 10.3322/caac.20124
   Li YP, 2022, MOL PAIN, V18, P0, DOI 10.1177/17448069221108717
   Lopez G, 2017, MED CLIN N AM, V101, P977, DOI 10.1016/j.mcna.2017.04.011
   Lundeberg T, 2008, ACUPUNCT MED, V26, P239, DOI 10.1136/aim.26.4.239
   MacLeod J, 2020, J ALTERN COMPLEM MED, V26, P766, DOI 10.1089/acm.2020.0269
   Mao JJ, 2022, J CLIN ONCOL, V40, P3998, DOI 10.1200/JCO.22.01357
   Mao JJ, 2016, PAIN MED, V17, P1181, DOI 10.1093/pm/pnw102
   Ng JY, 2021, PAIN PRACT, V21, P454, DOI 10.1111/papr.12964
   Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI 10.3322/caac.21708
   Stringer J, 2022, EUR J ONCOL NURS, V60, P0, DOI 10.1016/j.ejon.2022.102171
   VENTAFRIDDA V, 1985, INT J TISSUE REACT, V7, P93
   Witt Claudia M, 2017, JOURNAL OF THE NATIONAL CANCER INSTITUTE MONOGRAPHS, V0, PP3, DOI 10.1093/jncimonographs/lgx012
   Xinling L, 2022, SHENZHEN J INTEGRATI, V16, P28, DOI 10.16458/j.cnki.1007-0893.2022.16.009
   Xu DH, 2021, J PAIN RES, V14, P3601, DOI 10.2147/JPR.S346611
   Xu WB, 2021, J ACUPUNCT MERIDIAN, V14, P110, DOI 10.51507/j.jams.2021.14.3.110
   Yennurajalingam S, 2021, JAMA ONCOL, V7, P404, DOI 10.1001/jamaoncol.2020.6789
   Zhang X, 2015, ZHONGGUO ZHEN JIU, VS1, P30
NR 32
TC 2
Z9 2
U1 2
U2 15
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 2044-6055
EI 
J9 BMJ OPEN
JI BMJ Open
PD APR 15
PY 2023
VL 13
IS 4
BP 
EP 
DI 10.1136/bmjopen-2022-068232
PG 7
WC Medicine, General & Internal
SC General & Internal Medicine
GA Q5MG1
UT WOS:001057956000068
PM 37105691
DA 2026-01-16
ER

PT J
AU Ordoñez-Mora, LT
   Rosero, ID
   Morales-Osorio, MA
   Guil, R
   Jordan, GQ
   Jimenez, JAA
   Gonzalez-Ruiz, K
   Avila-Valencia, JC
AF Ordonez-Mora, Leidy Tatiana
   Rosero, Ilem D.
   Morales-Osorio, Marco Antonio
   Guil, Rocio
   Quintero Jordan, Giancarlo
   Agudelo Jimenez, Julian Alberto
   Gonzalez-Ruiz, Katherine
   Avila-Valencia, Juan Carlos
TI NEUROCANTRIAL: study protocol for a randomised controlled trial of a pain neuroscience education programme in adults with cancer pain
SO BMJ OPEN
LA English
DT Article
DE Cancer pain; Pain management; REHABILITATION MEDICINE; PALLIATIVE CARE; Health Education
ID quality-of-life; spanish version; musculoskeletal pain; validation; survivors; health; scale
AB IntroductionPain is the second most frequent symptom reported in patients with cancer among the main reasons for consultation. The incorporation of educational modalities in pain intervention processes has been suggested. This study aims to examine the efficacy of neuroscience pain education (PNE) in relation to pain, biopsychosocial variables and functional capacity in comparison with conventional treatment. It is hypothesised that an intervention based on PNE achieves better outcomes than conventional management, in terms of pain, biopsychosocial variables and functional capacity in adults with oncological pain.Methods and analysisThis will be a single-blind, controlled clinical trial in which two groups will be compared using changes in pain as the primary measure. The first group will receive conventional treatment in addition to PNE, and participants will undergo an intervention of nine sessions (one session per week, for a total of 9 weeks), each lasting 30-40 min. Specifically, these sessions will teach biophysiological elements using metaphors that allow the adoption of these concepts related to pain. The second group will receive conventional treatment (pharmacological treatment). For this study, a sample size calculation was made based on the background, where 80 adults with oncological pain were required. An initial evaluation will be made to establish the baseline characteristics, and then, according to the randomisation, the assignment to the PNE group or the control group will be made and the two groups will be summoned again. Ten weeks later, for the intervention evaluation, the statistical analysis plan will be established by protocol and by intention-to-treat.Ethics and disseminationThis protocol complies with all ethical considerations. The authors commit to presenting the study's results. This study was approved by the ethics committees of the Universidad Santiago de Cali, Clinica de Occidente/Angiografia de Occidente. The authors commit to presenting the study's results.Trial registration numberNCT05581784.
C1 [Ordonez-Mora, Leidy Tatiana] Univ Santiago Cali, Doctorate Appl Sci, Cali, Colombia.
   [Ordonez-Mora, Leidy Tatiana] Univ Cadiz, Doctorate Hlth Sci, Cadiz, Spain.
   [Rosero, Ilem D.; Gonzalez-Ruiz, Katherine; Avila-Valencia, Juan Carlos] Univ Santiago Cali, Dept Hlth, Physiotherapy Program, Cali, Colombia.
   [Morales-Osorio, Marco Antonio] Univ Costa, Dept Hlth, Barranquilla, Colombia.
   [Morales-Osorio, Marco Antonio] Univ Valle Puebla, Dept Hlth, Puebla, Mexico.
   [Guil, Rocio] Univ Cadiz, Dept Psychol, Puerto Real, Spain.
   [Quintero Jordan, Giancarlo] Univ Santiago Cali, Hlth & Movement Res Grp, Cali, Colombia.
   [Agudelo Jimenez, Julian Alberto; Avila-Valencia, Juan Carlos] Ctr Med Clin Occidente, Grp Invest & Educ Clin Occidente GIECDO, Cali, Valle Del Cauca, Colombia.
C3 Universidad Santiago de Cali; Universidad de Cadiz; Universidad Santiago de Cali; Universidad de la Costa; Universidad de Cadiz; Universidad Santiago de Cali
RP Ordoñez-Mora, LT (corresponding author), Univ Santiago Cali, Doctorate Appl Sci, Cali, Colombia.
EM tatiana.ormora@gmail.com
FU General Directorate of Research initiation act of the Universidad Santiago de Cali [442- 621121- 3331]; Direccion General de Investigaciones of Universidad Santiago de Cali [02-2023]
CR Alfonso Mora M, 2017, COLOMB MED, V48, P19, DOI 10.25100/cm.v48i1.2384
   Badia X, 2003, MED CLIN-BARCELONA, V120, P52, DOI 10.1157/13042265
   Brown MRD, 2014, BRIT J PAIN, V8, P139, DOI 10.1177/2049463714542605
   Buffart LM, 2020, CLIN PSYCHOL REV, V80, P0, DOI 10.1016/j.cpr.2020.101882
   Butcher NJ, 2022, JAMA-J AM MED ASSOC, V328, P2252, DOI 10.1001/jama.2022.21022
   Butler DS, 2010, EXPLICANDO EL DOLOR, V0, P0
   Chan AW, 2013, BMJ-BRIT MED J, V346, P0, DOI 10.1136/bmj.e7586
   Dams L, 2024, ANAT REC, V307, P248, DOI 10.1002/ar.25127
   De Groef A, 2019, BMJ OPEN, V9, P0, DOI 10.1136/bmjopen-2018-025742
   Dworkin RH, 2005, PAIN, V113, P9, DOI 10.1016/j.pain.2004.09.012
   Fallon M, 2018, ANN ONCOL, V29, P166, DOI 10.1093/annonc/mdy152
   Campayo JG, 2008, MED CLIN-BARCELONA, V131, P487
   Geneen LJ, 2015, SYST REV-LONDON, V4, P0, DOI 10.1186/s13643-015-0120-5
   Gil L, 2015, INT J GERIATR PSYCH, V30, P655, DOI 10.1002/gps.4199
   Glare PA, 2014, J CLIN ONCOL, V32, P1739, DOI 10.1200/JCO.2013.52.4629
   Gómez-Pérez L, 2011, J PAIN, V12, P425, DOI 10.1016/j.jpain.2010.08.004
   González NF, 2017, REV COLOMB CARDIOL, V24, P626, DOI 10.1016/j.rccar.2017.01.004
   Harrington S, 2014, REHABIL ONCOL, V32, P13, DOI 10.1097/01893697-201432010-00004
   Hita-Contreras F, 2014, RHEUMATOL INT, V34, P929, DOI 10.1007/s00296-014-2960-z
   Instituto Nacional de Cancerologia (INC), 2022, ANUARIO ESTADISTICO 2021, V0, P0
   Kim H, 2021, KOREAN J FAM MED, V42, P204, DOI 10.4082/kjfm.20.0060
   Lahousse A, 2022, J CLIN MED, V11, P0, DOI 10.3390/jcm11010195
   Laroche F, 2017, PLOS ONE, V12, P0, DOI 10.1371/journal.pone.0187165
   Lema MJ, 2010, ONCOLOGIST, V15, P3, DOI 10.1634/theoncologist.2009-S505
   Leysen L, 2019, PAIN PRACT, V19, P183, DOI 10.1111/papr.12732
   Girbés EL, 2013, PHYS THER, V93, P842, DOI 10.2522/ptj.20120253
   Louw A, 1900, P106, V0, P0
   Louw A, 2016, PHYSIOTHER THEOR PR, V32, P332, DOI 10.1080/09593985.2016.1194646
   Maldonado-Avendaño N, 2023, REV COLOMB PSIQUIATR, V52, PS51, DOI 10.1016/j.rcp.2021.08.007
   Malfliet A, 2017, BRAZ J PHYS THER, V21, P378, DOI 10.1016/j.bjpt.2017.06.019
   Manfuku M, 2021, SUPPORT CARE CANCER, V29, P5351, DOI 10.1007/s00520-021-06103-1
   Moreno J, 2013, ARCHMED, V13, P41, DOI 10.30554/archmed.13.1.21.2013
   Moseley GL, 2015, J PAIN, V16, P807, DOI 10.1016/j.jpain.2015.05.005
   Moseley L, 2002, AUST J PHYSIOTHER, V48, P297, DOI 10.1016/S0004-9514(14)60169-0
   Nijs J, 2019, BRAZ J PHYS THER, V23, P367, DOI 10.1016/j.bjpt.2018.12.003
   Nijs J, 2015, MANUAL THER, V20, P216, DOI 10.1016/j.math.2014.07.004
   Ordonez-Mora LT, 2022, INT J ENV RES PUB HE, V19, P0, DOI 10.3390/ijerph19052559
   Pas R, 2020, J BODYW MOV THER, V24, P239, DOI 10.1016/j.jbmt.2020.06.027
   Perez C, 2007, HEALTH QUAL LIFE OUT, V5, P0, DOI 10.1186/1477-7525-5-66
   Rietman J, 2004, DISABIL REHABIL, V26, P78, DOI 10.1080/09638280310001629642
   Roldán-Jiménez C, 2021, PAIN PRACT, V21, P740, DOI 10.1111/papr.13009
   Sánchez-Pedraza Ricardo, 2020, REV.COLOMB.CANCEROL., V24, P61, DOI 10.35509/01239015.128
   Schulz KF, 2010, BMJ-BRIT MED J, V340, P0, DOI 10.1136/bmj.c869
   SCOTT J, 1979, ANN RHEUM DIS, V38, P560, DOI 10.1136/ard.38.6.560
   Swarm RA, 2019, J NATL COMPR CANC NE, V17, P977, DOI 10.6004/jnccn.2019.0038
NR 48
TC 1
Z9 1
U1 0
U2 2
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 2044-6055
EI 
J9 BMJ OPEN
JI BMJ Open
PD SEP 15
PY 2023
VL 13
IS 9
BP 
EP 
DI 10.1136/bmjopen-2022-071493
PG 10
WC Medicine, General & Internal
SC General & Internal Medicine
GA T4BO7
UT WOS:001077459700027
PM 37758676
DA 2026-01-16
ER

PT J
AU Ben-Arye, E
   Segev, Y
   Galil, G
   Marom, I
   Gressel, O
   Stein, N
   Hirsh, I
   Samuels, N
   Schmidt, M
   Schiff, E
   Lurie, I
   Lavie, O
AF Ben-Arye, Eran
   Segev, Yakir
   Galil, Galit
   Marom, Inbal
   Gressel, Orit
   Stein, Nili
   Hirsh, Irena
   Samuels, Noah
   Schmidt, Meirav
   Schiff, Elad
   Lurie, Irina
   Lavie, Ofer
TI Acupuncture during gynecological oncology surgery: A randomized controlled trial
SO Cancer
LA English
DT Journal Article
DE acupuncture; anxiety; gynecological oncology; integrative medicine; integrative oncology; pain; peri-operative
AB BACKGROUND: In this study, the impact of a multimodal integrative oncology pre-  and intraoperative intervention on pain and anxiety among patients undergoing  gynecological oncology surgery was explored. METHODS: Study participants were  randomized to three groups: Group A received preoperative touch/relaxation  techniques, followed by intraoperative acupuncture; Group B received preoperative  touch/relaxation only; and a control group (Group C) received standard care. Pain  and anxiety were scored before and after surgery using the Measure Yourself  Concerns and Wellbeing (MYCAW) and Quality of Recovery (QOR-15) questionnaires,  using Part B of the QOR to assess pain, anxiety, and other quality-of-life  parameters. RESULTS: A total of 99 patients participated in the study: 45 in  Group A, 25 in Group B, and 29 in Group C. The three groups had similar baseline  demographic and surgery-related characteristics. Postoperative QOR-Part B scores  were significantly higher in the treatment groups (A and B) when compared with  controls (p = .005), including for severe pain (p = .011) and anxiety (p = .007).  Between-group improvement for severe pain was observed in Group A compared with  controls (p = .011). Within-group improvement for QOR depression subscales was  observed in only the intervention groups (p <0.0001). Compared with Group B,  Group A had better improvement of MYCAW-reported concerns (p = .025).  CONCLUSIONS: A preoperative touch/relaxation intervention may significantly  reduce postoperative anxiety, possibly depression, in patients undergoing  gynecological oncology surgery. The addition of intraoperative acupuncture  significantly reduced severe pain when compared with controls. Further research  is needed to confirm these findings and better understand the impact of  intraoperative acupuncture on postoperative pain. PLAIN LANGUAGE SUMMARY:  Integrative oncology programs are increasingly becoming part of  supportive/palliative care, with many working within the Society for Integrative  Oncology. This study examined the impact of a multimodal integrative oncology  program on pain and anxiety among 99 patients undergoing gynecological oncology  surgery. Participants were randomized to three groups: preoperative  touch/relaxation treatments, followed by intraoperative acupuncture; preoperative  touch/relaxation without acupuncture; and a control group receiving standard care  only. The preoperative touch/relaxation intervention significantly reduced  perioperative anxiety, with the addition of intraoperative acupuncture  significantly reducing severe pain as well, when compared with controls. Further  research is needed to confirm these findings.
C1 Integrative Oncology Program, The Oncology Service, Lin, Zebulun, and Carmel Medical Centers, Clalit Health Services, Haifa, Israel.
   Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, 
   Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel.
   Department of Obstetrics and Gynecology, Carmel Medical Center, Haifa, Israel.
   Integrative Oncology Program, The Oncology Service, Lin, Zebulun, and Carmel Medical Centers, Clalit Health Services, Haifa, Israel.
   Department of Obstetrics and Gynecology, Carmel Medical Center, Haifa, Israel.
   Integrative Oncology Program, The Oncology Service, Lin, Zebulun, and Carmel Medical Centers, Clalit Health Services, Haifa, Israel.
   Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, 
   Department of Community Medicine and Epidemiology, Carmel Medical Center, Haifa, Israel.
   Department of Anesthesiology, Critical Care and Pain Medicine, Carmel Medical Center, Haifa, Israel.
   Center for Integrative Complementary Medicine, Shaarei Zedek Medical Center, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.
   Department of Obstetrics and Gynecology, Carmel Medical Center, Haifa, Israel.
   Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel.
   Department of Internal Medicine & Integrative Medicine Service, Bnai-Zion, 
   Department of Obstetrics and Gynecology, Carmel Medical Center, Haifa, Israel.
   Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel.
   Department of Obstetrics and Gynecology, Carmel Medical Center, Haifa, Israel.
NR 0
TC 0
SN 1097-014
EI 
J9 Cancer
PD JAN 18
PY 2023
VL 129
IS 6
BP 908
EP 919
DI 10.1002/cncr.34542
PG 11
WC Female; Humans; Acupuncture Therapy; Genital Neoplasms, Female; surgery; Anxiety; etiology; Pain, Postoperative; etiology; Medical Oncology
UT PubMed:36647622
PM 36647622
DA 2023-01-18
ER

PT J
AU Wu, Z
   Liu, Q
AF Wu, Zanhua
   Liu, Qinghua
TI Effects of repetitive transcranial magnetic stimulation combined with acupuncture
SO American journal of translational research
LA English
DT Journal Article
DE IGF-1; NLRP3; Repetitive transcranial magnetic stimulation; acupuncture; inflammatory factor; neuropathic pain
AB PURPOSE: This study aimed to investigate whether repetitive transcranial magnetic  stimulation (rTMS) combined with acupuncture could alleviate pain in patients  suffering from postherpetic neuralgia (PHN) by inhibiting NOD-like receptor 3  (NLRP3) inflammasome activation. METHODS: Data of 92 PHN patients were  retrospectively collected. The patients were grouped as control (nerve block),  rTMS, and rTMS + acupuncture groups according to treatment methods. The visual  analogue scale (VAS) score, as well as tumor necrosis factor (TNF)-α, interleukin  (IL)-1β, IL-6, NLRP3, and Caspase-1 levels of patients in each group prior and  post-treatment were analyzed. RESULTS: The rTMS + acupuncture group showed higher  efficacy than the rTMS group and the control group, contributing to markedly  lower VAS score, as well as TNF-α, IL-1β, IL-6, NLRP3 and Caspase-1 levels than  the other two groups (P < 0.05). CONCLUSION: rTMS plus acupuncture can reduce the  inflammatory immune response and ease the pain in patients by inhibiting NLRP3  inflammasome and its resulting inflammatory factors, Caspase-1 and IL-1β.
C1 Department of Rehabilitation Medicine, People's Hospital of Guangxi Zhuang Autonomous Region Nanning 530000, Guangxi, The People's Republic of China.
   Department of Rehabilitation Medicine, People's Hospital of Guangxi Zhuang Autonomous Region Nanning 530000, Guangxi, The People's Republic of China.
   Department of Orthopaedics, Hanzhong 3201 Hospital Hanzhong 723000, Shaanxi, The
NR 0
TC 0
SN 1943-814
EI 1943-814
J9 Am J Transl Res
PD AUG 10
PY 2023
VL 15
IS 7
BP 4699
EP 4708
DI 
PG 9
UT PubMed:37560225
PM 37560225
DA 2023-08-10
ER

PT J
AU Yin, Y
   Wang, LA
   Zhao, L
   Lin, L
   Shen, XY
AF Yin, Yue
   Wang, Lina
   Zhao, Ling
   Lin, Lin
   Shen, Xueyong
TI Effect of 10.6 μm laser moxibustion on inflammation in diabetic peripheral neuropathy rats
SO FRONTIERS IN ENDOCRINOLOGY
LA English
DT Article
DE diabetes mellitus; diabetic peripheral neuropathy; laser moxibustion; inflammation; NF- kappa B
ID nf-kappa-b; acupuncture
AB Diabetic peripheral neuropathy (DPN) is the main cause of disability in diabetes patients but the efficacy of available drugs is poor. Moxibustion is an adjunctive treatment for DPN that can reduce symptoms. The peak value of the far infrared wavelength of 10.6 & mu;m laser moxibustion is close to the infrared radiation spectrum of traditional moxibustion. Its effect is similar to that of moxibustion and does not cause pain, infection or produce irritating smoke. Twenty-four male SD rats were divided into control (Con), DPN, laser moxibustion (LM), and pyrrolidine dithiocarbamate (PDTC) groups (n=6/group). The DPN, LM and PDTC group rats were intraperitoneally injected with 1% streptozotocin (STZ) to induce a model of DPN. LM group rats were irradiated with a laser at bilateral ST36 acupoints for 15 min, once every other day, for 14 days. PDTC group rats were intraperitoneally injected with PDTC once a day. Body weight, blood glucose, and paw withdrawal mechanical threshold (PWMT) were measured and laser speckle imaging (LSI) performed before and after modeling and at 1 and 2 weeks after intervention. Two weeks after intervention, changes in serum interleukin 1 & beta; (IL1 & beta;), interleukin 6 (IL6), tumor necrosis factor & alpha; (TNF & alpha;) and nerve growth factor (NGF) were analyzed, and the abundance of NF-& kappa;B and I & kappa;B-& alpha; proteins and levels of NF-& kappa;B and I & kappa;B-& alpha; mRNAs in the sciatic nerve were observed. The results showed that 10.6 & mu;m laser moxibustion can relieve pain, improve microcirculation, and alleviate inflammation in DPN rats, possibly via the NF-& kappa;B inflammatory pathway.
C1 [Yin, Yue; Wang, Lina; Zhao, Ling; Shen, Xueyong] Shanghai Univ Tradit Chinese Med, Sch Acupuncture Moxibust & Tuina, Shanghai, Peoples R China.
   [Lin, Lin] Shanghai Univ Tradit Chinese Med, Sch Nursing, Shanghai, Peoples R China.
   [Shen, Xueyong] Shanghai Res Ctr Acupuncture & Meridian, Lab Syst Physiol Acupuncture & Meridian, Shanghai, Peoples R China.
C3 Shanghai University of Traditional Chinese Medicine; Shanghai University of Traditional Chinese Medicine
RP Shen, XY (corresponding author), Shanghai Univ Tradit Chinese Med, Sch Acupuncture Moxibust & Tuina, Shanghai, Peoples R China.; Lin, L (corresponding author), Shanghai Univ Tradit Chinese Med, Sch Nursing, Shanghai, Peoples R China.; Shen, XY (corresponding author), Shanghai Res Ctr Acupuncture & Meridian, Lab Syst Physiol Acupuncture & Meridian, Shanghai, Peoples R China.
EM linlin5200@shutcm.edu.cn; sxy1@shutcm.edu.cn
CR Abraham E, 2000, CRIT CARE MED, V28, PN100, DOI 10.1097/00003246-200004001-00012
   Artlett CM, 2013, J PATHOL, V229, P157, DOI 10.1002/path.4116
   Beckmann KH, 2014, EVID-BASED COMPL ALT, V2014, P0, DOI 10.1155/2014/626127
   Binns-Hall O, 2018, DIABETIC MED, V35, P887, DOI 10.1111/dme.13630
   Chao MT, 2019, PAIN MED, V20, P2292, DOI 10.1093/pm/pnz117
   Chen W, 2013, PLOS ONE, V8, P0, DOI 10.1371/journal.pone.0073764
   Dombrowski Y, 2011, SCI TRANSL MED, V3, P0, DOI 10.1126/scitranslmed.3002001
   Foresto-Neto O, 2020, FRONT PHYSIOL, V11, P0, DOI 10.3389/fphys.2020.00084
   Galiero R, 2023, INT J MOL SCI, V24, P0, DOI 10.3390/ijms24043554
   Galletti G, 1991, J CLIN LASER MED SURG, V9, P179
   Gao ZF, 2017, PAIN PHYSICIAN, V20, PE551, DOI 10.36076/ppj.2017.e561
   Garrow AP, 2014, ACUPUNCT MED, V32, P242, DOI 10.1136/acupmed-2013-010495
   Kiyani M, 2020, NEUROL-CLIN PRACT, V10, P47, DOI 10.1212/CPJ.0000000000000671
   Ko EY, 2017, FISH SHELLFISH IMMUN, V68, P525, DOI 10.1016/j.fsi.2017.07.041
   Lee EH, 2017, BIOCHEM PHARMACOL, V143, P107, DOI 10.1016/j.bcp.2017.07.011
   Lewin Gary R, 2014, HANDB EXP PHARMACOL, V220, P251, DOI 10.1007/978-3-642-45106-5_10
   Li J, 2019, APPL BIOCHEM BIOTECH, V189, P1167, DOI 10.1007/s12010-019-03052-8
   Li Y, 2020, J INTEGR NEUROSCI, V19, P295, DOI 10.31083/j.jin.2020.02.33
   Li Y, 2020, PHOTOBIOMOD PHOTOMED, V38, P237, DOI 10.1089/photob.2019.4744
   Li Y, 2020, CHIN J INTEGR MED, V26, P33, DOI 10.1007/s11655-019-3084-9
   Li Y, 2020, PHOTOBIOMOD PHOTOMED, V38, P43, DOI 10.1089/photob.2019.4716
   Lin T, 2021, COMPLEMENT THER CLIN, V43, P0, DOI 10.1016/j.ctcp.2021.101375
   Lu MK, 2023, ACTA BIOMATER, V155, P333, DOI 10.1016/j.actbio.2022.10.004
   Makihara E, 2005, PHOTOMED LASER SURG, V23, P191, DOI 10.1089/pho.2005.23.191
   Mennes OA, 2021, J CLIN MED, V10, P0, DOI 10.3390/jcm10173844
   Meyer-Hamme G, 2018, BMC NEUROL, V18, P0, DOI 10.1186/s12883-018-1037-0
   Nori SL, 2013, EVID-BASED COMPL ALT, V2013, P0, DOI 10.1155/2013/652735
   Pan H, 2019, J DIABETES, V11, P928, DOI 10.1111/1753-0407.12916
   Pop-Busui R, 2022, DIAGNOSIS AND TREATMENT OF PAINFUL DIABETIC PERIPHERAL NEUROPATHY, V2022, P1, DOI 10.2337/DB2022-01
   Pop-Busui R, 2016, CURR DIABETES REP, V16, P0, DOI 10.1007/s11892-016-0727-5
   Rosenberg CJ, 2015, PROSTHET ORTHOT INT, V39, P17, DOI 10.1177/0309364614542266
   Schott C, 2022, ENG LIFE SCI, V22, P288, DOI 10.1002/elsc.202100086
   Selvarajah D, 2019, LANCET DIABETES ENDO, V7, P938, DOI 10.1016/S2213-8587(19)30081-6
   Shen D, 2020, EXP DERMATOL, V29, P499, DOI 10.1111/exd.14093
   Shen XY, 2008, AM J CHINESE MED, V36, P211, DOI 10.1142/S0192415X08005722
   Sun H, 2022, DIABETES RES CLIN PR, V183, P0, DOI 10.1016/j.diabres.2021.109119
   Tang HY, 2020, J PHYSIOL SCI, V70, P0, DOI 10.1186/s12576-020-00769-8
   Toscano CM, 2018, INT J ENV RES PUB HE, V15, P0, DOI 10.3390/ijerph15010089
   Van Dam PS, 2013, EUR J PHARMACOL, V719, P180, DOI 10.1016/j.ejphar.2013.07.017
   Wang F, 2020, EUR J PHARMACOL, V880, P0, DOI 10.1016/j.ejphar.2020.173189
   Wang X, 2020, BIOCHEM PHARMACOL, V182, P0, DOI 10.1016/j.bcp.2020.114221
   Wei J, 1900, V40, V0, PP227, DOI 10.16466/j.issn1005-5509.2016.04.001
   Xu J, 2014, EVID-BASED COMPL ALT, V2014, P0, DOI 10.1155/2014/783704
   Xue TY, 2021, FRONT PHARMACOL, V12, P0, DOI 10.3389/fphar.2021.748193
   Yamakawa I, 2011, AM J PHYSIOL-ENDOC M, V301, PE844, DOI 10.1152/ajpendo.00029.2011
   Yang K, 2022, BIOMED PHARMACOTHER, V148, P0, DOI 10.1016/j.biopha.2022.112717
   Yu XM, 2021, FRONT ENDOCRINOL, V12, P0, DOI 10.3389/fendo.2021.608183
   Zhang Q, 2021, FRONT NEUROSCI-SWITZ, V15, P0, DOI 10.3389/fnins.2021.636172
NR 48
TC 5
Z9 6
U1 0
U2 16
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-2392
EI 
J9 FRONT ENDOCRINOL
JI Front. Endocrinol.
PD AUG 1
PY 2023
VL 14
IS 
BP 
EP 
DI 10.3389/fendo.2023.1203677
PG 9
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA P1CI5
UT WOS:001048082300001
PM 37593350
DA 2026-01-16
ER

PT J
AU Harorani, M
   Salehi, M
   Shahrodi, M
   Rafiei, F
AF Harorani, Mehdi
   Salehi, Mehdi
   Shahrodi, Mohadese
   Rafiei, Fatemeh
TI Effect of localized acupressure massage on anxiety during chemotherapy in patients with breast cancer: A single-blind randomized clinical trial
SO EUROPEAN JOURNAL OF INTEGRATIVE MEDICINE
LA English
DT Article
DE Anxiety; Breast cancer; Chemotherapy; Acupressure massage
ID alternative medicine; shiatsu massage; hand massage; therapy; complementary; pain; relaxation; depression; surgery; women
AB Introduction: Patients with breast cancer are prone to numerous physical and mental complications due to their disease and treatments . Anxiety is acommon psychological complication observed in such patients. This study aimed to investigate the effect of acupressure massage on anxiety during chemotherapy in patients with breast cancer.Methods: This single-blind randomized clinical trial study was conducted on 70 cancer patients undergoing chemotherapy. The intervention group (n = 35) received acupressure massage in three 5 min periods with 2 min breaks between them. However, in the control group (n = 35), the same area was only touched for a while in a similar way to that performed in the intervention group. Patients' anxiety was measured before and after the intervention using the Spielberger State-Trait Anxiety Inventory. The collected data from both groups were analyzed in SPSS software (version16).Results: The difference between patients' anxiety was significant after the intervention in the two groups. The level of anxiety among patients in the experimental group was significantly reduced after the intervention, compared to the control group (P=0.0001).Conclusion: Due to the simplicity and low cost of massage, it is recommended that this method be adopted to reduce patients' anxiety along with other treatments. Trial registration: IRCT20151002024290N2).
C1 [Harorani, Mehdi] Arak Univ Med Sci, Shazand Sch Nursing, Dept Nursing, Arak, Iran.
   [Harorani, Mehdi; Salehi, Mehdi] Arak Univ Med Sci, Tradit & Complementary Med Res Ctr TCMRC, Arak, Iran.
   [Shahrodi, Mohadese] Islamic Azad Univ, Gonbad Kavoos branch, Gonbad Kavous, Iran.
   [Rafiei, Fatemeh] Univ Tehran Med Sci, Sci Res Ctr, Sch Hlth, Dept Epidemiol & Biostat, Tehran, Iran.
C3 Islamic Azad University; Tehran University of Medical Sciences
RP Harorani, M (corresponding author), Arak Univ Med Sci, Shazand Sch Nursing, Dept Nursing, Arak, Iran.
EM m.harorani@yahoo.com
FU Arak University of Medical Sciences, Arak, Iran;  [3358]
CR Ardabili FM, 2015, WORLD J PLAST SURG, V4, P36
   Bieling PJ, 1998, BEHAV RES THER, V36, P777, DOI 10.1016/S0005-7967(98)00023-0
   Chen X, 2021, SUPPORT CARE CANCER, V29, P4773, DOI 10.1007/s00520-021-05994-4
   Dreyer NE, 2015, COMPLEMENT THER CLIN, V21, P154, DOI 10.1016/j.ctcp.2015.06.004
   Erzincanli S, 2021, PAIN MANAG NURS, V22, P356, DOI 10.1016/j.pmn.2020.12.005
   Farahani MF, 2020, J PERIANESTH NURS, V35, P277, DOI 10.1016/j.jopan.2019.10.010
   Fazlollah A, 2021, COMPLEMENT THER MED, V60, P0, DOI 10.1016/j.ctim.2021.102738
   Gunnarsdottir TJ, 2007, J CLIN NURS, V16, P777, DOI 10.1111/j.1365-2702.2006.01634.x
   Harorani M, 2021, HEART LUNG, V50, P893, DOI 10.1016/j.hrtlng.2021.07.013
   Harorani M, 2020, COMPLEMENT THER MED, V50, P0, DOI 10.1016/j.ctim.2020.102344
   Harorani M, 2020, SUPPORT CARE CANCER, V28, P405, DOI 10.1007/s00520-019-05025-3
   Hattan J, 2002, J ADV NURS, V37, P199, DOI 10.1046/j.1365-2648.2002.02083.x
   Honda K, 2005, PREV MED, V40, P46, DOI 10.1016/j.ypmed.2004.05.001
   Jafarimanesh H, 2020, INTEGR CANCER THER, V19, P0, DOI 10.1177/1534735420967084
   Kissane DW, 2003, PSYCHO-ONCOLOGY, V12, P532, DOI 10.1002/pon.683
   Kobayashi D, 2019, COMPLEMENT THER MED, V45, P33, DOI 10.1016/j.ctim.2019.05.019
   Lanza G, 2018, COMPLEMENT THER MED, V38, P74, DOI 10.1016/j.ctim.2018.04.013
   Lei SY, 2021, CANCER COMMUN, V41, P1183, DOI 10.1002/cac2.12207
   Li J, 2021, BMJ OPEN, V11, P0, DOI 10.1136/bmjopen-2020-041588
   Li ZH, 2021, EXPLORE-NY, V17, P410, DOI 10.1016/j.explore.2020.08.016
   Long AF, 2008, J ALTERN COMPLEM MED, V14, P921, DOI 10.1089/acm.2008.0085
   Long AF, 2009, COMPLEMENT THER MED, V17, P168, DOI 10.1016/j.ctim.2008.09.004
   Maajani K, 2019, CLIN BREAST CANCER, V19, P165, DOI 10.1016/j.clbc.2019.01.006
   Mirtajadini H, 2016, MIL CARING SCI, V3, P27
   Moyer CA, 2011, J BODYW MOV THER, V15, P3, DOI 10.1016/j.jbmt.2010.06.001
   Nakamura ZM, 2021, ONCOLOGIST, V26, P147, DOI 10.1002/onco.13528
   Pelekasis P, 2016, INTEGR CANCER THER, V15, P165, DOI 10.1177/1534735415598225
   Sebri V, 2021, FRONT PSYCHOL, V12, P0, DOI 10.3389/fpsyg.2021.611954
   Siegel RL, 2020, CA-CANCER J CLIN, V70, P7, DOI 10.3322/caac.21590
   Spilioti E, 2017, INT J CARING SCI, V10, P1465
   Thomson P, 2014, COMPLEMENT THER CLIN, V20, P302, DOI 10.1016/j.ctcp.2014.09.004
   Tsiormpatzis S, 2019, EUR J INTEGR MED, V32, P0, DOI 10.1016/j.eujim.2019.101006
   Villani V, 2017, NEUROL SCI, V38, P999, DOI 10.1007/s10072-017-2888-7
   Williams AM, 2021, BREAST CANCER RES TR, V187, P275, DOI 10.1007/s10549-020-06067-6
   Yoon HG, 2019, APPL NURS RES, V48, P45, DOI 10.1016/j.apnr.2019.05.009
   Zhang JY, 2018, CANCER NURS, V41, P62, DOI 10.1097/NCC.0000000000000451
   Zhao HH, 2022, J ADV NURS, V78, P750, DOI 10.1111/jan.15004
NR 37
TC 1
Z9 1
U1 1
U2 14
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1876-3820
EI 1876-3839
J9 EUR J INTEGR MED
JI Eur. J. Integr. Med.
PD JAN 15
PY 2023
VL 57
IS 
BP 
EP 
DI 10.1016/j.eujim.2022.102209
EA DEC 2022
PG 5
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA 7M0HK
UT WOS:000906337900001
DA 2026-01-16
ER

PT J
AU Zhang, QX
   Zhou, MM
   Huo, MZ
   Si, YX
   Zhang, YL
   Fang, YX
   Zhang, D
AF Zhang, Qingxiang
   Zhou, Mengmeng
   Huo, Mingzhu
   Si, Yuxin
   Zhang, Youlin
   Fang, Yuxin
   Zhang, Di
TI Mechanisms of acupuncture-electroacupuncture on inflammatory pain
SO MOLECULAR PAIN
LA English
DT Review
DE Acupuncture; analgesia; central nerve system; inflammatory pain; peripheral nerve system
ID receptor potential v1; toll-like receptors; bone cancer pain; spinal-cord; neuropathic pain; protein-kinase; mouse model; synaptic plasticity; pathological pain; glial activation
AB Acupuncture, as a traditional treatment, has been extensively used in China for thousands of years. According to the World Health Organization (WHO), acupuncture is recommended for the treatment of 77 diseases. And 16 of these diseases are related to inflammatory pain. As a combination of traditional acupuncture and modern electrotherapy, electroacupuncture (EA) has satisfactory analgesic effects on various acute and chronic pain. Because of its good analgesic effects and no side effects, acupuncture has been widely accepted all over the world. Despite the increase in the number of studies, the mechanisms via which acupuncture exerts its analgesic effects have not been conclusively established. A literature review of related research is of great significance to elaborate on its mechanisms and to inform on further research directions. We elucidated on its mechanisms of action on inflammatory pain from two levels: peripheral and central. It includes the mechanisms of acupuncture in the periphery (immune cells and neurons, purinergic pathway, nociceptive ion channel, cannabinoid receptor and endogenous opioid peptide system) and central nervous system (TPRV1, glutamate and its receptors, glial cells, GABAergic interneurons and signaling molecules). In this review, we collected relevant recent studies to systematically explain the mechanisms of acupuncture in treating inflammatory pain, with a view to providing direction for future applications of acupuncture in inflammatory pain and promoting clinical development.
C1 [Zhang, Qingxiang; Zhou, Mengmeng; Huo, Mingzhu; Si, Yuxin; Zhang, Youlin; Fang, Yuxin] Tianjin Univ Tradit Chinese Med, Coll Acumox & Tuina, Res Ctr Expt Acupuncture Sci, Tianjin, Peoples R China.
   [Zhang, Di] Tianjin Univ Tradit Chinese Med, Coll Pharmaceut Engn Tradit Chinese Med, Tianjin, Peoples R China.
   [Zhang, Di] Haihe Lab Modern Chinese Med, Tianjin, Peoples R China.
   [Fang, Yuxin] Tianjin Univ Tradit Chinese Med, Coll Acumox & Tuina, Res Ctr Expt Acupuncture Sci, 10 Poyanghu Rd, Tianjin 301617, Peoples R China.
   [Zhang, Di] Tianjin Univ Tradit Chinese Med, Coll Pharmaceut Engn Tradit Chinese Med, 10 Poyanghu Rd, Tianjin 301617, Peoples R China.
   [Zhang, Di] Haihe Lab Modern Chinese Med, Tianjin 301617, Peoples R China.
C3 Tianjin University of Traditional Chinese Medicine; Tianjin University of Traditional Chinese Medicine; Tianjin University of Traditional Chinese Medicine; Tianjin University of Traditional Chinese Medicine
RP Fang, YX (corresponding author), Tianjin Univ Tradit Chinese Med, Coll Acumox & Tuina, Res Ctr Expt Acupuncture Sci, 10 Poyanghu Rd, Tianjin 301617, Peoples R China.; Zhang, D (corresponding author), Tianjin Univ Tradit Chinese Med, Coll Pharmaceut Engn Tradit Chinese Med, 10 Poyanghu Rd, Tianjin 301617, Peoples R China.; Zhang, D (corresponding author), Haihe Lab Modern Chinese Med, Tianjin 301617, Peoples R China.
EM meng99_2006@126.com; 43987073@qq.com
FU National Natural Science Foundation of China (NSFC); Natural Science Foundation of Tianjin [81973944, 20JCYBJC00200]; Youth Talent Promotion Project of the Tianjin Association for Science and Technology [22JCYBJC00990];  [TJSQNTJ-2020-15]
CR Akoolo L, 2022, FRONT IMMUNOL, V13, P0, DOI 10.3389/fimmu.2022.930287
   Antonioli L, 2019, PHARMACOL REV, V71, P345, DOI 10.1124/pr.117.014878
   Arnoux I, 2015, NEURAL PLAST, V2015, P0, DOI 10.1155/2015/689404
   Atianjoh FE, 2010, PAIN, V151, P226, DOI 10.1016/j.pain.2010.07.017
   Bae SJ, 2019, FRONT NEUROSCI-SWITZ, V13, P0, DOI 10.3389/fnins.2019.00652
   Bhatia HS, 2017, SCI REP-UK, V7, P0, DOI 10.1038/s41598-017-00225-5
   Breivik H, 2006, EUR J PAIN, V10, P287, DOI 10.1016/j.ejpain.2005.06.009
   Carbone E, 2017, J PHYSIOL-LONDON, V595, P2413, DOI 10.1113/JP274103
   Chai WX, 2018, EVID-BASED COMPL ALT, V2018, P0, DOI 10.1155/2018/2598975
   Chen YJ, 2010, P NATL ACAD SCI USA, V107, P21818, DOI 10.1073/pnas.1010669107
   Chen Y, 2022, BIOL RES, V55, P0, DOI 10.1186/s40659-022-00374-6
   Cheng Zedong, 2018, ZHONGGUO ZHEN JIU, V38, P179, DOI 10.13703/j.0255-2930.2018.02.020
   Cook AD, 2018, TRENDS IMMUNOL, V39, P240, DOI 10.1016/j.it.2017.12.003
   Dembla S, 2017, ELIFE, V6, P0, DOI 10.7554/eLife.26280
   Quintao JLD, 2021, EUR J PHARMACOL, V896, P0, DOI 10.1016/j.ejphar.2021.173900
   Du JY, 2020, BRAIN RES, V1733, P0, DOI 10.1016/j.brainres.2020.146719
   Du JY, 2017, NEURAL PLAST, V2017, P0, DOI 10.1155/2017/3728752
   Du Q, 2019, FRONT PHYSIOL, V10, P0, DOI 10.3389/fphys.2019.01064
   Duan-Mu CL, 2021, FRONT NEUROSCI-SWITZ, V15, P0, DOI 10.3389/fnins.2021.687173
   Duffy SS, 2019, J NEUROSCI, V39, P2326, DOI 10.1523/JNEUROSCI.1815-18.2019
   Fan AY, 2017, CHIN J INTEGR MED, V23, P83, DOI 10.1007/s11655-017-2800-6
   Fang JQ, 2018, LIFE SCI, V200, P69, DOI 10.1016/j.lfs.2018.03.028
   Fang JQ, 2013, MOL PAIN, V9, P0, DOI 10.1186/1744-8069-9-13
   Frias B, 2016, MOLECULES, V21, P0, DOI 10.3390/molecules21060797
   Gao F, 2018, BRAIN BEHAV IMMUN, V67, P91, DOI 10.1016/j.bbi.2017.08.004
   Gao YJ, 2010, NEUROTHERAPEUTICS, V7, P482, DOI 10.1016/j.nurt.2010.05.016
   Gu YX, 2020, NEURAL PLAST, V2020, P0, DOI 10.1155/2020/8861994
   Guerrero-Alba R, 2019, FRONT PHARMACOL, V9, P0, DOI 10.3389/fphar.2018.01496
   Han KY, 2019, PAIN, V160, P712, DOI 10.1097/j.pain.0000000000001450
   Hong SH, 2021, ACUPUNCT MED, V39, P673, DOI 10.1177/0964528421997435
   Hong SS, 2015, GASTROENTEROLOGY, V148, P148, DOI 10.1053/j.gastro.2014.09.032
   Hsiao IH, 2022, SCI REP-UK, V12, P0, DOI 10.1038/s41598-022-12771-8
   Hsu HC, 2019, ACUPUNCT MED, V37, P356, DOI 10.1136/acupmed-2017-011469
   Hu ML, 2017, EVID-BASED COMPL ALT, V2017, P0, DOI 10.1155/2017/7531060
   Huang HY, 2020, EVID-BASED COMPL ALT, V2020, P0, DOI 10.1155/2020/4951591
   Inoue K, 2017, P JPN ACAD B-PHYS, V93, P174, DOI 10.2183/pjab.93.011
   Inprasit C, 2020, INT J MOL SCI, V21, P0, DOI 10.3390/ijms21093312
   Ip WKE, 2017, SCIENCE, V356, P513, DOI 10.1126/science.aal3535
   Jackson T, 2015, LANCET, V385, P10, DOI 10.1016/S0140-6736(15)60805-4
   Jin Y, 2021, ACUPUNCT MED, V39, P708, DOI 10.1177/09645284211020766
   Juarez-Salinas DL, 2019, BRAIN, V142, P2655, DOI 10.1093/brain/awz203
   Jung YH, 2017, ACS CHEM NEUROSCI, V8, P1465, DOI 10.1021/acschemneuro.6b00401
   Kalynovska N, 2017, PHYSIOL RES, V66, P549, DOI 10.33549/physiolres.933613
   Kang MS, 2020, NUTRIENTS, V12, P0, DOI 10.3390/nu12010135
   Ke P, 2016, PLOS ONE, V11, P0, DOI 10.1371/journal.pone.0155076
   Kepecs A, 2014, NATURE, V505, P318, DOI 10.1038/nature12983
   Kielian T, 2006, J NEUROSCI RES, V83, P711, DOI 10.1002/jnr.20767
   Kim D, 2007, J BIOL CHEM, V282, P14975, DOI 10.1074/jbc.M607277200
   Koda K, 2016, OSTEOARTHR CARTILAGE, V24, P1254, DOI 10.1016/j.joca.2016.02.010
   Koga K, 2018, MOL PAIN, V14, P0, DOI 10.1177/1744806918783478
   Kong WL, 2017, BRAIN BEHAV IMMUN, V64, P354, DOI 10.1016/j.bbi.2017.03.007
   Laing RJ, 2016, NEUROSCIENTIST, V22, P171, DOI 10.1177/1073858414567884
   Lehnardt S, 2006, J IMMUNOL, V177, P583, DOI 10.4049/jimmunol.177.1.583
   Li AL, 2018, NEUROSCI BULL, V34, P85, DOI 10.1007/s12264-017-0142-1
   Li YH, 2019, J PAIN RES, V12, P2663, DOI 10.2147/JPR.S205987
   Liao HY, 2022, IRAN J BASIC MED SCI, V25, P451, DOI 10.22038/IJBMS.2022.60121.13327
   Liao HY, 2021, AM J CHINESE MED, V49, P1417, DOI 10.1142/S0192415X2150066X
   Liao HY, 2017, SCI REP-UK, V7, P0, DOI 10.1038/s41598-017-16031-y
   Liao HY, 2017, SCI REP-UK, V7, P0, DOI 10.1038/srep42531
   Lin YW, 2020, BRAIN BEHAV IMMUN, V89, P604, DOI 10.1016/j.bbi.2020.06.033
   Liu J, 2015, EXP NEUROL, V273, P253, DOI 10.1016/j.expneurol.2015.09.005
   Liu L, 2021, FRONT NEUROSCI-SWITZ, V15, P0, DOI 10.3389/fnins.2021.668616
   Liu Q, 2019, MOL PAIN, V15, P0, DOI 10.1177/1744806919866529
   Liu YJ, 2018, EVID-BASED COMPL ALT, V2018, P0, DOI 10.1155/2018/9102107
   Liu YJ, 2021, PHYSIOL RES, V70, P635, DOI 10.33549/physiolres.934649
   Lu KW, 2016, SCI REP-UK, V6, P0, DOI 10.1038/srep22123
   Luo C, 2014, TRENDS NEUROSCI, V37, P343, DOI 10.1016/j.tins.2014.04.002
   Luo ZY, 2020, BIOL PSYCHIAT, V87, P926, DOI 10.1016/j.biopsych.2019.10.021
   Lv ZT, 2019, ARTHRITIS RES THER, V21, P0, DOI 10.1186/s13075-019-1899-6
   Machelska H, 2006, J NEUROIMMUNE PHARM, V1, P90, DOI 10.1007/s11481-005-9002-2
   Malek N, 2015, MOL CELL NEUROSCI, V65, P1, DOI 10.1016/j.mcn.2015.02.001
   Marrone MC, 2017, NAT COMMUN, V8, P0, DOI 10.1038/ncomms15292
   Mei L, 2008, NAT REV NEUROSCI, V9, P437, DOI 10.1038/nrn2392
   Mei L, 2014, NEURON, V83, P27, DOI 10.1016/j.neuron.2014.06.007
   Muley MM, 2016, CNS NEUROSCI THER, V22, P88, DOI 10.1111/cns.12486
   Ni HD, 2016, J NEUROSCI RES, V94, P50, DOI 10.1002/jnr.23672
   OConnor TM, 2004, J CELL PHYSIOL, V201, P167, DOI 10.1002/jcp.20061
   Oehler B, 2017, FRONT MOL NEUROSCI, V10, P0, DOI 10.3389/fnmol.2017.00242
   Peng JY, 2016, NAT COMMUN, V7, P0, DOI 10.1038/ncomms12029
   Pinho-Ribeiro FA, 2017, TRENDS IMMUNOL, V38, P5, DOI 10.1016/j.it.2016.10.001
   Ren WJ, 2020, EVID-BASED COMPL ALT, V2020, P0, DOI 10.1155/2020/5917910
   Ribas C, 2007, BBA-BIOMEMBRANES, V1768, P913, DOI 10.1016/j.bbamem.2006.09.019
   Richards CJ, 2017, ORTHOP CLIN N AM, V48, P433, DOI 10.1016/j.ocl.2017.06.002
   Rittner HL, 2009, PLOS PATHOG, V5, P0, DOI 10.1371/journal.ppat.1000362
   Rom S, 2013, J NEUROIMMUNE PHARM, V8, P608, DOI 10.1007/s11481-013-9445-9
   Ronchetti S, 2017, BIOMED PHARMACOTHER, V96, P1445, DOI 10.1016/j.biopha.2017.12.001
   Sawynok J, 2016, NEUROSCIENCE, V338, P1, DOI 10.1016/j.neuroscience.2015.10.031
   Schnare M, 2001, NAT IMMUNOL, V2, P947, DOI 10.1038/ni712
   Schoneboom BA, 2016, NURS OUTLOOK, V64, P459, DOI 10.1016/j.outlook.2016.05.010
   Shao FB, 2021, FRONT NEUROSCI-SWITZ, V15, P0, DOI 10.3389/fnins.2021.691931
   Shen D, 2021, PURINERG SIGNAL, V17, P411, DOI 10.1007/s11302-021-09777-8
   Shiers S, 2018, J NEUROSCI, V38, P7337, DOI 10.1523/JNEUROSCI.0713-18.2018
   Shim JW, 2016, EVID-BASED COMPL ALT, V2016, P0, DOI 10.1155/2016/3485875
   Shiozaki Y, 2017, FRONT PHYSIOL, V8, P0, DOI 10.3389/fphys.2017.00003
   Silva RL, 2017, NEUROBIOL DIS, V105, P109, DOI 10.1016/j.nbd.2017.06.001
   STEIN C, 1990, P NATL ACAD SCI USA, V87, P5935, DOI 10.1073/pnas.87.15.5935
   Stempel AV, 2016, NEURON, V90, P795, DOI 10.1016/j.neuron.2016.03.034
   Sugimoto MA, 2016, FRONT IMMUNOL, V7, P0, DOI 10.3389/fimmu.2016.00160
   Sun YE, 2016, AM J TRANSL RES, V8, P1144
   Svensson CI, 2003, J NEUROCHEM, V86, P1534, DOI 10.1046/j.1471-4159.2003.01969.x
   Tan Q, 2022, J PAIN RES, V15, P93, DOI 10.2147/JPR.S346242
   Taneja A, 2017, EUR J CLIN PHARMACOL, V73, P1219, DOI 10.1007/s00228-017-2301-8
   Tang Y, 2019, BRAIN RES BULL, V151, P144, DOI 10.1016/j.brainresbull.2018.10.015
   Tang Y, 2016, NEUROSCIENTIST, V22, P563, DOI 10.1177/1073858416654453
   Tian NX, 2018, J NEUROSCI, V38, P1756, DOI 10.1523/JNEUROSCI.2242-17.2018
   Turcotte C, 2016, CELL MOL LIFE SCI, V73, P4449, DOI 10.1007/s00018-016-2300-4
   Vieira C, 2021, PFLUG ARCH EUR J PHY, V473, P683, DOI 10.1007/s00424-020-02502-1
   Vincent L, 2016, HAEMATOLOGICA, V101, P566, DOI 10.3324/haematol.2015.136523
   Wan CF, 2021, FRONT NEUROSCI-SWITZ, V15, P0, DOI 10.3389/fnins.2021.636348
   Wang HJ, 2018, FRONT PHARMACOL, V9, P0, DOI 10.3389/fphar.2018.00592
   Wang K, 2016, ANESTH ANALG, V123, P1603, DOI 10.1213/ANE.0000000000001535
   Wang SM, 2008, ANESTH ANALG, V106, P602, DOI 10.1213/01.ane.0000277493.42335.7b
   Wang YL, 2019, NEUROPEPTIDES, V77, P0, DOI 10.1016/j.npep.2019.101957
   Wang Y, 2014, PLOS ONE, V9, P0, DOI 10.1371/journal.pone.0094696
   Wang Y, 2021, AGING-US, V13, P8720, DOI 10.18632/aging.202684
   Webster Lynn R, 2016, ANESTHESIOL CLIN, V34, P341, DOI 10.1016/j.anclin.2016.01.002
   Wei JY, 2022, J PAIN RES, V15, P1071, DOI 10.2147/JPR.S360555
   White A, 2004, RHEUMATOLOGY, V43, P662, DOI 10.1093/rheumatology/keg005
   Wilkerson JL, 2012, PAIN, V153, P1091, DOI 10.1016/j.pain.2012.02.015
   Wilkerson JL, 2011, ISRN ANESTHESIOL, V2011, P593894, DOI 10.5402/2011/593894
   Wu QY, 2021, NEUROCHEM INT, V145, P0, DOI 10.1016/j.neuint.2021.104983
   Wynn TA, 2013, NATURE, V496, P445, DOI 10.1038/nature12034
   Xiang XN, 2019, INT J MOL SCI, V20, P0, DOI 10.3390/ijms20133248
   Xu Y, 2018, AM J CHINESE MED, V46, P997, DOI 10.1142/S0192415X18500520
   Yang FM, 2021, EVID-BASED COMPL ALT, V2021, P0, DOI 10.1155/2021/9430501
   Yang J, 2017, BIOMED RES INT, V2017, P0, DOI 10.1155/2017/5068347
   Yang J, 2017, ONCOTARGET, V8, P85537, DOI 10.18632/oncotarget.20246
   Yen CM, 2019, INT J MOL SCI, V20, P0, DOI 10.3390/ijms20184471
   Yu LL, 2018, FRONT NEUROSCI-SWITZ, V12, P0, DOI 10.3389/fnins.2018.00775
   Yu ML, 2020, INFLAMMATION, V43, P1233, DOI 10.1007/s10753-020-01203-2
   Yu NN, 2023, ACUPUNCT MED, V41, P96, DOI 10.1177/09645284221085278
   Yu ZG, 2016, EVID-BASED COMPL ALT, V2016, P0, DOI 10.1155/2016/7074563
   Yuan XC, 2018, J PAIN RES, V11, P2797, DOI 10.2147/JPR.S171664
   Yue J, 2018, BRAIN RES BULL, V137, P156, DOI 10.1016/j.brainresbull.2017.12.002
   Zazueta-Favela D, 2019, IMMUNOPHARM IMMUNOT, V41, P463, DOI 10.1080/08923973.2019.1641114
   Zeng J, 2018, J MOL NEUROSCI, V65, P93, DOI 10.1007/s12031-018-1072-8
   Zhang DK, 2004, SCIENCE, V303, P1522, DOI 10.1126/science.1094351
   Zhang H, 2022, FRONT PHARMACOL, V13, P0, DOI 10.3389/fphar.2022.861799
   Zhang RY, 2020, ARQ NEURO-PSIQUIAT, V78, P617, DOI 10.1590/0004-282X20200078
   Zhang RX, 2014, ANESTHESIOLOGY, V120, P482, DOI 10.1097/ALN.0000000000000101
   Zhang RX, 2005, PAIN, V118, P125, DOI 10.1016/j.pain.2005.08.001
   Zhang Y, 2016, NEUROCHEM INT, V99, P215, DOI 10.1016/j.neuint.2016.07.007
   Zhang YD, 2022, LIFE SCI, V306, P0, DOI 10.1016/j.lfs.2022.120839
   Zhao H, 2017, BRIT J ANAESTH, V118, P504, DOI 10.1093/bja/aex006
   Zhao JG, 2017, ACUPUNCT MED, V35, P224, DOI 10.1136/acupmed-2016-011107
   Zheng WW, 2011, MOL PAIN, V7, P0, DOI 10.1186/1744-8069-7-40
NR 146
TC 37
Z9 40
U1 7
U2 44
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 
EI 1744-8069
J9 MOL PAIN
JI Mol. Pain
PD SEP 15
PY 2023
VL 19
IS 
BP 
EP 
DI 10.1177/17448069231202882
PG 22
WC Neurosciences
SC Neurosciences & Neurology
GA S2OH7
UT WOS:001069610400001
PM 37678839
DA 2026-01-16
ER

PT J
AU Lu, C
   Li, GL
   Deng, DH
   Li, RR
   Li, XY
   Feng, XK
   Wu, TP
   Shao, XY
   Chen, WJ
AF Lu, Chao
   Li, Guangliang
   Deng, Dehou
   Li, Rongrong
   Li, Xiaoyu
   Feng, Xukang
   Wu, Taoping
   Shao, Xiying
   Chen, Weiji
TI Efficacy of electroacupuncture in the treatment of peripheral neuropathy caused by Utidelone: Study protocol for a randomized controlled trial
SO FRONTIERS IN NEUROLOGY
LA English
DT Article
DE breast cancer; electroacupuncture (EA); Utidelone (UTD1); chemotherapy-induced peripheral neuropathy (CIPN); peripheral neuropathy (PN); protocol
ID quality-of-life; european-organization; plus capecitabine; pain-intensity; chemotherapy; questionnaire; acupuncture; reliability; validity; scales
AB Introduction: Utidelone (UTD1) is a new chemotherapeutic drug for recurrent or metastatic breast cancer. However, it usually leads to severe peripheral neuropathy (PN) and causes numbness of the hands and feet and significant pain in patients' life. Electroacupuncture (EA) is considered beneficial in improving PN and relieving numbness of the hands and feet. This trial aims to evaluate the therapeutic effect of EA on PN caused by UTD1 in patients with advanced breast cancer.Methods and analysis: This study is a prospective randomized controlled trial. A total of 70 patients with PN caused by UTD1 will be randomly assigned to the EA treatment group and the control group in a ratio of 1:1. The patients in the EA treatment group will receive 2 Hz EA three times a week for 4 weeks. The patients in the control group will take mecobalamin (MeCbl) tablets orally, one tablet each, three times a day for 4 weeks. The main outcome measures will be the evaluation scale of peripheral neurotoxicity of chemotherapeutic drugs according to the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-CIPN 20-item (EORTC QLQ-CIPN20) and the peripheral neurotoxicity assessment rating according to NCI CTCAE version 5.0. Secondary outcomes will be the quality of life scale according to the European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire (EORTC QLQ-C30). The results will be evaluated at baseline, post-treatment phase, and follow-up. All major analyses will be based on the intention-to-treat principle.Ethics and dissemination: This protocol was approved by the Medical Ethics Committee of Zhejiang Cancer Hospital on 26 July 2022. The license number is IRB-2022-425. This study will provide clinical efficacy data on EA in the treatment of PN caused by UTD1 and will help to prove whether EA is an effective and safe therapy. The study results will be shared with healthcare professionals through the publication of manuscripts and conference reports.
C1 [Lu, Chao; Deng, Dehou] Zhejiang Canc Hosp, Dept Tradit Chinese Med, Hangzhou, Peoples R China.
   [Li, Guangliang; Shao, Xiying] Zhejiang Canc Hosp, Dept Breast Med Oncol, Hangzhou, Peoples R China.
   [Li, Rongrong; Li, Xiaoyu; Chen, Weiji] Zhejiang Chinese Med Univ, Zhongshan Hosp Zhejiang Prov, Dept Acupuncture & Moxibust, Affiliated Hosp 3, Hangzhou, Peoples R China.
   [Li, Xiaoyu; Feng, Xukang; Wu, Taoping] Zhejiang Chinese Med Univ, Clin Med Coll 3, Hangzhou, Peoples R China.
C3 Zhejiang Cancer Hospital; Zhejiang Cancer Hospital; Zhejiang Chinese Medical University; Zhejiang Chinese Medical University
RP Chen, WJ (corresponding author), Zhejiang Chinese Med Univ, Zhongshan Hosp Zhejiang Prov, Dept Acupuncture & Moxibust, Affiliated Hosp 3, Hangzhou, Peoples R China.
EM chenweiji163@163.com
FU Traditional Chinese Medicine Scientific Research Fund Project of Zhejiang Province [2022ZB058, 2022ZB183, 2023ZL019]
CR AARONSON NK, 1993, J NATL CANCER I, V85, P365, DOI 10.1093/jnci/85.5.365
   Areti A, 2014, REDOX BIOL, V2, P289, DOI 10.1016/j.redox.2014.01.006
   Bandos H, 2018, JNCI-J NATL CANCER I, V110, P0, DOI 10.1093/jnci/djx162
   Bao T, 2021, ONCOLOGIST, V26, PE2070, DOI 10.1002/onco.13933
   Bao T, 2018, EUR J CANCER, V101, P12, DOI 10.1016/j.ejca.2018.06.008
   Basch E, 2014, JNCI-J NATL CANCER I, V106, P0, DOI 10.1093/jnci/dju244
   Beijers AJM, 2016, SUPPORT CARE CANCER, V24, P2411, DOI 10.1007/s00520-015-3032-y
   Boyette-Davis JA, 2018, PAIN MANAG, V8, P363, DOI 10.2217/pmt-2018-0020
   Briani C, 2014, J PERIPHER NERV SYST, V19, P299, DOI 10.1111/jns.12097
   Burgess J, 2021, ONCOL THER, V9, P385, DOI 10.1007/s40487-021-00168-y
   Cavaletti G, 2013, ANN ONCOL, V24, P454, DOI 10.1093/annonc/mds329
   Chan AW, 2013, ANN INTERN MED, V158, P200, DOI 10.7326/0003-4819-158-3-201302050-00583
   Connelly M, 2010, J PAIN, V11, P1451, DOI 10.1016/j.jpain.2010.04.011
   [崔光卫 Cui Guangwei], 2017, 中华中医药杂志 CHINA JOURNAL OF TRADITIONAL CHINESE MEDICINE AND PHARMACY, V32, P2670
   Donald GK, 2011, ACUPUNCT MED, V29, P230, DOI 10.1136/acupmed.2011.010025
   Fumagalli G, 2021, FRONT IMMUNOL, V11, P0, DOI 10.3389/fimmu.2020.626687
   Garcia MK, 2014, J HEMATOL ONCOL, V7, P0, DOI 10.1186/1756-8722-7-41
   Gradishar WJ, 2022, J NATL COMPR CANC NE, V20, P691, DOI 10.6004/jnccn.2022.0030
   Han XY, 2017, BMC CANCER, V17, P0, DOI 10.1186/s12885-016-3037-z
   Han YJ, 2018, MINERVA ENDOCRINOL, V43, P11, DOI 10.23736/S0391-1977.16.02505-0
   Hjermstad MJ, 2011, J PAIN SYMPTOM MANAG, V41, P1073, DOI 10.1016/j.jpainsymman.2010.08.016
   Hu LY, 2019, CURR NEUROPHARMACOL, V17, P184, DOI 10.2174/1570159X15666170915143217
   Jin YX, 2020, EVID-BASED COMPL ALT, V2020, P0, DOI 10.1155/2020/8875433
   Kim HY, 2014, J KOREAN ACAD NURS, V44, P735, DOI 10.4040/jkan.2014.44.6.735
   Kuang Biyao LM, 2019, TIANJIN J TRADIT CHI, V36, P673
   Leal AD, 2014, CANCER-AM CANCER SOC, V120, P1890, DOI 10.1002/cncr.28654
   Li FL, 2021, CELL DEATH DIS, V12, P0, DOI 10.1038/s41419-021-03619-6
   Li Y, 2019, MOL PAIN, V43, P496
   Li YY, 2019, INT J MOL SCI, V20, P0, DOI 10.3390/ijms20235917
   Loprinzi CL, 2020, J CLIN ONCOL, V38, P0, DOI 10.1200/JCO.20.01399
   Ma JC, 2018, CANCER-AM CANCER SOC, V124, P2289, DOI 10.1002/cncr.31248
   Meng XZ, 2011, BRAIN RES, V1414, P58, DOI 10.1016/j.brainres.2011.08.004
   Postma TJ, 2005, EUR J CANCER, V41, P1135, DOI 10.1016/j.ejca.2005.02.012
   Qiu Tao, 2011, ZHONGGUO ZHEN JIU, V31, P827
   Sawangjit R, 2020, J ALTERN COMPLEM MED, V26, P1117, DOI 10.1089/acm.2020.0068
   Schröder S, 2007, EUR J NEUROL, V14, P276, DOI 10.1111/j.1468-1331.2006.01632.x
   Seretny M, 2014, PAIN, V155, P2461, DOI 10.1016/j.pain.2014.09.020
   Smith EML, 2013, JAMA-J AM MED ASSOC, V309, P1359, DOI 10.1001/jama.2013.2813
   Staff NP, 2017, ANN NEUROL, V81, P772, DOI 10.1002/ana.24951
   Sung H, 2021, CA-CANCER J CLIN, V71, P209, DOI 10.3322/caac.21660
   Xu B, 2021, ANN ONCOL, V32, P218, DOI 10.1016/j.annonc.2020.10.600
   Xu JN, 2020, FRONT ONCOL, V10, P0, DOI 10.3389/fonc.2020.524223
   Yokoyama S, 2022, SUPPORT CARE CANCER, V30, P1765, DOI 10.1007/s00520-021-06585-z
   Zajaczkowska R, 2019, INT J MOL SCI, V20, P0, DOI 10.3390/ijms20061451
   Zhang P, 2017, LANCET ONCOL, V18, P371, DOI 10.1016/S1470-2045(17)30088-8
   Zhang P, 2016, J HEMATOL ONCOL, V9, P0, DOI 10.1186/s13045-016-0297-7
   Zhang P, 2011, CANCER CHEMOTH PHARM, V68, P971, DOI 10.1007/s00280-011-1571-6
NR 47
TC 1
Z9 2
U1 4
U2 11
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-2295
EI 
J9 FRONT NEUROL
JI Front. Neurol.
PD FEB 9
PY 2023
VL 14
IS 
BP 
EP 
DI 10.3389/fneur.2023.1065635
PG 9
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 9E8EB
UT WOS:000937011500001
PM 36846114
DA 2026-01-16
ER

PT J
AU Yu, NN
   Yang, FM
   Zhao, X
   Guo, YM
   Xu, Y
   Pang, GC
   Gong, YN
   Wang, SJ
   Liu, YY
   Fang, YX
   Yu, K
   Yao, L
   Wang, H
   Zhang, K
   Liu, BH
   Wang, ZG
   Guo, Y
   Xu, ZF
AF Yu, Nannan
   Yang, Fuming
   Zhao, Xue
   Guo, Yongming
   Xu, Yuan
   Pang, Guangchang
   Gong, Yinan
   Wang, Shenjun
   Liu, Yangyang
   Fang, Yuxin
   Yu, Kun
   Yao, Lin
   Wang, Hui
   Zhang, Kuo
   Liu, Baohu
   Wang, Zhenguo
   Guo, Yi
   Xu, Zhifang
TI Manual acupuncture at ST36 attenuates rheumatoid arthritis by inhibiting M1 macrophage polarization and enhancing Treg cell populations in adjuvant-induced arthritic rats
SO ACUPUNCTURE IN MEDICINE
LA English
DT Article
DE adjuvant-induced arthritis; macrophage polarization; manual acupuncture; regulatory T cells; transforming growth factor beta 1
ID regulatory t-cells; pathogenesis; inflammation; modulation; cytokines; pathways; th17
AB Objectives: Acupuncture has been found to be effective at relieving many inflammatory pain conditions, including rheumatoid arthritis (RA). We aimed to assess the anti-inflammatory potential of manual acupuncture (MA) treatment of RA using adjuvant-induced arthritic (AIA) rats and to explore the underlying mechanisms. Methods: The anti-inflammatory and analgesic actions of MA at ST36 (Zusanli) in AIA rats were assessed using paw withdrawal latency and swelling, histological examination and cytokine detection by enzyme-linked immunoassay (ELISA). The cell-cell communication (CCC) network was analyzed with a multiplex immunoassay of 24 immune factors expressed in the inflamed joints, and the macrophage and Treg populations and associated cytokines regulated by MA were investigated using reverse-transcription quantitative polymerase chain reaction (RT-qPCR), ELISA and flow cytometry. Results: MA markedly decreased heat hyperalgesia and paw swelling in AIA rats. MA-treated rats also exhibited decreased levels of pro-inflammatory cytokines (tumor necrosis factor (TNF)-alpha, interleukin (1L)-1 beta) coupled with increased anti-inflammatory cytokines (1L-10, transforming growth factor (TGF)-beta 1) in the ankle joints at protein and mRNA levels. CCC network analysis confirmed that macrophages are of critical importance and are potential therapeutic targets in RA. Repeated treatment with MA triggered a macrophage phenotypic switch in the paws, with fewer M1 macrophages. Prominent increases in the Treg cell population and TGF-beta 1 in the popliteal lymph nodes demonstrated the immunomodulatory effects of MA. Furthermore, a selective TGF-beta 1-receptor inhibitor, SB431542, attenuated the anti-inflammatory effects of MA and MA-induced suppression of the levels of M1-released cytokines. Conclusion: These findings provide novel evidence that the anti-inflammatory and analgesic effects of MA on RA act through phenotypic modulation involving the inhibition of M1 macrophage polarization and an increase in the Treg cell population, highlighting the potential therapeutic advantages of acupuncture in controlling pain and ameliorating inflammatory conditions.
C1 [Yu, Nannan; Yang, Fuming; Zhao, Xue; Guo, Yongming; Xu, Yuan; Gong, Yinan; Wang, Shenjun; Liu, Yangyang; Fang, Yuxin; Yu, Kun; Yao, Lin; Wang, Hui; Zhang, Kuo; Guo, Yi; Xu, Zhifang] Tianjin Univ Tradit Chinese Med, Res Ctr Expt Acupuncture Sci, Tianjin, Peoples R China.
   [Yu, Nannan] Air Force Med Univ, Affiliated Hosp 1, Dept Tradit Chinese Med, Xian, Peoples R China.
   [Zhao, Xue; Guo, Yongming; Xu, Yuan; Wang, Shenjun; Liu, Yangyang; Fang, Yuxin; Guo, Yi; Xu, Zhifang] Natl Clin Res Ctr Chinese Med Acupuncture & Moxib, Tianjin, Peoples R China.
   [Zhao, Xue; Guo, Yongming; Xu, Yuan; Wang, Shenjun; Liu, Yangyang; Fang, Yuxin; Xu, Zhifang] Tianjin Univ Tradit Chinese Med, Sch Acupuncture & Moxibust & Tuina, 10 Poyang Lake Rd, Tianjin 301617, Peoples R China.
   [Pang, Guangchang] Tianjin Univ Commerce, Coll Biotechnol & Food Sci, Tianjin Key Lab Food Biotechnol, Tianjin, Peoples R China.
   [Liu, Baohu] China Acad Chinese Med Sci, Dept Rehabil, Wangjing Hosp, Beijing, Peoples R China.
   [Wang, Zhenguo] Xian Encephalopathy Hosp Tradit Chinese Med, Xian, Peoples R China.
   [Guo, Yi] Tianjin Univ Tradit Chinese Med, Sch Tradit Chinese Med, 10 Poyang Lake Rd, Tianjin 301617, Peoples R China.
C3 Tianjin University of Traditional Chinese Medicine; Air Force Medical University; Tianjin University of Traditional Chinese Medicine; Tianjin University of Commerce; Wang Jing Hospital, CACMS; China Academy of Chinese Medical Sciences; Tianjin University of Traditional Chinese Medicine
RP Xu, ZF (corresponding author), Tianjin Univ Tradit Chinese Med, Sch Acupuncture & Moxibust & Tuina, 10 Poyang Lake Rd, Tianjin 301617, Peoples R China.; Guo, Y (corresponding author), Tianjin Univ Tradit Chinese Med, Sch Tradit Chinese Med, 10 Poyang Lake Rd, Tianjin 301617, Peoples R China.
EM guoyi_168@163.com; xuzhifangmsn@hotmail.com
FU National Natural Science Foundation of China (NSFC) [81873369, 81904281, 81330088, 81704146]; Shaanxi Administration of Traditional Chinese Medicine [2019-ZZ-JC013]
CR Astry B, 2011, J INTERF CYTOK RES, V31, P927, DOI 10.1089/jir.2011.0094
   Chen J, 2013, CELL PHYSIOL BIOCHEM, V32, P1265, DOI 10.1159/000354525
   Choudhary N, 2018, IMMUNOPHARM IMMUNOT, V40, P193, DOI 10.1080/08923973.2018.1434793
   Choy EHS, 2001, NEW ENGL J MED, V344, P907, DOI 10.1056/NEJM200103223441207
   Croia C, 2019, CLIN EXP RHEUMATOL, V37, P347
   Dey I, 2020, EXP MOL PATHOL, V116, P0, DOI 10.1016/j.yexmp.2020.104485
   Dougados M, 2014, ANN RHEUM DIS, V73, P62, DOI 10.1136/annrheumdis-2013-204223
   Firestein GS, 2003, NATURE, V423, P356, DOI 10.1038/nature01661
   Jovanovic DV, 1998, J IMMUNOL, V160, P3513
   Kryczek I, 2007, CANCER RES, V67, P8900, DOI 10.1158/0008-5472.CAN-07-1866
   Liu GW, 2011, IMMUNOL CELL BIOL, V89, P130, DOI 10.1038/icb.2010.70
   Municio C, 2018, ANN RHEUM DIS, V77, P752, DOI 10.1136/annrheumdis-2017-212537
   Roberts CA, 2015, FRONT IMMUNOL, V6, P1, DOI 10.3389/fimmu.2015.00571
   Scott David L, 2010, LANCET, V376, P1094, DOI 10.1016/S0140-6736(10)60826-4
   Sultana F, 2017, COLLOID SURFACE B, V155, P349, DOI 10.1016/j.colsurfb.2017.04.046
   Taams LS, 2005, HUM IMMUNOL, V66, P222, DOI 10.1016/j.humimm.2004.12.006
   Tam Lai-Shan, 2007, BMC COMPLEMENT ALTERN MED, V7, P35, DOI 10.1186/1472-6882-7-35
   Tiemessen MM, 2007, P NATL ACAD SCI USA, V104, P19446, DOI 10.1073/pnas.0706832104
   Toh ML, 2007, CURR OPIN RHEUMATOL, V19, P284, DOI 10.1097/BOR.0b013e32805e87e0
   Torres-Rosas R, 2014, NAT MED, V20, P291, DOI 10.1038/nm.3479
   Udalova IA, 2016, NAT REV RHEUMATOL, V12, P472, DOI 10.1038/nrrheum.2016.91
   World Health Organization, 2002, ACUPUNCTURE: REVIEW AND ANALYSIS OF REPORTS ON CONTROLLED CLINICAL TRIALS, V0, P0
   Wynn TA, 2013, NATURE, V496, P445, DOI 10.1038/nature12034
   Xu Y, 2018, AM J CHINESE MED, V46, P997, DOI 10.1142/S0192415X18500520
   Yuan XS, 2016, BIOCHEM PHARMACOL, V101, P87, DOI 10.1016/j.bcp.2015.11.025
   ZHANG K, 2018, EVID-BASED COMPL ALT, V2018, P0, DOI 10.1155/2018/9260630
NR 26
TC 14
Z9 18
U1 4
U2 50
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 0964-5284
EI 1759-9873
J9 ACUPUNCT MED
JI Acupunct. Med.
PD APR 15
PY 2023
VL 41
IS 2
BP 96
EP 109
DI 10.1177/09645284221085278
EA MAY 2022
PG 14
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA E4PH3
UT WOS:000799715200001
PM 35585798
DA 2026-01-16
ER

PT J
AU Qi, L
   Shi, HS
   Zhang, YS
   Zhang, XC
   Jia, HL
   Tian, H
AF Qi, Lin
   Shi, Hongshuo
   Zhang, Yunsong
   Zhang, Xuecheng
   Jia, Hongling
   Tian, Hu
TI The effect of acupuncture on recovery after colorectal cancer resection: A systematic review meta-analysis of randomized controlled trials
SO MEDICINE
LA English
DT Review
DE abdominal surgery; acupuncture; colorectal cancer; meta-analysis
ID postoperative nausea; electroacupuncture; surgery; chemotherapy; prevention; mechanisms; motility
AB Background:To evaluate the efficacy and safety of acupuncture by systematically reviewing the literature on colorectal cancer resection.Methods:Seven electronic databases were searched from inception to February 28, 2023. Randomized controlled trials on acupuncture in patients after CRC resection were included. Two reviewers independently selected relevant trials, extracted data, and assessed the risk of bias. A random-effects meta-analysis model was used to obtain summary effect estimates. The data were pooled and analyzed using RevMan 5.3. The heterogeneity of selected studies was evaluated by evaluating the I-squared (I2) statistics.Results:Twenty-two studies with 1878 patients were included. Results of the meta-analysis showed there was a low level evidence that acupuncture may improve early postoperative symptoms, such as time to first flatus (n = 876, MD -0.77h, 95% CI -1.22 to -0.33 h, I2 = 89%), time to first bowel movement (n = 671, MD -1.41h, 95% CI -2.20 to -0.63 h, I2 = 95%), time to first defecation (n = 556, MD -1.03h, 95% CI -1.88 to -0.18 h, I2 = 95%), and nausea/vomiting (n = 1488, RR 0.72, 95% CI 0.59-0.89, I2 = 49%) compared with usual care and sham acupuncture. However, there were no statistically significant differences in postoperative pain (n = 1188, MD-0.21, 95% CI -0.59 to 0.17, I2 = 74%). And there was no sufficient evidence of improving long-term functional outcomes. There was substantial heterogeneity across trials. The adverse events associated with acupuncture stimulation were minor in include studies.Conclusion subsections:There is currently low-level evidence supporting the use of acupuncture on postoperative symptoms for patients after colorectal cancer resection. More investigations should be established based on the STRICTA statement strictly.
C1 [Qi, Lin; Shi, Hongshuo; Tian, Hu] Shandong Univ Tradit Chinese Med, Coll Tradit Chinese Med, Jinan, Peoples R China.
   [Zhang, Yunsong] Shandong Univ Tradit Chinese Med, Affiliated Hosp 1, Jinan, Peoples R China.
   [Zhang, Xuecheng] Beijing Univ Chinese Med, Beijing, Peoples R China.
   [Jia, Hongling] Shandong Univ Tradit Chinese Med, Affiliated Hosp 2, Jinan, Peoples R China.
   [Qi, Lin] Shandong Univ Tradit Chinese Med, Coll Tradit Chinese Med, Jinan 250010, Shandong, Peoples R China.
C3 Shandong University of Traditional Chinese Medicine; Shandong University of Traditional Chinese Medicine; Beijing University of Chinese Medicine; Shandong University of Traditional Chinese Medicine; Shandong University of Traditional Chinese Medicine
RP Qi, L (corresponding author), Shandong Univ Tradit Chinese Med, Coll Tradit Chinese Med, Jinan 250010, Shandong, Peoples R China.
EM tcmqilin@163.com; 2015111@sdutcm.edu.cn; zhangxuecheng@bucm.edu.cn; zhangxuecheng@bucm.edu.cn; jiahl1969@163.com; sdzyydxth@163.com
CR Unknown -, 2009, BMJ-BRIT MED J, V6, Pe1000097, DOI 10.1136/bmj.b2535, 10.1371/journal.pmed.1000097, 10.1371/JOURNAL.PMED.1000097
   Balshem H, 2011, J CLIN EPIDEMIOL, V64, P401, DOI 10.1016/j.jclinepi.2010.07.015
   Bray F, 2020, CA-CANCER J CLIN, V70, P313, DOI 10.3322/caac.21609
   Cao XZ, 2017, J ANESTH, V31, P617, DOI 10.1007/s00540-017-2363-x
   Chan KY, 2020, TRIALS, V21, P0, DOI 10.1186/s13063-019-3972-5
   Chen JB, 2020, INT J SURG, V73, P57, DOI 10.1016/j.ijsu.2019.10.036
   Chen KB, 2019, INT J SURG, V70, P93, DOI 10.1016/j.ijsu.2019.08.034
   ChiCtr, 2020, STUDY ON THE EFFECT OF ACUPUNCTURE ON THE GASTROINTESTINAL FUNCTION OF PATIENTS WITH COLORECTAL CANCER AFTER OPERATION: A RANDOMIZED CONTROLLED TRIAL, V0, P0
   ChiCtr, 2019, ELECTROACUPUNCTURE FOR POSTOPERATIVE ILEUS AFTER COLORECTAL CANCER SURGERY: A RANDOMIZED CONTROLLED CLINICAL STUDY, V0, P0
   Deng G, 2013, ANN SURG ONCOL, V20, P1164, DOI 10.1245/s10434-012-2759-7
   Du XT, 2021, WORLD J ACUPUNCT-MOX, V31, P83, DOI 10.1016/j.wjam.2020.11.013
   Frey UH, 2009, BRIT J ANAESTH, V102, P620, DOI 10.1093/bja/aep014
   Haddaway NR, 2022, CAMPBELL SYST REV, V18, P0, DOI 10.1002/cl2.1230
   Kim KH, 2016, ACUPUNCT MED, V34, P248, DOI 10.1136/acupmed-2015-010941
   Lan Z, 2019, GEN NURS, V17, P206
   Lee Y, 2020, SURG ONCOL, V32, P75, DOI 10.1016/j.suronc.2019.11.004
   Li FF, 2018, WORLD J ACUPUNCT-MOX, V28, P151, DOI 10.1016/j.wjam.2018.08.001
   Li Huai-Yu, 2022, ZHONGGUO ZHEN JIU, V42, P595, DOI 10.13703/j.0255-2930.20210214-0003
   Li L, 2006, CHINA ACUPUNCT MOXIBUSTION, V26, P65
   Lin JG, 2008, AM J CHINESE MED, V36, P635, DOI 10.1142/S0192415X08006107
   Ling X, 2016, SHANDONG J TRADIT CHIN MED, V35, P701
   Liska D, 2021, ANN SURG, V273, P772, DOI 10.1097/SLA.0000000000003438
   Liu M, 2017, JOURNAL OF SHANGHAI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE, V31, P38
   Liu XY, 2021, CHIN J COLORECTAL DIS, V10, P605, DOI 10.3877/cma.j.issn.2095-3224.2021.06.007
   Liu YH, 2018, EVID-BASED COMPL ALT, V2018, P0, DOI 10.1155/2018/3178472
   Luo DH, 2018, STAT METHODS MED RES, V27, P1785, DOI 10.1177/0962280216669183
   MacPherson H, 2010, PLOS MED, V7, P0, DOI 10.1371/journal.pmed.1000261
   Mai Sicong, 2017, ZHONGGUO ZHEN JIU, V37, P483, DOI 10.13703/j.0255-2930.2017.05.008
   Ng S S M, 2013, HONG KONG MED J, V19 Suppl 9, P33
   Ni XF, 2019, INT J SURG, V69, P108, DOI 10.1016/j.ijsu.2019.07.034
   Ni XF, 2019, J GASTROINTEST SURG, V23, P1502, DOI 10.1007/s11605-019-04170-8
   Oh JE, 2022, FRONT IMMUNOL, V12, P0, DOI 10.3389/fimmu.2021.813748
   Patel SG, 2022, LANCET GASTROENTEROL, V7, P262, DOI 10.1016/S2468-1253(21)00426-X
   Stein DJ, 1997, ANESTH ANALG, V84, P342, DOI 10.1097/00000539-199702000-00018
   Sun Hui, 2021, ZHEN CI YAN JIU, V46, P592, DOI 10.13702/j.1000-0607.200647
   The World Health Organization, 1992, CANCER, V03, P254
   Wang D, 2022, PAIN RES MANAG, V2022, P0, DOI 10.1155/2022/7570533
   Wang XL, 2022, EVID-BASED COMPL ALT, V2022, P0, DOI 10.1155/2022/7837711
   Wanyun T, 2014, INTRODUCTION TRADIT CHIN MED, V20, P39
   Xiangdong P, 2016, CHINA ACUPUNCT MOXIBUSTION, V36, P613
   Xuying G, 2020, ACUPUNCT RES, V45, P315
   Yang JW, 2022, ECLINICALMEDICINE, V49, P0, DOI 10.1016/j.eclinm.2022.101472
   Yang NN, 2020, NEUROGASTROENT MOTIL, V32, P0, DOI 10.1111/nmo.13808
   [姚新宇 Yao Xinyu], 2012, 中华麻醉学杂志 CHINESE JOURNAL OF ANESTHESIOLOGY, V32, P820
   Ye Z, 2022, PLOS ONE, V17, P0, DOI 10.1371/journal.pone.0271580
   Yi W, 2019, CLIN J ACUPUNCT MOXIBUSTION MOXIBUSTION, V35, P26
   Ying L, 2021, J GUANGZHOU UNIV CHIN MED, V38, P518
   Yu B, 2021, AM J CHINESE MED, V49, P1151, DOI 10.1142/S0192415X21500555
   Yuan W, 2019, CHINESE MED J-PEKING, V132, P707, DOI 10.1097/CM9.0000000000000123
   Yun S, 2019, INTEGRATED TRADIT CHIN WEST MED NURS, V5, P41
   Zhang RX, 2014, ANESTHESIOLOGY, V120, P482, DOI 10.1097/ALN.0000000000000101
   Zhang S, 2020, ZHEJIANG J TRADIT CHIN MED, V55, P215
   Zhang Shuang-yan, 2011, ZHONGGUO ZHEN JIU, V31, P513
   Zhang WL, 2022, AM J CHINESE MED, V50, P961, DOI 10.1142/S0192415X22500392
   Zhang ZD, 2014, ACUPUNCT MED, V32, P223, DOI 10.1136/acupmed-2013-010490
   Zhao ZQ, 2008, PROG NEUROBIOL, V85, P355, DOI 10.1016/j.pneurobio.2008.05.004
NR 57
TC 5
Z9 6
U1 0
U2 14
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0025-7974
EI 1536-5964
J9 MEDICINE
JI Medicine (Baltimore)
PD SEP 1
PY 2023
VL 102
IS 35
BP 
EP 
DI 10.1097/MD.0000000000034678
PG 15
WC Medicine, General & Internal
SC General & Internal Medicine
GA Q8JQ7
UT WOS:001059934400012
PM 37657054
DA 2026-01-16
ER

PT J
AU Wang, HZ
   Qu, SY
   Zhou, TS
   Hu, QQ
   Zhao, XX
   Yang, QJ
   Chi, HY
   Luo, SL
   Li, XY
   Ke, HX
   He, XF
   Zhao, HL
   Zhao, HL
AF Wang, Hanzhi
   Qu, Siying
   Zhou, Tianshu
   Hu, Qunqi
   Zhao, Xiaoxuan
   Yang, Qujia
   Chi, Hengyu
   Luo, Shiling
   Li, Xinyue
   Ke, Huanxiao
   He, Xiaofen
   Zhao, Hongli
   Zhao, Hongli
TI Current Perspectives and Trend of Acupuncture in Breast Cancer-Related Symptoms: A Bibliometric Study
SO JOURNAL OF PAIN RESEARCH
LA English
DT Review
DE breast cancer-related symptoms; acupuncture; bibliometric study; cancer pain; CiteSpace; VOSviewer
ID induced peripheral neuropathy; quality-of-life; joint pain; chemotherapy; women; electroacupuncture; therapy; recommendations; prevention; management
AB Purpose: This bibliometric research aims to delineate global publication trends and emerging research interests in the use of acupuncture for breast cancer (BC)-related symptoms treatment over the past three decades. Furthermore, it identifies influential institutions, potential collaborative partners, and future research trends, thereby providing guidance for relevant, novel research directions. Methods: Scientific publications related to acupuncture for BC-related symptoms were gathered from the Web of Science Core Collection (WoSCC) from 1993 to 2023. Four software applications were principally used to analyze the resulting data: the "bibliometrix" package in the R environment (version 4.2.3), VOSviewer, CiteSpace6.1.R6, and the bibliometrics website. These applications were employed to evaluate different parameters. Results: A total of 621 papers on acupuncture in BC-related symptoms treatment were analyzed. The United States, China, and South Korea contributed the most, with Memorial Sloan Kettering Cancer Center, and Columbia University leading institutions. It is interesting to mention that Mao, Jun J. and Molassiotis, A. feature among the top 10 authors and co-cited authors. JAMA is the leading journal, with an ongoing focus on acupuncture's effectiveness. Keywords show that the initial research focus was mainly on "vasomotor symptoms", but in recent years there has been a gradual shift towards "pain", "chemotherapy-induced peripheral neuropathy (CIPN)", "electroacupuncture", and "non-specific effects". Conclusion: Acupuncture has demonstrated a unique value in the process of adjuvant treatment of BC-related symptoms, and has been shown to be effective in reducing pain, eliminating fatigue, and improving quality of life. The study of the mechanisms of acupuncture and the application of electroacupuncture are possible future research priorities in this field. This study offers a deep perspective on acupuncture for BC research, highlighting key points and future trends.
C1 [Wang, Hanzhi; Zhao, Xiaoxuan; Yang, Qujia; Luo, Shiling; Ke, Huanxiao; Zhao, Hongli; Zhao, Hongli] Zhejiang Chinese Med Univ, Hangzhou Hosp Tradit Chinese Med, Dept Tradit Chinese Med TCM Gynecol, 453 Tiyuchang Rd, Hangzhou, Zhejiang, Peoples R China.
   [Wang, Hanzhi; Qu, Siying; Hu, Qunqi; Yang, Qujia; Chi, Hengyu; Ke, Huanxiao] Zhejiang Chinese Med Univ, Hangzhou, Zhejiang, Peoples R China.
   [Zhou, Tianshu] Wenzhou Med Univ, Wenzhou, Zhejiang, Peoples R China.
   [Li, Xinyue] Zhejiang Univ, Womens Hosp, Sch Med, Hangzhou, Zhejiang, Peoples R China.
   [He, Xiaofen] Zhejiang Chinese Med Univ, Clin Med Coll 3, Dept Neurobiol & Acupuncture Res, Key Lab Acupuncture & Neurol Zhejiang Prov, 548 Binwen Rd, Hangzhou, Zhejiang, Peoples R China.
C3 Zhejiang Chinese Medical University; Zhejiang Chinese Medical University; Wenzhou Medical University; Zhejiang University; Zhejiang Chinese Medical University
RP Zhao, HL (corresponding author), Zhejiang Chinese Med Univ, Hangzhou Hosp Tradit Chinese Med, Dept Tradit Chinese Med TCM Gynecol, 453 Tiyuchang Rd, Hangzhou, Zhejiang, Peoples R China.; He, XF (corresponding author), Zhejiang Chinese Med Univ, Clin Med Coll 3, Dept Neurobiol & Acupuncture Res, Key Lab Acupuncture & Neurol Zhejiang Prov, 548 Binwen Rd, Hangzhou, Zhejiang, Peoples R China.
EM zjhxf1986@163.com; z6hl@163.com
FU National Natural Science Foundation of China [81804181]; Hangzhou Science and Technology Development Plan Project [202004A13]
CR Abbasi J, 2018, JAMA-J AM MED ASSOC, V320, P744, DOI 10.1001/jama.2018.11068
   Unknown -, 2007, LANCET, V369, P880
   Bae K, 2023, CRIT REV ONCOL HEMAT, V181, P0, DOI 10.1016/j.critrevonc.2022.103898
   Bao T, 2018, EUR J CANCER, V101, P12, DOI 10.1016/j.ejca.2018.06.008
   Birch S, 2019, INTEGR MED RES, V8, P160, DOI 10.1016/j.imr.2019.05.002
   Bokmand S, 2013, BREAST, V22, P320, DOI 10.1016/j.breast.2012.07.015
   Bottomley A, 2002, LANCET ONCOL, V3, P620, DOI 10.1016/S1470-2045(02)00876-8
   Bower JE, 2021, CANCER-AM CANCER SOC, V127, P1334, DOI 10.1002/cncr.33327
   Cai MC, 2023, J OVARIAN RES, V16, P0, DOI 10.1186/s13048-022-01072-3
   Carpenter Janet S, 2002, ONCOL NURS FORUM, V29, PE16, DOI 10.1188/02.ONF.E16-E25
   Chien TJ, 2020, CLIMACTERIC, V23, P130, DOI 10.1080/13697137.2019.1664460
   Cui LF, 2018, SCI REP-UK, V8, P0, DOI 10.1038/s41598-018-29946-x
   de Valois B, 2022, SUPPORT CARE CANCER, V30, P5063, DOI 10.1007/s00520-022-06898-7
   Deng G, 2013, SUPPORT CARE CANCER, V21, P1735, DOI 10.1007/s00520-013-1720-z
   DeSantis CE, 2019, CA-CANCER J CLIN, V69, P211, DOI 10.3322/caac.21555
   Dong R, 2019, FRONT HUM NEUROSCI, V13, P0, DOI 10.3389/fnhum.2019.00259
   Filshie Jacqueline, 2005, ACUPUNCT MED, V23, P171
   Garcia MK, 2013, J CLIN ONCOL, V31, P952, DOI 10.1200/JCO.2012.43.5818
   Ge L, 2022, CHIN MED-UK, V17, P0, DOI 10.1186/s13020-021-00558-4
   Giordano SH, 2018, J NATL COMPR CANC NE, V16, P605, DOI 10.6004/jnccn.2018.0043
   Greenlee H, 2017, CA-CANCER J CLIN, V67, P195, DOI 10.3322/caac.21397
   Han XY, 2017, BMC CANCER, V17, P0, DOI 10.1186/s12885-016-3037-z
   Harbeck N, 2019, NAT REV DIS PRIMERS, V5, P0, DOI 10.1038/s41572-019-0122-z
   He YH, 2020, JAMA ONCOL, V6, P271, DOI 10.1001/jamaoncol.2019.5233
   Hershman DL, 2018, JAMA-J AM MED ASSOC, V320, P2270, DOI 10.1001/jama.2018.16744
   Hershman DL, 2018, JAMA-J AM MED ASSOC, V320, P167, DOI 10.1001/jama.2018.8907
   Hershman DL, 2014, J CLIN ONCOL, V32, P1941, DOI 10.1200/JCO.2013.54.0914
   Hervik J, 2009, BREAST CANCER RES TR, V116, P311, DOI 10.1007/s10549-008-0210-3
   Jiang X, 2019, INT J MED SCI, V16, P1642, DOI 10.7150/ijms.38521
   Jiao HG, 2022, J PAIN RES, V15, P3711, DOI 10.2147/JPR.S392796
   Khosla A, 2023, MED ONCOL, V40, P0, DOI 10.1007/s12032-023-02083-w
   KRONENBERG F, 1994, EXP GERONTOL, V29, P319, DOI 10.1016/0531-5565(94)90012-4
   Lesi G, 2016, J CLIN ONCOL, V34, P1795, DOI 10.1200/JCO.2015.63.2893
   Li JX, 2023, SUPPORT CARE CANCER, V31, P0, DOI 10.1007/s00520-023-07967-1
   Li QW, 2020, CHIN MED-UK, V15, P0, DOI 10.1186/s13020-020-00333-x
   Li QW, 2017, TRIALS, V18, P0, DOI 10.1186/s13063-017-1927-2
   Li RR, 2020, J PAIN RES, V13, P1901, DOI 10.2147/JPR.S258739
   Linde K, 2010, BMC MED, V8, P0, DOI 10.1186/1741-7015-8-75
   Liu C, 2022, FRONT IMMUNOL, V13, P0, DOI 10.3389/fimmu.2022.972079
   Lv Z, 2022, FRONT ENDOCRINOL, V13, P0, DOI 10.3389/fendo.2022.921119
   Lyman GH, 2018, J CLIN ONCOL, V36, P2647, DOI 10.1200/JCO.2018.79.2721
   Malla R, 2022, J PHARM ANAL, V12, P221, DOI 10.1016/j.jpha.2021.11.004
   Mao JJ, 2014, EUR J CANCER, V50, P267, DOI 10.1016/j.ejca.2013.09.022
   Mazor M, 2018, J PAIN SYMPTOM MANAG, V55, P1138, DOI 10.1016/j.jpainsymman.2017.11.030
   McEvoy MP, 2021, CLIN BREAST CANCER, V21, P128, DOI 10.1016/j.clbc.2021.02.009
   Molassiotis A, 2012, J CLIN ONCOL, V30, P4470, DOI 10.1200/JCO.2012.41.6222
   Mom CH, 2006, CRIT REV ONCOL HEMAT, V57, P63, DOI 10.1016/j.critrevonc.2005.04.009
   Napadow V, 2005, HUM BRAIN MAPP, V24, P193, DOI 10.1002/hbm.20081
   Pei ZR, 2022, J CONTROL RELEASE, V352, P211, DOI 10.1016/j.jconrel.2022.10.023
   Pilevarzadeh M, 2019, BREAST CANCER RES TR, V176, P519, DOI 10.1007/s10549-019-05271-3
   Portenoy RK, 2011, LANCET, V377, P2236, DOI 10.1016/S0140-6736(11)60236-5
   Rosenberg SM, 2015, ONCOLOGIST, V20, P598, DOI 10.1634/theoncologist.2015-0007
   Seretny M, 2014, PAIN, V155, P2461, DOI 10.1016/j.pain.2014.09.020
   Sicart CSVA, 2023, SUPPORT CARE CANCER, V31, P0, DOI 10.1007/s00520-023-07616-7
   Siegel RL, 2020, CA-CANCER J CLIN, V70, P7, DOI 10.3322/caac.21590
   Singer DS, 2016, SCIENCE, V353, P1105, DOI 10.1126/science.aai7862
   Thompson DF, 2015, PHARMACOTHERAPY, V35, P551, DOI 10.1002/phar.1586
   Walker EM, 2010, J CLIN ONCOL, V28, P634, DOI 10.1200/JCO.2009.23.5150
   White AR, 2001, COMPLEMENT THER MED, V9, P237, DOI 10.1054/ctim.2001.0489
   Xiang HC, 2021, FRONT PSYCHOL, V12, P0, DOI 10.3389/fpsyg.2021.721872
   Yang M, 2019, FRONT ONCOL, V9, P0, DOI 10.3389/fonc.2019.00576
   Zhang XW, 2022, PHYTOMEDICINE, V106, P0, DOI 10.1016/j.phymed.2022.154430
   Zhang XH, 2021, FRONT NEUROSCI-SWITZ, V15, P0, DOI 10.3389/fnins.2021.657507
   Zhang Y, 2018, SUPPORT CARE CANCER, V26, P415, DOI 10.1007/s00520-017-3955-6
NR 64
TC 5
Z9 5
U1 2
U2 32
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1178-7090
EI 
J9 J PAIN RES
JI J. Pain Res.
PD JUN 15
PY 2023
VL 16
IS 
BP 4165
EP 4180
DI 10.2147/JPR.S442151
PG 16
WC Clinical Neurology
SC Neurosciences & Neurology
GA AL3L8
UT WOS:001118580500001
PM 38078016
DA 2026-01-16
ER

PT J
AU Mentink, M
   Verbeek, D
   Noordman, J
   Timmer-Bonte, A
   von Rosenstiel, I
   van Dulmen, S
AF Mentink, Marit
   Verbeek, Danielle
   Noordman, Janneke
   Timmer-Bonte, Anja
   von Rosenstiel, Ines
   van Dulmen, Sandra
TI The Effects of Complementary Therapies on Patient-Reported Outcomes: An Overview of Recent Systematic Reviews in Oncology
SO CANCERS
LA English
DT Review
DE complementary medicine; oncology; patient-reported outcomes (PROMS); overview of systematic reviews; meta-analysis
ID cancer-related fatigue; alternative medicine use; health-related quality; breast-cancer; integrative medicine; massage therapy; metaanalysis; interventions; communication; chemotherapy
AB Simple Summary Complementary therapies, such as acupuncture, yoga and herbal medicine are used by many patients with cancer to relieve symptoms and side effects from anti-cancer treatment. Clinicians in oncology often lack the knowledge to adequately advise patients about the potential benefits and risks of complementary therapies. This study aims to provide an overview of recently published systematic reviews of the effects of complementary therapies on patient-reported health outcomes in patients with cancer. One hundred systematic reviews were included, and the results suggest that several complementary therapies can improve patient-reported health outcomes in patients with cancer. For instance, acupuncture to relieve pain and yoga to improve cancer-related fatigue. The results remain inconclusive for other complementary therapies. Many included systematic reviews did not assess the impact of bias on their results. Nonetheless, the results from this study can help clinicians to find information about the evidence base for complementary therapies when counselling patients on this topic.Abstract Many patients with cancer make use of complementary medicine alongside conventional medicine, but clinicians in oncology often lack the knowledge to adequately advise patients on the evidence base for complementary therapies. This study aims to provide an overview of recently published systematic reviews that assess the effects of complementary therapies on patient-reported health outcomes in patients with cancer. Systematic reviews, including a meta-analysis of at least two randomized controlled trials, were identified from the PubMed, Embase, Cochrane Library, CINAHL and PsycINFO databases. The methodological quality was assessed with AMSTAR 2. One hundred systematic reviews were included. The results suggest that several complementary therapies can improve health outcomes reported by patients with cancer, such as acupuncture to relieve pain, music interventions to reduce anxiety and yoga to improve cancer-related fatigue. The side effects related to complementary therapy use are generally mild. The results remain inconclusive for some intervention-outcome combinations. Many of the included systematic reviews insufficiently assessed the causes and impact of bias in their interpretation of the results. This overview of systematic reviews can support clinicians in counselling their patients on this topic and provide directions for future research and clinical practice guidelines in the field of complementary medicine.
C1 [Mentink, Marit; Noordman, Janneke; van Dulmen, Sandra] Nivel Netherlands Inst Hlth Serv Res, Otterstr 118, NL-3512 CR Utrecht, Netherlands.
   [Mentink, Marit; van Dulmen, Sandra] Radboud Univ Nijmegen, Radboud Inst Hlth Sci, Dept Primary & Community Care, Med Ctr, Geert Grooteplein Zuid 21, NL-6525 EZ Nijmegen, Netherlands.
   [Verbeek, Danielle] Praktijk Integratieve Oncol, Heesterpoort 18, NL-9713 KZ Groningen, Netherlands.
   [Timmer-Bonte, Anja] Radboud Univ Nijmegen, Med Ctr, Dept Med Oncol, Geert Grooteplein Zuid 10, NL-6525 GA Nijmegen, Netherlands.
   [von Rosenstiel, Ines] Rijnstate Hosp, Dept Integrat Oncol, Wagnerlaan 55, NL-6815 AD Arnhem, Netherlands.
   [van Dulmen, Sandra] Univ Boras, Fac Caring Sci, Work Life & Social Welf, Allegatan 1, S-50190 Boras, Sweden.
C3 Netherlands Institute for Health Services Research; Radboud University Nijmegen; Radboud University Nijmegen; Rijnstate Hospital; University of Boras
RP Mentink, M (corresponding author), Nivel Netherlands Inst Hlth Serv Res, Otterstr 118, NL-3512 CR Utrecht, Netherlands.; Mentink, M (corresponding author), Radboud Univ Nijmegen, Radboud Inst Hlth Sci, Dept Primary & Community Care, Med Ctr, Geert Grooteplein Zuid 21, NL-6525 EZ Nijmegen, Netherlands.
EM m.mentink@nivel.nl; integratieve.oncologie@gmail.com; j.noordman@nivel.nl; anja.timmer-bonte@radboudumc.nl; ivonrosenstiel@rijnstate.nl; s.vandulmen@nivel.nl
FU The authors would like to thank Alice Tillema (A.T.), librarian at Radboud University medical center, for her support in establishing the search strategy, and Mette van Ginkel (M.v.G.), researcher at Nivel, for her help in appraising the methodological qua
CR Armer JS, 2020, JNCI CANCER SPECT, V4, P0, DOI 10.1093/jncics/pkz098
   Bai X, 2022, EVID-BASED COMPL ALT, V2022, P0, DOI 10.1155/2022/3123878
   Balneaves LG, 2022, JNCI-J NATL CANCER I, V114, P25, DOI 10.1093/jnci/djab048
   Belloni S, 2023, CLIN THER, V45, PE54, DOI 10.1016/j.clinthera.2022.12.001
   Boyd C, 2016, PAIN MED, V17, P1553, DOI 10.1093/pm/pnw100
   Bro ML, 2018, PSYCHO-ONCOLOGY, V27, P386, DOI 10.1002/pon.4470
   Cai Q, 2022, COMPLEMENT THER CLIN, V46, P0, DOI 10.1016/j.ctcp.2021.101510
   Carr PJ, 2018, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD011429.pub2
   Chan YT, 2021, EVID-BASED COMPL ALT, V2021, P0, DOI 10.1155/2021/9949777
   Chang YC, 2021, CANCER NURS, V44, PE703, DOI 10.1097/NCC.0000000000000889
   Chen CY, 2018, COMPLEMENT MED RES, V25, P406, DOI 10.1159/000491693
   Chen LC, 2021, EVID-BASED COMPL ALT, V2021, P0, DOI 10.1155/2021/8868720
   Chen ST, 2020, J CANCER RES CLIN, V146, P2913, DOI 10.1007/s00432-020-03353-0
   Chen YY, 2021, FRONT ONCOL, V11, P0, DOI 10.3389/fonc.2021.629132
   Chen ZQ, 2019, COMPLEMENT THER MED, V47, P0, DOI 10.1016/j.ctim.2019.08.001
   Chien TJ, 2020, CLIMACTERIC, V23, P130, DOI 10.1080/13697137.2019.1664460
   Chien TJ, 2019, INTEGR CANCER THER, V18, P0, DOI 10.1177/1534735419886662
   Cohen MH, 2002, ANN INTERN MED, V136, P596, DOI 10.7326/0003-4819-136-8-200204160-00009
   Coutiño-Escamilla L, 2019, BREAST, V44, P135, DOI 10.1016/j.breast.2019.01.006
   da Silva FP, 2019, J MANIP PHYSIOL THER, V42, P503, DOI 10.1016/j.jmpt.2018.12.007
   Dai L, 2021, J PALLIAT MED, V24, P1078, DOI 10.1089/jpm.2020.0405
   Danon N, 2022, PSYCHO-ONCOLOGY, V31, P345, DOI 10.1002/pon.5821
   Davis EL, 2012, ONCOLOGIST, V17, P1475, DOI 10.1634/theoncologist.2012-0223
   Deng B, 2018, PHYTOTHER RES, V32, P1211, DOI 10.1002/ptr.6068
   Deng GE, 2013, CHEST, V143, PE420, DOI 10.1378/chest.12-2364
   Dong B, 2021, BMC COMPLEMENT MED, V21, P0, DOI 10.1186/s12906-020-03193-y
   Dong B, 2019, BREAST CANCER RES TR, V177, P5, DOI 10.1007/s10549-019-05278-w
   El-Hashimi D, 2019, J EVID-BASED INTEGR, V24, P0, DOI 10.1177/2515690X19828325
   Foley H, 2019, SCI REP-UK, V9, P0, DOI 10.1038/s41598-018-38279-8
   Gao Y, 2021, INTEGR CANCER THER, V20, P0, DOI 10.1177/15347354211044107
   Gonzalez M, 2021, PSYCHO-ONCOLOGY, V30, P1196, DOI 10.1002/pon.5671
   Greenlee H, 2017, CA-CANCER J CLIN, V67, P195, DOI 10.3322/caac.21397
   Haussmann A, 2022, CANCERS, V14, P0, DOI 10.3390/cancers14082016
   He J, 2020, J NATL MED ASSOC, V112, P387, DOI 10.1016/j.jnma.2020.04.006
   He YH, 2020, JAMA ONCOL, V6, P271, DOI 10.1001/jamaoncol.2019.5233
   Hou XB, 2020, TMR INTEGR MED, V4, Pe20019, DOI 10.53388/tmrim202004019
   Hsieh SH, 2021, CANCER NURS, V44, PE578, DOI 10.1097/NCC.0000000000000997
   Hsueh EJ, 2021, BREAST CANCER-TOKYO, V28, P264, DOI 10.1007/s12282-020-01209-6
   Hu JQ, 2022, FRONT ONCOL, V12, P0, DOI 10.3389/fonc.2022.828450
   Huang ZK, 2020, EVID-BASED COMPL ALT, V2020, P0, DOI 10.1155/2020/2456873
   Huebner J, 2014, BREAST CARE, V9, P60, DOI 10.1159/000360381
   Jang A, 2020, INTEGR CANCER THER, V19, P0, DOI 10.1177/1534735420949679
   Jang S, 2020, MEDICINE, V99, P0, DOI 10.1097/MD.0000000000021820
   Jin H, 2021, MEDICINE, V100, P0, DOI 10.1097/MD.0000000000027163
   Jin YX, 2020, EVID-BASED COMPL ALT, V2020, P0, DOI 10.1155/2020/8875433
   Jing XM, 2018, COMPLEMENT THER CLIN, V31, P282, DOI 10.1016/j.ctcp.2018.03.005
   Kabat-Zin Jon, 1990, FULL CATASTROPHE LIV, V0, P0
   Kannan P, 2022, QUAL LIFE RES, V31, P951, DOI 10.1007/s11136-021-02926-x
   Keene MR, 2019, COMPLEMENT THER CLIN, V35, P33, DOI 10.1016/j.ctcp.2019.01.004
   Kemppainen LM, 2018, SCAND J PUBLIC HEALT, V46, P448, DOI 10.1177/1403494817733869
   Kim D, 2022, BMC COMPLEMENT MED, V22, P0, DOI 10.1186/s12906-022-03614-0
   King N, 2015, INTEGR CANCER THER, V14, P515, DOI 10.1177/1534735415589984
   Kuo CC, 2021, EVID-BASED COMPL ALT, V2021, P0, DOI 10.1155/2021/6651238
   Kwon CY, 2021, PHYTOTHER RES, V35, P751, DOI 10.1002/ptr.6860
   Lee SM, 2019, INTEGR CANCER THER, V18, P0, DOI 10.1177/1534735419890029
   Lee SH, 2015, INTEGR CANCER THER, V14, P297, DOI 10.1177/1534735415572885
   Li DH, 2021, EVID-BASED COMPL ALT, V2021, P0, DOI 10.1155/2021/5558590
   Li HJ, 2021, J ALTERN COMPLEM MED, V27, P1084, DOI 10.1089/acm.2021.0133
   Li L, 2021, FRONT ONCOL, V11, P0, DOI 10.3389/fonc.2021.661925
   Li ML, 2019, BMC COMPLEM ALTERN M, V19, P0, DOI 10.1186/s12906-019-2441-8
   Li S, 2020, FRONT ONCOL, V10, P0, DOI 10.3389/fonc.2020.599073
   Li YF, 2020, J ADV NURS, V76, P1111, DOI 10.1111/jan.14313
   Li YC, 2020, FRONT PHARMACOL, V11, P0, DOI 10.3389/fphar.2020.00132
   Li ZY, 2019, EVID-BASED COMPL ALT, V2019, P0, DOI 10.1155/2019/1029626
   Lin LY, 2022, J CLIN PSYCHOL MED S, V29, P432, DOI 10.1007/s10880-022-09862-z
   Lin WF, 2019, CANCER MANAG RES, V11, P6663, DOI 10.2147/CMAR.S195935
   Lin Y, 2022, CLIN BREAST CANCER, V22, PE664, DOI 10.1016/j.clbc.2022.01.013
   Liu C, 2021, EVID-BASED COMPL ALT, V2021, P0, DOI 10.1155/2021/9980940
   Liu J, 2020, EVID-BASED COMPL ALT, V2020, P0, DOI 10.1155/2020/4243175
   Liu LZ, 2020, COMPLEMENT THER CLIN, V38, P0, DOI 10.1016/j.ctcp.2019.101078
   Liu XM, 2021, INTEGR CANCER THER, V20, P0, DOI 10.1177/1534735420980811
   Liu YH, 2018, INTEGR CANCER THER, V18, P0, DOI 10.1177/1534735418817833
   Lu Y, 2021, FRONT PHARMACOL, V12, P0, DOI 10.3389/fphar.2021.698371
   Luo XC, 2020, FRONT ONCOL, V10, P0, DOI 10.3389/fonc.2020.00607
   Lyman GH, 2018, J CLIN ONCOL, V36, P2647, DOI 10.1200/JCO.2018.79.2721
   Ma HL, 2019, EUR J INTEGR MED, V30, P0, DOI 10.1016/j.eujim.2019.100960
   Mai QL, 2022, EUR J INTEGR MED, V51, P0, DOI 10.1016/j.eujim.2022.102120
   Mao JJ, 2022, J CLIN ONCOL, V40, P3998, DOI 10.1200/JCO.22.01357
   Mazzocco K, 2023, CANCERS, V15, P0, DOI 10.3390/cancers15041176
   Mentink M, 2021, BMJ OPEN, V11, P0, DOI 10.1136/bmjopen-2021-053005
   Ni XS, 2019, SUPPORT CARE CANCER, V27, P3701, DOI 10.1007/s00520-019-04911-0
   Ni XX, 2020, INTEGR CANCER THER, V19, P0, DOI 10.1177/1534735420980825
   ONeill M, 2020, INTEGR CANCER THER, V19, P0, DOI 10.1177/1534735420959882
   Qi YS, 2021, SUPPORT CARE CANCER, V29, P3461, DOI 10.1007/s00520-021-05986-4
   Qiao J, 2023, CANCER NURS, V46, P159, DOI 10.1097/NCC.0000000000001061
   Roter DL, 2016, PATIENT EDUC COUNS, V99, P1519, DOI 10.1016/j.pec.2016.06.002
   Schell LK, 2019, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD011518.pub2
   She YQ, 2021, FRONT PHARMACOL, V12, P0, DOI 10.3389/fphar.2021.714287
   Shea BJ, 2017, BMJ-BRIT MED J, V358, P0, DOI 10.1136/bmj.j4008
   Shi G, 2021, GLAND SURG, V10, P1744, DOI 10.21037/gs-21-284
   Sinha MK, 2021, INDIAN J PALLIAT CAR, V27, P336, DOI 10.25259/IJPC_136_21
   Song JH, 2021, ONCOL NURS FORUM, V48, P207, DOI 10.1188/21.ONF.207-228
   Song SJ, 2018, SUPPORT CARE CANCER, V26, P2091, DOI 10.1007/s00520-018-4136-y
   Suh HW, 2021, COMPLEMENT THER MED, V57, P0, DOI 10.1016/j.ctim.2021.102667
   Sun H, 2021, CLIN NUTR, V40, P1682, DOI 10.1016/j.clnu.2020.11.032
   Tan JY, 2021, COMPLEMENT THER CLIN, V45, P0, DOI 10.1016/j.ctcp.2021.101490
   Tang MF, 2019, SLEEP MED REV, V47, P1, DOI 10.1016/j.smrv.2019.05.003
   Uslu-Sahan F, 2023, J INTEGR MED-JIM, V21, P377, DOI 10.1016/j.joim.2023.06.003
   Wang LC, 2020, COMPLEMENT THER MED, V52, P0, DOI 10.1016/j.ctim.2020.102472
   Wang RY, 2019, FRONT ONCOL, V9, P0, DOI 10.3389/fonc.2019.00730
   Wang R, 2021, FRONT MED-LAUSANNE, V8, P0, DOI 10.3389/fmed.2021.684058
   Wang WL, 2020, BMC PSYCHIATRY, V20, P0, DOI 10.1186/s12888-020-02566-4
   Wang XP, 2018, J CANCER RES THER, V14, PS600, DOI 10.4103/0973-1482.183174
   Wang YH, 2021, CHIN J INTEGR MED, V27, P713, DOI 10.1007/s11655-020-3423-x
   Wang YX, 2021, EVID-BASED COMPL ALT, V2021, P0, DOI 10.1155/2021/3996101
   Wu JM, 2019, EVID-BASED COMPL ALT, V2019, P0, DOI 10.1155/2019/5015824
   Xie CY, 2020, J PSYCHOSOM RES, V130, P0, DOI 10.1016/j.jpsychores.2019.109916
   Xu GX, 2021, EVID-BASED COMPL ALT, V2021, P0, DOI 10.1155/2021/7858252
   Xunlin NG, 2020, SUPPORT CARE CANCER, V28, P1563, DOI 10.1007/s00520-019-05219-9
   Yang JN, 2020, SUPPORT CARE CANCER, V28, P3571, DOI 10.1007/s00520-020-05433-w
   Yang T, 2021, COMPLEMENT THER CLIN, V44, P0, DOI 10.1016/j.ctcp.2021.101416
   Yangöz ST, 2019, J ADV NURS, V75, P3362, DOI 10.1111/jan.14184
   Yao ZQ, 2022, COMPLEMENT THER CLIN, V46, P0, DOI 10.1016/j.ctcp.2021.101527
   Yi LJ, 2021, ANN PALLIAT MED, V10, P1961, DOI 10.21037/apm-20-1484
   Yin JC, 2020, MENT HEALTH PHYS ACT, V19, P0, DOI 10.1016/j.mhpa.2020.100347
   Yoon JH, 2021, FRONT PHARMACOL, V12, P0, DOI 10.3389/fphar.2021.753140
   Pan YQ, 2020, INTEGR CANCER THER, V19, P0, DOI 10.1177/1534735420940394
   Zeng J, 2022, GLAND SURG, V11, P588, DOI 10.21037/gs-22-114
   Zeng YC, 2020, INT J NURS STUD, V104, P0, DOI 10.1016/j.ijnurstu.2019.103514
   Zhang HW, 2018, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD010559.pub2
   Zhang XW, 2018, AM J CHINESE MED, V46, P923, DOI 10.1142/S0192415X18500490
   Zhang Y, 2018, SUPPORT CARE CANCER, V26, P415, DOI 10.1007/s00520-017-3955-6
   Zhang YZ, 2021, FRONT ONCOL, V11, P0, DOI 10.3389/fonc.2021.646315
   Zhao YY, 2020, J TRADIT CHIN MED, V40, P738, DOI 10.19852/j.cnki.jtcm.2020.05.003
   Zhu XY, 2021, FRONT ONCOL, V11, P0, DOI 10.3389/fonc.2021.745280
NR 127
TC 7
Z9 9
U1 1
U2 39
PU MDPI
PI BASEL
PA MDPI AG, Grosspeteranlage 5, CH-4052 BASEL, SWITZERLAND
SN 
EI 2072-6694
J9 CANCERS
JI Cancers
PD SEP 15
PY 2023
VL 15
IS 18
BP 
EP 
DI 10.3390/cancers15184513
PG 21
WC Oncology
SC Oncology
GA S4ZI3
UT WOS:001071261000001
PM 37760483
DA 2026-01-16
ER

PT J
AU Zhang, S
   Luo, J
   Zeng, Y
   Ren, H
   Chen, Z
   Ren, Y
AF Zhang, Su
   Luo, Jun
   Zeng, YiWei
   Ren, Huan
   Chen, Zhihan
   Ren, Yulan
TI Acupuncture for protracted amphetamine abstinence syndrome: study protocol for a
SO BMJ open
LA English
DT Journal Article
DE complementary medicine; psychiatry; substance misuse
AB INTRODUCTION: Amphetamine-type stimulants (ATSs) are presenting a great challenge  to global public health along with its worldwide abuse in recent years.  Protracted amphetamine abstinence syndrome (PAAS) is one of the primary causes of  relapse for ATS abusers during withdrawal. However, different conclusions are  reached by previous trials. This study is designed to evaluate the efficacy and  safety of acupuncture in treating PAAS. METHODS AND ANALYSIS: Cochrane Central  Register of Controlled Trials, PubMed, Embase, Web of Science, Cumulative Index  to Nursing and Allied Health Literature (CINAHL), PsycINFO, ProQuest Dissertation  and Theses, Allied and Complementary Medicine Database (AMED), ClinicalTrials.gov  and who.int/trialsearch will be searched from the inception to February 2023 and  language will be restricted to English and Chinese. Eligible randomised  controlled trials will be included. The primary outcome is the intensity of  withdrawal syndrome. The secondary outcomes include: (1) intensity of pain,  anxiety, depression and other associated symptoms; (2) number of participants  with relapse; (3) retention of treatment and (4) nature and rate of adverse  effects. Data synthesis will be performed by using RevMan (V.5.4). The quality of  evidence will be evaluated by the Grading of Recommendations, Assessment,  Development and Evaluation approach. This study will strictly adhere to the  Preferred Reporting Items for Systematic Review and Meta-Analysis guidelines.  ETHICS AND DISSEMINATION: Ethical approval is not required as this is a  systematic review and meta-analysis based on previously published studies that do  not involve patients' privacy. The results of this study will be disseminated in  a peer-reviewed journal. PROSPERO REGISTRATION NUMBER: CRD42022297761.
C1 School of Acupuncture and Tuina, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China.
   School of Chinese Classics, Chengdu University of Traditional Chinese Medicine, Chengdu, China.
   School of Acupuncture and Tuina, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China.
   School of Acupuncture and Tuina, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China.
   School of Acupuncture and Tuina, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China.
   School of Chinese Classics, Chengdu University of Traditional Chinese Medicine, Chengdu, China renxg2468@163.com.
NR 0
TC 0
SN 2044-605
EI 
J9 BMJ Open
PD APR 22
PY 2023
VL 13
IS 4
BP e062491
EP e062491
DI 10.1136/bmjopen-2022-062491
PG 1
WC Humans; Amphetamine; Neoplasm Recurrence, Local; Systematic Reviews as Topic; Meta-Analysis as Topic; Acupuncture Therapy; methods; Chronic Disease; Research Design
UT PubMed:37085314
PM 37085314
DA 2023-04-22
ER

PT J
AU Zhao, ZN
   Li, JW
   Wen, JM
   He, YY
   Sun, ZL
AF Zhao, Zhenni
   Li, Jiawei
   Wen, Jiamin
   He, Yanyan
   Sun, Zhiling
TI Effect of Moxibustion on Inflammatory Cytokines for Low Back Pain: A Systematic Review, Meta-Analysis and Meta-Regression
SO THERAPEUTICS AND CLINICAL RISK MANAGEMENT
LA English
DT Review
DE low back pain; moxibustion; cytokines; tumor necrosis factors; interleukins
ID disc degeneration; expression
AB Background and Objective: Moxibustion is effective for low back pain (LBP), and inflammatory cytokines may play an important role in the mechanism of moxibustion treatment. The purpose of this meta-analysis was to explore the mechanism of moxibustion in LBP in terms of inflammatory cytokines. Methods: We searched China National Knowledge Infrastructure, Wanfang database, Cochrane Central Register of Controlled Trials, Ovid MEDLINE, Embase, PubMed, and Web of Science to identify eligible randomized controlled trials (RCTs). There was no restriction on the publication date. Results: Thirty RCTs measuring interleukin (IL-) 1, IL-1 beta, IL-6, IL-12, IL-17, IL-23, and tumor necrosis factor (TNF-) alpha were included in this meta-analysis. Compared to controls: single moxibustion could effectively decrease levels IL-6 and IL-23 (SMD, -0.71, 95% CI: -1.25 to -0.17, p = 0.01; SMD, -1.61, 95% CI: -2.20 to -1.03, p < 0.01, respectively); combined moxibustion had significant effects on IL-1, IL-1 beta, IL-6, IL-12, IL-17, and TNF-alpha (p < 0.05). Overall, for LBP, single or combined moxibustion could effectively down-regulate levels of pro-inflammatory cytokines (p = 0.007 and p < 0.00001, respectively). For safety of moxibustion, the incidence rate of side effects was similar to that of controls (RD, -0.01, 95% CI: -0.02 to 0.01, p = 0.59). Sensitivity analysis showed that the pooled estimates were robust, and publication bias analysis showed there was a significant small study effect (Egger's test p = 0.0000). High statistical heterogeneity existed between included RCTs, meta-regression showed there was no potential factor explaining the source of heterogeneity. Conclusion: For LBP, moxibustion can effectively decrease levels of IL-1, IL-1 beta, IL-6, IL-12, IL-17, IL-23, and TNF-alpha to achieve analgesia. Because the side effects of moxibustion are transient, it is relatively safe for clinical use. However, based on high heterogeneity in this meta-analysis, rigorously designed RCTs are required to further confirm the results in this review.
C1 [Zhao, Zhenni] Zhejiang Univ, Sch Med, Sir Run Run Shaw Hosp, Nursing Dept, Hangzhou, Zhejiang, Peoples R China.
   [Li, Jiawei; Wen, Jiamin; He, Yanyan; Sun, Zhiling] Nanjing Univ Chinese Med, Sch Nursing, Nanjing, Peoples R China.
C3 Zhejiang University; Nanjing University of Chinese Medicine
RP Sun, ZL (corresponding author), Nanjing Univ Chinese Med, Sch Nursing, 138 Xian Lin Rd, Nanjing, Peoples R China.
EM szl@njucm.edu.cn
FU Postgraduate Research & Practice Innovation Program of Jiangsu Province [SJCX23_0735]
CR Bao CH, 2019, WORLD J GASTROENTERO, V25, P4696, DOI 10.3748/wjg.v25.i32.4696
   Berman BM, 2010, NEW ENGL J MED, V363, P454, DOI 10.1056/NEJMct0806114
   Canli K, 2022, PAIN MED, V23, P1947, DOI 10.1093/pm/pnac091
   Cao X, 2013, THE RESEARCH OF THE INFLUENCE OF DUMOXIBUSTION AND ACUPUNCTURE TO IL- 1, V0, P0
   Cashin AG, 2021, BMJ-BRIT MED J, V374, P0, DOI 10.1136/bmj.n1446
   Chen FQ, 2020, COMPLEMENT THER CLIN, V39, P0, DOI 10.1016/j.ctcp.2020.101130
   Cheng CW, 2013, J INTEGR MED-JIM, V11, P54, DOI 10.3736/jintegrmed2013009
   Cui J, 2019, J CERVICODYNIA LUMBODYNIA, V40, P2
   Quintao JLD, 2021, EUR J PHARMACOL, V896, P0, DOI 10.1016/j.ejphar.2021.173900
   Djuric N, 2020, EUR SPINE J, V29, P1649, DOI 10.1007/s00586-019-06220-w
   Dubois MY, 2014, PAIN MED, V15, P1243, DOI 10.1111/pme.12513
   Fan Y, 2019, MED J AIR FORCE, V35, P338
   Fragoulis GE, 2020, RHEUMATOLOGY, V59, P79, DOI 10.1093/rheumatology/keaa435
   Furlan AD, 2015, SPINE, V40, P1660, DOI 10.1097/BRS.0000000000001061
   Gong P, 2020, J CLIN ACUPUNCT MOXIBUSTION, V36, P17
   Gruber HE, 2013, BIOTECH HISTOCHEM, V88, P302, DOI 10.3109/10520295.2013.783235
   Hartvigsen J, 2018, LANCET, V391, P2356, DOI 10.1016/S0140-6736(18)30480-X
   Helm S, 2021, PAIN PHYSICIAN, V24, PS209, DOI 10.36076/ppj.2021.24.s209-s232
   Higgins JPT, 1900, DOI 10.1002/9781119536604, V0, P0
   Hong K, 2016, FUJIAN J TRADIT CHIN MED, V47, P1
   Hu Jing, 2021, ZHONGGUO ZHEN JIU, V41, P1147, DOI 10.13703/j.0255-2930.20201020-0002
   Hu X, 2020, CHIN MED MOD DISTAN EDUC CHIN, V18, P92
   Hua FH, 2021, MEDICINE, V100, P0, DOI 10.1097/MD.0000000000024347
   Jiang X, 2020, CHIN MED MOD DISTAN EDUC CHIN, V18, P98
   Khan AN, 2017, ANN NY ACAD SCI, V1410, P68, DOI 10.1111/nyas.13551
   Knezevic NN, 2021, LANCET, V398, P78, DOI 10.1016/S0140-6736(21)00733-9
   Kong L, 2014, THE RESEARCH OF INFLUENCE ABOUT DUMOXIBUSTION ON INFLAMMATORY INDICATORS OF ANKYLOSING SPONDYLITIS (THE KIDNEY YANG DEFICIENCY SYNDROME), V0, P0
   Li X, 2019, ASIA PACIFIC TRADIT MED, V15, P144
   Li X, 2021, MED J CHIN PEOPLE HEALTH, V33, P22
   Li Y, 2019, SHANGHAI J ACUPUNCT MOXIBUST, V38, P1035
   Li Z, 2020, CHIN FOREIGN MED TREAT, V39, P177
   Liu, 2020, GUANG J CHIN MED., V35, P3250
   Lu TC, 2021, AM J TRANSL RES, V13, P5059
   Lyu M, 2018, GUANG J CHIN MED, V33, P2086
   Lyu S, 2018, J CLIN ACUPUNCT MOXIBUSTION, V34, P26
   Lyu ZL, 2019, XIN ZHONG YI, V51, P247
   Ma B, 2016, PLOS ONE, V11, P0
   Niu L, 2022, J PRACT TRADIT CHIN MED., V38, P280
   Page MJ, 2021, BMJ-BRIT MED J, V372, P0, DOI 10.1136/bmj.n160
   Qin H, 2021, J N CHIN MED, V53, P135
   Qin Q, 2012, TEMPERATURE ACUPUNCTURE TREATMENT OF SCIATICA AND EFFECT ON PGE2, V0, P0
   Sanabria-Mazo JP, 2022, FRONT IMMUNOL, V13, P0, DOI 10.3389/fimmu.2022.945513
   Shamji MF, 2010, ARTHRITIS RHEUM-US, V62, P1974, DOI 10.1002/art.27444
   Tan JH, 2022, CELL BIOL INT, V46, P535, DOI 10.1002/cbin.11767
   Teodorezyk-Injeyan JA, 2019, CLIN J PAIN, V35, P818, DOI 10.1097/AJP.0000000000000745
   van den Berg R, 2018, SPINE J, V18, P2140, DOI 10.1016/j.spinee.2018.06.349
   Wang YJ, 2020, BIOMED PHARMACOTHER, V131, P0, DOI 10.1016/j.biopha.2020.110660
   Xu C, 2021, J CLIN EPIDEMIOL, V135, P70, DOI 10.1016/j.jclinepi.2021.02.012
   Xu J, 2012, J GANSU UNIV CHIN MED, V29, P55
   Xu K, 2013, CHINESE J REHABILITATION MED, V12, P1
   Xu X, 2022, J TRADIT COMPL MED, V12, P518, DOI 10.1016/j.jtcme.2022.04.002
   [闫仲凯 Yan Zhongkai], 2015, 中国针灸 CHINESE ACUPUNCTURE AND MOXIBUSTION, V35, P1121
   Yang W, 2015, CLIN CHIM ACTA, V450, P262, DOI 10.1016/j.cca.2015.08.029
   Yang YQ, 2020, CHIN MANIPULAT REHABILITAT MED, V11, P62
   Yao Y, 2022, EVID-BASED COMPL ALT, V2022, P0, DOI 10.1155/2022/6114417
   Yin J, 2008, CLINICAL STUDY ON TREATMENT OF LUMBAR DISC HERNIATION WITH WARM ACUPUNCTURE AND MOXIBUSTION, V0, P0
   Zhang B, 2019, AM J TRANSL RES, V11, P6221
   Zhang G, 2012, CHIN J EXPER TRADIT MED FORMUL, V18, P255
   Zhang M, 2021, CLINICAL OBSERVATION OF BAMBOO CIRCLE SALT MOXIBUSTION IN THE TREATMENT OF CHRONIC NON-SPECIFIC LOW BACK PAIN WITH KIDNEY-YANG DEFICIENCY, V0, P0, DOI DOI 10.27021/d.cnki.gfjzc.2021.000085
   Zhao Y, 2021, JIANGSU J TRADIT CHIN MED., V53, P57
   Zhong YM, 2020, EVID-BASED COMPL ALT, V2020, P0, DOI 10.1155/2020/6108619
   Zhu X, 2019, CHIN MED MOD DISTAN EDUC CHIN, V17, P97
   Zuo Zheng, 2018, ZHONGGUO ZHEN JIU, V38, P1053, DOI 10.13703/j.0255-2930.2018.10.006
NR 63
TC 9
Z9 10
U1 0
U2 4
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 
EI 1178-203X
J9 THER CLIN RISK MANAG
JI Therap. Clin. Risk Manag.
PD JUN 15
PY 2023
VL 19
IS 
BP 811
EP 827
DI 10.2147/TCRM.S429469
PG 17
WC Health Care Sciences & Services
SC Health Care Sciences & Services
GA IV1E9
UT WOS:001169012800001
PM 37873037
DA 2026-01-16
ER

PT J
AU Liao, C
   Tao, S
   Xiong, Y
   Dai, J
   Bai, Y
   Wang, X
   Li, Y
   Wu, P
AF Liao, Chenxi
   Tao, Siyu
   Xiong, Yan
   Dai, Jingyang
   Bai, Yu
   Wang, Xue
   Li, Yuan
   Wu, Ping
TI The Effects and Potential Mechanisms of Moxibustion for Rheumatoid
SO Journal of pain research
LA English
DT Journal Article
DE inflammatory factor; moxibustion; pain; rheumatoid arthritis
AB PURPOSE: To investigate the effects of moxibustion in relieving pain, and other  clinical symptoms for patients with rheumatoid arthritis (RA), and explore the  potential mechanism of moxibustion treatment for RA. PATIENTS AND METHODS:  Seventy qualified RA patients were randomly assigned in a 1:1 ratio to the  moxibustion group or the routine group. The routine group only took oral  methotrexate tablets and folic acid tablets. The moxibustion group was treated  with moxibustion based on oral pharmaceutical. Moxibustion was performed two  times weekly for 8 weeks, a total of 16 sessions. Patients scored their pain on a  visual analog scale (VAS). The American College of Rheumatology improvement  criteria of 20%, 50% and 70% (ACR20, ACR50 and ACR70) after treatment were  investigated. Clinical symptoms, a disease activity score using 28 joint counts  (DAS28), simplified disease activity index (SDAI), clinical disease activity  index (CDAI), health assessment questionnaire (HAQ), interleukin 1β (IL-1β),  tumor necrosis factor-alpha (TNF-α), and vascular endothelial growth factor  (VEGF) of RA patients were analyzed before and after treatment. RESULTS: After  treatment, the VAS scores, tender and swollen joint counts, morning stiffness  scores, disease activity scores (DAS28, SDAI, CDAI), HAQ scores in the two groups  were both improved, and the effects of moxibustion group were more obvious (P <  0.05). The ACR20 and ACR50 of the moxibustion group were greater than that of the  routine group (P < 0.05), no significant difference of the ACR70 existed between  the two groups (P > 0.05). In addition, the decreases of IL-1β, TNF-α, VEGF of  the moxibustion group were better than that of the routine group (P < 0.05).  CONCLUSION: Moxibustion could effectively relieve pain, ameliorate the clinical  symptoms, and decrease the disease activity of RA. The potential mechanism may be  the decrease in the level of serum inflammatory factors.
C1 Acupuncture and Tuina School, Chengdu University of Traditional Chinese Medicine, Chengdu, People's Republic of China.
   Acupuncture and Tuina School, Chengdu University of Traditional Chinese Medicine, Chengdu, People's Republic of China.
   Department of Osteoporosis, Huaxi Fourth Hospital, Sichuan University, Chengdu, People's Republic of China.
   Department of Traditional Chinese Medicine, Chengdu Fifth People's Hospital, Chengdu, People's Republic of China.
   Department of Traditional Chinese Medicine, Chengdu Second People's Hospital, Chengdu, People's Republic of China.
   Acupuncture and Tuina School, Chengdu University of Traditional Chinese Medicine, Chengdu, People's Republic of China.
   Department of Rheumatology, The Affiliated Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, People's Republic of China.
   Acupuncture and Tuina School, Chengdu University of Traditional Chinese Medicine, Chengdu, People's Republic of China.
NR 0
TC 0
SN 1178-709
EI 1178-709
J9 J Pain Res
PD JUN 1
PY 2023
VL 16
IS 
BP 1739
EP 1749
DI 10.2147/JPR.S408814
PG 10
UT PubMed:37261035
PM 37261035
DA 2023-06-01
ER

PT J
AU Levy, Yurkovski I
   Andreazzoli, F
   Ben-Arye, E
   Attias, S
   Tadmor, T
AF Levy Yurkovski, Ilana
   Andreazzoli, Francesca
   Ben-Arye, Eran
   Attias, Samuel
   Tadmor, Tamar
TI Integrative Approaches in the Treatment of Patients Affected by Lymphoma.
SO Current oncology reports
LA English
DT Review
DE Complementary medicine; Haemato-oncology; Integrative medicine; Lymphoma
AB PURPOSE OF REVIEW: Lymphoma is the most frequent hematological malignancy with  wide disease spectrum of watchful waiting period, active treatment, survivorship,  and palliative care. All these steps impose unmet needs in terms of prevention,  symptom alleviation, or prognosis. Complementary and integrative medicine (CIM)  is widely used by patients with lymphoma to cope with such issues. Here, we  describe the different CIM modalities that may be effective and safe for the  management of patients with lymphoma. RECENT FINDINGS: Low inflammatory diet and  ginseng seem effective for lymphoma prevention. Pain and neuropathy may be  improved using acupuncture, touch therapy and specific dietary supplements.  Nausea/vomiting, fatigue, and insomnia may be relieved by acupuncture, mind-body,  touch therapy, and certain dietary supplements. Vitamin D, curcumin, and some  traditional medicine herbs may positively impact lymphoma prognosis. Finally,  safety issues should be considered especially for the concomitant use of dietary  supplements and lymphoma-directed therapies. CIM may be beneficial along the  continuum of lymphoma management although safety concerns should be considered  when used concomitantly with conventional therapy.
C1 Hematology Unit, Bnai Zion Medical Center, Golomb 47, 33394, Haifa, Israel. ilana.e.levy@gmail.com.
   Complementary Medicine Service, Bnai Zion Medical Center, Haifa, Israel. 
   Rappaport Faculty of Medicine, Technion- Israel Institute of Technology, Haifa, Israel. ilana.e.levy@gmail.com.
   Department of Hematology, Versilia's Hospital, Camaiore, Italy.
   Rappaport Faculty of Medicine, Technion- Israel Institute of Technology, Haifa, Israel.
   Integrative Oncology Program, The Oncology Service, Lin, Carmel & Zebulun Medical 
   Complementary Medicine Service, Bnai Zion Medical Center, Haifa, Israel.
   Hematology Unit, Bnai Zion Medical Center, Golomb 47, 33394, Haifa, Israel.
   Rappaport Faculty of Medicine, Technion- Israel Institute of Technology, Haifa,
NR 0
TC 0
SN 1534-626
EI 
J9 Curr Oncol Rep
PD DEC 7
PY 2023
VL 25
IS 12
BP 1523
EP 1534
DI 10.1007/s11912-023-01476-4
PG 11
WC Humans; Complementary Therapies; Acupuncture Therapy; Lymphoma; therapy; Diet; Nausea; Integrative Medicine
UT PubMed:38060095
PM 38060095
DA 2023-12-07
ER

PT J
AU Zhao, Z
   Li, J
   Wen, J
   He, Y
   Sun, Z
AF Zhao, Zhenni
   Li, Jiawei
   Wen, Jiamin
   He, Yanyan
   Sun, Zhiling
TI Effect of Moxibustion on Inflammatory Cytokines for Low Back Pain: A Systematic
SO Therapeutics and clinical risk management
LA English
DT Review
DE cytokines; interleukins; low back pain; moxibustion; tumor necrosis factors
AB BACKGROUND AND OBJECTIVE: Moxibustion is effective for low back pain (LBP), and  inflammatory cytokines may play an important role in the mechanism of moxibustion  treatment. The purpose of this meta-analysis was to explore the mechanism of  moxibustion in LBP in terms of inflammatory cytokines. METHODS: We searched China  National Knowledge Infrastructure, Wanfang database, Cochrane Central Register of  Controlled Trials, Ovid MEDLINE, Embase, PubMed, and Web of Science to identify  eligible randomized controlled trials (RCTs). There was no restriction on the  publication date. RESULTS: Thirty RCTs measuring interleukin (IL-) 1, IL-1β,  IL-6, IL-12, IL-17, IL-23, and tumor necrosis factor (TNF-) α were included in  this meta-analysis. Compared to controls: single moxibustion could effectively  decrease levels IL-6 and IL-23 (SMD, -0.71, 95% CI: -1.25 to -0.17, p = 0.01;  SMD, -1.61, 95% CI: -2.20 to -1.03, p < 0.01, respectively); combined moxibustion  had significant effects on IL-1, IL-1β, IL-6, IL-12, IL-17, and TNF-α (p < 0.05).  Overall, for LBP, single or combined moxibustion could effectively down-regulate  levels of pro-inflammatory cytokines (p = 0.007 and p < 0.00001, respectively).  For safety of moxibustion, the incidence rate of side effects was similar to that  of controls (RD, -0.01, 95% CI: -0.02 to 0.01, p = 0.59). Sensitivity analysis  showed that the pooled estimates were robust, and publication bias analysis  showed there was a significant small study effect (Egger's test p = 0.0000). High  statistical heterogeneity existed between included RCTs, meta-regression showed  there was no potential factor explaining the source of heterogeneity. CONCLUSION:  For LBP, moxibustion can effectively decrease levels of IL-1, IL-1β, IL-6, IL-12,  IL-17, IL-23, and TNF-α to achieve analgesia. Because the side effects of  moxibustion are transient, it is relatively safe for clinical use. However, based  on high heterogeneity in this meta-analysis, rigorously designed RCTs are  required to further confirm the results in this review.
C1 Nursing Department, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Zhejiang, People's Republic of China.
   School of Nursing, Nanjing University of Chinese Medicine, Nanjing, People's Republic of China.
   School of Nursing, Nanjing University of Chinese Medicine, Nanjing, People's Republic of China.
   School of Nursing, Nanjing University of Chinese Medicine, Nanjing, People's Republic of China.
   School of Nursing, Nanjing University of Chinese Medicine, Nanjing, People's Republic of China.
NR 0
TC 0
SN 1178-203
EI 1176-633
J9 Ther Clin Risk Manag
PD OCT 24
PY 2023
VL 19
IS 
BP 811
EP 827
DI 10.2147/TCRM.S429469
PG 16
UT PubMed:37873037
PM 37873037
DA 2023-10-24
ER

PT J
AU Lo, YJ
   Mishra, VK
   Lo, HY
   Dubey, NK
   Lo, WC
AF Lo, Yun-Jo
   Mishra, Viraj Krishna
   Lo, Hung-Yao
   Dubey, Navneet Kumar
   Lo, Wen-Cheng
TI Clinical Spectrum and Trajectory of Innovative Therapeutic Interventions for Insomnia: A Perspective
SO AGING AND DISEASE
LA English
DT Article
DE insomnia; cognitive behavioral therapy; whole-body cryotherapy; traditional chinese medicine; pulsed magnetic field therapy; acupressure
ID cognitive-behavioral therapy; whole-body cryotherapy; major depressive disorder; short-sleep duration; cranial electrotherapy stimulation; generalized anxiety disorder; orexin receptor antagonists; magnetic-field therapy; cortical gaba levels; fatty liver-disease
AB Increasing incidences of insomnia in adults, as well as the aging population, have been reported for their negative impact on the quality of life. Insomnia episodes may be associated with neurocognitive, musculoskeletal, cardiovascular, gastrointestinal, renal, hepatic, and metabolic disorders. Epidemiological evidence also revealed the association of insomnia with oncologic and asthmatic complications, which has been indicated as bidirectional. Two therapeutic approaches including cognitive behavioral therapy (CBT) and drugs-based therapies are being practiced for a long time. However, the adverse events associated with drugs limit their wide and long-term application. Further, Traditional Chinese medicine, acupressure, and pulsed magnetic field therapy may also provide therapeutic relief. Notably, the recently introduced cryotherapy has been demonstrated as a potential candidate for insomnia which could reduce pain, by suppressing oxidative stress and inflammation. It seems that the synergistic therapeutic approach of cryotherapy and the above-mentioned approaches might offer promising prospects to further improve efficacy and safety. Considering these facts, this perspective presents a comprehensive summary of recent advances in pathological aetiologies of insomnia including COVID-19, and its therapeutic management with a greater emphasis on cryotherapy.
C1 [Lo, Yun-Jo; Lo, Hung-Yao] EUDA Wellness, Taipei 114, Taiwan.
   [Mishra, Viraj Krishna] Biosource Tech, Ambala 133101, Haryana, India.
   [Dubey, Navneet Kumar] Victory Biotechnol Co Ltd, Taipei 114757, Taiwan.
   [Dubey, Navneet Kumar] ShiNeo Technol Co Ltd, New Taipei 24262, Taiwan.
   [Lo, Wen-Cheng] Taipei Med Univ, Sch Med, Div Neurosurg, Dept Surg,Coll Med, Taipei 11031, Taiwan.
   [Lo, Wen-Cheng] Taipei Med Univ Hosp, Dept Neurosurg, Taipei 11031, Taiwan.
   [Lo, Wen-Cheng] Taipei Med Univ, Taipei Neurosci Inst, Taipei 11031, Taiwan.
C3 Taipei Medical University; Taipei Medical University Hospital; Taipei Medical University; Taipei Medical University
RP Dubey, NK (corresponding author), Victory Biotechnol Co Ltd, Taipei 114757, Taiwan.; Lo, WC (corresponding author), Taipei Med Univ, Sch Med, Div Neurosurg, Dept Surg,Coll Med, Taipei 11031, Taiwan.
EM nkd@victorybio.com.tw; drlons@h.tmu.edu.tw
CR Abdo SM, 2020, PHYSIOTHERAPY QUARTERLY, V28, P30, DOI 10.5114/pq.2019.86462
   Adamantidis AR, 2007, NATURE, V450, P420, DOI 10.1038/nature06310
   Adem K, 2020, PSYCHIATRY JOURNAL, V2019, P2020, DOI 10.1155/2020/1402712
   Adie S, 2012, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD007911.pub2
   Ahmed AE, 2017, ETHNIC HEALTH, V22, P285, DOI 10.1080/13557858.2016.1244624
   Akin YA, 2021, GULHANE TIP DERGISI, V63, P141
   Alfano CA, 2013, J AFFECT DISORDERS, V147, P379, DOI 10.1016/j.jad.2012.08.015
   Alimoradi Z, 2021, ECLINICALMEDICINE, V36, P0, DOI 10.1016/j.eclinm.2021.100916
   Antza C, 2022, J ENDOCRINOL, V252, P125, DOI 10.1530/JOE-21-0155
   Archer SN, 2018, SLEEP MED REV, V40, P109, DOI 10.1016/j.smrv.2017.10.008
   Arnulf I, 2008, ARCH NEUROL-CHICAGO, V65, P482, DOI 10.1001/archneur.65.4.482
   Asarnow LD, 2019, SLEEP MED CLIN, V14, P177, DOI 10.1016/j.jsmc.2019.01.009
   Atas DB, 2021, PLOS ONE, V16, P0, DOI 10.1371/journal.pone.0248117
   Attele A S, 2000, ALTERN MED REV, V5, P249
   Azizi Elnaz, 2022, BASIC CLIN NEUROSCI, V13, P519, DOI 10.32598/bcn.2022.2610.1
   Baglioni C, 2019, J SLEEP RES, V0, PP12967, DOI 10.1111/jsr.12967
   Baglioni C, 2011, J AFFECT DISORDERS, V135, P10, DOI 10.1016/j.jad.2011.01.011
   Baker FC, 2018, NAT SCI SLEEP, V10, P73, DOI 10.2147/NSS.S125807
   Bala MM, 2019, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD009058.pub3
   Bamer AM, 2008, MULT SCLER J, V14, P1127, DOI 10.1177/1352458508092807
   Baranov A, 2019, LOW TEMPERATURE TECH, V0, P0
   Barbera J, 2005, DRUG SAFETY, V28, P301, DOI 10.2165/00002018-200528040-00003
   Barbosa GM, 2019, SCI REP-UK, V9, P0, DOI 10.1038/s41598-019-50958-8
   Barragan R, 2022, J CLIN MED, V11, P0, DOI 10.3390/jcm11010076
   Bathgate CJ, 2017, SLEEP, V40, P0, DOI 10.1093/sleep/zsw012
   Bathgate CJ, 2016, SLEEP, V39, P1037, DOI 10.5665/sleep.5748
   Baust JG, 2004, CRYOBIOLOGY, V48, P190, DOI 10.1016/j.cryobiol.2004.01.005
   Baylan S, 2020, SLEEP MED REV, V49, P0, DOI 10.1016/j.smrv.2019.101222
   Beck F, 2013, REV NEUROL-FRANCE, V169, P956, DOI 10.1016/j.neurol.2013.02.011
   Bellesi M, 2017, J NEUROSCI, V37, P5263, DOI 10.1523/JNEUROSCI.3981-16.2017
   Benoliel R, 2009, J OROFAC PAIN, V23, P330
   Bernsmeier C, 2015, PLOS ONE, V10, P0, DOI 10.1371/journal.pone.0143293
   Bertisch SM, 2018, SLEEP, V41, P0, DOI 10.1093/sleep/zsy047
   Besedovsky L, 2019, PHYSIOL REV, V99, P1325, DOI 10.1152/physrev.00010.2018
   Besedovsky L, 2012, PFLUG ARCH EUR J PHY, V463, P121, DOI 10.1007/s00424-011-1044-0
   Bhaskar Swapna, 2016, J FAMILY MED PRIM CARE, V5, P780, DOI 10.4103/2249-4863.201153
   Bjoroy I, 2020, FRONT PSYCHOL, V11, P0, DOI 10.3389/fpsyg.2020.00527
   Bjorvatn B, 2021, FRONT PSYCHOL, V12, P0, DOI 10.3389/fpsyg.2021.639198
   Bláfoss R, 2019, FRONT PUBLIC HEALTH, V7, P0, DOI 10.3389/fpubh.2019.00117
   Blake J, 2021, MENOPAUSE, V28, P973, DOI 10.1097/GME.0000000000001831
   Blask DE, 2009, SLEEP MED REV, V13, P257, DOI 10.1016/j.smrv.2008.07.007
   Bonilla-Jaime H, 2021, INT J MOL SCI, V22, P0, DOI 10.3390/ijms222212531
   Bonnet M H, 1997, SLEEP MED REV, V1, P97, DOI 10.1016/S1087-0792(97)90012-5
   Bouzigon R, 2016, J THERM BIOL, V61, P67, DOI 10.1016/j.jtherbio.2016.08.009
   Bragantini D, 2019, BMC MED GENET, V20, P0, DOI 10.1186/s12881-019-0916-6
   Bragantini D, 2019, CHRONOBIOL INT, V36, P681, DOI 10.1080/07420528.2019.1582540
   Briançon-Marjollet A, 2015, DIABETOL METAB SYNDR, V7, P0, DOI 10.1186/s13098-015-0018-3
   Brosseau L, 2003, COCHRANE DB SYST REV, V0, PPCD004259, DOI 10.1002/14651858.CD004522
   Bruno A, 2020, INT J ENV RES PUB HE, V17, P0, DOI 10.3390/ijerph17041176
   Brunyé TT, 2021, FRONT HUM NEUROSCI, V15, P0, DOI 10.3389/fnhum.2021.625321
   Bruyneel M, 2018, NAT SCI SLEEP, V10, P369, DOI 10.2147/NSS.S186665
   Bryczkowska I, 2018, FAM MED PRIM CARE RE, V20, P214, DOI 10.5114/fmpcr.2018.78253
   Budhiraja R, 2011, SLEEP, V34, P859, DOI 10.5665/SLEEP.1114
   Butler AC, 2006, CLIN PSYCHOL REV, V26, P17, DOI 10.1016/j.cpr.2005.07.003
   Buysse DJ, 2008, SLEEP, V31, P473, DOI 10.1093/sleep/31.4.473
   Byrne EM, 2013, AM J MED GENET B, V162B, P439, DOI 10.1002/ajmg.b.32168
   Cai GH, 2018, SLEEP MED, V46, P81, DOI 10.1016/j.sleep.2018.03.009
   Callander GE, 2013, FRONT NEUROSCI-SWITZ, V7, P0, DOI 10.3389/fnins.2013.00230
   Cao XL, 2017, PLOS ONE, V12, P0, DOI 10.1371/journal.pone.0170772
   Cardinali DP, 2012, J PINEAL RES, V52, P365, DOI 10.1111/j.1600-079X.2011.00962.x
   Cauley JA, 2019, J BONE MINER RES, V34, P464, DOI 10.1002/jbmr.3619
   Chang M, 2020, RELATIONSHIP ANXIETY, V8, P6
   Cheng J, 2020, FRONT NEUROSCI-SWITZ, V14, P0, DOI 10.3389/fnins.2020.615854
   Cheng ZM, 2021, REV ECON HOUSEHOLD, V19, P123, DOI 10.1007/s11150-020-09538-3
   Chiao YW, 2021, FRONT NEUROL, V11, P0, DOI 10.3389/fneur.2020.583485
   Chrusciak Tomasz, 2016, REUMATOLOGIA (WARSAW), V54, P291, DOI 10.5114/reum.2016.64904
   Chung KF, 2015, J CLIN PSYCHIAT, V76, PE752, DOI 10.4088/JCP.14m09124
   Chung S, 2020, PSYCHIAT INVEST, V17, P533, DOI 10.30773/pi.2019.0218
   Clark JW, 2020, SLEEP MED REV, V53, P0, DOI 10.1016/j.smrv.2020.101332
   Clebak KT, 2020, AM FAM PHYSICIAN, V101, P399
   Collins NC, 2008, EMERG MED J, V25, P65, DOI 10.1136/emj.2007.051664
   [Colten A.B. Institute of Medicine (US) Committee on Sleep Medicine and Research Institute of Medicine (US) Committee on Sleep Medicine and Research], 2006, SLEEP DISORDERS AND SLEEP DEPRIVATION: AN UNMET PUBLIC HEALTH PROBLEM, V0, P0
   Conley S, 2021, DIGEST DIS SCI, V66, P181, DOI 10.1007/s10620-020-06213-6
   Copinschi G, 2014, FRONT HORM RES, V42, P59, DOI 10.1159/000358858
   Cordes F, 2019, EUR HEART J-CASE REP, V3, P0, DOI 10.1093/ehjcr/ytz221
   Cuijpers P, 2014, AM J PSYCHIAT, V171, P453, DOI 10.1176/appi.ajp.2013.13030325
   Dahl J, 2016, ACTA PSYCHIAT SCAND, V134, P40, DOI 10.1111/acps.12576
   Dantas LO, 2019, J PHYSIOTHER, V65, P215, DOI 10.1016/j.jphys.2019.08.004
   Freitas DCDV, 2013, REV ESC ENFERM USP, V47, P867, DOI 10.1590/S0080-623420130000400014
   Dhaliwal A, 2022, WORLD J GASTRO ENDOS, V14, P17, DOI 10.4253/wjge.v14.i1.17
   Dijk DJ, 2010, SLEEP MED REV, V14, P151, DOI 10.1016/j.smrv.2009.07.002
   Ding CZ, 2018, J OBES METAB SYNDR, V27, P4, DOI 10.7570/jomes.2018.27.1.4
   Ding M, 2018, PROG NEURO-PSYCHOPH, V86, P180, DOI 10.1016/j.pnpbp.2018.05.026
   Doets JJR, 2021, COMPLEMENT THER MED, V63, P0, DOI 10.1016/j.ctim.2021.102783
   Dolsen MR, 2019, CURR PSYCHIAT REP, V21, P0, DOI 10.1007/s11920-019-0993-4
   Dombrovski AY, 2008, DEPRESS ANXIETY, V25, P1060, DOI 10.1002/da.20467
   Dong Jia-Zi, 2018, ZHEN CI YAN JIU, V43, P335, DOI 10.13702/j.1000-0607.171010
   Dong YJ, 2021, BIOMED PHARMACOTHER, V143, P0, DOI 10.1016/j.biopha.2021.112141
   Dopheide JA, 2020, AM J MANAG CARE, V26, PS76, DOI 10.37765/ajmc.2020.42769
   Douzi Wafa, 2019, EUR J SPORT SCI, V19, P860, DOI 10.1080/17461391.2018.1551937
   Douzi W, 2019, BMC RES NOTES, V12, P0, DOI 10.1186/s13104-019-4172-9
   Du SQ, 2018, CNS NEUROSCI THER, V24, P39, DOI 10.1111/cns.12773
   Dubey AK, 2015, J PHARMACOL PHARMACO, V6, P118, DOI 10.4103/0976-500X.155496
   Dubey V, 2006, BIOMATERIALS, V27, P3491, DOI 10.1016/j.biomaterials.2006.01.060
   Dündar Y, 2004, HEALTH TECHNOL ASSES, V8, P1
   Dworak M, 2007, PEDIATRICS, V120, P978, DOI 10.1542/peds.2007-0476
   Dziadkowiak E, 2021, INT J MOL SCI, V22, P0, DOI 10.3390/ijms22147370
   Edinger JD, 2013, SLEEP, V36, P1179, DOI 10.5665/sleep.2882
   Fang HF, 2015, J CANCER, V6, P1140, DOI 10.7150/jca.12490
   Fawzy RM, 2022, EGYPT RHEUMATOL REH, V49, P0, DOI 10.1186/s43166-021-00108-8
   Ferini-Strambi L, 2017, PAIN THER, V6, PS19, DOI 10.1007/s40122-017-0089-y
   Fernandez-Mendoza J, 2021, SLEEP, V44, P0, DOI 10.1093/sleep/zsaa150
   Fernandez-Mendoza J, 2020, SLEEP HEALTH, V6, P71, DOI 10.1016/j.sleh.2019.09.003
   Flo E, 2013, OCCUP ENVIRON MED, V70, P238, DOI 10.1136/oemed-2012-101091
   Ford ES, 2014, SLEEP, V37, P1283, DOI 10.5665/sleep.3914
   Formentin Chiara, 2018, CURR HEPATOL REP, V17, P52, DOI 10.1007/s11901-018-0390-1
   Fossum IN, 2014, BEHAV SLEEP MED, V12, P343, DOI 10.1080/15402002.2013.819468
   Fuggle NR, 2018, OSTEOPOROSIS INT, V29, P1581, DOI 10.1007/s00198-018-4503-z
   Garbarino S, 2021, COMMUN BIOL, V4, P0, DOI 10.1038/s42003-021-02825-4
   Garcia C, 2021, PAIN THER, V10, P81, DOI 10.1007/s40122-020-00225-w
   Garland SN, 2019, JNCI-J NATL CANCER I, V111, P1323, DOI 10.1093/jnci/djz050
   Garland SN, 2018, MED HYPOTHESES, V120, P72, DOI 10.1016/j.mehy.2018.08.019
   Gasparro R, 2021, CANCERS, V13, P0, DOI 10.3390/cancers13081855
   Gauthier S, 2006, LANCET, V367, P1262, DOI 10.1016/S0140-6736(06)68542-5
   Gazal M, 2013, PSYCHIAT RES, V209, P742, DOI 10.1016/j.psychres.2013.03.002
   George Mathew, 2015, ASIAN PAC J CANCER PREV, V16, P6711, DOI 10.7314/apjcp.2015.16.15.6711
   Giménez-Arnau A, 2013, EUR J DERMATOL, V23, P694, DOI 10.1684/ejd.2013.2099
   Godse Kiran Vasant, 2009, INDIAN J DERMATOL, V54, P310, DOI 10.4103/0019-5154.57603
   Goforth HW, 2009, EXPERT OPIN PHARMACO, V10, P1649, DOI 10.1517/14656560903005587
   Goodman Anna O G, 2010, PLOS CURR, V2, PRRN1189, DOI 10.1371/currents.RRN1189
   Gooneratne NS, 2007, LUNG CANCER, V58, P403, DOI 10.1016/j.lungcan.2007.07.011
   Grandner MA, 2016, CURR DIABETES REP, V16, P0, DOI 10.1007/s11892-016-0805-8
   Grandner MA, 2015, SLEEP HEALTH, V1, P158, DOI 10.1016/j.sleh.2015.06.003
   Grandner MA, 2016, SLEEP MED, V18, P7, DOI 10.1016/j.sleep.2015.01.020
   Green MJ, 2017, BMC PSYCHIATRY, V17, P0, DOI 10.1186/s12888-017-1268-4
   Grima M, 2017, MOL MECH SLEEP WAKE, V0, P0
   Grunder Wilfried, 2003, Z MED PHYS, V13, P203
   Guillot X, 2017, JOINT BONE SPINE, V84, P477, DOI 10.1016/j.jbspin.2016.09.004
   Haack M, 2007, SLEEP, V30, P1145, DOI 10.1093/sleep/30.9.1145
   Hale L, 2015, SLEEP MED REV, V21, P50, DOI 10.1016/j.smrv.2014.07.007
   Hammond L, 2020, J THERM BIOL, V91, P0, DOI 10.1016/j.jtherbio.2020.102633
   Han QQ, 2021, J CANCER, V12, P7003, DOI 10.7150/jca.55803
   Hantsoo L, 2013, J PSYCHOSOM RES, V74, P283, DOI 10.1016/j.jpsychores.2013.01.014
   Hassan M, 2020, MIDDLE EAST CURR PSY, V27, P0, DOI 10.1186/s43045-020-00030-3
   Haus EL, 2013, SLEEP MED REV, V17, P273, DOI 10.1016/j.smrv.2012.08.003
   Hawkins J, 2017, MED RES ARCH, V5, P0
   Haynes J, 2018, SOUTH MED J, V111, P75, DOI 10.14423/SMJ.0000000000000769
   He Y, 2021, PHYS ACTIVITY HLTH, V5, P0
   Heffner KL, 2018, CLIN J PAIN, V34, P1133, DOI 10.1097/AJP.0000000000000644
   Herzog-Krzywoszanska R, 2019, FRONT PSYCHIATRY, V10, P0, DOI 10.3389/fpsyt.2019.00221
   Higuchi S, 2005, J SLEEP RES, V14, P267, DOI 10.1111/j.1365-2869.2005.00463.x
   Hirvonen H, 2017, RHEUMATOL INT, V37, P1481, DOI 10.1007/s00296-017-3771-9
   Hirvonen HE, 2006, CLIN EXP RHEUMATOL, V24, P295
   Hjetland GJ, 2021, FRONT PUBLIC HEALTH, V9, P0, DOI 10.3389/fpubh.2021.794307
   Hofmann SG, 2011, AN INTRODUCTION TO MODERN CBT: PSYCHOLOGICAL SOLUTIONS TO MENTAL HEALTH PROBLEMS, V0, P0
   Hofmann SG, 2012, COGNITIVE THER RES, V36, P427, DOI 10.1007/s10608-012-9476-1
   Huo ZY, 2021, SLEEP MED, V87, P183, DOI 10.1016/j.sleep.2021.06.044
   Inutsuka Ayumu, 2013, FRONT ENDOCRINOL (LAUSANNE), V4, P18, DOI 10.3389/fendo.2013.00018
   Inutsuka A, 2013, NAGOYA J MED SCI, V75, P29
   Irwin M, 2003, BRAIN BEHAV IMMUN, V17, P365, DOI 10.1016/S0889-1591(03)00031-X
   Irwin M, 1999, J CLIN ENDOCR METAB, V84, P1979, DOI 10.1210/jc.84.6.1979
   Irwin MR, 2019, NAT REV IMMUNOL, V19, P702, DOI 10.1038/s41577-019-0190-z
   Irwin MR, 2017, NEUROPSYCHOPHARMACOL, V42, P129, DOI 10.1038/npp.2016.148
   Irwin MR, 2015, BRAIN BEHAV IMMUN, V47, P86, DOI 10.1016/j.bbi.2014.09.017
   Irwin MR, 2015, ANNU REV PSYCHOL, V66, P143, DOI 10.1146/annurev-psych-010213-115205
   Jafari-koulaee A, 2020, COMPLEMENT THER MED, V49, P0, DOI 10.1016/j.ctim.2020.102326
   Janson C, 2001, SLEEP, V24, P425, DOI 10.1093/sleep/24.4.425
   Jansson C, 2009, CLIN GASTROENTEROL H, V7, P960, DOI 10.1016/j.cgh.2009.03.007
   Jarrar MH, 2008, ALIMENT PHARM THER, V27, P412, DOI 10.1111/j.1365-2036.2007.03586.x
   Jehan S, 2018, SLEEP MED DISORD INT, V2, P127
   Jing RZ, 2021, SLEEP MED, V85, P66, DOI 10.1016/j.sleep.2021.06.034
   Johnson EO, 2006, J PSYCHIATR RES, V40, P700, DOI 10.1016/j.jpsychires.2006.07.008
   Kalmbach DA, 2020, SLEEP MED, V71, P151, DOI 10.1016/j.sleep.2019.11.1184
   Kalmbach DA, 2018, NAT SCI SLEEP, V10, P193, DOI 10.2147/NSS.S138823
   Kaminska M, 2011, J NEUROL SCI, V302, P7, DOI 10.1016/j.jns.2010.12.008
   Kandeger A, 2019, EAT WEIGHT DISORD-ST, V24, P47, DOI 10.1007/s40519-018-0518-x
   Kasmi S, 2020, APPL PSYCHOL-HLTH WE, V12, P259, DOI 10.1111/aphw.12183
   Kaur H, 2021, STATPEARLS PUBLISHING, V0, P0
   Kavanagh J, 2018, CURR OPIN PULM MED, V24, P569, DOI 10.1097/MCP.0000000000000526
   Kavirajan HC, 2014, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD010521.pub2
   Kéri S, 2014, BRAIN BEHAV IMMUN, V40, P235, DOI 10.1016/j.bbi.2014.03.020
   Khaled SM, 2021, BMC PSYCHIATRY, V21, P0, DOI 10.1186/s12888-020-03035-8
   Khan IW, 2018, SLEEP SCI, V11, P166, DOI 10.5935/1984-0063.20180031
   Khanijow Vikesh, 2015, GASTROENTEROL HEPATOL (N Y), V11, P817
   Khurshid Khurshid A, 2018, INNOV CLIN NEUROSCI, V15, P28
   Kim DJ, 2021, SCI REP-UK, V11, P0, DOI 10.1038/s41598-021-01291-6
   Kim SH, 2021, MEDICINE, V100, P0, DOI 10.1097/MD.0000000000026223
   Kirsch DL, 2013, PSYCHIAT CLIN N AM, V36, P169, DOI 10.1016/j.psc.2013.01.006
   Klemm P, 2021, ADV RHEUMATOL, V61, P0
   Koffel EA, 2015, SLEEP MED REV, V19, P6, DOI 10.1016/j.smrv.2014.05.001
   Kroeger D, 2018, NAT COMMUN, V9, P0, DOI 10.1038/s41467-018-06590-7
   Krzystanek M, 2021, PHARM BASEL, V14, P0
   Ksiezopolska-Orlowska K, 2016, DISABIL REHABIL, V38, P1034, DOI 10.3109/09638288.2015.1060265
   Kubrak T, 2022, MOLECULES, V27, P0, DOI 10.3390/molecules27030731
   Kumar M, 2021, J CLIN EXP HEPATOL, V11, P453, DOI 10.1016/j.jceh.2020.10.006
   Kwon Dong Rak, 2019, JOURNAL OF SLEEP MEDICINE, V16, P36, DOI 10.13078/jsm.19029
   Lai CC, 2021, CRIT REV ONCOL HEMAT, V160, P0, DOI 10.1016/j.critrevonc.2021.103276
   Lallukka T, 2012, BMC PUBLIC HEALTH, V12, P0, DOI 10.1186/1471-2458-12-565
   Lande R Gregory, 2018, PRIM CARE COMPANION CNS DISORD, V20, P0, DOI 10.4088/pcc.17m02214
   Langin D, 2006, TRENDS ENDOCRIN MET, V17, P314, DOI 10.1016/j.tem.2006.08.003
   Lao XQ, 2018, J CLIN SLEEP MED, V14, P109, DOI 10.5664/jcsm.6894
   Lee CL, 2021, SCI REP-UK, V11, P0, DOI 10.1038/s41598-021-88739-x
   Lee JY, 2019, POL ARCH INTERN MED, V129, P839, DOI 10.20452/pamw.4391
   Lee MS, 2008, INT J CLIN PRACT, V62, P1744, DOI 10.1111/j.1742-1241.2008.01876.x
   Lee SH, 2016, BMC COMPLEM ALTERN M, V16, P0, DOI 10.1186/s12906-016-1220-z
   Leger D, 2000, J SLEEP RES, V9, P35, DOI 10.1046/j.1365-2869.2000.00178.x
   Léger D, 2010, SLEEP MED REV, V14, P379, DOI 10.1016/j.smrv.2010.01.003
   Legrand FD, 2020, COMPLEMENT THER MED, V55, P0, DOI 10.1016/j.ctim.2020.102539
   Lemoine P, 2011, THER CLIN RISK MANAG, V7, P301, DOI 10.2147/TCRM.S23036
   Levenson JC, 2015, CHEST, V147, P1179, DOI 10.1378/chest.14-1617
   Li C, 2020, FRONT PHARMACOL, V11, P0, DOI 10.3389/fphar.2020.00586
   Li FG, 2016, EVID-BASED COMPL ALT, V2016, P0, DOI 10.1155/2016/8034263
   Li J, 2019, ACUPUNCT MED, V37, P107, DOI 10.1177/0964528419828733
   Li LJ, 2018, STROKE VASC NEUROL, V3, P197, DOI 10.1136/svn-2017-000136
   Li SS, 2020, NAT SCI SLEEP, V12, P1201, DOI 10.2147/NSS.S282315
   Li SS, 2018, ACUPUNCT MED, V36, P295, DOI 10.1136/acupmed-2017-011530
   Li XM, 2009, CURR OPIN ALLERGY CL, V9, P161, DOI 10.1097/ACI.0b013e328329226f
   Li Y, 2015, HYPERTENSION, V65, P644, DOI 10.1161/HYPERTENSIONAHA.114.04604
   Liang L, 2019, SLEEP MED, V62, P6, DOI 10.1016/j.sleep.2019.03.016
   Lie Janette D, 2015, P T, V40, P759
   Lim MM, 2014, NEURODEGENER DIS MAN, V4, P351, DOI 10.2217/NMT.14.33
   Lind MJ, 2016, BRAIN SCI, V6, P0, DOI 10.3390/brainsci6040064
   Liu FG, 2021, EVID-BASED COMPL ALT, V2021, P0, DOI 10.1155/2021/6621993
   Lombardi F, 2020, J NEUROSCI, V40, P171, DOI 10.1523/JNEUROSCI.1278-19.2019
   Lopresti AL, 2017, AUST NZ J PSYCHIAT, V51, P565, DOI 10.1177/0004867417701996
   Lu JL, 2018, MAYO CLIN PROC, V93, P1563, DOI 10.1016/j.mayocp.2018.05.032
   Lucassen EA, 2017, PLOS ONE, V12, P0, DOI 10.1371/journal.pone.0176685
   Lucassen EA, 2012, ANN NY ACAD SCI, V1264, P110, DOI 10.1111/j.1749-6632.2012.06655.x
   Lufiyani I, 2019, ENFERM CLIN, V29, P331, DOI 10.1016/j.enfcli.2019.04.141
   Luyster FS, 2016, CHEST, V150, P1242, DOI 10.1016/j.chest.2016.09.020
   Madari S, 2021, NEUROTHERAPEUTICS, V18, P44, DOI 10.1007/s13311-021-01010-z
   Maes M, 2011, PROG NEURO-PSYCHOPH, V35, P676, DOI 10.1016/j.pnpbp.2010.05.004
   Main LC, 2009, RES SPORTS MED, V17, P121, DOI 10.1080/15438620802689757
   Mallon Lena, 2014, SLEEP DISORD, V2014, P843126, DOI 10.1155/2014/843126
   Manecke G, 2011, PRINCIPLES AND PRACTICE OF ANESTHESIA FOR THORACIC SURGERY, V0, PP537, DOI 10.1007/978-1-4419-0184-2_38
   Månsson KNT, 2021, INT J COGN THER, V14, P182, DOI 10.1007/s41811-020-00089-0
   Marilena V, 2018, MELATONIN, V0, P0
   Martinez SA, 2018, PLOS ONE, V13, P0, DOI 10.1371/journal.pone.0192451
   Maywood ES, 2010, J NEUROSCI, V30, P10199, DOI 10.1523/JNEUROSCI.1694-10.2010
   McAlpine CS, 2022, J EXP MED, V219, P0, DOI 10.1084/jem.20220081
   McCurry SM, 2021, JAMA INTERN MED, V181, P530, DOI 10.1001/jamainternmed.2020.9049
   Melancon MO, 2014, PATHOL BIOL, V62, P276, DOI 10.1016/j.patbio.2014.07.004
   Mendes-Neto José Marden, 2020, BRJP, V3, P53, DOI 10.5935/2595-0118.20200012
   Metz M, 2010, ANN ALLERG ASTHMA IM, V104, P86, DOI 10.1016/j.anai.2009.11.013
   Michelson D, 2014, LANCET NEUROL, V13, P461, DOI 10.1016/S1474-4422(14)70053-5
   Miller E, 2011, WORLD J BIOL PSYCHIA, V12, P223, DOI 10.3109/15622975.2010.518626
   Miller E, 2010, J THERM BIOL, V35, P406, DOI 10.1016/j.jtherbio.2010.08.006
   Miller Elzbieta, 2010, WIAD LEK, V63, P41
   Mirza-Aghazadeh-Attari M, 2022, CANCER CELL INT, V22, P0, DOI 10.1186/s12935-022-02472-7
   Mitchell LJ, 2019, SLEEP MED REV, V47, P90, DOI 10.1016/j.smrv.2019.06.002
   Mitchell MD, 2012, BMC FAM PRACT, V13, P0, DOI 10.1186/1471-2296-13-40
   Moberg LT, 2021, J EAT DISORD, V9, P0, DOI 10.1186/s40337-021-00430-8
   Moderie C, 2021, SLEEP DISORDERS PATI, V0, P0
   Monti JM, 2000, SLEEP MED REV, V4, P263, DOI 10.1053/smrv.1999.0096
   Moore RY, 2007, SLEEP MED, V8, PS27, DOI 10.1016/j.sleep.2007.10.003
   Moreira FP, 2015, J NEUROIMMUNOL, V285, P143, DOI 10.1016/j.jneuroim.2015.06.004
   Morey SS, 1998, AM FAM PHYSICIAN, V57, P2545
   Morgan PT, 2012, SLEEP, V35, P807, DOI 10.5665/sleep.1880
   Morin CM, 2021, SLEEP MED, V77, P346, DOI 10.1016/j.sleep.2020.06.005
   Morin CM, 2012, LANCET, V379, P1129, DOI 10.1016/S0140-6736(11)60750-2
   Morin CM, 2006, SLEEP MED, V7, P123, DOI 10.1016/j.sleep.2005.08.008
   Morin CM, 2004, J CLIN PSYCHIAT, V65, P33
   Morphy H, 2007, SLEEP, V30, P274
   Moylan S, 2013, MOL PSYCHIATR, V18, P595, DOI 10.1038/mp.2012.33
   Murtagh KN, 2004, AM J PUBLIC HEALTH, V94, P1406, DOI 10.2105/AJPH.94.8.1406
   Nam HW, 2012, ALCOHOL CLIN EXP RES, V36, P1117, DOI 10.1111/j.1530-0277.2011.01722.x
   Neutel D, 2015, SLEEP MED, V16, P754, DOI 10.1016/j.sleep.2014.12.021
   Neves GSL, 2016, REVISTA BRASILEIRA DE NEUROLOGIA, V51, P0
   Ni XJ, 2019, J ALTERN COMPLEM MED, V25, P8, DOI 10.1089/acm.2018.0249
   Ni XJ, 2015, SLEEP MED, V16, P1462, DOI 10.1016/j.sleep.2015.08.012
   Nofzinger EA, 2004, AM J PSYCHIAT, V161, P2126, DOI 10.1176/appi.ajp.161.11.2126
   Norman JL, 2016, NAT SCI SLEEP, V8, P239, DOI 10.2147/NSS.S76910
   Ochs-Balcom HM, 2020, J BONE MINER RES, V35, P261, DOI 10.1002/jbmr.3879
   Ohayon MM, 2019, SLEEP MED REV, V47, P28, DOI 10.1016/j.smrv.2019.06.001
   Ohayon MM, 2010, SLEEP MED, V11, P980, DOI 10.1016/j.sleep.2010.07.012
   Ohayon MM, 2002, SLEEP MED, V3, P115, DOI 10.1016/S1389-9457(01)00158-7
   Ohayon MM, 2002, ENCEPHALE, V28, P420
   Macêdo PJOM, 2017, EPILEPSY RES, V135, P158, DOI 10.1016/j.eplepsyres.2017.05.014
   Oroz R, 2021, SLEEP SCI PRACT, V5, P3
   Orr WC, 2020, LANCET GASTROENTEROL, V5, P616, DOI 10.1016/S2468-1253(19)30412-1
   Palagini L, 2018, J CLIN SLEEP MED, V14, P759, DOI 10.5664/jcsm.7100
   Palagini L, 2014, SLEEP MED REV, V18, P225, DOI 10.1016/j.smrv.2013.05.002
   Palesh O, 2018, BRIT J CANCER, V119, P274, DOI 10.1038/s41416-018-0154-2
   Panda S, 2012, NEUROL INDIA, V60, P68, DOI 10.4103/0028-3886.93601
   Park HJ, 2011, CELL MOL NEUROBIOL, V31, P1123, DOI 10.1007/s10571-011-9718-x
   Park J, 2012, ACUPUNCT MED, V30, P195, DOI 10.1136/acupmed-2012-010144
   Park S, 2020, SLEEP MED, V71, P1, DOI 10.1016/j.sleep.2020.02.018
   Pasche B, 2004, BIOELECTROMAGNETIC M, V0, P324
   Patel D, 2018, J CLIN SLEEP MED, V14, P1017, DOI 10.5664/jcsm.7172
   Pavloya MK, 2019, NAT SCI SLEEP, V11, P189, DOI 10.2147/NSS.S198944
   Pelka RB, 2001, ADV THER, V18, P101, DOI 10.1007/BF02850298
   Pelka RB, 2001, ADV THER, V18, P174, DOI 10.1007/BF02850111
   Perlis M L, 2013, ENCYCLOPEDIA OF SLEEP; 2013, V0, P199
   Perlis ML, 1997, J SLEEP RES, V6, P179, DOI 10.1046/j.1365-2869.1997.00045.x
   Pétein C, 2021, THER ADV PSYCHOPHARM, V11, P0, DOI 10.1177/20451253211011874
   Petersén Å, 2012, J HUNTINGTONS DIS, V1, P5, DOI 10.3233/JHD-2012-120006
   Pigeon WR, 2008, SLEEP, V31, P481, DOI 10.1093/sleep/31.4.481
   Pillai V, 2017, SLEEP, V40, P0, DOI 10.1093/sleep/zsw044
   Pini L, 2020, HUM BRAIN MAPP, V41, P256, DOI 10.1002/hbm.24790
   Planas-Ballvé A, 2022, NEUROLOGIA, V37, P639, DOI 10.1016/j.nrleng.2019.07.008
   Plante DT, 2012, SLEEP, V35, P741, DOI 10.5665/sleep.1854
   Plotogea OM, 2021, J PERS MED, V11, P0, DOI 10.3390/jpm11121387
   Politis M, 2008, BRAIN, V131, P2860, DOI 10.1093/brain/awn244
   Porkka-Heiskanen T, 1997, SCIENCE, V276, P1265, DOI 10.1126/science.276.5316.1265
   Porramezani N, 2019, JOURNAL OF ADVANCES IN MEDICAL AND BIOMEDICAL RESEARCH, V27, P37, DOI 10.30699/jambs.27.124.37
   Portas CM, 2000, PROG NEUROBIOL, V60, P13, DOI 10.1016/S0301-0082(98)00097-5
   Prather AA, 2009, BIOL PSYCHOL, V82, P12, DOI 10.1016/j.biopsycho.2009.04.008
   Qi ZZ, 2021, PHARMACEUTICS, V13, P0, DOI 10.3390/pharmaceutics13122198
   Quartana PJ, 2015, BRAIN BEHAV IMMUN, V47, P228, DOI 10.1016/j.bbi.2014.12.010
   Quigg M, 2016, EPILEPSY RES, V122, P91, DOI 10.1016/j.eplepsyres.2016.02.014
   Reddy M S, 2011, INDIAN J PSYCHOL MED, V33, P1, DOI 10.4103/0253-7176.85388
   Redfern RE, 2018, J PEDIATR NURS, V38, P1, DOI 10.1016/j.pedn.2017.09.009
   Ren CY, 2021, SLEEP MED, V81, P42, DOI 10.1016/j.sleep.2021.02.005
   Ren R, 2021, TRANSL PSYCHIAT, V11, P0, DOI 10.1038/s41398-021-01672-5
   Reutrakul S, 2018, METABOLISM, V84, P56, DOI 10.1016/j.metabol.2018.02.010
   Riemann D, 2010, SLEEP MED REV, V14, P19, DOI 10.1016/j.smrv.2009.04.002
   Rivera J, 2018, RHEUMATOL INT, V38, P2243, DOI 10.1007/s00296-018-4176-0
   Roach M, 2021, INT J NEUROSCI, V131, P1058, DOI 10.1080/00207454.2020.1773460
   Robertson ME, 2016, SPRINGERPLUS, V5, P0, DOI 10.1186/s40064-016-2578-6
   Rogers NL, 2003, SLEEP, V26, P1058
   Rose KM, 2009, APPL NURS RES, V22, P119, DOI 10.1016/j.apnr.2007.06.001
   Rossman J, 2019, AM J LIFESTYLE MED, V13, P544, DOI 10.1177/1559827619867677
   Roth T, 2010, CURR MED RES OPIN, V26, P2411, DOI 10.1185/03007995.2010.516142
   Roth T, 2009, AM J MANAG CARE, V15, P0
   Roy SK, 2015, INTERNATIONAL JOURNAL OF MEDICINE AND PUBLIC HEALTH, V5, P293
   Royant-Parola S, 2018, ENCEPHALE, V44, P321, DOI 10.1016/j.encep.2017.03.009
   Rymaszewska J, 2008, ARCH IMMUNOL THER EX, V56, P63, DOI 10.1007/s00005-008-0006-5
   Rymaszewska J, 2021, EXP GERONTOL, V146, P0, DOI 10.1016/j.exger.2021.111237
   Rymaszewska J, 2020, FRONT PSYCHIATRY, V11, P0, DOI 10.3389/fpsyt.2020.00522
   Rymaszewska J, 2019, PSYCHIATR POL, V53, P1053, DOI 10.12740/PP/OnlineFirst/91298
   Rymaszewska J, 2018, CRYOLETTERS, V39, P190
   Rymaszewska J, 2008, ARCH PSYCHIATR PSYCH, V10, P49
   Sadura-Sieklucka Teresa, 2019, REUMATOLOGIA (WARSAW), V57, P320, DOI 10.5114/reum.2019.90825
   Sakurai T, 2005, NEURON, V46, P297, DOI 10.1016/j.neuron.2005.03.010
   Santos LF, 2018, EUR J PHARM SCI, V118, P49, DOI 10.1016/j.ejps.2018.03.020
   Santoso AMM, 2019, SLEEP MED REV, V47, P62, DOI 10.1016/j.smrv.2019.06.003
   Saper CB, 2005, NATURE, V437, P1257, DOI 10.1038/nature04284
   Saponaro C, 2015, CURR DIABETES REP, V15, P0, DOI 10.1007/s11892-015-0607-4
   Sasaki S, 2018, SLEEP BREATH, V22, P257, DOI 10.1007/s11325-017-1508-3
   Sauer LA, 2007, J NUTR BIOCHEM, V18, P637, DOI 10.1016/j.jnutbio.2006.12.009
   Sauvet F, 2010, J APPL PHYSIOL, V108, P68, DOI 10.1152/japplphysiol.00851.2009
   Savard J, 2003, PSYCHOSOM MED, V65, P211, DOI 10.1097/01.PSY.0000033126.22740.F3
   Schmitt K, 2016, ANN MED, V48, P42, DOI 10.3109/07853890.2015.1131327
   Schutte-Rodin S, 2008, J CLIN SLEEP MED, V4, P487
   Seixas AA, 2018, MEDICINE, V97, P0, DOI 10.1097/MD.0000000000011939
   Senczyszyn A, 2021, FRONT PSYCHIATRY, V12, P0, DOI 10.3389/fpsyt.2021.649066
   Shi TT, 2020, J SLEEP RES, V29, P0, DOI 10.1111/jsr.12876
   Shiao YC, 2021, SCI REP-UK, V11, P0, DOI 10.1038/s41598-021-99410-w
   Shoji S, 2009, JPN J CLIN MED, V67, P1525
   Sieron A, 2007, REHABIL PRAKTYCE, V3, P34
   Sieron A, 2007, KRIOTERAPIA LECZENIE, V15, P149
   Silva Adriana Lucia Pastore, 2007, ACTA ORTOP. BRAS., V15, P204
   Singh A, 2017, INT REV NEUROBIOL, V135, P97, DOI 10.1016/bs.irn.2017.02.006
   Sivertsen B, 2012, PSYCHOSOM MED, V74, P758, DOI 10.1097/PSY.0b013e3182648619
   Slade AN, 2020, SUPPORT CARE CANCER, V28, P551, DOI 10.1007/s00520-019-04849-3
   Smith LL, 2000, MED SCI SPORT EXER, V32, P317, DOI 10.1097/00005768-200002000-00011
   Soehner AM, 2014, J AFFECT DISORDERS, V167, P93, DOI 10.1016/j.jad.2014.05.060
   Sofi F, 2014, EUR J PREV CARDIOL, V21, P57, DOI 10.1177/2047487312460020
   Spence DW, 2004, J NEUROPSYCH CLIN N, V16, P19, DOI 10.1176/appi.neuropsych.16.1.19
   Spiegel K, 2004, J CLIN ENDOCR METAB, V89, P5762, DOI 10.1210/jc.2004-1003
   Spiegel K, 2011, J CLIN ENDOCR METAB, V96, P486, DOI 10.1210/jc.2010-1978
   Stahl SM, 2009, CNS SPECTRUMS, V14, P536, DOI 10.1017/S1092852900024020
   Stanczykiewicz B, 2015, EUR PSYCHIAT, V30, P0, DOI 10.1016/S0924-9338(15)31127-5
   Stanek A, 2005, BALNEOL POL, V47, P24
   Stanek A, 2020, ANTIOXIDANTS-BASEL, V9, P0, DOI 10.3390/antiox9121308
   Stanek A, 2019, OXID MED CELL LONGEV, V2019, P0, DOI 10.1155/2019/7524878
   Stanek A, 2018, MEDIAT INFLAMM, V2018, P0, DOI 10.1155/2018/8592532
   Stanek A, 2016, ADV CLIN EXP MED, V25, P1281, DOI 10.17219/acem/65980
   Stanek A, 2015, BIOMED RES INT, V2015, P0, DOI 10.1155/2015/404259
   Stanhope BA, 2020, CURR BIOL, V30, P1092, DOI 10.1016/j.cub.2020.02.057
   Su Y, 2017, OSTEOPOROSIS INT, V28, P151, DOI 10.1007/s00198-016-3785-2
   Sumowski JF, 2021, ANN CLIN TRANSL NEUR, V8, P1172, DOI 10.1002/acn3.51262
   Sun HZ, 2020, BIOSCIENCE REP, V40, P0, DOI 10.1042/BSR20201084
   Suszko R, 2003, MED REHABIL, V7, P63
   Swanson CM, 2018, METABOLISM, V84, P28, DOI 10.1016/j.metabol.2017.12.002
   Tachikawa M, 2012, J PHARMACOL EXP THER, V343, P608, DOI 10.1124/jpet.112.197012
   Tahmasian M, 2020, COMMUN BIOL, V3, P0, DOI 10.1038/s42003-020-0892-6
   Tan DX, 2016, MED HYPOTHESES, V86, P3, DOI 10.1016/j.mehy.2015.11.018
   Tang HT, 2018, CHIN MED-UK, V13, P0, DOI 10.1186/s13020-018-0165-1
   Tang JS, 2017, SCI REP-UK, V7, P0, DOI 10.1038/srep43690
   Tang WK, 2015, TOP STROKE REHABIL, V22, P201, DOI 10.1179/1074935714Z.0000000026
   Tang YC, 2021, ARCH OSTEOPOROS, V16, P0, DOI 10.1007/s11657-021-01025-1
   Taylor DJ, 2010, J AFFECT DISORDERS, V123, P181, DOI 10.1016/j.jad.2009.08.007
   Taylor-Gjevre RM, 2011, MUSCULOSKELET CARE, V9, P152, DOI 10.1002/msc.208
   Thakkar MM, 2011, SLEEP MED REV, V15, P65, DOI 10.1016/j.smrv.2010.06.004
   Toi N, 2019, J CLIN TRANSL ENDOCR, V15, P37, DOI 10.1016/j.jcte.2018.12.006
   Tsai Wen-Hsin, 2013, J TRADIT COMPLEMENT MED, V3, P142, DOI 10.4103/2225-4110.114898
   Tsega SS, 2021, PLOS ONE, V16, P0, DOI 10.1371/journal.pone.0261386
   Um YH, 2022, SLEEP BREATH, V26, P865, DOI 10.1007/s11325-021-02459-0
   Urade Y, 2010, FUTUR NEUROL, V5, P363, DOI 10.2217/FNL.10.18
   Ursin R, 2002, SLEEP MED REV, V6, P57, DOI 10.1053/smrv.2001.0174
   Valero-Cabré A, 2017, NEUROSCI BIOBEHAV R, V83, P381, DOI 10.1016/j.neubiorev.2017.10.006
   Van den Bulck J, 2004, SLEEP, V27, P101, DOI 10.1093/sleep/27.1.101
   van der Zweerde T, 2019, SLEEP MED REV, V48, P0, DOI 10.1016/j.smrv.2019.08.002
   van Leeuwen WMA, 2009, PLOS ONE, V4, P0, DOI 10.1371/journal.pone.0004589
   Vasey C, 2021, NUTRIENTS, V13, P0, DOI 10.3390/nu13103480
   Vashadze Sh V, 2007, GEORGIAN MED NEWS, V0, P22
   Vendrame M, 2013, J CLIN SLEEP MED, V9, P141, DOI 10.5664/jcsm.2410
   Venner A, 2019, CURR BIOL, V29, P4155, DOI 10.1016/j.cub.2019.10.026
   Vgontzas AN, 2013, SLEEP MED REV, V17, P241, DOI 10.1016/j.smrv.2012.09.005
   Vgontzas AN, 2012, SLEEP, V35, P61, DOI 10.5665/sleep.1586
   Vgontzas AN, 2009, DIABETES CARE, V32, P1980, DOI 10.2337/dc09-0284
   Vgontzas AN, 2009, SLEEP, V32, P491, DOI 10.1093/sleep/32.4.491
   Vinik A, 2010, J CLIN ENDOCR METAB, V95, P4802, DOI 10.1210/jc.2010-0892
   Vitiello MV, 2009, J CLIN SLEEP MED, V5, P355
   Voysey Z, 2021, J NEUROL, V268, P2275, DOI 10.1007/s00415-020-10334-3
   Wade AG, 2011, NEUROPSYCH DIS TREAT, V7, P1, DOI 10.2147/NDT.S15123
   Walsh JK, 2011, SLEEP, V34, P997, DOI 10.5665/SLEEP.1150
   Wang XY, 2020, MEDICINE, V99, P0, DOI 10.1097/MD.0000000000022462
   Wiecek M, 2021, BIOMOLECULES, V11, P0, DOI 10.3390/biom11071041
   Wijarnpreecha K, 2017, J POSTGRAD MED, V63, P226, DOI 10.4103/jpgm.JPGM_140_17
   Wijarnpreecha K, 2016, QJM-INT J MED, V109, P461, DOI 10.1093/qjmed/hcv172
   Wojtecka-Lukasik E, 2010, INFLAMM RES, V59, P253, DOI 10.1007/s00011-009-0144-1
   Wright B, 2020, J SMALL ANIM PRACT, V61, P267, DOI 10.1111/jsap.13130
   Wuyts J, 2012, INT J PSYCHOPHYSIOL, V83, P8, DOI 10.1016/j.ijpsycho.2011.09.016
   Xie CL, 2013, BMC COMPLEM ALTERN M, V13, P0, DOI 10.1186/1472-6882-13-18
   Xie YP, 2020, MEDICINE, V99, P0, DOI 10.1097/MD.0000000000021598
   Xu HC, 2019, EVID-BASED COMPL ALT, V2019, P0, DOI 10.1155/2019/8961748
   Yan B, 2021, J AM HEART ASSOC, V10, P0, DOI 10.1161/JAHA.120.016201
   Yennurajalingam S, 2018, J PAIN SYMPTOM MANAG, V55, P198, DOI 10.1016/j.jpainsymman.2017.08.027
   Yeung WF, 2021, NAT SCI SLEEP, V13, P1195, DOI 10.2147/NSS.S318874
   Yeung WF, 2012, EVID-BASED COMPL ALT, V2012, P0, DOI 10.1155/2012/902578
   Yi Sun Shin, 2018, J MENOPAUSAL MED, V24, P143, DOI 10.6118/jmm.2018.24.3.143
   You Wei, 2010, ZHEN CI YAN JIU, V35, P261
   Yu P, 2022, CHEM ENG J, V430, P0, DOI 10.1016/j.cej.2021.132633
   Yun Seokho, 2021, YEUNGNAM UNIV J MED, V38, P267, DOI 10.12701/yujm.2021.01424
   Zachariae R, 2018, JNCI-J NATL CANCER I, V110, P880, DOI 10.1093/jnci/djx293
   Zeng LN, 2020, FRONT PSYCHIATRY, V11, P0, DOI 10.3389/fpsyt.2020.577429
   Zhang LX, 2020, PSYCHOL HEALTH MED, V25, P1201, DOI 10.1080/13548506.2020.1738015
   Zhang MM, 2019, MEDICINE, V98, P0, DOI 10.1097/MD.0000000000017842
   Zhang P, 2020, NAT SCI SLEEP, V12, P693, DOI 10.2147/NSS.S263528
   Zhao J, 2021, SLEEP MED, V81, P375, DOI 10.1016/j.sleep.2021.03.005
   Zhao J, 2021, PEERJ, V9, P0, DOI 10.7717/peerj.10956
   Zhao KC, 2013, INT REV NEUROBIOL, V111, P217, DOI 10.1016/B978-0-12-411545-3.00011-0
   ZHENG S, 2021, CHINESE J PRACTICAL, V0, P103
   Zheng W, 2019, IEEE T APPL SUPERCON, V29, P0, DOI 10.1109/TASC.2018.2882069
   Zhou L, 2014, CRYOBIOLOGY, V68, P79, DOI 10.1016/j.cryobiol.2013.12.004
   Zhou RR, 2021, AGING-US, V13, P25153, DOI 10.18632/aging.203733
   Zhou Yan-Li, 2012, ZHEN CI YAN JIU, V37, P302
   Ziemann E, 2012, J ATHL TRAINING, V47, P664, DOI 10.4085/1062-6050-47.6.13
   Zisapel N, 2007, CELL MOL LIFE SCI, V64, P1174, DOI 10.1007/s00018-007-6529-9
NR 432
TC 7
Z9 8
U1 2
U2 29
PU INT SOC AGING & DISEASE
PI FORT WORTH
PA EDITORIAL OFF, 3400 CAMP BOWIE BLVD, FORT WORTH, TX 76106 USA
SN 2152-5250
EI 
J9 AGING DIS
JI Aging Dis.
PD JUL 31
PY 2023
VL 14
IS 4
BP 1038
EP 1069
DI 10.14336/AD.2022.1203
EA DEC 2022
PG 32
WC Geriatrics & Gerontology
SC Geriatrics & Gerontology
GA X9ZS5
UT WOS:000894246900001
PM 37163444
DA 2026-01-16
ER

PT J
AU Chiu, WS
   Lu, YW
   Lien, TH
AF Chiu, Wen-Shan
   Lu, Yu-Wen
   Lien, Ting-Hsuan
TI Iatrogenic Pneumothorax during Acupuncture: Case Report.
SO Medicina (Kaunas, Lithuania)
LA English
DT Journal Article
DE acupuncture; chronic pulmonary diseases; iatrogenic pneumothorax; imaging
AB Acupuncture treatment in local areas is commonly used to treat pain or soreness;  however, acupuncture around the neck or shoulder may be a risk factor for  pneumothorax. Herein, we report two cases of iatrogenic pneumothorax after  acupuncture. These points indicate that physicians should be aware of these risk  factors through history-taking before acupuncture. Chronic pulmonary diseases,  such as chronic bronchitis, emphysema, tuberculosis, lung cancer, pneumonia, and  thoracic surgery, may be associated with a higher risk of iatrogenic pneumothorax  after acupuncture. Even if the incidence of pneumothorax should be low under  caution and fully evaluated, it is still recommended to arrange further imaging  examinations to rule out the possibility of iatrogenic pneumothorax.
C1 Department of Chinese Medicine, Show Chawn Memorial Hospital, Changhua 500, Taiwan.
   Department of Chinese Medicine, Show Chawn Memorial Hospital, Changhua 500, Taiwan.
   Department of Chinese Medicine, Show Chawn Memorial Hospital, Changhua 500, Taiwan.
NR 0
TC 0
SN 1648-914
EI 1010-660
J9 Medicina (Kaunas)
PD JUN 28
PY 2023
VL 59
IS 6
BP 
EP 
DI 10.3390/medicina59061100
PG 0
WC Humans; Pneumothorax; etiology; Acupuncture Therapy; adverse effects; Pain; etiology; Pulmonary Emphysema; complications; Iatrogenic Disease
UT PubMed:37374304
PM 37374304
DA 2023-06-28
ER

PT J
AU Ma, T
   Xue, G
   Zhang, J
   Qin, X
AF Ma, Taoye
   Xue, Guoqiang
   Zhang, Jie
   Qin, Xiaoyu
TI Effects of acupuncture on postoperative pain in patients undergoing breast cancer
SO Asian journal of surgery
LA English
DT Letter
DE Acupuncture; Breast cancer surgery; Meta-analysis; Postoperative pain; Systematic review
C1 Gansu Province Central Hospital, Lanzhou, Gansu, 730070, China
   Gansu Provincial Maternal and Child Health Hospital, Lanzhou, Gansu, 730050, China.
   Department of Urology, The Second People's Hospital of Gansu Province, Lanzhou, Gansu, 730030, China
   Department of Urology, Affiliated Hospital of NorthwestMinzu University, Lanzhou, Gansu, 730030, China.
   Anesthesia and Pain Medical Center, Gansu Hospital of TCM, Lanzhou, Gansu, 730050, China.
   Department of Anesthesiology, Shanghai East Hospital, Shanghai, 200120, China.
EM qxyznl@163.com
NR 0
TC 0
SN 0219-310
EI 
J9 Asian J Surg
PD JUN 22
PY 2023
VL 46
IS 11
BP 5029
EP 5031
DI 10.1016/j.asjsur.2023.06.060
PG 2
WC Humans; Female; Breast Neoplasms; surgery; Acupuncture Therapy; Mastectomy; Pain, Postoperative
UT PubMed:37344321
PM 37344321
DA 2023-06-22
ER

PT J
AU Li, QY
   Yang, WX
   Liu, H
   Jiao, LJ
   Gong, YB
   Shi, J
AF Li, Quan-Yao
   Yang, Wen-Xiao
   Liu, Hui
   Jiao, Li-Jing
   Gong, Ya-Bin
   Shi, Jun
TI Research on Electroacupuncture Parameters for Cancer Pain Based on Data Mining.
SO Integrative cancer therapies
LA English
DT Review
DE cancer pain; data mining; electroacupuncture; parameter; traditional Chinese medicine
AB BACKGROUND: Cancer pain, a common complication of this disease, has been widely  treated by electroacupuncture in recent years. However, there are numerous  treatment parameters that are not conducive to clinical translation applications.  This study aims to summarize the stimulation parameters commonly used in  electroacupuncture treating cancer pain by data mining and visualization  techniques to provide a basis for the future acupuncture technology  transformation and selection of optimal stimulation parameters. METHODS: Nine  databases, including Pubmed, Cochrane Library, Embase, Web of Science, OVID,  China National Knowledge Infrastructure Database, China Biology Medicine disk,  China Science and Technology Journal Database, and Wanfang Database, were  searched for clinical studies on electroacupuncture treatment cancer pain  published between January 2012 and September 2022. A database was established  using Microsoft Excel 2020 and analyzed with SPSS Modeler 18.1 software and SPSS  statistics 26.0 software. RESULTS: Twenty-four articles were included according  to the established criteria. The most used electroacupuncture stimulation  parameters were a dilatational wave, the current frequency of 2/100 Hz,  stimulation duration of 30 minutes per treatment, and frequency of treatment once  a day. Fifty-eight acupoints were mentioned, and the total frequency of acupoints  involved was 156 times. The most used ones include Zusanli (ST36), Sanyinjiao  (SP06), Hegu (LI04), Neiguan (PC06), Quchi (LI11), Taichong (LR03), Ashi point,  Jiaji point, and those most generally used acupoints that are closely arranged on  the Stomach Channel of Foot Yangming and the Spleen Channel of Foot Taiyin. The  association analysis of acupoints revealed that the most supported acupoint pair  was Sanyinjiao (SP06) and Zusanli (ST36). Cluster analysis demonstrated 3 groups,  1 for obligatory acupoints, 1 for Ashi point, and the third for Jiaji point.  CONCLUSIONS: A dilatational wave, the current frequency of 2/100 Hz, 30-minute  stimulation, and acupoints of the Stomach Channel of Foot Yangming and the Spleen  Channel of Foot Taiyin selection are frequently used in electroacupuncture for  treating cancer pain. Due to the limitations of this study, further research and  more standardized, multi-center, large-sample clinical trials can be carried out  to guide optimizing acupuncture treatment schemes and promote the formation of  TCM-characteristic technologies for cancer pain.
C1 Department of Oncology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine Affiliated to Shanghai University of Traditional ChineseMedicine, Shanghai, China.
   Department of Oncology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine Affiliated to Shanghai University of Traditional ChineseMedicine, Shanghai, China.
   Department of Oncology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine Affiliated to Shanghai University of Traditional ChineseMedicine, Shanghai, China.
   Department of Oncology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine Affiliated to Shanghai University of Traditional ChineseMedicine, Shanghai, China.
   Department of Oncology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine Affiliated to Shanghai University of Traditional ChineseMedicine, Shanghai, China.
   Department of Oncology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine Affiliated to Shanghai University of Traditional ChineseMedicine, Shanghai, China.
NR 0
TC 0
SN 1552-695
EI 1534-735
J9 Integr Cancer Ther
PD AUG 8
PY 2023
VL 22
IS 
BP 15347354231192017
EP 15347354231192017
DI 10.1177/15347354231192017
PG 1
WC Humans; Electroacupuncture; Meridians; Cancer Pain; therapy; Acupuncture Therapy; Data Mining; Neoplasms; complications
UT PubMed:37551854
PM 37551854
DA 2023-08-08
ER

PT J
AU Chu, EC
   Lee, WT
AF Chu, Eric Chun-Pu
   Lee, Wai Ting
TI Prostate Cancer Presenting as Hip Pain at the Chiropractic Office: A Case Report
SO Cureus
LA English
DT Journal Article
DE chiropractic; hip cancer; hip metastasis; hip pain; prostate cancer
AB Prostate cancer is one of the most common cancers found in males, and it tends to  metastasize to bony parts such as the hip, spine, and pelvis, resulting in pain  and/or radicular pain, which can present similarly to musculoskeletal complaints.  The lack of routine screening and musculoskeletal symptoms present challenges in  the diagnosis of prostate cancer. We report the case of a 62-year-old male with  no history of cancer and no previous prostate cancer screening who visited a  chiropractor for the care of worsening left hip pain after a marathon. The  patient visited other healthcare providers and was suggested to have degenerative  conditions; he received nonsteroidal anti-inflammatory medication, physiotherapy,  and acupuncture. Given the patient's limited improvement by other providers and  neurological symptoms, the chiropractor requested lumbar spine radiography, which  revealed suspected bone metastasis, and ordered a hip MRI accordingly. MRI  findings suggested prostate cancer, and the chiropractor referred the patient to  an oncologist, who performed additional imaging and testing to make a presumptive  prostate cancer diagnosis. A literature search found nine cases of undiagnosed  prostate cancer presenting to a chiropractor for care. All patients included in  this case were older males with no previous prostate screening or bone  metastasis. The study is focused on the need for a comprehensive evaluation of  patients with hip pain during a chiropractic visit due to the chances of prostate  cancer. There are higher chances of ignoring cancer symptoms during a hip  examination. Comprehensive evaluation and advanced imaging could help  chiropractors detect patients with prostate cancer.
C1 Department of Chiropractic and Physiotherapy, New York Chiropractic and Physiotherapy Centre, Hong Kong, HKG.
   Department of Chiropractic and Physiotherapy, New York Chiropractic and Physiotherapy Centre, Hong Kong, HKG.
NR 0
TC 0
SN 2168-818
EI 2168-818
J9 Cureus
PD FEB 25
PY 2023
VL 15
IS 1
BP e34049
EP e34049
DI 10.7759/cureus.34049
PG 1
UT PubMed:36824534
PM 36824534
DA 2023-02-25
ER

PT J
AU Bas-Cutrina, F
   Loras, C
   Pardo, A
   Ballester-Clau, R
   Huertas, C
   Guarner-Argente, C
   Colan-Hernandez, J
   Consiglieri, CF
   Andujar, X
   González-Huix, F
   Vilanova-Serra, M
   Pardo-Grau, L
   Maisterra, S
   Ruiz-Ramírez, P
   Garcia-Sumalla, A
   Tebé, C
   Videla, S
   Gornals, JB
AF Bas-Cutrina, Francesc
   Loras, Carme
   Pardo, Albert
   Ballester-Clau, Raquel
   Huertas, Carlos
   Guarner-Argente, Carlos
   Colan-Hernandez, Juan
   Consiglieri, Claudia F.
   Andujar, Xavi
   Gonzalez-Huix, Ferran
   Vilanova-Serra, Magdalena
   Pardo-Grau, Laura
   Maisterra, Sandra
   Ruiz-Ramirez, Pablo
   Garcia-Sumalla, Albert
   Tebe, Cristian
   Videla, Sebastia
   Gornals, Joan B.
TI Management of small subepithelial tumors by endoscopic banding without resection and single-incision needle-knife-assisted biopsy sampling: a prospective multicenter study
SO GASTROINTESTINAL ENDOSCOPY
LA English
DT Article
ID stromal tumors; diagnosis; ligation
AB Background and Aims: Endoscopic band ligation (EBL) without resection combined with single-incision needle-knife (SINK) biopsy sampling may have a positive impact on small GI subepithelial tumor (SET) management, but the method needs to be tested. The aim was to evaluate the feasibility of this strategy in small-sized SETs. Methods: This prospective multicenter observational cohort study in 7 centers included patients with SETs <= 15 mm (confirmed by EUS) between March 2017 and March 2020. The primary outcome was clinical success at 4 weeks, defined as complete SET disappearance on EUS. Secondary outcomes were long-term (1-year) clinical success, technical difficulty level, clinical impact, yield pathology, and safety. Results: Of 273 patients screened, 122 (62.3% women; mean age, 60.9 +/- 13.2 years) were included with SETs (mean size, 9 +/- 2.8 mm; gastric location, 77%; superficial layer dependence, 63%). The primary endpoint was achieved in 73.6% of patients (95% confidence interval [CI], 64.8-81.2). At the 1-year follow-up, the success rate was 68.4% (95% CI, 59.1-76.8). A favorable clinical impact was observed in 97 cases (79.5%; 95% CI, 71.3-86.3). Pathology diagnosis was known in 70%. Potentially malignant lesions were present in 24.7%. The related adverse events rate was 4.1% (95% CI, 1.3-9.3; all mild: 2 bleeding, 2 abdominal pain). On multivariable analysis, the <= 10-mm SET group was associated with a greater success rate (1 year, 87%; relative risk, 5.07; 95% CI, 2.63-9.8) and clinical impact rate (92.7%; relative risk, 6.15; 95% CI, 2.72-13.93). Conclusions: EBL plus SINK biopsy sampling seems to be feasible and safe, and it may offer a favorable clinical impact in small-sized SETs. In particular, SETs <= 10 mm are the best candidates.
C1 [Bas-Cutrina, Francesc; Consiglieri, Claudia F.; Maisterra, Sandra; Garcia-Sumalla, Albert; Gornals, Joan B.] Hosp Univ Bellvitge, Dept Digest Dis, Endoscopy Unit, Barcelona, Spain.
   [Bas-Cutrina, Francesc; Consiglieri, Claudia F.; Maisterra, Sandra; Garcia-Sumalla, Albert; Tebe, Cristian; Videla, Sebastia; Gornals, Joan B.] Bellvitge Biomed Res Inst IDIBELL, Barcelona, Spain.
   [Bas-Cutrina, Francesc; Consiglieri, Claudia F.; Maisterra, Sandra; Garcia-Sumalla, Albert; Videla, Sebastia; Gornals, Joan B.] Univ Barcelona, Sch Med & Hlth Sci, Dept Clin Sci, Barcelona, Spain.
   [Bas-Cutrina, Francesc] Hosp Gen Granollers, Digest Dis Unit, Barcelona, Spain.
   [Loras, Carme; Andujar, Xavi; Ruiz-Ramirez, Pablo] Hosp Univ Mutua Terrassa, Dept Digest Dis, Endoscopy Unit, Barcelona, Spain.
   [Loras, Carme; Andujar, Xavi; Ruiz-Ramirez, Pablo] Inst Salud Carlos III, Ctr Invest Biomed Red Enfermedades Hepat & Digest, Madrid, Spain.
   [Loras, Carme; Gornals, Joan B.] Univ Oberta Catalunya, Fac Hlth Sci, Barcelona, Spain.
   [Pardo, Albert; Vilanova-Serra, Magdalena] Hosp Univ Joan XXIII, IISPV, Tarragona 43005, Spain.
   [Ballester-Clau, Raquel; Gonzalez-Huix, Ferran] Hosp Arnau Vilanova, Dept Digest Dis, Endoscopy Unit, Lleida, Spain.
   [Guarner-Argente, Carlos; Pardo-Grau, Laura] Hosp Univ Doctor Josep Trueta, Endoscopy Unit, Dept Digest Dis, Girona, Spain.
   [Guarner-Argente, Carlos] UAB, Hosp Santa Creu i St Pau, Digest Pathol Serv, Endoscopy Unit, Barcelona, Spain.
   [Colan-Hernandez, Juan] Hosp Badalona Germans Trias & Pujol, Dept Digest Dis, Endoscopy Unit, Barcelona, Spain.
   [Tebe, Cristian] Bellvitge Biomed Res Inst IDIBELL, Stat Advisory Serv, Barcelona, Spain.
   [Videla, Sebastia] Hosp Univ Bellvitge, IDIBELL, Clin Res & Clin Trial Unit UICEC, Barcelona, Spain.
   [Gornals, Joan B.] Univ Barcelona, Hosp Univ Bellvitge, Bellvitge Biomed Res Inst IDIBELL, Dept Digest Dis,Endoscopy Unit, Feixa Llarga S-N, Barcelona 08907, Spain.
C3 University of Barcelona; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Bellvitge University Hospital; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); University of Barcelona; Hospital Universitario Mutua Terrassa; CIBER - Centro de Investigacion Biomedica en Red; CIBEREHD; Instituto de Salud Carlos III; UOC Universitat Oberta de Catalunya; Universitat Rovira i Virgili; Institut d'Investigacio Sanitaria Pere Virgili (IISPV); University Hospital Arnau de Vilanova; Universitat de Girona; Girona University Hospital Dr. Josep Trueta; Autonomous University of Barcelona; Hospital Germans Trias i Pujol; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); University of Barcelona; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Bellvitge University Hospital; University of Barcelona; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Bellvitge University Hospital
RP Gornals, JB (corresponding author), Univ Barcelona, Hosp Univ Bellvitge, Bellvitge Biomed Res Inst IDIBELL, Dept Digest Dis,Endoscopy Unit, Feixa Llarga S-N, Barcelona 08907, Spain.
FU Fundacio Mutual Medica, Societat Catalana de Digestologia (SCD); Sociedad Espanola de Endoscopia DIgestiva (SEED)
CR Bas-Cutrina F, 2020, ENDOSCOPY, V52, PE370, DOI 10.1055/a-1134-4742
   Bas-Cutrina F, 2019, ENDOSCOPY, V51, PE191, DOI 10.1055/a-0875-3958
   Binmoeller KF, 2014, GASTROINTEST ENDOSC, V79, P750, DOI 10.1016/j.gie.2013.09.028
   Casali PG, 2022, ANN ONCOL, V33, P20, DOI 10.1016/j.annonc.2021.09.005
   Chen HM, 2019, AM J GASTROENTEROL, V114, P718, DOI 10.14309/ajg.0000000000000196
   de la Serna-Higuera C, 2011, GASTROINTEST ENDOSC, V74, P672, DOI 10.1016/j.gie.2011.05.042
   Deprez PH, 2022, ENDOSCOPY, V54, P412, DOI 10.1055/a-1751-5742
   Dhaliwal A, 2020, ANN GASTROENTEROL, V33, P155, DOI 10.20524/aog.2020.0460
   Diaz-Cervantes E, 2007, AM J GASTROENTEROL, V102, P1640, DOI 10.1111/j.1572-0241.2007.01256.x
   Gottschalk U, 2018, ENDOSC ULTRASOUND, V7, P270, DOI 10.4103/eus.eus_18_17
   Gralnek IM, 2020, ENDOSCOPY, V52, P483, DOI 10.1055/a-1155-6229
   Hwang JH, 2015, GASTROINTEST ENDOSC, V82, P215, DOI 10.1016/j.gie.2015.05.001
   Ibáñez-Sanz G, 2016, REV ESP ENFERM DIG, V108, P250, DOI 10.17235/reed.2016.4031/2015
   Khara HS, 2019, ENDOSC INT OPEN, V7, PE302, DOI 10.1055/a-0684-9563
   Lee SH, 2009, GASTROINTEST ENDOSC, V69, P964, DOI 10.1016/j.gie.2008.05.062
   Li B, 2019, SURG ENDOSC, V33, P2553, DOI 10.1007/s00464-018-6549-6
   Salord S, 2012, ENDOSCOPY, V44, PE171, DOI 10.1055/s-0031-1291755
   Sanaei O, 2020, ENDOSC INT OPEN, V8, PE266, DOI 10.1055/a-1075-1900
   Scherer JR, 2015, J CLIN GASTROENTEROL, V49, P289, DOI 10.1097/MCG.0000000000000085
   Sharzehi K, 2022, CLIN GASTROENTEROL H, V20, P2435, DOI 10.1016/j.cgh.2022.05.054
   Song JH, 2015, ENDOSCOPY, V47, P675, DOI 10.1055/s-0034-1391967
   Sun SY, 2007, SURG ENDOSC, V21, P574, DOI 10.1007/s00464-006-9028-4
   Sun S, 2009, GASTROINTEST ENDOSC, V69, P492, DOI 10.1016/j.gie.2008.05.025
   Xing XB, 2012, ENDOSCOPY, V44, PE296, DOI 10.1055/s-0032-1309916
   Xu MD, 2012, GASTROINTEST ENDOSC, V75, P195, DOI 10.1016/j.gie.2011.08.018
NR 25
TC 3
Z9 4
U1 0
U2 2
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0016-5107
EI 1097-6779
J9 GASTROINTEST ENDOSC
JI Gastrointest. Endosc.
PD DEC 15
PY 2023
VL 98
IS 6
BP 911
EP +
DI 10.1016/j.gie.2023.05.057
EA NOV 2023
PG 19
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA CC6Y7
UT WOS:001123102600001
PM 37263361
DA 2026-01-16
ER

PT J
AU Ding, YY
   Xu, F
   Wang, YF
   Han, LL
   Huang, SQ
   Zhao, S
   Ma, LL
   Zhang, TH
   Zhao, WJ
   Chen, XD
AF Ding, Yuan-Yuan
   Xu, Feng
   Wang, Ya-Feng
   Han, Lin-Lin
   Huang, Shi-Qian
   Zhao, Shuai
   Ma, Lu-Lin
   Zhang, Tian-Hao
   Zhao, Wen-Jing
   Chen, Xiang-Dong
TI Electroacupuncture alleviates postoperative pain through inhibiting
SO Journal of integrative medicine
LA English
DT Journal Article
DE Electroacupuncture; Inflammation; Pain; Primary sensory neurons; Stimulator of interferon genes; Type-1 interferon
AB OBJECTIVE: This work explores the impact of electroacupuncture (EA) on acute  postoperative pain (APP) and the role of stimulator of interferon genes/type-1  interferon (STING/IFN-1) signaling pathway modulation in the analgesic effect of  EA in APP rats. METHODS: The APP rat model was initiated through abdominal  surgery and the animals received two 30 min sessions of EA at bilateral ST36  (Zusanli) and SP6 (Sanyinjiao) acupoints. Mechanical, thermal and cold  sensitivity tests were performed to measure the pain threshold, and  electroencephalograms were recorded in the primary somatosensory cortex to  identify the effects of EA treatment on APP. Western blotting and  immunofluorescence were used to examine the expression and distribution of  proteins in the STING/IFN-1 pathway as well as neuroinflammation. A STING  inhibitor (C-176) was administered intrathecally to verify its role in EA.  RESULTS: APP rats displayed mechanical and thermal hypersensitivities compared to  the control group (P < 0.05). APP significantly reduced the amplitude of θ, α and  γ oscillations compared to their baseline values (P < 0.05). Interestingly,  expression levels of proteins in the STING/IFN-1 pathway were downregulated after  inducing APP (P < 0.05). Further, APP increased pro-inflammatory factors,  including interleukin-6, tumor necrosis factor-α and inducible nitric oxide  synthase, and downregulated anti-inflammatory factors, including interleukin-10  and arginase-1 (P < 0.05). EA effectively attenuated APP-induced painful  hypersensitivities (P < 0.05) and restored the θ, α and γ power in APP rats  (P < 0.05). Meanwhile, EA distinctly activated the STING/IFN-1 pathway and  mitigated the neuroinflammatory response (P < 0.05). Furthermore, STING/IFN-1 was  predominantly expressed in isolectin-B4- or  calcitonin-gene-related-peptide-labeled dorsal root ganglion neurons and  superficial laminae of the spinal dorsal horn. Inhibition of the STING/IFN-1  pathway by intrathecal injection of C-176 weakened the analgesic and  anti-inflammatory effects of EA on APP (P < 0.05). CONCLUSION: EA can generate  robust analgesic and anti-inflammatory effects on APP, and these effects may be  linked to activating the STING/IFN-1 pathway, suggesting that STING/IFN-1 may be  a target for relieving APP. Please cite this article as: Ding YY, Xu F, Wang YF,  Han LL, Huang SQ, Zhao S, Ma LL, Zhang TH, Zhao WJ, Chen XD. Electroacupuncture  alleviates postoperative pain through inhibiting neuroinflammation via stimulator  of interferon genes/type-1 interferon pathway. J Integr Med. 2023; 21(5):  496-508.
C1 Department of Anesthesiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, Hubei Province, China.
   Department of Anesthesiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, Hubei Province, China.
   Department of Anesthesiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, Hubei Province, China.
   Department of Anesthesiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, Hubei Province, China.
   Department of Anesthesiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, Hubei Province, China.
   Department of Anesthesiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, Hubei Province, China.
   Department of Anesthesiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, Hubei Province, China.
   Department of Anesthesiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, Hubei Province, China.
   Department of Anesthesiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, Hubei Province, China.
   Department of Anesthesiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, Hubei Province, China.
EM xdchen@hust.edu.cn
NR 0
TC 0
SN 
EI 2095-496
J9 J Integr Med
PD JUL 31
PY 2023
VL 21
IS 5
BP 496
EP 508
DI 10.1016/j.joim.2023.07.001
PG 12
WC Rats; Animals; Rats, Sprague-Dawley; Neuroinflammatory Diseases; Electroacupuncture; Pain, Postoperative; Interferons
UT PubMed:37517892
PM 37517892
DA 2023-07-31
ER

PT J
AU Plaut, S
AF Plaut, Shiloh
TI Suggesting a mechanism for acupuncture as a global percutaneous needle fasciotomy that respects tensegrity principles for treating fibromyalgia
SO FRONTIERS IN MEDICINE
LA English
DT Article
DE acupuncture; fascial armoring; fibromyalgia; mechanism; myofibroblast; needling; pain; treatment
ID myofascial trigger points; smooth muscle actin; connective-tissue; underlying mechanisms; joint hypermobility; controlled-trial; double-blind; pain; therapy; management
AB Acupuncture is a minimally invasive therapeutic method that uses small caliber needles while inserting them through the skin into various areas of the body. Some empirical studies find evidence to support the use of acupuncture as a treatment for certain medical conditions, however, this peculiar practice is widely considered as the domain of alternative and non-evidence-based medicine. Several mechanisms have been suggested in an attempt to explain the therapeutic action of acupuncture, but the way in which acupuncture alleviates chronic non-cancer pain or psychosomatic and psychiatric disorders is not fully understood. A recent study suggested a theoretical model (coined "Fascial Armoring") with a cellular pathway to help explain the pathogenesis of myofascial pain/fibromyalgia syndrome and functional psychosomatic syndromes. It proposes that these syndromes are a spectrum of a single medical entity that involves myofibroblasts with contractile activity in fascia and aberrant extracellular matrix (ECM) remodeling, which may lead to widespread mechanical tension and compression. This can help explain diverse psycho-somatic manifestations of fibromyalgia-like syndromes. Fascia is a continuous interconnected tissue network that extends throughout the body and has qualities of bio-tensegrity. Previous studies show that a mechanical action by needling induces soft tissue changes and lowers the shear modulus and stiffness in myofascial tissue. This hypothesis and theory paper offers a new mechanism for acupuncture therapy as a global percutaneous needle fasciotomy that respects tensegrity principles (tensegrity-based needling), in light of the theoretical model of "Fascial Armoring." The translation of this model to other medical conditions carries potential to advance therapies. These days opioid overuse and over-prescription are ubiquitous, as well as chronic pain and suffering.
C1 [Plaut, Shiloh] Univ Nicosia, Dept Primary Care & Populat Hlth, Med Sch, Nicosia, Cyprus.
C3 University of Nicosia
RP Plaut, S (corresponding author), Univ Nicosia, Dept Primary Care & Populat Hlth, Med Sch, Nicosia, Cyprus.
EM shilowhale@gmail.com
CR Acasuso-Díaz M, 1998, ARTHRIT CARE RES, V11, P39, DOI 10.1002/art.1790110107
   ARORA PD, 1994, J CELL PHYSIOL, V161, P187, DOI 10.1002/jcp.1041610202
   Balfour William, 1815, EDINB MED SURG J, V11, P168
   Bensoussan A, 2000, ARCH FAM MED, V9, P1071, DOI 10.1001/archfami.9.10.1071
   Bisson MA, 2003, J HAND SURG-BRIT EUR, V28B, P351, DOI 10.1016/S0266-7681(03)00135-9
   Bose A, 2018, MOL NEUROBIOL, V55, P6558, DOI 10.1007/s12035-017-0861-3
   Cabioglu MT, 2008, AM J CHINESE MED, V36, P25, DOI 10.1142/S0192415X08005552
   Caldeira P, 2020, SPORTS MED-OPEN, V6, P0, DOI 10.1186/s40798-020-00253-y
   Calvo-Lobo C, 2018, J GERIATR PHYS THER, V41, P1, DOI 10.1519/JPT.0000000000000079
   Castella LF, 2010, J CELL SCI, V123, P1751, DOI 10.1242/jcs.066795
   Chen G, 2021, J PSYCHOSOM RES, V148, P0, DOI 10.1016/j.jpsychores.2021.110556
   Chiarelli N, 2021, CELLS-BASEL, V10, P0, DOI 10.3390/cells10113236
   Chiarelli N, 2021, BBA-MOL BASIS DIS, V1867, P0, DOI 10.1016/j.bbadis.2020.166051
   Cirka H, 2016, BIOPHYS J, V110, P1845, DOI 10.1016/j.bpj.2016.02.036
   Cummings TM, 2001, ARCH PHYS MED REHAB, V82, P986, DOI 10.1053/apmr.2001.24023
   De Meulemeester K, 2022, AM J PHYS MED REHAB, V101, P18, DOI 10.1097/PHM.0000000000001732
   Deare JC, 2013, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD007070.pub2
   Discher DE, 2005, SCIENCE, V310, P1139, DOI 10.1126/science.1116995
   DORIGO B, 1979, PAIN, V6, P183, DOI 10.1016/0304-3959(79)90125-8
   Doss BL, 2020, P NATL ACAD SCI USA, V117, P12817, DOI 10.1073/pnas.1917555117
   Ernberg M, 1999, LIFE SCI, V65, P313, DOI 10.1016/S0024-3205(99)00250-7
   Ernst E, 1997, PAIN, V71, P123, DOI 10.1016/S0304-3959(97)03368-X
   Evdokimov D, 2020, J RHEUMATOL, V47, P140, DOI 10.3899/jrheum.190248
   Fernández-De-Las-Peñas C, 2021, PAIN RES MANAG, V2021, P0, DOI 10.1155/2021/8836427
   Firestein GS, 2013, KELLEYS TXB RHEUMATO, V9th, P0
   Focks C, 2008, ATLAS OF ACUPUNCTURE, V0, P0
   Fox JR, 2014, J ALTERN COMPLEM MED, V20, P290, DOI 10.1089/acm.2013.0397
   FROST FA, 1980, LANCET, V1, P499
   Furlan AD, 2005, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD001351.pub2
   Gattie E, 2017, J ORTHOP SPORT PHYS, V47, P133, DOI 10.2519/jospt.2017.7096
   GEDALIA A, 1993, ANN RHEUM DIS, V52, P494, DOI 10.1136/ard.52.7.494
   Geist KT, 2021, J BODYW MOV THER, V26, P158, DOI 10.1016/j.jbmt.2020.12.021
   Gerdle B, 2010, J REHABIL MED, V42, P679, DOI 10.2340/16501977-0581
   Goffin JM, 2006, J CELL BIOL, V172, P259, DOI 10.1083/jcb.200506179
   Grafstein B, 2000, ANN NEUROL, V47, P18, DOI 10.1002/1531-8249(200001)47:1<18::AID-ANA6>3.3.CO;2-E
   Gronemann ST, 2004, RHEUMATOLOGY, V43, P27, DOI 10.1093/rheumatology/keg452
   Gu Y, 2012, BIOMATERIALS, V33, P6672, DOI 10.1016/j.biomaterials.2012.06.006
   Guo Q, 2021, FRONT NEUROSCI-SWITZ, V15, P0, DOI 10.3389/fnins.2021.713548
   Harty J, 2005, FOOT ANKLE INT, V26, P1089, DOI 10.1177/107110070502601215
   Hopwood V, 2004, ACUPUNCTURE PHYSIOTH, V1st, P0
   Hsieh YL, 2011, ARCH PHYS MED REHAB, V92, P1098, DOI 10.1016/j.apmr.2010.11.018
   Hu HT, 2018, MEDICINE, V97, P0, DOI 10.1097/MD.0000000000011225
   Jiang WB, 2020, SPINE, V45, PE1296, DOI 10.1097/BRS.0000000000003602
   Kalia V, 2021, J BODYW MOV THER, V25, P146, DOI 10.1016/j.jbmt.2020.10.014
   KALYANRAMAN UP, 1984, J RHEUMATOL, V11, P808
   Kaptchuk TJ, 2002, ANN INTERN MED, V136, P374, DOI 10.7326/0003-4819-136-5-200203050-00010
   Karagounis Panagiotis, 2011, FOOT ANKLE SPEC, V4, P226, DOI 10.1177/1938640011407320
   Katz RS, 2021, J RHEUMATOL, V48, P598, DOI 10.3899/jrheum.191068
   Kayal C, 2020, ADV HEALTHC MATER, V9, P0, DOI 10.1002/adhm.201901036
   Kluger BM, 2016, MOVEMENT DISORD, V31, P1027, DOI 10.1002/mds.26597
   Kural MH, 2016, ACTA BIOMATER, V32, P223, DOI 10.1016/j.actbio.2015.12.031
   Labovitz Jonathan M, 2011, FOOT ANKLE SPEC, V4, P141, DOI 10.1177/1938640010397341
   Langevin HM, 2007, J ALTERN COMPLEM MED, V13, P355, DOI 10.1089/acm.2007.6351
   Langevin Helene M, 2002, ANATOMICAL RECORD, V269, P257, DOI 10.1002/ar.10185
   Langevin HM, 2006, J CELL PHYSIOL, V207, P767, DOI 10.1002/jcp.20623
   Langevin HM, 2004, HISTOCHEM CELL BIOL, V122, P7, DOI 10.1007/s00418-004-0667-z
   Langevin HM, 2002, FASEB J, V16, P872, DOI 10.1096/fj.01-0925fje
   Langevin HM, 2004, ULTRASOUND MED BIOL, V30, P1173, DOI 10.1016/j.ultrasmedbio.2004.07.010
   Langevin HM, 2001, FASEB J, V15, P2275, DOI 10.1096/fj.01-0015hyp
   Langevin HM, 2001, J APPL PHYSIOL, V91, P2471, DOI 10.1152/jappl.2001.91.6.2471
   LEWIT K, 1979, PAIN, V6, P83, DOI 10.1016/0304-3959(79)90142-8
   Li ADR, 2021, IEEE T BIO-MED ENG, V68, P1477, DOI 10.1109/TBME.2021.3054922
   Li ADR, 2020, SCI REP-UK, V10, P0, DOI 10.1038/s41598-020-68596-w
   Li XX, 2017, PAIN PHYSICIAN, V20, P0
   Linde K, 2016, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD001218.pub3
   Linde K, 2016, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD007587.pub2
   Liu L, 2018, ARCH PHYS MED REHAB, V99, P144, DOI 10.1016/j.apmr.2017.06.008
   Liu L, 2015, ARCH PHYS MED REHAB, V96, P944, DOI 10.1016/j.apmr.2014.12.015
   Llamas-Ramos R, 2014, J ORTHOP SPORT PHYS, V44, P852, DOI 10.2519/jospt.2014.5229
   Lu LM, 2022, BMJ-BRIT MED J, V376, P0, DOI 10.1136/bmj-2021-067475
   Luan S, 2019, AM J PHYS MED REHAB, V98, P677, DOI 10.1097/PHM.0000000000001173
   Lumley MA, 2017, PAIN, V158, P2354, DOI 10.1097/j.pain.0000000000001036
   Ma H, 2020, MACROMOL BIOSCI, V20, P0, DOI 10.1002/mabi.202000268
   Maher RM, 2013, ARCH PHYS MED REHAB, V94, P2146, DOI 10.1016/j.apmr.2013.04.021
   Martín-Pintado-Zugasti A, 2018, J BODYW MOV THER, V22, P941, DOI 10.1016/j.jbmt.2018.01.003
   Mejuto-Vázquez MJ, 2014, J ORTHOP SPORT PHYS, V44, P252, DOI 10.2519/jospt.2014.5108
   Melchart D, 2005, BMJ-BRIT MED J, V331, P376, DOI 10.1136/bmj.38512.405440.8F
   MELZACK R, 1977, PAIN, V3, P3, DOI 10.1016/0304-3959(77)90032-X
   Mercier F, 2000, J COMP NEUROL, V420, P445, DOI 10.1002/(SICI)1096-9861(20000515)420:4<445::AID-CNE4>3.0.CO;2-3
   Mercier F, 2001, J COMP NEUROL, V431, P88, DOI 10.1002/1096-9861(20010226)431:1<88::AID-CNE1057>3.0.CO;2-D
   Mishra AK, 2014, AM J SPORT MED, V42, P463, DOI 10.1177/0363546513494359
   Mist SD, 2018, PAIN MED, V19, P1862, DOI 10.1093/pm/pnx322
   Moog P, 2019, ARCH ORTHOP TRAUM SU, V139, P1471, DOI 10.1007/s00402-019-03247-y
   Moraska AF, 2013, ARCH PHYS MED REHAB, V94, P196, DOI 10.1016/j.apmr.2012.08.216
   Morf S, 2005, ARTHRITIS RES THER, V7, PR209, DOI 10.1186/ar1459
   Ng CP, 2005, J CELL SCI, V118, P4731, DOI 10.1242/jcs.02605
   Nordez A, 2017, SPORTS MED, V47, P1925, DOI 10.1007/s40279-017-0703-5
   Padhi A, 2020, COMMUN BIOL, V3, P0, DOI 10.1038/s42003-020-01117-7
   Perreault T, 2021, J CLIN MED, V10, P0, DOI 10.3390/jcm10102189
   Plaut S, 2022, PLOS ONE, V17, P0, DOI 10.1371/journal.pone.0263087
   Raja GP, 2022, CLIN ANAT, V35, P340, DOI 10.1002/ca.23835
   Rajkannan P, 2019, J BODYW MOV THER, V23, P94, DOI 10.1016/j.jbmt.2018.01.004
   Ramírez-Tejero JA, 2020, NUTRIENTS, V12, P0, DOI 10.3390/nu12082386
   Sacheti A, 1997, J PAIN SYMPTOM MANAG, V14, P88, DOI 10.1016/S0885-3924(97)00007-9
   Sánchez-Infante J, 2021, J PAIN, V22, P817, DOI 10.1016/j.jpain.2021.02.004
   Sasabe R, 2017, J ORTHOP RES, V35, P1998, DOI 10.1002/jor.23498
   Scarr G, 2020, J BODYW MOV THER, V24, P134, DOI 10.1016/j.jbmt.2019.09.006
   Schleip R, 2019, CLIN ANAT, V32, P891, DOI 10.1002/ca.23391
   Schleip R, 2019, FRONT PHYSIOL, V10, P0, DOI 10.3389/fphys.2019.00336
   Shah JP, 2008, J BODYW MOV THER, V12, P371, DOI 10.1016/j.jbmt.2008.06.006
   Shin KM, 2013, TRIALS, V14, P0, DOI 10.1186/1745-6215-14-174
   Sluka KA, 2016, NEUROSCIENCE, V338, P114, DOI 10.1016/j.neuroscience.2016.06.006
   Smith CA, 2018, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD004046.pub4
   Soiné JRD, 2016, INTERFACE FOCUS, V6, P0, DOI 10.1098/rsfs.2016.0024
   Soreide E, 2018, BONE JOINT J, V100B, P1138, DOI 10.1302/0301-620X.100B9.BJJ-2017-1194.R2
   Sprott H, 2004, ANN RHEUM DIS, V63, P245, DOI 10.1136/ard.2002.004762
   Staud R, 2011, BEST PRACT RES CL RH, V25, P155, DOI 10.1016/j.berh.2010.01.010
   Stecco A, 2009, J BODYW MOV THER, V13, P53, DOI 10.1016/j.jbmt.2007.04.009
   Tadeo I, 2014, FRONT ONCOL, V4, P0, DOI 10.3389/fonc.2014.00039
   Tan R, 1991, AM J SURG PATHOL, V0, P0
   TOMASEK JJ, 1992, ANAT REC, V232, P359, DOI 10.1002/ar.1092320305
   Tomasek JJ, 2002, NAT REV MOL CELL BIO, V3, P349, DOI 10.1038/nrm809
   VANDEBERG JS, 1982, PLAST RECONSTR SURG, V69, P835, DOI 10.1097/00006534-198205000-00021
   Vassaux M, 2017, BIOMECH MODEL MECHAN, V16, P1295, DOI 10.1007/s10237-017-0888-4
   Veith I, 1972, HUANG TI NEI CHING SU WEN: THE YELLOW EMPERORS CLASSIC OF INTERNAL MEDICINE, V0, P0
   Verjee LS, 2009, J HAND SURG-AM, V34A, P1785, DOI 10.1016/j.jhsa.2009.08.005
   Vickers AJ, 2018, J PAIN, V19, P455, DOI 10.1016/j.jpain.2017.11.005
   Vincent C, 2001, BRIT MED J, V323, P467, DOI 10.1136/bmj.323.7311.467
   Wan R, 2021, WOUND REPAIR REGEN, V29, P573, DOI 10.1111/wrr.12954
   Wang WM, 2021, ACUPUNCT MED, V39, P272, DOI 10.1177/0964528420947739
   Wen JY, 2021, AM J CHINESE MED, V49, P1, DOI 10.1142/S0192415X21500014
   Wessely S, 1999, BEST PRACT RES CL RH, V13, P427, DOI 10.1053/berh.1999.0032
   Wilke J, 2019, CLIN ANAT, V32, P934, DOI 10.1002/ca.23424
   Wilke J, 2018, J APPL PHYSIOL, V124, P234, DOI 10.1152/japplphysiol.00565.2017
   Wilke J, 2016, ARCH PHYS MED REHAB, V97, P454, DOI 10.1016/j.apmr.2015.07.023
   WILLIAMS PE, 1984, J ANAT, V138, P343
   Wolfson B, 2017, MOL CELL BIOL, V37, P0, DOI 10.1128/MCB.00461-16
   Wu LJ, 2007, CLIN BIOMECH, V22, P221, DOI 10.1016/j.clinbiomech.2006.09.009
   Yamashita H, 1998, JAMA-J AM MED ASSOC, V280, P1563, DOI 10.1001/jama.280.18.1563-a
   Yamashita H, 2001, COMPLEMENT THER MED, V9, P98, DOI 10.1054/ctim.2001.0446
   Yang WL, 2019, J MOL CELL CARDIOL, V134, P119, DOI 10.1016/j.yjmcc.2019.07.004
   Yang Z, 2020, YELLOW EMPERORS INNE, V0, P0
   Yip AK, 2013, BIOPHYS J, V104, P19, DOI 10.1016/j.bpj.2012.11.3805
   Yuan QL, 2016, SCI REP-UK, V6, P0, DOI 10.1038/srep30675
   Zhang D, 2011, EVID-BASED COMPL ALT, V2011, P1, DOI 10.1093/ecam/nep050
   Zhang XC, 2019, J PAIN RES, V12, P527, DOI 10.2147/JPR.S186227
   Zheng N, 2017, SCI REP-UK, V7, P0, DOI 10.1038/s41598-017-06863-z
   Zoppi N, 2018, BBA-MOL BASIS DIS, V1864, P1010, DOI 10.1016/j.bbadis.2018.01.005
NR 138
TC 7
Z9 8
U1 1
U2 5
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 
EI 2296-858X
J9 FRONT MED-LAUSANNE
JI Front. Med.
PD JAN 27
PY 2023
VL 9
IS 
BP 
EP 
DI 10.3389/fmed.2022.952159
PG 15
WC Medicine, General & Internal
SC General & Internal Medicine
GA 8T1NM
UT WOS:000929035500001
PM 36777160
DA 2026-01-16
ER

PT J
AU Wang, J
   Lu, FF
   Ge, MM
   Wang, LW
   Wang, G
   Gong, GW
   Liu, XX
   Zhang, WZ
   Ning, FL
   Chen, BH
   Liu, Y
   Quan, HG
   Jiang, ZW
AF Wang, Jun
   Lu, Fei-Fei
   Ge, Miao-Miao
   Wang, Li-Wen
   Wang, Gang
   Gong, Guan-Wen
   Liu, Xin-Xin
   Zhang, Wen-Zhuo
   Ning, Fei-Long
   Chen, Bao-He
   Liu, Yang
   Quan, Hong-Guang
   Jiang, Zhi-Wei
TI Transcutaneous Electrical Acupoint Stimulation Improves Postoperative Sleep Quality in Patients Undergoing Laparoscopic Gastrointestinal Tumor Surgery: A Prospective, Randomized Controlled Trial
SO PAIN AND THERAPY
LA English
DT Article
DE Transcutaneous electrical acupoint stimulation; Sleep quality; Gastrointestinal tumor; NRF2; Inflammation
ID oxidative stress; electroacupuncture; pain; deprivation; dysfunction; activation
AB Introduction: This study was conducted to observe the effect of transcutaneous electrical acupoint stimulation (TEAS) on the postoperative sleep quality of patients undergoing gastrointestinal tumor surgery and to verify the possible mechanism.Methods: Eighty-three patients were allocated to the TEAS or Sham group. Patients in the TEAS group received TEAS treatment (disperse-dense waves; frequency, 2/100 Hz) on bilateral Shenmen (HT7), Neiguan (PC6) and Zusanli (ST36) points for 30 min each time, total three times in the perioperative period. In the Sham group, electrodes were placed; however, no current was given. Sleep quality was assessed on the day before surgery (P1) and the first and third days after surgery (D1 and D3) using the Pittsburgh Sleep Quality Index (PSQI) and Athens Insomnia Scale (AIS). Postoperative pain was assessed using visual analog scale (VAS) 72 h postoperatively. The incidences of abdominal distension, dizziness, postoperative nausea and vomiting (PONV) and pulmonary complications were recorded. Serum levels of inflammatory cytokines and the expression of key factors of oxidative stress and key molecules of the nuclear factor erythroid 2-related factor 2/antioxidant response element (Nrf2/ARE) signal pathway were measured.Results: EAS ameliorated sleep quality at D1 and D3 (PSQI P < 0.05, AIS P < 0.05) and decreased postoperative pain as demonstrated by lower VAS scores compared to the Sham group (P < 0.05). The incidences of abdominal distension and PONV were also lower in the TEAS group. Markers of oxidative stress were increased (P < 0.05), and the serum concentration of interleukin-6 (IL-6) was significantly lower in the TEAS group. The key mediators of the Nrf2/ARE pathway were enhanced after TEAS.Conclusion: Perioperative TEAS improved postoperative sleep quality, reduced postoperative pain and alleviated postoperative adverse effects in patients undergoing laparoscopic gastrointestinal tumor surgery resection. This may be associated with activating Nrf2/ARE signal pathway and decreasing its inflammatory actions.
C1 [Wang, Jun; Lu, Fei-Fei; Wang, Li-Wen; Jiang, Zhi-Wei] Nanjing Univ Chinese Med, Nanjing, Peoples R China.
   [Wang, Jun; Lu, Fei-Fei; Ge, Miao-Miao; Wang, Li-Wen; Wang, Gang; Gong, Guan-Wen; Liu, Xin-Xin; Jiang, Zhi-Wei] Nanjing Univ Chinese Med, Affiliated Hosp, Dept Gen Surg, Nanjing, Peoples R China.
   [Wang, Jun; Lu, Fei-Fei; Zhang, Wen-Zhuo; Ning, Fei-Long; Chen, Bao-He; Liu, Yang; Quan, Hong-Guang] Nanjing Univ Chinese Med, Xuzhou Tradit Chinese Med Hosp, Dept Gen Surg, Xuzhou, Peoples R China.
C3 Nanjing University of Chinese Medicine; Nanjing University of Chinese Medicine; Nanjing University of Chinese Medicine
RP Jiang, ZW (corresponding author), Nanjing Univ Chinese Med, Nanjing, Peoples R China.
EM surgery34@163.com
FU Project of National Clinical Research Base of Traditional Chinese Medicine in Jiangsu Province, China [JD2022SZ18]; Xuzhou Science and Technology Innovation Project [KC19023, KC22181]; Key Subject Project of Jiangsu Province: Surgery of Traditional Chinese Medicine [js2251]; Rapid Service Fee
CR Alam A, 2018, EBIOMEDICINE, V37, P547, DOI 10.1016/j.ebiom.2018.10.021
   Goes ACAD, 2014, ACTA CIR BRAS, V29, P787, DOI 10.1590/S0102-86502014001900004
   Arjmandi-Rad S, 2022, EXP BRAIN RES, V240, P3259, DOI 10.1007/s00221-022-06471-y
   Atrooz F, 2020, ADV PROTEIN CHEM STR, V119, P309, DOI 10.1016/bs.apcsb.2019.03.001
   Atrooz F, 2019, NEUROSCIENCE, V406, P22, DOI 10.1016/j.neuroscience.2019.02.021
   Bellezza I, 2018, BBA-MOL CELL RES, V1865, P721, DOI 10.1016/j.bbamcr.2018.02.010
   Besedovsky L, 2019, PHYSIOL REV, V99, P1325, DOI 10.1152/physrev.00010.2018
   Bian HT, 2020, J NEUROINFLAMM, V17, P0, DOI 10.1186/s12974-020-01836-y
   Bishir M, 2020, BIOMED RES INT, V2020, P0, DOI 10.1155/2020/5764017
   Chen JB, 2020, INT J SURG, V73, P57, DOI 10.1016/j.ijsu.2019.10.036
   Chen XL, 2023, DIGEST DIS SCI, V68, P98, DOI 10.1007/s10620-022-07495-8
   Chouchou F, 2014, SLEEP MED REV, V18, P273, DOI 10.1016/j.smrv.2013.07.002
   Craner JR, 2022, PAIN PRACT, V22, P171, DOI 10.1111/papr.13075
   DASILVA AMT, 1993, NEW ENGL J MED, V328, P1457, DOI 10.1056/NEJM199305203282005
   Gao Junlong, 2015, ZHONGGUO ZHEN JIU, V35, P269
   Gao W, 2021, SURGERY, V170, P1618, DOI 10.1016/j.surg.2021.08.007
   Gulec M, 2012, PROG NEURO-PSYCHOPH, V37, P247, DOI 10.1016/j.pnpbp.2012.02.011
   Haack M, 2020, NEUROPSYCHOPHARMACOL, V45, P205, DOI 10.1038/s41386-019-0439-z
   Huang BH, 2022, BRIT J SPORT MED, V56, P718, DOI 10.1136/bjsports-2021-104046
   Imeri L, 2009, NAT REV NEUROSCI, V10, P199, DOI 10.1038/nrn2576
   Irwin MR, 2019, NAT REV IMMUNOL, V19, P702, DOI 10.1038/s41577-019-0190-z
   Irwin MR, 2016, BIOL PSYCHIAT, V80, P40, DOI 10.1016/j.biopsych.2015.05.014
   Jiang ZM, 2018, CLIN J PAIN, V34, P1126, DOI 10.1097/AJP.0000000000000645
   Kempf A, 2019, NATURE, V568, P230, DOI 10.1038/s41586-019-1034-5
   Kobayashi EH, 2016, NAT COMMUN, V7, P0, DOI 10.1038/ncomms11624
   Kong XN, 2010, J IMMUNOL, V185, P569, DOI 10.4049/jimmunol.0902315
   Künzel H, 2020, PSYCHONEUROENDOCRINO, V120, P0, DOI 10.1016/j.psyneuen.2020.104799
   Lao LX, 2001, J PAIN, V2, P111, DOI 10.1054/jpai.2001.19575
   Letzen JE, 2020, HUM BRAIN MAPP, V41, P581, DOI 10.1002/hbm.24824
   Li GY, 2013, EXP THER MED, V6, P699, DOI 10.3892/etm.2013.1225
   Li Q, 2019, ACTA NEUROPATHOL COM, V7, P0, DOI 10.1186/s40478-019-0868-2
   Longo UG, 2019, MEDICINA-LITHUANIA, V55, P0, DOI 10.3390/medicina55080453
   Lu ZH, 2021, J CLIN ANESTH, V74, P0, DOI 10.1016/j.jclinane.2021.110453
   Miller Mark W, 2018, HARV REV PSYCHIATRY, V26, P57, DOI 10.1097/HRP.0000000000000167
   Mollayeva T, 2016, SLEEP MED REV, V25, P52, DOI 10.1016/j.smrv.2015.01.009
   Palagini L, 2022, CNS SPECTRUMS, V27, P298, DOI 10.1017/S1092852921000018
   Petti Filomena Bangrazi, 2002, J TRADIT CHIN MED, V22, P104
   Pisani MA, 2020, CHEST, V157, P977, DOI 10.1016/j.chest.2019.12.003
   Rakel B, 2003, J PAIN, V4, P455, DOI 10.1067/S1526-5900(03)00780-6
   Ren XY, 2021, ENVIRON POLLUT, V269, P0, DOI 10.1016/j.envpol.2020.116112
   RosenbergAdamsen S, 1996, BRIT J ANAESTH, V76, P552, DOI 10.1093/bja/76.4.552
   Rushworth SA, 2011, J IMMUNOL, V187, P702, DOI 10.4049/jimmunol.1004117
   Saha S, 2020, MOLECULES, V25, P0, DOI 10.3390/molecules25225474
   Salehabadi A, 2022, ENVIRON SCI POLLUT R, V29, P55457, DOI 10.1007/s11356-022-20996-3
   Saner NJ, 2021, MOL METAB, V43, P0, DOI 10.1016/j.molmet.2020.101110
   Soldatos CR, 2003, J PSYCHOSOM RES, V55, P263, DOI 10.1016/S0022-3999(02)00604-9
   Song BJ, 2020, NAT SCI SLEEP, V12, P809, DOI 10.2147/NSS.S270739
   Song BJ, 2021, SLEEP BREATH, V25, P571, DOI 10.1007/s11325-020-02187-x
   Spiers JG, 2019, FRONT MOL NEUROSCI, V12, P0, DOI 10.3389/fnmol.2019.00086
   Su X, 2018, CURR OPIN ANESTHESIO, V31, P83, DOI 10.1097/ACO.0000000000000538
   Sul OJ, 2021, MOLECULES, V26, P0, DOI 10.3390/molecules26226949
   Sun K, 2017, CLIN J PAIN, V33, P340, DOI 10.1097/AJP.0000000000000400
   Sutton EL, 2021, ANN INTERN MED, V174, PITC33, DOI 10.7326/AITC202103160
   Tu WJ, 2019, AGING DIS, V10, P637, DOI 10.14336/AD.2018.0513
   Vaccaro A, 2020, CELL, V181, P1307, DOI 10.1016/j.cell.2020.04.049
   Villafuerte G, 2015, OXID MED CELL LONGEV, V2015, P0, DOI 10.1155/2015/234952
   Wang T, 2019, CHINESE MED J-PEKING, V132, P1582, DOI 10.1097/CM9.0000000000000279
   Wang WJ, 2020, BRAIN RES BULL, V160, P141, DOI 10.1016/j.brainresbull.2020.03.010
   Wible RS, 2018, ELIFE, V7, P0, DOI 10.7554/eLife.31656
   Wick EC, 2017, JAMA SURG, V152, P691, DOI 10.1001/jamasurg.2017.0898
   Xiao Y, 2022, CLIN TRANSL GASTROEN, V13, P0, DOI 10.14309/ctg.0000000000000485
   Xing RY, 2022, PAIN THER, V11, P1327, DOI 10.1007/s40122-022-00429-2
   Xue R, 2019, FRONT IMMUNOL, V10, P0, DOI 10.3389/fimmu.2019.02546
   Zeng YX, 2022, J CLIN GASTROENTEROL, V56, P875, DOI 10.1097/MCG.0000000000001645
   Zhang MM, 2019, MEDICINE, V98, P0, DOI 10.1097/MD.0000000000017842
   Zielinski MR, 2022, FRONT CELL INFECT MI, V12, P0, DOI 10.3389/fcimb.2022.853096
NR 66
TC 19
Z9 24
U1 8
U2 39
PU SPRINGER INT PUBL AG
PI CHAM
PA GEWERBESTRASSE 11, CHAM, CH-6330, SWITZERLAND
SN 2193-8237
EI 2193-651X
J9 PAIN THER
JI PAIN THER.
PD JUN 15
PY 2023
VL 12
IS 3
BP 707
EP 722
DI 10.1007/s40122-023-00493-2
EA MAR 2023
PG 16
WC Clinical Neurology
SC Neurosciences & Neurology
GA G4NV7
UT WOS:000952984500001
PM 36928500
DA 2026-01-16
ER

PT J
AU Teng, C
   Egger, S
   Blinman, PL
   Vardy, JL
AF Teng, Christina
   Egger, Sam
   Blinman, Prunella L.
   Vardy, Janette L.
TI Evaluating laser photobiomodulation for chemotherapy-induced peripheral neuropathy: a randomised phase II trial
SO SUPPORTIVE CARE IN CANCER
LA English
DT Article
DE Chemotherapy-induced peripheral neuropathy; Photobiomodulation; Laser therapy; Survivorship; Neurotoxicity; Patient-reported outcomes
ID quality-of-life; functional-assessment; cancer; neurotoxicity; acupuncture; therapy; pain; complementary; questionnaire; excitability
AB Purpose This study aims to evaluate the efficacy and safety of laser photobiomodulation (PBM) for treatment of established chemotherapy-induced peripheral neuropathy (CIPN) in cancer survivors. Methods We conducted a randomised phase II, non-comparative, sham-controlled, single-blinded clinical trial in 44 cancer survivors reporting CIPN symptoms at least 3 months following completion of neurotoxic chemotherapy. Participants were randomised 2:1 to either PBM laser or sham control delivered twice weekly for 12 sessions. Assessments were conducted at baseline, the end of intervention (6 weeks), and 6 weeks post intervention (12 weeks). Participants completed neuropathy, quality of life and function questionnaires, and a clinical neurological assessment. The primary outcome was proportion of participants with CIPN response, defined as either symptom resolution or reduction of minimally clinically important difference. Results In the laser and control groups, CIPN response rates were - 48% and 53% at 6 weeks and 45% and 33% at 12 weeks, respectively. The null hypothesis that the true response rate is 5% in the laser arm was rejected at both 6 and 12 weeks (p < 0.001 for both). Compared to baseline, patient-reported CIPN improved in both laser and control groups after the intervention. At 12 weeks, improvement was sustained in the laser group and approaching baseline in the control group. Clinical signs, quality of life, and function remained stable in both groups. Low-grade "side-effects " were observed in both arms. Conclusion PBM may offer clinically meaningful symptom benefit in cancer survivors with established CIPN with improvement potentially continuing beyond completion of the intervention. A larger study is warranted to evaluate this further.
C1 [Teng, Christina; Blinman, Prunella L.; Vardy, Janette L.] Concord Canc Ctr, Concord, NSW, Australia.
   [Teng, Christina; Blinman, Prunella L.; Vardy, Janette L.] Univ Sydney, Fac Med & Hlth, Camperdown, NSW, Australia.
   [Teng, Christina] Cent Coast Canc Ctr, Gosford, NSW, Australia.
   [Egger, Sam] Daffodil Ctr, Canc Council NSW, Kings Cross, NSW, Australia.
   [Egger, Sam] Univ Sydney, Kings Cross, NSW, Australia.
C3 University of Sydney; Cancer Council New South Wales; University of Sydney
RP Vardy, JL (corresponding author), Concord Canc Ctr, Concord, NSW, Australia.; Vardy, JL (corresponding author), Univ Sydney, Fac Med & Hlth, Camperdown, NSW, Australia.
EM Janette.vardy@sydney.edu.au
FU Concord Cancer Centre Research Grant; Australian Government through a National Health Medical Research Council Investigator Grant;  [APP1176221]
CR Argenta PA, 2017, GYNECOL ONCOL, V144, P159, DOI 10.1016/j.ygyno.2016.11.013
   Australian and New Zealand Clinical Trials Registry, 2005, US, V0, P0
   Cotler HB, 2015, MOJ ORTHOPEDICS & RHEUMATOLOGY, V2, P0, DOI 10.15406/mojor.2015.02.00068
   Bjordal JM, 2003, AUST J PHYSIOTHER, V49, P107, DOI 10.1016/S0004-9514(14)60127-6
   Boutron I, 2008, ANN INTERN MED, V148, P295, DOI 10.7326/0003-4819-148-4-200802190-00008
   Brami C, 2016, CRIT REV ONCOL HEMAT, V98, P325, DOI 10.1016/j.critrevonc.2015.11.014
   Braun L, 2014, ASIA-PAC J CLIN ONCO, V10, P289, DOI 10.1111/ajco.12227
   Butkovic D, 2005, PEDIATR ANESTH, V15, P37, DOI 10.1111/j.1460-9592.2004.01388.x
   Calhoun EA, 2003, INT J GYNECOL CANCER, V13, P741, DOI 10.1111/j.1525-1438.2003.13603.x
   Cavaletti G, 2007, J PERIPHER NERV SYST, V12, P210, DOI 10.1111/j.1529-8027.2007.00141.x
   CELLA DF, 1993, J CLIN ONCOL, V11, P570, DOI 10.1200/JCO.1993.11.3.570
   Cg Shashi Kumar, 2015, LASER THER, V24, P195, DOI 10.5978/islsm.15-or-12
   Cheng HL, 2020, HEALTH QUAL LIFE OUT, V18, P0, DOI 10.1186/s12955-020-01493-y
   Chow R, 2011, PHOTOMED LASER SURG, V29, P365, DOI 10.1089/pho.2010.2928
   Chung H, 2012, ANN BIOMED ENG, V40, P516, DOI 10.1007/s10439-011-0454-7
   Ellis A, 2013, BRIT J ANAESTH, V111, P26, DOI 10.1093/bja/aet128
   Fujimaki Y, 2003, J CLIN LASER MED SUR, V21, P165, DOI 10.1089/104454703321895635
   Gornstein EL, 2017, EXP NEUROL, V288, P153, DOI 10.1016/j.expneurol.2016.11.015
   Gottschling S, 2008, PAIN, V137, P405, DOI 10.1016/j.pain.2007.10.004
   Grisold W, 2012, NEURO-ONCOLOGY, V14, P45, DOI 10.1093/neuonc/nos203
   Heide R, 2018, CLIN NEUROPHYSIOL, V129, P694, DOI 10.1016/j.clinph.2017.11.015
   Hershman DL, 2014, J CLIN ONCOL, V32, P1941, DOI 10.1200/JCO.2013.54.0914
   Hsieh YL, 2016, ACUPUNCT MED, V34, P398, DOI 10.1136/acupmed-2016-011112
   Joy L, 2022, SUPPORT CARE CANCER, V30, P5509, DOI 10.1007/s00520-022-06975-x
   Khamseh ME, 2011, LASER MED SCI, V26, P831, DOI 10.1007/s10103-011-0977-z
   Klausner G, 2022, SUPPORT CARE CANCER, V30, P13, DOI 10.1007/s00520-021-06518-w
   Kleckner IR, 2018, SUPPORT CARE CANCER, V26, P1019, DOI 10.1007/s00520-017-4013-0
   Lodewijckx J, 2020, PHOTOBIOMOD PHOTOMED, V38, P348, DOI 10.1089/photob.2019.4771
   McCrary JM, 2019, J NATL COMPR CANC NE, V17, P949, DOI 10.6004/jnccn.2019.7290
   Paglioni MD, 2019, ORAL ONCOL, V93, P21, DOI 10.1016/j.oraloncology.2019.04.004
   Park SB, 2013, CA-CANCER J CLIN, V63, P419, DOI 10.3322/caac.21204
   Pereira FC, 2017, LASER SURG MED, V49, P844, DOI 10.1002/lsm.22696
   Postma TJ, 2005, EUR J CANCER, V41, P1135, DOI 10.1016/j.ejca.2005.02.012
   SCHAG CC, 1984, J CLIN ONCOL, V2, P187, DOI 10.1200/JCO.1984.2.3.187
   Seretny M, 2014, PAIN, V155, P2461, DOI 10.1016/j.pain.2014.09.020
   SIMON R, 1989, CONTROL CLIN TRIALS, V10, P1, DOI 10.1016/0197-2456(89)90015-9
   Smith EML, 2013, JAMA-J AM MED ASSOC, V309, P1359, DOI 10.1001/jama.2013.2813
   Teng CA, 2022, SUPPORT CARE CANCER, V30, P33, DOI 10.1007/s00520-021-06502-4
   Trotti A, 2003, SEMIN RADIAT ONCOL, V13, P176, DOI 10.1016/S1053-4296(03)00031-6
   Winters-Stone KM, 2017, J CLIN ONCOL, V35, P2604, DOI 10.1200/JCO.2016.71.3552
   Yeo F, 2019, SUPPORT CARE CANCER, V27, P4753, DOI 10.1007/s00520-019-04771-8
   Zadik Y, 2019, SUPPORT CARE CANCER, V27, P3969, DOI 10.1007/s00520-019-04890-2
   Zajaczkowska R, 2019, INT J MOL SCI, V20, P0, DOI 10.3390/ijms20061451
   Zhang HJ, 2014, ANESTHESIOLOGY, V120, P1463, DOI 10.1097/ALN.0000000000000176
NR 44
TC 11
Z9 15
U1 4
U2 7
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0941-4355
EI 1433-7339
J9 SUPPORT CARE CANCER
JI Support. Care Cancer
PD JAN 15
PY 2023
VL 31
IS 1
BP 
EP 
DI 10.1007/s00520-022-07463-y
PG 11
WC Oncology; Health Care Sciences & Services; Rehabilitation
SC Oncology; Health Care Sciences & Services; Rehabilitation
GA 7C6ZK
UT WOS:000899958400003
PM 36526802
DA 2026-01-16
ER

PT J
AU Cheng, HL
   Yeung, WF
   Wong, HF
   Lo, HT
   Molassiotis, A
AF Cheng, Hui-Lin
   Yeung, Wing-Fai
   Wong, Hon-Fat
   Lo, Huen-Ting
   Molassiotis, Alex
TI Self-Acupressure for Symptom Management in Cancer Patients: A Systematic Review
SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT
LA English
DT Review
DE Cancer; symptom; acupressure; systematic review; nausea; vomiting
ID chemotherapy-induced nausea; administered acupressure; fatigue; acupuncture; fidelity; therapy
AB Context. Acupressure is a popular nonpharmacological intervention that is increasingly proven to effectively alleviate symptoms in patients with cancer. However, the effects of self-acupressure on cancer symptom management are less clear.Objectives. This systematic review is the first to summarize the current experimental evidence on self-acupressure for symptom management in cancer patients.Methods. Eight electronic databases were searched for experimental studies that examined self-acupressure for cancer patients with symptoms and published in peer-reviewed English or Chinese journals. The methodological quality of the included studies was evaluated using the revised Cochrane risk-of-bias assessment tool and the JBI critical appraisal checklist for quasi-experimental studies. Data were extracted as predefined and synthesized narratively. The Template for Intervention Description and Replication checklist was used to report the intervention characteristics.Results. A total of 11 studies were included in this study, six as feasibility or pilot trials. The methodological quality of included studies was suboptimal. Substantial heterogeneity was observed in acupressure training, acupoint selection, intervention duration, dosage, and timing. Self-acupressure was only associated with reduced nausea and vomiting (P = 0.006 and P = 0.001).Conclusion. The limited evidence from this review precludes the definitive conclusions on intervention effectiveness for cancer symptoms. Future research should consider developing the standard protocol for intervention delivery, improving the methodology of self-acupressure trials, and conducting large-scale research to advance the science of self-acupressure for cancer symptom management. J Pain Symptom Manage 2023;66:e109-e128.& COPY; 2023 American Academy of Hospice and Palliative Medicine. Published by Elsevier Inc. All rights reserved.
C1 [Cheng, Hui-Lin; Yeung, Wing-Fai; Wong, Hon-Fat; Lo, Huen-Ting] Hong Kong Polytech Univ, Sch Nursing, Hung Hom, Kowloon, Hong Kong, Peoples R China.
   [Molassiotis, Alex] Univ Derby, Coll Arts Humanities & Educ, Derby, England.
   [Cheng, Hui-Lin] Hong Kong Polytech Univ, Sch Nursing, Hung Hom, Kowloon, FG 511,11 Yuk Choi Rd, Hong Kong, Peoples R China.
C3 Hong Kong Polytechnic University; University of Derby; Hong Kong Polytechnic University
RP Cheng, HL (corresponding author), Hong Kong Polytech Univ, Sch Nursing, Hung Hom, Kowloon, FG 511,11 Yuk Choi Rd, Hong Kong, Peoples R China.
EM eileen.cheng@polyu.edu.hk
FU Departmental General Research Fund at the Hong Kong Polytechnic University [P0014025]
CR Unknown -, 2010, SURGERY, V0, P0, DOI DOI 10.1016/J.SURG.2009.06.030
   Arch JJ, 2018, PSYCHO-ONCOLOGY, V27, P1434, DOI 10.1002/pon.4526
   Armstrong Terri S, 2003, ONCOL NURS FORUM, V30, P601, DOI 10.1188/03.ONF.601-606
   Bellg AJ, 2004, HEALTH PSYCHOL, V23, P443, DOI 10.1037/0278-6133.23.5.443
   Blödt S, 2018, AM J OBSTET GYNECOL, V218, P0, DOI 10.1016/j.ajog.2017.11.570
   Cheung DST, 2022, EUR J CANCER CARE, V31, P0, DOI 10.1111/ecc.13314
   Cheung DST, 2020, ACUPUNCT MED, V38, P75, DOI 10.1177/0964528419883269
   Chyr LC, 2022, J PAIN SYMPTOM MANAG, V64, PE363, DOI 10.1016/j.jpainsymman.2022.08.008
   Dibble SL, 2007, ONCOL NURS FORUM, V34, P815, DOI 10.1188/07.ONF.813-820
   Dogan Nurhan, 2020, ALTERN THER HEALTH MED, V26, P49
   Ernst Edzard, 2010, J PAIN SYMPTOM MANAGE, V40, Pe3, DOI 10.1016/j.jpainsymman.2010.07.003
   Garland SN, 2018, SUPPORT CARE CANCER, V26, P2407, DOI 10.1007/s00520-018-4086-4
   Hoffmann TC, 2014, BMJ-BRIT MED J, V348, P0, DOI 10.1136/bmj.g1687
   Hou PW, 2015, EVID-BASED COMPL ALT, V2015, P0, DOI 10.1155/2015/495684
   Hsieh SH, 2021, CANCER NURS, V44, PE578, DOI 10.1097/NCC.0000000000000997
   Hughes JG, 2015, EUR J INTEGR MED, V7, P623, DOI 10.1016/j.eujim.2015.08.003
   Huong HTX, 2022, SLEEP BREATH, V26, P445, DOI 10.1007/s11325-021-02370-8
   Kim SY, 2021, ASIAN ONCOL NURS, V21, P129, DOI 10.5388/aon.2021.21.3.129
   Kwon CY, 2022, J ACUPUNCT MERIDIAN, V15, P214, DOI 10.51507/j.jams.2022.15.4.214
   Lee EJ, 2011, J PAIN SYMPTOM MANAG, V42, P589, DOI 10.1016/j.jpainsymman.2011.01.007
   Lin L, 2020, PATIENT PREFER ADHER, V14, P1275, DOI 10.2147/PPA.S261466
   Liu XL, 2020, EVID-BASED COMPL ALT, V2020, P0, DOI 10.1155/2020/2591320
   MacPherson H, 2004, COMPLEMENT THER MED, V12, P136, DOI 10.1016/j.ctim.2004.07.043
   Mai QL, 2022, EUR J INTEGR MED, V51, P0, DOI 10.1016/j.eujim.2022.102120
   Miao J, 2017, INT J NURS STUD, V70, P27, DOI 10.1016/j.ijnurstu.2017.02.014
   Molassiotis A, 2007, COMPLEMENT THER MED, V15, P228, DOI 10.1016/j.ctim.2006.09.009
   Okitsu R, 2012, COMPLEMENT THER MED, V20, P207, DOI 10.1016/j.ctim.2011.12.005
   Shi GX, 2012, TRIALS, V13, P0, DOI 10.1186/1745-6215-13-42
   Shin YH, 2004, CANCER NURS, V27, P267, DOI 10.1097/00002820-200407000-00002
   Song HJ, 2015, COMPLEMENT THER MED, V23, P68, DOI 10.1016/j.ctim.2014.11.002
   Sterne JAC, 2019, BMJ-BRIT MED J, V366, P0, DOI 10.1136/bmj.l4898
   Tang WR, 2014, COMPLEMENT THER MED, V22, P581, DOI 10.1016/j.ctim.2014.05.006
   Tiwari AK, 2017, BIOMECH MODEL MECHAN, V16, P395, DOI 10.1007/s10237-016-0824-z
   WHO Regional Office for the Western Pacific, 2008, WHO STAND AC POINT L, V0, P0
   Wyatt G, 2015, ALTERN THER HEALTH M, V21, P18
   Yeung WF, 2022, PHYTOMEDICINE, V99, P0, DOI 10.1016/j.phymed.2022.153993
   Yeung WF, 2012, EVID-BASED COMPL ALT, V2012, P0, DOI 10.1155/2012/902578
   Zick SM, 2016, JAMA ONCOL, V2, P1470, DOI 10.1001/jamaoncol.2016.1867
   Zick SM, 2011, EVID-BASED COMPL ALT, V2011, P0, DOI 10.1155/2011/142913
NR 40
TC 13
Z9 15
U1 2
U2 9
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0885-3924
EI 1873-6513
J9 J PAIN SYMPTOM MANAG
JI J. Pain Symptom Manage.
PD JUL 15
PY 2023
VL 66
IS 1
BP E109
EP E128
DI 10.1016/j.jpainsymman.2023.03.002
EA JUN 2023
PG 20
WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology
SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology
GA M2HL4
UT WOS:001028442900001
PM 36898639
DA 2026-01-16
ER

PT J
AU Shi, Y
   Nguyen, T
   Farrell, M
   Rodgers-Melnick, S
   Moss, G
   Kaiser, C
   Dusek, JA
   Mendiratta, P
   Adan, F
   Lee, RT
AF Shi, Yuming
   Nguyen, Thuy
   Farrell, Megan
   Rodgers-Melnick, Samuel
   Moss, Gabriel
   Kaiser, Christine
   Dusek, Jeffery A
   Mendiratta, Prateek
   Adan, Francoise
   Lee, Richard T
TI Retrospective Outcomes of a New Acupuncture Service at a Comprehensive Cancer
SO Journal of integrative and complementary medicine
LA English
DT Journal Article
DE acupuncture; cancer; integrative oncology; symptom management
AB Introduction: Among cancer centers, patients' interest in acupuncture is growing,  in addition to clinical research in the intervention. Their National Cancer  Institute-designated comprehensive cancer center piloted an acupuncture service.  Their aim was to assess whether acupuncture impacted patient self-reported  symptoms as delivered clinically and discuss their implementation strategy.  Methods: Patients undergoing acupuncture at a comprehensive cancer center from  June 2019 to March 2020 were asked to complete a modified Edmonton Symptom  Assessment Scale (ESAS) before and after each session. The authors evaluated  symptom changes after acupuncture in both outpatient and inpatient settings. A  change of ≥1 U, on the 0-10 scale, was considered clinically significant.  Results: Three hundred and nine outpatient and 394 inpatient acupuncture sessions  were provided to patients at the comprehensive cancer center during this period,  of which surveys from 186 outpatient (34 patients) and 124 inpatient (57  patients) sessions were available for analysis. The highest pretreatment symptoms  reported by outpatients were neuropathy (5.78), pain (5.58), and tiredness  (5.59). Outpatients receiving acupuncture reported clinically significant  improvements in pain (ESAS score change of -2.97), neuropathy (-2.68), decreased  lack of well-being (-2.60), tiredness (-1.85), nausea (-1.83), anxiety (-1.56),  activities of daily living issues (-1.32), depression (-1.23), anorexia (-1.19),  insomnia (-1.14), and shortness of breath (-1.14). The most severe pretreatment  symptoms reported by inpatients were pain (6.90), insomnia (6.16), and  constipation (5.44). Inpatients receiving acupuncture reported clinically  significant improvements in anxiety (-3.69), nausea (-3.61), insomnia (-3.26),  depression (-2.98), pain (-2.77), neuropathy (-2.68), anorexia (-2.20),  constipation (-1.95), and diarrhea (-1.26). Conclusion: Both outpatient and  inpatient participants in this pilot acupuncture program reported clinically  significant improvements in symptoms after a single acupuncture treatment. Some  differences between the outpatient and inpatient settings warrant further  investigation.
C1 Case Western Reserve University, Cleveland, OH, USA.
   University Hospitals Connor Whole Health, Cleveland, OH, USA.
   Cleveland Clinic, Cleveland, OH, USA.
   Case Western Reserve University, Cleveland, OH, USA.
   Case Western Reserve University, Cleveland, OH, USA.
   University Hospitals Connor Whole Health, Cleveland, OH, USA.
   Case Western Reserve University, Cleveland, OH, USA.
   University Hospitals Connor Whole Health, Cleveland, OH, USA.
   Case Western Reserve University, Cleveland, OH, USA.
   University Hospitals Connor Whole Health, Cleveland, OH, USA.
   Case Western Reserve University, Cleveland, OH, USA.
   University Hospitals Cleveland Medical Center, Cleveland, OH, USA.
   Case Western Reserve University, Cleveland, OH, USA.
   University Hospitals Connor Whole Health, Cleveland, OH, USA.
   Case Western Reserve University, Cleveland, OH, USA.
   University Hospitals Cleveland Medical Center, Cleveland, OH, USA.
   Integrative Medicine Program, Departments of Supportive Care Medicine and Medical Oncology, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.
NR 0
TC 0
SN 2768-361
EI 
J9 J Integr Complement Med
PD MAY 30
PY 2023
VL 29
IS 10
BP 674
EP 682
DI 10.1089/jicm.2022.0709
PG 8
WC Humans; Sleep Initiation and Maintenance Disorders; Retrospective Studies; Activities of Daily Living; Anorexia; Pain; Acupuncture Therapy; Constipation; therapy; Nausea; etiology; Neoplasms; complications
UT PubMed:37252748
PM 37252748
DA 2023-05-30
ER

PT J
AU Zhang, J
   Qin, Z
   So, TH
   Chang, TY
   Yang, S
   Chen, H
   Yeung, WF
   Chung, KF
   Chan, PY
   Huang, Y
   Xu, S
   Chiang, CY
   Lao, L
   Zhang, ZJ
AF Zhang, Jialing
   Qin, Zongshi
   So, Tsz Him
   Chang, Tien Yee
   Yang, Sichang
   Chen, Haiyong
   Yeung, Wing Fai
   Chung, Ka Fai
   Chan, Pui Yan
   Huang, Yong
   Xu, Shifen
   Chiang, Chun Yuan
   Lao, Lixing
   Zhang, Zhang-Jin
TI Acupuncture for chemotherapy-associated insomnia in breast cancer patients: an
SO Breast cancer research : BCR
LA English
DT Journal Article
DE Acupuncture; Breast cancer; Cessation rate of sleeping medications; Chemotherapy-associated insomnia
AB BACKGROUND: Insomnia is a highly prevalent symptom occurred during and  post-chemotherapy. Acupuncture may have beneficial effects in the management of  chemotherapy-associated insomnia. This study was conducted to determine the  efficacy and safety of acupuncture in improving chemotherapy-associated insomnia  in breast cancer patients. METHODS: This assessor-participant blinded,  randomized, sham-controlled trial was conducted from November 2019 to January  2022 (follow-up completed July 2022). Participants were referred by oncologists  from two Hong Kong hospitals. Assessments and interventions were conducted at the  outpatient clinic of School of Chinese Medicine, the University of Hong Kong. The  138 breast cancer patients with chemotherapy-associated insomnia were randomly  assigned to receive either 15 sessions of active acupuncture regimen by combining  needling into body acupoints and acupressure on auricular acupoints or sham  acupuncture control (69 each) for 18 weeks, followed by 24 weeks of follow-up.  The primary outcome was measured using Insomnia Severity Index (ISI). Secondary  outcomes included the Pittsburgh Sleep Quality Index, Actiwatch and sleep diary  for sleep parameters, depression and anxiety, fatigue and pain, and quality of  life. RESULTS: There were 87.7% (121/138) participants who completed the primary  endpoint (week-6). The active acupuncture regimen was not superior to the sham  control in reducing ISI score from baseline to 6 weeks (mean difference: - 0.4,  95% CI - 1.8-1.1; P = 0.609), but produced short-term treatment and long-term  follow-up better outcomes in improving sleep onset latency, total sleep time,  sleep efficiency, anxiety, depression, and quality of life. Participants of the  active acupuncture group had a pronouncedly higher cessation rate of sleeping  medications than the sham control (56.5% vs. 14.3%, P = 0.011). All  treatment-related adverse events were mild. No participants discontinued  treatments due to adverse events. CONCLUSION: The active acupuncture regimen  could be considered as an effective option for the management of  chemotherapy-associated insomnia. It also could serve as a tapering approach to  reduce and even replace the use of sleeping medications in breast cancer  patients. Trial registration Clinicaltrials.gov : NCT04144309. Registered 30  October 2019.
C1 School of Chinese Medicine, LKS Faculty of Medicine, The University of Hong Kong, 10 Sassoon Road, Pokfulam, Hong Kong, China.
   School of Chinese Medicine, Hong Kong Baptist University, Kowloon Tong, Hong 
   School of Chinese Medicine, LKS Faculty of Medicine, The University of Hong Kong, 10 Sassoon Road, Pokfulam, Hong Kong, China.
   Department of Clinical Oncology, LKS Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong, China.
   Comprehensive Oncology Centre, Hong Kong Sanatorium & Hospital, Happy Valley, Hong Kong, China.
   School of Chinese Medicine, LKS Faculty of Medicine, The University of Hong Kong, 10 Sassoon Road, Pokfulam, Hong Kong, China.
   School of Chinese Medicine, LKS Faculty of Medicine, The University of Hong Kong, 10 Sassoon Road, Pokfulam, Hong Kong, China.
   School of Nursing, The Hong Kong Polytechnic University, Hung Hom, Hong Kong, China.
   Department of Psychiatry, The University of Hong Kong, Pokfulam, Hong Kong, China.
   School of Chinese Medicine, LKS Faculty of Medicine, The University of Hong Kong, 10 Sassoon Road, Pokfulam, Hong Kong, China.
   School of Traditional Chinese Medicine, Southern Medical University, Guangzhou, 510515, Guangdong, China.
   Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 200071, China.
   Hong Kong Institute of Cell & Molecular Medicine and Digital Centre of State-Key-Laboratory on Quality Appraisal of TCM, Hong Kong, China.
   School of Chinese Medicine, LKS Faculty of Medicine, The University of Hong Kong, 10 Sassoon Road, Pokfulam, Hong Kong, China. llao@vuim.edu.
   Virginia University of Integrative Medicine, Fairfax, VA, 22031, USA. 
   School of Chinese Medicine, LKS Faculty of Medicine, The University of Hong Kong, 10 Sassoon Road, Pokfulam, Hong Kong, China. zhangzj@hku.hk.
   Department of Chinese Medicine, The University of Hong Kong Shenzhen Hospital
NR 0
TC 0
SN 1465-542
EI 1465-541
J9 Breast Cancer Res
PD APR 27
PY 2023
VL 25
IS 1
BP 49
EP 49
DI 10.1186/s13058-023-01645-0
PG 0
WC Humans; Female; Sleep Initiation and Maintenance Disorders; chemically induced; Breast Neoplasms; complications; Quality of Life; Acupuncture Therapy; adverse effects; Sleep; Treatment Outcome
UT PubMed:37101228
PM 37101228
DA 2023-04-27
ER

PT J
AU Qu, SY
   Wang, HZ
   Hu, QQ
   Ma, YQ
   Kang, YR
   Ma, LQ
   Li, X
   Chen, LH
   Liu, BY
   Shao, XM
   Liu, BY
   Du, JY
   Liang, Y
   Zhao, HL
   Jiang, YL
   Fang, JQ
   He, XF
AF Qu, Si-Ying
   Wang, Han-Zhi
   Hu, Qun-Qi
   Ma, Yi-Qi
   Kang, Yu-Rong
   Ma, Li-Qian
   Li, Xiang
   Chen, Lu-Hang
   Liu, Bo-Yu
   Shao, Xiao-Mei
   Liu, Bo-Yi
   Du, Jun-Ying
   Liang, Yi
   Zhao, Hong-Li
   Jiang, Yong-Liang
   Fang, Jian-Qiao
   He, Xiao-Fen
TI Electroacupuncture may alleviate diabetic neuropathic pain by inhibiting the
SO Purinergic signalling
LA English
DT Journal Article
DE Diabetic neuropathic pain; Electroacupuncture; Microglia; P2X4R; Spinal cord
AB Diabetic neuropathic pain (DNP) is a common and destructive complication of  diabetes mellitus. The discovery of effective therapeutic methods for DNP is  vitally imperative because of the lack of effective treatments. Although 2 Hz  electroacupuncture (EA) was a successful approach for relieving DNP, the  mechanism underlying the effect of EA on DNP is still poorly understood. Here, we  established a rat model of DNP that was induced by streptozotocin (STZ)  injection. P2X4R was upregulated in the spinal cord after STZ-injection. The  upregulation of P2X4R was mainly expressed on activated microglia. Intrathecal  injection of a P2X4R antagonist or microglia inhibitor attenuated STZ-induced  nociceptive thermal hyperalgesia and reduced the overexpression of brain-derived  neurotrophic factor (BDNF), interleukin-1β (IL-1β) and tumor necrosis factor-α  (TNF-α) in the spinal cord. We also assessed the effects of EA treatment on the  pain hypersensitivities of DNP rats, and further investigated the possible  mechanism underlying the analgesic effect of EA. EA relieved the hyperalgesia of  DNP. In terms of mechanism, EA reduced the upregulation of P2X4R on activated  microglia and decreased BDNF, IL-1β and TNF-α in the spinal cord. Mechanistic  research of EA's analgesic impact would be beneficial in ensuring its prospective  therapeutic effect on DNP as well as in extending EA's applicability.
C1 Zhejiang Chinese Medical University, Hangzhou, 310053, Zhejiang, China.
   Zhejiang Chinese Medical University, Hangzhou, 310053, Zhejiang, China.
   Department of TCM Gynecology, Hangzhou Hospital of Traditional Chinese Medicine 
   Zhejiang Chinese Medical University, Hangzhou, 310053, Zhejiang, China.
   Zhejiang Chinese Medical University, Hangzhou, 310053, Zhejiang, China.
   Zhejiang Chinese Medical University, Hangzhou, 310053, Zhejiang, China.
   Zhejiang Chinese Medical University, Hangzhou, 310053, Zhejiang, China.
   Zhejiang Chinese Medical University, Hangzhou, 310053, Zhejiang, China.
   Zhejiang Chinese Medical University, Hangzhou, 310053, Zhejiang, China.
   Zhejiang Chinese Medical University, Hangzhou, 310053, Zhejiang, China.
   Key Laboratory of Acupuncture and Neurology of Zhejiang Province, Department of 
   Zhejiang Chinese Medical University, Hangzhou, 310053, Zhejiang, China.
   Key Laboratory of Acupuncture and Neurology of Zhejiang Province, Department of 
   Zhejiang Chinese Medical University, Hangzhou, 310053, Zhejiang, China.
   Key Laboratory of Acupuncture and Neurology of Zhejiang Province, Department of 
   Zhejiang Chinese Medical University, Hangzhou, 310053, Zhejiang, China.
   Key Laboratory of Acupuncture and Neurology of Zhejiang Province, Department of 
   Zhejiang Chinese Medical University, Hangzhou, 310053, Zhejiang, China.
   Key Laboratory of Acupuncture and Neurology of Zhejiang Province, Department of 
   Department of TCM Gynecology, Hangzhou Hospital of Traditional Chinese Medicine Affiliated to Zhejiang Chinese Medical University, Hangzhou, 310000, China.
   Zhejiang Chinese Medical University, Hangzhou, 310053, Zhejiang, China. jyl2182@126.com.
   Key Laboratory of Acupuncture and Neurology of Zhejiang Province, Department of 
   Zhejiang Chinese Medical University, Hangzhou, 310053, Zhejiang, China. fangjianqiao7532@163.com.
   Key Laboratory of Acupuncture and Neurology of Zhejiang Province, Department of 
   Zhejiang Chinese Medical University, Hangzhou, 310053, Zhejiang, China. zjhxf1986@163.com.
   Key Laboratory of Acupuncture and Neurology of Zhejiang Province, Department of
NR 0
TC 0
SN 1573-954
EI 1573-953
J9 Purinergic Signal
PD OCT 23
PY 2023
VL 21
IS 4
BP 533
EP 547
DI 10.1007/s11302-023-09972-9
PG 14
WC Animals; Electroacupuncture; methods; Microglia; metabolism; Receptors, Purinergic P2X4; metabolism; Diabetic Neuropathies; metabolism; Rats; Male; Rats, Sprague-Dawley; Neuroinflammatory Diseases; metabolism; Neuralgia; metabolism; Diabetes Mellitus, Experimental; metabolism; Spinal Cord; metabolism
UT PubMed:37870716
PM 37870716
DA 2023-10-23
ER

PT J
AU Mentink, M
   Verbeek, D
   Noordman, J
   Timmer-Bonte, A
   von, Rosenstiel I
   van, Dulmen S
AF Mentink, Marit
   Verbeek, Daniëlle
   Noordman, Janneke
   Timmer-Bonte, Anja
   von Rosenstiel, Ines
   van Dulmen, Sandra
TI The Effects of Complementary Therapies on Patient-Reported Outcomes: An Overview
SO Cancers
LA English
DT Review
DE complementary medicine; meta-analysis; oncology; overview of systematic reviews; patient-reported outcomes (PROMS)
AB Many patients with cancer make use of complementary medicine alongside  conventional medicine, but clinicians in oncology often lack the knowledge to  adequately advise patients on the evidence base for complementary therapies. This  study aims to provide an overview of recently published systematic reviews that  assess the effects of complementary therapies on patient-reported health outcomes  in patients with cancer. Systematic reviews, including a meta-analysis of at  least two randomized controlled trials, were identified from the PubMed, Embase,  Cochrane Library, CINAHL and PsycINFO databases. The methodological quality was  assessed with AMSTAR 2. One hundred systematic reviews were included. The results  suggest that several complementary therapies can improve health outcomes reported  by patients with cancer, such as acupuncture to relieve pain, music interventions  to reduce anxiety and yoga to improve cancer-related fatigue. The side effects  related to complementary therapy use are generally mild. The results remain  inconclusive for some intervention-outcome combinations. Many of the included  systematic reviews insufficiently assessed the causes and impact of bias in their  interpretation of the results. This overview of systematic reviews can support  clinicians in counselling their patients on this topic and provide directions for  future research and clinical practice guidelines in the field of complementary  medicine.
C1 Nivel (Netherlands Institute of Health Services Research), Otterstraat 118, 3512 CR Utrecht, The Netherlands.
   Department of Primary and Community Care, Radboud Institute for Health Sciences, 
   Praktijk Integratieve Oncologie, Heesterpoort 18, 9713 KZ Groningen, The Netherlands.
   Nivel (Netherlands Institute of Health Services Research), Otterstraat 118, 3512 CR Utrecht, The Netherlands.
   Department of Medical Oncology, Radboud University Medical Center, Geert Grooteplein Zuid 10, 6525 GA Nijmegen, The Netherlands.
   Department of Integrative Oncology, Rijnstate Hospital, Wagnerlaan 55, 6815 AD Arnhem, The Netherlands.
   Nivel (Netherlands Institute of Health Services Research), Otterstraat 118, 3512 CR Utrecht, The Netherlands.
   Department of Primary and Community Care, Radboud Institute for Health Sciences, 
   Faculty of Caring Science, University of Borås, Work Life and Social Welfare, Allégatan 1, 501 90 Borås, Sweden.
NR 0
TC 0
SN 2072-669
EI 2072-669
J9 Cancers (Basel)
PD SEP 28
PY 2023
VL 15
IS 18
BP 
EP 
DI 10.3390/cancers15184513
PG 0
UT PubMed:37760483
PM 37760483
DA 2023-09-28
ER

PT J
AU Ben-Arye, E
   Gamus, D
   Samuels, N
   Schiff, E
   Hausner, D
   Gressel, O
   Attias, S
   Lavie, O
   David, A
   Shulman, K
   Agbarya, A
AF Ben-Arye, Eran
   Gamus, Dorit
   Samuels, Noah
   Schiff, Elad
   Hausner, David
   Gressel, Orit
   Attias, Samuel
   Lavie, Ofer
   David, Adi
   Shulman, Katerina
   Agbarya, Abed
TI Acupuncture and integrative oncology for taxane-induced peripheral neuropathy: a randomized multicentered study
SO INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
LA English
DT Article
DE Quality of Life (PRO); Palliative Care
ID breast-cancer patients; chemotherapy; electroacupuncture; paclitaxel; therapy; safety; trial; prevention; efficacy; women
AB Objective To compare the effectiveness of acupuncture alone or with additional integrative oncology modalities for taxane-induced peripheral neuropathy-related symptoms in patients with gynecological and breast cancer.Methods The study was a prospective evaluation of patients undergoing twice-weekly treatments with either acupuncture alone (single-modality, group A) or with additional manual-movement and mind- body therapies (multimodality, group B), for 6 weeks. Symptom severity was assessed at baseline, 6 weeks, and 9 weeks using the Functional Assessment of Cancer Therapy-Taxane (FACT-Tax) tool; and von Frey perception thresholds. Additional symptoms were also assessed with the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ- C30) and the Measure Yourself Concerns and Wellbeing (MYCaW) study tool.Results For the 120 participants (60 in each study arm), baseline to 6- week scores were similar in both groups for improved FACT- Tax physical wellbeing and scores for hand numbness/tingling; EORTC physical functioning and global health status; and MYCaW scores. FACT- Tax taxane subscales and scores for foot numbness/tingling improved only in group A (p=0.038), while emotional wellbeing FACT-Tax (p=0.02) and EORTC pain (p=0.005) improved only in group B. Group B showed greater improvement for FACT-Tax neuropathy-related concerns than group A at 24 hours (p=0.043) and 7 days (p=0.009) after the first treatment.Conclusion Acupuncture alone or with additional integrative oncology modalities may help reduce neuropathy-related symptoms. The single-modality group demonstrated greater improvement for foot numbness/ tingling, and the multimodality group demonstrated improvement for pain and improved emotional wellbeing and neuropathy-related concerns in the first week of treatment.
C1 [Ben-Arye, Eran; Gressel, Orit] Clalit Hlth Serv, Lin Med Ctr, Oncol Serv, Haifa, Israel.
   [Ben-Arye, Eran; Schiff, Elad; Lavie, Ofer] Technion Israel Inst Technol, Haifa, Israel.
   [Gamus, Dorit; Hausner, David; David, Adi] Sheba Med Ctr, Tel Hashomer, Israel.
   [Samuels, Noah] Shaare Zedek Med Ctr, Jerusalem, Israel.
   [Schiff, Elad] Dept Internal Med, Haifa, Israel.
   [Schiff, Elad; Attias, Samuel; Agbarya, Abed] Bnai Zion Med Ctr, Haifa, Israel.
   [Lavie, Ofer] Lady Davies Carmel Med Ctr, Haifa, Israel.
   [Shulman, Katerina] LIN Med Ctr, Haifa, Israel.
C3 Clalit Health Services; Technion Israel Institute of Technology; Tel Aviv University; Chaim Sheba Medical Center; Hebrew University of Jerusalem; Shaare Zedek Medical Center; Bnai Zion Medical Center; Clalit Health Services; Carmel Medical Center
RP Ben-Arye, E (corresponding author), Clalit Hlth Serv, Lin Med Ctr, Oncol Serv, Haifa, Israel.
EM eranben@netvision.net.il
FU Adelis Foundation
CR AARONSON NK, 1993, J NATL CANCER I, V85, P365, DOI 10.1093/jnci/85.5.365
   Bao T, 2018, EUR J CANCER, V101, P12, DOI 10.1016/j.ejca.2018.06.008
   Bao T, 2014, CANCER-AM CANCER SOC, V120, P381, DOI 10.1002/cncr.28352
   Bauml Joshua, 2014, JOURNAL OF THE NATIONAL CANCER INSTITUTE MONOGRAPHS, V0, PP302, DOI 10.1093/jncimonographs/lgu029
   Ben-Arye E, 2022, CANCER-AM CANCER SOC, V128, P3641, DOI 10.1002/cncr.34422
   Ben-Horin I, 2017, INTEGR CANCER THER, V16, P258, DOI 10.1177/1534735417690254
   Bhatnagar B, 2014, SPRINGERPLUS, V3, P0, DOI 10.1186/2193-1801-3-366
   Cavaletti G, 2010, EUR J CANCER, V46, P479, DOI 10.1016/j.ejca.2009.12.008
   Cella D, 2003, CANCER-AM CANCER SOC, V98, P822, DOI 10.1002/cncr.11578
   Chung KF, 2015, CLIN J PAIN, V31, P922, DOI 10.1097/AJP.0000000000000189
   Cybularz PA, 2015, MED ACUPUNCT, V27, P224, DOI 10.1089/acu.2015.1099
   Engvall K, 2021, BRIT J CANCER, V125, P445, DOI 10.1038/s41416-021-01429-3
   Ernst G, 2003, COMPLEMENT THER MED, V11, P93, DOI 10.1016/S0965-2299(03)00004-9
   Galantino ML, 2019, INTEGR CANCER THER, V18, P0, DOI 10.1177/1534735419850627
   Greenlee H, 2016, BREAST CANCER RES TR, V156, P453, DOI 10.1007/s10549-016-3759-2
   Griffiths C, 2018, SUPPORT CARE CANCER, V26, P3461, DOI 10.1007/s00520-018-4199-9
   Huang CC, 2021, J CLIN MED, V10, P0, DOI 10.3390/jcm10163694
   Iravani S, 2020, PAIN RES MANAG, V2020, P0, DOI 10.1155/2020/2504674
   Izgu N, 2019, EUR J ONCOL NURS, V40, P36, DOI 10.1016/j.ejon.2019.03.002
   Jeong YJ, 2018, EVID-BASED COMPL ALT, V2018, P0, DOI 10.1155/2018/5367014
   Kleckner IR, 2021, BREAST CANCER RES TR, V189, P521, DOI 10.1007/s10549-021-06304-6
   Kurt S, 2018, EUR J ONCOL NURS, V32, P12, DOI 10.1016/j.ejon.2017.11.001
   Li YY, 2019, INT J MOL SCI, V20, P0, DOI 10.3390/ijms20235917
   Loprinzi CL, 2020, J CLIN ONCOL, V38, P0, DOI 10.1200/JCO.20.01399
   Lu WD, 2020, MED ACUPUNCT, V32, P398, DOI 10.1089/acu.2020.1496
   Lu WD, 2020, ONCOLOGIST, V25, P310, DOI 10.1634/theoncologist.2019-0489
   Lu WD, 2010, CURR TREAT OPTION ON, V11, P141, DOI 10.1007/s11864-010-0126-0
   Mao JJ, 2022, J CLIN ONCOL, V40, P3998, DOI 10.1200/JCO.22.01357
   Mao JJ, 2022, CA-CANCER J CLIN, V72, P144, DOI 10.3322/caac.21706
   Noh GO, 2019, EUR J ONCOL NURS, V42, P82, DOI 10.1016/j.ejon.2019.08.007
   Pabst L, 2020, BREAST J, V26, P2376, DOI 10.1111/tbj.14123
   Park JE, 2010, J ALTERN COMPLEM MED, V16, P959, DOI 10.1089/acm.2009.0415
   Paterson C, 2007, COMPLEMENT THER MED, V15, P38, DOI 10.1016/j.ctim.2006.03.006
   Paterson Charlotte, 2006, BMC COMPLEMENT ALTERN MED, V6, P7, DOI 10.1186/1472-6882-6-7
   Saeedi-Saedi H, 2015, IRAN J CANCER PREV, V8, P36
   Samuels N, 2020, CURR ONCOL REP, V22, P0, DOI 10.1007/s11912-020-0891-2
   Tu JF, 2022, JAMA NETW OPEN, V5, P0, DOI 10.1001/jamanetworkopen.2022.25735
   Viel E, 2021, MED ACUPUNCT, V33, P212, DOI 10.1089/acu.2020.1506
   Wang JN, 2017, CHINESE J CANCER RES, V29, P411, DOI 10.21147/j.issn.1000-9604.2017.05.05
   Witt Claudia M, 2017, JOURNAL OF THE NATIONAL CANCER INSTITUTE MONOGRAPHS, V0, PP3, DOI 10.1093/jncimonographs/lgx012
   Zhang Y, 2018, EUR J PAIN, V22, P679, DOI 10.1002/ejp.1132
   Zhao XM, 2019, PHYSIOL RES, V68, P501, DOI 10.33549/physiolres.934084
NR 42
TC 4
Z9 6
U1 2
U2 23
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 1048-891X
EI 1525-1438
J9 INT J GYNECOL CANCER
JI Int. J. Gynecol. Cancer
PD MAY 15
PY 2023
VL 33
IS 5
BP 792
EP 801
DI 10.1136/ijgc-2022-004004
EA DEC 2022
PG 10
WC Oncology; Obstetrics & Gynecology
SC Oncology; Obstetrics & Gynecology
GA AU2W9
UT WOS:000903154300001
PM 36600535
DA 2026-01-16
ER

PT J
AU Liu, LM
   Yin, P
   Dong, YY
   Fan, Q
   Huai, YS
   Zhang, SJ
   Lv, SY
   Wang, XY
   Chen, YL
AF Liu, Lumin
   Yin, Ping
   Dong, Yiyue
   Fan, Qian
   Huai, Yisheng
   Zhang, Shijie
   Lv, Shunyi
   Wang, Xueyang
   Chen, Yuelai
TI Neurological mechanism and efficacy of acupuncture for breast cancer-related insomnia: a study protocol for randomized clinical trial
SO FRONTIERS IN NEUROLOGY
LA English
DT Article
DE breast cancer; insomnia; acupuncture; fMRI; randomized controlled trial; protocol
ID sleep; depression; anxiety; women
AB Background: Breast cancer survivors (BCSs) are at a higher risk of developing insomnia. The negative effects of cancer-related insomnia (CRI) include depression, anxiety, fatigue, aggressive pain, impaired immune functioning, decreased quality of life, and even increased cancer mortality. Although preliminary progress has been made in the treatment of CRI with acupuncture, the evidence is insufficient and the neurological mechanism underlying the effect of acupuncture is still unclear.Methods: The study employs a single-blinded, randomized, controlled trial design. A total of 80 participants will be randomly allocated in a 1:1 ratio to either the treatment group (n = 40) or the control group (n = 40). The former will receive acupuncture treatment, while the latter will receive sham acupuncture treatment. Both groups will receive 12 sessions over a 4-week period, three times per week (every other day), and each session will last for 30 min. Follow-up assessments will be conducted in week 8. The primary outcome will be the treatment response rate. Secondary outcomes include the change in Insomnia Severity Index (ISI), the treatment remission rate, actigraphy sleep assessment, Generalized Anxiety Disorder Scale (GAD-7), Patient Health Questionnaire-9 (PHQ-9), Quality of Life Core Scale (QLQ-C30), the weekly usage of remedial drugs, and functional magnetic resonance imaging (fMRI) analysis. Data for the outcomes will be collected at week 0 (the baseline), week 1 (the intervention period), week 4 (the post-treatment period), and week 8 (the follow-up period).Discussion: The objective of this study is to assess the efficacy of acupuncture for patients with CRI in comparison with sham acupuncture. Additionally, the research aims to explore the neuropathological mechanisms of CRI and provide the first evidence on the characteristics of acupuncture treatment using fMRI. We expect that the results of this study will provide valuable scientific evidence of acupuncture treatment for CRI.
C1 [Liu, Lumin; Yin, Ping; Dong, Yiyue; Fan, Qian; Huai, Yisheng; Zhang, Shijie; Lv, Shunyi; Wang, Xueyang; Chen, Yuelai] Shanghai Univ Tradit Chinese Med, LongHua Hosp, Shanghai, Peoples R China.
C3 Shanghai University of Traditional Chinese Medicine
RP Chen, YL (corresponding author), Shanghai Univ Tradit Chinese Med, LongHua Hosp, Shanghai, Peoples R China.
EM chenyuelai@163.com
FU Clinical Incubation Program of the National Medical Center of LongHua Hospital SHUTCM [GY202201]; Shanghai Shenkang Hospital Development Center demonstration research ward construction project [SHDC2022CRW006]; Shanghai Famous Old Chinese Medicine Experts Academic Experience Research Studio Construction Project [SHGZS-202232]; Shanghai Municipal Health Commission Health Industry Clinical Research Special Top Project [202340110]
CR Aggeli P, 2021, ASIA-PAC J ONCOL NUR, V8, P147, DOI 10.4103/apjon.apjon_65_20
   Unknown -, 1980, DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS, V3rd, P0, DOI 10.1176/APPI.BOOKS.9780890425596
   Bean HR, 2021, BEHAV SLEEP MED, V19, P814, DOI 10.1080/15402002.2020.1869005
   Feng Y, 2011, J TRADIT CHIN MED, V31, P199, DOI 10.1016/S0254-6272(11)60042-3
   Frisk J, 2012, SUPPORT CARE CANCER, V20, P715, DOI 10.1007/s00520-011-1134-8
   Gao L, 2014, EVID-BASED COMPL ALT, V2014, P0, DOI 10.1155/2014/465760
   Hajj A, 2021, BMC CANCER, V21, P0, DOI 10.1186/s12885-021-08615-9
   Husson O, 2020, ONCOLOGIST, V25, PE722, DOI 10.1634/theoncologist.2019-0348
   Kripke DF, 2012, BMJ OPEN, V2, P0, DOI 10.1136/bmjopen-2012-000850
   Kwak A, 2020, BREAST CANCER RES TR, V181, P269, DOI 10.1007/s10549-020-05635-0
   Li J, 2017, J MED IMAG HEALTH IN, V7, P1594, DOI 10.1166/jmihi.2017.2171
   Liu ZS, 2017, JAMA-J AM MED ASSOC, V317, P2493, DOI 10.1001/jama.2017.7220
   Madsen MT, 2015, SLEEP MED REV, V20, P73, DOI 10.1016/j.smrv.2014.07.002
   Morin CM, 2020, JAMA PSYCHIAT, V77, P1107, DOI 10.1001/jamapsychiatry.2020.1767
   Morin CM, 2011, SLEEP, V34, P601, DOI 10.1093/sleep/34.5.601
   Otte JL, 2011, CLIN NURSE SPEC, V25, P228, DOI 10.1097/NUR.0b013e318229950b
   Patel JS, 2019, DEPRESS ANXIETY, V36, P813, DOI 10.1002/da.22940
   Reynolds-Cowie P, 2021, BRIT J HEALTH PSYCH, V26, P33, DOI 10.1111/bjhp.12446
   Sung H, 2021, CA-CANCER J CLIN, V71, P209, DOI 10.3322/caac.21660
   Toussaint A, 2020, J AFFECT DISORDERS, V265, P395, DOI 10.1016/j.jad.2020.01.032
   Wang YK, 2020, BMC COMPLEMENT MED, V20, P0, DOI 10.1186/s12906-020-02969-6
   Zhang JL, 2023, BREAST CANCER RES, V25, P0, DOI 10.1186/s13058-023-01645-0
   Zhang JL, 2022, PHYTOMEDICINE, V102, P0, DOI 10.1016/j.phymed.2022.154160
   Zhang JL, 2021, INTEGR CANCER THER, V20, P0, DOI 10.1177/15347354211019103
   Zollman FS, 2012, J HEAD TRAUMA REHAB, V27, P135, DOI 10.1097/HTR.0b013e3182051397
NR 25
TC 4
Z9 4
U1 2
U2 14
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-2295
EI 
J9 FRONT NEUROL
JI Front. Neurol.
PD DEC 22
PY 2023
VL 14
IS 
BP 
EP 
DI 10.3389/fneur.2023.1278564
PG 9
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA EB7B2
UT WOS:001136503100001
PM 38187141
DA 2026-01-16
ER

PT J
AU Szymoniuk, M
   Chin, JH
   Domagalski, L
   Biszewski, M
   Józwik, K
   Kamieniak, P
AF Szymoniuk, Michal
   Chin, Jia-Hsuan
   Domagalski, Lukasz
   Biszewski, Mateusz
   Jozwik, Katarzyna
   Kamieniak, Piotr
TI Brain stimulation for chronic pain management: a narrative review of analgesic mechanisms and clinical evidence
SO NEUROSURGICAL REVIEW
LA English
DT Review
DE Chronic pain; Treatment; Deep brain stimulation; Motor cortex stimulation; Non-invasive brain stimulation
ID motor cortex stimulation; transcranial magnetic stimulation; cranial electrotherapy stimulation; chronic neuropathic pain; spinal-cord-injury; deep brain; double-blind; electrical-stimulation; follow-up; cluster headache
AB Chronic pain constitutes one of the most common chronic complaints that people experience. According to the International Association for the Study of Pain, chronic pain is defined as pain that persists or recurs longer than 3 months. Chronic pain has a significant impact on individuals' well-being and psychosocial health and the economy of healthcare systems as well. Despite the availability of numerous therapeutic modalities, treatment of chronic pain can be challenging. Only about 30% of individuals with non-cancer chronic pain achieve improvement from standard pharmacological treatment. Therefore, numerous therapeutic approaches were proposed as a potential treatment for chronic pain including non-opioid pharmacological agents, nerve blocks, acupuncture, cannabidiol, stem cells, exosomes, and neurostimulation techniques. Although some neurostimulation methods such as spinal cord stimulation were successfully introduced into clinical practice as a therapy for chronic pain, the current evidence for brain stimulation efficacy in the treatment of chronic pain remains unclear. Hence, this narrative literature review aimed to give an up-to-date overview of brain stimulation methods, including deep brain stimulation, motor cortex stimulation, transcranial direct current stimulation, repetitive transcranial magnetic stimulation, cranial electrotherapy stimulation, and reduced impedance non-invasive cortical electrostimulation as a potential treatment for chronic pain.
C1 [Szymoniuk, Michal; Chin, Jia-Hsuan; Domagalski, Lukasz; Biszewski, Mateusz; Jozwik, Katarzyna] Med Univ Lublin, Dept Neurosurg, Student Sci Assoc, Lublin, Poland.
   [Kamieniak, Piotr] Med Univ Lublin, Dept Neurosurg, Lublin, Poland.
C3 Medical University of Lublin; Medical University of Lublin
RP Domagalski, L (corresponding author), Med Univ Lublin, Dept Neurosurg, Student Sci Assoc, Lublin, Poland.
EM lukdom4@gmail.com
CR Abreu V, 2022, NEUROCHIRURGIE, V68, P52, DOI 10.1016/j.neuchi.2021.06.006
   Ahn H, 2020, J CLIN NEUROSCI, V77, P128, DOI 10.1016/j.jocn.2020.05.003
   Ahn H, 2017, BRAIN STIMUL, V10, P902, DOI 10.1016/j.brs.2017.05.007
   Alamri A, 2022, NEUROSURG CLIN N AM, V33, P311, DOI 10.1016/j.nec.2022.02.013
   André-Obadia N, 2014, PAIN PHYSICIAN, V17, P53
   Unknown -, 2022, MEDTR ANN FDA APPR S, V0, P0
   Ansari AH, 2021, ACS CHEM NEUROSCI, V12, P256, DOI 10.1021/acschemneuro.0c00785
   Antony AB, 2019, PAIN PHYSICIAN, V22, P447, DOI 10.36076/ppj/2019.22.447
   Attal N, 2021, REV NEUROL-FRANCE, V177, P606, DOI 10.1016/j.neurol.2020.07.003
   Avery N, 2022, BMJ, V4, P377
   Ayache SS, 2016, FRONT NEUROSCI-SWITZ, V10, P0, DOI 10.3389/fnins.2016.00147
   Baethge C, 2019, RES INTEGR PEER REV, V4, P0, DOI 10.1186/s41073-019-0064-8
   Bai Y, 2017, NEUROIMAGE-CLIN, V15, P702, DOI 10.1016/j.nicl.2017.01.025
   Belasen A, 2017, J NEUROSURG, V126, P397, DOI 10.3171/2016.2.JNS152231
   Bergeron D, 2021, BRAIN SCI, V11, P0, DOI 10.3390/brainsci11050639
   Bicego A, 2021, PLOS ONE, V16, P0, DOI 10.1371/journal.pone.0256001
   Bielewicz J, 2023, J CLIN MED, V12, P0, DOI 10.3390/jcm12041380
   Boggio PS, 2009, CLIN J PAIN, V25, P691, DOI 10.1097/AJP.0b013e3181af1414
   Breivik H, 2006, EUR J PAIN, V10, P287, DOI 10.1016/j.ejpain.2005.06.009
   Brietzke AP, 2016, FRONT NEUROSCI-SWITZ, V9, P0, DOI 10.3389/fnins.2015.00498
   Brunoni AR, 2017, BRAIN STIMUL, V10, P260, DOI 10.1016/j.brs.2016.11.005
   Brunye TT, 2021, FRONTIERS IN HUMAN NEUROSCIENCE, V1, P12
   Buchanan RJ, 2014, NEUROREPORT, V25, P715, DOI 10.1097/WNR.0000000000000174
   Bursali C, 2021, PAIN PHYSICIAN, V24, P0
   Cha M, 2017, SCI REP-UK, V7, P0, DOI 10.1038/s41598-017-08208-2
   Chang WJ, 2017, PLOS ONE, V12, P6
   Ching PY, 2022, FRONT PSYCHIATRY, V9, P13
   Choi GS, 2018, J REHABIL MED, V50, P246, DOI 10.2340/16501977-2321
   Choi GS, 2018, INT J NEUROSCI, V128, P110, DOI 10.1080/00207454.2017.1367682
   Chung CLH, 2020, ANN NEUROL, V88, P933, DOI 10.1002/ana.25881
   Cohen SP, 2021, LANCET, V397, P2082, DOI 10.1016/S0140-6736(21)00393-7
   Dahlhamer J, 2018, MMWR-MORBID MORTAL W, V67, P1001, DOI 10.15585/mmwr.mm6736a2
   Dale R, 2016, MED CLIN N AM, V100, P55, DOI 10.1016/j.mcna.2015.08.012
   De Risio L, 2020, TRANSL PSYCHIAT, V10, P0, DOI 10.1038/s41398-020-01055-2
   Deer TR, 2019, BRAIN SCI, V9, P0, DOI 10.3390/brainsci9020023
   Delavallée M, 2014, ACTA NEUROCHIR, V156, P2289, DOI 10.1007/s00701-014-2240-4
   Deuschl G, 2013, NEW ENGL J MED, V368, P2038, DOI 10.1056/NEJMc1303485
   Soler MD, 2010, BRAIN, V133, P2565, DOI 10.1093/brain/awq184
   Dondé C, 2017, PROG NEURO-PSYCHOPH, V78, P123, DOI 10.1016/j.pnpbp.2017.05.021
   Donnell A, 2015, BRAIN STIMUL, V8, P1085, DOI 10.1016/j.brs.2015.06.008
   Doyal A, 2022, STATPEARLS, V0, P0
   Els C, 2017, COCHRANE DB SYST REV, V10, P10
   FEIGHNER JP, 1973, J NERV MENT DIS, V157, P121, DOI 10.1097/00005053-197308000-00004
   Fitzgibbon BM, 2018, EUR J PAIN, V22, P1255, DOI 10.1002/ejp.1213
   Fontaine D, 2010, J HEADACHE PAIN, V11, P23, DOI 10.1007/s10194-009-0169-4
   Fontaine D, 2009, J NEUROSURG, V110, P251, DOI 10.3171/2008.6.17602
   Fregni F, 2018, BRAIN STIMUL, V11, P299, DOI 10.1016/j.brs.2017.11.009
   Fregni F, 2006, ARTHRITIS RHEUM-US, V54, P3988, DOI 10.1002/art.22195
   Fregni F, 2006, PAIN, V122, P197, DOI 10.1016/j.pain.2006.02.023
   Freire RC, 2020, ADV EXP MED BIOL, V1191, P331, DOI 10.1007/978-981-32-9705-0_18
   Fricová J, 2013, PHYSIOL RES, V62, PS125, DOI 10.33549/physiolres.932575
   Gabis L, 2009, J REHABIL MED, V41, P256, DOI 10.2340/16501977-0315
   Galletta EE, 2011, TOP STROKE REHABIL, V18, P87, DOI 10.1310/tsr1802-87
   George B, 2019, SUPPORT CARE CANCER, V27, P3105, DOI 10.1007/s00520-019-04828-8
   Gopalakrishnan R, 2018, J NEUROPHYSIOL, V119, P2118, DOI 10.1152/jn.00830.2017
   Grider J, 2016, PAIN PHYSICIAN, V19, PE33, DOI 10.36076/ppj/2016.19.e33
   Gruber D, 2018, BRAIN STIMUL, V11, P1368, DOI 10.1016/j.brs.2018.08.006
   Hagenacker T, 2014, J HEADACHE PAIN, V15, P0, DOI 10.1186/1129-2377-15-78
   Hamani C, 2021, BRAIN, V144, P2994, DOI 10.1093/brain/awab189
   Hargrove JB, 2012, PAIN MED, V13, P115, DOI 10.1111/j.1526-4637.2011.01292.x
   Harvey MP, 2017, CLIN INTERV AGING, V12, P937, DOI 10.2147/CIA.S133423
   Hazime FA, 2017, EUR J PAIN, V21, P1132, DOI 10.1002/ejp.1037
   Helm S, 2021, PAIN THER, V10, P985, DOI 10.1007/s40122-021-00306-4
   Henssen D, 2020, SCI REP-UK, V10, P0, DOI 10.1038/s41598-020-64177-z
   Henssen DJHA, 2018, PLOS ONE, V13, P0, DOI 10.1371/journal.pone.0191774
   Hylands-White N, 2017, RHEUMATOL INT, V37, P29, DOI 10.1007/s00296-016-3481-8
   Im SH, 2015, STEREOT FUNCT NEUROS, V93, P212, DOI 10.1159/000381557
   Inst Med, 2011, RELIEVING PAIN IN AMERICA: A BLUEPRINT FOR TRANSFORMING PREVENTION, V0, P0
   Isagulyan E D, 2015, ZH VOPR NEIROKHIR IM N N BURDENKO, V79, P46, DOI 10.17116/neiro201579646-60
   Ivanishvili Z, 2017, NEUROMODULATION, V20, P497, DOI 10.1111/ner.12610
   Jensen MP, 2013, CLIN NEUROPHYSIOL, V124, P2016, DOI 10.1016/j.clinph.2013.04.009
   Jiang WL, 2022, ASIAN J PSYCHIATR, V73, P0, DOI 10.1016/j.ajp.2022.103100
   Kalso E, 2004, PAIN, V112, P372, DOI 10.1016/j.pain.2004.09.019
   Kang HW, 2020, J INT MED RES, V48, P0, DOI 10.1177/0300060520939370
   Katta MR, 2022, J ONCOL PHARM PRACT, V28, P1859, DOI 10.1177/10781552221098437
   Kaye AD, 2018, CURR PAIN HEADACHE R, V22, P0, DOI 10.1007/s11916-018-0674-8
   Khedr EM, 2017, BRAIN STIMUL, V10, P893, DOI 10.1016/j.brs.2017.06.006
   Kim YJ, 2013, ANN REHABIL MED-ARM, V37, P766, DOI 10.5535/arm.2013.37.6.766
   Kirsch DL, 2013, PSYCHIAT CLIN N AM, V36, P169, DOI 10.1016/j.psc.2013.01.006
   Klein J, 2020, J NEUROSURG, V134, P1244, DOI 10.3171/2019.12.JNS192261
   Knotkova H, 2021, LANCET, V397, P2111, DOI 10.1016/S0140-6736(21)00794-7
   Kogan M, 2019, NEUROSURG CLIN N AM, V30, P137, DOI 10.1016/j.nec.2019.01.001
   Komatsu T, 2022, J NEUROL SCI, V443, P0, DOI 10.1016/j.jns.2022.120473
   Kumar A, 2021, NEUROL SCI, V42, P131, DOI 10.1007/s10072-020-04505-3
   Kustermans L, 2017, J CRANIO MAXILL SURG, V45, P39, DOI 10.1016/j.jcms.2016.10.014
   Lagueux É, 2018, CLIN J PAIN, V34, P145, DOI 10.1097/AJP.0000000000000522
   Lanska DJ, 2002, NEUROLOGY, V58, P452, DOI 10.1212/WNL.58.3.452
   Lefaucheur JP, 2014, CLIN NEUROPHYSIOL, V125, P2150, DOI 10.1016/j.clinph.2014.05.021
   Lempka SF, 2017, ANN NEUROL, V81, P653, DOI 10.1002/ana.24927
   Lenoir C, 2018, J PHYSIOL-LONDON, V596, P4767, DOI 10.1113/JP276359
   Leung A, 2016, NEUROMODULATION, V19, P133, DOI 10.1111/ner.12364
   Li JP, 2021, PAIN PHYSICIAN, V24, P533
   LIPPOLD OCJ, 1964, BRIT J PSYCHIAT, V110, P768, DOI 10.1192/bjp.110.469.768
   Litak J, 2022, CANCERS, V14, P0, DOI 10.3390/cancers14194599
   Lubejko ST, 2022, FRONT SYST NEUROSCI, V14, P132
   Luedtke K, 2015, BMJ, V16, P350
   Ma QY, 2023, INT J CLIN HLTH PSYC, V23, P0, DOI 10.1016/j.ijchp.2022.100355
   Maarrawi J, 2007, NEUROLOGY, V69, P827, DOI 10.1212/01.wnl.0000269783.86997.37
   Marques A, 2013, NEUROLOGY, V81, P633, DOI 10.1212/WNL.0b013e3182a08d00
   Martin DM, 2011, J AFFECT DISORDERS, V134, P459, DOI 10.1016/j.jad.2011.05.018
   Mattoo B, 2019, INDIAN J MED RES, V150, P73, DOI 10.4103/ijmr.IJMR_97_18
   Meints SM, 2018, PROG NEURO-PSYCHOPH, V87, P168, DOI 10.1016/j.pnpbp.2018.01.017
   Mendonca ME, 2016, FRONT HUM NEUROSCI, V10, P0, DOI 10.3389/fnhum.2016.00068
   Mills SEE, 2019, BRIT J ANAESTH, V123, PE273, DOI 10.1016/j.bja.2019.03.023
   Mischoulon D, 2015, J PSYCHIATR RES, V70, P98, DOI 10.1016/j.jpsychires.2015.08.016
   Moisset X, 2021, REV NEUROL-FRANCE, V177, P834, DOI 10.1016/j.neurol.2021.07.004
   Moisset X, 2020, J NEURAL TRANSM, V127, P673, DOI 10.1007/s00702-019-02092-y
   Mori F, 2010, J PAIN, V11, P436, DOI 10.1016/j.jpain.2009.08.011
   Navarro-López V, 2022, EUR J PHYS REHAB MED, V58, P738, DOI 10.23736/S1973-9087.22.07439-1
   Ngernyam N, 2015, CLIN NEUROPHYSIOL, V126, P382, DOI 10.1016/j.clinph.2014.05.034
   Nicholas M, 2019, PAIN, V160, P28, DOI 10.1097/j.pain.0000000000001390
   Nurmikko T, 2016, NEUROMODULATION, V19, P669, DOI 10.1111/ner.12444
   OConnell NE, 2018, COCHRANE DB SYST REV, V4, P4
   ONeill F, 2018, J PAIN RES, V11, P3117, DOI 10.2147/JPR.S186079
   Ojala J, 2022, NEUROMODULATION, V25, P538, DOI 10.1111/ner.13496
   Ostergard T, 2014, NEUROSURG CLIN N AM, V25, P693, DOI 10.1016/j.nec.2014.06.004
   Pagano RL, 2012, PAIN, V153, P2359, DOI 10.1016/j.pain.2012.08.002
   Parravano DC, 2019, NEUROSURGERY, V84, P451, DOI 10.1093/neuros/nyy060
   Poreisz C, 2007, BRAIN RES BULL, V72, P208, DOI 10.1016/j.brainresbull.2007.01.004
   Quesada C, 2020, PAIN, V161, P718, DOI 10.1097/j.pain.0000000000001760
   Radic JAE, 2015, CAN J NEUROL SCI, V42, P401, DOI 10.1017/cjn.2015.292
   Ramos-Fresnedo A, 2022, NEUROMODULATION, V25, P211, DOI 10.1016/j.neurom.2021.10.025
   Rapisarda A, 2021, EUR NEUROL, V84, P151, DOI 10.1159/000514827
   Rasche D, 2016, NEUROSURGERY, V79, P655, DOI 10.1227/NEU.0000000000001353
   Ren JX, 2019, CURR STEM CELL RES T, V14, P644, DOI 10.2174/1574888X14666190912162504
   Rintala DH, 2010, PARKINSONS DIS-US, V2010, P0, DOI 10.4061/2010/569154
   Sabbagh M, 2020, ALZHEIMERS DEMENT, V16, P641, DOI 10.1016/j.jalz.2019.08.197
   Sachs AJ, 2014, NEUROMODULATION, V17, P303, DOI 10.1111/ner.12181
   Säisänen L, 2022, NEUROPHYSIOL CLIN, V52, P95, DOI 10.1016/j.neucli.2022.03.001
   Sakrajai P, 2014, CLIN J PAIN, V30, P1076, DOI 10.1097/AJP.0000000000000069
   Sanger TD, 2020, DEV MED CHILD NEUROL, V62, P28, DOI 10.1111/dmcn.14295
   Saxena V, 2021, CLIN PSYCHOPHARM NEU, V19, P589, DOI 10.9758/cpn.2021.19.4.589
   Schoenen J, 2013, CEPHALALGIA, V33, P816, DOI 10.1177/0333102412473667
   Shekelle P, 2018, EFF RISKS CRANIAL EL, V0, P0
   Shekelle PG, 2018, ANN INTERN MED, V168, P414, DOI 10.7326/M17-1970
   Shirvalkar P, 2018, FRONT COMPUT NEUROSC, V12, P0, DOI 10.3389/fncom.2018.00018
   Silva GD, 2015, J NEUROINFLAMM, V12, P0, DOI 10.1186/s12974-014-0216-1
   Sims-Williams H, 2017, NEUROIMAGE, V146, P833, DOI 10.1016/j.neuroimage.2016.08.038
   Sluka KA, 2016, NEUROSCIENCE, V338, P114, DOI 10.1016/j.neuroscience.2016.06.006
   Sobstyl M, 2020, SEIZURE-EUR J EPILEP, V81, P58, DOI 10.1016/j.seizure.2020.07.022
   Sokal P, 2019, J PAIN RES, V12, P1863, DOI 10.2147/JPR.S195867
   Sokal P, 2015, ADV CLIN EXP MED, V24, P289, DOI 10.17219/acem/40452
   Son BC, 2014, STEREOT FUNCT NEUROS, V92, P218, DOI 10.1159/000362933
   Sonmez AI, 2019, PSYCHIAT RES, V273, P770, DOI 10.1016/j.psychres.2018.12.041
   Souto G, 2014, CLIN J PAIN, V30, P809, DOI 10.1097/AJP.0000000000000037
   De Souza CG, 2021, BRAIN STIMUL, V14, P541, DOI 10.1016/j.brs.2021.02.015
   Lopes PSS, 2019, BEHAV BRAIN FUNCT, V15, P0, DOI 10.1186/s12993-019-0156-0
   Szewczyk AK, 2023, DIAGNOSTICS, V13, P0, DOI 10.3390/diagnostics13010108
   Szymoniuk M, 2023, CELLS-BASEL, V12, P0, DOI 10.3390/cells12010120
   Tan G, 2011, J SPINAL CORD MED, V34, P285, DOI 10.1179/2045772311Y.0000000008
   Tanei T, 2018, NEUROL MED-CHIR, V58, P422, DOI 10.2176/nmc.oa.2018-0106
   Taylor AG, 2013, PAIN MANAG NURS, V14, P327, DOI 10.1016/j.pmn.2011.07.002
   Thair H, 2017, FRONT NEUROSCI-SWITZ, V11, P0, DOI 10.3389/fnins.2017.00641
   Thibaut A, 2017, NEUROSCI LETT, V658, P19, DOI 10.1016/j.neulet.2017.08.024
   Treede RD, 2015, PAIN, V156, P1003, DOI 10.1097/j.pain.0000000000000160
   Tronnier V, 2013, HANDB CLIN NEUROL, V116, P343, DOI 10.1016/B978-0-444-53497-2.00028-0
   TSUBOKAWA T, 1991, PACE, V14, P131, DOI 10.1111/j.1540-8159.1991.tb04058.x
   Umezaki Y, 2016, BRAIN STIMUL, V9, P234, DOI 10.1016/j.brs.2015.10.005
   Urits I, 2020, BEST PRAC RES-CL ANA, V34, P463, DOI 10.1016/j.bpa.2020.06.004
   Uzair M, 2022, NEURAL REGEN RES, V17, P251, DOI 10.4103/1673-5374.317962
   van Dun K, 2016, FRONT HUM NEUROSCI, V10, P0, DOI 10.3389/fnhum.2016.00199
   VENTAFRIDDA V, 1985, INT J TISSUE REACT, V7, P93
   Villamar MF, 2013, J PAIN, V14, P371, DOI 10.1016/j.jpain.2012.12.007
   Volz MS, 2016, PAIN, V157, P429, DOI 10.1097/j.pain.0000000000000386
   Winkelmueller M, 2016, J NEUROL SURG PART A, V77, P63, DOI 10.1055/s-0035-1558419
   Woods AJ, 2016, CLIN NEUROPHYSIOL, V127, P1031, DOI 10.1016/j.clinph.2015.11.012
   Wrigley PJ, 2013, PAIN, V154, P2178, DOI 10.1016/j.pain.2013.06.045
   Wylde V, 2017, BJS-BRIT J SURG, V104, P1293, DOI 10.1002/bjs.10601
   Xiong HY, 2022, FRONT MOL NEUROSCI, V26, P15
   Yang L, 2018, CURR MED SCI, V38, P482, DOI 10.1007/s11596-018-1904-3
   Yennurajalingam S, 2018, J PAIN SYMPTOM MANAG, V55, P198, DOI 10.1016/j.jpainsymman.2017.08.027
   Yokoi Y, 2018, CLIN EEG NEUROSCI, V49, P93, DOI 10.1177/1550059417732247
   Yong RJ, 2022, PAIN, V163, PE328, DOI 10.1097/j.pain.0000000000002291
   Yu BB, 2020, AM J PHYS MED REHAB, V99, P811, DOI 10.1097/PHM.0000000000001421
   Zhang HJ, 2022, CURR ONCOL REP, V24, P223, DOI 10.1007/s11912-021-01166-z
   Zhang XL, 2018, STEREOT FUNCT NEUROS, V96, P239, DOI 10.1159/000492056
   Zhang XL, 2017, NEUROMODULATION, V20, P492, DOI 10.1111/ner.12547
   Zhao RH, 2018, FRONT CELL NEUROSCI, V12, P0, DOI 10.3389/fncel.2018.00107
   Zhuo M, 2016, TRENDS NEUROSCI, V39, P136, DOI 10.1016/j.tins.2016.01.006
NR 180
TC 16
Z9 22
U1 3
U2 22
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0344-5607
EI 1437-2320
J9 NEUROSURG REV
JI Neurosurg. Rev.
PD MAY 29
PY 2023
VL 46
IS 1
BP 
EP 
DI 10.1007/s10143-023-02032-1
PG 32
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA H8WZ4
UT WOS:000998711900001
PM 37247036
DA 2026-01-16
ER

PT J
AU Lu, C
   Li, G
   Deng, D
   Li, R
   Li, X
   Feng, X
   Wu, T
   Shao, X
   Chen, W
AF Lu, Chao
   Li, Guangliang
   Deng, Dehou
   Li, Rongrong
   Li, Xiaoyu
   Feng, Xukang
   Wu, Taoping
   Shao, Xiying
   Chen, Weiji
TI Efficacy of electroacupuncture in the treatment of peripheral neuropathy caused
SO Frontiers in neurology
LA English
DT Journal Article
DE Utidelone (UTD1); breast cancer; chemotherapy-induced peripheral neuropathy (CIPN); electroacupuncture (EA); peripheral neuropathy (PN); protocol
AB INTRODUCTION: Utidelone (UTD1) is a new chemotherapeutic drug for recurrent or  metastatic breast cancer. However, it usually leads to severe peripheral  neuropathy (PN) and causes numbness of the hands and feet and significant pain in  patients' life. Electroacupuncture (EA) is considered beneficial in improving PN  and relieving numbness of the hands and feet. This trial aims to evaluate the  therapeutic effect of EA on PN caused by UTD1 in patients with advanced breast  cancer. METHODS AND ANALYSIS: This study is a prospective randomized controlled  trial. A total of 70 patients with PN caused by UTD1 will be randomly assigned to  the EA treatment group and the control group in a ratio of 1:1. The patients in  the EA treatment group will receive 2 Hz EA three times a week for 4 weeks. The  patients in the control group will take mecobalamin (MeCbl) tablets orally, one  tablet each, three times a day for 4 weeks. The main outcome measures will be the  evaluation scale of peripheral neurotoxicity of chemotherapeutic drugs according  to the European Organization for Research and Treatment of Cancer Quality of Life  Questionnaire-CIPN 20-item (EORTC QLQ-CIPN20) and the peripheral neurotoxicity  assessment rating according to NCI CTCAE version 5.0. Secondary outcomes will be  the quality of life scale according to the European Organization for Research and  Treatment of Cancer Core Quality of Life Questionnaire (EORTC QLQ-C30). The  results will be evaluated at baseline, post-treatment phase, and follow-up. All  major analyses will be based on the intention-to-treat principle. ETHICS AND  DISSEMINATION: This protocol was approved by the Medical Ethics Committee of  Zhejiang Cancer Hospital on 26 July 2022. The license number is IRB-2022-425.  This study will provide clinical efficacy data on EA in the treatment of PN  caused by UTD1 and will help to prove whether EA is an effective and safe  therapy. The study results will be shared with healthcare professionals through  the publication of manuscripts and conference reports. TRIAL REGISTRATION NUMBER:  ChiCTR2200062741.
C1 Department of Traditional Chinese Medicine, Zhejiang Cancer Hospital, Hangzhou, China.
   Department of Breast Medical Oncology, Zhejiang Cancer Hospital, Hangzhou, China.
   Department of Traditional Chinese Medicine, Zhejiang Cancer Hospital, Hangzhou, China.
   Department of Acupuncture and Moxibustion, The Third Affiliated Hospital of Zhejiang Chinese Medical University (Zhongshan Hospital of Zhejiang Province),Hangzhou, China.
   Department of Acupuncture and Moxibustion, The Third Affiliated Hospital of Zhejiang Chinese Medical University (Zhongshan Hospital of Zhejiang Province),Hangzhou, China.
   The Third Clinical Medical College, Zhejiang Chinese Medical University, 
   The Third Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, China.
   The Third Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, China.
   Department of Breast Medical Oncology, Zhejiang Cancer Hospital, Hangzhou, China.
   Department of Acupuncture and Moxibustion, The Third Affiliated Hospital of Zhejiang Chinese Medical University (Zhongshan Hospital of Zhejiang Province),Hangzhou, China.
NR 0
TC 0
SN 1664-229
EI 1664-229
J9 Front Neurol
PD FEB 28
PY 2023
VL 14
IS 
BP 1065635
EP 1065635
DI 10.3389/fneur.2023.1065635
PG 0
UT PubMed:36846114
PM 36846114
DA 2023-02-28
ER

PT J
AU Zheng, J
   Yang, F
   Yuan, PW
   Fan, JJ
   Zheng, XH
   Zhu, R
   Li, YL
AF Zheng, Jie
   Yang, Feng
   Yuan, Pu-Wei
   Fan, Jing-Jie
   Zheng, Xiao-Hui
   Zhu, Rui
   Li, Yang-le
TI [Effect of electroacupuncture on the expression of Iba-1 in spinal dorsal horn
SO Zhen ci yan jiu = Acupuncture research
LA chi
DT Journal Article
DE Electroacupuncture; Hippocampus; Ionized calcium binding adapter molecule 1; Knee osteoarthritis; Pain; Spinal dorsal horn
AB OBJECTIVE: To observe the effect of electroacupuncture(EA) on pain-ralated  behaviors, morphology of hippocampus, concentrations of inflammatory cytokines  and expression of ionized calcium binding adapter molecule 1(Iba-1) in dorsal  horn of the spinal cord and the hippocampus, and brain-derived neurotrophic  factor (BDNF) in hippocampus of rats with knee osteoarthritis (KOA), so as to  explore the mechanism of EA in improving chronic pain of KOA. METHODS: Forty SD  rats were randomly divided into blank group, saline group, model group and EA  group, with 10 rats in each group. Monosodium iodoacetate(MIA, 80 mg/mL, 50 μL)  was injected into the left knee joint cavity of rats in the model group and EA  group to establish the chronic pain model of KOA, while the same volume of normal  saline was injected into the left knee joint cavity of rats in the saline group.  Rats in the EA group received EA stimulation(2 Hz/100 Hz, 1-2 mA) at left  "Yanglingquan"(GB34) and "Neixiyan"(EX-LE4) for 15 min, 14 d after MIA injection.  The treatment was given once daily, 5 d as 1 session and 2 sessions of treatment  were required. Methanical withdrawl threshold(MWT) and weight-bearing capacity  tests on left hind limbs were carried out 1 d before, 7 d，14 d, 20 d and 26 d  after MIA injection. At the 27(th) day, rats were sacrificed and HE staining was  used to observe the morphology of hippocampal CA1 area. Concentrations of  interleukin(IL)-1β and tumor necrosis factor(TNF)-α in the left L3-L5 spinal  dorsal horn and hippocampal CA1 area were detected by ELISA, the expressions of  Iba-1 in the spinal dorsal horn and hippo-campal CA1 area were detected by  immunofluorescence, and the expression of BDNF in left hippocampal CA1 area was  detected by Western blot. RESULTS: The HE staining results of the hippocampal CA1  area showed reduced number of neurons, unclear cell contour and boundary between  nucleus and cytoplasm, and nuclear pyknosis in the model group, which was  relatively milder in the EA group. Compared with the blank group, MWT and  weight-bearing capacity of rats' left hind limbs, and expression of BDNF protein  in hippocampal CA1 area were significantly decreased (P<0.01), while the contents  of IL-1β and TNF-α, the expression of Iba-1 in spinal dorsal horn and hippocampal  CA1 area were significantly increased (P<0.01) in the model group. In comparison  with the model group, MWT and weight-bearing capacity of rats' left hind limbs,  and protein expression of BDNF in hippocampal CA1 area were significantly  increased (P<0.01), while the contents of IL-1β and TNF-α, and the expression of  Iba-1 protein in spinal dorsal horn and hippocampal CA1 area were significantly  decreased after EA intervention(P<0.01). CONCLUSION: EA at GB34 and EX-LE4 can  alleviate the pain-related behaviors of KOA rats. The mechanism might be related  to the inhibition of inflammatory reaction mediated by microglia in spinal dorsal  horn and hippocampus, and the up-regulation of BDNF expression in hippocampus.
C1 Institution of Acupuncture-moxibustion and Tuina, Shaanxi University of Chinese Medicine, Xianyang 712046, Shaanxi Province, China
   Shaanxi Key Laboratory ofAcupuncture and Herbal Medicine, Xianyang 712046, Shaanxi Province.
   First Clinical Medical College, Shaanxi University of Chinese Medicine, Xianyang 712046, Shaanxi Province.
   First Clinical Medical College, Shaanxi University of Chinese Medicine, Xianyang 712046, Shaanxi Province.
   Institution of Acupuncture-moxibustion and Tuina, Shaanxi University of Chinese Medicine, Xianyang 712046, Shaanxi Province, China.
   Institution of Acupuncture-moxibustion and Tuina, Shaanxi University of Chinese Medicine, Xianyang 712046, Shaanxi Province, China.
   Institution of Acupuncture-moxibustion and Tuina, Shaanxi University of Chinese Medicine, Xianyang 712046, Shaanxi Province, China.
   Institution of Acupuncture-moxibustion and Tuina, Shaanxi University of Chinese Medicine, Xianyang 712046, Shaanxi Province, China.
NR 0
TC 0
SN 
EI 1000-060
J9 Zhen Ci Yan Jiu
PD MAY 30
PY 2023
VL 48
IS 5
BP 431
EP 7
DI 10.13702/j.1000-0607.20211398
PG -424
WC Rats; Animals; Rats, Sprague-Dawley; Chronic Pain; Brain-Derived Neurotrophic Factor; metabolism; Osteoarthritis, Knee; genetics; Electroacupuncture; methods; Tumor Necrosis Factor-alpha; metabolism; Hippocampus; metabolism; Spinal Cord Dorsal Horn; metabolism
UT PubMed:37247855
PM 37247855
DA 2023-05-30
ER

PT J
AU Li, X
   Zhi, L
   Han, KY
   Li, SQ
   Ahmad, K
   Seluzicki, C
   Wang, R
   Bao, T
AF Li, Xiaotong
   Zhi, Lilly
   Han, Katherine Y
   Li, Susan Q
   Ahmad, Khalada
   Seluzicki, Christina
   Wang, Rui
   Bao, Ting
TI Impact of Baseline Expectancy on Outcome Prediction of Real and Sham Acupuncture
SO Integrative cancer therapies
LA English
DT Journal Article
DE acupuncture; acupuncture expectancy; chemotherapy-induced peripheral neuropathy; pain; sham acupuncture
AB BACKGROUND: Chemotherapy-induced peripheral neuropathy (CIPN) pain significantly  worsens cancer survivors' quality of life. Expectancy may play an important role  in acupuncture response. We sought to explore whether expectancy predicts pain  outcome in real acupuncture (RA) and sham acupuncture (SA) in cancer survivors.  METHODS: We analyzed data from a randomized clinical trial that evaluated the  effect of RA on CIPN symptoms compared to SA and wait list control (WLC) in 75  cancer survivors. This secondary analysis was limited to CIPN pain measured by  the Numeric Rating Scale (NRS), graded from 0 to 10. Interventions were delivered  over 8 weeks. SA was implemented using a combination of non-acupuncture points  and a non-insertion procedure. Patient expectancy was measured by the Acupuncture  Expectancy Scale (AES) 3 times during the study. We used a linear regression  model to evaluate if the NRS score was associated with the baseline AES score at  the end of treatment (week 8), adjusting for baseline NRS score. RESULTS: AES was  similar among 3 groups at baseline (RA: 11.8 ± 2.7; SA: 12.1 ± 3.8.; WLC:  14.6 ± 4.2; P = .062). Baseline AES was not found to be significantly associated  with the week 8 NRS score among patients in all RA, SA, and WLC groups (all  P > .05). However, we found a trend that higher baseline AES predicted lower NRS  score at week 8 in the SA group: a one-point higher score on baseline expectancy  was associated with a 0.3-point reduction in NRS pain score (P = .059) at week 8.  CONCLUSIONS: The association of baseline expectancy and acupuncture response was  similar between RA and SA. However, SA seemed to rely more on expectancy than RA.  Further studies with larger sample sizes are needed to confirm this finding.
C1 Memorial Sloan Kettering Cancer Center, New York, NY, USA.
   Ward Melville High School, East Setauket, NY, USA.
   Memorial Sloan Kettering Cancer Center, New York, NY, USA.
   Memorial Sloan Kettering Cancer Center, New York, NY, USA.
   AdventHealth Cancer Institute Clinical Research, AdventHealth Great Lakes Region, Hinsdale, IL, USA.
   Memorial Sloan Kettering Cancer Center, New York, NY, USA.
   Memorial Sloan Kettering Cancer Center, New York, NY, USA.
   Memorial Sloan Kettering Cancer Center, New York, NY, USA.
NR 0
TC 0
SN 1552-695
EI 1534-735
J9 Integr Cancer Ther
PD JAN 25
PY 2023
VL 22
IS 
BP 15347354221149992
EP 15347354221149992
DI 10.1177/15347354221149992
PG 1
WC Humans; Quality of Life; Acupuncture Therapy; methods; Pain; Peripheral Nervous System Diseases; chemically induced; Neoplasms; Cancer Survivors; Antineoplastic Agents; adverse effects; Treatment Outcome
UT PubMed:36691937
PM 36691937
DA 2023-01-25
ER

PT J
AU Ge, W
   Qu, Y
   Hou, T
   Zhang, J
   Li, Q
   Yang, L
   Cao, L
   Li, J
   Zhang, S
AF Ge, Wanbao
   Qu, Yuan
   Hou, Tingting
   Zhang, Jiayin
   Li, Qiuju
   Yang, Lili
   Cao, Lanqing
   Li, Jindong
   Zhang, Shanyong
TI Case report: Surgical treatment of a primary giant epithelioid
SO Frontiers in oncology
LA English
DT Journal Article
DE epithelioid hemangioendothelioma; giant; total en-bloc spondylectomy; vascular neoplasm; vertebral lesion
AB BACKGROUND: Epithelioid hemangioendothelioma (EHE) is an extremely uncommon  malignant neoplasm that originates from vascular endothelial or pre-endothelial  cells. In this report, we present the case of patient who was diagnosed with a  primary giant EHE of the spine and underwent treatment with total en-bloc  spondylectomy (TES). CASE PRESENTATION: A 43-year-old male patient with a history  of he presented to our hospital with chronic and progressive back pain. Physical  examination revealed weakened sensation of acupuncture and touch on the left  costal arch, while relatively normal neurological functions were preserved.  Radiological examinations identified a giant destructive soft tissue lesion  occupying the T8 vertebral region, with moderate destruction of the pedicle and  lamina, as well as the 7(th) left rib. A preoperative biopsy of the 8th vertebra  resulted in a diagnosis of epithelioid hemangioendothelioma(EHE). Postoperative  immunohistochemical and pathological reports confirmed the presence of EHE in the  left ribs and T8 ribs. The patient underwent resection of the 7th left rib and  posterior pedicle screw fixation with 8 pairs of screws and a titanium mesh cage.  Subsequently, thoracic en bloc spondylectomy was performed on the T8 vertebra.  The patient did not receive radiation or chemotherapy following surgery. Over a  period of 3 years, the patient remained free of disease and relapse. CONCLUSION:  The use of transarterial embolization with spherical embolic agents (TES) has  been demonstrated to be a safe, effective, and reliable treatment option for  hepatic epithelioid hemangioendothelioma (EHE). Nevertheless, it is crucial to  conduct long-term follow-up of this patient in order to assess their clinical  outcome.
C1 Department of Spine Surgery, Second Affiliated Hospital of Jilin University, Changchun, Jilin, China.
   Department of Spine Surgery, Second Affiliated Hospital of Jilin University, Changchun, Jilin, China.
   Department of Spine Surgery, Second Affiliated Hospital of Jilin University, Changchun, Jilin, China.
   Department of Spine Surgery, Second Affiliated Hospital of Jilin University, Changchun, Jilin, China.
   Department of Spine Surgery, Second Affiliated Hospital of Jilin University, Changchun, Jilin, China.
   Department of Spine Surgery, Second Affiliated Hospital of Jilin University, Changchun, Jilin, China.
   Department of Pathology, Second Affiliated Hospital of Jilin University, Changchun, Jilin, China.
   Department of Thoracic Surgery, Second Affiliated Hospital of Jilin University, Changchun, Jilin, China.
   Department of Spine Surgery, Second Affiliated Hospital of Jilin University, Changchun, Jilin, China.
NR 0
TC 0
SN 2234-943
EI 2234-943
J9 Front Oncol
PD APR 15
PY 2023
VL 13
IS 
BP 1109643
EP 1109643
DI 10.3389/fonc.2023.1109643
PG 0
UT PubMed:37056332
PM 37056332
DA 2023-04-15
ER

PT J
AU Hoang, BX
   Han, BO
   Tran, HQ
   Fang, WH
   Tran, HD
AF Hoang, Ba X
   Han, B O
   Tran, Hung Q
   Fang, William H
   Tran, Hau D
TI Successful Phytotherapy for Acute Refractory Radiation Cystitis in a Cervical
SO Cancer diagnosis & prognosis
LA English
DT Journal Article
DE Ich Nieu Khang; Radiation cystitis; cervical cancer; food supplements; phytotherapy
AB BACKGROUND/AIM: Radiation cystitis is a frequent complication that can occur  after therapeutic irradiation of pelvic cancers. The current treatment for this  condition is complex and often ineffective. CASE REPORT: We present a clinical  case of a 54-year-old patient diagnosed with small cell cervical cancer FIGO  stage IIIC who developed grade 2-3 radiation cystitis following post-operational  chemoradiation therapy. The patient exhibited increased urinary urgency and  frequency, dysuria, and low abdominal pain, which failed to respond to  acupuncture and corticosteroid treatments. A course of Ich Nieu Khang  phytotherapy tablets, resulted in significant improvement of symptoms within 24  hours of initiation. The symptoms resolved completely within 10 days, and  ultrasonography documented a marked decrease in bladder wall thickening and  improved bladder evacuation function. The phytotherapy was well-tolerated, and no  side-effects were observed during the 60-day treatment period. CONCLUSION: These  findings suggest that phytotherapy may be viable for managing radiation cystitis.  However, further controlled clinical trials are needed to confirm the efficacy of  Ich Nieu Khang and promote its broader clinical applications.
C1 Nimni-Cordoba Tissue Engineering and Drug Discovery Laboratory, Department of Surgery, Keck School of Medicine, University of Southern California, Los Angeles,CA, U.S.A.
   Nimni-Cordoba Tissue Engineering and Drug Discovery Laboratory, Department of Surgery, Keck School of Medicine, University of Southern California, Los Angeles,CA, U.S.A.
   Department of Oncology, Phenikaa University, Hanoi, Vietnam.
   Department of Translational Research, Western University of Health Sciences, Pomona, CA, U.S.A.
   Department of Oncology, National Children Hospital of Vietnam, Hanoi, Vietnam.
NR 0
TC 0
SN 2732-778
EI 
J9 Cancer Diagn Progn
PD MAY 12
PY 2023
VL 3
IS 3
BP 383
EP 386
DI 10.21873/cdp.10228
PG 3
UT PubMed:37168975
PM 37168975
DA 2023-05-12
ER

PT J
AU Lam, CS
   Zhou, K
   Loong, HH
   Chung, VC
   Ngan, CK
   Cheung, YT
AF Lam, Chun Sing
   Zhou, Keary
   Loong, Herbert Ho-Fung
   Chung, Vincent Chi-Ho
   Ngan, Chun-Kit
   Cheung, Yin Ting
TI The Use of Traditional, Complementary, and Integrative Medicine in Cancer:
SO Journal of medical Internet research
LA English
DT Journal Article
DE TCIM; cancer; cancer care; complementary; forums, digital health; integrative; machine learning; perceptions; social media; traditional; traditional, complementary, and integrative medicine
AB BACKGROUND: Patients with cancer are increasingly using forums and social media  platforms to access health information and share their experiences, particularly  in the use of traditional, complementary, and integrative medicine (TCIM).  Despite the popularity of TCIM among patients with cancer, few related studies  have used data from these web-based sources to explore the use of TCIM among  patients with cancer. OBJECTIVE: This study leveraged multiple forums and social  media platforms to explore patients' use, interest, and perception of TCIM for  cancer care. METHODS: Posts (in English) related to TCIM were collected from  Facebook, Twitter, Reddit, and 16 health forums from inception until February  2022. Both manual assessments and natural language processing were performed.  Descriptive analyses were performed to explore the most commonly discussed TCIM  modalities for each symptom and cancer type. Sentiment analyses were performed to  measure the polarity of each post or comment, and themes were identified from  posts with positive and negative sentiments. TCIM modalities that are emerging or  recommended in the guidelines were identified a priori. Exploratory  topic-modeling analyses with latent Dirichlet allocation were conducted to  investigate the patients' perceptions of these modalities. RESULTS: Among the  1,620,755 posts available, cancer-related symptoms, such as pain (10/10, 100%  cancer types), anxiety and depression (9/10, 90%), and poor sleep (9/10, 90%),  were commonly discussed. Cannabis was among the most frequently discussed TCIM  modalities for pain in 7 (70%) out of 10 cancer types, as well as nausea and  vomiting, loss of appetite, anxiety and depression, and poor sleep. A total of 7  positive and 7 negative themes were also identified. The positive themes included  TCIM, making symptoms manageable, and reducing the need for medication and their  side effects. The belief that TCIM and conventional treatments were not mutually  exclusive and intolerance to conventional treatment may facilitate TCIM use.  Conversely, TCIM was viewed as leading to patients' refusal of conventional  treatment or delays in diagnosis and treatment. Doctors' ignorance regarding TCIM  and the lack of information provided about TCIM may be barriers to its use.  Exploratory analyses showed that TCIM recommendations were well discussed among  patients; however, these modalities were also used for many other indications.  Other notable topics included concerns about the legalization of cannabis,  acupressure techniques, and positive experiences of meditation. CONCLUSIONS:  Using machine learning techniques, social media and health forums provide a  valuable resource for patient-generated data regarding the pattern of use and  patients' perceptions of TCIM. Such information will help clarify patients' needs  and concerns and provide directions for research on integrating TCIM into cancer  care. Our results also suggest that effective communication about TCIM should be  achieved and that doctors should be more open-minded to actively discuss TCIM use  with their patients.
C1 School of Pharmacy, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, China (Hong Kong).
   School of Pharmacy, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, China (Hong Kong).
   Department of Clinical Oncology, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, China (Hong Kong).
   School of Chinese Medicine, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, China (Hong Kong).
   Jockey Club School of Public Health and Primary Care, Faculty of Medicine, The 
   Data Science Program, Worcester Polytechnic Institute, Worcester, MA, United States.
   School of Pharmacy, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, China (Hong Kong).
NR 0
TC 0
SN 1438-887
EI 1439-445
J9 J Med Internet Res
PD APR 21
PY 2023
VL 25
IS 
BP e45408
EP e45408
DI 10.2196/45408
PG 1
WC Humans; Social Media; Integrative Medicine; Neoplasms; therapy; Data Mining; methods; Drug-Related Side Effects and Adverse Reactions
UT PubMed:37083752
PM 37083752
DA 2023-04-21
ER

PT J
AU Plaut, S
AF Plaut, Shiloh
TI Suggesting a mechanism for acupuncture as a global percutaneous needle fasciotomy
SO Frontiers in medicine
LA English
DT Journal Article
DE acupuncture; fascial armoring; fibromyalgia; mechanism; myofibroblast; needling; pain; treatment
AB Acupuncture is a minimally invasive therapeutic method that uses small caliber  needles while inserting them through the skin into various areas of the body.  Some empirical studies find evidence to support the use of acupuncture as a  treatment for certain medical conditions, however, this peculiar practice is  widely considered as the domain of alternative and non-evidence-based medicine.  Several mechanisms have been suggested in an attempt to explain the therapeutic  action of acupuncture, but the way in which acupuncture alleviates chronic  non-cancer pain or psychosomatic and psychiatric disorders is not fully  understood. A recent study suggested a theoretical model (coined "Fascial  Armoring") with a cellular pathway to help explain the pathogenesis of myofascial  pain/fibromyalgia syndrome and functional psychosomatic syndromes. It proposes  that these syndromes are a spectrum of a single medical entity that involves  myofibroblasts with contractile activity in fascia and aberrant extracellular  matrix (ECM) remodeling, which may lead to widespread mechanical tension and  compression. This can help explain diverse psycho-somatic manifestations of  fibromyalgia-like syndromes. Fascia is a continuous interconnected tissue network  that extends throughout the body and has qualities of bio-tensegrity. Previous  studies show that a mechanical action by needling induces soft tissue changes and  lowers the shear modulus and stiffness in myofascial tissue. This hypothesis and  theory paper offers a new mechanism for acupuncture therapy as a global  percutaneous needle fasciotomy that respects tensegrity principles  (tensegrity-based needling), in light of the theoretical model of "Fascial  Armoring." The translation of this model to other medical conditions carries  potential to advance therapies. These days opioid overuse and over-prescription  are ubiquitous, as well as chronic pain and suffering.
C1 Department of Primary Care and Population Health, University of Nicosia Medical School, Nicosia, Cyprus.
NR 0
TC 0
SN 2296-858
EI 2296-858
J9 Front Med (Lausanne)
PD FEB 14
PY 2023
VL 9
IS 
BP 952159
EP 952159
DI 10.3389/fmed.2022.952159
PG 0
UT PubMed:36777160
PM 36777160
DA 2023-02-14
ER

PT J
AU de Sousa, TR
   Mattos, S
   Marcon, G
   Furtado, T
   da Silva, MD
AF de Sousa, Tatiane Regina
   Mattos, Suzana
   Marcon, Giovanna
   Furtado, Thayna
   Duarte da silva, Morgana
TI Acupuncture techniques and acupoints used in individuals under chemotherapy or radiotherapy treatment of cancer: A systematic review
SO JOURNAL OF CLINICAL NURSING
LA English
DT Review
DE acupoints; acupuncture; cancer; pain
ID induced peripheral neuropathy; breast-cancer; symptom burden; pain; management; electroacupuncture; efficacy; fatigue; tumor
AB Aims and ObjectivesTo describe the main acupuncture techniques and parameters that have been used in the most varied symptoms of different types of cancer. BackgroundClinical evidence about the potential effectiveness of acupuncture and related therapies to control signs and symptoms associated with cancer or its treatment has been in several studies. Currently, there is already evidence of the use of acupuncture for the treatment of nausea and vomiting, fatigue, dry mouth, anxiety, depression, insomnia and pain. However, many studies lack firm rights or reproducible guidelines for treatment. DesignThis study performs a systematic review of clinical trials related to the topic, based on the PRISMA protocol. Thus, a search was carried out in the Scopus, Pubmed and Web of Science databases, covering studies since January 2007. MethodsStructured and organised according to PICO standards, using keywords ("cancer" OR "malignant tumour" OR "chemotherapy" OR "radiotherapy") AND ("acupuncture" OR "electroacupuncture") AND ("pain" OR "nausea" OR "vomit" OR "fatigue" OR "xerostomia" OR "insomnia" OR "depression" OR "neuropathy"). ResultsAfter the selection and evaluation phase, 23 studies were included and analysed. ConclusionBased on this analysis, it is concluded that acupuncture is safe and there is evidence of the reduction of gastrointestinal symptoms, chemotherapy-induced peripheral neuropathy, pain, dry mouth, fatigue, insomnia, and improvement of cognitive capacity. Relevance to clinical practiceAcupuncture treatments could act by minimising the side effects of conventional treatments and reducing symptoms induced by tumours. No Patient or Public ContributionThe patients had no direct involvement with the study in question.
C1 [de Sousa, Tatiane Regina; Duarte da silva, Morgana] Univ Fed Santa Catarina, Program Postgrad Neurosci, Florianopolis, Brazil.
   [de Sousa, Tatiane Regina; Duarte da silva, Morgana] Univ Fed Santa Catarina, Ctr Biol Sci, Dept Physiol Sci, Lab Neurobiol Pain & Inflammat LANDI, Florianopolis, Brazil.
   [Mattos, Suzana; Marcon, Giovanna; Furtado, Thayna] Estacio Santa Catarina Univ Ctr, Dept physiotherapy, Sao Jose, Brazil.
   [de Sousa, Tatiane Regina; Duarte da silva, Morgana] Univ Fed Santa Catarina, Program Postgrad Neurosci, Univ Campus, BR-88040900 Florianopolis, SC, Brazil.
C3 Universidade Federal de Santa Catarina (UFSC); Universidade Federal de Santa Catarina (UFSC); Universidade Federal de Santa Catarina (UFSC)
RP de Sousa, TR; da Silva, MD (corresponding author), Univ Fed Santa Catarina, Program Postgrad Neurosci, Univ Campus, BR-88040900 Florianopolis, SC, Brazil.
EM tatianereginafisio@gmail.com; morgana.silva@ufsc.br
CR Bao T, 2020, JAMA NETW OPEN, V3, P0, DOI 10.1001/jamanetworkopen.2020.0681
   Bao T, 2018, EUR J CANCER, V101, P12, DOI 10.1016/j.ejca.2018.06.008
   Bao T, 2018, ACUPUNCT MED, V36, P80, DOI 10.1136/acupmed-2017-011435
   Bao T, 2018, BREAST CANCER RES TR, V170, P77, DOI 10.1007/s10549-018-4743-9
   Bardia A, 2006, J CLIN ONCOL, V24, P5457, DOI 10.1200/JCO.2006.08.3725
   Campos MPO, 2011, ANN ONCOL, V22, P1273, DOI 10.1093/annonc/mdq458
   Costa Aline Isabella Saraiva, 2012, REV. DOR, V13, P45
   Deng G, 2018, SUPPORT CARE CANCER, V26, P657, DOI 10.1007/s00520-017-3881-7
   Dev R, 2014, CANCER-AM CANCER SOC, V120, P1586, DOI 10.1002/cncr.28619
   Eisbruch A, 2001, INT J RADIAT ONCOL, V50, P695, DOI 10.1016/S0360-3016(01)01512-7
   Garcia MK, 2019, REDE JAMA, V12, P0
   Garland SN, 2019, JNCI-J NATL CANCER I, V111, P1323, DOI 10.1093/jnci/djz050
   Gomes CHR, 2012, REV BRAS CANCEROL, V58, P41
   Han XY, 2017, BMC CANCER, V17, P0, DOI 10.1186/s12885-016-3037-z
   Hershman DL, 2018, JAMA-J AM MED ASSOC, V320, P167, DOI 10.1001/jama.2018.8907
   Iravani S, 2020, PAIN RES MANAG, V2020, P0, DOI 10.1155/2020/2504674
   Jeong YJ, 2017, EVID-BASED COMPL ALT, V21, P0
   Katta MR, 2022, J ONCOL PHARM PRACT, V28, P1859, DOI 10.1177/10781552221098437
   Kim K, 2018, INTEGR CANCER THER, V17, P1137, DOI 10.1177/1534735418786797
   Kurita GP, 2011, REV ASSOC MED BRAS, V54, P529
   Langevin Helene M, 2002, ANATOMICAL RECORD, V269, P257, DOI 10.1002/ar.10185
   Lawrence JA, 2016, J CANCER SURVIV, V10, P176, DOI 10.1007/s11764-015-0463-x
   Lee H, 2005, EUR J PAIN, V9, P437, DOI 10.1016/j.ejpain.2004.10.004
   Li YF, 2020, ONCOTARGETS THER, V13, P11743, DOI 10.2147/OTT.S272747
   Liu MY, 2021, MEDICINE, V100, P0, DOI 10.1097/MD.0000000000024588
   Lu WD, 2020, ONCOLOGIST, V25, P310, DOI 10.1634/theoncologist.2019-0489
   MacPherson H, 2001, BMJ-BRIT MED J, V323, P486, DOI 10.1136/bmj.323.7311.486
   Meng FF, 2018, MEDICINE, V97, P0, DOI 10.1097/MD.0000000000013736
   Molassiotis A, 2019, INTEGR CANCER THER, V18, P0, DOI 10.1177/1534735419836501
   Navari RM, 2013, DRUGS, V73, P249, DOI 10.1007/s40265-013-0019-1
   Ridner Sheila H, 2013, SEMIN ONCOL NURS, V29, P4, DOI 10.1016/j.soncn.2012.11.002
   Ruela LD, 2018, REV ESC ENFERM USP, V52, P0, DOI 10.1590/S1980-220X2017040503402
   Saraswati W, 2019, MED ACUPUNCT, V31, P29, DOI 10.1089/acu.2018.1316
   Savard J, 2011, J CLIN ONCOL, V29, P3580, DOI 10.1200/JCO.2010.33.2247
   Smith Mary Elizabeth, 2012, SEMIN ONCOL NURS, V28, P64, DOI 10.1016/j.soncn.2011.11.007
   Tong TS, 2018, MED SCI MONITOR, V24, P2919, DOI 10.12659/MSM.909712
   Towler P, 2013, SUPPORT CARE CANCER, V21, P2913, DOI 10.1007/s00520-013-1882-8
   Zeng YC, 2014, INTEGR CANCER THER, V13, P193, DOI 10.1177/1534735413510024
   Zhang SQ, 2017, J TRADIT CHIN MED, V37, P179
   Zhi WI, 2018, INTEGR CANCER THER, V17, P1079, DOI 10.1177/1534735418788667
   Zhou J, 2017, CURR ONCOL, V24, PE1, DOI 10.3747/co.24.3296
NR 41
TC 16
Z9 17
U1 5
U2 32
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0962-1067
EI 1365-2702
J9 J CLIN NURS
JI J. Clin. Nurs.
PD OCT 15
PY 2023
VL 32
IS 19-20
BP 6917
EP 6933
DI 10.1111/jocn.16812
EA JUN 2023
PG 17
WC Nursing
SC Nursing
GA U0VB3
UT WOS:001018232200001
PM 37382085
DA 2026-01-16
ER

PT J
AU Lyu, Z
   Tian, S
   Bao, G
   Huang, R
   Gong, L
   Zhou, J
   Kong, X
   Zhang, W
   Ran, R
   Nie, N
   Liu, Y
   Ji, C
   Liu, S
   Shao, X
   Kai, G
   Lin, X
   Fang, J
   Liang, Y
AF Lyu, Zhengyi
   Tian, Shuxin
   Bao, Guanai
   Huang, Rui
   Gong, Liyan
   Zhou, Jie
   Kong, Xiangming
   Zhang, Weiping
   Ran, Ran
   Nie, Na
   Liu, Yang
   Ji, Conghua
   Liu, Shan
   Shao, Xiaomei
   Kai, Guoyin
   Lin, Xianming
   Fang, Jianqiao
   Liang, Yi
TI Transcutaneous electrical acupoint stimulation for cancer-related pain management
SO Supportive care in cancer : official journal of the Multinational Association of
LA English
DT Journal Article
DE Acupuncture,; Cancer-related pain,; Chronic opioid therapy,; Transcutaneous electrical acupoint stimulation,; Transcutaneous electrical nerve stimulation
AB PURPOSE: The opioid crisis resulting from its use disorder and overdose poses  additional challenges for cancer pain management. The American Society of  Clinical Oncology Practice Guideline recommends acupuncture therapy for the  management of adult cancer-related pain (CRP), but the effectiveness of  transcutaneous electrical acupoint stimulation (TEAS) on CRP remains uncertain.  METHODS: This 5-week prospective randomized clinical trial was conducted at 2  hospitals in China, and participants with CRP receiving chronic opioid therapy  were randomized 1:1 into two groups between December 2014 and June 2018. The true  TEAS group underwent 15 sessions of TEAS treatments over 3 consecutive weeks,  while the control group received sham stimulation. The primary outcome was the  numerical rating scale (NRS) score in the past 24h at week 3. The secondary  outcomes included morphine equivalent daily dose, quality of life and adverse  events. RESULTS: A total of 159 participants were included in the modified  intention-to-treat population. The baseline characteristics were similar in both  groups. The mean NRS scores were 0.98 points at week 3 in the true TEAS group and  1.41 points in the sham group, with the mean difference between groups of -0.43  points (P < 0.001; OR = 0.68, P < 0.05). The proportion of patients with NRS  reduction more than thirty percentage at week 3 was 50.00% in the true TEAS group  and 35.44% in the sham group (RD = 0.15, P > 0.05; RR = 1.41, P > 0.05). No  significant difference in pain intensity between the two groups was observed  during the follow-up period without TEAS intervention (week 4, OR = 0.83,  P > 0.05; week 5, OR = 0.83, P > 0.05). The Karnofsky Performance Status value  suggested that patients in the true TEAS group experienced an improved quality of  life (Between-group differences: week 3, 3.5%, P < 0.05; week 4, 4.6%, P < 0.001;  week 5, 5.6%, P < 0.001). CONCLUSIONS: The 3-week application of TEAS in patients  with CRP receiving chronic opioid therapy resulted in a statistically significant  reduction in pain scores, but the observed reduction was of uncertain clinical  significance. The prolonged analgesic effect of TEAS was not confirmed in this  trial. CLINICALTRIAL: GOV: ChiCTR-TRC-13003803.
C1 The Third Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, 310005, China.
   The Third Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, 310005, China.
   Department of Integrated Chinese Traditional Medicine and Western Medicine, Zhejiang Cancer Hospital, Hangzhou, 310022, China.
   Department of Acupuncture and Tuina, Wenzhou Central Hospital, Wenzhou, 325000, China.
   Department of Integrated Chinese Traditional Medicine and Western Medicine, Zhejiang Cancer Hospital, Hangzhou, 310022, China.
   Department of Acupuncture, The Third Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, 310000, China.
   Department of Integrated Chinese Traditional Medicine and Western Medicine, Zhejiang Cancer Hospital, Hangzhou, 310022, China.
   Department of Oncology, The Third Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, 310000, China.
   Department of Oncology, The Third Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, 310000, China.
   Department of Acupuncture, The Third Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, 310000, China.
   The Third Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, 310005, China.
   Zhejiang Chinese Medical University, Hangzhou, 310005, China.
   Department of Clinical Evaluation Center, Zhejiang Provincial Hospital of Traditional Chinese Medicine, Hangzhou, 310000, China.
   Department of Acupuncture, The Third Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, 310000, China.
   Zhejiang Chinese Medical University, Hangzhou, 310005, China.
   Department of Acupuncture, The Third Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, 310000, China.
   Department of Acupuncture, The Third Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, 310000, China. fangjianqiao7532@163.com.
   Department of Acupuncture, The Third Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, 310000, China. liangyiwww@126.com.
NR 0
TC 0
SN 1433-733
EI 
J9 Support Care Cancer
PD DEC 12
PY 2023
VL 32
IS 1
BP 16
EP 16
DI 10.1007/s00520-023-08240-1
PG 0
WC Adult; Humans; Acupuncture Points; Analgesics, Opioid; adverse effects; Cancer Pain; drug therapy; Morphine; Neoplasms; therapy; Pain Management; Prospective Studies; Quality of Life; Transcutaneous Electric Nerve Stimulation; methods
UT PubMed:38085376
PM 38085376
DA 2023-12-12
ER

PT J
AU Choi, HS
   Lee, YJ
   Hahm, DH
   Lee, H
   Ha, IH
AF Choi, Hee-Seung
   Lee, Yoon Jae
   Hahm, Dae-Hyun
   Lee, Hyangsook
   Ha, In-Hyuk
TI The effect of integrative Korean medicine treatment on symptomatic lumbar facet
SO Explore (New York, N.Y.)
LA English
DT Journal Article
DE Facet joint cyst; Integrative Korean medicine treatment; Lumbar; Zygapophyseal joint
AB OBJECTIVE: The optimal treatment for facet joint cysts (FJCs) has remained  controversial. Despite a higher success rate than the conservative option,  surgical treatments may pose risks of postoperative complications and  comorbidities may make the surgical approach difficult. Thus, this study reports  four cases of pain amelioration and resorption of FJCs through noninvasive  integrative Korean Medicine treatment. METHODS: For intervention, four patients  with symptomatic FJCs underwent integrative Korean medicine treatment with  acupuncture, herbal medicine, pharmacopuncture, and Chuna manual therapy; after  completion of the series of treatment sessions, patients were re-examined with  magnetic resonance imaging (MRI). RESULTS: Pain disappeared within 2 months for  all four patients; the amelioration of pain was sustained for more than 6 months.  Furthermore, the disappearance of FJCs was confirmed by MRI after a certain  period from the time of pain disappearance. CONCLUSIONS: This study reported the  effectiveness of non-invasive, integrative Korean medicine treatment for patients  with FJCs; this method shows promise as a conservative treatment option for  patients with FJCs.
C1 Jaseng Hospital of Korean Medicine, Republic of Korea
   Acupuncture and Meridian Science Research Center, College of Korean Medicine, Kyung Hee University,Republic of Korea.
   Jaseng Spine and Joint Research Institute, Jaseng Medical Foundation, Republic of Korea.
   Department of Physiology, College of Medicine, Kyung Hee University, Republic of Korea.
   Acupuncture and Meridian Science Research Center, College of Korean Medicine, Kyung Hee University, Republic of Korea.
   Jaseng Spine and Joint Research Institute, Jaseng Medical Foundation, Republic of Korea.
EM hanihata@gmail.com
NR 0
TC 0
SN 1878-754
EI 
J9 Explore (NY)
PD JUN 24
PY 2023
VL 20
IS 1
BP 130
EP 137
DI 10.1016/j.explore.2023.06.003
PG 7
WC Humans; Zygapophyseal Joint; diagnostic imaging; Low Back Pain; drug therapy; Lumbar Vertebrae; diagnostic imaging; Cysts; complications; Republic of Korea
UT PubMed:37353459
PM 37353459
DA 2023-06-24
ER

PT J
AU Jiang, YY
   Wu, L
   Wang, Y
   Tan, J
   Wang, L
   Cai, JQ
   Zhou, YH
   Sun, GW
   Song, ZH
   Gu, LB
AF Jiang, Yueyi
   Wu, Lei
   Wang, Yue
   Tan, Jing
   Wang, Li
   Cai, Jiaqin
   Zhou, Yihu
   Sun, Guowei
   Song, Zhenghuan
   Gu, Lianbing
TI Effects of Press Needling combined with general anesthesia on postoperative analgesia in thoracoscopic pulmonary resection for lung cancer: A randomized, single-blind, controlled trial
SO COMPLEMENTARY THERAPIES IN MEDICINE
LA English
DT Article
DE Analgesia; Lung surgery; Postoperative pulmonary complications; Press needle acupuncture; Video-assisted thoracoscopic surgery
ID electrical acupoint stimulation; assisted thoracic-surgery; acupuncture; pain; complications
AB Objectives: To investigate the effects of press needle therapy on postoperative analgesia and other relevant complications in patients undergoing thoracoscopic pulmonary resection. Design: randomized, single-blind, controlled trial Setting: Teaching hospitals affiliated with universities. Interventions: Eighty-six patients were randomized into: the Acu group (press-needle group) and the control group Main outcome measures: Pain levels 24, 48, and three months after surgery were measured using the numeric rating scale (NRS). Perioperative hemodynamics, total and effective pressing numbers of patient-controlled intravenous analgesia (PCIA), and incidence of postoperative pulmonary complications were recorded. Peripheral blood samples were collected to measure the levels of inflammatory mediators Results: Acu group had significantly lower NRS scores at 24 and 48 h after operation (NRS scores on movement at 24 h after surgery: Acu vs. Control, 3 (2,3) vs. 3 (3,5), Z = 3.393, P < 0.01 and NRS scores on movement at 48 h after surgery: 2 (1,3) vs. 3 (2,5), Z = 3.641, P < 0.01), lower number of PCIA attempts and effective rates (mean total pressing numbers: 4(2,8) vs. 6(3,19), Z = 1.994, P = 0.046 and mean effective pressing numbers: 3(2,8) vs. 6(3,16), Z = 2.116, P = 0.034). The Acu group had significantly reduced IL-1 (14.52 +/- 3.84 vs. 16.36 +/- 3.30, mean difference (MD): 1.85, 95% confidence interval (CI): 3.46, 0.23, P = 0.026), HIF-1 alpha (10.15 +/- 1.71 vs. 10.96 +/- 1.73, MD: 0.81, 95% CI: 1.59, 0.04, P = 0.040) and the incidence of pulmonary complications after surgery. Conclusion: Press needles are a non-invasive and feasible adjunctive intervention for postoperative analgesic management in patients undergoing thoracoscopic pulmonary resection.
C1 [Jiang, Yueyi; Wang, Yue; Zhou, Yihu; Gu, Lianbing] Nanjing Med Univ, Nanjing, Peoples R China.
   [Wu, Lei; Tan, Jing; Wang, Li; Song, Zhenghuan; Gu, Lianbing] Jiangsu Canc Hosp, Dept Anesthesiol, Nanjing, Peoples R China.
   [Cai, Jiaqin] Xuzhou Med Univ, Xuzhou, Peoples R China.
   [Sun, Guowei] Dalian Med Univ, Dalian, Peoples R China.
C3 Nanjing Medical University; Nanjing Medical University; Xuzhou Medical University; Dalian Medical University
RP Gu, LB (corresponding author), Nanjing Med Univ, Nanjing, Peoples R China.; Song, ZH; Gu, LB (corresponding author), Jiangsu Canc Hosp, Dept Anesthesiol, Nanjing, Peoples R China.
EM ongzhenghuan@njmu.edu.cn; 13951947684@163.com
FU Jiangsu Province Traditional Chinese Medicine Science and Technology Development Project [YB201986]
CR Bendixen M, 2016, LANCET ONCOL, V17, P836, DOI 10.1016/S1470-2045(16)00173-X
   Calvo E, 2019, ARCH ORTHOP TRAUM SU, V139, P669, DOI 10.1007/s00402-018-3100-0
   Chen HY, 2013, BMC COMPLEM ALTERN M, V13, P0, DOI 10.1186/1472-6882-13-362
   Chen JH, 2020, THORAC CANCER, V11, P928, DOI 10.1111/1759-7714.13343
   [陈永菊 Chen Yongju], 2019, 实用口腔医学杂志 JOURNAL OF PRACTICAL STOMATOLOGY, V35, P81
   Cheng D, 2007, INNOVATIONS, V2, P261, DOI 10.1097/IMI.0b013e3181662c6a
   Dai FQ, 2016, J THORAC DIS, V8, P2872, DOI 10.21037/jtd.2016.10.27
   De Conno E, 2009, ANESTHESIOLOGY, V110, P1316, DOI 10.1097/ALN.0b013e3181a10731
   de la Gala F, 2017, BRIT J ANAESTH, V119, P655, DOI 10.1093/bja/aex230
   Deng G, 2008, J THORAC CARDIOV SUR, V136, P1464, DOI 10.1016/j.jtcvs.2008.07.053
   Fan Min, 2022, CHINA MED PHARM, V12, P113
   Feng JJ, 2020, SHANGHAI J ACUPUNCT MOXIBUST, V39, P584
   Fiorelli A, 2012, EUR J CARDIO-THORAC, V41, P861, DOI 10.1093/ejcts/ezr108
   [傅国强 Fu Guoqiang], 2011, 针刺研究 ACUPUNCTURE RESEARCH, V36, P361
   Gao Y, 2017, BEIJING J TRADIT CHIN MED, V36, P373
   Gavronsky S, 2012, PAIN MANAG NURS, V13, P150, DOI 10.1016/j.pmn.2009.08.001
   Han JS, 2011, PAIN, V152, PS41, DOI 10.1016/j.pain.2010.10.012
   Hieber S, 2009, EUR J ANAESTH, V26, P201, DOI 10.1097/EJA.0b013e3283212cbb
   Hsu HC, 2022, J NURS SCHOLARSHIP, V54, P411, DOI 10.1111/jnu.12751
   Huang S, 2017, J ANESTH, V31, P58, DOI 10.1007/s00540-015-2057-1
   Jin H, 2021, WORLD LATEST MED INF, V21, P102
   Liang F, 2019, GUID J TRADIT CHIN MED PHARMACOL, V25, P122
   Liou KT, 2021, SUPPORT CARE CANCER, V29, P427, DOI 10.1007/s00520-020-05504-y
   Liu Tongshuai, 2016, ZHONGGUO ZHEN JIU, V36, P1135, DOI 10.13703/j.0255-2930.2016.11.005
   MacPherson Hugh, 2010, J EVID BASED MED, V3, P140, DOI 10.1111/j.1756-5391.2010.01086.x
   Park S, 2021, PLOS ONE, V16, P0, DOI 10.1371/journal.pone.0254093
   Paul-Clark MJ, 2009, AM J RESP CRIT CARE, V179, P299, DOI 10.1164/rccm.200707-1019OC
   Ren Q, 2011, CHIN J SURG INTEGR TRADIT WEST MED., V17, P250
   Ruengwongroj P, 2020, COMPLEMENT THER CLIN, V40, P0, DOI 10.1016/j.ctcp.2020.101202
   Sun Y, 2008, BRIT J ANAESTH, V101, P151, DOI 10.1093/bja/aen146
   Tang JH, 2023, TRADIT CHIN MED RES, V36, P92, DOI 10.3969/J.ISSN.1001-6910.2023.01.24
   Verhage RJJ, 2014, BRIT J ANAESTH, V112, P920, DOI 10.1093/bja/aet476
   Wang H, 2014, BRIT J ANAESTH, V112, P1075, DOI 10.1093/bja/aeu001
   Wetzel B, 2011, CLIN J PAIN, V27, P262, DOI 10.1097/AJP.0b013e3181fd516c
   White Adrian, 2004, ACUPUNCT MED, V22, P122
   Xu Y, 2021, EVID-BASED COMPL ALT, V2021, P0, DOI 10.1155/2021/5578104
   Yang L, 2020, MED SCI MONITOR, V26, P0, DOI 10.12659/MSM.920648
   Yao T, 2020, WORLD LATEST MED INF, V20, P71
   Zhang RX, 2014, ANESTHESIOLOGY, V120, P482, DOI 10.1097/ALN.0000000000000101
NR 39
TC 4
Z9 4
U1 3
U2 14
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 0965-2299
EI 1873-6963
J9 COMPLEMENT THER MED
JI Complement. Ther. Med.
PD OCT 15
PY 2023
VL 77
IS 
BP 
EP 
DI 10.1016/j.ctim.2023.102980
EA AUG 2023
PG 8
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA S2KK1
UT WOS:001069506900001
PM 37640166
DA 2026-01-16
ER

PT J
AU Li, KW
   Chu, HR
   Ruan, JR
   Wang, JJ
   Chen, JY
   Zhu, SS
   Zou, L
   Liao, LM
   Tong, TT
AF Li, Kui-Wu
   Chu, Hao-Ran
   Ruan, Jing-Ru
   Wang, Jiao-Jiao
   Chen, Jin-Yu
   Zhu, Shan-Shan
   Zou, Ling
   Liao, Lu-Min
   Tong, Ting-Ting
TI [Effect of moxibustion on immune function homeostasis in rats with diarrhea
SO Zhongguo zhen jiu = Chinese acupuncture & moxibustion
LA chi
DT Journal Article
DE diarrhea irritable bowel syndrome; immune function; moxibustion; stem cell factor/tyrosine kinase receptor (SCF/c-kit) signaling pathway
AB OBJECTIVE: To observe the effects of moxibustion on the stem cell factor  (SCF)/tyrosine kinase receptor (c-kit) signaling pathway and immune function in  rats with diarrhea irritable bowel syndrome (IBS-D), and to explore the mechanism  of moxibustion for IBS-D. METHODS: Among 52 young rats born from 6 healthy  pregnant SPF rats, 12 rats were randomly selected into the normal group, and the  remaining 40 rats were treated with the three-factor combination method of  maternal separation, acetic acid enema and chronic restraint stress to establish  the IBS-D rat model. Thirty-six rats with successful IBS-D model were randomly  divided into a model group, a moxibustion group, and a medication group, 12 rats  in each group. The rats in the moxibustion group were treated with suspension  moxibustion at "Tianshu" (ST 25) and "Shangjuxu" (ST 37); the rats in the  medication group were treated with intragastric administration of rifaximin  suspension (150 mg/kg). All the treatments were given once a day for 7  consecutive days. The body mass, loose stool rate (LSR), the minimum volume  threshold when abdominal withdrawal reflex (AWR) scored 3 were measured before  acetic acid enema (35 days old), after modeling (45 days old), and after  intervention (53 days old). After intervention (53 days old), HE staining was  used to observe the morphology of colon tissue, and spleen and thymus  coefficients were measured; ELISA method was used to detect serum inflammatory  factors (tumor necrosis factor a [TNF-a], interleukin [IL]-10, IL-8),  T-lymphocyte subsets (CD(+)(4), CD(+)(8), CD(+)(45)), value of CD(+)(4)/CD(+)(8)  and immune globulin (IgA, IgG, IgM); real-time PCR method and Western blot method  was used to detect the expression of SCF, c-kit mRNA and protein in colon tissue;  immunofluorescence staining method were used to detect positive expression of SCF  and c-kit. RESULTS: After intervention, compared with the normal group, in the  model group, the body mass and the minimum volume threshold when AWR scored 3  were decreased (P<0.01), LSR, spleen and thymus coefficients, serum levels of  TNF-α, IL-8, CD(+)(4), CD(+)(45), CD(+)(4)/CD(+)(8), IgA, IgG, IgM were increased  (P<0.01), serum IL-10 level and protein and mRNA expression of SCF and c-kit in  colon tissue were decreased (P<0.01), and the positive expression of SCF and  c-kit was decreased (P<0.01). Compared with the model group, in the moxibustion  group and the medication group, the body mass and the minimum volume threshold  when AWR scored 3 were increased (P<0.01, P<0.05), LSR, spleen and thymus  coefficients, serum levels of TNF-α, IL-8, CD(+)(4), CD(+)(8), CD(+)(45),  CD(+)(4)/CD(+)(8), IgA, IgG, IgM were decreased (P<0.01, P<0.05), serum IL-10  level and protein and mRNA expression of SCF and c-kit in colon tissue were  increased (P<0.01), and the positive expression of SCF and c-kit was increased  (P<0.01). Compared with the medication group, in the moxibustion group, the level  of serum CD(+)(4) was decreased (P<0.05), the value of CD(+)(4)/CD(+)(8) was  increased (P<0.01), and there was no significant difference in other indexes  (P>0.05). The expression of SCF and c-kit mRNA was positively correlated with the  minimum volume threshold when AWR scored 3 and IL-10 (P<0.01), and negatively  correlated with remaining indexes (P<0.01, P<0.05). CONCLUSION: Moxibustion could  reduce visceral hypersensitivity, improve symptoms of abdominal pain and diarrhea  in IBS-D rats, and its mechanism may be related to up-regulation of the  expression of SCF/c-kit signaling pathway and improvement of IBS-D immune  function.
C1 Second Clinical Medical College of Anhui University of CM, Hefei 230061, China.
   Famous Doctor Clinic, Second Affiliated Hospital of Anhui University of CM/Anhui Acupuncture and Moxibustion Hospital, Hefei 230061
   Clinical Research Instituteof Acupuncture and Moxibustion of Anhui Academy of TCM, Hefei 230061
   AnhuiClinical Medical Research Center of Acupuncture and Moxibustion, Hefei 230061.
   Second Clinical Medical College of Anhui University of CM, Hefei 230061, China.
   Second Clinical Medical College of Anhui University of CM, Hefei 230061, China.
   Second Clinical Medical College of Anhui University of CM, Hefei 230061, China.
   Second Clinical Medical College of Anhui University of CM, Hefei 230061, China.
   Second Clinical Medical College of Anhui University of CM, Hefei 230061, China.
   Second Clinical Medical College of Anhui University of CM, Hefei 230061, China.
   Second Clinical Medical College of Anhui University of CM, Hefei 230061, China.
NR 0
TC 0
SN 
EI 0255-293
J9 Zhongguo Zhen Jiu
PD FEB 23
PY 2023
VL 43
IS 2
BP 177
EP 85
DI 10.13703/j.0255-2930.20220108-k0007
PG -92
WC Rats; Animals; Irritable Bowel Syndrome; therapy; Moxibustion; methods; Rats, Sprague-Dawley; Interleukin-10; Interleukin-8; Maternal Deprivation; Tumor Necrosis Factor-alpha; Diarrhea; Signal Transduction; Homeostasis; Receptor Protein-Tyrosine Kinases; Immunity; Immunoglobulin A; Immunoglobulin M
UT PubMed:36808512
PM 36808512
DA 2023-02-23
ER

PT J
AU Zhang, Y
   Zhang, Y
   Liu, S
   Li, B
   Song, Z
   Han, Q
   Wang, C
   Wang, Y
   Yu, Y
   Xia, H
   Wang, C
   Li, J
AF Zhang, Yanji
   Zhang, Yingrong
   Liu, Suzhen
   Li, Bocun
   Song, Zhe
   Han, Qi
   Wang, Chang
   Wang, Yiwei
   Yu, Yanxin
   Xia, Hongjie
   Wang, Chun
   Li, Jia
TI Acupuncture for cancer pain: a scoping review of systematic reviews and
SO Frontiers in oncology
LA English
DT Journal Article
DE acupuncture; alternative medicine (AM); cancer pain; scoping review; systematic reviews and meta-analyses
AB BACKGROUND: Due to the effectiveness and safety, acupuncture, one of the  traditional therapies of Chinese medicine, has been widely used in clinical  practice globally. A few systematic review or meta-analyses have proved its  effectiveness and safety towards patients with cancer pain, while there are no  syntheses among those evidence. The aim of this scoping review is to summarize  the evidence from systematic reviews of acupuncture for the treatment of cancer  pain and evaluate the breadth and methodological quality of these evidence as  well. METHODS: The scoping review process was guided by the methodology framework  of Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension  for scoping reviews (PRISMA ScR) and "Arkseyand O'Malley six-stage framework".  Electronic searches were carried out in several online databases from inception  to Jan 2022. Systematic reviews and meta-analyses that involve any type of  acupuncture for patients with cancer pain will be included. A pair of reviewers  independently screened full texts. Moreover, review characteristics were  extracted, and methodological quality was assessed using the AMSTAR 2 tool.  RESULTS: Twenty-five systematic reviews and meta-analyses were included. Manual  acupuncture is the most frequently included types of test group intervention  (48%), followed by acupuncture + medicine (28%), and auricular acupuncture (12%).  All the reviews have declared that acupuncture is an effective method for cancer  pain treatment. Eleven reviews (44%) aiming at evaluating the safety also have  confirmed that acupuncture is safe for treating cancer pain. However, most  included studies were conducted in China. With certain geographical limitations,  the findings were not representative within the region. The results of our review  may owe to the synthesis of all kinds of cancer pain, and only 2 reviews  described the type of cancer pain in detail. CONCLUSIONS: This scoping review  synthesizes and evaluates existing evidence of acupuncture for cancer pain. From  this scoping review of systematic reviews and meta-analyses, there are clear  recommendations for future studies: expanding the region of research in the world  and trying to conduct the study of different types of cancer pain in details as  much as possible. Evidences of acupuncture for cancer pain can inform clinical  decision-making. SYSTEMATIC REVIEW REGISTRATION:  https://inplasy.com/inplasy-2022-1-0073/, identifier INPLASY202210073.
C1 College of Acupuncture and Orthopedics, Hubei University of Chinese Medicine, Wuhan, Hubei, China.
   College of Acupuncture and Orthopedics, Hubei University of Chinese Medicine, Wuhan, Hubei, China.
   College of Acupuncture and Orthopedics, Hubei University of Chinese Medicine, Wuhan, Hubei, China.
   College of Acupuncture and Orthopedics, Hubei University of Chinese Medicine, Wuhan, Hubei, China.
   School of Biomedical Engineering and Imaging, Hubei University of Science and Technology, Xianning, Hubei, China.
   Xianning Central Hospital, The First Affiliated Hospital of Hubei University of Science and Technology, Xianning, Hubei, China.
   School of Biomedical Engineering and Imaging, Hubei University of Science and Technology, Xianning, Hubei, China.
   College of Acupuncture and Orthopedics, Hubei University of Chinese Medicine, Wuhan, Hubei, China.
   College of Acupuncture and Orthopedics, Hubei University of Chinese Medicine, Wuhan, Hubei, China.
   College of Acupuncture and Orthopedics, Hubei University of Chinese Medicine, Wuhan, Hubei, China.
   College of Acupuncture and Orthopedics, Hubei University of Chinese Medicine, Wuhan, Hubei, China.
   College of Acupuncture and Orthopedics, Hubei University of Chinese Medicine, Wuhan, Hubei, China.
NR 0
TC 0
SN 2234-943
EI 2234-943
J9 Front Oncol
PD MAY 31
PY 2023
VL 13
IS 
BP 1169458
EP 1169458
DI 10.3389/fonc.2023.1169458
PG 0
WC Systematic Reviews as Topic
UT PubMed:37256179
PM 37256179
DA 2023-05-31
ER

PT J
AU Han, XR
   Yue, W
   Chen, HC
   He, W
   Chen, SX
   Liu, N
   Yang, M
AF Han, Xin-rui
   Yue, Wei
   Chen, Hui-chao
   He, Wei
   Chen, Shan-xia
   Liu, Na
   Yang, Ming
TI Treatment duration of wrist-ankle acupuncture for relieving post-thyroidectomy pain: A randomized controlled trial
SO JOURNAL OF INTEGRATIVE MEDICINE-JIM
LA English
DT Article
DE Thyroidectomy; Thyroid tumor; Wrist -ankle acupuncture; Post -operative pain; Randomized controlled trial
ID postoperative pain; association guidelines; management; cancer; nausea
AB Background: Treatment duration of wrist-ankle acupuncture (WAA) is uncertain for post-thyroidectomy pain relief.Objective: This study evaluated the effect of different WAA treatment duration on post-operative pain relief and other discomforts associated with thyroidectomy. Design, setting, participants and intervention: This randomized controlled trial was conducted at a single research site in Guangzhou, China. A total of 132 patients receiving thyroidectomy were randomly divided into the control group (sham WAA, 30 min) and three intervention groups (group 1: WAA, 30 min; group 2: WAA, 45 min; group 3: WAA, 60 min), with group allocation ratio of 1:1:1:1. Acupuncture was administered within 1 hour of leaving the operating room. Outcomes and measures: Primary outcome was patients' pain at the surgical site assessed by visual analogue scale (VAS) at the moment after acupuncture treatment (post-intervention). Secondary outcomes included the patients' pain VAS scores at 6, 12, 24, 48 and 72 h after the thyroidectomy, the 40-item Quality of Recovery (QoR-40) score, the grade of post-operative nausea and vomiting (PONV), and the use of additional analgesic therapy. Results: The adjusted mean difference (AMD) in VAS scores from baseline to post-intervention in group 1 was -0.89 (95% confidence interval [CI], -1.02 to -0.76). The decrease in VAS score at post-intervention was statistically significant in group 1 compared to the control group (AMD, -0.43; 95% CI, -0.58 to -0.28; P < 0.001), and in groups 2 and 3 compared to group 1 (group 2 vs group 1: AMD, -0.65; 95% CI, -0.81 to -0.48; P < 0.001; group 3 vs group 1: AMD, -0.66; 95% CI, -0.86 to -0.47; P < 0.001). The VAS scores in the four groups converged beyond 24 h after the operation. Fewer patients in group 2 and group 3 experienced PONV in the first 24 h after operation. No statistical differences were measured in QoR-40 score and the number of patients with additional analgesic therapy.Conclusion: Compared with the 30 min intervention, WAA treatment with longer needle retention time (45 or 60 min) had an advantage in pain relief within 6 h after surgery. WAA's analgesic effect lasted for 6-12 h post-operatively. Please cite this article as: Han XR, Yue W, Chen HC, He W, Luo JH, Chen SX, Liu N, Yang M. Treatment duration of wrist-ankle acupuncture for relieving post-thyroidectomy pain: A randomized controlled trial. J Integr Med. 2023; 21(2): 168-175. (c) 2023 Shanghai Yueyang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine. All rights reserved.
C1 [Han, Xin-rui] Chengdu Integrated TCM & Western Med Hosp, Dept Nursing, Chengdu 610041, Sichuan, Peoples R China.
   [Yue, Wei; Chen, Shan-xia; Liu, Na; Yang, Ming] Guangzhou Univ Chinese Med, Sch Nursing, Guangzhou 510006, Guangdong, Peoples R China.
   [Chen, Hui-chao] Guangdong Prov Hosp Tradit Chinese Med, Dept Nursing, Guangzhou 510120, Guangdong, Peoples R China.
   [He, Wei] Guangdong Prov Hosp Tradit Chinese Med, Dept Gen Surg, Guangzhou 510120, Guangdong, Peoples R China.
   [He, Wei] Guangzhou Women & Childrens Med Ctr, Dept Gynecol & Obstet, Guangzhou 510120, Guangdong, Peoples R China.
C3 Guangzhou University of Chinese Medicine; Guangzhou University of Chinese Medicine; Guangzhou University of Chinese Medicine
RP Yang, M (corresponding author), Guangzhou Univ Chinese Med, Sch Nursing, Guangzhou 510006, Guangdong, Peoples R China.
EM hlym@gzucm.edu.cn
FU Postgraduate Education Innovation Program in Guangdong Province [2022SFKC030]; Humanities and Social Sciences Program in Guangzhou University of Chinese Medicine [2021SKYB08]; Teaching Quality and Teaching Reform Program in Guangzhou University of Chinese Medicine (GZUCM Office [2021]) [323]
CR Unknown -, 2012, SPSS STAT WIND, V0, P0, DOI DOI 10.1111/B.9781444331899.2011.00023.X
   Unknown -, 2010, BMJ-BRIT MED J, V340, P0, DOI 10.1136/BMJ.C332
   Brummett CM, 2019, J MANAG CARE SPEC PH, V25, P973, DOI 10.18553/jmcp.2019.19055
   Chen Y, 2019, CHIN J HOSP PHARM, V39, P2245, DOI 10.13286/j.cnki.chinhosppharmacyj.2019.22.01
   Chen YF, 2017, BMC COMPLEM ALTERN M, V17, P0, DOI 10.1186/s12906-017-1923-9
   Chou R, 2016, J PAIN, V17, P131, DOI 10.1016/j.jpain.2015.12.008
   Desu MM, 1990, SAMPLE SIZE METHODOL, V0, P0
   Dhillon VK, 2020, OTOLARYNG CLIN N AM, V53, P779, DOI 10.1016/j.otc.2020.05.007
   Ferlay J, 2010, BREAST CANCER EPIDEMIOLOGY, V0, PP1, DOI 10.1007/978-1-4419-0685-4_1
   Ferrell JK, 2021, HEAD NECK-J SCI SPEC, V43, P2281, DOI 10.1002/hed.26774
   Fitzmaurice C, 2019, JAMA ONCOL, V5, P1749, DOI 10.1001/jamaoncol.2019.2996
   Gan TJ, 2014, ANESTH ANALG, V118, P85, DOI 10.1213/ANE.0000000000000002
   Gornall BF, 2013, BRIT J ANAESTH, V111, P161, DOI 10.1093/bja/aet014
   Haugen BR, 2016, THYROID, V26, P1, DOI 10.1089/thy.2015.0020
   Heikkinen M, 2021, WORLD J SURG, V45, P765, DOI 10.1007/s00268-020-05863-x
   [胡侠 Hu Xia], 2004, 中国针灸 CHINESE ACUPUNCTURE AND MOXIBUSTION, V24, P361
   Jiang X, 2004, ZHONGGUO ZHONG YI JI, V10, P76
   Kraus WE, 2019, LANCET DIABETES ENDO, V7, P673, DOI 10.1016/S2213-8587(19)30151-2
   Lao HH, 1999, WRIST ANKLE ACUPUNCT, V2nd, P0
   Le May M, 2021, JAMA-J AM MED ASSOC, V326, P1494, DOI 10.1001/jama.2021.15703
   Li Y, 2020, WORLD J ACUPUNCT-MOX, V30, P183, DOI 10.1016/j.wjam.2020.05.007
   Lim Hoi Jeong, 2004, J PREV MED PUBLIC HEALTH, V37, P381
   Liu Wei-Ting, 2020, ZHEN CI YAN JIU, V45, P623, DOI 10.13702/j.1000-0607.190794
   Lu IC, 2017, GLAND SURG, V6, P469, DOI 10.21037/gs.2017.05.02
   MacPherson Hugh, 2010, J EVID BASED MED, V3, P140, DOI 10.1111/j.1756-5391.2010.01086.x
   Mitra S, 2018, CURR PAIN HEADACHE R, V22, P0, DOI 10.1007/s11916-018-0690-8
   Myles PS, 2017, BRIT J ANAESTH, V118, P424, DOI 10.1093/bja/aew466
   PASS 15, 2017, PASS 15 POWER ANALYSIS AND SAMPLE SIZE SOFTWARE, V0, P0
   Patel KN, 2020, ANN SURG, V271, PE21, DOI 10.1097/SLA.0000000000003580
   Roberts C, 2021, STAT MED, V40, P349, DOI 10.1002/sim.8778
   Ross DS, 2016, THYROID, V26, P1343, DOI 10.1089/thy.2016.0229
   Shindo M, 2018, JAMA OTOLARYNGOL, V144, P1098, DOI 10.1001/jamaoto.2018.2427
   Siu PM, 2021, ANN INTERN MED, V174, P1050, DOI 10.7326/M20-7014
   Standardization Work Committee of Chinese Acupuncture and Moxibustion Society, 2009, 21709192009 GBT STAN, V0, P2
   Tharakan T, 2019, OTOLARYNG HEAD NECK, V160, P394, DOI 10.1177/0194599818797574
   Uhlmann RA, 2019, J SURG RES, V241, P107, DOI 10.1016/j.jss.2019.03.050
   Vas J, 2006, PAIN, V126, P245, DOI 10.1016/j.pain.2006.07.002
   Vignaud M, 2021, ANAESTH CRIT CARE PA, V40, P0, DOI 10.1016/j.accpm.2021.100822
   Ware JH, 2012, NEW ENGL J MED, V367, P1353, DOI 10.1056/NEJMsm1210043
   Wu Qiu-Lan, 2019, ZHONGGUO ZHEN JIU, V39, P1051, DOI 10.13703/j.0255-2930.2019.10.005
   Xian XJ, 1995, LIAONING ZHONG YI ZA, V22, P182
   Xu LP, 2020, COMPLEMENT THER CLIN, V39, P0, DOI 10.1016/j.ctcp.2020.101170
   Yang MX, 2017, PLOS ONE, V12, P0, DOI 10.1371/journal.pone.0170952
   Ye QH, 2018, FRONT MICROBIOL, V9, P0, DOI 10.3389/fmicb.2018.01709
   Zeng K, 2014, AM J CHINESE MED, V42, P289, DOI 10.1142/S0192415X14500190
   Zhai SJ, 2020, MEDICINE, V99, P0, DOI 10.1097/MD.0000000000019496
   Zhang CP, 2020, CHIN MED-UK, V15, P0, DOI 10.1186/s13020-020-0289-y
   Zhang X, 1991, J CHIN MED, V37, P5
   Zhao L, 2019, JAMA INTERN MED, V179, P1388, DOI 10.1001/jamainternmed.2019.2407
   Zhu LB, 2014, EVID-BASED COMPL ALT, V2014, P0, DOI 10.1155/2014/261709
NR 50
TC 8
Z9 11
U1 1
U2 28
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 2095-4964
EI 
J9 J INTEGR MED-JIM
JI J. Integr. Med.-JIM
PD MAR 15
PY 2023
VL 21
IS 2
BP 168
EP 175
DI 10.1016/j.joim.2023.02.001
EA MAR 2023
PG 8
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA G7TO6
UT WOS:000991140200001
PM 36841749
DA 2026-01-16
ER

PT J
AU Bao, T
   Zhi, WI
   Baser, RE
   Li, QS
   Weitzman, M
   Gillespie, EF
   Robson, M
   Mao, JJ
AF Bao, Ting
   Zhi, W. Iris
   Baser, Raymond E.
   Li, Q. Susan
   Weitzman, Matthew
   Gillespie, Erin F.
   Robson, Mark
   Mao, Jun J.
TI Electro-acupuncture versus battle field auricular acupuncture in breast cancer survivors with chronic musculoskeletal pain: subgroup analysis of a randomized clinical trial
SO BREAST CANCER RESEARCH AND TREATMENT
LA English
DT Article
DE Pain; Breast cancer; Acupuncture; Quality of life
ID aromatase inhibitors; women
AB Purpose Chronic musculoskeletal pain is common and debilitating among breast cancer survivors. The PEACE trial demonstrated that electro-acupuncture (EA) and battle field auricular acupuncture (BFAA) both reduced pain more than usual care (UC) in cancer survivors. However, the comparative effectiveness between EA and BFAA among breast cancer survivors is unknown. Methods EA and BFAA received ten weekly treatments. UC was offered ten EA treatments after week 12. The primary endpoint was change in mean Brief Pain Inventory (BPI) pain severity from baseline to week 12. We analyzed the subset of 165 (46%) trial participants with a breast cancer primary diagnosis. We conducted constrained linear mixed model analyses, which constrained all arms to a common pre-randomization baseline mean. Model-based mean estimates at weeks 12 and 24 were compared between arms using model contrasts. Results Among 165 breast cancer survivors, common pre-randomization mean pain severity was 5.35 [95% Confidence Interval (CI) 5.04, 5.66]. At week 12, BPI pain severity score was 2.69 (2.26. 3.13) in EA, 3.60 (3.17, 4.02) in BFAA, and 5.06 (4.47, 5.65) in UC. EA reduced pain severity significantly more than BFAA at weeks 12 [- 0.90 (- 1.45, - 0.36), p=0.001] and 24 [- 0.82, (- 1.38, - 0.27), p=0.004]. EA and BFAA significantly improved both Patient-Reported Outcomes Measurement Information System (PROMIS) - Global Health physical health and mental health component scores at week 12 compared to UC. Mild toxicities were reported. Conclusion EA was more effective than BFAA at reducing pain severity, but both similarly improved physical and mental health scores. Breast cancer survivors with chronic musculoskeletal pain may consider EA before BFAA.
C1 [Bao, Ting; Li, Q. Susan; Weitzman, Matthew; Mao, Jun J.] Mem Sloan Kettering Canc Ctr, Dept Med, Integrat Med Serv, New York, NY 10065 USA.
   [Bao, Ting; Zhi, W. Iris; Robson, Mark] Mem Sloan Kettering Canc Ctr, Solid Tumor Div, Dept Med, Breast Med Serv, New York, NY 10065 USA.
   [Baser, Raymond E.] Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, New York, NY USA.
   [Gillespie, Erin F.] Univ Washington, Dept Radiat Oncol, Sch Med, Seattle, WA USA.
   [Bao, Ting] Mem Sloan Kettering Canc Ctr, Dept Med, Integrat Med Serv, 321 E 61st St,4th Floor, New York, NY 10065 USA.
C3 Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; University of Washington; University of Washington Seattle; Memorial Sloan Kettering Cancer Center
RP Bao, T (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Med, Integrat Med Serv, New York, NY 10065 USA.; Bao, T (corresponding author), Mem Sloan Kettering Canc Ctr, Solid Tumor Div, Dept Med, Breast Med Serv, New York, NY 10065 USA.; Bao, T (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Med, Integrat Med Serv, 321 E 61st St,4th Floor, New York, NY 10065 USA.
EM tingbao@gmail.com
FU Department of Defense office of the Congressionally Directed Medical Research Programs through the Peer Reviewed Medical Research Program Clinical Trial Award [W81XWH-15-1-0245]; National Institutes of Health/National Cancer Institute (NIH/NCI) Cancer Center Support Grant [P30 CA008748]; NCI [R37 CA248563, 1 R01 CA240417, K08 CA252640]; National Cancer Institute [K08CA252640, P30CA008748, R01CA240417, R37CA248563] Funding Source: NIH RePORTER
CR American Cancer Society, 2022, BREAST CANCER, V0, P0
   Bao T, 2018, BREAST CANCER RES TR, V169, P133, DOI 10.1007/s10549-018-4670-9
   Bauml J, 2014, ACUPUNCT MED, V32, P183, DOI 10.1136/acupmed-2013-010459
   Cleeland CS, 1994, ANNALS ACADEMY OF MEDICINE SINGAPORE, V23, P129
   Crew KD, 2007, J CLIN ONCOL, V25, P3877, DOI 10.1200/JCO.2007.10.7573
   Djaali W, 2020, MED ACUPUNCT, V32, P157, DOI 10.1089/acu.2020.1410
   Fan AY, 2018, J INTEGR MED-JIM, V16, P1, DOI 10.1016/j.joim.2017.12.003
   Han JS, 2003, TRENDS NEUROSCI, V26, P17, DOI 10.1016/S0166-2236(02)00006-1
   Hays RD, 2009, QUAL LIFE RES, V18, P873, DOI 10.1007/s11136-009-9496-9
   He W, 2012, EVID-BASED COMPL ALT, V2012, P0, DOI 10.1155/2012/786839
   Hershman DL, 2021, J CLIN ONCOL, V39, P0, DOI 10.1200/JCO.2021.39.15_suppl.12018
   Hershman DL, 2018, JAMA-J AM MED ASSOC, V320, P167, DOI 10.1001/jama.2018.8907
   Jeong HJ, 2003, AM J CHINESE MED, V31, P945, DOI 10.1142/S0192415X03001661
   Liou KT, 2020, MEDICINE, V99, P0, DOI 10.1097/MD.0000000000020085
   Liu GHF, 2009, STAT MED, V28, P2509, DOI 10.1002/sim.3639
   Liu SB, 2021, NATURE, V598, P641, DOI 10.1038/s41586-021-04001-4
   Mao JJ, 2021, JAMA ONCOL, V7, P720, DOI 10.1001/jamaoncol.2021.0310
   Niemtzow R, 2018, MIL MED, V183, PE486, DOI 10.1093/milmed/usy028
   Niemtzow RC, 2020, MED ACUPUNCT, V32, P377, DOI 10.1089/acu.2020.1470
   Niemtzow RC, 2018, MED ACUPUNCT, V30, P57, DOI 10.1089/acu.2018.29077.rcn
   Sedhom R, 2021, JCO ONCOL PRACT, V17, P587, DOI 10.1200/OP.21.00361
   Vickers AJ, 2018, J PAIN, V19, P455, DOI 10.1016/j.jpain.2017.11.005
   Yang YL, 2020, EVID-BASED COMPL ALT, V2020, P0, DOI 10.1155/2020/1618767
NR 23
TC 9
Z9 9
U1 1
U2 18
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0167-6806
EI 1573-7217
J9 BREAST CANCER RES TR
JI Breast Cancer Res. Treat.
PD NOV 23
PY 2023
VL 202
IS 2
BP 287
EP 295
DI 10.1007/s10549-023-07072-1
PG 9
WC Oncology
SC Oncology
GA W6FP5
UT WOS:001092567600002
PM 37612534
DA 2026-01-16
ER

PT J
AU Lee, B
   Kwon, CY
   Lee, HW
   Nielsen, A
   Wieland, LS
   Kim, TH
   Birch, S
   Alraek, T
   Lee, MS
AF Lee, Boram
   Kwon, Chan-Young
   Lee, Hye Won
   Nielsen, Arya
   Wieland, L. Susan
   Kim, Tae-Hun
   Birch, Stephen
   Alraek, Terje
   Lee, Myeong Soo
TI Different Outcomes According to Needling Point Location Used in Sham Acupuncture for Cancer-Related Pain: A Systematic Review and Network Meta-Analysis
SO CANCERS
LA English
DT Review
DE acupuncture therapy; cancer pain; cancer-related pain; placebo; sham acupuncture
ID auricular acupuncture; controlled-trial; breast-cancer; interventions; management; symptoms; society; women; real; care
AB Simple Summary When sham acupuncture was set as a control in previous acupuncture clinical trials, the sham procedure was conducted either at the same points that were used for the verum acupuncture group or at nonindicated points. The network meta-analysis according to needling point location used in sham acupuncture for cancer-related pain revealed no significant difference in pain severity between verum acupuncture and sham acupuncture using the same points as verum acupuncture. However, verum acupuncture significantly improved the pain severity compared to sham acupuncture at sham points. Sham acupuncture needling at the same points as verum acupuncture is not a true placebo due to the lack of consideration for acupuncture point specificity.Abstract Numerous acupuncture studies have been conducted on cancer-related pain; however, its efficacy compared to sham acupuncture remains controversial. We confirmed whether the outcome of acupuncture differs according to the needling points of sham acupuncture for cancer-related pain. We searched 10 databases on 23 May 2023 to screen acupuncture trials using sham acupuncture or waiting list as controls for cancer-related pain. Sham acupuncture was classified into two types, depending on whether the needling was applied at the same locations as verum acupuncture (SATV) or not (SATS). A network meta-analysis (NMA) was performed on the basis of a frequentist approach to assess pain severity. Eight studies (n = 574 participants) were included in the review, seven of which (n = 527 participants) were included in the NMA. The pain severity was not significantly different between SATV and verum acupuncture, but verum acupuncture significantly improved pain severity compared to SATS. The risk of bias affecting the comparisons between the verum and sham acupuncture was generally low. Previous acupuncture trials for cancer-related pain showed differing outcomes of sham and verum acupuncture, depending on the needling points of sham acupuncture. The application of SATV cannot be considered a true placebo, which leads to an underestimation of the efficacy of verum acupuncture.
C1 [Lee, Boram; Lee, Myeong Soo] Korea Inst Oriental Med, KM Sci Res Div, Daejeon 34054, South Korea.
   [Kwon, Chan-Young] Dong Eui Univ, Coll Korean Med, Dept Oriental Neuropsychiat, Pusan 47227, South Korea.
   [Lee, Hye Won] Korea Inst Oriental Med, KM Convergence Res Div, Daejeon 305811, South Korea.
   [Nielsen, Arya] Icahn Sch Med Mt Sinai, Dept Family Med & Community Hlth, New York, NY 10029 USA.
   [Wieland, L. Susan] Univ Maryland, Sch Med, Ctr Integrat Med, Baltimore, MD 21201 USA.
   [Kim, Tae-Hun] Kyung Hee Univ, Korean Med Hosp, Korean Med Clin Trial Ctr, Seoul 02447, South Korea.
   [Birch, Stephen; Alraek, Terje] Kristiania Univ Coll, Sch Hlth Sci, N-0317 Oslo, Norway.
   [Alraek, Terje] Natl Res Ctr Complementary & Alternat Med NAFKAM, Inst Hlth Sci, Fac Hlth Sci, Dept Community Med, N-9037 Tromso, Norway.
C3 Korea Institute of Oriental Medicine (KIOM); Dong-Eui University; Korea Institute of Oriental Medicine (KIOM); Icahn School of Medicine at Mount Sinai; University System of Maryland; University of Maryland Baltimore; Kyung Hee University; Kristiania University College
RP Lee, MS (corresponding author), Korea Inst Oriental Med, KM Sci Res Div, Daejeon 34054, South Korea.
EM qhfka9357@kiom.re.kr; beanalogue@naver.com; hwlee@kiom.re.kr; arya@guasha.com; lswieland@gmail.com; rockandmineral@gmail.com; sjbirch@gmail.com; terje.alrak@uit.no; drmslee@gmail.com
FU Korea Institute of Oriental Medicine
CR Alimi D, 2003, J CLIN ONCOL, V21, P4120, DOI 10.1200/JCO.2003.09.011
   Bao T, 2013, BREAST CANCER RES TR, V138, P167, DOI 10.1007/s10549-013-2427-z
   Birch S, 2022, INTEGR MED RES, V11, P0, DOI 10.1016/j.imr.2021.100725
   Booker SQ, 2021, PAIN MANAG NURS, V22, P21, DOI 10.1016/j.pmn.2020.08.003
   Brignardello-Petersen R, 2018, J CLIN EPIDEMIOL, V93, P36, DOI 10.1016/j.jclinepi.2017.10.005
   Caraceni A, 2019, CANCERS, V11, P0, DOI 10.3390/cancers11040510
   Chahin M, 2021, CUREUS J MED SCIENCE, V13, P0, DOI 10.7759/cureus.19500
   Chiu HY, 2017, EUR J CANCER CARE, V26, P0, DOI 10.1111/ecc.12457
   Choi EM, 2012, CHIN MED-UK, V7, P0, DOI 10.1186/1749-8546-7-4
   Crew KD, 2010, J CLIN ONCOL, V28, P1154, DOI 10.1200/JCO.2009.23.4708
   Deng G, 2008, J THORAC CARDIOV SUR, V136, P1464, DOI 10.1016/j.jtcvs.2008.07.053
   Dincer F, 2003, COMPLEMENT THER MED, V11, P235, DOI 10.1016/S0965-2299(03)00124-9
   Ge L, 2022, CHIN MED-UK, V17, P0, DOI 10.1186/s13020-021-00558-4
   He YH, 2020, JAMA ONCOL, V6, P271, DOI 10.1001/jamaoncol.2019.5233
   Hershman DL, 2018, JAMA-J AM MED ASSOC, V320, P167, DOI 10.1001/jama.2018.8907
   Higgins Julian P T, 2011, BMJ, V343, Pd5928, DOI 10.1136/bmj.d5928
   Höxtermann MD, 2022, CANCER-AM CANCER SOC, V128, P2159, DOI 10.1002/cncr.34165
   Hozo S, 2005, BMC MED RES METHODOL, V5, P13, DOI 10.1186/1471-2288-5-13
   Hu CQ, 2016, EVID-BASED COMPL ALT, V2016, P0, DOI 10.1155/2016/1720239
   Hu H, 2016, EVIDENCE BASED RES M, V0, PP55, DOI 10.1007/978-981-10-2290-64
   Hutton B, 2015, ANN INTERN MED, V162, P777, DOI 10.7326/M14-2385
   Katta MR, 2022, J ONCOL PHARM PRACT, V28, P1859, DOI 10.1177/10781552221098437
   Kim K, 2018, INTEGR CANCER THER, V17, P1137, DOI 10.1177/1534735418786797
   Kim TH, 2022, J ACUPUNCT MERIDIAN, V15, P333, DOI 10.51507/j.jams.2022.15.6.333
   Kim TH, 2020, ACUPUNCT MED, V38, P37, DOI 10.1136/acupmed-2018-011671
   Langevin HM, 2011, EVID-BASED COMPL ALT, V2011, P0, DOI 10.1155/2011/180805
   Lee B, 2023, P 2 WORLD C INTEGRAT, V0, P0
   Lee BR, 2023, JAMA NETW OPEN, V6, P0, DOI 10.1001/jamanetworkopen.2023.32452
   Lee BR, 2023, FRONT MED-LAUSANNE, V9, P0, DOI 10.3389/fmed.2022.1061878
   Lund Irene, 2009, CHIN MED, V4, P1, DOI 10.1186/1749-8546-4-1
   MacPherson H, 2016, J ALTERN COMPLEM MED, V22, P101, DOI 10.1089/acm.2015.0184
   MacPherson H, 2014, PLOS ONE, V9, P0, DOI 10.1371/journal.pone.0093739
   Mao JJ, 2022, J CLIN ONCOL, V40, P3998, DOI 10.1200/JCO.22.01357
   Ots T, 2020, ACUPUNCT MED, V38, P211, DOI 10.1177/0964528419889636
   Paley CA, 2015, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD007753.pub3
   Park J, 1999, ACUPUNCT MED, V17, P110
   Ruela LD, 2018, REV ESC ENFERM USP, V52, P0, DOI 10.1590/S1980-220X2017040503402
   Sharfstein JM, 2019, JAMA-J AM MED ASSOC, V322, P809, DOI 10.1001/jama.2019.9794
   Shi GX, 2012, TRIALS, V13, P0, DOI 10.1186/1745-6215-13-42
   Simone CB II, 2012, CLIN J PAIN, V28, P157, DOI 10.1097/AJP.0b013e318223be30
   Snijders RAH, 2023, CANCERS, V15, P0, DOI 10.3390/cancers15030591
   So EWS, 2009, HUM REPROD, V24, P341, DOI 10.1093/humrep/den380
   Swarm RA, 2019, J NATL COMPR CANC NE, V17, P977, DOI 10.6004/jnccn.2019.0038
   Tick H, 2018, EXPLORE-NY, V14, P177, DOI 10.1016/j.explore.2018.02.001
   Wang XQ, 2022, EXPLORE-NY, V18, P36, DOI 10.1016/j.explore.2021.09.007
   Wengström Y, 2014, EUR J ONCOL NURS, V18, P127, DOI 10.1016/j.ejon.2013.11.009
   Wode K, 2019, BMC COMPLEM ALTERN M, V19, P0, DOI 10.1186/s12906-019-2452-5
   Xing JJ, 2013, INT REV NEUROBIOL, V111, P49, DOI 10.1016/B978-0-12-411545-3.00003-1
   Zhang CS, 2015, PLOS ONE, V10, P0, DOI 10.1371/journal.pone.0140825
   Zhang ZJ, 2012, EVID-BASED COMPL ALT, V2012, P0, DOI 10.1155/2012/429412
   Zia Farah Z, 2017, JOURNAL OF THE NATIONAL CANCER INSTITUTE MONOGRAPHS, V0, PP68, DOI 10.1093/jncimonographs/lgx005
NR 54
TC 10
Z9 12
U1 9
U2 36
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
SN 
EI 2072-6694
J9 CANCERS
JI Cancers
PD DEC 15
PY 2023
VL 15
IS 24
BP 
EP 
DI 10.3390/cancers15245875
PG 12
WC Oncology
SC Oncology
GA DH8R1
UT WOS:001131236100001
PM 38136419
DA 2026-01-16
ER

PT J
AU Zhang, YJ
   Zhang, YR
   Liu, SZ
   Li, BC
   Song, Z
   Han, Q
   Wang, C
   Wang, YW
   Yu, YX
   Xia, HJ
   Wang, C
   Li, J
AF Zhang, Yanji
   Zhang, Yingrong
   Liu, Suzhen
   Li, Bocun
   Song, Zhe
   Han, Qi
   Wang, Chang
   Wang, Yiwei
   Yu, Yanxin
   Xia, Hongjie
   Wang, Chun
   Li, Jia
TI Acupuncture for cancer pain: a scoping review of systematic reviews and meta-analyses
SO FRONTIERS IN ONCOLOGY
LA English
DT Article
DE acupuncture; cancer pain; scoping review; systematic reviews and meta-analyses; alternative medicine (AM)
ID therapy; management; quality
AB Background: Due to the effectiveness and safety, acupuncture, one of the traditional therapies of Chinese medicine, has been widely used in clinical practice globally. A few systematic review or meta-analyses have proved its effectiveness and safety towards patients with cancer pain, while there are no syntheses among those evidence. The aim of this scoping review is to summarize the evidence from systematic reviews of acupuncture for the treatment of cancer pain and evaluate the breadth and methodological quality of these evidence as well. Methods: The scoping review process was guided by the methodology framework of Preferred Reporting Items for Systematic Reviews and MetaAnalyses extension for scoping reviews (PRISMA ScR) and "Arkseyand O'Malley six-stage framework". Electronic searches were carried out in several online databases from inception to Jan 2022. Systematic reviews and meta-analyses that involve any type of acupuncture for patients with cancer pain will be included. A pair of reviewers independently screened full texts. Moreover, review characteristics were extracted, and methodological quality was assessed using the AMSTAR 2 tool. Results: Twenty-five systematic reviews and meta-analyses were included. Manual acupuncture is the most frequently included types of test group intervention (48%), followed by acupuncture + medicine (28%), and auricular acupuncture (12%). All the reviews have declared that acupuncture is an effective method for cancer pain treatment. Eleven reviews (44%) aiming at evaluating the safety also have confirmed that acupuncture is safe for treating cancer pain. However, most included studies were conducted in China. With certain geographical limitations, the findings were not representative within the region. The results of our review may owe to the synthesis of all kinds of cancer pain, and only 2 reviews described the type of cancer pain in detail.Conclusions: This scoping review synthesizes and evaluates existing evidence of acupuncture for cancer pain. From this scoping review of systematic reviews and meta-analyses, there are clear recommendations for future studies: expanding the region of research in the world and trying to conduct the study of different types of cancer pain in details as much as possible. Evidences of acupuncture for cancer pain can inform clinical decision-making.
C1 [Zhang, Yanji; Zhang, Yingrong; Liu, Suzhen; Li, Bocun; Wang, Yiwei; Yu, Yanxin; Xia, Hongjie; Wang, Chun; Li, Jia] Hubei Univ Chinese Med, Coll Acupuncture & Orthoped, Wuhan, Hubei, Peoples R China.
   [Song, Zhe; Wang, Chang] Hubei Univ Sci & Technol, Sch Biomed Engn & Imaging, Xianning, Hubei, Peoples R China.
   [Han, Qi] Hubei Univ Sci & Technol, Affiliated Hosp 1, Xianning Cent Hosp, Xianning, Hubei, Peoples R China.
   Univ Alberta, Fac Med & Dent, Edmonton, AB, Canada.
C3 Hubei University of Chinese Medicine; Hubei University of Science & Technology; Hubei University of Science & Technology; University of Alberta
RP Wang, C; Li, J (corresponding author), Hubei Univ Chinese Med, Coll Acupuncture & Orthoped, Wuhan, Hubei, Peoples R China.
EM hispen@126.com; ljlijia@163.com
FU National Administration of Traditional Chinese Medicine [75[2022]]; Seventh Batch of National Old Chinese Medicine Experts Academic Experience Inheritance Project [272[2021]]; Hubei University of Science and Technology Fund Project [2022-23X05]; Hubei Province Natural Science Foundation [2018XYA003]; 2018 Xianning Central Hospital Scientific Research Project [[2019]47]; 2nd Hubei Province's Outstanding Medical Academic Leader Program [284 (2018)]; Qihuang Engineering Project of National Administration of Traditional Chinese Medicine;  [2022CFB367]
CR Unknown -, 2013, SUPPORT CARE CANCER, V21, P1217, DOI 10.1007/s00520-012-1704-4, 10.1007/S00520-012-1704-4
   [边双林 Bian Shuanglin], 2020, 中国中医基础医学杂志 CHINESE JOURNAL OF BASIC MEDICINE IN TRADITIONAL CHINESE MEDICINE, V26, P1143
   Boveldt NT, 2013, PAIN PHYSICIAN, V16, P379
   Burrows M, 1998, ONCOL NURS FORUM, V25, P735
   Caiqiong H, 2015, CLIN INNOVATION STAN, V2015, P141
   Cheon S, 2018, COMPLEMENT THER CLIN, V33, P138, DOI 10.1016/j.ctcp.2018.09.008
   Choi TY, 2012, SUPPORT CARE CANCER, V20, P1147, DOI 10.1007/s00520-012-1432-9
   Deng G, 2019, CANCER J, V25, P343, DOI 10.1097/PPO.0000000000000399
   Dong B, 2021, BMC COMPLEMENT MED, V21, P0, DOI 10.1186/s12906-020-03193-y
   Ge L, 2022, CHIN MED-UK, V17, P0, DOI 10.1186/s13020-021-00558-4
   Ge S, 2011, CHIN ARCH TRADITIONA, V33, P1715
   He YH, 2020, JAMA ONCOL, V6, P271, DOI 10.1001/jamaoncol.2019.5233
   Hu CQ, 2016, EVID-BASED COMPL ALT, V2016, P0, DOI 10.1155/2016/1720239
   Hurlow A, 2012, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD006276.pub3
   Jingchun Z, 2020, MEDICINE, V99, P0, DOI 10.1097/MD.000applicable0000000023119
   Kurita GP, 2021, POL ARCH INTERN MED, V131, P0, DOI 10.20452/pamw.16136
   Kurtin S, 2019, SEMIN ONCOL NURS, V35, P284, DOI 10.1016/j.soncn.2019.04.010
   Lee H, 2005, EUR J PAIN, V9, P437, DOI 10.1016/j.ejpain.2004.10.004
   Li DH, 2021, EVID-BASED COMPL ALT, V2021, P0, DOI 10.1155/2021/5558590
   Neufeld NJ, 2017, FUTURE ONCOL, V13, P833, DOI 10.2217/fon-2016-0423
   Paice JA, 2016, J CLIN ONCOL, V34, P3325, DOI 10.1200/JCO.2016.68.5206
   Paley CA, 2015, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD007753.pub3
   Paley CA, 2011, BMJ SUPPORT PALLIAT, V1, P51, DOI 10.1136/bmjspcare-2011-000022
   Paley CA, 2011, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD007753.pub2
   Paul AK, 2021, PHARMACEUTICALS-BASE, V14, P0, DOI 10.3390/ph14111091
   Peng Hao, 2010, ZHONG XI YI JIE HE XUE BAO, V8, P501
   Pu Y, 2021, SHANGHAI J ACUPUNCTU, V40, P366, DOI 10.13460/j.issn.1005-0957.2021.03.0366
   Qizhe S, 2013, ALL HLTH, V7, P184
   Robb KA, 2008, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD006276.pub2
   Ruano A, 2022, J PAIN SYMPTOM MANAG, V63, PE505, DOI 10.1016/j.jpainsymman.2021.12.021
   Simone CB II, 2012, CLIN J PAIN, V28, P157, DOI 10.1097/AJP.0b013e318223be30
   Sutton D, 2019, ACUPUNCTURE FOR CHRONIC NON-CANCER PAIN: A REVIEW OF CLINICAL EFFECTIVENESS, V0, P0
   Tingyu C, 2019, CLIN J TRADITIONAL C, V31, P706, DOI 10.16448/j.cjtcm.2019.0207
   Tricco AC, 2018, ANN INTERN MED, V169, P467, DOI 10.7326/M18-0850
   Wang JF, 2020, J EMERG TRADIT CHIN -MED, V29, P1140, DOI 10.3969/j.issn.1004-745X.2020.07.005
   Wang JS, 2019, MEDICINE, V98, P0, DOI 10.1097/MD.0000000000013954
   Wu XY, 2015, SCI REP-UK, V5, P0, DOI 10.1038/srep16776
   Yang J, 2020, BMJ OPEN, V10, P0, DOI 10.1136/bmjopen-2020-039087
   Yang J, 2021, BMJ SUPPORT PALLIAT, V11, P264, DOI 10.1136/bmjspcare-2020-002638
   Yang YL, 2020, EVID-BASED COMPL ALT, V2020, P0, DOI 10.1155/2020/1618767
   Yu ML, 2020, EVID-BASED COMPL ALT, V2020, P0, DOI 10.1155/2020/5606823
   Yu Z, 2018, CHIN EVIDENCE BASED, V4, P309, DOI 10.3969/j.issn.2095-8668.2018.04.003
   Zheng Y, 2014, J LIAONING UNIV TRADIT CHIN MED, V16, P152, DOI 10.13194/j.issn.1673-842x.2014.01.055
   Zhou J, 2014, CHIN ARCH TRADIT CHIN MED, V32, P2326
   Zhou J, 2014, J ZHEJIANG CHINESE M, V7, P927, DOI 10.16466/J.ISSN1005-5509.2014.07.024
NR 46
TC 11
Z9 12
U1 2
U2 29
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 2234-943X
EI 
J9 FRONT ONCOL
JI Front. Oncol.
PD MAY 15
PY 2023
VL 13
IS 
BP 
EP 
DI 10.3389/fonc.2023.1169458
PG 13
WC Oncology
SC Oncology
GA H8IV5
UT WOS:000998342300001
PM 37256179
DA 2026-01-16
ER

PT J
AU Zhang, YY
   Wang, ST
   Ma, XM
   Yuan, Y
   Cheng, H
   Lin, L
   Tian, L
AF Zhang, Yueyue
   Wang, Shaotong
   Ma, Xiaomin
   Yuan, Yang
   Cheng, Hui
   Lin, Lu
   Tian, Li
TI Massage therapy can effectively relieve cancer pain: A meta-analysis
SO MEDICINE
LA English
DT Review
DE cancer pain; cancer patients; massage therapy; meta-analysis
ID induced peripheral neuropathy; symptom cluster; supportive care; back massage; prevalence; management; patient; intervention; reflexology; fatigue
AB Background:To critically evaluate the effects of massage therapy on cancer pain. Methods:Nine Chinese and English databases (PubMed, Cochrane Library, Embase, SCOPUS, Web of Science core, China Biomedical Literature Database, China National Knowledge Infrastructure, Wanfang, and VIP) were systematically searched from the inception of databases to November 2022 for randomized controlled trials. According to Cochrane Collaboration, 2 reviewers independently assessed the risk of bias and extracted data from the included studies. All analyses were performed with Review Manager 5.4. Results:Thirteen randomized controlled trials were included in the meta-analysis, containing 1000 patients (498 in the massage therapy group and 502 in the control group). Massage therapy could significantly relieve cancer pain in patients (standardized mean difference = -1.16, 95% confidence interval [-1.39, -0.93], P < .00001), especially those in the perioperative period and those with hematological malignancies. Foot reflexology and hand acupressure had a moderate effect on cancer pain relief, with hand acupressure being more effective. Massage duration of 10 to 30 minutes and a program length of & GE;1 week had a better effect and could significantly relieve pain. The occurrence of adverse events was reported in 4 of the 13 studies, all of which were no adverse events. Conclusions:Massage therapy can be used as a complementary alternative therapy to relieve cancer pain in patients with hematological malignancies, breast cancer, and cancers of the digestive system. It is suggested that chemotherapy patients use foot reflexology, and perioperative period patients use hand acupressure. A massage duration of 10 to 30 minutes and a program length of & GE;1 week is recommended to achieve better effects.
C1 [Zhang, Yueyue; Wang, Shaotong; Yuan, Yang; Cheng, Hui; Lin, Lu; Tian, Li] Soochow Univ, Sch Nursing, Suzhou Med Coll, Suzhou, Peoples R China.
   [Zhang, Yueyue; Lin, Lu; Tian, Li] Soochow Univ, Affiliated Hosp 1, Suzhou, Peoples R China.
   [Ma, Xiaomin] First Peoples Hosp Kunshan, Suzhou, Peoples R China.
   [Tian, Li] Soochow Univ, Sch Nursing, Affiliated Hosp 1, Med Coll, 188 Shizi Rd, Suzhou 215006, Peoples R China.
C3 Soochow University - China; Soochow University - China; Soochow University - China
RP Tian, L (corresponding author), Soochow Univ, Sch Nursing, Affiliated Hosp 1, Med Coll, 188 Shizi Rd, Suzhou 215006, Peoples R China.
EM 20204231007@stu.suda.edu.cn; 20204231008@stu.suda.edu.cn; mxm18913241931@163.com; 20194231009@stu.suda.edu.cn; 20205231004@stu.suda.edu.cn; linlu@suda.edu.cn; tianlisz@suda.edu.cn
CR Anderson KD, 2021, CLIN J ONCOL NURS, V25, P539, DOI 10.1188/21.CJON.539-545
   Unknown -, 2019, CLIN ED GEN PRACT, V17, P4
   Bao YJ, 2014, EVID-BASED COMPL ALT, V2014, P0, DOI 10.1155/2014/170396
   Bassampour SH, 2008, HAYAT, V14, P23
   Boyd C, 2016, PAIN MED, V17, P1553, DOI 10.1093/pm/pnw100
   Breivik H, 2009, ANN ONCOL, V20, P1420, DOI 10.1093/annonc/mdp001
   Cao M, 2021, CHIN J FRONT MED (ELECTRONIC EDITION), V13, P63, DOI 10.12037/YXQY.2021.03-10
   Cassileth Barrie, 2007, CURR PAIN HEADACHE REP, V11, P265, DOI 10.1007/s11916-007-0202-8
   Cohen J, 1988, STATISTICAL POWER ANALYSES FOR BEHAVIORAL SCIENCES, V2nd, P0, DOI 10.1016/C2013-0-10517-X
   Cunningham JE, 2011, SUPPORT CARE CANCER, V19, P1473, DOI 10.1007/s00520-011-1231-8
   Deng G, 2019, CANCER J, V25, P343, DOI 10.1097/PPO.0000000000000399
   Ernst E, 2003, RHEUMATOLOGY, V42, P1101, DOI 10.1093/rheumatology/keg306
   Evans D, 2005, PEDIATR ANESTH, V15, P131, DOI 10.1111/j.1460-9592.2005.01407.x
   Fitri SYR, 2021, COMPLEMENT THER MED, V59, P0, DOI 10.1016/j.ctim.2021.102735
   Furlan AD, 2006, CAN MED ASSOC J, V174, P1589, DOI 10.1503/cmaj.051528
   Geng Y, 2016, CHIN MANIPULATION RE, V7, P23
   Guo JM, 2017, FRONT PHYSIOL, V8, P0, DOI 10.3389/fphys.2017.00747
   Henson LA, 2020, J CLIN ONCOL, V38, P905, DOI 10.1200/JCO.19.00470
   Huang W, 2017, CHENGDU UNITRADIT CH, V0, P0
   Hulme J, 1999, J ADV NURS, V30, P460
   Izgu N, 2019, EUR J ONCOL NURS, V40, P36, DOI 10.1016/j.ejon.2019.03.002
   Jahani S, 2018, ASIAN JOURNAL OF PHARMACEUTICAL AND CLINICAL RESEARCH, V11, P401, DOI 10.22159/ajpcr.2018.v11i6.25212
   Jamsek MC, 2013, REMEDIAL MASSAGE THE, V0, P3
   Karagozoglu S, 2013, APPL NURS RES, V26, P210, DOI 10.1016/j.apnr.2013.07.002
   Kwekkeboom KL, 2012, J PAIN SYMPTOM MANAG, V44, P810, DOI 10.1016/j.jpainsymman.2011.12.281
   Li J, 2020, JIA YOU YUN BAO, V2, P112
   Li X, 2014, TIANJIN JOURNAL OF NURSING, V0, P0
   刘霆, 2012, 中华血液学杂志 CHINESE JOURNAL OF HEMATOLOGY, V33, P73
   Loew LM, 2014, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD003528.pub2
   Lu J, 2014, SHANGHAI J ACUPUNCT, V33, P520522
   Magee D, 2019, PAIN MANAG, V9, P63, DOI 10.2217/pmt-2018-0031
   [秘营昌 Mi Yingchang], 2011, 循证医学 THE JOURNAL OF EVIDENCE-BASED MEDICINE, V11, P260
   Miake-Lye IM, 2019, J ALTERN COMPLEM MED, V25, P475, DOI 10.1089/acm.2018.0282
   Miladinia M, 2017, CANCER NURS, V40, P31, DOI 10.1097/NCC.0000000000000353
   Moher D, 2009, ANN INTERN MED, V151, P264, DOI 10.7326/0003-4819-151-4-200908180-00135
   Musarezaie Amir, 2014, J EDUC HEALTH PROMOT, V3, P64, DOI 10.4103/2277-9531.134778
   Nachman JB, 2009, J CLIN ONCOL, V27, P5189, DOI 10.1200/JCO.2008.20.8959
   Nia HS, 2017, INT J NURS PRACT, V23, P0, DOI 10.1111/ijn.12513
   Paice JA, 2011, CA-CANCER J CLIN, V61, P157, DOI 10.3322/caac.20112
   Pan Y, 2015, EVIDENCE BASED RES P, V0, P0
   Post-White Janice, 2003, INTEGR CANCER THER, V2, P332, DOI 10.1177/1534735403259064
   Rambod M, 2019, EUR J ONCOL NURS, V43, P0, DOI 10.1016/j.ejon.2019.101678
   Rizi MS, 2017, COMPLEMENT THER CLIN, V29, P136, DOI 10.1016/j.ctcp.2017.09.002
   Song Jie Song Jie, 2014, JOURNAL OF NANJING FORESTRY UNIVERSITY (NATURAL SCIENCES EDITION), V38, P135
   Su J, 2016, CHIN NURS RES, V30, P4241
   Tian L, 2011, CHIN J MOD NURS, V17, P3997
   Tsay SL, 2008, CANCER NURS, V31, P109, DOI 10.1097/01.NCC.0000305694.74754.7b
   van den Beuken-van Everdingen MHJ, 2016, J PAIN SYMPTOM MANAG, V51, P1070, DOI 10.1016/j.jpainsymman.2015.12.340
   Villars P, 2007, J PAIN SYMPTOM MANAG, V33, P67, DOI 10.1016/j.jpainsymman.2006.07.011
   Wang X, 2021, CHINA FOREIGN MED TR, V40, P108
   [王亚玲 Wang Yaling], 2018, 介入放射学杂志 JOURNAL OF INTERVENTIONAL RADIOLOGY, V27, P1202
   Wyatt G, 2012, ONCOL NURS FORUM, V39, P568, DOI 10.1188/12.ONF.568-577
   Zeng HM, 2018, LANCET GLOB HEALTH, V6, PE555, DOI 10.1016/S2214-109X(18)30127-X
   Zhao W, 2021, SHANDONG J TRADIT CH, V40, P162
   Zheng Z, 2015, CHINA PRAC MED, V10, P235
   Zhong G, 2022, J CLIN ACUPUNCT MOXI, V38, P91
   Zhu C, 2020, J ANHUI UNIV CHIN MED, V39, P47, DOI 10.3969/J.ISSN.2095-7246.2020.06.014
NR 58
TC 20
Z9 26
U1 2
U2 26
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0025-7974
EI 1536-5964
J9 MEDICINE
JI Medicine (Baltimore)
PD JUL 7
PY 2023
VL 102
IS 27
BP 
EP 
DI 10.1097/MD.0000000000033939
PG 10
WC Medicine, General & Internal
SC General & Internal Medicine
GA L8IQ1
UT WOS:001025647200006
PM 37417622
DA 2026-01-16
ER

PT J
AU Holz, SC
AF Holz, Sara Christensen
TI Aromatase Inhibitor Musculoskeletal Syndrome and Bone Loss: a Review of the Current Literature
SO CURRENT ONCOLOGY REPORTS
LA English
DT Review
DE Aromatase inhibitor; Musculoskeletal complications; Cancer rehabilitation; Cancer treatment side effects
ID breast-cancer survivors; induced arthralgia; postmenopausal women; risk-factors; trial; symptoms; pain; anastrozole; exemestane; letrozole
AB Purpose of Review The study aims to review the literature regarding musculoskeletal complications of aromatase inhibitors and treatment options for these complications. Recent Findings Aromatase inhibitors are common medications to treat hormone receptor-positive breast cancer in postmenopausal women and have been shown to improve survival and prevent disease recurrence. However, 20-60% patients stop treatment prematurely due to side effects. Side effects include joint stiffness and pain, tendonitis, tendon tears, muscle pain, and carpal tunnel syndrome known as aromatase inhibitor musculoskeletal syndrome (AIMSS) as well as bone loss. Proposed mechanisms of AIMSS include decreased estrogen levels, inflammation, and genetic factors. Switching aromatase inhibitors, exercise, non-steroidal anti-inflammatory medications, duloxetine, acupuncture, prednisone, and bisphosphonates are some treatment options for this syndrome and will be discussed in more detail in this review. Summary Aromatase inhibitors are important in the treatment of hormone receptor-positive breast cancer in postmenopausal women. As we study the incidence of side effects of these medications including bone loss and AIMSS and determine the mechanisms of these symptoms and possible treatment options, we will decrease the incidence of patients discontinuing treatment prematurely and improve symptoms, quality of life, and survival in this patient population.
C1 [Holz, Sara Christensen] Univ Wisconsin, Sch Med & Publ Hlth, Madison, WI 53705 USA.
C3 University of Wisconsin System; University of Wisconsin Madison
RP Holz, SC (corresponding author), Univ Wisconsin, Sch Med & Publ Hlth, Madison, WI 53705 USA.
EM christensenholz@rehab.wisc.edu
CR Anand K, 2019, CURR ONCOL REP, V21, P0, DOI 10.1007/s11912-019-0795-1
   Arem H, 2016, J CANCER SURVIV, V10, P654, DOI 10.1007/s11764-015-0511-6
   Bertolini E, 2011, JOINT BONE SPINE, V78, P62, DOI 10.1016/j.jbspin.2010.05.016
   Boing L, 2020, MATURITAS, V141, P71, DOI 10.1016/j.maturitas.2020.06.022
   Briot K, 2010, BREAST CANCER RES TR, V120, P127, DOI 10.1007/s10549-009-0692-7
   Bruzzese V, 2011, INT J IMMUNOPATH PH, V24, P1099, DOI 10.1177/039463201102400430
   Caprioli M, 2017, RMD OPEN, V3, P0, DOI 10.1136/rmdopen-2017-000523
   Chao J, 2009, J RHEUMATOL, V36, P1087, DOI 10.3899/jrheum.080648
   Chung KY, 2022, PLAST RECONSTR SURG, V149, P445E, DOI 10.1097/PRS.0000000000008835
   Coleman R, 2014, ANN ONCOL, V25, P124, DOI 10.1093/annonc/mdu103
   Colleoni M, 2018, LANCET ONCOL, V19, P127, DOI 10.1016/S1470-2045(17)30715-5
   De Placido S, 2018, LANCET ONCOL, V19, P474, DOI 10.1016/S1470-2045(18)30116-5
   Din OS, 2010, BREAST CANCER RES TR, V120, P525, DOI 10.1007/s10549-010-0757-7
   Dowsett M, 2015, LANCET, V386, P1341, DOI 10.1016/S0140-6736(15)61074-1
   Eastell R, 2008, J CLIN ONCOL, V26, P1051, DOI 10.1200/JCO.2007.11.0726
   Henry NL, 2018, J CLIN ONCOL, V36, P326, DOI 10.1200/JCO.2017.74.6651
   Henry NL, 2012, J CLIN ONCOL, V30, P936, DOI 10.1200/JCO.2011.38.0261
   Hershman DL, 2018, JAMA-J AM MED ASSOC, V320, P167, DOI 10.1001/jama.2018.8907
   Hyder T, 2021, FRONT ENDOCRINOL, V12, P0, DOI 10.3389/fendo.2021.713700
   Kubo M, 2012, ANTICANCER RES, V32, P2331
   Lustberg MB, 2018, BREAST CANCER RES TR, V167, P709, DOI 10.1007/s10549-017-4559-z
   Mao JJ, 2009, CANCER, V115, P3631, DOI 10.1002/cncr.24419
   Martens HA, 2007, RHEUMATOLOGY, V46, P1619, DOI 10.1093/rheumatology/kem213
   Mitsimponas N, 2018, CASE REP ONCOL, V11, P557, DOI 10.1159/000491874
   Morales L, 2007, BREAST CANCER RES TR, V104, P87, DOI 10.1007/s10549-006-9394-6
   Niravath P, 2013, ANN ONCOL, V24, P1443, DOI 10.1093/annonc/mdt037
   Paulo TRS, 2019, HEALTH QUAL LIFE OUT, V17, P0, DOI 10.1186/s12955-019-1090-4
   Pedersini R, 2019, JAMA NETW OPEN, V2, P0, DOI 10.1001/jamanetworkopen.2019.11080
   Presant CA, 2007, CLIN BREAST CANCER, V7, P775, DOI 10.3816/CBC.2007.n.038
   Roberts KE, 2022, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD013167.pub2
   Santa-Maria CA, 2018, BREAST CANCER RES TR, V171, P121, DOI 10.1007/s10549-018-4811-1
   Sestak I, 2008, LANCET ONCOL, V9, P866, DOI 10.1016/S1470-2045(08)70182-7
   Shen S, 2018, BREAST CANCER RES TR, V172, P603, DOI 10.1007/s10549-018-4946-0
   Sheng JY, 2019, BREAST CANCER RES TR, V176, P617, DOI 10.1007/s10549-019-05270-4
   Shin DJ, 2022, MEDICINE, V101, P0, DOI 10.1097/MD.0000000000028786
   Tenti S, 2020, INT J MOL SCI, V21, P0, DOI 10.3390/ijms21165625
   Wagner LI, 2018, BREAST CANCER RES TR, V169, P537, DOI 10.1007/s10549-018-4713-2
   Xu XQ, 2019, BREAST CANCER RES TR, V174, P785, DOI 10.1007/s10549-018-05086-8
   Yardley DA, 2016, BREAST CANCER-TARGET, V8, P73, DOI 10.2147/BCTT.S97963
   Zhu XY, 2021, FRONT ONCOL, V11, P0, DOI 10.3389/fonc.2021.745280
NR 40
TC 7
Z9 7
U1 1
U2 11
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 1523-3790
EI 1534-6269
J9 CURR ONCOL REP
JI Curr. Oncol. Rep.
PD JUL 15
PY 2023
VL 25
IS 7
BP 825
EP 831
DI 10.1007/s11912-023-01413-5
PG 7
WC Oncology
SC Oncology
GA LG1P9
UT WOS:001185540600001
PM 37052869
DA 2026-01-16
ER

PT J
AU Qi, L
   Shi, H
   Zhang, Y
   Zhang, X
   Jia, H
   Tian, H
AF Qi, Lin
   Shi, Hongshuo
   Zhang, Yunsong
   Zhang, Xuecheng
   Jia, Hongling
   Tian, Hu
TI The effect of acupuncture on recovery after colorectal cancer resection: A
SO Medicine
LA English
DT Journal Article
AB BACKGROUND: To evaluate the efficacy and safety of acupuncture by systematically  reviewing the literature on colorectal cancer resection. METHODS: Seven  electronic databases were searched from inception to February 28, 2023.  Randomized controlled trials on acupuncture in patients after CRC resection were  included. Two reviewers independently selected relevant trials, extracted data,  and assessed the risk of bias. A random-effects meta-analysis model was used to  obtain summary effect estimates. The data were pooled and analyzed using RevMan  5.3. The heterogeneity of selected studies was evaluated by evaluating the  I-squared (I2) statistics. RESULTS: Twenty-two studies with 1878 patients were  included. Results of the meta-analysis showed there was a low level evidence that  acupuncture may improve early postoperative symptoms, such as time to first  flatus (n = 876, MD -0.77h, 95% CI -1.22 to -0.33 h, I2 = 89%), time to first  bowel movement (n = 671, MD -1.41h, 95% CI -2.20 to -0.63 h, I2 = 95%), time to  first defecation (n = 556, MD -1.03h, 95% CI -1.88 to -0.18 h, I2 = 95%), and  nausea/vomiting (n = 1488, RR 0.72, 95% CI 0.59-0.89, I2 = 49%) compared with  usual care and sham acupuncture. However, there were no statistically significant  differences in postoperative pain (n = 1188, MD-0.21, 95% CI -0.59 to 0.17, I2 =  74%). And there was no sufficient evidence of improving long-term functional  outcomes. There was substantial heterogeneity across trials. The adverse events  associated with acupuncture stimulation were minor in include studies. CONCLUSION  SUBSECTIONS: There is currently low-level evidence supporting the use of  acupuncture on postoperative symptoms for patients after colorectal cancer  resection. More investigations should be established based on the STRICTA  statement strictly.
C1 College of Traditional Chinese Medicine, Shandong University of Traditional Chinese Medicine, Jinan, China.
   College of Traditional Chinese Medicine, Shandong University of Traditional Chinese Medicine, Jinan, China.
   The First Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, China.
   Beijing University of Chinese Medicine, Beijing, China.
   The Second Affiliated Hospital of Shandong University of traditional Chinese Medicine, Jinan, China.
   College of Traditional Chinese Medicine, Shandong University of Traditional Chinese Medicine, Jinan, China.
NR 0
TC 0
SN 1536-596
EI 0025-797
J9 Medicine (Baltimore)
PD SEP 1
PY 2023
VL 102
IS 35
BP e34678
EP e34678
DI 10.1097/MD.0000000000034678
PG 1
WC Humans; Randomized Controlled Trials as Topic; Acupuncture Therapy; Pain, Postoperative; Databases, Factual; Colorectal Neoplasms; surgery
UT PubMed:37657054
PM 37657054
DA 2023-09-01
ER

PT J
AU Yurkovski, IL
   Andreazzoli, F
   Ben-Arye, E
   Attias, S
   Tadmor, T
AF Yurkovski, Ilana Levy
   Andreazzoli, Francesca
   Ben-Arye, Eran
   Attias, Samuel
   Tadmor, Tamar
TI Integrative Approaches in the Treatment of Patients Affected by Lymphoma
SO CURRENT ONCOLOGY REPORTS
LA English
DT Review
DE Integrative medicine; Lymphoma; Complementary medicine; Haemato-oncology
ID non-hodgkin-lymphoma; cancer-related fatigue; vincristine-induced neuropathy; induced peripheral neuropathy; chemotherapy-induced nausea; oral polyphenon e; vitamin-d levels; b-cell lymphoma; rai stage 0; alternative medicine
AB Purpose of ReviewLymphoma is the most frequent hematological malignancy with wide disease spectrum of watchful waiting period, active treatment, survivorship, and palliative care. All these steps impose unmet needs in terms of prevention, symptom alleviation, or prognosis. Complementary and integrative medicine (CIM) is widely used by patients with lymphoma to cope with such issues. Here, we describe the different CIM modalities that may be effective and safe for the management of patients with lymphoma.Recent FindingsLow inflammatory diet and ginseng seem effective for lymphoma prevention. Pain and neuropathy may be improved using acupuncture, touch therapy and specific dietary supplements. Nausea/vomiting, fatigue, and insomnia may be relieved by acupuncture, mind-body, touch therapy, and certain dietary supplements. Vitamin D, curcumin, and some traditional medicine herbs may positively impact lymphoma prognosis. Finally, safety issues should be considered especially for the concomitant use of dietary supplements and lymphoma-directed therapies.SummaryCIM may be beneficial along the continuum of lymphoma management although safety concerns should be considered when used concomitantly with conventional therapy.
C1 [Yurkovski, Ilana Levy; Tadmor, Tamar] Bnai Zion Med Ctr, Rheumatol Unit, Golomb 47, Haifa 38041, Israel.
   [Yurkovski, Ilana Levy; Attias, Samuel] Bnai Zion Med Ctr, Complementary Med Serv, Hefa, Israel.
   [Yurkovski, Ilana Levy; Ben-Arye, Eran; Tadmor, Tamar] Technion Israel Inst Technol, Rappaport Fac Med, Haifa, Israel.
   [Andreazzoli, Francesca] Versilias Hosp, Dept Hematol, Camaiore, Italy.
   [Ben-Arye, Eran] Lin Carmel & Zebulun Med Ctr, Integrat Oncol Program, Oncol Serv, Clalit Hlth Serv, Haifa, Israel.
C3 Bnai Zion Medical Center; Bnai Zion Medical Center; Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Clalit Health Services
RP Yurkovski, IL (corresponding author), Bnai Zion Med Ctr, Rheumatol Unit, Golomb 47, Haifa 38041, Israel.; Yurkovski, IL (corresponding author), Bnai Zion Med Ctr, Complementary Med Serv, Hefa, Israel.; Yurkovski, IL (corresponding author), Technion Israel Inst Technol, Rappaport Fac Med, Haifa, Israel.
EM ilana.e.levy@gmail.com
CR Abad ANamvaran Abbas, 2011, CHINESE JOURNAL OF NATURAL MEDICINES, V9, P126, DOI 10.3724/SP.J.1009.2011.00126
   Abad Ali Namvaran Abbas, 2011, CHINESE JOURNAL OF NATURAL MEDICINES, V9, P354, DOI 10.3724/SP.J.1009.2011.00354
   Afungchwi GM, 2017, BMC COMPLEM ALTERN M, V17, P0, DOI 10.1186/s12906-017-1719-y
   Almanza-Aguilera E, 2023, SEMIN CANCER BIOL, V95, P103, DOI 10.1016/j.semcancer.2023.08.001
   Alparslan GB, 2012, J AUST TRADIT-MED SO, V18, P15
   Amatya B, 2021, J REHABIL MED, V53, P0, DOI 10.2340/16501977-2810
   Andreazzoli F, 2023, INT J MOL SCI, V24, P0, DOI 10.3390/ijms24021732
   Atas U, 2023, NUTR CANCER, V75, P591, DOI 10.1080/01635581.2022.2142248
   Baysal M, 2021, NIGER J CLIN PRACT, V24, P1194, DOI 10.4103/njcp.njcp_429_20
   Ben-Arye E, 2022, IMPACT ACUPUNCTURE I, V0, P0
   Ben-Arye E, 2010, LEUKEMIA LYMPHOMA, V51, P1414, DOI 10.3109/10428194.2010.487622
   Bertrand KA, 2017, AM J CLIN NUTR, V106, P650, DOI 10.3945/ajcn.117.155010
   Borchmann S, 2019, J CLIN ONCOL, V37, P3528, DOI 10.1200/JCO.19.00985
   Bruns H, 2015, SCI TRANSL MED, V7, P0, DOI 10.1126/scitranslmed.aaa3230
   Chang YD, 2018, AM J HOSP PALLIAT ME, V35, P144, DOI 10.1177/1049909117695733
   Chen KW, 2002, J ALTERN COMPLEM MED, V8, P615, DOI 10.1089/107555302320825138
   Choi J, 2022, NUTRIENTS, V14, P0, DOI 10.3390/nu14234982
   Cohen L, 2004, CANCER-AM CANCER SOC, V100, P2253, DOI 10.1002/cncr.20236
   Drake MT, 2010, J CLIN ONCOL, V28, P4191, DOI 10.1200/JCO.2010.28.6674
   Eikeland SA, 2021, ACTA ONCOL, V60, P911, DOI 10.1080/0284186X.2021.1917776
   El Iskandarani S, 2022, BLOOD REV, V56, P0, DOI 10.1016/j.blre.2022.100985
   Fancher KM, 2020, CANCER CHEMOTH PHARM, V86, P507, DOI 10.1007/s00280-020-04137-6
   Felbel S, 2014, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD010146.pub2
   Frenkel M, 2015, CURR ONCOL REP, V17, P0, DOI 10.1007/s11912-015-0445-1
   Geyer HL, 2020, BLOOD, V135, P2354, DOI 10.1182/blood.2019003116
   Ghirardi O, 2005, ANTICANCER RES, V25, P2681
   Gupta Kush, 2021, CANCER TREAT RES COMMUN, V26, P100278, DOI 10.1016/j.ctarc.2020.100278
   Habermann TM, 2009, AM J HEMATOL, V84, P795, DOI 10.1002/ajh.21554
   Hamilton AS, 2013, INTEGR CANCER THER, V12, P225, DOI 10.1177/1534735412449733
   Hathiramani S, 2021, J CANCER SURVIV, V15, P470, DOI 10.1007/s11764-020-00941-4
   Hohaus S, 2018, CANCER MED-US, V7, P270, DOI 10.1002/cam4.1166
   Huang Q, 2021, FRONT PHARMACOL, V12, P0, DOI 10.3389/fphar.2021.787816
   Hübner J, 2021, DTSCH ARZTEBL INT, V118, P654, DOI 10.3238/arztebl.m2021.0277
   Hutchinson K, 2015, LEUKEMIA LYMPHOMA, V56, P508, DOI 10.3109/10428194.2014.919633
   International Agency for Research on Cancer. World Health Organization, 2023, FACT SHEET: PCAOB IMPOSES HISTORIC SANCTIONS ON CHINA-BASED AUDIT FIRMS, V0, P0
   Jang DK, 2020, BIOMOLECULES, V10, P0, DOI 10.3390/biom10020324
   Jiménez-Cortegana C, 2021, CANCERS, V13, P0, DOI 10.3390/cancers13184622
   Jung JS, 2017, CASE REP ONCOL, V10, P515, DOI 10.1159/000472248
   Kaur Gurpreet, 2018, INT J YOGA, V11, P249, DOI 10.4103/ijoy.ijoy_17_18
   Kayo T, 2024, J INTEGR COMPLEMENT, V30, P77, DOI 10.1089/jicm.2022.0710
   Kelly JL, 2015, J CLIN ONCOL, V33, P1482, DOI 10.1200/JCO.2014.57.5092
   Kelly JL, 2009, CANCER INVEST, V27, P942, DOI 10.3109/07357900902849632
   Kim K, 2018, EUR J ONCOL NURS, V33, P91, DOI 10.1016/j.ejon.2018.01.012
   Konstantinidis Theocharis I, 2019, ASIAN PAC J CANCER PREV, V20, P1487, DOI 10.31557/apjcp.2019.20.5.1487
   Kulling PM, 2017, EUR J HAEMATOL, V98, P187, DOI 10.1111/ejh.12818
   Kumagai T, 2007, LEUKEMIA RES, V31, P523, DOI 10.1016/j.leukres.2006.08.019
   Kutcher AM, 2022, WESTERN J NURS RES, V44, P169, DOI 10.1177/0193945921992538
   Lee S, 2021, EXPLORE-NY, V17, P265, DOI 10.1016/j.explore.2020.10.004
   Lemke EA, 2021, J ADV PRACT ONCOL, V12, P0
   Li DH, 2021, EVID-BASED COMPL ALT, V2021, P0, DOI 10.1155/2021/5558590
   Li WY, 2022, BMC INFECT DIS, V22, P0, DOI 10.1186/s12879-022-07338-x
   Li XX, 2022, FRONT NUTR, V9, P0, DOI 10.3389/fnut.2022.1060783
   Liang H, 2023, INTEGR CANCER THER, V22, P0, DOI 10.1177/15347354221147515
   Liu WP, 2020, CANCER MED-US, V9, P3765, DOI 10.1002/cam4.3037
   Ma Y, 2022, FRONT ONCOL, V12, P1
   Mahurin HM, 2021, COMPLEMENT THER MED, V61, P0, DOI 10.1016/j.ctim.2021.102762
   Mao JJ, 2022, J CLIN ONCOL, V40, P3998, DOI 10.1200/JCO.22.01357
   Marx W, 2017, NUTRIENTS, V9, P0, DOI 10.3390/nu9080867
   Marx W, 2017, CRIT REV FOOD SCI, V57, P141, DOI 10.1080/10408398.2013.865590
   Matsukawa T, 2020, ANN HEMATOL, V99, P2859, DOI 10.1007/s00277-020-04262-5
   Mora DC, 2022, BMC COMPLEMENT MED, V22, P0, DOI 10.1186/s12906-022-03537-w
   Nagata A, 2020, HEMATOL ONCOL, V38, P309, DOI 10.1002/hon.2732
   Nakamura N, 2022, LEUKEMIA LYMPHOMA, V63, P1323, DOI 10.1080/10428194.2021.2020777
   Nath K, 2022, TRANSPL CELL THER, V28, P0, DOI 10.1016/j.jtct.2022.08.001
   Ni F, 2018, SCI REP-UK, V8, P0, DOI 10.1038/s41598-018-21570-z
   Okolo ON, 2019, CURR HEMATOL MALIG R, V14, P328, DOI 10.1007/s11899-019-00526-8
   Pradhan P, 2023, J NUTR, V153, P1170, DOI 10.1016/j.tjnut.2023.02.032
   Psaltopoulou T, 2018, NUTR CANCER, V70, P821, DOI 10.1080/01635581.2018.1490444
   Rambod M, 2019, EUR J ONCOL NURS, V43, P0, DOI 10.1016/j.ejon.2019.101678
   Hosnijeh FS, 2021, INT J CANCER, V148, P2115, DOI 10.1002/ijc.33369
   Samuels N, 2020, PHARMACEUTICALS-BASE, V13, P0, DOI 10.3390/ph13120455
   Sands S, 2017, SUPPORT CARE CANCER, V25, P701, DOI 10.1007/s00520-016-3441-6
   Sarisoy P, 2020, HOLIST NURS PRACT, V34, P345, DOI 10.1097/HNP.0000000000000412
   Sato T, 2015, MOL MED REP, V12, P6215, DOI 10.3892/mmr.2015.4137
   Satoh T, 2016, J PHARM PHARM SCI, V19, P188, DOI 10.18433/J3MS5C
   Schloss JM, 2017, SUPPORT CARE CANCER, V25, P195, DOI 10.1007/s00520-016-3404-y
   Sezgin MG, 2022, SUPPORT CARE CANCER, V30, P8733, DOI 10.1007/s00520-022-07198-w
   Shan SN, 2023, SUPPORT CARE CANCER, V31, P0, DOI 10.1007/s00520-023-07926-w
   Shanafelt TD, 2013, CANCER-AM CANCER SOC, V119, P363, DOI 10.1002/cncr.27719
   Shanafelt TD, 2009, J CLIN ONCOL, V27, P3808, DOI 10.1200/JCO.2008.21.1284
   Shivappa N, 2017, CANCER CAUSE CONTROL, V28, P791, DOI 10.1007/s10552-017-0905-z
   Solans M, 2020, EUR J NUTR, V59, P813, DOI 10.1007/s00394-019-01947-0
   Solans M, 2019, INT J CANCER, V145, P122, DOI 10.1002/ijc.32091
   Solimini AG, 2016, CANCER CAUSE CONTROL, V27, P595, DOI 10.1007/s10552-016-0745-2
   Stephenson NLN, 2007, ONCOL NURS FORUM, V34, P127, DOI 10.1188/07.ONF.127-132
   Tabatabaee Amir, 2016, MED ARCH, V70, P142, DOI 10.5455/medarh.2016.70.142-147
   Talib WH, 2022, FRONT NUTR, V9, P0, DOI 10.3389/fnut.2022.905658
   Tan BL, 2019, MOLECULES, V24, P0, DOI 10.3390/molecules24142527
   Tao YX, 2021, FUTURE ONCOL, V17, P1825, DOI 10.2217/fon-2020-0914
   Tretli S, 2012, CANCER CAUSE CONTROL, V23, P363, DOI 10.1007/s10552-011-9885-6
   Vargas-Roman K, 2022, J CLIN MED, V11, P0
   Viscuse PV, 2017, CURR OPIN ONCOL, V29, P235, DOI 10.1097/CCO.0000000000000376
   Wang HN, 2018, CHEM-BIOL INTERACT, V281, P11, DOI 10.1016/j.cbi.2017.12.017
   Wang XS, 2002, J CLIN ONCOL, V20, P1319, DOI 10.1200/JCO.20.5.1319
   Weinhold KR, 2023, NUTR CANCER, V75, P937, DOI 10.1080/01635581.2023.2173259
   Wu T, 2015, J EXP CLIN CANC RES, V34, P0, DOI 10.1186/s13046-015-0133-x
   Wu WC, 2023, CANCER MED-US, V12, P9439, DOI 10.1002/cam4.5706
   Yang S, 2010, CLIN CANCER RES, V16, P4755, DOI 10.1158/1078-0432.CCR-10-0883
   Yeh ML, 2016, EUR J ONCOL NURS, V23, P81, DOI 10.1016/j.ejon.2016.05.003
   Zhang W, 2020, BIOCHEM BIOPH RES CO, V524, P70, DOI 10.1016/j.bbrc.2019.12.129
   Zhang Y, 2021, FRONT ONCOL, V11, P1
   Zhang Y, 2018, SUPPORT CARE CANCER, V26, P415, DOI 10.1007/s00520-017-3955-6
   Zhang YJ, 2022, HEMATOLOGY, V27, P653, DOI 10.1080/16078454.2022.2078040
   Zhang YY, 2023, MEDICINE, V102, P0, DOI 10.1097/MD.0000000000033939
NR 104
TC 5
Z9 5
U1 2
U2 9
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 1523-3790
EI 1534-6269
J9 CURR ONCOL REP
JI Curr. Oncol. Rep.
PD DEC 15
PY 2023
VL 25
IS 12
BP 1523
EP 1534
DI 10.1007/s11912-023-01476-4
EA DEC 2023
PG 12
WC Oncology
SC Oncology
GA CE8P5
UT WOS:001115083700001
PM 38060095
DA 2026-01-16
ER

PT J
AU Dan-Feng, Z
   Jian-Cheng, R
   Shu-Zhen, Z
   Kun, Z
   Hong-Zhi, Y
   Lian-Sheng, Y
   Chun-Zhi, T
AF Dan-Feng, Zhou
   Jian-Cheng, Rong
   Shu-Zhen, Zheng
   Kun, Zhang
   Hong-Zhi, Yang
   Lian-Sheng, Yang
   Chun-Zhi, Tang
TI Enhanced acupuncture therapy for radiotherapy-related neuropathic pain in
SO Frontiers in neurology
LA English
DT Journal Article
DE acupuncture; cancer; case report; neuropathic pain; radiotherapy
AB As radiation therapy is increasingly utilized in the treatment of cancer,  neuropathic pain (NP) is a common radiotherapy-related adverse effect and has a  significant impact on clinical outcomes negatively. However, despite an improved  understanding of neuropathic pain management, pain is often undertreated in  patients with cancer. Herein, we reported two cases with radiotherapy-related  neuropathic pain (RRNP) who presented a positive reaction to acupuncture. Patient  1 (a 73-year-old woman) with gynecologic cancer complained of burning and  electric shock-like pain in the lower limb after radiotherapy. With the accepted  combination of acupuncture and drugs, the pain was alleviated completely in 8  weeks. Patient 2 (a 64-year-old woman) accepted acupuncture in the absence of  medication because of her inability to tolerate the adverse events of  anticonvulsant drugs. She achieved remission of pain 4 weeks later. The results  of this study showed that acupuncture might be promising for controlling the RRNP  in patients with cancer, especially who were intolerant or unresponsive to  medications.
C1 Department of Acupuncture and Moxibustion, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
   Department of Rehabilitation, Jiangmen Central Hospital, Jiangmen, China.
   Department of Acupuncture and Moxibustion, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
   Department of Acupuncture and Moxibustion, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
   Department of Traditional Chinese Medicine, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
   Department of Acupuncture and Moxibustion, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
   Medical College of Acu-Moxi and Rehabilitation, Guangzhou University of Chinese 
   South China Research Center for Acupuncture and Moxibustion, Medical College of Acu-Moxi and Rehabilitation, Guangzhou University of Chinese Medicine, Guangzhou,China.
NR 0
TC 0
SN 1664-229
EI 1664-229
J9 Front Neurol
PD JUN 23
PY 2023
VL 14
IS 
BP 1163990
EP 1163990
DI 10.3389/fneur.2023.1163990
PG 0
UT PubMed:37351267
PM 37351267
DA 2023-06-23
ER

PT J
AU Guo, F
   Han, RL
   Sun, L
   Zheng, LL
   Wang, YZ
   Yan, YT
   Liu, C
   Qin, Y
   Yuan, C
   Wang, S
   Sun, XD
   Gao, CJ
AF Guo, Fei
   Han, Ruili
   Sun, Li
   Zheng, Lanlan
   Wang, Yanzheng
   Yan, Yuting
   Liu, Chen
   Qin, Yuan
   Yuan, Chen
   Wang, Shuang
   Sun, Xude
   Gao, Changjun
TI Effect of transcutaneous electrical acupoint stimulation on postoperative cognitive function in older patients with lung cancer: A randomized, double-blind, placebo-controlled trial
SO HELIYON
LA English
DT Article
DE Transcutaneous electrical acupoint stimulation; (TEAS); Postoperative cognitive dysfunction(POCD); Quality of life; Lung cancer; Older patients
ID dysfunction; anesthesia; delirium; decline; surgery; prevention; fatigue; stress; sleep; pain
AB Objective: This trial was to examine the effect of transcutaneous electrical acupoint stimulation (TEAS) on postoperative cognitive function in older patients who underwent thoracoscopic pulmonary resection.Methods: This was a prospective, randomized, double-blind, placebo-controlled study. 128 patients scheduled for surgery were randomly assigned to the TEAS group and sham-TEAS group. A standardized intervention of TEAS or sham-TEAS on the acupoints of Baihui (DU20) and bilateral Neiguan (PC6), Hegu (LI4), and Zusanli (ST36) from 30 min before anesthesia induction until the end of the surgery, combined with a general anesthetic protocol performed in the two groups respectively. The primary outcome was the incidence of postoperative cognitive dysfunction (POCD) assessed via the Montreal Cognitive Assessment (MoCA) scale at each time point. The secondary outcomes included the results of the Mini-Mental State Examination (MMSE) score, the Numerical Rating Scale (NRS) on pain and sleep, the European Organization for Research and Treatment of Cancer Quality of Life (EORTC-QLQ-C30), and a chronic pain questionnaire at relative time points.Results: Participants who completed the 12-month trial of the two groups were well-matched in baseline demographic and clinical parameters. At postoperative day 1, day 7, and day 30 time points, the incidence of POCD in the sham-TEAS group was always significantly higher than in the TEAS group (65.4% vs 20%, 43.6% vs 7.3%, 40% vs 3.6%, all P < 0.001). Also, the TEAS group showed better scores of MMSE, sleep, and pain compared with the sham-TEAS group (all P < 0.001). At 6 and 12 months points, the global health scores of the TEAS group were still significantly higher than the sham-TEAS group, and the prevalence of chronic pain was significantly lower than the sham-TEAS group (all P < 0.05).Conclusion: TEAS could effectively improve the postoperative cognitive function and long-term life quality of geriatric patients with lung cancer.
C1 [Guo, Fei; Han, Ruili; Sun, Li; Zheng, Lanlan; Wang, Yanzheng; Liu, Chen; Qin, Yuan; Yuan, Chen; Wang, Shuang; Sun, Xude; Gao, Changjun] Air Force Med Univ, Dept Anesthesiol, Affiliated Hosp 2, Xian, Peoples R China.
   [Sun, Xude; Gao, Changjun] Air Force Med Univ, Dept Anesthesiol, Affiliated Hosp 2, Xian 710038, Peoples R China.
C3 Air Force Medical University; Air Force Medical University
RP Sun, XD; Gao, CJ (corresponding author), Air Force Med Univ, Dept Anesthesiol, Affiliated Hosp 2, Xian 710038, Peoples R China.
EM sunxude@fmmu.edu.cn; gaocj74@163.com
FU National Natural Science Foundation of China [81971225]; Clinical Research Project of the Air Force Medical University [2021LC2207]
CR AARONSON NK, 1993, J NATL CANCER I, V85, P365, DOI 10.1093/jnci/85.5.365
   Avidan MS, 2017, LANCET, V390, P267, DOI 10.1016/S0140-6736(17)31467-8
   Batchelor TJP, 2019, EUR J CARDIO-THORAC, V55, P91, DOI 10.1093/ejcts/ezy301
   BRAEKHUS A, 1992, J AM GERIATR SOC, V40, P1139, DOI 10.1111/j.1532-5415.1992.tb01804.x
   Chen JB, 2020, INT J SURG, V73, P57, DOI 10.1016/j.ijsu.2019.10.036
   Chen YQ, 2015, INT J CLIN EXP MED, V8, P5781
   Chi YL, 2019, AM J CHINESE MED, V47, P1445, DOI 10.1142/S0192415X19500745
   Deiner S, 2021, ANN SURG, V274, PE1108, DOI 10.1097/SLA.0000000000003764
   Ding X, 2021, J MOL NEUROSCI, V71, P515, DOI 10.1007/s12031-020-01673-x
   Evered L, 2018, BRIT J ANAESTH, V121, P1005, DOI 10.1016/j.bja.2017.11.087
   Ezhevskaya AA, 2019, J NEUROSURG-SPINE, V31, P894, DOI 10.3171/2019.4.SPINE184
   Fan YX, 2017, J CLIN ANESTH, V39, P77, DOI 10.1016/j.jclinane.2017.03.023
   Feng B, 2019, PSYCHIAT CLIN NEUROS, V73, P179, DOI 10.1111/pcn.12810
   Gao F, 2018, CLIN INTERV AGING, V13, P2127, DOI 10.2147/CIA.S183698
   Hoffman AJ, 2007, ONCOL NURS FORUM, V34, P785, DOI 10.1188/07.ONF.785-792
   Hou LL, 2017, J THORAC DIS, V9, P1959, DOI 10.21037/jtd.2017.06.05
   Kotekar N, 2018, CLIN INTERV AGING, V13, P2267, DOI 10.2147/CIA.S133896
   Li H, 2021, BMJ OPEN, V11, P0, DOI 10.1136/bmjopen-2021-053309
   Liu BY, 2022, CNS NEUROSCI THER, V28, P470, DOI 10.1111/cns.13763
   Liu SB, 2021, NATURE, V598, P641, DOI 10.1038/s41586-021-04001-4
   Lu ZH, 2021, J CLIN ANESTH, V74, P0, DOI 10.1016/j.jclinane.2021.110453
   Moller JT, 1998, LANCET, V351, P857, DOI 10.1016/S0140-6736(97)07382-0
   Monk TG, 2008, ANESTHESIOLOGY, V108, P18, DOI 10.1097/01.anes.0000296071.19434.1e
   Nasreddine ZS, 2005, J AM GERIATR SOC, V53, P695, DOI 10.1111/j.1532-5415.2005.53221.x
   OGara BP, 2021, ANESTHESIOLOGY, V135, P1132, DOI 10.1097/ALN.0000000000004046
   Patel D, 2016, ANAESTHESIA, V71, P1144, DOI 10.1111/anae.13571
   Radtke FM, 2013, BRIT J ANAESTH, V110, P98, DOI 10.1093/bja/aet055
   Ritmala-Castren M, 2014, SCAND J CARING SCI, V28, P435, DOI 10.1111/scs.12072
   Rodriguez C S, 2001, PAIN MANAG NURS, V2, P38, DOI 10.1053/jpmn.2001.23746
   Rundshagen I, 2014, DTSCH ARZTEBL INT, V111, P0, DOI 10.3238/arztebl.2014.0119
   Schabath MB, 2019, CANCER EPIDEM BIOMAR, V28, P1563, DOI 10.1158/1055-9965.EPI-19-0221
   Shen Y, 2022, GERONTOLOGY, V68, P538, DOI 10.1159/000517511
   Sikkes SAM, 2021, ALZHEIMERS DEMENT, V17, P255, DOI 10.1002/alz.12188
   Small C, 2020, BJS-BRIT J SURG, V107, PE70, DOI 10.1002/bjs.11477
   Steinmetz J, 2009, ANESTHESIOLOGY, V110, P548, DOI 10.1097/ALN.0b013e318195b569
   Sung H, 2021, CA-CANCER J CLIN, V71, P209, DOI 10.3322/caac.21660
   Tida JA, 2018, ACUPUNCT MED, V36, P386, DOI 10.1136/acupmed-2017-011515
   van der Stouwe ECD, 2021, BMC PSYCHIATRY, V21, P0, DOI 10.1186/s12888-021-03579-3
   Wang H, 2014, BRIT J ANAESTH, V112, P1075, DOI 10.1093/bja/aeu001
   Weerink LBM, 2018, ANN SURG ONCOL, V25, P231, DOI 10.1245/s10434-017-6118-6
   Xie ZZ, 2017, NEUROL RES, V39, P559, DOI 10.1080/01616412.2017.1315864
   Yalcin EK, 2021, EXPERT OPIN EMERG DR, V26, P371, DOI 10.1080/14728214.2021.2009799
   Zhou J, 2015, MEDICINE, V94, P0, DOI 10.1097/MD.0000000000000933
NR 43
TC 6
Z9 8
U1 4
U2 14
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 
EI 2405-8440
J9 HELIYON
JI Heliyon
PD SEP 15
PY 2023
VL 9
IS 9
BP 
EP 
DI 10.1016/j.heliyon.2023.e19386
EA AUG 2023
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA T6NR3
UT WOS:001079138500001
PM 37809441
DA 2026-01-16
ER

PT J
AU Jung, MS
   Kim, M
   Sohn, EH
   Lee, JS
AF Jung, Mi Sook
   Kim, Mijung
   Sohn, Eun Hee
   Lee, Jin Sun
TI The Effectiveness and Safety of Nurse-Led Auricular Acupressure on Chemotherapy-Induced Peripheral Neuropathy Among Patients With Breast Cancer
SO CANCER NURSING
LA English
DT Article; Early Access
DE Auriculotherapy; Breast neoplasms; Drug toxicity; Peripheral nervous system disease
ID point acupressure; outcome measures; pain; neurotoxicity; acupuncture; prevalence; prevention; management; consensus; toxicity
AB Background Chemotherapy-induced peripheral neuropathy (CIPN) is a major symptom of distress among chemotherapy-treated cancer survivors. Although various interventions have been attempted, there is no criterion-standard treatment. Objective The aim of this study was to examine the efficacy and safety of auricular acupressure (AA) in improving peripheral neuropathy symptoms in breast cancer patients undergoing taxane-based treatment. Methods A total of 51 eligible participants were enrolled and randomly allocated (1:1) to AA or sham control groups. The intervention was performed weekly for 3 weeks using different ear points, depending on the group. The Total Neuropathy Score was used to measure CIPN objectively. The Numerical Rating Scale and the European Organization for Research and Treatment of Cancer Quality of Life Chemotherapy-Induced Peripheral Neuropathy-20 were used to measure the subjective symptoms of CIPN. Outcomes were compared between groups by time interaction using generalized estimating equations based on the intention-to-treat principle. Results Only 1 participant dropped out because of nausea and mild fever. The results of generalized estimating equations showed significant improvement in Numerical Rating Scale scores on the hands and feet and total Chemotherapy-Induced Peripheral Neuropathy-20 in the experimental group compared with the sham control group (all Ps < .05). Although the experimental group showed a greater reduction in Total Neuropathy Score scores than the sham control group, no significant differences were found. Conclusion Auricular acupressure is an effective and safe nurse-led intervention for managing CIPN symptoms in breast cancer patients. Implications for Practice The findings help nurses to integrate AA easily and usefully into nursing care, contributing to managing symptoms of CIPN in cancer patients and survivors.
C1 [Jung, Mi Sook] Chungnam Natl Univ, Coll Nursing, Daejeon, South Korea.
   [Kim, Mijung] Catholic Kkottongnae Univ, Dept Nursing, 133 Sangsam Gil, Cheongju 28211, South Korea.
   [Sohn, Eun Hee] Chungnam Natl Univ Hosp, Dept Neurol, Daejeon, South Korea.
   [Lee, Jin Sun] Chungnam Natl Univ, Coll Med, Dept Surg, Daejeon, South Korea.
   [Lee, Jin Sun] Chungnam Natl Univ, Res Inst Med Sci, Coll Med, Daejeon, South Korea.
C3 Chungnam National University; Chungnam National University; Chungnam National University Hospital; Chungnam National University; Chungnam National University
RP Kim, M (corresponding author), Catholic Kkottongnae Univ, Dept Nursing, 133 Sangsam Gil, Cheongju 28211, South Korea.
EM msj713@gmail.com; cipnmj@gmail.com; seh337@daum.net; leejin123@cnu.ac.kr
FU National Research Foundation of Korea [2017R1A2B4004328]
CR AL-Atiyyat N, 2017, INT J PALLIAT NURS, V23, P13, DOI 10.12968/ijpn.2017.23.1.13
   Alberti P, 2014, ANN ONCOL, V25, P257, DOI 10.1093/annonc/mdt409
   Alimi D, 2003, J CLIN ONCOL, V21, P4120, DOI 10.1200/JCO.2003.09.011
   Alimi D, 2002, MED ACUPUNCT, V13, P18
   Armstrong T, 2005, ONCOL NURS FORUM, V32, P305, DOI 10.1188/05.ONF.305-311
   Arts A, 2007, AURICULAR MED AURICU, V0, P0
   Asher GN, 2010, J ALTERN COMPLEM MED, V16, P1097, DOI 10.1089/acm.2009.0451
   Bao T, 2021, ONCOLOGIST, V26, PE2070, DOI 10.1002/onco.13933
   Bao T, 2016, BREAST CANCER RES TR, V159, P327, DOI 10.1007/s10549-016-3939-0
   Cavaletti G, 2013, ANN ONCOL, V24, P454, DOI 10.1093/annonc/mds329
   Cavaletti G, 2007, J PERIPHER NERV SYST, V12, P210, DOI 10.1111/j.1529-8027.2007.00141.x
   Chien TJ, 2019, INTEGR CANCER THER, V18, P0, DOI 10.1177/1534735419866910
   Cunningham JA, 2013, BMC MED RES METHODOL, V13, P0, DOI 10.1186/1471-2288-13-150
   Di Maio M, 2015, J CLIN ONCOL, V33, P910, DOI 10.1200/JCO.2014.57.9334
   Greenlee H, 2016, BREAST CANCER RES TR, V156, P453, DOI 10.1007/s10549-016-3759-2
   Han Q, 2020, J ADV NURS, V76, P1924, DOI 10.1111/jan.14375
   He W, 2012, EVID-BASED COMPL ALT, V2012, P0, DOI 10.1155/2012/786839
   Hou PW, 2015, EVID-BASED COMPL ALT, V2015, P0, DOI 10.1155/2015/495684
   Hsieh CH, 2010, AM J CHINESE MED, V38, P675, DOI 10.1142/S0192415X10008147
   Hwang MS, 2020, MEDICINE, V99, P0, DOI 10.1097/MD.0000000000019837
   Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43
   Jordan B, 2020, ANN ONCOL, V31, P1306, DOI 10.1016/j.annonc.2020.07.003
   Jouya S, 2018, EVID BASED CARE J, V7, P55
   Jung MS, 2021, ANN PALLIAT MED, V10, P721, DOI 10.21037/apm-20-1469
   Kim SY, 2021, ASIAN ONCOL NURS, V21, P129, DOI 10.5388/aon.2021.21.3.129
   Li T, 2022, QUAL LIFE RES, V31, P3091, DOI 10.1007/s11136-022-03154-7
   Lin WC, 2015, EVID-BASED COMPL ALT, V2015, P0, DOI 10.1155/2015/103570
   Mai QL, 2022, EUR J INTEGR MED, V51, P0, DOI 10.1016/j.eujim.2022.102120
   mijung Kim, 2020, THE JOURNAL OF FUNDAMENTALS OF NURSING, V0, P0
   Oh PJ, 2018, J KOREAN ACAD NURS, V48, P123, DOI 10.4040/jkan.2018.48.2.123
   OKEN MM, 1982, AM J CLIN ONCOL-CANC, V5, P649, DOI 10.1097/00000421-198212000-00014
   Oleson T, 2014, AURICULOTHERAPY MANUAL: CHINESE AND WESTERN SYSTEMS OF EAR ACUPUNCTURE, V0, P0
   Paice JA, 1997, CANCER NURS, V20, P88, DOI 10.1097/00002820-199704000-00002
   Postma TJ, 2005, EUR J CANCER, V41, P1135, DOI 10.1016/j.ejca.2005.02.012
   Romoli M, 2014, NEUROL SCI, V35, PS189, DOI 10.1007/s10072-014-1768-7
   Seretny M, 2014, PAIN, V155, P2461, DOI 10.1016/j.pain.2014.09.020
   Sung H, 2021, CA-CANCER J CLIN, V71, P209, DOI 10.3322/caac.21660
   Tan JY, 2014, EVID-BASED COMPL ALT, V2014, P0, DOI 10.1155/2014/506758
   TAN JY, 2014, EVID-BASED COMPL ALT, V2014, P0
   Visovsky Constance, 2007, CLIN J ONCOL NURS, V11, P901
   White AR, 2001, COMPLEMENT THER MED, V9, P237, DOI 10.1054/ctim.2001.0489
   Williamson A, 2005, J CLIN NURS, V14, P798, DOI 10.1111/j.1365-2702.2005.01121.x
   Willson ML, 2019, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD004421.pub3
   Winters-Stone KM, 2017, J CLIN ONCOL, V35, P2604, DOI 10.1200/JCO.2016.71.3552
   Yang YL, 2020, EVID-BASED COMPL ALT, V2020, P0, DOI 10.1155/2020/1618767
   Yeh CH, 2019, PAIN MANAG NURS, V20, P614, DOI 10.1016/j.pmn.2019.04.005
   Yeh CH, 2016, CANCER NURS, V39, P402, DOI 10.1097/NCC.0000000000000303
   Yeh CH, 2015, PAIN MED, V16, P1857, DOI 10.1111/pme.12789
   Zhang CS, 2014, J ALTERN COMPLEM MED, V20, P147, DOI 10.1089/acm.2013.0238
   Zheng SH, 2018, FRONTIERS OF NURSING, V5, P227, DOI 10.1515/fon-2018-0030
   Zhong Baoliang, 2009, J THORAC DIS, V1, P51
NR 51
TC 4
Z9 6
U1 12
U2 29
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0162-220X
EI 1538-9804
J9 CANCER NURS
JI Cancer Nurs.
PD OCT 17
PY 2023
VL 0
IS 
BP 
EP 
DI 10.1097/NCC.0000000000001286
EA OCT 2023
PG 12
WC Oncology; Nursing
SC Oncology; Nursing
GA GM8A2
UT WOS:001153166100002
PM 37851514
DA 2026-01-16
ER

PT J
AU Yang, X
   Liang, B
   Xue, DM
   Liang, J
   Zaslawski, C
   Chen, J
AF Yang, Xia
   Liang, Bing
   Xue, Demin
   Liang, Jing
   Zaslawski, Chris
   Chen, Ji
TI Global research trends in acupuncture for cancer pain: A bibliometric analysis
SO MEDICINE
LA English
DT Review
DE acupuncture; bibliometric analysis; cancer pain; CiteSpace; visualization; VOSviewer
ID inhibitor-induced arthralgia; breast-cancer; electroacupuncture; chemotherapy; expression; trial
AB Background: In recent years, acupuncture has gained popularity in the management of cancer-related pain (CRP). This study aims to use bibliometric analysis to investigate the historical development, recent hotspots and research trends in this field.Methods: The Web of Science Core Collection database was selected as the data source for this study to retrieve and obtain literature related to acupuncture and CRP. Data analyses were performed with CiteSpace and VOSviewer to conduct the bibliometric analysis.Results: This bibliometric analysis was conducted from 2000 to 2022. A total of 664 publications were included in this work. The number of publications has steadily increased over the last 2 decades. The United States has the largest number of published articles (244 papers), while the People's Republic of China has the highest centrality (0.48). The primary research institutions were Memorial Sloan-Kettering Cancer Center, Kyung Hee University and Beijing University of Chinese Medicine. Mao Jun J. was the most prolific author, while Heather Greenlee was the most cited one. The most productive journal was Integrative Cancer Therapies. The most frequent keywords excluding the search subject were "electroacupuncture," "management," "quality of life," "breast cancer," "Aromatase inhibitor," "neuropathic pain," "mechanisms," and "protocol."Conclusion: This study explored the application value of acupuncture in the management of CRP with bibliometric analysis, offering an intuitive understanding of this topic and revealing the hotspots and research trends.
C1 [Yang, Xia; Liang, Bing] Chengdu Univ Tradit Chinese Med, Basic Med Coll, Chengdu, Peoples R China.
   [Xue, Demin] Chengdu Univ Tradit Chinese Med, Sch Chinese Class, Chengdu, Peoples R China.
   [Liang, Jing; Chen, Ji] Chengdu Univ Tradit Chinese Med, Sch Foreign Languages, Chengdu, Peoples R China.
   [Zaslawski, Chris] Univ Technol Sydney, Fac Sci, Sydney, NSW, Australia.
   [Chen, Ji] Chengdu Univ Tradit Chinese Med, Sch Foreign Languages, Chengdu 611137, Peoples R China.
C3 Chengdu University of Traditional Chinese Medicine; Chengdu University of Traditional Chinese Medicine; Chengdu University of Traditional Chinese Medicine; University of Technology Sydney; Chengdu University of Traditional Chinese Medicine
RP Chen, J (corresponding author), Chengdu Univ Tradit Chinese Med, Sch Foreign Languages, Chengdu 611137, Peoples R China.
EM tyr_yang@126.com; drliangjing@163.com; 2679214114@qq.com; drliangjing@163.com; Chris.Zaslawski@uts.edu.au; jeanelle_chin@126.com
FU National Social Science Fund of China [19XXW005]; Key R&D Programs of Sichuan Provincial Department of Science and Technology [2018SZ0072]
CR Abd El-Hameed AM, 2021, METAB BRAIN DIS, V36, P2047, DOI 10.1007/s11011-021-00766-9
   Azizoddin DR, 2021, CANCER-AM CANCER SOC, V127, P3239, DOI 10.1002/cncr.33532
   Bao T, 2020, JAMA NETW OPEN, V3, P0, DOI 10.1001/jamanetworkopen.2020.0681
   Bao T, 2018, EUR J CANCER, V101, P12, DOI 10.1016/j.ejca.2018.06.008
   Chan KY, 2020, TRIALS, V21, P0, DOI 10.1186/s13063-019-3972-5
   Colwell J, 2021, CANCER DISCOV, V11, P524, DOI 10.1158/2159-8290.cd-nb2021-0302
   Gao F, 2018, BRAIN BEHAV IMMUN, V67, P91, DOI 10.1016/j.bbi.2017.08.004
   George B, 2019, SUPPORT CARE CANCER, V27, P3105, DOI 10.1007/s00520-019-04828-8
   Goo B, 2021, TOXINS, V13, P0, DOI 10.3390/toxins13090661
   Halamkova J, 2022, KLIN ONKOL, V35, P94, DOI 10.48095/ccko202294
   He YH, 2020, JAMA ONCOL, V6, P271, DOI 10.1001/jamaoncol.2019.5233
   Hershman DL, 2022, JAMA NETW OPEN, V5, P0, DOI 10.1001/jamanetworkopen.2022.41720
   Hershman DL, 2018, JAMA-J AM MED ASSOC, V320, P167, DOI 10.1001/jama.2018.8907
   Jiang B, 2021, INTEGR CANCER THER, V20, P0, DOI 10.1177/1534735421995237
   Lao LX, 2003, ALTERN THER HEALTH M, V9, P72
   Lee JH, 2020, TOXINS, V12, P0, DOI 10.3390/toxins12120737
   Li DX, 2020, TOXINS, V12, P0, DOI 10.3390/toxins12120775
   Li YY, 2019, INT J MOL SCI, V20, P0, DOI 10.3390/ijms20235917
   Liu SB, 2021, NATURE, V598, P641, DOI 10.1038/s41586-021-04001-4
   Liu SB, 2020, NEURON, V108, P436, DOI 10.1016/j.neuron.2020.07.015
   Lu WD, 2008, HEMATOL ONCOL CLIN N, V22, P631, DOI 10.1016/j.hoc.2008.04.005
   Lu WD, 2020, ONCOLOGIST, V25, P310, DOI 10.1634/theoncologist.2019-0489
   Lu WD, 2013, CURR PAIN HEADACHE R, V17, P0, DOI 10.1007/s11916-013-0321-3
   Ma QF, 2022, CURR OPIN NEUROBIOL, V76, P0, DOI 10.1016/j.conb.2022.102602
   Mallory MJ, 2015, AM J CHINESE MED, V43, P45, DOI 10.1142/S0192415X15500032
   Mao JJ, 2014, EUR J CANCER, V50, P267, DOI 10.1016/j.ejca.2013.09.022
   Mezzanotte JN, 2022, CURR TREAT OPTION ON, V23, P29, DOI 10.1007/s11864-021-00926-0
   Niravath P, 2013, ANN ONCOL, V24, P1443, DOI 10.1093/annonc/mdt037
   Papadopoulou M, 2023, IN VIVO, V37, P47, DOI 10.21873/invivo.13053
   Russo MM, 2019, SEMIN ONCOL NURS, V35, P223, DOI 10.1016/j.soncn.2019.04.002
   Siegel RL, 2023, CA-CANCER J CLIN, V73, P17, DOI 10.3322/caac.21763
   Tian SX, 2023, PURINERG SIGNAL, V19, P13, DOI 10.1007/s11302-022-09861-7
   Tichy EM, 2021, AM J HEALTH-SYST PH, V78, P1294, DOI 10.1093/ajhp/zxab160
   Wang W, 2021, FRONT PHARMACOL, V12, P0, DOI 10.3389/fphar.2021.593043
   Wengström Y, 2014, EUR J ONCOL NURS, V18, P127, DOI 10.1016/j.ejon.2013.11.009
   Wong Raimond, 2006, ACUPUNCT MED, V24, P87
   Wu QY, 2021, MOL PAIN, V17, P0, DOI 10.1177/1744806921997654
   Xu M, 2021, ACS CHEM NEUROSCI, V12, P3323, DOI 10.1021/acschemneuro.1c00224
   Yeh CH, 2023, PAIN MANAG NURS, V24, P19, DOI 10.1016/j.pmn.2022.11.004
   Yeh CH, 2017, ONCOL NURS FORUM, V44, P476, DOI 10.1188/17.ONF.476-487
   Zhang QH, 2016, SYST REV-LONDON, V5, P0, DOI 10.1186/s13643-016-0257-x
   Zhang RX, 2007, ANESTH ANALG, V105, P1482, DOI 10.1213/01.ane.0000284705.34629.c5
   Zhang Y, 2018, EUR J PAIN, V22, P679, DOI 10.1002/ejp.1132
   Zheng YY, 2020, BRAIN RES BULL, V162, P1, DOI 10.1016/j.brainresbull.2020.04.020
   Zhi WI, 2023, BREAST CANCER RES TR, V197, P535, DOI 10.1007/s10549-022-06846-3
NR 46
TC 1
Z9 1
U1 11
U2 76
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0025-7974
EI 1536-5964
J9 MEDICINE
JI Medicine (Baltimore)
PD OCT 13
PY 2023
VL 102
IS 41
BP 
EP 
DI 10.1097/MD.0000000000034739
PG 15
WC Medicine, General & Internal
SC General & Internal Medicine
GA U7IO1
UT WOS:001086507200040
PM 37832094
DA 2026-01-16
ER

PT J
AU Wang, LJ
   Xu, T
   Sun, MS
   Wan, SP
   Ying, J
   Luo, L
   Fan, Y
   Yang, Y
   You, FM
   Hu, BY
   Li, QY
   Yan, WL
   Wang, YH
   Yu, X
   Yuan, Y
   Gao, XY
   Zhao, L
AF Wang, Linjia
   Xu, Tao
   Sun, Mingsheng
   Wan, Shaoping
   Ying, Jian
   Luo, Lun
   Fan, Yi
   Yang, Yong
   You, Fengming
   Hu, Binyu
   Li, Qiuyue
   Yan, Wanlin
   Wang, Yuhan
   Yu, Xin
   Yuan, Yu
   Gao, Xiaoyu
   Zhao, Ling
TI Electro-acupuncture for gastrointestinal dysfunction after colorectal cancer surgery: A protocol for three-arm randomized controlled trial
SO EUROPEAN JOURNAL OF INTEGRATIVE MEDICINE
LA English
DT Article
DE Colorectal cancer; Electro-acupuncture; Postoperative gastrointestinal dysfunction; Protocol; Randomized controlled trial
ID quality-of-life; postoperative morbidity survey; laparoscopic surgery; enhanced recovery; colonic surgery; ileus; acupuncture; analgesia; outcm
AB Introduction: Postoperative gastrointestinal dysfunction (POGD) is one of the most common complications after colorectal cancer (CRC) surgery and seriously affects the prognosis of patients. Furthermore, current clinical treatment measures have controversial efficacy or strong side effects. Electro-acupuncture (EA) is a safe therapeutic modality for POGD; however, high-quality evidence is scarce at present. This study will aim to evaluate the efficacy and safety of EA for POGD in patients with CRC.Methods: A total of 270 patients with POGD after CRC surgery will be recruited from five hospitals in China and assigned to EA, sham electro-acupuncture (SA), and routine treatment (RT) groups in a 1:1:1 ratio. Patients in the RT group will receive treatment based on enhanced recovery after surgery (ERAS), health education, and routine care. Patients in the EA and SA groups will be treated with EA or SA on the basis of RT, respectively, from postoperative days one to three, once per day. Follow-up will be performed at seven and fourteen days after surgery. The primary outcome is the time to the first postoperative passing flatus. Secondary outcomes include the following: time of first postoperative bowel movement, postoperative bowel sound recovery time, gastro-intestinal symptom rating scale, I-FEED (intake, feeling nauseated, emesis, physical exam, duration of symptoms) scale, postoperative surgical site pain degree, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Version 3.0 (EORTC QLQ-C30 (V3.0)), EORTC Quality of Life Questionnaire -Colorectal Cancer 29 (EORTC QLQ-CR29), postoperative complications, adverse acupuncture events, etc.Discussion: This study design is rigorous, and a scientific placebo acupuncture method is used. The advantages are (1) multi-center, prospective, large sample randomized control with strict quality control; (2) the placebo control method can minimize the true acupuncture effect on the basis of blinding patients as much as possible; (3) the gastrointestinal function and quality of life of POGD patients after passing flatus and defecation will be analyzed. Conclusion: The findings of the 3-arm clinical trial will demonstrate whether EA is effective and safe for patients with POGD after CRC surgery.Trial registration: ChiCTR2200062275 (registered on 31-07-2022).
C1 [Wang, Linjia; Xu, Tao; Sun, Mingsheng; Hu, Binyu; Li, Qiuyue; Yan, Wanlin; Wang, Yuhan; Yuan, Yu; Gao, Xiaoyu; Zhao, Ling] Chengdu Univ Tradit Chinese Med, Sch Acu Mox & Tuina, 37 Shi Er Qiao Rd, Chengdu 610075, Peoples R China.
   [Wan, Shaoping] Sichuan Canc Hosp & Inst, 55,Sect 4,South Renmin Rd, Chengdu 610041, Peoples R China.
   [Ying, Jian; Fan, Yi] Chongqing Hosp Tradit Chinese Med, 6 Panxiqizhi Rd, Chongqing 400021, Peoples R China.
   [Luo, Lun; Yu, Xin] Chengdu Second Peoples Hosp, 10 South Qingyun St, Chengdu 610021, Peoples R China.
   [Yang, Yong] Deyang Peoples Hosp, 173 North Taishan Rd, Deyang 618099, Peoples R China.
   [You, Fengming] Hosp Chengdu Univ Tradit Chinese Med, 39 Shi Er Qiao Rd, Chengdu 610075, Peoples R China.
C3 Chengdu University of Traditional Chinese Medicine; Chengdu University of Traditional Chinese Medicine
RP Zhao, L (corresponding author), Chengdu Univ Tradit Chinese Med, Sch Acu Mox & Tuina, 37 Shi Er Qiao Rd, Chengdu 610075, Peoples R China.; Ying, J (corresponding author), Chongqing Hosp Tradit Chinese Med, 6 Panxiqizhi Rd, Chongqing 400021, Peoples R China.
EM 329924692@qq.com; zhaoling@cdutcm.edu.cn
FU Sichuan Province Science and Technology Support Program [2021ZYD0103, BSH2023018]; Chengdu University of Traditional Chinese Medicine "Xinglin Scholars" Discipline Talent Research Promotion Plan-Postdoctoral Program;  [2020YFS0304]
CR Azad A, 2013, J CLIN ONCOL, V31, P2057, DOI 10.1200/JCO.2012.47.8750
   Azhar RA, 2016, EUR UROL, V70, P176, DOI 10.1016/j.eururo.2016.02.051
   BARDRAM L, 1995, LANCET, V345, P763, DOI 10.1016/S0140-6736(95)90643-6
   Becker G, 2009, LANCET, V373, P1198, DOI 10.1016/S0140-6736(09)60139-2
   Bennett-Guerrero E, 1999, ANESTH ANALG, V89, P514, DOI 10.1097/00000539-199908000-00050
   Benson AB, 2021, J NATL COMPR CANC NE, V0, P0, DOI DOI 10.6004/JNCCN.2021.0012
   Biller LH, 2021, JAMA-J AM MED ASSOC, V325, P669, DOI 10.1001/jama.2021.0106
   Bjordal K, 2000, EUR J CANCER, V36, P1796, DOI 10.1016/S0959-8049(00)00186-6
   Braga M, 2014, WORLD J SURG, V38, P2960, DOI 10.1007/s00268-014-2653-5
   Carli F, 2001, DIS COLON RECTUM, V44, P1083, DOI 10.1007/BF02234626
   Chen WQ, 2012, CHINESE J CANCER RES, V24, P1, DOI 10.1007/s11670-012-0001-6
   Dekker E, 2019, LANCET, V394, P1467, DOI 10.1016/S0140-6736(19)32319-0
   Diener HC, 2006, LANCET NEUROL, V5, P310, DOI 10.1016/S1474-4422(06)70382-9
   Dindo D, 2004, ANN SURG, V240, P205, DOI 10.17116/hirurgia2018090162
   Drake TM, 2016, J GASTROINTEST SURG, V20, P1253, DOI 10.1007/s11605-016-3140-0
   Fang JF, 2017, SCI REP-UK, V7, P0, DOI 10.1038/srep39801
   Gao W, 2021, SURGERY, V170, P1618, DOI 10.1016/j.surg.2021.08.007
   Grocott MPW, 2007, J CLIN EPIDEMIOL, V60, P919, DOI 10.1016/j.jclinepi.2006.12.003
   Gujral S, 2007, EUR J CANCER, V43, P1564, DOI 10.1016/j.ejca.2007.04.005
   Guyatt GH, 2007, MAYO CLIN PROC, V82, P1229, DOI 10.4065/82.10.1229
   Hedrick TL, 2018, ANESTH ANALG, V126, P1896, DOI 10.1213/ANE.0000000000002742
   Hu Han-Tong, 2021, ZHEN CI YAN JIU, V46, P631, DOI 10.13702/j.1000-0607.200526
   Iyer S, 2009, J MANAGE CARE PHARM, V15, P485, DOI 10.18553/jmcp.2009.15.6.485
   Kehlet H, 2005, RECENT RES CANCER, V165, P8, DOI 10.1007/3-540-27449-9_2
   Kehlet H, 2001, AM J SURG, V182, P3S, DOI 10.1016/S0002-9610(01)00781-4
   Kurz A, 2003, DRUGS, V63, P649, DOI 10.2165/00003495-200363070-00003
   Lam D, 2020, BEST PRACT RES CL GA, V48-49, P0, DOI 10.1016/j.bpg.2020.101705
   Lembo AJ, 2009, AM J GASTROENTEROL, V104, P1489, DOI 10.1038/ajg.2009.156
   Liu ZS, 2016, ANN INTERN MED, V165, P761, DOI 10.7326/M15-3118
   MacPherson H, 2014, PLOS ONE, V9, P0, DOI 10.1371/journal.pone.0093739
   Mao JJ, 2022, CA-CANCER J CLIN, V72, P144, DOI 10.3322/caac.21706
   Mazzotta E, 2020, FRONT PHARMACOL, V11, P0, DOI 10.3389/fphar.2020.583422
   Meng ZQ, 2010, WORLD J GASTROENTERO, V16, P104, DOI 10.3748/wjg.v16.i1.104
   Miedema BW, 2003, LANCET ONCOL, V4, P365, DOI 10.1016/S1470-2045(03)01118-5
   Mythen MG, 2005, ANESTH ANALG, V100, P196, DOI 10.1213/01.ANE.0000139376.45591.17
   Nair CK, 2014, INDIA J SURG ONCOL, V5, P266, DOI 10.1007/s13193-014-0346-z
   National Health Commission of the Peoples Republic of China, 2020, ZHONGHUA WAI KE ZA ZHI, V58, P561, DOI 10.3760/cma.j.cn112139-20200518-00390
   Ng SSM, 2013, GASTROENTEROLOGY, V144, P307, DOI 10.1053/j.gastro.2012.10.050
   Pocock SJ, 2016, NEW ENGL J MED, V375, P861, DOI 10.1056/NEJMra1510064
   Shao JK, 2021, TRIALS, V22, P0, DOI 10.1186/s13063-021-05564-3
   [孙敦坡 Sun Dunpo], 2021, 南京中医药大学学报 JOURNAL OF NANJING UNIVERSITY OF TRADITIONAL CHINESE MEDICINE, V37, P41
   SVEDLUND J, 1988, DIGEST DIS SCI, V33, P129, DOI 10.1007/BF01535722
   Taguchi A, 2001, NEW ENGL J MED, V345, P935, DOI 10.1056/NEJMoa010564
   Takahashi T, 2006, J GASTROENTEROL, V41, P408, DOI 10.1007/s00535-006-1773-6
   Tang H, 2022, ANZ J SURG, V92, P1461, DOI 10.1111/ans.17602
   Traut U, 2008, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD004930.pub3
   van Bree SHW, 2012, NAT REV GASTRO HEPAT, V9, P675, DOI 10.1038/nrgastro.2012.134
   Wang Y, 2023, JAMA SURG, V158, P20, DOI 10.1001/jamasurg.2022.5674
   Yang NN, 2020, NEUROGASTROENT MOTIL, V32, P0, DOI 10.1111/nmo.13808
   Ye Z, 2022, PLOS ONE, V17, P0, DOI 10.1371/journal.pone.0271580
   Zerillo JA, 2017, JAMA ONCOL, V3, P686, DOI 10.1001/jamaoncol.2017.0417
   Zhang ZD, 2014, ACUPUNCT MED, V32, P223, DOI 10.1136/acupmed-2013-010490
   Zhong F, 2013, PHD DISSERTATION, V0, P0
NR 54
TC 1
Z9 1
U1 3
U2 31
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1876-3820
EI 1876-3839
J9 EUR J INTEGR MED
JI Eur. J. Integr. Med.
PD SEP 15
PY 2023
VL 62
IS 
BP 
EP 
DI 10.1016/j.eujim.2023.102277
EA AUG 2023
PG 9
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA Q7MR5
UT WOS:001059333800001
DA 2026-01-16
ER

PT J
AU Papadopoulou, M
   Stamou, M
   Bakalidou, D
   Moschovos, C
   Zouvelou, V
   Zis, P
   Tzartos, J
   Chroni, E
   Michopoulos, I
   Tsivgoulis, G
AF Papadopoulou, Marianna
   Stamou, Magda
   Bakalidou, Daphne
   Moschovos, Christos
   Zouvelou, Vasiliki
   Zis, Panagiotis
   Tzartos, John
   Chroni, Elisabeth
   Michopoulos, Ioannis
   Tsivgoulis, Georgios
TI Non-pharmacological Interventions on Pain and Quality of Life in Chemotherapy Induced Polyneuropathy: Systematic Review and Meta-Analysis
SO IN VIVO
LA English
DT Review
DE Chemotherapy-induced polyneuropathy; non-pharmacological interventions; pain; quality of life; acupuncture; yoga; review
ID induced peripheral neuropathy; cancer-patients; exercise; acupuncture; balance
AB Background/Aim: Chemotherapy-induced peripheral neuropathy (CIPN) is a common side effect of cancer treatment, resulting in pain, numbness, instability, and thus affecting quality of life (QoL), occasionally leading to discontinuation of chemotherapy. Pharmacological treatments are not sufficient. Non-pharmacological interventions (NPIs) have also been tried. This study aimed to systematically review the efficacy of NPIs on pain and QoL in patients suffering from CIPN. Materials and Methods: The databases searched were Pubmed, Cohrane, and Scopus for randomized controlled trials (RCTs) published in the last 5 years (2017-2022). Studies were considered eligible, if they assessed adult patients suffering from CIPN because of any chemotherapeutic drug for any type and any stage of cancer and if study protocols included non pharmacological intervention with a structured protocol. Results: A total of 1,496 records were identified. Finally, 10 RCTs including 495 patients (253 in the intervention group and 242 in the control group) were included for meta-analysis. Intervention protocols included acupuncture (n=6), exercise (n=3), and yoga (n=1). NPIs significantly reduced neuropathic pain. However, the effect on QoL was not significant. Conclusion: NPIs are beneficial in the treatment of pain in patients with CIPN but their impact on QoL is not statistically supported. Larger sample sizes, more homogenous in outcome measures and interventions are needed to further explore NPIs' efficacy on CIPN symptoms.
C1 [Papadopoulou, Marianna; Stamou, Magda; Bakalidou, Daphne; Zouvelou, Vasiliki] Univ West Attica, Dept Physiotherapy, Athens, Greece.
   [Papadopoulou, Marianna; Moschovos, Christos; Zis, Panagiotis; Tzartos, John; Tsivgoulis, Georgios] Natl & Kapodistrian Univ Athens, Attikon Univ Gen Hosp, Med Sch, Dept Neurol 2, Athens, Greece.
   [Zouvelou, Vasiliki; Michopoulos, Ioannis] Natl & Kapodistrian Univ Athens, Eginit Univ Hosp, Sch Med, Dept Neurol 1, Athens, Greece.
   [Chroni, Elisabeth] Univ Patras, Sch Med, Dept Neurol, Patras, Greece.
   [Michopoulos, Ioannis] Natl & Kapodistrian Univ Athens, Attikon Univ Gen Hosp, Med Sch, Dept Psychiat 2, Athens, Greece.
   [Papadopoulou, Marianna] Univ West Attica, Physiotherapy Dept, 28 Ag Spyridonos, Athens 12243, Greece.
C3 University of West Attica; National & Kapodistrian University of Athens; University Hospital Attikon; National & Kapodistrian University of Athens; University of Patras; University Hospital Attikon; National & Kapodistrian University of Athens; University of West Attica
RP Papadopoulou, M (corresponding author), Univ West Attica, Physiotherapy Dept, 28 Ag Spyridonos, Athens 12243, Greece.
EM marpapgr@yahoo.co.uk
CR AARONSON NK, 1993, J NATL CANCER I, V85, P365, DOI 10.1093/jnci/85.5.365
   Unknown -, 2020, J PHYSIOTHER, V66, P59, DOI 10.1016/j.jphys.2019.08.005
   Unknown -, 2020, PEDRO, V0, P0
   Bao T, 2021, ONCOLOGIST, V26, PE2070, DOI 10.1002/onco.13933
   Bao T, 2020, JNCI CANCER SPECT, V4, P0, DOI 10.1093/jncics/pkaa048
   Belavy DL, 2021, NEUROSCI BIOBEHAV R, V120, P100, DOI 10.1016/j.neubiorev.2020.11.012
   Brayall P, 2018, REHABIL ONCOL, V36, P161, DOI 10.1097/01.REO.0000000000000111
   Brozou V, 2018, PAIN THER, V7, P105, DOI 10.1007/s40122-017-0092-3
   Cleeland CS, 1994, ANNALS ACADEMY OF MEDICINE SINGAPORE, V23, P129
   Colvin LA, 2019, PAIN, V160, PS1, DOI 10.1097/j.pain.0000000000001540
   DAlessandro EG, 2022, BMJ SUPPORT PALLIAT, V12, P64, DOI 10.1136/bmjspcare-2018-001542
   Dhawan S, 2020, CANCER NURS, V43, P269, DOI 10.1097/NCC.0000000000000693
   Duregon F, 2018, CRIT REV ONCOL HEMAT, V121, P90, DOI 10.1016/j.critrevonc.2017.11.002
   Franco KFM, 2021, EUR J PAIN, V25, P51, DOI 10.1002/ejp.1666
   Geneen LJ, 2017, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD011279.pub2
   Girach A, 2019, PAIN RES MANAG, V2019, P0, DOI 10.1155/2019/2091960
   Han XY, 2017, BMC CANCER, V17, P0, DOI 10.1186/s12885-016-3037-z
   Hershman DL, 2014, J CLIN ONCOL, V32, P1941, DOI 10.1200/JCO.2013.54.0914
   Higgins JPT, 2003, BMJ-BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Hou S, 2018, PAIN PHYSICIAN, V21, P571, DOI 10.36076/ppj.2018.6.571
   Iravani S, 2020, PAIN RES MANAG, V2020, P0, DOI 10.1155/2020/2504674
   Jin YX, 2020, EVID-BASED COMPL ALT, V2020, P0, DOI 10.1155/2020/8875433
   Li K, 2019, CURR ONCOL, V26, PE147, DOI 10.3747/co.26.4261
   Liampas A, 2021, PAIN THER, V10, P55, DOI 10.1007/s40122-020-00210-3
   Liampas A, 2020, ADV THER, V37, P4096, DOI 10.1007/s12325-020-01462-3
   Lu WD, 2020, ONCOLOGIST, V25, P310, DOI 10.1634/theoncologist.2019-0489
   Molassiotis A, 2019, INTEGR CANCER THER, V18, P0, DOI 10.1177/1534735419836501
   Saraboon C, 2021, J BODYW MOV THER, V28, P164, DOI 10.1016/j.jbmt.2021.07.013
   Vickers AJ, 2012, ARCH INTERN MED, V172, P1444, DOI 10.1001/archinternmed.2012.3654
   Yuan QL, 2016, SCI REP-UK, V6, P0, DOI 10.1038/srep30675
   Zimmer P, 2018, SUPPORT CARE CANCER, V26, P615, DOI 10.1007/s00520-017-3875-5
NR 35
TC 24
Z9 26
U1 1
U2 11
PU INT INST ANTICANCER RESEARCH
PI ATHENS
PA EDITORIAL OFFICE 1ST KM KAPANDRITIOU-KALAMOU RD KAPANDRITI, PO BOX 22, ATHENS 19014, GREECE
SN 0258-851X
EI 1791-7549
J9 IN VIVO
JI In Vivo
PD JAN-FEB 15
PY 2023
VL 37
IS 1
BP 47
EP 56
DI 10.21873/invivo.13053
PG 10
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA L8QX3
UT WOS:001025866500005
PM 36593011
DA 2026-01-16
ER

PT J
AU Yang, JX
   Lan, XD
   Cai, QC
   Lu, ZH
   Wang, YJ
AF Yang, Jiaxiang
   Lan, Xiangdong
   Cai, Qingcheng
   Lu, Ziheng
   Wang, Yanjun
TI Exercise Plus Acupuncture on Consensus Acupoints Versus Acupoints Selected by the Theory of Equal Impact on Tendons, Bones, and Muscles for Knee Osteoarthritis
SO ALTERNATIVE THERAPIES IN HEALTH AND MEDICINE
LA English
DT Article
ID nf-kappa-b; matrix metalloproteinases; medical-management; recommendations; prevalence; pain
AB Context center dot Knee osteoarthritis (KOA) is a degenerative disorder that significantly affects patients' quality of life. Acupuncture and exercise are the most popular treatments currently. The outcomes for acupuncture for KOA, however, are controversial, with some researchers finding that the addition of acupuncture to exercise therapy provided no additional improvement in pain scores. Objective center dot The study intended to evaluate the therapeutic effects for KOA of exercise in combination with acupuncture on acupoints selected using the Traditional Chinse Medicine (TCM) theory of Equal Impact on Tendons, Bones, and Muscles (EITBM) in comparison with that of acupoints selected using classical consensus for the treatment. Design center dot The research team performed a randomized controlled trial. Setting center dot The study took place in the Department of Acupuncture and Moxibustion at the First Affiliated Hospital of Hebei University of Chinese Medicine in Shijiazhuang, Hebei, China. Participants center dot Participants were 70 patients with KOA who visited the hospital between December 2020 and February 2021. Intervention center dot Participants in both group received acupuncture plus exercise therapy. The research team randomly assigned participants to one of two groups: (1) 35 to the intervention group, which received acupuncture using acupoints selected using EITBM, and (2) 35 to the control group, which received acupuncture using the classical consensus acupoints. Both groups performed a 25-min session of acupuncture three times weekly for 4 weeks, with the exercise therapy following the acupuncture each time. Outcome Measures center dot The research team assessed clinical efficacy at baseline and postintervention. The primary outcome measures included assessments: (1) of knee joint pain using a visual analog scale (VAS), (2) of knee joint pain, flexibility, and function using the Western Ontario and McMaster University Osteoarthritis Index (WOMAC) pain subscale; and (3) joint range of motion (ROM). The secondary outcome measures included measurement of serum levels of interleukin-1 beta (IL-1 beta), tumor necrosis factor alpha (TNF-alpha), and matrix metalloproteinase-13 (MMP-13) using enzyme-linked immunosorbent assays (ELISA). Results center dot The VAS and WOMAC scores significantly decreased for both groups between baseline and postintervention, and the intervention group's decrease was significantly greater than that of the control group. The ROM of knee flexion was significantly higher in both groups postintervention than at baseline, and the intervention group's increase was significantly higher than that of the control group. The serum IL-1 beta, TNF-alpha, and MMP-13 also significantly decreased postintervention in both groups, and the intervention group's levels were significantly lower than those of the control group. The total effective rate was 94.1% in the intervention group, 32 out of 34 participants, and 75.8% in the control group, 25 out of 33 participants, which was significantly different. Conclusions center dot Acupuncture, in combination with exercise, can relieve symptoms, improve joint function, and reduce pro-inflammatory cytokines (IL-1 beta and TNF-alpha) as well as MMP-13 for patients with KOA. The outcomes for acupuncture using EITBM acupoints were significantly better than those of the acupoints selected using classical consensus.
C1 [Yang, Jiaxiang; Lan, Xiangdong; Cai, Qingcheng; Lu, Ziheng; Wang, Yanjun] Hebei Univ Chinese Med, Dept Acupuncture & Moxibust, Affiliated Hosp 1, Shijiazhuang, Hebei, Peoples R China.
C3 Hebei University of Chinese Medicine
RP Wang, YJ (corresponding author), Hebei Univ Chinese Med, Dept Acupuncture & Moxibust, Affiliated Hosp 1, Shijiazhuang, Hebei, Peoples R China.
EM wangyj8055@sina.com
FU National Key Research and Development Plan Key Special Program of TCM Modernization Research [2018YFC1707803]; Key Project of Hebei Provincial Administration of Traditional Chinese Medicine [Z2022009]; General Project of Scientific Research Plan of Hebei Administration of Traditional Chinese Medicine [2022057]; National Health and Medical Research Council (NHMRC) [2022057] Funding Source: National Health and Medical Research Council (NHMRC)
CR Altman RD, 2000, ARTHRITIS RHEUM-US, V43, P1905
   Bartholdy C, 2017, SEMIN ARTHRITIS RHEU, V47, P9, DOI 10.1016/j.semarthrit.2017.03.007
   Bennell KL, 2008, RHEUM DIS CLIN N AM, V34, P731, DOI 10.1016/j.rdc.2008.05.005
   Breivik H, 2006, EUR J PAIN, V10, P287, DOI 10.1016/j.ejpain.2005.06.009
   Cao W, 2017, SHANGHAI J ACUPUNCT, V36, P0
   Chen CH, 2017, INT IMMUNOPHARMACOL, V52, P218, DOI 10.1016/j.intimp.2017.09.017
   Elboim-Gabyzon M, 2013, CLIN INTERV AGING, V8, P1071, DOI 10.2147/CIA.S42094
   Foster NE, 2007, BMJ-BRIT MED J, V335, P436, DOI 10.1136/bmj.39280.509803.BE
   Hinman RS, 2012, BMC COMPLEM ALTERN M, V12, P0, DOI 10.1186/1472-6882-12-161
   HOCHBERG MC, 1995, ARTHRITIS RHEUM, V38, P1541, DOI 10.1002/art.1780381104
   Hunter DJ, 2019, LANCET, V393, P1745, DOI 10.1016/S0140-6736(19)30417-9
   Jimi Eijiro, 2016, CLIN CALCIUM, V26, P298
   Kannan S, 2015, PERSPECT CLIN RES, V6, P120, DOI 10.4103/2229-3485.154020
   Kwon H, 2016, CELL MOL LIFE SCI, V73, P1173, DOI 10.1007/s00018-015-2115-8
   Li H, 2012, CLIN LAB, V58, P755, DOI 10.7754/Clin.Lab.2011.110823
   Liao ZH, 2019, MOL CANCER, V18, P0, DOI 10.1186/s12943-019-0961-y
   Liu X, 2011, INTEGRATIVE MED CLIN, V0, P0
   Liu YX, 2017, ONCOTARGET, V8, P38602, DOI 10.18632/oncotarget.16199
   Medicine NAoTC, 1994, DIAGN TREATM CRIT TR, V165, P0
   Muraki S, 2015, BMC MUSCULOSKEL DIS, V16, P0, DOI 10.1186/s12891-015-0737-5
   ONeill TW, 2018, BEST PRACT RES CL RH, V32, P312, DOI 10.1016/j.berh.2018.10.007
   Paiva KBS, 2017, PROG MOL BIOL TRANSL, V148, P203, DOI 10.1016/bs.pmbts.2017.05.001
   Pendleton A, 2000, ANN RHEUM DIS, V59, P936, DOI 10.1136/ard.59.12.936
   Roos EM, 1999, SCAND J RHEUMATOL, V28, P210
   Roos EM, 2011, NAT REV RHEUMATOL, V7, P57, DOI 10.1038/nrrheum.2010.195
   Shiomi T, 2010, PATHOL INT, V60, P477, DOI 10.1111/j.1440-1827.2010.02547.x
   Sun S, 2017, CHINA MED HERALD, V14, P127
   Tu JF, 2021, ARTHRITIS RHEUMATOL, V73, P448, DOI 10.1002/art.41584
   Wallace IJ, 2017, P NATL ACAD SCI USA, V114, P9332, DOI 10.1073/pnas.1703856114
   Wang MN, 2013, ARTHRITIS RES THER, V15, P0, DOI 10.1186/ar4133
   Wang TT, 2018, CYTOKINE GROWTH F R, V44, P38, DOI 10.1016/j.cytogfr.2018.10.002
   White A, 2007, RHEUMATOLOGY, V46, P384, DOI 10.1093/rheumatology/kel413
   Woodell-May J, 2011, J ORTHOP RES, V29, P1320, DOI 10.1002/jor.21384
   Zhao YP, 2016, INFLAMMATION, V39, P385, DOI 10.1007/s10753-015-0260-8
   Zheng X, 2002, PRINCIPAL GUIDELINE, V349, P0
NR 35
TC 1
Z9 2
U1 1
U2 8
PU InnoVision Professional Media
PI Eagan
PA 3470 Washington Drive Suite 102, Eagan, MN 55122, UNITED STATES
SN 1078-6791
EI 
J9 ALTERN THER HEALTH M
JI Altern. Ther. Health Med.
PD JUL-AUG 15
PY 2023
VL 29
IS 5
BP 262
EP 267
DI 
PG 6
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA M2TQ1
UT WOS:001028759700039
PM 37052974
DA 2026-01-16
ER

PT J
AU Li, XT
   Zhi, L
   Han, KY
   Li, SQ
   Ahmad, K
   Seluzicki, C
   Wang, R
   Bao, T
AF Li, Xiaotong
   Zhi, Lilly
   Han, Katherine Y.
   Li, Susan Q.
   Ahmad, Khalada
   Seluzicki, Christina
   Wang, Rui
   Bao, Ting
TI Impact of Baseline Expectancy on Outcome Prediction of Real and Sham Acupuncture for Persistent Chemotherapy-Induced Peripheral Neuropathy Pain in Solid Tumor Survivors: A Secondary Analysis of a Randomized Clinical Trial
SO INTEGRATIVE CANCER THERAPIES
LA English
DT Article
DE acupuncture expectancy; acupuncture; chemotherapy-induced peripheral neuropathy; sham acupuncture; pain
ID prevention; validation; management; scale
AB Background:Chemotherapy-induced peripheral neuropathy (CIPN) pain significantly worsens cancer survivors' quality of life. Expectancy may play an important role in acupuncture response. We sought to explore whether expectancy predicts pain outcome in real acupuncture (RA) and sham acupuncture (SA) in cancer survivors. Methods:We analyzed data from a randomized clinical trial that evaluated the effect of RA on CIPN symptoms compared to SA and wait list control (WLC) in 75 cancer survivors. This secondary analysis was limited to CIPN pain measured by the Numeric Rating Scale (NRS), graded from 0 to 10. Interventions were delivered over 8 weeks. SA was implemented using a combination of non-acupuncture points and a non-insertion procedure. Patient expectancy was measured by the Acupuncture Expectancy Scale (AES) 3 times during the study. We used a linear regression model to evaluate if the NRS score was associated with the baseline AES score at the end of treatment (week 8), adjusting for baseline NRS score. Results:AES was similar among 3 groups at baseline (RA: 11.8 & PLUSMN; 2.7; SA: 12.1 & PLUSMN; 3.8.; WLC: 14.6 & PLUSMN; 4.2; P = .062). Baseline AES was not found to be significantly associated with the week 8 NRS score among patients in all RA, SA, and WLC groups (all P > .05). However, we found a trend that higher baseline AES predicted lower NRS score at week 8 in the SA group: a one-point higher score on baseline expectancy was associated with a 0.3-point reduction in NRS pain score (P = .059) at week 8. Conclusions:The association of baseline expectancy and acupuncture response was similar between RA and SA. However, SA seemed to rely more on expectancy than RA. Further studies with larger sample sizes are needed to confirm this finding.
C1 [Li, Xiaotong; Han, Katherine Y.; Li, Susan Q.; Seluzicki, Christina; Wang, Rui; Bao, Ting] Mem Sloan Kettering Canc Ctr, New York, NY USA.
   [Zhi, Lilly] Ward Melville High Sch, East Setauket, NY USA.
   [Ahmad, Khalada] Advent Hlth Great Lakes Reg, Advent Hlth Canc Inst Clin Res, Hinsdale, IL USA.
   [Bao, Ting] Mem Sloan Kettering Canc Ctr, Dept Med, Integrat Med Serv, 321 East 61st St,4th Floor, New York, NY 10065 USA.
C3 Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center
RP Bao, T (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Med, Integrat Med Serv, 321 East 61st St,4th Floor, New York, NY 10065 USA.
EM baot@mskcc.org
FU National Cancer Institute [P30CA008748] Funding Source: NIH RePORTER; NCI NIH HHS [R37 CA248563, R01 CA251470, P30 CA008748] Funding Source: Medline
CR Atlas LY, 2012, J NEUROSCI, V32, P8053, DOI 10.1523/JNEUROSCI.0383-12.2012
   Bao T, 2020, JAMA NETW OPEN, V3, P0, DOI 10.1001/jamanetworkopen.2020.0681
   Bao T, 2014, INTEGR CANCER THER, V13, P396, DOI 10.1177/1534735414534729
   Bauml Joshua, 2014, JOURNAL OF THE NATIONAL CANCER INSTITUTE MONOGRAPHS, V0, PP302, DOI 10.1093/jncimonographs/lgu029
   Brunelli C, 2010, HEALTH QUAL LIFE OUT, V8, P0, DOI 10.1186/1477-7525-8-42
   Childs JD, 2005, SPINE, V30, P1331, DOI 10.1097/01.brs.0000164099.92112.29
   Colagiuri B, 2012, EVID-BASED COMPL ALT, V2012, P0, DOI 10.1155/2012/857804
   DOWNIE WW, 1978, ANN RHEUM DIS, V37, P378, DOI 10.1136/ard.37.4.378
   Efverman A, 2020, COMPLEMENT THER MED, V52, P0, DOI 10.1016/j.ctim.2020.102404
   Farrar JT, 2001, PAIN, V94, P149, DOI 10.1016/S0304-3959(01)00349-9
   FERRAZ MB, 1990, J RHEUMATOL, V17, P1022
   Finniss DG, 2010, LANCET, V375, P686, DOI 10.1016/S0140-6736(09)61706-2
   Harris RE, 2009, NEUROIMAGE, V47, P1077, DOI 10.1016/j.neuroimage.2009.05.083
   Hausheer FH, 2006, SEMIN ONCOL, V33, P15, DOI 10.1053/j.seminoncol.2005.12.010
   Hershman DL, 2018, JAMA-J AM MED ASSOC, V320, P167, DOI 10.1001/jama.2018.8907
   Hershman DL, 2014, J CLIN ONCOL, V32, P1941, DOI 10.1200/JCO.2013.54.0914
   Kaptchuk TJ, 2002, ANN INTERN MED, V136, P817, DOI 10.7326/0003-4819-136-11-200206040-00011
   Kirsch I, 1990, CHANGING EXPECTATION, V0, P0
   Kong J, 2009, NEUROIMAGE, V45, P940, DOI 10.1016/j.neuroimage.2008.12.025
   Linde K, 2010, BMC MED, V8, P0, DOI 10.1186/1741-7015-8-75
   Loprinzi CL, 2020, J CLIN ONCOL, V38, P0, DOI 10.1200/JCO.20.01399
   Lundeberg T, 2011, EVID-BASED COMPL ALT, V2011, P1, DOI 10.1093/ecam/nep049
   Mao JJ, 2007, EXPLORE-NY, V3, P372, DOI 10.1016/j.explore.2006.12.003
   Mao JJ, 2010, ALTERN THER HEALTH M, V16, P22
   Moon JY, 2020, MEDICINE, V99, P0
   Pariente J, 2005, NEUROIMAGE, V25, P1161, DOI 10.1016/j.neuroimage.2005.01.016
   Pike Crystal T, 2012, CHEMOTHER RES PRACT, V2012, P913848, DOI 10.1155/2012/913848
   Prady SL, 2015, COMPLEMENT THER MED, V23, P185, DOI 10.1016/j.ctim.2015.01.007
   Staff NP, 2017, ANN NEUROL, V81, P772, DOI 10.1002/ana.24951
   Wolf S, 2008, EUR J CANCER, V44, P1507, DOI 10.1016/j.ejca.2008.04.018
NR 30
TC 7
Z9 7
U1 2
U2 13
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1534-7354
EI 1552-695X
J9 INTEGR CANCER THER
JI Integr. Cancer Ther.
PD JUN 15
PY 2023
VL 22
IS 
BP 
EP 
DI 10.1177/15347354221149992
PG 8
WC Oncology; Integrative & Complementary Medicine
SC Oncology; Integrative & Complementary Medicine
GA R0DV3
UT WOS:001061139200001
PM 36691937
DA 2026-01-16
ER

PT J
AU Zhang, QL
   Yuan, YT
   Zhang, ML
   Qiao, BH
   Cui, YY
   Wang, Y
   Feng, L
AF Zhang, Qinglin
   Yuan, Yuntong
   Zhang, Meiling
   Qiao, Baohua
   Cui, Yiyuan
   Wang, Ying
   Feng, Li
TI Efficacy and safety of acupuncture-point stimulation combined with opioids for the treatment of moderate to severe cancer pain: a network meta-analysis of randomized controlled trials
SO FRONTIERS IN ONCOLOGY
LA English
DT Article
DE cancer pain; acupuncture-point stimulation; opioid; supplementary alternative therapy; network meta-analysis
AB Background Pain is one of the most common and troublesome symptoms of cancer. Although potential positive effects of acupuncture-point stimulation (APS) on cancer pain have been observed, knowledge regarding the selection of the optimal APS remains unclear because of a lack of evidence from head-to-head randomized controlled trials (RCTs).ObjectiveThis study aimed to carry out a network meta-analysis to compare the efficacy and safety of different APS combined with opioids in treating moderate to severe cancer pain and rank these methods for practical consideration.Methods A comprehensive search of eight electronic databases was conducted to obtain RCTs involving different APS combined with opioids for moderate to severe cancer pain. Data were screened and extracted independently using predesigned forms. The quality of RCTs was appraised with the Cochrane Collaboration risk-of-bias tool. The primary outcome was the total pain relief rate. Secondary outcomes were the total incidence of adverse reactions, the incidence of nausea and vomiting, and the incidence of constipation. We applied a frequentist, fixed-effect network meta-analysis model to pool effect sizes across trials using rate ratios (RR) with their 95% confidence intervals (CI). Network meta-analysis was performed using Stata/SE 16.0.Results We included 48 RCTs, which consisted of 4,026 patients, and investigated nine interventions. A network meta-analysis showed that a combination of APS and opioids was superior in relieving moderate to severe cancer pain and reducing the incidence of adverse reactions such as nausea, vomiting, and constipation compared to opioids alone. The ranking of total pain relief rates was as follows: fire needle (surface under the cumulative ranking curve (SUCRA) = 91.1%), body acupuncture (SUCRA = 85.0%), point embedding (SUCRA = 67.7%), auricular acupuncture (SUCRA = 53.8%), moxibustion (SUCRA = 41.9%), transcutaneous electrical acupoint stimulation (TEAS) (SUCRA = 39.0%), electroacupuncture (SUCRA = 37.4%), and wrist-ankle acupuncture (SUCRA = 34.1%). The ranking of total incidence of adverse reactions was as follows: auricular acupuncture (SUCRA = 23.3%), electroacupuncture (SUCRA = 25.1%), fire needle (SUCRA = 27.2%), point embedding (SUCRA = 42.6%), moxibustion (SUCRA = 48.2%), body acupuncture (SUCRA = 49.8%), wrist-ankle acupuncture (SUCRA = 57.8%), TEAS (SUCRA = 76.3%), and opioids alone (SUCRA = 99.7%).Conclusions APS seemed to be effective in relieving cancer pain and reducing opioid-related adverse reactions. Fire needle combined with opioids may be a promising intervention to reduce moderate to severe cancer pain as well as reduce opioid-related adverse reactions. However, the evidence was not conclusive. More high-quality trials investigating the stability of evidence levels of different interventions on cancer pain must be conducted.Systematic Review Registration, identifier CRD42022362054.
C1 [Zhang, Qinglin; Zhang, Meiling] Zhejiang Chinese Med Univ, Clin Med Coll 3, Dept Oncol, Hangzhou, Peoples R China.
   [Zhang, Qinglin; Yuan, Yuntong; Qiao, Baohua; Wang, Ying] Beijing Univ Chinese Med, Dongzhimen Hosp, Beijing, Peoples R China.
   [Zhang, Qinglin; Cui, Yiyuan; Wang, Ying; Feng, Li] Chinese Acad Med Sci & Peking Union Med Coll, Canc Hosp, Natl Canc Ctr, Natl Clin Res Ctr Canc, Beijing, Peoples R China.
C3 Zhejiang Chinese Medical University; Beijing University of Chinese Medicine; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; Cancer Institute & Hospital - CAMS
RP Feng, L (corresponding author), Chinese Acad Med Sci & Peking Union Med Coll, Canc Hosp, Natl Canc Ctr, Natl Clin Res Ctr Canc, Beijing, Peoples R China.
EM fengli663@126.com
FU Project of the Central Public Scientific Research Institute of Cancer Hospital, Chinese Academy of Medical Sciences [2019XK320072]; Special Research Project of the Capital Health Development [2020-2-4026]
CR Abali AE, 2022, J BURN CARE RES, V43, P389, DOI 10.1093/jbcr/irab142
   Asher GN, 2010, J ALTERN COMPLEM MED, V16, P1097, DOI 10.1089/acm.2009.0451
   Bell TJ, 2009, PAIN MED, V10, P35, DOI 10.1111/j.1526-4637.2008.00495.x
   Bennett Mike, 2017, AM SOC CLIN ONCOL EDUC BOOK, V37, P705, DOI 10.1200/edbk_180469
   Bing L, 2020, J SHANDONG U TRADITI, V44, P539, DOI 10.16294/j.cnki.1007-659x.2020.05.017
   Chao Z, 2019, WOMENS HLTH RES, V2019, P119
   Chen J, 2020, SHAANXI TRADITIONAL CHINESE MEDICINE, V41, P105
   Chen LX, 2020, J ACUPUNCT TUINA SCI, V18, P276, DOI 10.1007/s11726-020-1188-6
   Chen Z, 2021, SHANGHAI J ACUPUNCT MOXIBUSTION, V40, P411, DOI 10.13460/j.issn.1005-0957.2021.04.0411
   Chu-ting X, 2020, ZHEJIANG J TRADITION, V55, P295, DOI 10.13633/j.cnki.zjtcm.2020.04.035
   Cumpston M, 2019, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.ED000142
   Ding QG, 2015, CHIN MED MODERN DIST EDU CHIN, V13, P65
   Eshkevari Ladan, 2017, ANNU REV NURS RES, V35, P117, DOI 10.1891/0739-6686.35.117
   Fan LY, 2017, HEBEI J TRADITIONAL CHINESE MED., V29, P36, DOI 10.3969/j.issn.1672-0369.2017.11.017
   Fengying Y, 2011, CHIN PRACT J RURAL D, V18, P56, DOI 10.3969/j.issn.1672-7185.2011.02.036
   Fu Yuan-Bo, 2021, ZHONGGUO ZHEN JIU, V41, P493, DOI 10.13703/j.0255-2930.20200708-k0003
   Gao Xin, 2020, ZHONGGUO ZHEN JIU, V40, P601, DOI 10.13703/j.0255-2930.20190531-k0001
   Guo-dong Z, 2021, WORLD LATEST MED INF, V21, P9, DOI 10.3969/j.issn.1671-3141.2021.20.005
   Guo-dong Z, 2018, CHINA HLTH CARE NUTR, V28, P36, DOI 10.3969/j.issn.1004-7484.2018.27.021
   He YH, 2020, JAMA ONCOL, V6, P271, DOI 10.1001/jamaoncol.2019.5233
   Hongyan X, 2018, CARDIOVASC DIS ELECT, V6, P147+50, DOI 10.16282/j.cnki.cn11-9336/r.2018.09.103
   Huang L, 2021, J PAIN RES, V14, P343, DOI 10.2147/JPR.S292657
   Hutton B, 2015, ANN INTERN MED, V162, P777, DOI 10.7326/M14-2385
   Jahn F, 2022, DTSCH ARZTEBL INT, V119, P382, DOI 10.3238/arztebl.m2022.0093
   Jang JH, 2021, PAIN, V162, P514, DOI 10.1097/j.pain.0000000000002031
   Jian-chun P, 2021, CHIN J CLIN ONCOL RE, V28, P1243, DOI 10.13455/j.cnki.cjcor.2021.10.24
   Jiao G, 2020, CLIN RES PRACT, V5, P115, DOI 10.19347/j.cnki.2096-1413.202007049
   Jing X, 2017, CHIN MED MODERN DIST, V15, P112
   Kelly RB, 2019, AM FAM PHYSICIAN, V100, P89
   Kwon JH, 2014, J CLIN ONCOL, V32, P1727, DOI 10.1200/JCO.2013.52.4827
   Li DH, 2017, J GUANGZHOU UNIV TRADIT CHIN MED, V34, P344
   Li Dan, 2020, ZHONGGUO ZHEN JIU, V40, P257, DOI 10.13703/j.0255-2930.20190311-k0001
   [李俊 Li Jun], 2014, 中国全科医学 CHINESE GENERAL PRACTICE, V17, P325
   Ling-ling W, 2021, SHANGHAI J ACUPUNCTU, V40, P1336, DOI 10.13460/j.issn.1005-0957.2021.11.1336
   Liqiong L, 2021, RES INTEGRATED TRADI, V13, P284
   Liu L, 2020, SHANG J ACUPUNCT, V39, P692
   Lu Dian-Rong, 2021, ZHONGGUO ZHEN JIU, V41, P121, DOI 10.13703/j.0255-2930.20190320-0010
   Lu DR, 2018, WORLD J INTEGR TRADIT WEST MED, V13, P116, DOI 10.13935/j.cnki.sjzx.180132
   Lu Y, 2022, SLEEP MED, V93, P39, DOI 10.1016/j.sleep.2022.03.012
   MacPherson H, 2001, BMJ-BRIT MED J, V323, P486, DOI 10.1136/bmj.323.7311.486
   Ming-hua W, 2015, HLTH RES, V35, P562, DOI 10.3969/j.issn.1674-6449.2015.05.032
   Murakami M, 2017, PAIN MED, V18, P551, DOI 10.1093/pm/pnw215
   Page MJ, 2021, BMJ-BRIT MED J, V372, P0, DOI 10.1136/bmj.n160
   Ping X, 2021, LAB MED CLIN, V18, P2875
   Qiaotong H, 2014, GUANGXI J TRADITIONA, V37, P37
   Qing-quan W, 2016, J EXTERNAL THER TRAD, V25, P18
   Qiuhong L, 2015, PRACT J CANC, V30, P922, DOI 10.3969/j.issn.1001-5930.2015.06.042
   Run C, 2021, MED J W CHINA, V33, P1683
   Shih CY, 2022, INT J NURS STUD, V130, P0, DOI 10.1016/j.ijnurstu.2022.104220
   Streitberger K, 2006, AUTON NEUROSCI-BASIC, V129, P107, DOI 10.1016/j.autneu.2006.07.015
   Su PL, 2022, FRONT PHARMACOL, V12, P0, DOI 10.3389/fphar.2021.803676
   Su-e S, 2000, CHIN ACUPUNCTURE MOX, V2000, P15, DOI 10.13703/j.0255-2930.2000.03.008
   Sung H, 2021, CA-CANCER J CLIN, V71, P209, DOI 10.3322/caac.21660
   Swarm RA, 2019, J NATL COMPR CANC NE, V17, P977, DOI 10.6004/jnccn.2019.0038
   Usichenko T, 2017, BRAIN STIMUL, V10, P1042, DOI 10.1016/j.brs.2017.07.013
   Vickers AJ, 2014, JAMA-J AM MED ASSOC, V311, P955, DOI 10.1001/jama.2013.285478
   Wang C, 2019, J NEW CHIN MED, V51, P242, DOI 10.13457/J.CNKI.JNCM.2019.10.069
   Wang H, 2018, HENAN TRADIT. CHIN. MED., V38, P454, DOI 10.16367/J.ISSN.1003-5028.2018.03.0120
   Wang LJ, 2021, J PAIN RES, V14, P1097, DOI 10.2147/JPR.S310385
   Wang Y, 2019, EVID-BASED COMPL ALT, V2019, P0, DOI 10.1155/2019/4706865
   Wei S, 2016, CHIN MANIPULATION RE, V7, P24
   Weiji L, 2012, CHINA HLTH CARE NUTR, V2012, P78
   Weijie B, 2019, CHIN MANIPULATION RE, V10, P14
   Wu XY, 2015, SCI REP-UK, V5, P0, DOI 10.1038/srep16776
   Xiang-hong W, 2021, CHIN EVIDENCE BASED, V7, P2497, DOI 10.12102/j.issn.2095-8668.2021.18.015
   Xiaodan H, 2019, CHIN COMMUNITY DOCTO, V35, P90, DOI 10.3969/j.issn.1007-614x.2019.24.064
   Xu JC, 2019, CNS NEUROL DISORD-DR, V18, P245, DOI 10.2174/1871527318666190204111701
   Xue N, 2022, MOD. J. INTEGR. TRADIT. CHIN. WEST. MED., V31, P334
   Yang J, 2021, BMJ SUPPORT PALLIAT, V11, P264, DOI 10.1136/bmjspcare-2020-002638
   Yang Z, 2021, J TRADIT CHIN MED ONCOL, V3, P30, DOI 10.1007/s12032-021-01474-1
   Yi D, 2015, MODERN J INTEGRATED, V24, P606
   Ying H, 2018, INNER MONGOLIA J TRA, V37, P58, DOI 10.16040/j.cnki.cn15-1101.2018.05.041
   Yougang W, 2016, J PREV MED CHIN PEOP, V34, P297, DOI 10.13704/j.cnki.jyyx.2016.s1.264
   Yun D, 2017, J N SICHUAN MED COLL, V32, P30, DOI 10.3969/j.issn.1005-3697.2017.01.009
   Zhang H, 2016, J GUIYANG COLL TRADIT CHIN MED, V38, P85
   Zhang RX, 2014, ANESTHESIOLOGY, V120, P482, DOI 10.1097/ALN.0000000000000101
   Zhipeng Z, 2020, V15, V0, PP753, DOI 10.13935/j.cnki.sjzx.200442
   Zhiwei Q, 2019, MODERN DIGESTION INT, V24, P0310
   [钟敏钰 Zhong Minyu], 2012, 中医杂志 JOURNAL OF TRADITIONAL CHINESE MEDICINE, V53, P1123
NR 79
TC 4
Z9 4
U1 3
U2 27
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 2234-943X
EI 
J9 FRONT ONCOL
JI Front. Oncol.
PD JUN 2
PY 2023
VL 13
IS 
BP 
EP 
DI 10.3389/fonc.2023.1166580
PG 12
WC Oncology
SC Oncology
GA J4FK3
UT WOS:001009184000001
PM 37333815
DA 2026-01-16
ER

PT J
AU Zhang, D
   Ji, Y
   Lv, L
   Zhou, Q
   Liu, Z
   Zhang, C
   Chen, S
AF Zhang, Di
   Ji, Yue
   Lv, Liu
   Zhou, Qiongyang
   Liu, Zhijiang
   Zhang, Chenlin
   Chen, Shanshan
TI An Overview of Systematic Reviews and Meta-Analyses of Clinical Studies of
SO Integrative cancer therapies
LA English
DT Review
DE acupuncture; cancer; evidence; overview; pain
AB BACKGROUND: Systematic reviews (SRs) and meta-analyses (MAs) for the use of  acupuncture for cancer pain have been increasing, but the evidence has not been  systematically and comprehensively assessed. We aimed to perform an overview of  the evidence quality of SRs/MAs of acupuncture for improving cancer pain.  METHODS: 8 databases were systematically searched to identify SRs/MAs of  acupuncture for improving cancer pain. The A Measurement Tool to Assess  Systematic Reviews 2 (AMSTAR-2), Risk of Bias in Systematic Reviews (ROBIS),  Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA), and  Grades of Recommendations, Assessment, Development, and Evaluation (GRADE),  respectively, were applied by 2 independent reviewers to evaluate the  methodological quality, risk of bias, reporting quality, and evidence quality.  RESULTS: A total of 14 SRs/MAs were included in the present study. By AMSTAR-2,  two reviews were rated as having high methodological quality, while 12 were given  a critically low rating. All SRs/MAs in Phase 1, Domain 1, and Domain 4,  according to ROBIS, were at low risk. Furthermore, 4 reviews in Domain 2, twelve  reviews in Domain 3, and ten SRs/MAs in Phase 3, were rated as having low risk of  bias. With reporting quality, some reporting flaws were identified in the topic  of protocol and registration, additional analyses, and search strategy. According  to GRADE, the level of evidence quality was "critically low" to "moderate," and  risk of bias was the most common downgraded factor. CONCLUSION: Acupuncture may  be beneficial in improving cancer pain. However, due to the identified  limitations and inconsistent findings, we recommend further rigorous, and more  standardized SRs/MAs to provide strong evidence for definitive conclusions.
C1 Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, China.
   Tianjin University of Traditional Chinese Medicine, Tianjin, China.
   Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China.
   The First People's Hospital of Wenling, Wenling, China.
   Gushi County Hospital of TCM, Gushi, China.
   Tianjin University of Traditional Chinese Medicine, Tianjin, China.
   Gansu Provincial Hospital of TCM, Lanzhou, China.
NR 0
TC 0
SN 1552-695
EI 1534-735
J9 Integr Cancer Ther
PD NOV 9
PY 2023
VL 22
IS 
BP 15347354231210288
EP 15347354231210288
DI 10.1177/15347354231210288
PG 1
WC Humans; Acupuncture Therapy; Cancer Pain; therapy; Databases, Factual; Neoplasms; complications; Systematic Reviews as Topic; Meta-Analysis as Topic
UT PubMed:37942632
PM 37942632
DA 2023-11-09
ER

PT J
AU Cohen, SA
   Veleber, S
   Siman, J
   Guthrie, KA
   McMillen, K
   Heit, M
   Wadhera, S
   Daniels, J
   Hansen, K
   Jacoby, M
   Taromina, K
   Chin, S
   Romeo, M
   Langley, BO
   Coveler, AL
   Hannan, LM
   King, G
   Purcell, T
   Safyan, RA
   Shankaran, V
   Zhen, DB
   Chiorean, EG
   Greenlee, H
AF Cohen, Stacey A
   Veleber, Susan
   Siman, Jonathan
   Guthrie, Katherine A
   McMillen, Kerry
   Heit, Madilyn
   Wadhera, Sonia
   Daniels, Jonathan
   Hansen, Kjell
   Jacoby, Madeline
   Taromina, Katherine
   Chin, Samantha
   Romeo, Melissa
   Langley, Blake O
   Coveler, Andrew L
   Hannan, Lindsay M
   King, Gentry
   Purcell, Tom
   Safyan, Rachael A
   Shankaran, Veena
   Zhen, David B
   Chiorean, E Gabriela
   Greenlee, Heather
TI Use of acupuncture with acupressure in addition to standard-of-care cryotherapy
SO Contemporary clinical trials
LA English
DT Journal Article
DE Colorectal cancer; Oxaliplatin; Pancreatic cancer; Peripheral neuropathy
AB BACKGROUND: Oxaliplatin is a key chemotherapeutic agent in the treatment of local  and metastatic gastrointestinal (GI) malignancies. Dose density and treatment  adherence can be limited by chemotherapy-induced peripheral neuropathy (CIPN).  Early research suggests CIPN incidence and severity may be mitigated by  acupuncture, but rigorous data in GI oncology patients is limited. Here, we  describe the protocol of a randomized, waitlist-controlled pilot study testing  the use of preemptive of acupuncture plus acupressure to decrease CIPN and  chemotherapy-related toxicities. METHODS: Patients with a GI malignancy (n = 56)  with planned 5-fluorouracil (5-FU) and oxaliplatin IV (FOLFOX, FOLFIRINOX) every  2 weeks are being recruited. Additional concurrent anti-neoplastic agents may be  used. Enrolled patients are randomized 1:1 to a 3-month intervention of Arm A:  acupuncture with acupressure and standard-of-care treatment, or Arm B:  standard-of-care alone. In Arm A, on days 1 and 3 of each chemotherapy cycle a  standardized acupuncture protocol is administered and patients are taught  self-acupressure to perform daily between chemotherapy treatments. Patients in  both arms are given standard-of-care oral and peripheral (hands/feet) ice chip  cryotherapy during oxaliplatin administration. CIPN and other symptoms are  assessed at baseline, 6 weeks, and 3 months from registration. The primary  endpoint is CIPN severity at 3 months (EORTC-CIPN 20). Additional endpoints  evaluate CIPN incidence (CTCAE, Neuropen, tuning fork); incidence of pain,  fatigue, nausea, oral dysesthesia, and anxiety; and feasibility (recruitment,  retention, adherence, acceptability). If warranted, trial results will inform the  design of a multi-center trial to expand testing of the intervention to a larger  patient cohort.
C1 Clinical Research Division, Fred Hutchinson Cancer Center, 825 Eastlake Ave E, Seattle, WA 98109, USA
   Division of Medical Oncology, University of WashingtonSchool of Medicine, USA. 
   Integrative Medicine Program, Division of Supportive Care, Fred Hutchinson Cancer Center, USA
   Division of Public Health Sciences, Fred Hutchinson Cancer Center,USA.
   Integrative Medicine Program, Division of Supportive Care, Fred Hutchinson Cancer Center, USA
   Division of Public Health Sciences, Fred Hutchinson Cancer Center,USA.
   Division of Public Health Sciences, Fred Hutchinson Cancer Center, USA.
   Clinical Research Division, Fred Hutchinson Cancer Center, 825 Eastlake Ave E, Seattle, WA 98109, USA.
   Clinical Research Division, Fred Hutchinson Cancer Center, 825 Eastlake Ave E, Seattle, WA 98109, USA
   Division of Medical Oncology, University of WashingtonSchool of Medicine, USA.
   Clinical Research Division, Fred Hutchinson Cancer Center, 825 Eastlake Ave E, Seattle, WA 98109, USA
   Division of Medical Oncology, University of WashingtonSchool of Medicine, USA.
   Clinical Research Division, Fred Hutchinson Cancer Center, 825 Eastlake Ave E, Seattle, WA 98109, USA
   Division of Medical Oncology, University of WashingtonSchool of Medicine, USA.
   Clinical Research Division, Fred Hutchinson Cancer Center, 825 Eastlake Ave E, Seattle, WA 98109, USA
   Division of Medical Oncology, University of WashingtonSchool of Medicine, USA.
   Clinical Research Division, Fred Hutchinson Cancer Center, 825 Eastlake Ave E, Seattle, WA 98109, USA
   Division of Medical Oncology, University of WashingtonSchool of Medicine, USA.
   Integrative Medicine Program, Division of Supportive Care, Fred Hutchinson Cancer Center, USA.
   Integrative Medicine Program, Division of Supportive Care, Fred Hutchinson Cancer Center, USA.
   Integrative Medicine Program, Division of Supportive Care, Fred Hutchinson Cancer Center, USA.
   Integrative Medicine Program, Division of Supportive Care, Fred Hutchinson Cancer Center, USA
   Division of Public Health Sciences, Fred Hutchinson Cancer Center,USA
   Department of Child, Family, and Population Health Nursing, University ofWashington, Seattle, WA 98195, USA.
   Clinical Research Division, Fred Hutchinson Cancer Center, 825 Eastlake Ave E, Seattle, WA 98109, USA
   Division of Medical Oncology, University of WashingtonSchool of Medicine, USA.
   Division of Medical Oncology, University of Washington School of Medicine, USA.
   Clinical Research Division, Fred Hutchinson Cancer Center, 825 Eastlake Ave E, Seattle, WA 98109, USA
   Division of Medical Oncology, University of WashingtonSchool of Medicine, USA.
   Clinical Research Division, Fred Hutchinson Cancer Center, 825 Eastlake Ave E, Seattle, WA 98109, USA
   Division of Medical Oncology, University of WashingtonSchool of Medicine, USA.
   Clinical Research Division, Fred Hutchinson Cancer Center, 825 Eastlake Ave E, Seattle, WA 98109, USA
   Division of Medical Oncology, University of WashingtonSchool of Medicine, USA.
   Clinical Research Division, Fred Hutchinson Cancer Center, 825 Eastlake Ave E, Seattle, WA 98109, USA
   Division of Medical Oncology, University of WashingtonSchool of Medicine, USA.
   Clinical Research Division, Fred Hutchinson Cancer Center, 825 Eastlake Ave E, Seattle, WA 98109, USA
   Division of Medical Oncology, University of WashingtonSchool of Medicine, USA.
   Clinical Research Division, Fred Hutchinson Cancer Center, 825 Eastlake Ave E, Seattle, WA 98109, USA
   Division of Medical Oncology, University of WashingtonSchool of Medicine, USA.
   Clinical Research Division, Fred Hutchinson Cancer Center, 825 Eastlake Ave E, Seattle, WA 98109, USA
   Division of Medical Oncology, University of WashingtonSchool of Medicine, USA
   Integrative Medicine Program, Division of SupportiveCare, Fred Hutchinson Cancer Center, USA
   Division of Public Health Sciences,Fred Hutchinson Cancer Center, USA.
EM shiovitz@uw.edu
NR 0
TC 0
SN 1559-203
EI 1551-714
J9 Contemp Clin Trials
PD JUN 29
PY 2023
VL 131
IS 
BP 107273
EP 107273
DI 10.1016/j.cct.2023.107273
PG 0
WC Humans; Oxaliplatin; adverse effects; Antineoplastic Combined Chemotherapy Protocols; adverse effects; Feasibility Studies; Acupressure; Pancreatic Neoplasms; Antineoplastic Agents; adverse effects; Peripheral Nervous System Diseases; chemically induced; Acupuncture Therapy; adverse effects; Gastrointestinal Neoplasms; drug therapy; Cryotherapy; Randomized Controlled Trials as Topic; Multicenter Studies as Topic
UT PubMed:37380021
PM 37380021
DA 2023-06-29
ER

PT J
AU Li, QY
   Yang, WX
   Yao, LQ
   Chen, H
   Li, ZR
   Gong, YB
   Shi, J
AF Li, Quan-yao
   Yang, Wen-xiao
   Yao, Li-qiu
   Chen, Hong
   Li, Zhen-rui
   Gong, Ya-bin
   Shi, Jun
TI Exploring the Rules of Related Parameters in Transcutaneous Electrical Nerve Stimulation for Cancer Pain Based on Data Mining
SO PAIN AND THERAPY
LA English
DT Article
DE Transcutaneous electrical nerve stimulation; Cancer; Cancer pain; Data mining; Parameters
ID tens; frequency; intensity; trial; site
AB IntroductionThis study aims to investigate the regularity of related parameters in the treatment of cancer pain using transcutaneous electrical nerve stimulation (TENS).MethodsA comprehensive literature search was conducted in databases such as PubMed, Cochrane Library, Embase, Web of Science, OVID, CNKI, CBM, VIP, and WANNGFANG from inception up to December 2022. A database was established, and data mining techniques were applied to analyze the relevant TENS parameters.ResultsA total of 27 articles were included, encompassing nine current frequencies, four retention times, four treatment frequencies, and two wave types. On the basis of the analysis of parameter association rules, the most closely related parameter combination for clinical TENS in the treatment of cancer pain was a current frequency of 2/100 Hz, a treatment frequency of once a day, a retention time of 30 min, and the dilatational wave. Moreover, the study involved 22 acupuncture points distributed along 13 meridians. According to the analysis of acupuncture point association rules, Hegu (LI04), Zusanli (ST36), and Sanyinjiao (SP06) were the most closely related acupuncture points and could be used in combination for clinical TENS in cancer pain treatment. Furthermore, cluster analysis was conducted on acupuncture points with a frequency & GE; 5, resulting in three categories: the first category included Sanyinjiao (SP06), Zusanli (ST36), Hegu (LI04), Jiaji point, and Neiguan (PC06); the second category included Ashi point; and the third category included Back shu point.ConclusionIn the treatment of cancer pain using TENS, it is recommended to use a current frequency of 2/100 Hz, a treatment frequency of once a day, a retention time of 30 min, and the dilatational wave. The electrode positions were primarily selected from Ashi point, Back shu point, Sanyinjiao (SP06), Zusanli (ST36), Hegu (LI04), Jiaji point, and Neiguan (PC06) to achieve the best analgesic effect.
C1 [Li, Quan-yao; Yang, Wen-xiao; Chen, Hong; Li, Zhen-rui; Gong, Ya-bin; Shi, Jun] Shanghai Univ Tradit Chinese Med, Yueyang Hosp Integrated Tradit Chinese & Western M, Shanghai 200437, Peoples R China.
   [Yao, Li-qiu] Jingan Dist Hosp Tradit Chinese Med, Shanghai 200072, Peoples R China.
C3 Shanghai University of Traditional Chinese Medicine
RP Gong, YB; Shi, J (corresponding author), Shanghai Univ Tradit Chinese Med, Yueyang Hosp Integrated Tradit Chinese & Western M, Shanghai 200437, Peoples R China.
EM gongyabin@hotmail.com; shijundoctor@163.com
FU National Natural Science Foundation of China [82205213]
CR Bannister K, 2015, PAIN, V156, P1803, DOI 10.1097/j.pain.0000000000000240
   Bao GA, 2016, ZHEJIANG U TRADIT CH, V6, P1
   Bao GA, 2017, SHANGHAI J ACUPUNCT, V36, P236, DOI 10.13460/j.issn.1005-0957.2017.02.0236
   Bennett MI, 2017, PAIN, V158, PS74, DOI 10.1097/j.pain.0000000000000825
   Bennett MI, 2010, J PAIN, V11, P351, DOI 10.1016/j.jpain.2009.08.002
   Carbonario F, 2013, EUR J PHYS REHAB MED, V49, P197
   Cheing GLY, 2009, J REHABIL MED, V41, P412, DOI 10.2340/16501977-0350
   Chen J, 2020, SHAANXI TRADITIONAL CHINESE MEDICINE, V41, P105
   Chen LL, 2002, ZHEJIANG J INTEGR TR, V08, P57
   Chesterton LS, 2003, PAIN, V106, P73, DOI 10.1016/S0304-3959(03)00292-6
   Chiu TTW, 2005, CLIN REHABIL, V19, P850, DOI 10.1191/0269215505cr920oa
   Chou YH, 2022, ASIA-PAC J ONCOL NUR, V9, P61, DOI 10.1016/j.apjon.2021.11.002
   Chwistek Marcin, 2017, F1000RES, V6, P945, DOI 10.12688/f1000research.10817.1
   Dailey DL, 2020, ARTHRITIS RHEUMATOL, V72, P824, DOI 10.1002/art.41170
   Davis S, 2021, EMERG MED AUSTRALAS, V33, P601, DOI 10.1111/1742-6723.13793
   Ferreira APD, 2017, J APPL ORAL SCI, V25, P112
   de Oliveira HU, 2020, J PAIN, V21, P820, DOI 10.1016/j.jpain.2019.11.009
   Deng Y, 2017, J N SICHUAN MED COLL, V32, P30
   Du WB, 2019, CHIN GEN PRACT, V22, P3997, DOI 10.12114/j.issn.1007-9572.2019.00.078
   EKBLOM A, 1985, ACTA PHYSIOL SCAND, V125, P541, DOI 10.1111/j.1748-1716.1985.tb07753.x
   Fu TF, 2017, J ZHEJIANG CHINESE M, V41, P447, DOI 10.16466/j.issn1005-5509.2017.06.001
   Gobbo M, 2014, J NEUROENG REHABIL, V11, P0, DOI 10.1186/1743-0003-11-17
   Gozani SN, 2019, J PAIN RES, V12, P3185, DOI 10.2147/JPR.S226600
   [郭寻竹 Guo Xunzhu], 2015, 中国全科医学 CHINESE GENERAL PRACTICE, V18, P903
   Hamza MA, 1999, ANESTHESIOLOGY, V91, P1232, DOI 10.1097/00000542-199911000-00012
   HAN JS, 1991, PAIN, V47, P295, DOI 10.1016/0304-3959(91)90218-M
   He L, 2012, HEBEI J TCM, V34, P882
   He LH, 2019, GUANGDONG MED J, V40, P1904
   He LH, 2021, MEDICINE, V100, P0, DOI 10.1097/MD.0000000000023748
   He YH, 2017, BMJ OPEN, V7, P0, DOI 10.1136/bmjopen-2017-018494
   Hojsted J, 2007, EUR J PAIN, V11, P490, DOI 10.1016/j.ejpain.2006.08.004
   Kirmaci ZIK, 2023, MULT SCLER RELAT DIS, V71, P0, DOI 10.1016/j.msard.2023.104541
   Lee JE, 2019, CANCER NURS, V42, P218, DOI 10.1097/NCC.0000000000000594
   [李俊 Li Jun], 2014, 中国全科医学 CHINESE GENERAL PRACTICE, V17, P325
   李倩, 2011, 中国疼痛医学杂志 CHINESE JOURNAL OF PAIN MEDICINE, V17, P116
   Li QH, 2015, J PRACT CANC, V30, P922
   [李小梅 Li Xiaomei], 2016, 中国疼痛医学杂志 CHINESE JOURNAL OF PAIN MEDICINE, V22, P364
   Liang F, 2016, ACUPUNCTURE AND MOXIBUSTION, V0, P0
   Lin ZG, 2019, CHINESE ARCHIVES OF TRADITIONAL CHINESE MEDICINE, V37, P877
   Lisi TL, 2006, J NEUROSCI METH, V150, P74, DOI 10.1016/j.jneumeth.2005.06.001
   Lisón JF, 2017, OBSTET GYNECOL, V129, P363, DOI 10.1097/AOG.0000000000001842
   Liu Y, 2018, ZHEJIANG U CHIN MED, V1, P1
   Loh J, 2015, PAIN MED, V16, P1204, DOI 10.1111/pme.12038
   Ma AQ, 2019, SHANGHAI U TRADIT CH, V0, P0, DOI DOI 10.27320/d.cnki.gszyu.2019.000273
   Maedai Y, 2007, BRAIN RES, V1136, P43, DOI 10.1016/j.brainres.2006.11.061
   MELZACK R, 1965, SCIENCE, V150, P971, DOI 10.1126/science.150.3699.971
   Moreno-Duarte I, 2014, NEUROIMAGE, V85, P1003, DOI 10.1016/j.neuroimage.2013.05.097
   Nakano J, 2020, INT J REHABIL RES, V43, P62, DOI 10.1097/MRR.0000000000000386
   National Health Commission of the Peoples Republic of China, 2018, CHIN CLIN ONCOL, V23, P937
   Özüm Ü, 2012, ACTA NEUROCHIR, V154, P1641, DOI 10.1007/s00701-012-1331-3
   Peng WW, 2019, NEUROIMAGE, V195, P396, DOI 10.1016/j.neuroimage.2019.03.077
   Qian, 2017, CHIN J TRADIT CHIN M, V35, P492, DOI 10.13193/j.iSSN.1673-7717
   Robb KA, 2007, J PAIN SYMPTOM MANAG, V33, P410, DOI 10.1016/j.jpainsymman.2006.09.020
   Sampaio LR, 2016, REV DOR-BRAZIL, V17, P0, DOI 10.5935/1806-0013.20160020
   Sato KL, 2012, J PAIN, V13, P884, DOI 10.1016/j.jpain.2012.06.004
   Schleder Juliana Carvalho, 2017, REV. DOR, V18, P316, DOI 10.5935/1806-0013.20170122
   Shan WQ, 2022, CHIN CLIN ONCOL, V50, P30
   Siemens W, 2020, SUPPORT CARE CANCER, V28, P5323, DOI 10.1007/s00520-020-05370-8
   Tang ZY, 2018, RES ANALGESIC MECH T, V0, P0
   Tousignant-Laflamme Y, 2017, PHYSIOTHER THEOR PR, V33, P361, DOI 10.1080/09593985.2017.1302540
   Turk DC, 2006, PAIN, V125, P208, DOI 10.1016/j.pain.2006.09.028
   Wang CY, 2011, ZHEJIANG J TRADIT CHIN MED, V46, P899
   Wang H, 2021, CHIN J FRONT MED SCI, V13, P60, DOI 10.12037/YXQY.2021.01-05
   Wang PS, 2016, SW DEFENSE MED, V26, P1176
   Weng MH, 2015, HLTH RES, V35, P562
   Xiang XH, 2014, J NEUROSCI RES, V92, P555, DOI 10.1002/jnr.23351
   Yarnitsky D, 2019, HEADACHE, V59, P1240, DOI 10.1111/head.13551
   [喻明 Yu Ming], 2015, 中国新药与临床杂志 CHINESE JOURNAL OF NEW DRUGS AND CLINICAL REMEDIES, V34, P617
   Yuan CP, 2015, ANTIINFECT PHARM, V12, P330
   Yunxiang X, 2014, J LIAONING UNIV TRADITIONAL CHIN MED, V16, P80
   Zhai FJ, 2022, NEUROSCI BULL, V38, P403, DOI 10.1007/s12264-022-00844-7
   Zhang H, 2016, J GUIYANG COLL TRADI, V38, P85, DOI 10.16588/j.carolcarrollnkiissn1002-1108.2016.04.023
   Zhang JZ, 2019, J HUNAN U TRADIT CHI, V39, P241
   Zheng SL, 2021, CHIN CANC CLIN REHAB, V28, P1243, DOI 10.13455/j.carolcarrollnkicjcor.2021.10.24
NR 74
TC 6
Z9 6
U1 2
U2 11
PU SPRINGER INT PUBL AG
PI CHAM
PA GEWERBESTRASSE 11, CHAM, CH-6330, SWITZERLAND
SN 2193-8237
EI 2193-651X
J9 PAIN THER
JI PAIN THER.
PD DEC 15
PY 2023
VL 12
IS 6
BP 1355
EP 1374
DI 10.1007/s40122-023-00549-3
EA AUG 2023
PG 20
WC Clinical Neurology
SC Neurosciences & Neurology
GA W4QA8
UT WOS:001048066600001
PM 37578681
DA 2026-01-16
ER

PT J
AU Liao, HY
   Satyanarayanan, SK
   Lin, YW
   Su, KP
AF Liao, Hsien-Yin
   Satyanarayanan, Senthil Kumaran
   Lin, Yi-Wen
   Su, Kuan-Pin
TI Clinical efficacy and immune effects of acupuncture in patients with comorbid chronic pain and major depression disorder: A double-blinded, randomized controlled crossover study
SO BRAIN BEHAVIOR AND IMMUNITY
LA English
DT Article
DE Acupuncture; Chronic pain; Major depression disorder; Comorbidity; Biomarkers; Inflammatory cytokines
ID low-back-pain; controlled-trial; adenosine pathways; inflammatory pain; ischemic-stroke; electroacupuncture; neuroinflammation; metaanalysis; multicenter; model
AB Background: Depression and pain are highly comorbid and share biological mechanisms. Acupuncture is commonly used to manage both pain and depression, but the choice of acupoints for specific disorders differs. This study aimed to investigate whether specific acupuncture intervention on pain-and depression-acupoints would have specific efficacy and immune effects in patients with comorbid chronic pain and major depressive disorder (MDD). Methods: We performed a subject-and assessor-blinded, crossover, and randomized controlled clinical trial of depression-and pain-specific acupuncture intervention and measured clinical responses and proinflammatory cytokines in patients with comorbid chronic pain and MDD. Specific acupoints for pain and depression were used in random order with a washout interval. Forty-seven patients were enrolled and randomly assigned to two groups: (1) the depression-pain group (23 patients who were treated with depression-specific acupoints and then the pain-specific acupoints after the washout) and (2) pain-depression group (24 patients with the reverse order). Results: The pain-specific acupoints for pain did not reduce Brief Pain Inventory scores to a significantly greater degree (-0.97 +/- 1.69) than the depression-specific acupoints (-0.28 +/- 1.88); likewise, the depression-specific acupoints did not significantly ameliorate Hamilton Depression Rating Scale (-4.59 +/- 6.02) than the pain-specific acupoints (-6.69 +/- 6.61). The pain-specific acupoints improved Beck Depression Inventory-Second Edition (-6.74 +/- 9.76) even better than the depression-specific acupoints (-1.92 +/- 10.74). The depression-specific acupoints did not significantly decrease the depression-related interleukin (IL)-6 level (-1.24 +/- 6.67) than the pain-specific acupoints (-0.60 +/- 4.36). The changed levels of IL-1 beta, tumor necrosis factor (TNF)-alpha be-tween the depression-specific acupoints (-37.41 +/- 194.49;-12.53 +/- 54.68) and the pain-specific acupoints (-15.46 +/- 87.56;-7.28 +/- 27.86) could not reach significantly different, too. Conclusion: This study rejected our hypothesis that the pain-specific acupoints might produce superior analgesic effects than the depression-specific acupoints and vice versa. The cytokine results might imply that pain and depression share common biological mechanisms. (trial registration: https://www.clinicaltrials.gov: NCT03328819).
C1 [Liao, Hsien-Yin] China Med Univ, Coll Chinese Med, Sch Postbaccalaureate Chinese Med, Taichung 40402, Taiwan.
   [Liao, Hsien-Yin] China Med Univ Hosp, Dept Acupuncture, Taichung 40402, Taiwan.
   [Lin, Yi-Wen] China Med Univ, Grad Inst Acupuncture Sci, Coll Chinese Med, Taichung 40402, Taiwan.
   [Lin, Yi-Wen] China Med Univ, Chinese Med Res Ctr, Taichung 40402, Taiwan.
   [Satyanarayanan, Senthil Kumaran; Su, Kuan-Pin] China Med Univ Hosp, Mind Body Interface Res Ctr, MBI Lab, Taichung, Taiwan.
   [Su, Kuan-Pin] China Med Univ, Coll Med, Taichung, Taiwan.
   [Su, Kuan-Pin] China Med Univ, An Nan Hosp, Depress Ctr, Tainan, Taiwan.
   [Lin, Yi-Wen; Su, Kuan-Pin] China Med Univ, Coll Med, 91 Hsueh Shih Rd, Taichung 40402, Taiwan.
C3 China Medical University Taiwan; China Medical University Taiwan; China Medical University Hospital - Taiwan; China Medical University Taiwan; China Medical University Taiwan; China Medical University Taiwan; China Medical University Hospital - Taiwan; China Medical University Taiwan; China Medical University Taiwan; China Medical University Taiwan
RP Lin, YW; Su, KP (corresponding author), China Med Univ, Coll Med, 91 Hsueh Shih Rd, Taichung 40402, Taiwan.
EM yiwenlin@mail.cmu.edu.tw; cobolsu@gmail.com
FU Ministry of Science and Technology, Taiwan [MOST 109-2314-B-039-042, 109-2320-B-038-057-MY3, 110-2321-B-006-004, 111-2321-B-006-008, 110-2811-B-039-507, 111-2320-B-039-043, 110-2320-B-039-048-MY2, 110-2320-B-039-047-MY3, 110-2813-C-039-327-B, 110-2314-B-039-029-MY3, 111-2314-B-039-041-MY3]; An-Nan Hospital, China Medical Univer-sity, Tainan, Taiwan [110-13, 110-26, 110-44, 110-45, 111-27, 111-28, 111-47, 111-48, 111-52, CMRC-CMA-2, HHC-111-8]; Higher Education Sprout Project by the Ministry of Education (MOE) , Taiwan [CMU 110-AWARD-02]; Chinese Medicine Research Center, China Medical University [110-N-17, 1110-SR-73, ANHRF 109-31]; China Medical University, Taichung, Taiwan [DMR-112-174];  [109-40];  [DMR 106-101];  [106-227];  [109-102];  [109-244];  [HHC-109-11];  [HHC-109-12];  [HHC-110-10];  [110-124];  [DMR-110-193];  [111-245]
CR Baune BT, 2008, PAIN, V138, P310, DOI 10.1016/j.pain.2008.01.002
   Beck AT, 1996, MANUAL FOR THE BECK DEPRESSION INVENTORY-II, V1, P0, DOI 10.1037/t00742-000
   Berman BM, 2010, NEW ENGL J MED, V363, P454, DOI 10.1056/NEJMct0806114
   Cho YJ, 2013, SPINE, V38, P549, DOI 10.1097/BRS.0b013e318275e601
   Cleeland CS, 1991, PAIN RESEARCH GROUP, V0, PP143, DOI 10.1037/t04175-000
   Doan L, 2015, NEURAL PLAST, V2015, P0, DOI 10.1155/2015/504691
   HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56
   Hu XF, 2017, BRAIN BEHAV IMMUN, V64, P180, DOI 10.1016/j.bbi.2017.03.005
   Hui D, 2015, J PAIN SYMPTOM MANAG, V49, P625, DOI 10.1016/j.jpainsymman.2014.11.294
   Keller S, 2004, CLIN J PAIN, V20, P309, DOI 10.1097/00002508-200409000-00005
   Kishi T, 2015, CROSS SECTIONAL SURV, V0, P0
   Kong J, 2013, PLOS ONE, V8, P0, DOI 10.1371/journal.pone.0081049
   Laumet G, 2017, BRAIN BEHAV IMMUN, V66, P94, DOI 10.1016/j.bbi.2017.07.008
   Leibing E, 2002, PAIN, V96, P189, DOI 10.1016/S0304-3959(01)00444-4
   Leucht S, 2013, J AFFECT DISORDERS, V148, P243, DOI 10.1016/j.jad.2012.12.001
   Liang ZH, 2013, EVID-BASED COMPL ALT, V2013, P0, DOI 10.1155/2013/620671
   Liao HY, 2017, SCI REP-UK, V7, P0, DOI 10.1038/s41598-017-16031-y
   Liao HY, 2017, SCI REP-UK, V7, P0, DOI 10.1038/srep42531
   Lin YW, 2020, BRAIN BEHAV IMMUN, V89, P604, DOI 10.1016/j.bbi.2020.06.033
   Liu Yi, 2013, ZHONGGUO ZHEN JIU, V33, P689
   Ma Y, 2015, W J TRADITIONAL CHIN, V28, P108
   MacPherson H, 2013, PLOS ONE, V8, P0, DOI 10.1371/journal.pone.0077438
   Mavrommatis CI, 2012, PAIN, V153, P1720, DOI 10.1016/j.pain.2012.05.005
   Molsberger AF, 2002, PAIN, V99, P579, DOI 10.1016/S0304-3959(02)00269-5
   Molsberger AF, 2010, PAIN, V151, P146, DOI 10.1016/j.pain.2010.06.036
   Ohayon MM, 2003, ARCH GEN PSYCHIAT, V60, P39, DOI 10.1001/archpsyc.60.1.39
   Qu SS, 2013, J PSYCHIATR RES, V47, P726, DOI 10.1016/j.jpsychires.2013.02.004
   Riedel M, 2010, J PSYCHIATR RES, V0, P0
   Satyanarayanan SK, 2019, BRAIN BEHAV IMMUN, V82, P230, DOI 10.1016/j.bbi.2019.08.190
   Sheehan DV, 1998, J CLIN PSYCHIAT, V59, P34, DOI 10.4088/JCP.09m05305whi
   Shen PF, 2012, AM J CHINESE MED, V40, P685, DOI 10.1142/S0192415X12500516
   Smith CA, 2010, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD004046.pub3
   Vas J, 2006, PAIN, V126, P245, DOI 10.1016/j.pain.2006.07.002
   Vis PMJ, 2005, ANN PHARMACOTHER, V39, P1798, DOI 10.1345/aph.1G076
   Walker AK, 2014, PHARMACOL REV, V66, P80, DOI 10.1124/pr.113.008144
   Wang H, 2008, J AFFECT DISORDERS, V111, P125, DOI 10.1016/j.jad.2008.04.020
   Wellek S, 2012, DTSCH ARZTEBL INT, V109, P276, DOI 10.3238/arztebl.2012.0276
   Witt CM, 2006, PAIN, V125, P98, DOI 10.1016/j.pain.2006.05.013
   You JY, 2021, PAIN RES MANAG, V2021, P0, DOI 10.1155/2021/6617075
   Yue N, 2018, FRONT MOL NEUROSCI, V0, P0
   Zhang SH, 2015, STROKE, V46, P1301, DOI 10.1161/STROKEAHA.114.007659
   Zhang ZJ, 2010, J AFFECT DISORDERS, V124, P9, DOI 10.1016/j.jad.2009.07.005
NR 42
TC 37
Z9 42
U1 5
U2 41
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0889-1591
EI 1090-2139
J9 BRAIN BEHAV IMMUN
JI Brain Behav. Immun.
PD MAY 15
PY 2023
VL 110
IS 
BP 339
EP 347
DI 10.1016/j.bbi.2023.03.016
EA MAR 2023
PG 9
WC Immunology; Neurosciences; Psychiatry
SC Immunology; Neurosciences & Neurology; Psychiatry
GA D0LR2
UT WOS:000965732900001
PM 36948325
DA 2026-01-16
ER

PT J
AU Ye, JN
   Su, CG
   Jiang, YQ
   Zhou, Y
   Sun, WX
   Zheng, XX
   Miao, JT
   Li, XY
   Zhu, J
AF Ye, Jiang-nan
   Su, Cheng-guo
   Jiang, Yu-qing
   Zhou, Yan
   Sun, Wen-xi
   Zheng, Xiao-xia
   Miao, Jin-tao
   Li, Xiang-yue
   Zhu, Jun
TI Effects of acupuncture on cartilage p38MAPK and mitochondrial pathways in animal model of knee osteoarthritis: A systematic evaluation and meta-analysis
SO FRONTIERS IN NEUROSCIENCE
LA English
DT Article
DE knee osteoarthritis; acupuncture; animal models; p38MAPK pathways; mitochondrial pathways; cytokines; meta-analysis
ID degeneration; inflammation; apoptosis; kinases; pain
AB Background: Most previous studies on acupuncture in the treatment of knee osteoarthritis (KOA) have focused on improving functional efficacy and safety, while related mechanisms have not been systematically reviewed. Acupuncture modulates cytokines to attenuate cartilage extracellular matrix degradation and apoptosis, key to the pathogenesis of KOA, but the mechanisms are complex.Objectives: The purpose of this study is to assess the efficacy of acupuncture quantitatively and summarily in animal studies of KOA.Methods: Nine databases including PubMed, Embase, Web of Science (including Medline), Cochrane library, Scopus, CNKI, Wan Fang, and VIP were searched to retrieve animal studies on acupuncture interventions in KOA published since the inception of the journal. Relevant literature was screened, and information extracted. Meta-analysis was performed using Revman 5.4 and Stata 17.0 software.Results: The 35 included studies involved 247 animals, half of which were in acupuncture groups and half in model groups. The mean quality level was 6.7, indicating moderate quality. Meta-analysis showed that acupuncture had the following significant effects on cytokine levels in p38MAPK and mitochondrial pathways: (1) p38MAPK pathway: It significantly inhibits p38MAPK, interleukin-1beta (IL-1 beta), tumor necrosis factor alpha (TNF-alpha), phosphorylated (p)-p38MAPK, matrix metalloproteinase-13 (MMP-13), MMP-1, a disintegrin and metalloproteinase with thrombospondin motifs-5 (ADAMST-5) expression, and significantly increased the expression of collagen II and aggrecan. (2) mitochondrial pathway: It significantly inhibited the expression of Bcl-2-associated X protein (Bax), cysteine protease-3 (caspase-3), caspase-9, and Cytochrome-c (Cyt-c). And significantly increased the expression of B cell lymphocytoma-2 (Bcl-2). In addition, acupuncture significantly reduced chondrocyte apoptosis, Mankin's score (a measure of cartilage damage), and improved cartilage morphometric characteristics.Conclusion: Acupuncture may inhibit cytokine expression in the p38MAPK pathway to attenuate cartilage extracellular matrix degradation, regulate cytokines in the mitochondrial pathway to inhibit chondrocyte apoptosis, and improve cartilage tissue-related phenotypes to delay cartilage degeneration. These findings provide possible explanations for the therapeutic mechanisms and clinical benefits of acupuncture for KOA.
C1 [Ye, Jiang-nan; Su, Cheng-guo; Jiang, Yu-qing; Miao, Jin-tao; Li, Xiang-yue; Zhu, Jun] Chengdu Univ Tradit Chinese Med, Sch Acupuncture Moxibust & Tuina, Chengdu, Peoples R China.
   [Zhou, Yan] China Acad Chinese Med Sci, Xiyuan Hosp, Beijing, Peoples R China.
   [Sun, Wen-xi; Zheng, Xiao-xia] Guangzhou Univ Chinese Med, Grad Sch, Guangzhou, Peoples R China.
C3 Chengdu University of Traditional Chinese Medicine; Xiyuan Hospital, CACMS; China Academy of Chinese Medical Sciences; Guangzhou University of Chinese Medicine
RP Zhu, J (corresponding author), Chengdu Univ Tradit Chinese Med, Sch Acupuncture Moxibust & Tuina, Chengdu, Peoples R China.
EM zhujuntcm@163.com
FU National Natural Science Foundation of China [81704152, 82004497]; Key Research and Development Project of Sichuan Provincial Science and Technology Department [23ZDYF1797]
CR Bannuru RR, 2019, OSTEOARTHR CARTILAGE, V27, P1578, DOI 10.1016/j.joca.2019.06.011
   Bao Fei, 2011, ZHONGGUO ZHEN JIU, V31, P241
   Bedenbaugh AV, 2021, CLINICOECONOMIC OUTC, V13, P421, DOI 10.2147/CEOR.S302289
   Brown KK, 2008, J INFLAMM-LOND, V5, P0, DOI 10.1186/1476-9255-5-22
   Chen J, 2020, EXP THER MED, V42, P1100
   Chen R, 2021, INVESTIGATE MECH ELE, V0, P0
   Corbett MS, 2013, OSTEOARTHR CARTILAGE, V21, P1290, DOI 10.1016/j.joca.2013.05.007
   Fu Ni-Ni, 2016, SICHUAN DA XUE XUE BAO YI XUE BAN, V47, P708
   [付妮妮 Fu Nini], 2016, 中国康复理论与实践 CHINESE JOURNAL OF REHABILITATION THEORY AND PRACTICE, V22, P38
   Goldring MB, 2015, CURR OPIN PHARMACOL, V22, P51, DOI 10.1016/j.coph.2015.03.004
   Hao XW, 2022, CHINESE J CATAL, V0, P1
   He L, 2020, STEM CELL RES THER, V11, P0, DOI 10.1186/s13287-020-01781-w
   Hinman RS, 2014, JAMA-J AM MED ASSOC, V312, P1313, DOI 10.1001/jama.2014.12660
   Hunziker EB, 2015, OSTEOARTHR CARTILAGE, V23, P334, DOI 10.1016/j.joca.2014.12.011
   Kapoor M, 2011, NAT REV RHEUMATOL, V7, P33, DOI 10.1038/nrrheum.2010.196
   Kolasinski SL, 2020, ARTHRITIS RHEUMATOL, V72, P220, DOI 10.1002/art.41142
   Lee S, 2022, FRONT IMMUNOL, V13, P0, DOI 10.3389/fimmu.2022.878463
   Li A, 2018, MEDICINE, V97, P0, DOI 10.1097/MD.0000000000013655
   Liang CX, 2015, APOPTOSIS, V0, P0
   Liang Chu-Xi, 2015, ZHEN CI YAN JIU, V40, P119
   Liao Y, 2016, ACUPUNCT MED, V34, P290, DOI 10.1136/acupmed-2015-010949
   Lieberthal J, 2015, OSTEOARTHR CARTILAGE, V23, P1825, DOI 10.1016/j.joca.2015.08.015
   [林道冠 Lin Daoguan], 2019, 中国免疫学杂志 CHINESE JOURNAL OF IMMUNOLOGY, V35, P2730
   Lin LL, 2020, PAIN, V161, P2532, DOI 10.1097/j.pain.0000000000001940
   Liu D, 2017, CHINESE MED J-PEKING, V44, P2652
   Liu D, 2021, J TRADIT CHIN MED, V41, P959, DOI 10.19852/j.cnki.jtcm.2021.06.013
   Liu H, 2021, EVID-BASED COMPL ALT, V2021, P0, DOI 10.1155/2021/2470182
   Liu JW, 2019, EVID-BASED COMPL ALT, V0, P0
   Liu JW, 2021, EVID-BASED COMPL ALT, V2021, P0, DOI 10.1155/2021/5523726
   Liu Nai-Gang, 2018, ZHEN CI YAN JIU, V43, P221, DOI 10.13702/j.1000-0607.170890
   Ma SN, 2017, EVID-BASED COMPL ALT, V2017, P0, DOI 10.1155/2017/4535326
   Mehana ESE, 2019, LIFE SCI, V234, P0, DOI 10.1016/j.lfs.2019.116786
   Moskowitz RW, 2006, OSTEOARTHR CARTILAGE, V14, P1, DOI 10.1016/j.joca.2005.08.015
   Murphy SP, 2010, J NEUROCHEM, V115, P805, DOI 10.1111/j.1471-4159.2010.06998.x
   Page MJ, 2021, REV ESP CARDIOL, V74, P790, DOI 10.1016/j.recesp.2021.06.016
   Pallante AL, 2009, AM J SPORT MED, V37, P24S, DOI 10.1177/0363546509351496
   Park C, 2018, INT J MOL SCI, V19, P0, DOI 10.3390/ijms19082308
   Qin LX, 2022, J TRADIT CHIN MED, V42, P389, DOI 10.19852/j.cnki.jtcm.2022.03.006
   Reinhold T, 2008, EUR J HEALTH ECON, V9, P209, DOI 10.1007/s10198-007-0062-5
   Ritskes-Hoitinga M, 2014, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.ED000078
   Schindler JF, 2007, J DENT RES, V86, P800, DOI 10.1177/154405910708600902
   Sun FF, 2019, OXID MED CELL LONGEV, V2019, P0, DOI 10.1155/2019/4695381
   Thomas BL, 2021, J EXTRACELL VESICLES, V10, P0, DOI 10.1002/jev2.12088
   Tong J, 2021, EVID-BASED COMPL ALT, V2021, P0, DOI 10.1155/2021/2047097
   Tu JF, 2021, ARTHRITIS RHEUMATOL, V73, P448, DOI 10.1002/art.41584
   Vakifahmetoglu-Norberg H, 2017, BIOCHEM BIOPH RES CO, V482, P426, DOI 10.1016/j.bbrc.2016.11.088
   Vina ER, 2021, ACR OPEN RHEUMATOL, V3, P660, DOI 10.1002/acr2.11307
   [万超 Wan Chao], 2021, 中国中医基础医学杂志 CHINESE JOURNAL OF BASIC MEDICINE IN TRADITIONAL CHINESE MEDICINE, V27, P432
   Wan Chao, 2019, ZHONGGUO ZHEN JIU, V39, P409, DOI 10.13703/j.0255-2930.2019.04.017
   Wang B, 2020, FRONT PHARMACOL, V0, P0
   Wang D, 2021, J NINGXIA MED U, V43, P1179
   Wang MN, 2013, ARTHRITIS RES THER, V15, P0, DOI 10.1186/ar4133
   Wang R, 2021, STEM CELL RES THER, V12, P0, DOI 10.1186/s13287-021-02533-0
   Wang ZK, 2020, EVID-BASED COMPL ALT, V2020, P0, DOI 10.1155/2020/5476064
   Wu GW, 2019, CHIN J INTEGR MED, V25, P677, DOI 10.1007/s11655-018-2916-8
   Wu YL, 2018, CHIN J INTEGR TRADIT, V37, P1372
   Wu YL, 2022, TISSUE ENG, V26, P0
   Xi Xiaofang, 2016, ZHONGGUO ZHEN JIU, V36, P1288, DOI 10.13703/j.0255-2930.2016.12.017
   Xie JW, 2021, AGEING RES REV, V70, P0, DOI 10.1016/j.arr.2021.101413
   Xiong Y, 2012, CHIN J TISSUE ENG RE, V16, P0
   Yu JN, 2016, EFFECT ACUPOTOMY ADJ, V0, P0
   Zeng WQ, 2021, REV SCI INSTRUM, V52, P19
   Zhang XH, 2014, DRUG DEVELOP RES, V75, P195, DOI 10.1002/ddr.21170
   Zhang Yuan-Yuan, 2019, ZHONGGUO ZHEN JIU, V39, P1081, DOI 10.13703/j.0255-2930.2019.10.013
   [张媛媛 Zhang Yuanyuan], 2019, 康复学报 REHABILITATION MEDICINE, V29, P30
   Zhou J, 2018, ACUPUNCT MED, V36, P37, DOI 10.1136/acupmed-2016-011258
   Zhou Y, 2015, APOPTOSIS, V20, P1187, DOI 10.1007/s10495-015-1152-y
   Zhu DY, 2021, CHINESE MED J-PEKING, V13, P7
   Zhu SQ, 2021, J CLIN INVEST, V25, P0
NR 69
TC 6
Z9 8
U1 2
U2 16
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 
EI 1662-453X
J9 FRONT NEUROSCI-SWITZ
JI Front. Neurosci.
PD JAN 11
PY 2023
VL 16
IS 
BP 
EP 
DI 10.3389/fnins.2022.1098311
PG 18
WC Neurosciences
SC Neurosciences & Neurology
GA 8T7LK
UT WOS:000929438400001
PM 36711149
DA 2026-01-16
ER

PT J
AU Ma, TY
   Xue, GQ
   Zhang, J
   Qin, XY
AF Ma, Taoye
   Xue, Guoqiang
   Zhang, Jie
   Qin, Xiaoyu
TI Effects of acupuncture on postoperative pain in patients undergoing breast cancer surgery: A systematic review and meta-analysis
SO ASIAN JOURNAL OF SURGERY
LA English
DT Letter
DE Acupuncture; Postoperative pain; Breast cancer surgery; Systematic review; Meta-analysis
C1 [Ma, Taoye] Gansu Prov Cent Hosp, Lanzhou 730070, Gansu, Peoples R China.
   [Ma, Taoye] Gansu Prov Maternal & Child Hlth Hosp, Lanzhou 730050, Gansu, Peoples R China.
   [Xue, Guoqiang] Second Peoples Hosp Gansu Prov, Dept Urol, Lanzhou 730030, Gansu, Peoples R China.
   [Xue, Guoqiang] Northwest Minzu Univ, Affiliated Hosp, Dept Urol, Lanzhou 730030, Gansu, Peoples R China.
   [Zhang, Jie] Gansu Hosp TCM, Anesthesia & Pain Med Ctr, Lanzhou 730050, Gansu, Peoples R China.
   [Qin, Xiaoyu] Shanghai East Hosp, Dept Anesthesiol, Shanghai 200120, Peoples R China.
   [Qin, Xiaoyu] Shanghai East Hosp, Dept Anesthesiol, 551 Pudong South Rd, Shanghai 200120, Peoples R China.
C3 Northwest Minzu University
RP Qin, XY (corresponding author), Shanghai East Hosp, Dept Anesthesiol, 551 Pudong South Rd, Shanghai 200120, Peoples R China.
EM qxyznl@163.com
FU Health Industry Research Proj-ect of Gansu Province [GSWSKY2022-37]
CR Abbas DN, 2018, PAIN PHYSICIAN, V21, P351, DOI 10.36076/ppj.2018.4.351
   Giron PS, 2016, SUPPORT CARE CANCER, V24, P2491, DOI 10.1007/s00520-015-3054-5
   Greenlee Heather, 2014, JOURNAL OF THE NATIONAL CANCER INSTITUTE MONOGRAPHS, V0, PP346, DOI 10.1093/jncimonographs/lgu041
   Hutchison RW, 2007, AM J HEALTH-SYST PH, V64, PS2, DOI 10.2146/ajhp060679
   National Center for Complementary and Integrative Health, 2015, USE OF COMPLEMENTARY HEALTH APPROACHES IN THE U.S.: TRENDS IN MIND AND BODY PRACTICES, V0, P0
NR 5
TC 2
Z9 2
U1 0
U2 23
PU ELSEVIER SINGAPORE PTE LTD
PI SINGAPORE
PA 3 KILLINEY ROAD 08-01, WINSLAND HOUSE 1, SINGAPORE, 239519, SINGAPORE
SN 1015-9584
EI 0219-3108
J9 ASIAN J SURG
JI Asian J. Surg.
PD NOV 15
PY 2023
VL 46
IS 11
BP 5029
EP 5031
DI 10.1016/j.asjsur.2023.06.060
EA NOV 2023
PG 3
WC Surgery
SC Surgery
GA Z1ZN3
UT WOS:001110132900001
PM 37344321
DA 2026-01-16
ER

PT J
AU Zeng, J
   Yang, YY
AF Zeng, Jin
   Yang, Yuanyuan
TI Diagnosis and treatment of varicella-zoster virus infection with herpetic visceral neuralgia without rash: A case report
SO MEDICINE
LA English
DT Article
DE diagnostic therapy; herpes zoster neuralgia; herpetic visceral neuralgia; postherpetic neuralgia; varicella-zoster virus
AB Rationale:Herpes zoster (HZ) is an infection caused by the varicella-zoster virus reactivation, often leading to peripheral nervous system infection and pain. This case report aimed to present 2 patients with damaged sensory nerves originating from the visceral neurons of the lateral horn of the spinal cord. Patient concerns:Two patients presented intractable, severe lower back pain and abdominal pain, but without rash or herpes. A female patient was admitted 2 months after symptom onset. She was presented with paroxysmal, acupuncture-like pain in the right upper quadrant and around the umbilicus without apparent incentives. A male patient was presented with recurrent episodes of paroxysmal and spastic colic in the left waist and left middle abdomen for 3 days. Abdominal examination showed no tumors or organic lesions in their intra-abdominal tissues or organs. Diagnoses:After excluding organic lesions on the waist and in abdominal organs, patients were diagnosed with herpetic visceral neuralgia without rash. Intervention:The treatment for herpes zoster neuralgia or postherpetic neuralgia was applied for 3 to 4 weeks. Outcome:Antibacterial and anti-inflammatory analgesics were not effective in either patient. The therapeutic effects of herpes zoster neuralgia or postherpetic neuralgia treatment were satisfactory. Lessons:Herpetic visceral neuralgia can be easily misdiagnosed due to the absence of a rash or herpes, resulting in delayed treatment. When patients have severe, intractable pain but no rash or herpes, and the biochemical and imaging examinations are normal, the treatment method for HZ neuralgia can be used. If the treatment is effective, HZ neuralgia is diagnosed. If not, shingles neuralgia can be ruled out. Further investigations are required to elucidate the mechanisms of pathophysiological changes in varicella-zoster virus-induced peripheral HZ neuralgia or visceral neuralgia without herpes.
C1 [Zeng, Jin] Guangxi Univ Sci & Technol, Affiliated Hosp 1, Dept Anesthesiol, Liuzhou, Peoples R China.
   [Yang, Yuanyuan] Guangxi Univ Sci & Technol, Affiliated Hosp 1, Liuzhou, Peoples R China.
   [Yang, Yuanyuan] Guangxi Univ Sci & Technol, Affiliated Hosp 1, 124 Yuejin Rd, Liuzhou 545002, Peoples R China.
C3 Guangxi University of Science & Technology; Guangxi University of Science & Technology; Guangxi University of Science & Technology
RP Yang, YY (corresponding author), Guangxi Univ Sci & Technol, Affiliated Hosp 1, 124 Yuejin Rd, Liuzhou 545002, Peoples R China.
EM zengjin1688@126.com; 2691245627@qq.com
CR Andrei G, 2021, MOLECULES, V26, P0, DOI 10.3390/molecules26041132
   Gao CR, 2013, DIAGNOSIS TREATMENT, V0, P662
   Henze L, 2022, ANN HEMATOL, V101, P491, DOI 10.1007/s00277-021-04746-y
   Jin Jill, 2018, JAMA, V320, P416, DOI 10.1001/jama.2018.7263
   Kawai K, 2014, BMJ OPEN, V4, P0, DOI 10.1136/bmjopen-2014-004833
   Li LM, 2020, GUID J TRADIT CHIN M, V26, P104
   Li RZ, 2021, FRONT NEUROL, V12, P0, DOI 10.3389/fneur.2021.741054
   Nalamachu S, 2012, DRUG AGING, V29, P863, DOI 10.1007/s40266-012-0014-3
   Zhang Y, 2017, MED RECAPITULATE, V23, P4256
NR 9
TC 1
Z9 2
U1 0
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0025-7974
EI 1536-5964
J9 MEDICINE
JI Medicine (Baltimore)
PD MAY 26
PY 2023
VL 102
IS 21
BP 
EP 
DI 10.1097/MD.0000000000033766
PG 3
WC Medicine, General & Internal
SC General & Internal Medicine
GA H4LV3
UT WOS:000995704800027
PM 37233427
DA 2026-01-16
ER

PT J
AU Yang, J
   Lan, X
   Cai, Q
   Lu, Z
   Wang, Y
AF Yang, Jiaxiang
   Lan, Xiangdong
   Cai, Qingcheng
   Lu, Ziheng
   Wang, Yanjun
TI Exercise Plus Acupuncture on Consensus Acupoints Versus Acupoints Selected by the
SO Alternative therapies in health and medicine
LA English
DT Journal Article
AB CONTEXT: Knee osteoarthritis (KOA) is a degenerative disorder that significantly  affects patients' quality of life. Acupuncture and exercise are the most popular  treatments currently. The outcomes for acupuncture for KOA, however, are  controversial, with some researchers finding that the addition of acupuncture to  exercise therapy provided no additional improvement in pain scores. OBJECTIVE:  The study intended to evaluate the therapeutic effects for KOA of exercise in  combination with acupuncture on acupoints selected using the Traditional Chinse  Medicine (TCM) theory of Equal Impact on Tendons, Bones, and Muscles (EITBM) in  comparison with that of acupoints selected using classical consensus for the  treatment. DESIGN: The research team performed a randomized controlled trial.  SETTING: The study took place in the Department of Acupuncture and Moxibustion at  the First Affiliated Hospital of Hebei University of Chinese Medicine in  Shijiazhuang, Hebei, China. PARTICIPANTS: Participants were 70 patients with KOA  who visited the hospital between December 2020 and February 2021. INTERVENTION:  Participants in both group received acupuncture plus exercise therapy. The  research team randomly assigned participants to one of two groups: (1) 35 to the  intervention group, which received acupuncture using acupoints selected using  EITBM, and (2) 35 to the control group, which received acupuncture using the  classical consensus acupoints. Both groups performed a 25-min session of  acupuncture three times weekly for 4 weeks, with the exercise therapy following  the acupuncture each time. OUTCOME MEASURES: The research team assessed clinical  efficacy at baseline and postintervention. The primary outcome measures included  assessments: (1) of knee joint pain using a visual analog scale (VAS), (2) of  knee joint pain, flexibility, and function using the Western Ontario and McMaster  University Osteoarthritis Index (WOMAC) pain subscale; and (3) joint range of  motion (ROM). The secondary outcome measures included measurement of serum levels  of interleukin-1 beta (IL-1ß), tumor necrosis factor alpha (TNF-α), and matrix  metalloproteinase-13 (MMP-13) using enzyme-linked immunosorbent assays (ELISA).  RESULTS: The VAS and WOMAC scores significantly decreased for both groups between  baseline and postintervention, and the intervention group's decrease was  significantly greater than that of the control group. The ROM of knee flexion was  significantly higher in both groups postintervention than at baseline, and the  intervention group's increase was significantly higher than that of the control  group. The serum IL-1ß, TNF-α, and MMP-13 also significantly decreased  postintervention in both groups, and the intervention group's levels were  significantly lower than those of the control group. The total effective rate was  94.1% in the intervention group, 32 out of 34 participants, and 75.8% in the  control group, 25 out of 33 participants, which was significantly different.  CONCLUSIONS: Acupuncture, in combination with exercise, can relieve symptoms,  improve joint function, and reduce pro-inflammatory cytokines (IL-1ß and TNF-a)  as well as MMP-13 for patients with KOA. The outcomes for acupuncture using EITBM  acupoints were significantly better than those of the acupoints selected using  classical consensus.
NR 0
TC 0
SN 
EI 1078-679
J9 Altern Ther Health Med
PD APR 14
PY 2023
VL 29
IS 5
BP 262
EP 267
DI 
PG 5
WC Humans; Osteoarthritis, Knee; therapy; Matrix Metalloproteinase 13; Acupuncture Points; Tumor Necrosis Factor-alpha; Consensus; Quality of Life; Acupuncture Therapy; Treatment Outcome; Pain; Tendons; Muscles; Arthralgia
UT PubMed:37052974
PM 37052974
DA 2023-04-14
ER

PT J
AU Ge, WB
   Qu, Y
   Hou, TT
   Zhang, JY
   Li, QJ
   Yang, LL
   Cao, LQ
   Li, JD
   Zhang, SY
AF Ge, Wanbao
   Qu, Yuan
   Hou, Tingting
   Zhang, Jiayin
   Li, Qiuju
   Yang, Lili
   Cao, Lanqing
   Li, Jindong
   Zhang, Shanyong
TI Case report: Surgical treatment of a primary giant epithelioid hemangioendothelioma of the spine with total en-bloc spondylectomy
SO FRONTIERS IN ONCOLOGY
LA English
DT Article
DE epithelioid hemangioendothelioma; total en-bloc spondylectomy; vertebral lesion; vascular neoplasm; giant
AB BackgroundEpithelioid hemangioendothelioma (EHE) is an extremely uncommon malignant neoplasm that originates from vascular endothelial or pre-endothelial cells. In this report, we present the case of patient who was diagnosed with a primary giant EHE of the spine and underwent treatment with total en-bloc spondylectomy (TES). Case presentationA 43-year-old male patient with a history of he presented to our hospital with chronic and progressive back pain. Physical examination revealed weakened sensation of acupuncture and touch on the left costal arch, while relatively normal neurological functions were preserved. Radiological examinations identified a giant destructive soft tissue lesion occupying the T8 vertebral region, with moderate destruction of the pedicle and lamina, as well as the 7(th) left rib. A preoperative biopsy of the 8th vertebra resulted in a diagnosis of epithelioid hemangioendothelioma(EHE). Postoperative immunohistochemical and pathological reports confirmed the presence of EHE in the left ribs and T8 ribs. The patient underwent resection of the 7th left rib and posterior pedicle screw fixation with 8 pairs of screws and a titanium mesh cage. Subsequently, thoracic en bloc spondylectomy was performed on the T8 vertebra. The patient did not receive radiation or chemotherapy following surgery. Over a period of 3 years, the patient remained free of disease and relapse. ConclusionThe use of transarterial embolization with spherical embolic agents (TES) has been demonstrated to be a safe, effective, and reliable treatment option for hepatic epithelioid hemangioendothelioma (EHE). Nevertheless, it is crucial to conduct long-term follow-up of this patient in order to assess their clinical outcome.
C1 [Ge, Wanbao; Qu, Yuan; Hou, Tingting; Zhang, Jiayin; Li, Qiuju; Yang, Lili; Zhang, Shanyong] Jilin Univ, Affiliated Hosp 2, Dept Spine Surg, Changchun, Jilin, Peoples R China.
   [Cao, Lanqing] Jilin Univ, Affiliated Hosp 2, Dept Pathol, Changchun, Jilin, Peoples R China.
   [Li, Jindong] Jilin Univ, Affiliated Hosp 2, Dept Thorac Surg, Changchun, Jilin, Peoples R China.
C3 Jilin University; Jilin University; Jilin University
RP Zhang, SY (corresponding author), Jilin Univ, Affiliated Hosp 2, Dept Spine Surg, Changchun, Jilin, Peoples R China.
EM jzhangshanyong@yeah.net
FU Natural Science Foundation of Science and Technology Department of Jilin Province [20200201551JC]
CR Aflatoon K, 2004, CLIN ORTHOP RELAT R, V0, P191
   Agulnik M, 2013, ANN ONCOL, V24, P257, DOI 10.1093/annonc/mds237
   Chevreau C, 2013, CANCER-AM CANCER SOC, V119, P2639, DOI 10.1002/cncr.28109
   Deyrup AT, 2008, AM J SURG PATHOL, V32A, P924, DOI 10.1097/PAS.0b013e31815bf8e6
   Doyle LA, 2016, AM J SURG PATHOL, V40, P94, DOI 10.1097/PAS.0000000000000511
   Flucke U, 2014, DIAGN PATHOL, V9, P0, DOI 10.1186/1746-1596-9-131
   Kerry G, 2012, CASE REP ONCOL, V5, P91, DOI 10.1159/000336947
   Kitaichi M, 1998, EUR RESPIR J, V12, P89, DOI 10.1183/09031936.98.12010089
   Lee SS, 2020, MEDICINE, V99, P0, DOI 10.1097/MD.0000000000019859
   Luzzati A, 2015, EUR SPINE J, V24, P2156, DOI 10.1007/s00586-014-3510-9
   Ma JM, 2011, EUR SPINE J, V20, P1371, DOI 10.1007/s00586-011-1798-2
   Mendlick MR, 2001, AM J SURG PATHOL, V25, P684, DOI 10.1097/00000478-200105000-00019
   Mentzel T, 1997, AM J SURG PATHOL, V21, P363, DOI 10.1097/00000478-199704000-00001
   Munier O, 2017, CANCER RADIOTHER, V21, P222, DOI 10.1016/j.canrad.2016.11.006
   OShea Bendan M, 2014, RADIOL CASE REP, V9, P984, DOI 10.2484/rcr.v9i4.984
   Riley DS, 2017, J CLIN EPIDEMIOL, V89, P218, DOI 10.1016/j.jclinepi.2017.04.026
   Rosenbaum E, 2020, MODERN PATHOL, V33, P591, DOI 10.1038/s41379-019-0368-8
   Sardaro A, 2014, ONCOL REV, V8, P82, DOI 10.4081/oncol.2014.259
   Shiba S, 2018, BMC CANCER, V18, P0, DOI 10.1186/s12885-018-4934-0
NR 19
TC 6
Z9 9
U1 0
U2 11
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 2234-943X
EI 
J9 FRONT ONCOL
JI Front. Oncol.
PD MAR 28
PY 2023
VL 13
IS 
BP 
EP 
DI 10.3389/fonc.2023.1109643
PG 8
WC Oncology
SC Oncology
GA D2FX9
UT WOS:000966943100001
PM 37056332
DA 2026-01-16
ER

PT J
AU Zhang, X
   Yang, WJ
   Shang, JL
   Dan, WC
   Shi, L
   Tong, L
   Yang, GW
AF Zhang, Xu
   Yang, Wenjing
   Shang, Junliang
   Dan, Wenchao
   Shi, Lin
   Tong, Li
   Yang, Guowang
TI The lower He-sea points playing a significant role in postoperative ileus in colorectal cancer treated with acupuncture: based on machine-learning
SO FRONTIERS IN ONCOLOGY
LA English
DT Article
DE acupuncture; postoperative ileus; colorectal cancer; machine-learning; association rules
ID zusanli st 36; laparoscopic surgery; electroacupuncture; stimulation; recovery; motility; acupoint
AB BackgroundPostoperative ileus (POI) is a common complication following abdominal surgery, which can lead to significant negative impacts on patients' well-being and healthcare costs. However, the efficacy of current treatments is not satisfactory. The purpose of this study was to evaluate the therapeutic effects of acupuncture intervention and explore the regulation of acupoint selection for treating POI in colorectal cancer (CRC) patients. MethodsWe searched eight electronic databases to identify randomized controlled trials (RCTs) on acupuncture for POI in CRC and conducted a meta-analysis. Subsequently, we utilized the Apriori algorithm and the Frequent pattern growth algorithm, in conjunction with complex network and cluster analysis, to identify association rules of acupoints. ResultsThe meta-analysis showed that acupuncture led to significant reductions in time to first defecation (MD=-20.93, 95%CI: -25.35, -16.51; I-2 = 93.0%; p < 0.01; n=2805), first flatus (MD=-15.08, 95%CI: -18.39, -11.76; I-2 = 96%; p < 0.01; n=3284), and bowel sounds recovery (MD=-10.96, 95%CI: -14.20, -7.72; I-2 = 94%; p < 0.01; n=2043). A subgroup analysis revealed that acupuncture not only reduced the duration of POI when administered alongside conventional care but also further expedited the recovery of gut function after colorectal surgery when integrated into the enhanced recovery after surgery (ERAS) pathway. The studies included in the analysis reported no instances of serious adverse events associated with acupuncture. We identified Zusanli (ST36), Shangjuxu (ST37), Neiguan (PC6), Sanyinjiao (SP6), Xiajuxu (ST39), Hegu (LI4), Tianshu (ST25), and Zhongwan (RN12) as primary acupoints for treating POI. Association rule mining suggested potential acupoint combinations including {ST37, ST39}& GE;{ST36}, {PC6, ST37}& GE;{ST36}, {SP6, ST37}& GE;{ST36}, and {ST25, ST37}& GE;{ST36}. ConclusionMeta-analysis indicates acupuncture's safety and superior effectiveness over postoperative care alone in facilitating gastrointestinal recovery. Machine-learning approaches highlight the importance of the lower He-sea points, including Zusanli (ST36) and Shangjuxu (ST37), in treating POI in CRC patients. Incorporating additional acupoints such as Neiguan (PC6) (for pain and vomiting) and Sanyinjiao (SP6) (for abdominal distension and poor appetite) can optimize treatment outcomes. These findings offer valuable insights for refining treatment protocols in both clinical and experimental settings, ultimately enhancing patient care.
C1 [Zhang, Xu; Tong, Li] Capital Med Univ, Beijing Hosp Tradit Chinese Med, Dept Nutr, Beijing, Peoples R China.
   [Yang, Wenjing; Shi, Lin; Yang, Guowang] Capital Med Univ, Beijing Hosp Tradit Chinese Med, Dept Oncol, Beijing, Peoples R China.
   [Shang, Junliang] Capital Med Univ, Beijing Hosp Tradit Chinese Med, Dept Surg, Beijing, Peoples R China.
   [Dan, Wenchao] Capital Med Univ, Sch Grad, Beijing, Peoples R China.
C3 Capital Medical University; Capital Medical University; Capital Medical University; Capital Medical University
RP Yang, GW (corresponding author), Capital Med Univ, Beijing Hosp Tradit Chinese Med, Dept Oncol, Beijing, Peoples R China.
EM guowang_yang@163.com
FU National Natural Science Foundation of China [82174453]; Hospital-level Project and Cooperation Project of Beijing Hospital of Traditional Chinese Medicine, Capital Medical University [LYYB202217]; Innovative Work Studio Project for Employees of Beijing Hospital of Traditional Chinese Medicine, Capital Medical University [ZT202108]
CR Ai K, 2016, WORLD J ACUPUNCT-MOX, V26, P26, DOI 10.1016/s1003-5257(17)30019-3
   Boeckxstaens GE, 2009, GUT, V58, P1300, DOI 10.1136/gut.2008.169250
   Bonjer HJ, 2005, LANCET ONCOL, V6, P477, DOI 10.1016/S1470-2045(05)70221-7
   Cai W, 2021, CHIN J CLIN ONCOL REHABIL, V28, P37, DOI 10.13455/J.CNKI.CJCOR.2021.01.10
   Chen JT, 2022, FRONT NEUROL, V13, P0, DOI 10.3389/fneur.2022.894951
   Chen Qian, 2018, ZHONGGUO ZHEN JIU, V38, P5053, DOI 10.13703/j.0255-2930.2018.05.015
   Cheong KB, 2014, COMPLEMENT THER MED, V22, P767, DOI 10.1016/j.ctim.2014.05.002
   Dai NA, 2022, COMPUT INTEL NEUROSC, V2022, P0, DOI 10.1155/2022/1817628
   de Jonge WJ, 2005, NAT IMMUNOL, V6, P844, DOI 10.1038/ni1229
   Farro G, 2016, NEUROGASTROENT MOTIL, V28, P934, DOI 10.1111/nmo.12796
   Fei ZQ, 2022, BEIJING J TRADITIONA, V41, P326
   Feng D, 2020, EFFECTS TRANSCUTANEO, V0, P0, DOI DOI 10.27374/d.cnki.gwnyy.2020.000294
   Fu H, 2022, CHINA MOD DOCT, V60, P15
   Gao W, 2021, SURGERY, V170, P1618, DOI 10.1016/j.surg.2021.08.007
   Gao ZX, 2010, J SHANXI DATONG U NA, V26, P42
   Huang W, 2019, J TRADIT CHIN MED, V39, P433
   Huang Wei, 2018, ZHEN CI YAN JIU, V43, P611, DOI 10.13702/j.1000-0607.180005
   Langevin HM, 2018, J ALTERN COMPLEM MED, V24, P200, DOI 10.1089/acm.2017.0366
   Lee SM, 2013, SURG ENDOSC, V27, P3902, DOI 10.1007/s00464-013-3006-4
   Li D, 2018, GUANGXI MED J, V40, P872
   Li W, 2021, CHIN J MED GUIDE, V27, P93
   Li Y, 2017, CLIN OBSERVATION ELE, V0, P0, DOI DOI 10.26994/d.cnki.gdlyu.2017.000249
   Liang C, 2018, NEUROGASTROENT MOTIL, V30, P0, DOI 10.1111/nmo.13318
   Liang Z, 2020, CHINA MED HERALD, V17, P0
   Liang Z, 2020, CHINA MED HERALD, V17, P125
   Liu MC, 2016, EVID-BASED COMPL ALT, V2016, P0, DOI 10.1155/2016/1935372
   Liu SB, 2021, NATURE, V598, P641, DOI 10.1038/s41586-021-04001-4
   Liu SB, 2020, NEURON, V108, P436, DOI 10.1016/j.neuron.2020.07.015
   Liu YH, 2018, EVID-BASED COMPL ALT, V2018, P0, DOI 10.1155/2018/3178472
   Long Y, 2021, J GUANGZHOU U CHIN M, V38, P518, DOI 10.13359/j.cnki.gzxbtcm.2021.03.016
   Mai Sicong, 2017, ZHONGGUO ZHEN JIU, V37, P483, DOI 10.13703/j.0255-2930.2017.05.008
   Meng ZQ, 2010, WORLD J GASTROENTERO, V16, P104, DOI 10.3748/wjg.v16.i1.104
   Ng SSM, 2013, GASTROENTEROLOGY, V144, P307, DOI 10.1053/j.gastro.2012.10.050
   Niu C, 2008, J CHANGCHUN U TRADIT, V01), P83, DOI 10.13463/j.cnki.cczyy.2008.01.035
   Noguchi E, 2010, AUTON NEUROSCI-BASIC, V156, P15, DOI 10.1016/j.autneu.2010.06.010
   Ren Z, 2021, JIANGSU MED, V47, P1017, DOI 10.19460/j.cnki.0253-3685.2021.10.012
   Si JG, 2015, J PRACT TRADITION CHIN MED, V31, P754, DOI 10.3969/j.issn.1004-2814.2015.08.050
   Sommer NP, 2021, INT J COLORECTAL DIS, V36, P2017, DOI 10.1007/s00384-021-03939-1
   Song Y, 2020, CHIN J TRADITIONAL C, V35, P210, DOI 10.16368/j.issn.1674-8999.2020.01.046
   Sun Hui, 2021, ZHEN CI YAN JIU, V46, P592, DOI 10.13702/j.1000-0607.200647
   Tang Y, 2022, EVID-BASED COMPL ALT, V2022, P0, DOI 10.1155/2022/4251458
   Tong W, 2014, CHIN J MED GUIDE, V20, P39
   van Bree SHW, 2012, NAT REV GASTRO HEPAT, V9, P675, DOI 10.1038/nrgastro.2012.134
   Vather R, 2013, J GASTROINTEST SURG, V17, P962, DOI 10.1007/s11605-013-2148-y
   Wang D, 2021, EFFECTS TRANSCUTANEO, V0, P0, DOI DOI 10.26988/d.cnki.gcdzu.202l.000418
   Wang H, 2011, INFLUENCE ACUPUNCTUR, V0, P0
   Wang QL, 2019, GUANGXI J TRADITIONA, V42, P38
   Wang Tian-Yuan, 2018, ZHEN CI YAN JIU, V43, P797, DOI 10.13702/j.1000-0607.170381
   Wang XZ, 2022, CHIN J MOD DISTANCE EDUC CHIN MED, V20, P105, DOI 10.3969/j.issn.1672-2779.2022.15.040
   Wang Y, 2023, JAMA SURG, V158, P20, DOI 10.1001/jamasurg.2022.5674
   Wang YL, 2022, CHIN MED-UK, V17, P0, DOI 10.1186/s13020-022-00636-1
   Wei QL, 2019, CHIN J MOD NURS, V25, P2746, DOI 10.3760/CMA.J.ISSN.1674-2907.2019.21.024
   World Health Organization, 2007, WHO REGIONAL OFFICE, V0, P0
   Xiang ZY, 2004, COMP STUDY TREATMENT, V0, P0
   Xiao C, 2016, STUDY PROMOTION POST, V0, P0
   Xiao C, 2014, CLIN STUDY ELECTROAC, V0, P0
   Xiao L, 2016, J SHANDONG U TRADITI, V35, P701, DOI 10.16295/j.cnki.0257-358x.2016.08.0ll
   Xie J, 2014, NEW TRADITIONAL CHIN, V46, P226
   Xing JJ, 2013, INT REV NEUROBIOL, V111, P49, DOI 10.1016/B978-0-12-411545-3.00003-1
   Xu Y, 2021, INFECT INFLAMMATION, V22, P106
   Xu Y, 2006, SHANGHAI J TRADITION, V08), P36, DOI 10.16305/j.1007-1334.2006.08.019
   Xue Y, 2020, CLIN STUDY BILATERAL, V0, P0, DOI DOI 10.27044/d.cnki.ggzzu.2020.000610
   Yang J, 2011, STUDY EFFECT COMBINE, V0, P0
   Yang JW, 2022, ECLINICALMEDICINE, V49, P0, DOI 10.1016/j.eclinm.2022.101472
   Yang JJ, 2011, EFFECTS ELECTROACUPU, V0, P0
   Yang NN, 2021, THERANOSTICS, V11, P4078, DOI 10.7150/thno.52574
   Yang NN, 2020, NEUROGASTROENT MOTIL, V32, P0, DOI 10.1111/nmo.13808
   Yi W, 2019, CLIN J ACUPUNCT MOXIBUSTION MOXIBUSTION, V35, P26
   Yue S, 2021, EFFECTS TRANSCUTANEO, V0, P0, DOI DOI 10.27288/d.cnki.gsxyu.2021.000718
   Zhang H, 2020, MODERN ONCOL, V28, P611
   Zhang Hong, 2016, ZHONGGUO ZHEN JIU, V36, P1071, DOI 10.13703/j.0255-2930.2016.10.018
   Zhang K, 2022, HLTH READING, V1, P276
   Zhang Shuang-yan, 2011, ZHONGGUO ZHEN JIU, V31, P513
   Zhang ZD, 2014, ACUPUNCT MED, V32, P223, DOI 10.1136/acupmed-2013-010490
   Zhang ZY, 2021, LIFE SCI, V272, P0, DOI 10.1016/j.lfs.2021.119259
   Zhou Y, 2021, CLIN STUDY ELECTROAC, V0, PP12, DOI 10.27282/d.cnki.gsdzu.2021.000087
   Zhu SF, 2015, ACUPUNCT MED, V33, P115, DOI 10.1136/acupmed-2014-010646
   Zhu WJ, 2021, SHANGHAI J ACUPUNCT MOXIBUST, V40, P416, DOI 10.13460/j.issn.1005-0957.2021.04.0416
NR 78
TC 11
Z9 13
U1 4
U2 16
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 2234-943X
EI 
J9 FRONT ONCOL
JI Front. Oncol.
PD JUL 24
PY 2023
VL 13
IS 
BP 
EP 
DI 10.3389/fonc.2023.1206196
PG 19
WC Oncology
SC Oncology
GA O4GW2
UT WOS:001043425600001
PM 37564931
DA 2026-01-16
ER

PT J
AU Liao, HY
   Satyanarayanan, SK
   Lin, YW
   Su, KP
AF Liao, Hsien-Yin
   Satyanarayanan, Senthil Kumaran
   Lin, Yi-Wen
   Su, Kuan-Pin
TI Clinical efficacy and immune effects of acupuncture in patients with comorbid
SO Brain, behavior, and immunity
LA English
DT Journal Article
DE Acupuncture; Biomarkers; Chronic pain; Comorbidity; Inflammatory cytokines; Major depression disorder
AB BACKGROUND: Depression and pain are highly comorbid and share biological  mechanisms. Acupuncture is commonly used to manage both pain and depression, but  the choice of acupoints for specific disorders differs. This study aimed to  investigate whether specific acupuncture intervention on pain- and  depression-acupoints would have specific efficacy and immune effects in patients  with comorbid chronic pain and major depressive disorder (MDD). METHODS: We  performed a subject- and assessor-blinded, crossover, and randomized controlled  clinical trial of depression- and pain-specific acupuncture intervention and  measured clinical responses and proinflammatory cytokines in patients with  comorbid chronic pain and MDD. Specific acupoints for pain and depression were  used in random order with a washout interval. Forty-seven patients were enrolled  and randomly assigned to two groups: (1) the depression-pain group (23 patients  who were treated with depression-specific acupoints and then the pain-specific  acupoints after the washout) and (2) pain-depression group (24 patients with the  reverse order). RESULTS: The pain-specific acupoints for pain did not reduce  Brief Pain Inventory scores to a significantly greater degree (-0.97 ± 1.69) than  the depression-specific acupoints (-0.28 ± 1.88); likewise, the  depression-specific acupoints did not significantly ameliorate Hamilton  Depression Rating Scale (-4.59 ± 6.02) than the pain-specific acupoints  (-6.69 ± 6.61). The pain-specific acupoints improved Beck Depression  Inventory-Second Edition (-6.74 ± 9.76) even better than the depression-specific  acupoints (-1.92 ± 10.74). The depression-specific acupoints did not  significantly decrease the depression-related interleukin (IL)-6 level  (-1.24 ± 6.67) than the pain-specific acupoints (-0.60 ± 4.36). The changed  levels of IL-1β, tumor necrosis factor (TNF)-α between the depression-specific  acupoints (-37.41 ± 194.49; -12.53 ± 54.68) and the pain-specific acupoints  (-15.46 ± 87.56; -7.28 ± 27.86) could not reach significantly different, too.  CONCLUSION: This study rejected our hypothesis that the pain-specific acupoints  might produce superior analgesic effects than the depression-specific acupoints  and vice versa. The cytokine results might imply that pain and depression share  common biological mechanisms. (trial registration: https://www. CLINICALTRIALS:  gov: NCT03328819).
C1 School of Post-Baccalaureate Chinese Medicine, College of Chinese Medicine, China Medical University, Taichung 40402, Taiwan
   Department of Acupuncture, ChinaMedical University Hospital, Taichung 40402, Taiwan.
   Mind-Body Interface Research Center (MBI-Lab), China Medical University Hospital, Taichung, Taiwan.
   Graduate Institute of Acupuncture Science, College of Chinese Medicine, China Medical University, Taichung 40402, Taiwan
   Chinese Medicine Research Center,China Medical University, Taichung 40402, Taiwan. 
   Mind-Body Interface Research Center (MBI-Lab), China Medical University Hospital, Taichung, Taiwan
   College of Medicine, China Medical University, Taichung,Taiwan
   Depression Center, An-Nan Hospital, China Medical University, Tainan,Taiwan.
EM cobolsu@gmail.com
NR 0
TC 0
SN 1090-213
EI 
J9 Brain Behav Immun
PD MAR 23
PY 2023
VL 110
IS 
BP 339
EP 347
DI 10.1016/j.bbi.2023.03.016
PG 8
WC Humans; Depressive Disorder, Major; complications; Cross-Over Studies; Chronic Pain; therapy; Depression; Acupuncture Therapy; adverse effects; Treatment Outcome
UT PubMed:36948325
PM 36948325
DA 2023-03-23
ER

PT J
AU Bao, T
   Zhi, WI
   Baser, R
   Li, Q
   Mao, J
AF Bao, Ting
   Zhi, W. Iris
   Baser, Raymond
   Li, Qing
   Mao, Jun
TI Effectiveness of Electroacupuncture Versus Auricular Acupuncture in Reducing Pain and Improving Quality of Life in Breast Cancer Survivors with Chronic Musculoskeletal Pain
SO CANCER RESEARCH
LA English
DT Meeting Abstract
NR 0
TC 1
Z9 1
U1 1
U2 13
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD MAR 1
PY 2023
VL 83
IS 5
BP 
EP 
DI 10.1158/1538-7445.SABCS22-PD8-05
PG 2
WC Oncology
SC Oncology
GA I6XO5
UT WOS:001004196804068
DA 2026-01-16
ER

PT J
AU Zhang, M
   Zhao, N
   He, JH
   Li, JL
AF Zhang, Meng
   Zhao, Nan
   He, Jin-Hua
   Li, Jian-Li
TI [Effects of transcutaneous electrical acupoint stimulation on the postoperative
SO Zhongguo zhen jiu = Chinese acupuncture & moxibustion
LA chi
DT Journal Article
DE after surgery; frail elderly; inflammatory factors; randomized controlled trial (RCT); sleep quality; transcutaneous electrical acupoint stimulation
AB OBJECTIVE: To observe the effects of transcutaneous acupoint stimulation (TEAS)  on sleep quality and inflammatory factor in frail elderly patients undergoing  laparoscopic colorectal cancer surgery. METHODS: A total of 100 frail elderly  patients undergoing elective laparoscopic colorectal cancer surgery were randomly  divided into an observation group and a control group, 50 cases in each one.  Patients in the observation group received TEAS, 30 min before surgery until the  end of surgery, at 18:00 on the day of surgery and on the 1st, 2nd and 3rd day  after surgery (30 min each time). TEAS was delivered at bilateral Neiguan (PC 6),  Shenmen (HT 7) and Hegu (LI 4). The disperse-dense wave of 2 Hz/100 Hz was  selected, and the maximal stimulation intensity depended on patient's tolerance.  The operation procedure in the control group was same as the observation group,  but without electric stimulation exerted. The 1st day before surgery and on the  1st, 3rd and 7th day after surgery, the scores of Pittsburgh sleep quality index  (PSQI) and Athens insomnia scale (AIS), as well as the serum levels of C reactive  protein (CRP) and interleukin-6 (IL-6) were observed in the patients of two  groups. At 24 h, 48 h and 72 h after surgery, the score of pain visual analogue  scale (VAS) was recorded in the two groups, as well as the pressing times of  analgesic pump and the usage of flurbiprofen axetil during analgesic stage. The  occurrence of post operative adverse reactions was observed in the patients of  two groups. RESULTS: On the 1st and 3rd day after surgery, except the usage of  hypnotic drug scores, the scores of each item and the total scores of PSQI, as  well as AIS scores were all increased in the two groups compared with those of 1  day before surgery (P<0.05); and the scores in the observation group were lower  than those in the control group (P<0.05). On the 7th day after surgery, the  scores of each item and the total scores of PSQI, and AIS scores were not  different statistically in comparison between the two groups (P>0.05). On the  1st, 3rd and 7th day after surgery, serum levels of CRP and IL-6 were all  increased in the patients of two groups when compared with those of 1 day before  surgery (P<0.05), serum levels CRP and IL-6 in the patients of the observation  group were lower than those of the control group (P<0.05). The VAS scores of 24  h, 48 h and 72 h after surgery, the pressing times of analgesic pump, the  frequency and dosage of the remedies were not different statistically between the  two groups (P>0.05). CONCLUSION: TEAS can effectively improve sleep quality and  reduce inflammatory reaction in frail elderly patients undergoing laparoscopic  colorectal cancer surgery.
C1 Department of Anesthesia, Hebei People's Hospital, Shijiazhuang 050051, China.
   Department of Anesthesia, Third Hospital of Hebei Medical University.
   Department of Anesthesia, Hebei People's Hospital, Shijiazhuang 050051, China.
   Department of Anesthesia, Hebei People's Hospital, Shijiazhuang 050051, China.
NR 0
TC 0
SN 
EI 0255-293
J9 Zhongguo Zhen Jiu
PD JUL 11
PY 2023
VL 43
IS 7
BP 751
EP 5
DI 10.13703/j.0255-2930.20220919-k0002
PG -746
WC Aged; Humans; Acupuncture Points; Frail Elderly; Interleukin-6; Sleep Quality; C-Reactive Protein; Colorectal Neoplasms
UT PubMed:37429652
PM 37429652
DA 2023-07-11
ER

PT J
AU Ben-Arye, E
   Gamus, D
   Samuels, N
   Schiff, E
   Hausner, D
   Gressel, O
   Attias, S
   Lavie, O
   David, A
   Shulman, K
   Agbarya, A
AF Ben-Arye, Eran
   Gamus, Dorit
   Samuels, Noah
   Schiff, Elad
   Hausner, David
   Gressel, Orit
   Attias, Samuel
   Lavie, Ofer
   David, Adi
   Shulman, Katerina
   Agbarya, Abed
TI Acupuncture and integrative oncology for taxane-induced peripheral neuropathy: a
SO International journal of gynecological cancer : official journal of the
LA English
DT Journal Article
DE Quality of Life (PRO)/Palliative Care
AB OBJECTIVE: To compare the effectiveness of acupuncture alone or with additional  integrative oncology modalities for taxane-induced peripheral neuropathy-related  symptoms in patients with gynecological and breast cancer. METHODS: The study was  a prospective evaluation of patients undergoing twice-weekly treatments with  either acupuncture alone (single-modality, group A) or with additional  manual-movement and mind-body therapies (multimodality, group B), for 6 weeks.  Symptom severity was assessed at baseline, 6 weeks, and 9 weeks using the  Functional Assessment of Cancer Therapy-Taxane (FACT-Tax) tool; and von Frey  perception thresholds. Additional symptoms were also assessed with the European  Organization for Research and Treatment of Cancer Quality of Life Questionnaire  (EORTC QLQ-C30) and the Measure Yourself Concerns and Wellbeing (MYCaW) study  tool. RESULTS: For the 120 participants (60 in each study arm), baseline to  6-week scores were similar in both groups for improved FACT-Tax physical  wellbeing and scores for hand numbness/tingling; EORTC physical functioning and  global health status; and MYCaW scores. FACT-Tax taxane subscales and scores for  foot numbness/tingling improved only in group A (p=0.038), while emotional  wellbeing FACT-Tax (p=0.02) and EORTC pain (p=0.005) improved only in group B.  Group B showed greater improvement for FACT-Tax neuropathy-related concerns than  group A at 24 hours (p=0.043) and 7 days (p=0.009) after the first treatment.  CONCLUSION: Acupuncture alone or with additional integrative oncology modalities  may help reduce neuropathy-related symptoms. The single-modality group  demonstrated greater improvement for foot numbness/tingling, and the  multimodality group demonstrated improvement for pain and improved emotional  wellbeing and neuropathy-related concerns in the first week of treatment. TRIAL  REGISTRATION NUMBER: NCT03290976.
C1 The Oncology Service
   Lin Medical Center, Clalit Health Services
   Haifa and Western Galilee District, Haifa, Israel eranben@netvision.net.il.
   Technion Israel Institute of Technology, Haifa, Israel.
   Sheba Medical Center, Tel Hashomer, Israel.
   Shaare Zedek Medical Center, Jerusalem, Israel.
   Technion Israel Institute of Technology, Haifa, Israel.
   Department of Internal Medicine, Hospital, Haifa, Israel.
   Bnai Zion Medical Center, Haifa, Israel.
   Sheba Medical Center, Tel Hashomer, Israel.
   The Oncology Service
   Lin Medical Center, Clalit Health Services
   Haifa and Western Galilee District, Haifa, Israel.
   Bnai Zion Medical Center, Haifa, Israel.
   Technion Israel Institute of Technology, Haifa, Israel.
   Lady Davies Carmel Medical Center, Haifa, Israel.
   Sheba Medical Center, Tel Hashomer, Israel.
   LIN Medical Center, Haifa, Israel.
   Bnai Zion Medical Center, Haifa, Israel.
NR 0
TC 0
SN 1525-143
EI 
J9 Int J Gynecol Cancer
PD JAN 6
PY 2023
VL 33
IS 5
BP 792
EP 801
DI 10.1136/ijgc-2022-004004
PG 9
WC Humans; Integrative Oncology; Quality of Life; psychology; Hypesthesia; Acupuncture Therapy; Peripheral Nervous System Diseases; chemically induced; Taxoids; adverse effects; Pain; Surveys and Questionnaires
UT PubMed:36600535
PM 36600535
DA 2023-01-06
ER

PT J
AU Chen, J
   Fu, T
   Liu, L
   Xie, Y
   Li, Y
AF Chen, Jiu
   Fu, Tianxiao
   Liu, Li
   Xie, Yirui
   Li, Youdi
TI Effect of acupuncture inclusion in the enhanced recovery after surgery protocol
SO Frontiers in oncology
LA English
DT Journal Article
DE acupuncture; enhanced recovery after surgery; gastrointestinal function; meta-analysis; tumor
AB INTRODUCTION: Acupuncture has been shown to be effective in restoring  gastrointestinal function in tumor patients receiving the enhanced recovery after  surgery (ERAS) protocol. The present systematic review and meta-analysis aimed to  evaluate the rationality and efficacy of integrating acupuncture in the ERAS  strategy to recuperate gastrointestinal function. METHODS: We searched eleven  databases for relevant randomized clinical trials (RCTs) of acupuncture for the  treatment of gastrointestinal dysfunction in tumor patients treated with the ERAS  protocol. The quality of each article was assessed using the Cochrane  Collaboration risk of bias criteria and the modified Jadad Scale. As individual  symptoms, the primary outcomes were time to postoperative oral food intake, time  to first flatus, time to first distension and peristaltic sound recovery time  (PSRT). Pain control, adverse events, and acupoint names reported in the included  studies were also investigated. RESULTS: Of the 211 reviewed abstracts, 9 studies  (702 patients) met eligibility criteria and were included in the present  systematic review and meta‑analysis. Compared to control groups, acupuncture  groups showed a significant reduction in time to postoperative oral food intake  [standardized mean difference (SMD) = -0.77, 95% confidence interval (CI) -1.18  to -0.35], time to first flatus (SMD=-0.81, 95% CI -1.13 to -0.48), time to first  defecation (SMD=-0.91, 95% CI -1.41 to -0.41, PSRT (SMD=-0.92, 95% CI -1.93 to  0.08), and pain intensity (SMD=-0.60, 95% CI -0.83 to -0.37).The Zusanli (ST36)  and Shangjuxu (ST37) acupoints were used in eight of the nine included studies.  Adverse events related to acupuncture were observed in two studies, and only one  case of bruising was reported. DISCUSSION: The present systematic review and  meta‑analysis suggested that acupuncture significantly improves recovery of  gastrointestinal function and pain control in tumor patients receiving the ERAS  protocol compared to the control group. Moreover, ST36 and ST37 were the most  frequently used acupoints. Although the safety of acupuncture was poorly  described in the included studies, the available data suggested that acupuncture  is a safe treatment with only mild side effects. These findings provide  evidence-based recommendations for the inclusion of acupuncture in the ERAS  protocol for tumor patients. SYSTEMATIC REVIEW REGISTRATION:  https://www.crd.york.ac.uk/prospero/ PROSPERO, identifier CRD42023430211.
C1 Department of Traditional Chinese Medicine, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
   Department of Traditional Chinese Medicine, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
   Department of Library, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
   State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, Collaborative Innovation Centerfor Diagnosis and Treatment of Infectious Diseases, Hangzhou, China.
   The Department of Infectious Diseases, The First Affiliated Hospital, School of 
   Department of Traditional Chinese Medicine, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
NR 0
TC 0
SN 2234-943
EI 2234-943
J9 Front Oncol
PD SEP 1
PY 2023
VL 13
IS 
BP 1232754
EP 1232754
DI 10.3389/fonc.2023.1232754
PG 0
UT PubMed:37655096
PM 37655096
DA 2023-09-01
ER

PT J
AU Zhang, X
   Yang, W
   Shang, J
   Dan, W
   Shi, L
   Tong, L
   Yang, G
AF Zhang, Xu
   Yang, Wenjing
   Shang, Junliang
   Dan, Wenchao
   Shi, Lin
   Tong, Li
   Yang, Guowang
TI The lower He-sea points playing a significant role in postoperative ileus in
SO Frontiers in oncology
LA English
DT Journal Article
DE acupuncture; association rules; colorectal cancer; machine-learning; postoperative ileus
AB BACKGROUND: Postoperative ileus (POI) is a common complication following  abdominal surgery, which can lead to significant negative impacts on patients'  well-being and healthcare costs. However, the efficacy of current treatments is  not satisfactory. The purpose of this study was to evaluate the therapeutic  effects of acupuncture intervention and explore the regulation of acupoint  selection for treating POI in colorectal cancer (CRC) patients. METHODS: We  searched eight electronic databases to identify randomized controlled trials  (RCTs) on acupuncture for POI in CRC and conducted a meta-analysis. Subsequently,  we utilized the Apriori algorithm and the Frequent pattern growth algorithm, in  conjunction with complex network and cluster analysis, to identify association  rules of acupoints. RESULTS: The meta-analysis showed that acupuncture led to  significant reductions in time to first defecation (MD=-20.93, 95%CI: -25.35,  -16.51; I(2 =) 93.0%; p < 0.01; n=2805), first flatus (MD=-15.08, 95%CI: -18.39,  -11.76; I(2 =) 96%; p < 0.01; n=3284), and bowel sounds recovery (MD=-10.96,  95%CI: -14.20, -7.72; I(2 =) 94%; p < 0.01; n=2043). A subgroup analysis revealed  that acupuncture not only reduced the duration of POI when administered alongside  conventional care but also further expedited the recovery of gut function after  colorectal surgery when integrated into the enhanced recovery after surgery  (ERAS) pathway. The studies included in the analysis reported no instances of  serious adverse events associated with acupuncture. We identified Zusanli (ST36),  Shangjuxu (ST37), Neiguan (PC6), Sanyinjiao (SP6), Xiajuxu (ST39), Hegu (LI4),  Tianshu (ST25), and Zhongwan (RN12) as primary acupoints for treating POI.  Association rule mining suggested potential acupoint combinations including  {ST37, ST39}≥{ST36}, {PC6, ST37}≥{ST36}, {SP6, ST37}≥{ST36}, and {ST25,  ST37}≥{ST36}. CONCLUSION: Meta-analysis indicates acupuncture's safety and  superior effectiveness over postoperative care alone in facilitating  gastrointestinal recovery. Machine-learning approaches highlight the importance  of the lower He-sea points, including Zusanli (ST36) and Shangjuxu (ST37), in  treating POI in CRC patients. Incorporating additional acupoints such as Neiguan  (PC6) (for pain and vomiting) and Sanyinjiao (SP6) (for abdominal distension and  poor appetite) can optimize treatment outcomes. These findings offer valuable  insights for refining treatment protocols in both clinical and experimental  settings, ultimately enhancing patient care.
C1 Department of Nutrition, Beijing Hospital of Traditional Chinese Medicine, Capital Medical University, Beijing, China.
   Department of Oncology, Beijing Hospital of Traditional Chinese Medicine, Capital Medical University, Beijing, China.
   Department of Surgery, Beijing Hospital of Traditional Chinese Medicine, Capital Medical University, Beijing, China.
   School of Graduates, Capital Medical University, Beijing, China.
   Department of Oncology, Beijing Hospital of Traditional Chinese Medicine, Capital Medical University, Beijing, China.
   Department of Nutrition, Beijing Hospital of Traditional Chinese Medicine, Capital Medical University, Beijing, China.
   Department of Oncology, Beijing Hospital of Traditional Chinese Medicine, Capital Medical University, Beijing, China.
NR 0
TC 0
SN 2234-943
EI 2234-943
J9 Front Oncol
PD AUG 11
PY 2023
VL 13
IS 
BP 1206196
EP 1206196
DI 10.3389/fonc.2023.1206196
PG 0
UT PubMed:37564931
PM 37564931
DA 2023-08-11
ER

PT J
AU Lam, CS
   Zhou, K
   Loong, HHF
   Chung, VCH
   Ngan, CK
   Cheung, YT
AF Lam, Chun Sing
   Zhou, Keary
   Loong, Herbert Ho-Fung
   Chung, Vincent Chi-Ho
   Ngan, Chun-Kit
   Cheung, Yin Ting
TI The Use of Traditional, Complementary, and Integrative Medicine in Cancer: Data-Mining Study of 1 Million Web-Based Posts From Health Forums and Social Media Platforms
SO JOURNAL OF MEDICAL INTERNET RESEARCH
LA English
DT Article
DE traditional; complementary; integrative; social media; cancer; forums, digital health; traditional, complementary, and integrative medicine; TCIM; perceptions; machine learning; cancer care
ID quality-of-life; alternative medicine; cannabis use; therapy; communication; management; society
AB Background: Patients with cancer are increasingly using forums and social media platforms to access health information and share their experiences, particularly in the use of traditional, complementary, and integrative medicine (TCIM). Despite the popularity of TCIM among patients with cancer, few related studies have used data from these web-based sources to explore the use of TCIM among patients with cancer. Objective: This study leveraged multiple forums and social media platforms to explore patients' use, interest, and perception of TCIM for cancer care. Methods: Posts (in English) related to TCIM were collected from Facebook, Twitter, Reddit, and 16 health forums from inception until February 2022. Both manual assessments and natural language processing were performed. Descriptive analyses were performed to explore the most commonly discussed TCIM modalities for each symptom and cancer type. Sentiment analyses were performed to measure the polarity of each post or comment, and themes were identified from posts with positive and negative sentiments. TCIM modalities that are emerging or recommended in the guidelines were identified a priori. Exploratory topic-modeling analyses with latent Dirichlet allocation were conducted to investigate the patients' perceptions of these modalities. Results: Among the 1,620,755 posts available, cancer-related symptoms, such as pain (10/10, 100% cancer types), anxiety and depression (9/10, 90%), and poor sleep (9/10, 90%), were commonly discussed. Cannabis was among the most frequently discussed TCIM modalities for pain in 7 (70%) out of 10 cancer types, as well as nausea and vomiting, loss of appetite, anxiety and depression, and poor sleep. A total of 7 positive and 7 negative themes were also identified. The positive themes included TCIM, making symptoms manageable, and reducing the need for medication and their side effects. The belief that TCIM and conventional treatments were not mutually exclusive and intolerance to conventional treatment may facilitate TCIM use. Conversely, TCIM was viewed as leading to patients' refusal of conventional treatment or delays in diagnosis and treatment. Doctors' ignorance regarding TCIM and the lack of information provided about TCIM may be barriers to its use. Exploratory analyses showed that TCIM recommendations were well discussed among patients; however, these modalities were also used for many other indications. Other notable topics included concerns about the legalization of cannabis, acupressure techniques, and positive experiences of meditation. Conclusions: Using machine learning techniques, social media and health forums provide a valuable resource for patient-generated data regarding the pattern of use and patients' perceptions of TCIM. Such information will help clarify patients' needs and concerns and provide directions for research on integrating TCIM into cancer care. Our results also suggest that effective communication about TCIM should be achieved and that doctors should be more open-minded to actively discuss TCIM use with their patients.
C1 [Lam, Chun Sing; Zhou, Keary; Cheung, Yin Ting] Chinese Univ Hong Kong, Sch Pharm, Fac Med, Hong Kong, Peoples R China.
   [Loong, Herbert Ho-Fung] Chinese Univ Hong Kong, Fac Med, Dept Clin Oncol, Hong Kong, Peoples R China.
   [Chung, Vincent Chi-Ho] Chinese Univ Hong Kong, Sch Chinese Med, Fac Med, Hong Kong, Peoples R China.
   [Chung, Vincent Chi-Ho] Chinese Univ Hong Kong, Jockey Club Sch Publ Hlth & Primary Care, Fac Med, Hong Kong, Peoples R China.
   [Ngan, Chun-Kit] Worcester Polytech Inst, Data Sci Program, Worcester, MA USA.
   [Cheung, Yin Ting] Chinese Univ Hong Kong, Sch Pharm, Fac Med, Shatin, 8th Floor,Lo Kwee Seong Integrated Biomed Sci Bldg, Hong Kong, Peoples R China.
C3 Chinese University of Hong Kong; Chinese University of Hong Kong; Chinese University of Hong Kong; Chinese University of Hong Kong; Worcester Polytechnic Institute; Chinese University of Hong Kong
RP Cheung, YT (corresponding author), Chinese Univ Hong Kong, Sch Pharm, Fac Med, Shatin, 8th Floor,Lo Kwee Seong Integrated Biomed Sci Bldg, Hong Kong, Peoples R China.
EM yinting.cheung@cuhk.edu.hk
CR Unknown -, 2022, SEARCH ENG MARK SHAR, V0, P0
   Unknown -, 2017, TRADITIONAL COMPLEME, V0, P0
   Unknown -, 2021, MEDITATION: IN DEPTH, V0, P0
   Unknown -, 2013, WHO TRADITIONAL MED, V1st, P0
   Unknown -, 2022, GLOB CANN REP, V0, P0
   Attai DJ, 2016, FUTURE ONCOL, V12, P1549, DOI 10.2217/fon-2016-0065
   Babcock ZR, 2020, J CANCER SURVIV, V14, P89, DOI 10.1007/s11764-019-00837-y
   Balaji TK, 2021, COMPUT SCI REV, V40, P0, DOI 10.1016/j.cosrev.2021.100395
   Barde BV, 2017, 2017 INTERNATIONAL CONFERENCE ON INTELLIGENT COMPUTING AND CONTROL SYSTEMS (ICICCS), V0, PP745, DOI 10.1109/ICCONS.2017.8250563
   Bauer Mark S, 2015, BMC PSYCHOL, V3, P32, DOI 10.1186/s40359-015-0089-9
   Ben-Arye E, 2021, SUPPORT CARE CANCER, V29, P6155, DOI 10.1007/s00520-021-06205-w
   Beusterien K, 2013, ECANCERMEDICALSCIENC, V7, P0, DOI 10.3332/ecancer.2013.361
   Bird S, 2009, NATURAL LANGUAGE PROCESSING WITH PYTHON, V0, P0
   Blei DM, 2003, J MACH LEARN RES, V3, P993, DOI 10.1162/jmlr.2003.3.4-5.993
   Buckner CA, 2018, CURR ONCOL, V25, PE275, DOI 10.3747/co.25.3884
   Buis LR, 2011, CIN-COMPUT INFORM NU, V29, P461, DOI 10.1097/NCN.0b013e318214093b
   Reddy YCAP, 2018, INTERNATIONAL JOURNAL OF ENGINEERING & TECHNOLOGY, V7, P81, DOI 10.14419/ijet.v7i1.8.9977
   Chung VCH, 2011, EUR J INTEGR MED, V3, PE283, DOI 10.1016/j.eujim.2011.09.008
   Chung VCH, 2009, HEALTH POLICY, V90, P66, DOI 10.1016/j.healthpol.2008.09.005
   Cleeland Charles S, 2007, J NATL CANCER INST MONOGR, V0, P16
   Davis EL, 2012, ONCOLOGIST, V17, P1475, DOI 10.1634/theoncologist.2012-0223
   Degenhardt L, 2008, PLOS MED, V5, P1053, DOI 10.1371/journal.pmed.0050141
   Deng G, 2013, NAT REV CLIN ONCOL, V10, P656, DOI 10.1038/nrclinonc.2013.125
   Deng GE, 2013, CHEST, V143, PE420, DOI 10.1378/chest.12-2364
   Deshields T, 2014, SUPPORT CARE CANCER, V22, P1089, DOI 10.1007/s00520-013-2049-3
   Dhaoui C, 2017, J CONSUM MARK, V34, P480, DOI 10.1108/JCM-03-2017-2141
   Dinov IvoD, 2018, DATA SCIENCE AND PREDICTIVE ANALYTICS: BIOMEDICAL AND HEALTH APPLICATIONS USING R, V0, P0, DOI DOI 10.1007/978-3-319-72347-1
   Greenlee H, 2017, CA-CANCER J CLIN, V67, P195, DOI 10.3322/caac.21397
   Hasan A, 2017, LECT NOTES COMPUT SC, V10584, P125, DOI 10.1007/978-3-319-68765-0_11
   Honnibal Matthew, 2020, INDUSTRIAL-STRENGTH NATURAL LANGUAGE PROCESSING IN PYTHON, V0, P0
   Jagarlamudi Jagadeesh, 2012, EACL, V0, P204
   Johnson SB, 2018, JAMA ONCOL, V4, P1375, DOI 10.1001/jamaoncol.2018.2487
   Junger Jakob, 2019, FACEPAGER. AN APPLICATION FOR AUTOMATED DATA RETRIEVAL ON THE WEB, V0, P0
   Keene MR, 2019, COMPLEMENT THER CLIN, V35, P33, DOI 10.1016/j.ctcp.2019.01.004
   Lee RT, 2008, INTEGR CANCER THER, V7, P70, DOI 10.1177/1534735408319059
   Lognos B, 2019, JMIR CANCER, V5, P0, DOI 10.2196/12536
   Loria S, 2020, TEXTBLOB: SIMPLIFIED TEXT PROCESSING, V0, P0
   Mao JJ, 2022, J CLIN ONCOL, V40, P3998, DOI 10.1200/JCO.22.01357
   Mao JJ, 2022, CA-CANCER J CLIN, V72, P144, DOI 10.3322/caac.21706
   Martell K, 2018, CURR ONCOL, V25, P219, DOI 10.3747/co.25.3983
   Mazzocut M, 2016, J MED INTERNET RES, V18, P0, DOI 10.2196/jmir.5521
   Murphy CC, 2018, CANCER-AM CANCER SOC, V124, P2850, DOI 10.1002/cncr.31389
   Narayanan S, 2021, INTEGR CANCER THER, V20, P0, DOI 10.1177/1534735421999101
   Pergam SA, 2017, CANCER-AM CANCER SOC, V123, P4488, DOI 10.1002/cncr.30879
   Portier Kenneth, 2013, JOURNAL OF THE NATIONAL CANCER INSTITUTE MONOGRAPHS, V0, PP195, DOI 10.1093/jncimonographs/lgt025
   Robbins R, 2020, BJU INT, V125, P634, DOI 10.1111/bju.14986
   Roberts CS, 2005, J PSYCHOSOC ONCOL, V23, P35, DOI 10.1300/J077v23n04_03
   Schultz Pamela N, 2003, CLIN J ONCOL NURS, V7, P663
   Shneerson C, 2013, COMPLEMENT THER MED, V21, P417, DOI 10.1016/j.ctim.2013.05.003
   Sofaer S, 2005, ANNU REV PUBL HEALTH, V26, P513, DOI 10.1146/annurev.publhealth.25.050503.153958
   Stein KD, 2008, CANCER-AM CANCER SOC, V112, P2577, DOI 10.1002/cncr.23448
   SUTHERLAND LR, 1994, J CLIN GASTROENTEROL, V19, P194, DOI 10.1097/00004836-199410000-00004
   van der Weijden T, 2010, IMPLEMENT SCI, V5, P0, DOI 10.1186/1748-5908-5-10
   Verhoef MJ, 2009, CHRONIC DIS CAN, V29, P80
   Vyas MB, 2018, NURS OUTLOOK, V66, P56, DOI 10.1016/j.outlook.2017.08.012
   Wagner J, 2021, MOST POPULAR SOCIAL, V0, P0
   Wang JZ, 2020, J MED INTERNET RES, V22, P0, DOI 10.2196/22152
   Weeks Laura, 2014, OPEN MED, V8, P0
   Wilkie G, 2016, JAMA ONCOL, V2, P670, DOI 10.1001/jamaoncol.2016.0155
   Witt CM, 2022, J CANCER EDUC, V37, P499, DOI 10.1007/s13187-020-01829-8
   Wode K, 2019, BMC COMPLEM ALTERN M, V19, P0, DOI 10.1186/s12906-019-2452-5
   Worster B, 2022, JCO ONCOL PRACT, V18, P743, DOI 10.1200/OP.22.00080
   Zick SM, 2018, J ALTERN COMPLEM MED, V24, P1018, DOI 10.1089/acm.2018.0184
   Zörgo S, 2018, INTEGR CANCER THER, V17, P1270, DOI 10.1177/1534735418801533
NR 64
TC 10
Z9 12
U1 0
U2 12
PU JMIR PUBLICATIONS, INC
PI TORONTO
PA 130 QUEENS QUAY East, Unit 1100, TORONTO, ON M5A 0P6, CANADA
SN 1438-8871
EI 
J9 J MED INTERNET RES
JI J. Med. Internet Res.
PD APR 21
PY 2023
VL 25
IS 
BP 
EP 
DI 10.2196/45408
PG 13
WC Health Care Sciences & Services; Medical Informatics
SC Health Care Sciences & Services; Medical Informatics
GA I9OU6
UT WOS:001006009400001
PM 37083752
DA 2026-01-16
ER

PT J
AU Zhao, ZT
   Zhao, YK
   Chen, JL
   Zhu, TT
   Yan, XK
   Zhang, YF
AF Zhao, Zhong-Ting
   Zhao, Yi-Kun
   Chen, Jia-Lian
   Zhu, Tian-Tian
   Yan, Xing-Ke
   Zhang, Yan-Feng
TI [Effect of different suspension moxibustion methods on syndrome characteristics
SO Zhongguo zhen jiu = Chinese acupuncture & moxibustion
LA chi
DT Journal Article
DE heat bi syndrome; inflammatory response; moxibustion can be used for heat syndrome; rheumatoid arthritis; suspension moxibustion
AB OBJECTIVE: To observe the effects of different suspension moxibustion methods on  the syndrome characteristics and inflammatory factors of rats with rheumatoid  arthritis (RA) of heat bi syndrome and to prove the concept of "moxibustion can  be used for heat syndrome". METHODS: Among seventy Wistar rats, 12 rats were  randomly selected as a normal group, and the remaining rats were induced by  collagen combined with wind, dampness, and heat environmental stimulation to  establish the RA model of heat bi syndrome. Forty-eight rats with successful  model establishment were further randomly divided into a model group and three  moxibustion groups (mild moxibustion group, rotating moxibustion group and  sparrow-pecking moxibustion group), with 12 rats in each group. The acupoints  "Quchi" (LI 11), "Dazhui" (GV 14) and ashi point were used in all moxibustion  groups, with mild moxibustion, rotating moxibustion, and sparrow-pecking  moxibustion intervention given respectively, each acupoint was treated with  moxibustion for 10 min a day, and 6 days were considered one course of treatment,  with a total of three courses. After the intervention, the arthritis index (AI),  the Evans blue (EB) extravasated volume in the soft tissue of the right hind paw,  and the levels of tumor necrosis factor (TNF)-α and interleukin (IL)-10 in the  serum were measured by ELISA in each group. The volume of the bilateral hind paw  was measured; the infrared thermal imaging was collected to analyze the  temperature of the plantar area of the bilateral foot pads, and the reaction time  of plantar heat pain was calculated before and after modeling, as well as after  the 1st, 2nd and 3rd courses of interrention. The ankle dorsiflexion angle of the  right hind foot was also measured before and after modeling, as well as after the  intervention. RESULTS: After modeling, compared with the normal group, the rats  in the model group had more high-temperature areas in the bilateral hind limbs,  abnormal AI score, abnormal bilateral hind paw volume, abnormal temperature of  the plantar area of the bilateral foot pads, abnormal foot pain response time,  abnormal right hind ankle dorsiflexion angle, abnormal right hind paw soft tissue  EB extravasation, and abnormal serum TNF-α and IL-10 levels (P<0.01, P<0.05).  After the intervention, compared with the model group, the rats in each  moxibustion group had decreased or disappeared high-temperature areas in the  bilateral hind limbs, EB extravasated volume in the soft tissue of the right hind  paw was reduced (P<0.05), and the right ankle dorsiflexion angle was increased  (P<0.05), serum level of TNF-α was reduced, and level of IL-10 increased  (P<0.05); the AI scores in the mild moxibustion group and the sparrow-pecking  moxibustion group was decreased (P<0.01, P<0.05). After the 1st, 2nd and 3rd  courses of intervention, compared with the model group, the bilateral hind paw  volume of rats in each moxibustion group was decreased (P<0.05, P<0.01), and  plantar heat pain reaction time was increased (P<0.05). After the 2nd course and  the 3rd course of intervention, the temperature of the right hind paw pad area  was decreased in each moribustion group (P<0.05); after the 3rd courses of  intervention, the temperature of the left hind paw pad area was decreased in the  mild moxibustion group (P<0.05). CONCLUSION: Suspension moxibustion could adjust  the serum levels of TNF-α and IL-10 to improve the syndrome characteristics of RA  rats of heat bi syndrome, such as joint redness, swelling, heat, pain and  activity restriction. The effect of mild moxibustion is the most prominent. The  findings could provide scientific basis for "moxibustion can be used for heat  syndrome".
C1 College of Acupuncture-Moxibustion and Tuina, Gansu University of CM, Lanzhou 730101, China.
   College of Acupuncture-Moxibustion and Tuina, Gansu University of CM, Lanzhou 730101, China.
   College of Acupuncture-Moxibustion and Tuina, Gansu University of CM, Lanzhou 730101, China.
   College of Acupuncture-Moxibustion and Tuina, Gansu University of CM, Lanzhou 730101, China.
   College of Acupuncture-Moxibustion and Tuina, Gansu University of CM, Lanzhou 730101, China.
   College of Acupuncture-Moxibustion and Tuina, Gansu University of CM, Lanzhou 730101, China.
NR 0
TC 0
SN 
EI 0255-293
J9 Zhongguo Zhen Jiu
PD SEP 12
PY 2023
VL 43
IS 9
BP 1062
EP 9
DI 10.13703/j.0255-2930.20220807-0001
PG -1053
WC Animals; Rats; Arthritis, Rheumatoid; therapy; Evans Blue; Hot Temperature; Interleukin-10; genetics; Moxibustion; Rats, Wistar; Tumor Necrosis Factor-alpha; genetics
UT PubMed:37697883
PM 37697883
DA 2023-09-12
ER

PT J
AU Zhang, JW
   Liu, LY
   Zhu, MJ
   Zheng, XY
   Liang, Y
   Zhong, Y
   Xu, J
   Yang, J
AF Zhang, Jingwen
   Liu, Liying
   Zhu, Manjia
   Zheng, Xiaoyan
   Liang, Yun
   Zhong, Ying
   Xu, Jing
   Yang, Jie
TI Research Status and Prospects of Acupuncture in Perioperative Medicine Over the Past Decade: A Bibliometric Analysis
SO JOURNAL OF PAIN RESEARCH
LA English
DT Review
DE acupuncture; perioperative medicine; post-operative; mid-operative; CiteSpace; VOSviewer
ID electrical acupoint stimulation; postoperative pain; enhanced recovery; electroacupuncture; surgery; analgesia; trends; anesthesia; therapy; care
AB Background: Over the past decade, acupuncture in the perioperative period has attracted great interest, and a growing number of related literature has been published. Purpose: To analyze the general information and identify the research hotspots and trends of acupuncture in perioperative medicine in the last 10 years by bibliometric analysis. Methods: We searched the Web of Science Core Collection for publications on acupuncture in perioperative medicine from 2013 to 2023. The articles and reviews were collected with no language restriction. CiteSpace and VOSviewer software were used for bibliometric and visual analysis of relevant literature. Results: A total of 814 bibliographic records were retrieved. Overall, the annual number of publications showed an increasing trend. China and its institutions were in a leading position regarding the publication number. With comparatively more scientific collaboration with China, the USA ranked second. Shanghai University of Traditional Chinese Medicine was the most prolific institution. Ha, In-Hyuk had the most publications, and Han JS and Lee A were the most cited authors. Medicine was the most popular journal and Journal of Clinical Oncology had the highest impact factor. "Acupuncture", "electroacupuncture" and "postoperative pain" were the top three keywords. The most popular topics were postoperative pain, postoperative ileus, and postoperative nausea and vomiting according to the keywords and references. And the clusters of postoperative cognitive dysfunction, anxiety, and breast cancer attracted relatively more attention recently. Conclusion: This study summarized the research status, hotspots, and trends of acupuncture in perioperative medicine in the past decade, which may aid researchers in better understanding this field. The research hotspots primarily focused on postoperative pain management and postoperative gastrointestinal function. The research of acupuncture for postoperative cognitive dysfunction, cancer-related surgery, and psychological states were the main frontiers topics and may be the focus in the future.
C1 [Zhang, Jingwen; Liu, Liying; Zheng, Xiaoyan; Liang, Yun; Xu, Jing; Yang, Jie] Chengdu Univ Tradit Chinese Med, Acupuncture & Tuina Sch, Chengdu, Sichuan, Peoples R China.
   [Zhu, Manjia] Chengdu Univ Tradit Chinese Med, Basic Med Coll, Chengdu, Sichuan, Peoples R China.
   [Zheng, Xiaoyan; Zhong, Ying; Yang, Jie] Sichuan Jinxin Xinan Womens & Childrens Hosp, Chengdu, Sichuan, Peoples R China.
C3 Chengdu University of Traditional Chinese Medicine; Chengdu University of Traditional Chinese Medicine
RP Xu, J; Yang, J (corresponding author), Chengdu Univ Tradit Chinese Med, Acupuncture & Tuina Sch, Chengdu, Sichuan, Peoples R China.; Yang, J (corresponding author), Sichuan Jinxin Xinan Womens & Childrens Hosp, Chengdu, Sichuan, Peoples R China.
EM 195940644@qq.com; jenny_yang_jie@126.com
FU National Natural Science Foundation of China [82174517]; "Xinglin Scholars" Disciplinary Talent Research Promotion Plan Excellent Youth Project [YQRC2022001]
CR Adly AS, 2022, LASER MED SCI, V37, P499, DOI 10.1007/s10103-021-03287-0
   An LX, 2014, AM J CHINESE MED, V42, P1099, DOI 10.1142/S0192415X14500682
   Ao L, 2021, EXP THER MED, V21, P0, DOI 10.3892/etm.2021.9615
   Bain CR, 2023, ANAESTHESIA, V78, P356, DOI 10.1111/anae.15896
   Chen B, 2023, J PAIN RES, V16, P1197, DOI 10.2147/JPR.S398393
   Chen CM, 2014, EXPERT OPIN BIOL TH, V14, P1295, DOI 10.1517/14712598.2014.920813
   Chen CM, 2014, J ASSOC INF SCI TECH, V65, P334, DOI 10.1002/asi.22968
   Chen JB, 2020, INT J SURG, V73, P57, DOI 10.1016/j.ijsu.2019.10.036
   Chen JH, 2020, THORAC CANCER, V11, P928, DOI 10.1111/1759-7714.13343
   Chen KB, 2019, INT J SURG, V70, P93, DOI 10.1016/j.ijsu.2019.08.034
   CHEN XH, 1992, BEHAV BRAIN RES, V47, P143, DOI 10.1016/S0166-4328(05)80120-2
   Chen Y, 2019, SIGNAL TRANSDUCT TAR, V4, P0, DOI 10.1038/s41392-019-0061-x
   Cheong KB, 2013, PLOS ONE, V8, P0, DOI 10.1371/journal.pone.0082474
   Cho YH, 2015, PAIN PRACT, V15, P279, DOI 10.1111/papr.12208
   Dai WJ, 2019, EVID-BASED COMPL ALT, V2019, P0, DOI 10.1155/2019/8413576
   Almeida TCD, 2018, MEDIAT INFLAMM, V2018, P0, DOI 10.1155/2018/1094352
   Egholm JWM, 2018, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD008343.pub3
   Ellegaard O, 2015, SCIENTOMETRICS, V105, P1809, DOI 10.1007/s11192-015-1645-z
   Fang JF, 2017, SCI REP-UK, V7, P0, DOI 10.1038/srep39801
   Gao F, 2018, CLIN INTERV AGING, V13, P2127, DOI 10.2147/CIA.S183698
   Garcia MK, 2013, J CLIN ONCOL, V31, P952, DOI 10.1200/JCO.2012.43.5818
   Han JS, 2004, NEUROSCI LETT, V361, P258, DOI 10.1016/j.neulet.2003.12.019
   Han JS, 2003, TRENDS NEUROSCI, V26, P17, DOI 10.1016/S0166-2236(02)00006-1
   Heo I, 2021, BRIT J ANAESTH, V126, P692, DOI 10.1016/j.bja.2020.10.038
   Heo I, 2018, BMJ OPEN, V8, P0, DOI 10.1136/bmjopen-2017-018464
   Hirsch JE, 2005, P NATL ACAD SCI USA, V102, P16569, DOI 10.1073/pnas.0507655102
   Ji ZC, 2020, BMC COMPLEMENT MED, V20, P0, DOI 10.1186/s12906-020-03099-9
   Kang BX, 2023, BRAIN BEHAV, V13, P0, DOI 10.1002/brb3.2913
   Kelleher DC, 2020, REGION ANESTH PAIN M, V45, P468, DOI 10.1136/rapm-2019-100947
   Lee A, 2015, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD003281.pub4
   Li GY, 2013, EXP THER MED, V6, P699, DOI 10.3892/etm.2013.1225
   Li MM, 2020, NEUROMODULATION, V23, P838, DOI 10.1111/ner.13178
   Li WJ, 2021, J INTEGR MED-JIM, V19, P211, DOI 10.1016/j.joim.2021.01.005
   Li X, 2022, FRONT CARDIOVASC MED, V9, P0, DOI 10.3389/fcvm.2022.920491
   Liu PR, 2019, J INT MED RES, V47, P3860, DOI 10.1177/0300060519860026
   Liu X, 2015, ACUPUNCT MED, V33, P270, DOI 10.1136/acupmed-2014-010749
   Liu YH, 2018, EVID-BASED COMPL ALT, V2018, P0, DOI 10.1155/2018/3178472
   Liu YL, 2022, J PAIN RES, V15, P2085, DOI 10.2147/JPR.S371399
   Ljungqvist O, 2023, JAMA SURG, V158, P28, DOI 10.1001/jamasurg.2022.5683
   Ljungqvist O, 2017, JAMA SURG, V152, P292, DOI 10.1001/jamasurg.2016.4952
   Lu Z, 2015, BRIT J ANAESTH, V115, P183, DOI 10.1093/bja/aev227
   Lu ZH, 2021, J CLIN ANESTH, V74, P0, DOI 10.1016/j.jclinane.2021.110453
   Modha K, 2022, ANN INTERN MED, V175, PITC161, DOI 10.7326/AITC202211150
   Ng SSM, 2013, GASTROENTEROLOGY, V144, P307, DOI 10.1053/j.gastro.2012.10.050
   Patel M, 2020, BEST PRAC RES-CL ANA, V34, P603, DOI 10.1016/j.bpa.2020.08.005
   Pinto BB, 2019, EUR J ANAESTH, V36, P889, DOI 10.1097/EJA.0000000000001067
   Sun Y, 2008, BRIT J ANAESTH, V101, P151, DOI 10.1093/bja/aen146
   Tan MJ, 2015, CAN J ANESTH, V62, P203, DOI 10.1007/s12630-014-0275-x
   Tao XS, 2020, NEUROTHERAPEUTICS, V17, P886, DOI 10.1007/s13311-020-00892-9
   Wang Y, 2023, FRONT MOL NEUROSCI, V16, P0, DOI 10.3389/fnmol.2023.1115569
   Wang Y, 2023, JAMA SURG, V158, P20, DOI 10.1001/jamasurg.2022.5674
   Wu L, 2021, ANN PALLIAT MED, V10, P3194, DOI 10.21037/apm-21-477
   Wu MS, 2016, PLOS ONE, V11, P0, DOI 10.1371/journal.pone.0150367
   Wu Y, 2022, SCI REP-UK, V12, P0, DOI 10.1038/s41598-022-18729-0
   Xing RY, 2022, PAIN THER, V11, P1327, DOI 10.1007/s40122-022-00429-2
   Yu XD, 2020, TRIALS, V21, P0, DOI 10.1186/s13063-019-3892-4
   Zhang B, 2019, NEUROMODULATION, V22, P546, DOI 10.1111/ner.12856
   Zhang B, 2018, AM J GASTROENTEROL, V113, P1026, DOI 10.1038/s41395-018-0156-y
   Zhang WL, 2022, AM J CHINESE MED, V50, P961, DOI 10.1142/S0192415X22500392
   Zhang Y, 2020, PEDIATR ANESTH, V30, P552, DOI 10.1111/pan.13860
   Zhao TT, 2021, J PAIN RES, V14, P1399, DOI 10.2147/JPR.S306594
   Zhou HQ, 2018, PEERJ, V6, P0, DOI 10.7717/peerj.4354
   Zhu Y, 2020, NEUROMODULATION, V23, P1180, DOI 10.1111/ner.13158
NR 63
TC 7
Z9 7
U1 3
U2 34
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1178-7090
EI 
J9 J PAIN RES
JI J. Pain Res.
PD JUN 15
PY 2023
VL 16
IS 
BP 2189
EP 2204
DI 10.2147/JPR.S415998
PG 16
WC Clinical Neurology
SC Neurosciences & Neurology
GA L4US9
UT WOS:001023239200001
PM 37397275
DA 2026-01-16
ER

PT J
AU Narayanan, S
   Liu, WL
   Lopez, G
   Fellman, B
   Reddy, A
   Subbiah, IM
   Cohen, L
   Bruera, E
AF Narayanan, Santhosshi
   Liu, Wenli
   Lopez, Gabriel
   Fellman, Bryan
   Reddy, Akhila
   Subbiah, Ishwaria M.
   Cohen, Lorenzo
   Bruera, Eduardo
TI Practice Patterns on the Incorporation of Integrative Medicine Into the Oncologic Care of Patients With Cancer
SO INTEGRATIVE CANCER THERAPIES
LA English
DT Article
DE integrative oncology; complementary and alternative treatments; cancer; integrative medicine; patient reported outcomes; implementation research
ID consultations; complementary
AB Background: With rising interest in complementary approaches to symptom management, awareness of real-world practice patterns in the incorporation of integrative oncology (IO) into cancer care is limited. Therefore, we examined the reasons for referral, symptom burdens, and clinical outcomes for cancer patients who underwent initial IO consultations.Methods: The records of adult patients with cancer who underwent initial outpatient IO consultations at our cancer center for a representative 10-day period at the start of each month for 12 months starting January 1, 2017, were reviewed retrospectively. Patient demographic and medical characteristics and outpatient IO consultation details, including patient-reported outcome measures of symptom burden, were extracted. Descriptive summary statistics and logistic regression were used to analyze the data.Results: Among the 473 study patients, 71% were women, breast cancer (42%) was the most common cancer type, and 31% had metastatic cancer. Referring clinicians listed an integrative approach (57%) as the most common reason for referral, followed by diet (26%), pain (19%), discussion of herbs and supplements (18%), and stress (18%). In comparison, patients listed their primary concerns as diet (16%), pain (15%), and an integrative approach to overall health (11%). After the IO consultations, the highest likelihood of subsequent recommendations were acupuncture for hot flashes (odds ratio [OR], P = .002) or peripheral neuropathy (OR = 6.59, P < .001), oncology massage for pain (OR = 3.04, P < .001), psychology referral for patient's self-reported anxiety (OR = 2.35, P < .001), and mind-body therapies for stress (OR = 2.57, P < .001).Conclusion: Cancer patients' top concerns regarding IO consultation may not always match providers' reasons for referral. Longitudinal data analysis is needed to determine the effect of integrative interventions on symptom burden.
C1 [Narayanan, Santhosshi; Liu, Wenli; Lopez, Gabriel; Fellman, Bryan; Reddy, Akhila; Subbiah, Ishwaria M.; Cohen, Lorenzo; Bruera, Eduardo] Univ Texas MD Anderson Canc Ctr, Houston, TX USA.
   [Narayanan, Santhosshi] Univ Texas MD Anderson Canc, Dept Palliat Rehabil & Integrat Med, Unit 1414, 1400 Pressler St,1515 Holcombe Blvd, Houston, TX 77030 USA.
C3 University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center
RP Narayanan, S (corresponding author), Univ Texas MD Anderson Canc, Dept Palliat Rehabil & Integrat Med, Unit 1414, 1400 Pressler St,1515 Holcombe Blvd, Houston, TX 77030 USA.
EM snarayanan2@mdanderson.org
FU Duncan Family Institute for Cancer Prevention and Risk Assessment
CR ASCO in Action, 2018, NATIONAL SURVEY REVEALS SURPRISING NUMBER OF AMERICANS BELIEVE ALTERNATIVE THERAPIES CAN CURE CANCER, V0, P0
   Bao T, 2020, JAMA NETW OPEN, V3, P0, DOI 10.1001/jamanetworkopen.2020.0681
   Ben-Arye E, 2021, SUPPORT CARE CANCER, V29, P6155, DOI 10.1007/s00520-021-06205-w
   Berger Ann M, 2015, J NATL COMPR CANC NETW, V13, P1012
   Bruera E, 1991, J PALLIAT CARE, V7, P6
   Davis EL, 2012, ONCOLOGIST, V17, P1475, DOI 10.1634/theoncologist.2012-0223
   Falkensteiner M, 2011, ISRN NURS, V0, P2011
   Garcia MK, 2015, CANCER-AM CANCER SOC, V121, P3948, DOI 10.1002/cncr.29630
   Grant SJ, 2021, INTEGR CANCER THER, V20, P0
   Hays RD, 2009, QUAL LIFE RES, V18, P873, DOI 10.1007/s11136-009-9496-9
   Hui D, 2015, CANCER-AM CANCER SOC, V121, P3027, DOI 10.1002/cncr.29437
   Lee RT, 2014, J CLIN ONCOL, V32, P4095, DOI 10.1200/JCO.2014.55.8676
   Lopez G, 2017, J CANCER, V8, P395, DOI 10.7150/jca.17506
   Lyman GH, 2018, J CLIN ONCOL, V36, P2647, DOI 10.1200/JCO.2018.79.2721
   Mao JJ, 2023, JCO ONCOL PRACT, V19, P45, DOI 10.1200/OP.22.00622
   Narayanan S, 2021, INTEGR CANCER THER, V20, P0, DOI 10.1177/1534735421999101
   Paterson C, 2007, COMPLEMENT THER MED, V15, P38, DOI 10.1016/j.ctim.2006.03.006
   Witt Claudia M, 2017, JOURNAL OF THE NATIONAL CANCER INSTITUTE MONOGRAPHS, V0, PP3, DOI 10.1093/jncimonographs/lgx012
   Yun Hyeongjun, 2017, JOURNAL OF THE NATIONAL CANCER INSTITUTE MONOGRAPHS, V0, PP29, DOI 10.1093/jncimonographs/lgx004
   Zia Farah Z, 2017, JOURNAL OF THE NATIONAL CANCER INSTITUTE MONOGRAPHS, V0, PP68, DOI 10.1093/jncimonographs/lgx005
NR 21
TC 3
Z9 3
U1 0
U2 1
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1534-7354
EI 1552-695X
J9 INTEGR CANCER THER
JI Integr. Cancer Ther.
PD JUN 15
PY 2023
VL 22
IS 
BP 
EP 
DI 10.1177/15347354231213045
PG 7
WC Oncology; Integrative & Complementary Medicine
SC Oncology; Integrative & Complementary Medicine
GA CC8Q6
UT WOS:001123146900001
PM 37978821
DA 2026-01-16
ER

PT J
AU Molinares, D
   Kurtevski, S
   Zhu, YR
AF Molinares, Diana
   Kurtevski, Sara
   Zhu, Yingrong
TI Chemotherapy-Induced Peripheral Neuropathy: Diagnosis, Agents, General Clinical Presentation, and Treatments
SO CURRENT ONCOLOGY REPORTS
LA English
DT Review
DE Chemotherapy; Neuropathy; Cancer rehabilitation; CIPN; Survivorship
ID double-blind; topical amitriptyline; reduced glutathione; pilot trial; prevention; pain; management; cancer; neurotoxicity; acupuncture
AB Purpose of ReviewThis review aims to discuss pathophysiology, diagnosis, clinical presentation, and treatment of chemotherapy-induced peripheral neuropathy. Agent-specific presentation and pathophysiology is also being discussed.Recent FindingsAs new systemic oncological treatments continue to be developed, the number of cancer survivors continues to grow. Survivors are living longer with the long-term side effects of oncological treatments. We reviewed the pathophysiology of agent-specific chemotherapy-induced peripheral neuropathy and the updates in its treatment and preventative tools.SummaryChemotherapy-induced peripheral neuropathy is a debilitating long-term side effect that often impairs cancer survivors' function and quality of life. The increasing life expectancy of cancer survivors has resulted in increased prevalence of this condition. Understanding its intricacies can provide physicians with better treatment tools and research opportunities to develop or identify new therapeutic agents.
C1 [Molinares, Diana; Kurtevski, Sara; Zhu, Yingrong] Univ Miami, Miller Sch Med, Dept Phys Med & Rehabil, 1611 NW 12th Ave, Miami, FL 33136 USA.
C3 University of Miami
RP Molinares, D (corresponding author), Univ Miami, Miller Sch Med, Dept Phys Med & Rehabil, 1611 NW 12th Ave, Miami, FL 33136 USA.
EM dmolinares@med.miami.edu
CR Anand P, 2011, BRIT J ANAESTH, V107, P490, DOI 10.1093/bja/aer260
   Anand P, 2019, J PAIN RES, V12, P2039, DOI 10.2147/JPR.S213912
   Argyriou AA, 2014, CANCER MANAG RES, V6, P135, DOI 10.2147/CMAR.S44261
   Bailey AG, 2021, J ONCOL PHARM PRACT, V27, P156, DOI 10.1177/1078155220959431
   Burgess J, 2021, ONCOL THER, V9, P385, DOI 10.1007/s40487-021-00168-y
   Cascinu S, 2002, J CLIN ONCOL, V20, P3478, DOI 10.1200/JCO.2002.07.061
   CASCINU S, 1995, J CLIN ONCOL, V13, P26, DOI 10.1200/JCO.1995.13.1.26
   Chow R, 2023, BMJ SUPPORT PALLIAT, V13, P27, DOI 10.1136/spcare-2022-003815
   DSouza RS, 2022, BIOMEDICINES, V10, P0, DOI 10.3390/biomedicines10081909
   De Andrade DC, 2017, ONCOLOGIST, V22, P1154, DOI 10.1634/theoncologist.2017-0235
   Dimitrova A, 2017, J ALTERN COMPLEM MED, V23, P164, DOI 10.1089/acm.2016.0155
   Durand JP, 2012, ANN ONCOL, V23, P200, DOI 10.1093/annonc/mdr045
   Ege E, 2023, PAIN PRACT, V23, P793, DOI 10.1111/papr.13259
   Ernst Edzard, 2010, J PAIN SYMPTOM MANAGE, V40, Pe3, DOI 10.1016/j.jpainsymman.2010.03.010
   Gee NS, 1996, J BIOL CHEM, V271, P5768, DOI 10.1074/jbc.271.10.5768
   Gewandter JS, 2019, SUPPORT CARE CANCER, V27, P1765, DOI 10.1007/s00520-018-4424-6
   Gewandter JS, 2014, SUPPORT CARE CANCER, V22, P1807, DOI 10.1007/s00520-014-2158-7
   Greenlee H, 2016, BREAST CANCER RES TR, V156, P453, DOI 10.1007/s10549-016-3759-2
   Hamity MV, 2017, PAIN, V158, P962, DOI 10.1097/j.pain.0000000000000862
   Hammack JE, 2002, PAIN, V98, P195, DOI 10.1016/S0304-3959(02)00047-7
   Han XY, 2017, BMC CANCER, V17, P0, DOI 10.1186/s12885-016-3037-z
   Huang CC, 2021, J CLIN MED, V10, P0, DOI 10.3390/jcm10163694
   Izgu N, 2019, EUR J ONCOL NURS, V40, P36, DOI 10.1016/j.ejon.2019.03.002
   Izycki D, 2016, GINEKOL POL, V87, P516, DOI 10.5603/GP.2016.0036
   Jongen JLM, 2015, J NEURO-ONCOL, V121, P229, DOI 10.1007/s11060-014-1632-x
   Kautio AL, 2008, J PAIN SYMPTOM MANAG, V35, P31, DOI 10.1016/j.jpainsymman.2007.02.043
   Kautio AL, 2009, ANTICANCER RES, V29, P2601
   Kerckhove N, 2017, FRONT PHARMACOL, V8, P0, DOI 10.3389/fphar.2017.00086
   Kurt S, 2018, EUR J ONCOL NURS, V32, P12, DOI 10.1016/j.ejon.2017.11.001
   Leal AD, 2014, CANCER-AM CANCER SOC, V120, P1890, DOI 10.1002/cncr.28654
   Li T, 2021, NEUROL SCI, V42, P4109, DOI 10.1007/s10072-021-05576-6
   Loprinzi C, 2020, SUPPORT CARE CANCER, V28, P1183, DOI 10.1007/s00520-019-04881-3
   Loprinzi CL, 2020, J CLIN ONCOL, V38, P0, DOI 10.1200/JCO.20.01399
   Lu WD, 2020, ONCOLOGIST, V25, P310, DOI 10.1634/theoncologist.2019-0489
   Lu WD, 2010, CURR TREAT OPTION ON, V11, P141, DOI 10.1007/s11864-010-0126-0
   Lynch ME, 2014, J PAIN SYMPTOM MANAG, V47, P166, DOI 10.1016/j.jpainsymman.2013.02.018
   Lynch ME, 2005, J PAIN, V6, P644, DOI 10.1016/j.jpain.2005.04.008
   Madsen ML, 2019, CANCER CHEMOTH PHARM, V84, P471, DOI 10.1007/s00280-019-03884-5
   Moore RA, 2015, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD008242.pub3
   Rahn EJ, 2009, NEUROTHERAPEUTICS, V6, P713, DOI 10.1016/j.nurt.2009.08.002
   Rao RD, 2007, CANCER-AM CANCER SOC, V110, P2110, DOI 10.1002/cncr.23008
   Rodrigues-Amorim D, 2020, FRONT PSYCHIATRY, V11, P0, DOI 10.3389/fpsyt.2020.554899
   Rostock M, 2013, EVID-BASED COMPL ALT, V2013, P0, DOI 10.1155/2013/349653
   Saarto T, 2010, J NEUROL NEUROSUR PS, V81, P1372, DOI 10.1136/jnnp.2008.144964
   Saif MW, 2010, ANTICANCER RES, V30, P2927
   Salat K, 2020, PHARMACOL REP, V72, P508, DOI 10.1007/s43440-020-00106-1
   Schloss JM, 2015, SUPPORT CARE CANCER, V23, P1843, DOI 10.1007/s00520-015-2725-6
   Smith EML, 2013, JAMA-J AM MED ASSOC, V309, P1359, DOI 10.1001/jama.2013.2813
   Smith TJ, 2020, J PALLIAT CARE, V35, P53, DOI 10.1177/0825859719827589
   Smith T, 2007, VASC HEALTH RISK MAN, V3, P833
   Solomon LR, 2016, SUPPORT CARE CANCER, V24, P3489, DOI 10.1007/s00520-016-3175-5
   Staff NP, 2019, J PERIPHER NERV SYST, V24, PS26, DOI 10.1111/jns.12335
   Staff NP, 2017, ANN NEUROL, V81, P772, DOI 10.1002/ana.24951
   Timmins HC, 2020, SUPPORT CARE CANCER, V28, P4459, DOI 10.1007/s00520-020-05299-y
   Timmins HC, 2020, CLIN NEUROPHYSIOL, V131, P1979, DOI 10.1016/j.clinph.2020.02.028
   Tofthagen CS, 2020, CURR ONCOL REP, V22, P0, DOI 10.1007/s11912-020-00903-0
   van Haren F, 2022, CANCER REP-US, V5, P0, DOI 10.1002/cnr2.1577
   WIERNIK PH, 1992, CANCER INVEST, V10, P1, DOI 10.3109/07357909209032783
   Wiffen Philip J, 2017, COCHRANE DATABASE SYST REV, V6, PCD007938, DOI 10.1002/14651858.CD007938.pub4
   Zajaczkowska R, 2019, INT J MOL SCI, V20, P0, DOI 10.3390/ijms20061451
   Zhang SM, 2021, SEMIN ONCOL, V48, P193, DOI 10.1053/j.seminoncol.2021.09.004
   Zimmerman C, 2016, SUPPORT CARE CANCER, V24, P1071, DOI 10.1007/s00520-015-2876-5
NR 62
TC 10
Z9 13
U1 1
U2 17
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 1523-3790
EI 1534-6269
J9 CURR ONCOL REP
JI Curr. Oncol. Rep.
PD NOV 15
PY 2023
VL 25
IS 11
BP 1227
EP 1235
DI 10.1007/s11912-023-01449-7
EA SEP 2023
PG 9
WC Oncology
SC Oncology
GA X2QC8
UT WOS:001094589900001
PM 37702983
DA 2026-01-16
ER

PT J
AU Chin, Y
   Pan, XF
   Wang, B
   Zhao, MD
   Ai, YK
   Zhao, TY
AF Chin, Yenlie
   Pan, Xingfang
   Wang, Bin
   Zhao, Meidan
   Ai, Yanke
   Zhao, Tianyi
TI Network meta-analysis for comparative effectiveness and safety of acupuncture on chemotherapy-induced peripheral neuropathy: A protocol and Bayesian network meta-analysis
SO EUROPEAN JOURNAL OF INTEGRATIVE MEDICINE
LA English
DT Article
DE Acupuncture; Chemotherapy induced-peripheral neuropathy; Systematic review; Bayesian network meta-analysis
ID breast-cancer; systematic reviews; management; pain; prevention; survivors; quality; trial
AB Introduction: Chemotherapy-induced peripheral neuropathy (CIPN) reduces the quality-of-life, affects recovery, and increases the risk of chemotherapeutic failure. Acupuncture may be effective in treating CIPN. This study aims to evaluate the effectiveness and safety of different types of acupuncture through a systematic review and network meta-analysis. The objective of this study is to indicate the relative efficacy and safety among various types of acupuncture for CIPN via a network meta-analysis (NMA) and systematic review.Methods: Six electronic databases, namely Excerpta Medica Database [Embase], PubMed, Cochrane Central Register of Controlled Trials, Web of Science, China National Knowledge Infrastructure, and Wanfang Med Online, will be searched for publications from 2010 to 2022. All relevant randomized controlled trials (RCTs) meeting the eligibility criteria will be included. The primary outcome is the brief pain inventory score, including brief pain inventory-short form, and autonomic nerve symptoms. Secondary outcomes include the quality-of-life assessment of anxiety, depression, and sleep of people with CIPN and adverse events. Reviewers will conduct processes for study selection, data extraction, and risk-of-bias assessment. Stata version 15.0 will be used to perform pairwise and Bayesian network NMA. Each included study will be assessed for bias using the revised Cochrane risk-of-bias tool for randomized trials. A funnel plot will show publication bias.Discussion: We will assess the benefits and drawbacks of various acupuncture-related therapies, rank the efficacy of various acupuncture-related therapies for treating CIPN, and describe the best approaches or combinations of acupuncture interventions based on available data.Conclusion: This study will contribute to data on the safety and efficacy of acupuncture-related therapies for treating CIPN and will help clinicians better select acupuncture treatment types to deal with the different clinical problems of CIPN.Ethics and dissemination: There is no need for ethics approval for this systematic review and meta-analysis. The results will be published in a peer-reviewed journal.PROSPERO registration number: CRD42020198388
C1 [Chin, Yenlie; Wang, Bin] Tianjin Med Univ Canc Inst & Hosp, Natl Clin Res Ctr Canc, Tianjins Clin Res Ctr Canc, Key Lab Canc Prevent & Therapy, Tianjin 300181, Peoples R China.
   [Pan, Xingfang; Zhao, Meidan; Zhao, Tianyi] Tianjin Univ Tradit Chinese Med, Res Ctr Expt Acupuncture Sci, Tianjin 301617, Peoples R China.
   [Ai, Yanke] China Acad Chinese Med Sci, Inst Basic Res Clin Med, Beijing 100700, Peoples R China.
   [Zhao, Tianyi] Tianjin Univ Tradit Chinese Med, Sch Tradit Chinese Med, Tianjin 301617, Peoples R China.
C3 Tianjin Medical University; Tianjin University of Traditional Chinese Medicine; China Academy of Chinese Medical Sciences; Institute of Basic Research In Clinical Medicine, CACMS; Tianjin University of Traditional Chinese Medicine
RP Zhao, TY (corresponding author), Tianjin Univ Tradit Chinese Med, Res Ctr Expt Acupuncture Sci, Tianjin 301617, Peoples R China.; Ai, YK (corresponding author), China Acad Chinese Med Sci, Inst Basic Res Clin Med, Beijing 100700, Peoples R China.; Zhao, TY (corresponding author), Tianjin Univ Tradit Chinese Med, Sch Tradit Chinese Med, Tianjin 301617, Peoples R China.
EM aiyanke@163.com; zhaotianyi89@126.com
FU Scientific and technological innovation project of China Academy of Chinese Medical Sciences [CI2021B003]; Certification Center for Chinese Medicine Practitioners of State Administration of Traditional Chinese Medicine [TB2022003]
CR Bao T, 2018, EUR J CANCER, V101, P12, DOI 10.1016/j.ejca.2018.06.008
   Baviera AF, 2019, REV LAT-AM ENFERM, V27, P0, DOI 10.1590/1518-8345.2959.3126
   Ben-Arye E, 2022, CANCER-AM CANCER SOC, V128, P3641, DOI 10.1002/cncr.34422
   Bhatnagar B, 2014, SPRINGERPLUS, V3, P0, DOI 10.1186/2193-1801-3-366
   Chiavaroli L, 2018, BMJ OPEN, V8, P0, DOI 10.1136/bmjopen-2017-019438
   Chien TJ, 2019, INTEGR CANCER THER, V18, P0, DOI 10.1177/1534735419886662
   Dias S, 2018, NETWORK META ANAL DE, V0, P0
   Feng R, 2015, DIAGN PATHOL, V10, P0, DOI 10.1186/s13000-015-0382-1
   Fino PC, 2019, GAIT POSTURE, V69, P136, DOI 10.1016/j.gaitpost.2019.01.025
   Franconi G, 2013, EVID-BASED COMPL ALT, V2013, P0, DOI 10.1155/2013/516916
   Gelman A, 1992, STAT SCI, V7, P457, DOI 10.1214/SS/1177011136
   Greenlee H, 2016, BREAST CANCER RES TR, V156, P453, DOI 10.1007/s10549-016-3759-2
   Hausheer FH, 2006, SEMIN ONCOL, V33, P15, DOI 10.1053/j.seminoncol.2005.12.010
   Ho RST, 2017, SCI REP-UK, V7, P0, DOI 10.1038/s41598-017-09856-0
   Hutton B, 2015, ANN INTERN MED, V162, P777, DOI 10.7326/M14-2385
   Hwang MS, 2020, MEDICINE, V99, P0, DOI 10.1097/MD.0000000000019837
   Iravani S, 2020, PAIN RES MANAG, V2020, P0, DOI 10.1155/2020/2504674
   Jin YX, 2020, EVID-BASED COMPL ALT, V2020, P0, DOI 10.1155/2020/8875433
   Kachrani R, 2020, J PAIN PALLIAT CARE, V34, P141, DOI 10.1080/15360288.2020.1734144
   Li QY, 2022, FRONT PHARMACOL, V13, P0, DOI 10.3389/fphar.2022.764473
   Li XX, 2017, PAIN PHYSICIAN, V20, P0
   Loprinzi CL, 2000, LANCET, V356, P2059, DOI 10.1016/S0140-6736(00)03403-6
   Mao JJ, 2022, J CLIN ONCOL, V40, P3998, DOI 10.1200/JCO.22.01357
   Moher D, 2009, J CLIN EPIDEMIOL, V62, P1006, DOI 10.1016/j.jclinepi.2009.06.005
   Molassiotis A, 2019, INTEGR CANCER THER, V18, P0, DOI 10.1177/1534735419836501
   Pachman DR, 2011, CLIN PHARMACOL THER, V90, P377, DOI 10.1038/clpt.2011.115
   Pachman DR, 2014, SUPPORT CARE CANCER, V22, P2281, DOI 10.1007/s00520-014-2289-x
   Pike Crystal T, 2012, CHEMOTHER RES PRACT, V2012, P913848, DOI 10.1155/2012/913848
   Postma TJ, 2000, ANN ONCOL, V11, P509, DOI 10.1023/A:1008345613594
   Rosenberger KJ, 2021, BMC MED RES METHODOL, V21, P0, DOI 10.1186/s12874-021-01397-5
   Salanti G, 2014, PLOS ONE, V9, P0, DOI 10.1371/journal.pone.0099682
   Schünemann HJ, 2008, BMJ-BRIT MED J, V336, P1106, DOI 10.1136/bmj.39500.677199.AE
   Seretny M, 2014, PAIN, V155, P2461, DOI 10.1016/j.pain.2014.09.020
   Smith EML, 2013, JAMA-J AM MED ASSOC, V309, P1359, DOI 10.1001/jama.2013.2813
   Tender T, 2021, MED ONCOL, V38, P0, DOI 10.1007/s12032-021-01496-9
   Tomlinson A, 2019, EVID-BASED MENT HEAL, V22, P61, DOI 10.1136/ebmental-2019-300087
   Veroniki AA, 2013, INT J EPIDEMIOL, V42, P332, DOI 10.1093/ije/dys222
   Wan RH, 2022, FRONT IMMUNOL, V13, P0, DOI 10.3389/fimmu.2022.829409
   Winters-Stone KM, 2016, J CLIN ONCOL, V34, P0, DOI 10.1200/jco.2016.34.3_suppl.130
   Wong R, 2016, INTEGR CANCER THER, V15, P153, DOI 10.1177/1534735415627926
   Wu XM, 2022, BMJ OPEN, V12, P0, DOI 10.1136/bmjopen-2021-049778
   Xu ZH, 2022, FRONT NEUROL, V13, P0, DOI 10.3389/fneur.2022.963358
   Zanville NR, 2016, SUPPORT CARE CANCER, V24, P4779, DOI 10.1007/s00520-016-3329-5
NR 43
TC 1
Z9 1
U1 4
U2 20
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1876-3820
EI 1876-3839
J9 EUR J INTEGR MED
JI Eur. J. Integr. Med.
PD AUG 15
PY 2023
VL 61
IS 
BP 
EP 
DI 10.1016/j.eujim.2023.102261
EA JUN 2023
PG 6
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA N1OZ6
UT WOS:001034803000001
DA 2026-01-16
ER

PT J
AU Shen, LY
   Fu, XF
   Zeng, Q
   Mao, XW
   Hong, QY
   Liu, XJ
   Li, HQ
   Hu, H
AF Shen, Ling-Yu
   Fu, Xiao-Fei
   Zeng, Qin
   Mao, Xue-Wen
   Hong, Qiu-Yang
   Liu, Xiao-Jing
   Li, Huan-Qin
   Hu, Hui
TI Comparison of the efficacy of different frequency electroacupuncture in the
SO Zhen ci yan jiu = Acupuncture research
LA chi
DT Journal Article
DE Electroacupuncture; Frequency; Polycystic ovary syndrome; Randomized controlled trial
AB OBJECTIVES: To compare the effects of 2 Hz continuous wave and 2 Hz/100 Hz  dilatational wave setting in electroacupuncture(EA) on ovulation frequency,  hormone levels, body fat parameters, quality of life and depression-anxiety level  in polycystic ovary syndrome (PCOS) patients with abdominal obesity. METHODS:  PCOS patients with abdominal obesity were randomly divided into low-frequency  group (n=29) and dilatational wave group (n=29). Patients in both groups were  treated with "Tongtiaodaimai" (regulating Dai Meridian) acupuncture therapy, and  EA was applied to bilateral Daimai (GB26), Tianshu (ST25), Shenshu (BL23) and  Ciliao (BL32). The low-frequency group received EA using a continuous wave at a  frequency of 2 Hz, while the dilatational wave group received dilatational wave  at a frequency of 2 Hz/100 Hz. Both groups received treatment for 30 min each  time, 3 times per week for 12 consecutive weeks. Ovulation frequency was  calculated according to the ovulation cycle. The contents of serum anti-Mullerian  hormone (AMH) and sex hormone binding globulin (SHBG) were detected with  electrochemiluminescence method. Body weight (BW) and waist circumference (WC)  were measured, and body mass index (BMI) and waist-height ratio (WHtR) were  calculated. PCOS questionnaire (Chi-PCOSQ), self-rating anxiety scale (SAS) and  self-rating depression scale (SDS) were evaluated. RESULTS: Compared with before  treatment, both the low-frequency group and the dilatational wave group showed an  increase in ovulation frequency (P<0.01, P<0.05), and a decrease in BW, BMI, WC,  WHtR, and SDS score (P<0.01, P<0.05)；the dilatational wave group showed decreased  serum AMH contents (P<0.05) and increased serum SHBG contents (P<0.05), the  scores related to acne, fatigue, and dysmenorrhea in the Chi-PCOSQ increased  (P<0.01, P<0.05). Compared with the low-frequency group, the dilatational wave  group showed a reduction (P<0.05) in WC after treatment. CONCLUSIONS: 2 Hz/100 Hz  dilatational wave EA is equally effective as 2 Hz low-frequency EA in improving  ovulation frequency. In terms of reducing WC in abdominal obesity type PCOS  patients, 2 Hz/100 Hz dilatational wave EA is superior to 2 Hz low-frequency EA.  2 Hz/100 Hz dilatational wave EA can decrease serum AMH, increase serum SHBG, and  improve symptoms of acne, fatigue, and dysmenorrhea.
C1 Department of Acupuncture and Moxibustion, Beijing Shunyi Hospital of Traditional Chinese Medicine, Beijing 101300, China. 1017152977@qq.com.
   Department of Acupuncture and Moxibustion, Guangdong Provincial Hospital of TCM, Guangzhou 510120.
   Department of Acupuncture and Moxibustion, Beijing Shunyi Hospital of Traditional Chinese Medicine, Beijing 101300, China.
   Department of Acupuncture and Moxibustion, Beijing Shunyi Hospital of Traditional Chinese Medicine, Beijing 101300, China.
   Department of Acupuncture and Moxibustion, Beijing Shunyi Hospital of Traditional Chinese Medicine, Beijing 101300, China.
   Department of Acupuncture and Moxibustion, Beijing Shunyi Hospital of Traditional Chinese Medicine, Beijing 101300, China.
   Acupuncture Center, Beijing Hospital of Traditional Chinese Medicine Affiliated to Capital Medical University, Beijing 100010. carland95@126.com.
   Department of Acupuncture and Moxibustion, Dongfang Hospital Affiliated to Beijing University of Chinese Medicine, Beijing 100078. dfzhenjiu@126.com.
NR 0
TC 0
SN 
EI 1000-060
J9 Zhen Ci Yan Jiu
PD DEC 26
PY 2023
VL 48
IS 12
BP 1266
EP 1273
DI 10.13702/j.1000-0607.20230575
PG 7
WC Female; Humans; Electroacupuncture; Obesity, Abdominal; therapy; Quality of Life; Polycystic Ovary Syndrome; therapy; Dysmenorrhea; Acupuncture Points; Obesity; therapy; Acne Vulgaris
UT PubMed:38146250
PM 38146250
DA 2023-12-26
ER

PT J
AU Chen, H
   Wu, WY
   Xie, ZM
   Yang, Z
   Yang, B
   Tang, DX
AF Chen, Hui
   Wu, Wen-Yu
   Xie, Zhen-Ming
   Yang, Zhu
   Yang, Bing
   Tang, Dong-Xin
TI [Miao medicinal crossbow acupuncture therapy as adjuvant treatment for lung
SO Zhongguo zhen jiu = Chinese acupuncture & moxibustion
LA chi
DT Journal Article
DE Miao medicinal crossbow acupuncture therapy; adverse reactions of medication; lung cancer; oxycodone hydrochloride extended-release tablet; pain
AB OBJECTIVE: To observe the clinical efficacy of Miao medicinal crossbow  acupuncture therapy as adjuvant treatment for lung cancer pain based on oxycodone  hydrochloride extended-release tablet. METHODS: A total of 60 patients with lung  cancer pain were randomized into an observation group (30 cases, 1 case dropped  off) and a control group (30 cases). In the control group, oxycodone  hydrochloride extended-release tablet was given orally, 10 mg a time, once every  12 hours. On the basis of the treatment in the control group, Miao medicinal  crossbow acupuncture therapy was applied once every other day in the observation  group. The treatment of 14 days was required in the two groups. Before and after  treatment, the numerical rating scale (NRS) score, number of break-out pain and  Karnofsky performance status (KPS) score were observed in the two groups. The  equivalent oxycodone consumption and rate of adverse reactions were recorded, the  analgesic effect was evaluated in the two groups. RESULTS: Compared before  treatment, the NRS scores and number of break-out pain were decreased while the  KPS scores were increased after treatment in the two groups (P<0.01). After  treatment, the NRS score and number of break-out pain in the observation group  were lower than the control group (P<0.01), the KPS score in the observation  group was higher than the control group (P<0.05). The equivalent oxycodone  consumption of whole course and the rate of adverse reactions i.e. constipation,  drowsiness, nausea and vomiting in the observation group were lower than the  control group (P<0.05). The analgesic effect rate was 93.1% (27/29) in the  observation group, which was superior to 63.3% (19/30) in the control group  (P<0.05). CONCLUSION: On the basis of oxycodone hydrochloride extended-release  tablet, Miao medicinal crossbow acupuncture therapy as adjuvant treatment can  effectively relieve the pain degree, reduce the number of break-out pain and  improve the health status and quality of life in patients with lung cancer pain,  enhance the efficacy of medication and reduce its adverse reactions.
C1 First Clinical Medical College of Guizhou University of TCM, Guiyang 550002, China.
   Department of Oncology, First Affiliated Hospital of Guizhou University of TCM, Guiyang 550001.
   Department of Oncology, First Affiliated Hospital of Guizhou University of TCM, Guiyang 550001.
   First Clinical Medical College of Guizhou University of TCM, Guiyang 550002, China.
   First Clinical Medical College of Guizhou University of TCM, Guiyang 550002, China.
   Department of Oncology, First Affiliated Hospital of Guizhou University of TCM, Guiyang 550001.
NR 0
TC 0
SN 
EI 0255-293
J9 Zhongguo Zhen Jiu
PD MAR 2
PY 2023
VL 43
IS 3
BP 322
EP 6
DI 10.13703/j.0255-2930.20220816-k0001
PG -316
WC Humans; Cancer Pain; Oxycodone; Quality of Life; Lung Neoplasms; Pain; Acupuncture Therapy; Adjuvants, Immunologic; Lung; Analgesics
UT PubMed:36858396
PM 36858396
DA 2023-03-02
ER

PT J
AU Li, ZH
   Zhao, XD
   Ming, SR
   Li, X
   Hu, JW
   Chen, YL
AF Li, Zhi-Hao
   Zhao, Xue-Dan
   Ming, Shu-Ren
   Li, Xu
   Hu, Jun-Wei
   Chen, Yue-Lai
TI [Effect of electroacupuncture on the morphology of prostate and degranulation of
SO Zhen ci yan jiu = Acupuncture research
LA chi
DT Journal Article
DE Chronic nonbacterial prostatitis; Collagen fiber; Electroacupuncture; Mast cell; Prostate
AB OBJECTIVE: To observe the effect of electroacupuncture (EA) on the morphology of  prostate and degranulation of mast cells in prostate of rats with chronic  nonbacterial prostatitis (CNP). METHODS: Male SD rats were randomly divided into  sham operation group, model group and EA group, with 8 rats in each group. CNP  model was established by surgical castration combined with 17-β estradiol  injection once daily for 30 days. EA was applied to "Zhongji" (CV3), "Guanyuan"  (CV4) and bilateral "Dahe" (KI12) for 20 min, once daily for 8 days. The  mechanical pain threshold of scrotum skin area was tested before modeling, after  modeling and after intervention. The pathological morphology of the prostate was  observed by HE staining. Collagenous fiber was observed by Masson staining. The  infiltration of mast cells was observed by toluidine blue staining. The contents  of interleukin 6 (IL-6) and tumor necrosis factor α (TNF-α) in prostate were  determined by ELISA. The protein expression levels of tryptase and transforming  growth factor β1 (TGF-β1) in prostate were detected by Western blot. RESULTS: A  normal appearance with little inflammatory cell infiltration was observed in the  prostate of the sham operation group. Gland atrophy, epithelial destruction,  hyperemia and edema, diffuse inflammatory cell infiltration and visible collagen  fiber deposition were observed in prostate of the model group. The degree of  infiltration of inflammatory cells and collagen fiber deposition were reduced in  the EA group. Compared with the sham operation group, mechanical pain threshold  was decreased (P<0.01), while the collagen volu-me fraction (CVF) of prostate,  the degranulated rate of mast cells, the protein expression levels of tryptase  and TGF-β1, and the contents of IL-6 and TNF-α were increased (P<0.01) in the  model group. Following EA intervention, compared with the model group, the  mechanical pain threshold was increased (P<0.01), CVF of the prostate, the  degranulated rate of mast cells, the protein expression levels of tryptase and  TGF-β1, and the contents of IL-6 and TNF-α were decreased (P<0.05, P<0.01) in the  EA group. CONCLUSION: EA can relieve pain and reduce inflammation and fibrosis of  prostate in CNP rats, which may be related to inhibiting the degranulation of  prostate mast cells and down-regulating the expression of inflammatory factors  and TGF-β1.
C1 Department of Acupuncture-Moxibustion, Tuina and Traumatology, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiaotong University School of Medicine,Shanghai 200233, China.
   Department of Acupuncture and Moxibustion, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200032.
   Department of Acupuncture and Moxibustion, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of TraditionalChinese Medicine, Shanghai 200437.
   Department of Acupuncture and Moxibustion, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200032.
   Department of Acupuncture and Moxibustion, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200032.
   Department of Acupuncture and Moxibustion, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200032.
NR 0
TC 0
SN 
EI 1000-060
J9 Zhen Ci Yan Jiu
PD FEB 4
PY 2023
VL 48
IS 1
BP 56
EP 62
DI 10.13702/j.1000-0607.20211148
PG 6
WC Animals; Male; Rats; Electroacupuncture; Interleukin-6; genetics; Mast Cells; metabolism; Pain; Prostate; metabolism; Prostatitis; genetics; Rats, Sprague-Dawley; Transforming Growth Factor beta1; genetics; Tryptases; Tumor Necrosis Factor-alpha; genetics
UT PubMed:36734499
PM 36734499
DA 2023-02-04
ER

PT J
AU Lagerstedt, K
   Efverman, A
AF Lagerstedt, Kristina
   Efverman, Anna
TI A Randomized Sham-Controlled Mixed Methods Pilot Study of the Feasibility of Acupuncture for Chemotherapy-Induced Neuropathy: Lessons Learned From Patient Experiences in Integrative Cancer Care
SO INTEGRATIVE CANCER THERAPIES
LA English
DT Article
DE acupuncture; pain; neurotoxicity; neuropathy; complementary and alternative therapies; integrative oncology; nursing; physiotherapy; cancer rehabilitation
ID induced peripheral neuropathy; quality-of-life; oxaliplatin; pain; neurotoxicity; disability; cohort; women
AB ObjectiveSince there is a lack of effective pharmacological therapies for chemotherapy-induced neuropathy and many patients ask for integrative cancer therapies such as acupuncture, the objective of this pilot study was to describe patients' experiences, and to study the feasibility and short-term effects of genuine acupuncture for chemotherapy-induced neuropathic pain and unpleasant sensations compared to sham acupuncture. Methods:The pilot study used mixed methods, collecting quantitative and qualitative data. Patients (n = 12) with chemotherapy-induced neuropathy after colorectal cancer were blindly randomized to genuine acupuncture or telescopic sham acupuncture. Individual interviews were conducted, and were analyzed using qualitative content analysis. The patients registered pain and unpleasant sensations (100 mm Visual Analog Scales) before and after n = 120 sessions, n = 60 genuine and n = 60 sham acupuncture sessions. Results:Five categories of patient experiences were described. The neuropathy negatively affected life. Physical activity was perceived to be important for health, but neuropathy was a barrier. The neuropathy required symptom-managing strategies. Acupuncture was pleasant and valuable, but some patients presented doubts regarding its effect mechanisms. After the genuine acupuncture sessions, pain (mean -2.0 steps relief during each session) and unpleasant sensations (-2.4) in the face was reduced more than after sham acupuncture (+0.1 steps worse pain, P = .018, +0.1 steps worse unpleasant sensations, P = .036). After genuine acupuncture, unpleasant sensations in the hands were reduced less (-0.23) compared to after sham acupuncture (-5.5, P = .002). Pain or unpleasant sensations in the feet did not change. Conclusions:Patients experienced that the neuropathy negatively changed their life and that acupuncture was pleasant and valuable. Patients receiving genuine acupuncture had short-term effects regarding pain and unpleasant sensations in the face compared to patients receiving sham acupuncture, while hands and feet did not improve. The patients were successfully blinded and complied with the acupuncture. We welcome future full-scaled randomized sham-controlled acupuncture studies.
C1 [Lagerstedt, Kristina] Reg Kronoberg, Vaxjo, Sweden.
   [Efverman, Anna] Univ Gavle, Gavle, Sweden.
   [Efverman, Anna] Univ Gavle, Fac Hlth & Occupat Studies, Dept Caring Sci, S-80176 Gavle, Sweden.
C3 University of Gavle; University of Gavle
RP Efverman, A (corresponding author), Univ Gavle, Fac Hlth & Occupat Studies, Dept Caring Sci, S-80176 Gavle, Sweden.
EM anna.efverman@hig.se
CR Bai LJ, 2013, EVID-BASED COMPL ALT, V2013, P0, DOI 10.1155/2013/812568
   Battaglini E, 2021, J NATL COMPR CANC NE, V19, P821, DOI 10.6004/jnccn.2021.7026
   Burström K, 2001, QUAL LIFE RES, V10, P621, DOI 10.1023/A:1013171831202
   Carlsson Christer, 2002, ACUPUNCT MED, V20, P82
   Carozzi VA, 2015, NEUROSCI LETT, V596, P90, DOI 10.1016/j.neulet.2014.10.014
   Chae Y, 2017, ACUPUNCT MED, V35, P148, DOI 10.1136/acupmed-2016-011178
   Cormier S, 2016, PAIN, V157, P329, DOI 10.1097/j.pain.0000000000000379
   DAlessandro EG, 2022, BMJ SUPPORT PALLIAT, V12, P64, DOI 10.1136/bmjspcare-2018-001542
   de Boer AGEM, 2023, BRIT MED BULL, V145, P60, DOI 10.1093/bmb/ldac028
   Dworkin JD, 2016, J CLIN EPIDEMIOL, V72, P56, DOI 10.1016/j.jclinepi.2015.10.019
   Efverman A, 2022, INTEGR CANCER THER, V0, P0
   Friedemann T, 2022, PHYTOMEDICINE, V104, P0, DOI 10.1016/j.phymed.2022.154294
   Greenlee H, 2016, BREAST CANCER RES TR, V156, P453, DOI 10.1007/s10549-016-3759-2
   Gustafsson E, 2016, SUPPORT CARE CANCER, V24, P747, DOI 10.1007/s00520-015-2838-y
   Han XY, 2017, BMC CANCER, V17, P0, DOI 10.1186/s12885-016-3037-z
   Hjermstad MJ, 2011, J PAIN SYMPTOM MANAG, V41, P1073, DOI 10.1016/j.jpainsymman.2010.08.016
   Ho RST, 2022, INTEGR MED RES, V11, P0, DOI 10.1016/j.imr.2021.100771
   Kelley JM, 2014, PLOS ONE, V9, P0, DOI 10.1371/journal.pone.0094207
   Leonard GD, 2005, BMC CANCER, V5, P0, DOI 10.1186/1471-2407-5-116
   Liu JL, 2022, ACUPUNCT MED, V40, P524, DOI 10.1177/09645284221117848
   Lund Irene, 2005, BMC MED RES METHODOL, V5, P31, DOI 10.1186/1471-2288-5-31
   Ma JC, 2018, CANCER-AM CANCER SOC, V124, P2289, DOI 10.1002/cncr.31248
   MacPherson Hugh, 2010, J EVID BASED MED, V3, P140, DOI 10.1111/j.1756-5391.2010.01086.x
   Mao JJ, 2022, CA-CANCER J CLIN, V72, P144, DOI 10.3322/caac.21706
   McCrary JM, 2019, J NATL COMPR CANC NE, V17, P949, DOI 10.6004/jnccn.2019.7290
   Mendell JR, 2003, NEW ENGL J MED, V348, P1243, DOI 10.1056/NEJMcp022282
   Miaskowski C, 2018, J CANCER SURVIV, V12, P234, DOI 10.1007/s11764-017-0662-8
   Molassiotis A, 2019, INTEGR CANCER THER, V18, P0, DOI 10.1177/1534735419836501
   Mols F, 2013, J CLIN ONCOL, V31, P2699, DOI 10.1200/JCO.2013.49.1514
   OCathain A, 2010, BMJ-BRIT MED J, V341, P0, DOI 10.1136/bmj.c4587
   Padman S, 2015, SUPPORT CARE CANCER, V23, P861, DOI 10.1007/s00520-014-2423-9
   Park J, 1999, ACUPUNCT MED, V17, P110
   Paterson Charlotte, 2007, JOURNAL OF HEALTH SERVICES RESEARCH POLICY, V12, P39, DOI 10.1258/135581907780318356
   Pulvers JN, 2017, ASIA-PAC J CLIN ONCO, V13, P345, DOI 10.1111/ajco.12694
   Rabin R, 2001, ANN MED, V33, P337, DOI 10.3109/07853890109002087
   Raphael MJ, 2017, CLIN COLORECTAL CANC, V16, P397, DOI 10.1016/j.clcc.2017.03.013
   Rossi E, 2015, SUPPORT CARE CANCER, V23, P1795, DOI 10.1007/s00520-014-2517-4
   Ryan F, 2009, INT J THER REHABIL, V16, P309, DOI 10.12968/ijtr.2009.16.6.42433
   SHELLEY M, 1984, J AM STAT ASSOC, V79, P240, DOI 10.2307/2288384
   Smith EML, 2013, JAMA-J AM MED ASSOC, V309, P1359, DOI 10.1001/jama.2013.2813
   Takayama S, 2012, EVID-BASED COMPL ALT, V2012, P0, DOI 10.1155/2012/513638
   Tamburin S, 2022, CRIT REV ONCOL HEMAT, V171, P0, DOI 10.1016/j.critrevonc.2021.103575
   Thabane L, 2010, BMC MED RES METHODOL, V10, P0, DOI 10.1186/1471-2288-10-1
   Vatandoust S, 2014, SUPPORT CARE CANCER, V22, P513, DOI 10.1007/s00520-013-2004-3
   Winters-Stone KM, 2017, J CLIN ONCOL, V35, P2604, DOI 10.1200/JCO.2016.71.3552
   Ylva W, 2022, INTEGR CANCER THER, V21, P0, DOI 10.1177/15347354221077277
   Yuan HW, 2013, EVID-BASED COMPL ALT, V2013, P0, DOI 10.1155/2013/639302
   Zhang CS, 2015, PLOS ONE, V10, P0, DOI 10.1371/journal.pone.0140825
NR 48
TC 9
Z9 9
U1 7
U2 23
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1534-7354
EI 1552-695X
J9 INTEGR CANCER THER
JI Integr. Cancer Ther.
PD JUN 15
PY 2023
VL 22
IS 
BP 
EP 
DI 10.1177/15347354231178877
PG 14
WC Oncology; Integrative & Complementary Medicine
SC Oncology; Integrative & Complementary Medicine
GA I6IK0
UT WOS:001003798900001
PM 37294052
DA 2026-01-16
ER

PT J
AU Chen, J
   Fu, TX
   Liu, L
   Xie, YR
   Li, YD
AF Chen, Jiu
   Fu, Tianxiao
   Liu, Li
   Xie, Yirui
   Li, Youdi
TI Effect of acupuncture inclusion in the enhanced recovery after surgery protocol on tumor patient gastrointestinal function: a systematic review and meta-analysis of randomized controlled studies
SO FRONTIERS IN ONCOLOGY
LA English
DT Article
DE acupuncture; tumor; enhanced recovery after surgery; meta-analysis; gastrointestinal function
ID postoperative nausea; organ dysfunction; mechanisms; efficacy; safety
AB Introduction Acupuncture has been shown to be effective in restoring gastrointestinal function in tumor patients receiving the enhanced recovery after surgery (ERAS) protocol. The present systematic review and meta-analysis aimed to evaluate the rationality and efficacy of integrating acupuncture in the ERAS strategy to recuperate gastrointestinal function.Methods We searched eleven databases for relevant randomized clinical trials (RCTs) of acupuncture for the treatment of gastrointestinal dysfunction in tumor patients treated with the ERAS protocol. The quality of each article was assessed using the Cochrane Collaboration risk of bias criteria and the modified Jadad Scale. As individual symptoms, the primary outcomes were time to postoperative oral food intake, time to first flatus, time to first distension and peristaltic sound recovery time (PSRT). Pain control, adverse events, and acupoint names reported in the included studies were also investigated.Results Of the 211 reviewed abstracts, 9 studies (702 patients) met eligibility criteria and were included in the present systematic review and meta-analysis. Compared to control groups, acupuncture groups showed a significant reduction in time to postoperative oral food intake [standardized mean difference (SMD) = -0.77, 95% confidence interval (CI) -1.18 to -0.35], time to first flatus (SMD=-0.81, 95% CI -1.13 to -0.48), time to first defecation (SMD=-0.91, 95% CI -1.41 to -0.41, PSRT (SMD=-0.92, 95% CI -1.93 to 0.08), and pain intensity (SMD=-0.60, 95% CI -0.83 to -0.37).The Zusanli (ST36) and Shangjuxu (ST37) acupoints were used in eight of the nine included studies. Adverse events related to acupuncture were observed in two studies, and only one case of bruising was reported.Discussion The present systematic review and meta-analysis suggested that acupuncture significantly improves recovery of gastrointestinal function and pain control in tumor patients receiving the ERAS protocol compared to the control group. Moreover, ST36 and ST37 were the most frequently used acupoints. Although the safety of acupuncture was poorly described in the included studies, the available data suggested that acupuncture is a safe treatment with only mild side effects. These findings provide evidence-based recommendations for the inclusion of acupuncture in the ERAS protocol for tumor patients.
C1 [Chen, Jiu; Fu, Tianxiao; Li, Youdi] Zhejiang Univ, Affiliated Hosp 1, Sch Med, Dept Tradit Chinese Med, Hangzhou, Peoples R China.
   [Liu, Li] Zhejiang Univ, Affiliated Hosp 1, Sch Med, Dept Lib, Hangzhou, Peoples R China.
   [Xie, Yirui] Natl Clin Res Ctr Infect Dis, Collaborat Innovat Ctr Diag & Treatment Infect Dis, State Key Lab Diag & Treatment Infect Dis, Hangzhou, Peoples R China.
   [Xie, Yirui] Zhejiang Univ, Affiliated Hosp 1, Sch Med, Dept Infect Dis, Hangzhou, Peoples R China.
C3 Zhejiang University; Zhejiang University; Collaborative Innovation Center for Diagnosis & Treatment of Infectious Diseases; Zhejiang University
RP Chen, J (corresponding author), Zhejiang Univ, Affiliated Hosp 1, Sch Med, Dept Tradit Chinese Med, Hangzhou, Peoples R China.
EM chenjiu1982@163.com
FU This study was supported by the Natural Science Foundation of Zhejiang Province (award no:LBY22H270001).; Natural Science Foundation of Zhejiang Province;  [LBY22H270001]
CR Akanlwzy-Xs W, 2022, CHIN J CLIN ES, V35, P1570, DOI 10.13429/j.cnki.cjcr.2022.11.018
   Bik CK, 2016, J TRADIT CHIN MED, V36, P271, DOI 10.1016/S0254-6272(16)30038-3
   Brown ML, 2017, CHILDREN-BASEL, V4, P0, DOI 10.3390/children4060050
   Cai RL, 2018, J INTEGR MED-JIM, V16, P26, DOI 10.1016/j.joim.2017.12.002
   Cheng X, 2022, SEMIN CANCER BIOL, V86, P408, DOI 10.1016/j.semcancer.2022.01.006
   Cho E, 2021, INT J MOL SCI, V22, P0, DOI 10.3390/ijms22168575
   Cologne KG, 2021, SURG CLIN N AM, V101, P995, DOI 10.1016/j.suc.2021.05.026
   Dan Li DL, 2021, DIETETIC HLTH CARE, V37, P131
   De Luca R, 2023, EJSO-EUR J SURG ONC, V49, P542, DOI 10.1016/j.ejso.2022.12.006
   Dunkman WJ, 2018, SURG CLIN N AM, V98, P1171, DOI 10.1016/j.suc.2018.07.005
   Gelman D, 2018, MEDICINA-LITHUANIA, V54, P0, DOI 10.3390/medicina54020020
   Gillis C, 2022, BRIT J ANAESTH, V128, P434, DOI 10.1016/j.bja.2021.12.007
   Goldstein DS, 2021, AUTON NEUROSCI-BASIC, V236, P0, DOI 10.1016/j.autneu.2021.102889
   Guo M, 2022, WORLD J CLIN CASES, V10, P11427, DOI 10.12998/wjcc.v10.i31.11427
   Haas A, 2022, AUTON NEUROSCI-BASIC, V240, P0, DOI 10.1016/j.autneu.2022.102983
   Hedrick TL, 2018, ANESTH ANALG, V126, P1896, DOI 10.1213/ANE.0000000000002742
   Hui KKS, 2005, NEUROIMAGE, V27, P479, DOI 10.1016/j.neuroimage.2005.04.037
   Jindal V, 2008, J PEDIAT HEMATOL ONC, V30, P431, DOI 10.1097/MPH.0b013e318165b2cc
   Khabbazi S, 2019, N-S ARCH PHARMACOL, V392, P123, DOI 10.1007/s00210-019-01613-6
   Khawaja ZH, 2022, CUREUS J MED SCIENCE, V14, P0, DOI 10.7759/cureus.22652
   Kwon CY, 2021, J CLIN MED, V10, P0, DOI 10.3390/jcm10081575
   Lau CSM, 2017, WORLD J SURG, V41, P899, DOI 10.1007/s00268-016-3807-4
   Li DX, 2018, GUANGXI MED J, V40, P872, DOI 10.11675/j.issn.0253-4304.2018.08.02
   Li H, 2015, WORLD J GASTROENTERO, V21, P8304, DOI 10.3748/wjg.v21.i27.8304
   Li NC, 2021, J INFLAMM RES, V14, P7191, DOI 10.2147/JIR.S341581
   Lin JG, 2022, AM J TRANSL RES, V14, P1469
   Liu XY, 2021, CHIN J COLORECTAL DIS, V10, P605, DOI 10.3877/cma.j.issn.2095-3224.2021.06.007
   Lu MJ, 2019, EVID-BASED COMPL ALT, V2019, P0, DOI 10.1155/2019/7457485
   Ma QF, 2022, CURR OPIN NEUROBIOL, V76, P0, DOI 10.1016/j.conb.2022.102602
   Martinez L, 2019, CLIN THER, V41, P2612, DOI 10.1016/j.clinthera.2019.10.002
   Monteiro B, 2019, VET CLIN N AM-SMALL, V49, P993, DOI 10.1016/j.cvsm.2019.07.009
   Navarro-Santana MJ, 2021, ACUPUNCT MED, V39, P405, DOI 10.1177/0964528420967364
   Nimmo SM, 2017, J SURG ONCOL, V116, P583, DOI 10.1002/jso.24814
   Oh JE, 2022, FRONT IMMUNOL, V12, P0, DOI 10.3389/fimmu.2021.813748
   Page MJ, 2021, BMJ-BRIT MED J, V372, P0, DOI 10.1136/bmj.n160
   Prichard D, 2018, DIGEST DIS SCI, V63, P422, DOI 10.1007/s10620-017-4901-7
   Qu ZC, 2022, EVID-BASED COMPL ALT, V2022, P0, DOI 10.1155/2022/7140038
   Rajput K, 2022, CURR PAIN HEADACHE R, V26, P93, DOI 10.1007/s11916-022-01009-x
   Rollins KE, 2021, BEST PRAC RES-CL ANA, V35, P479, DOI 10.1016/j.bpa.2020.10.001
   Roslan F, 2020, J GASTROINTEST SURG, V24, P2643, DOI 10.1007/s11605-019-04507-3
   Schwartz J, 2020, BEST PRAC RES-CL ANA, V34, P687, DOI 10.1016/j.bpa.2020.07.011
   Schwenk W, 2021, CHIRURG, V92, P405, DOI 10.1007/s00104-020-01328-y
   Shi KJ, 2020, MEDICINE, V99, P0, DOI 10.1097/MD.0000000000020452
   Stott A, 2016, INT J NURS STUD, V64, P139, DOI 10.1016/j.ijnurstu.2016.07.004
   Tahir AH, 2021, FRONT NEUROSCI-SWITZ, V15, P0, DOI 10.3389/fnins.2021.696843
   Taurchini Marco, 2018, J VIS SURG, V4, P40, DOI 10.21037/jovs.2018.01.20
   Thiele RH, 2021, ANESTH ANALG, V133, P393, DOI 10.1213/ANE.0000000000005603
   Toro-Pérez J, 2021, REDOX REP, V26, P35, DOI 10.1080/13510002.2021.1891808
   Vickers AJ, 2018, J PAIN, V19, P455, DOI 10.1016/j.jpain.2017.11.005
   Wang L, 2022, PLOS ONE, V17, P0, DOI 10.1371/journal.pone.0263166
   Wei TH, 2020, INT J MOL SCI, V21, P0, DOI 10.3390/ijms21134693
   Wren AA, 2019, CHILDREN-BASEL, V6, P0, DOI 10.3390/children6020033
   Wu WJ, 2023, FRONT ONCOL, V13, P0, DOI 10.3389/fonc.2023.1049294
   [吴晓亮 Wu Xiaoliang], 2020, 中华中医药杂志 CHINA JOURNAL OF TRADITIONAL CHINESE MEDICINE AND PHARMACY, V35, P5291
   Xiong J, 2022, COMPLEMENT THER MED, V71, P0, DOI 10.1016/j.ctim.2022.102877
   Xu MM, 2022, J INTEGR MED-JIM, V20, P305, DOI 10.1016/j.joim.2022.05.002
   Yang NN, 2022, FRONT NEUROSCI-SWITZ, V15, P0, DOI 10.3389/fnins.2021.781215
   Yang XY, 2022, J INTEGR COMPLEMENT, V28, P202, DOI 10.1089/jicm.2021.0128
   Yao JP, 2022, J INTEGR MED-JIM, V20, P13, DOI 10.1016/j.joim.2021.11.001
   Zhang B, 2022, BIOSCI TRENDS, V16, P73, DOI 10.5582/bst.2022.01039
   Zhang XY, 2020, HEPATOB PANCREAT DIS, V19, P51, DOI 10.1016/j.hbpd.2019.09.006
   Zhu LP, 2018, EVID-BASED COMPL ALT, V2018, P0, DOI 10.1155/2018/2890465
   Zhu Qing-yan, 2015, ZHONGGUO ZHONG XI YI JIE HE ZA ZHI, V35, P608
   Zhu W, 2020, JIANGSU J TRADITIONA, V52, P69, DOI 10.19844/j.cnki.1672-397X.2020.10.04
   Zhu WJ, 2021, SHANGHAI J ACUPUNCT MOXIBUST, V40, P416, DOI 10.13460/j.issn.1005-0957.2021.04.0416
   Zunxiao Yj L, 2020, CHINA MED HERALD, V17, P125
NR 66
TC 6
Z9 7
U1 2
U2 18
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 2234-943X
EI 
J9 FRONT ONCOL
JI Front. Oncol.
PD AUG 15
PY 2023
VL 13
IS 
BP 
EP 
DI 10.3389/fonc.2023.1232754
PG 12
WC Oncology
SC Oncology
GA Q4NW4
UT WOS:001057313800001
PM 37655096
DA 2026-01-16
ER

PT J
AU Yang, MX
   Baser, RE
   Liou, KT
   Li, SQ
   Piulson, L
   Panageas, KS
   Mao, JJ
AF Yang, Mingxiao
   Baser, Raymond E.
   Liou, Kevin T.
   Li, Susan Q.
   Piulson, Lauren
   Panageas, Katherine S.
   Mao, Jun J.
TI Effect of acupuncture versus usual care on sleep quality in cancer survivors with chronic pain: Secondary analysis of a randomized clinical trial
SO CANCER
LA English
DT Article
DE cancer survivor; chronic pain; clinical trial; integrative care; sleep disturbance
ID insomnia; disturbance; adults; medication; management; efficacy; therapy; fatigue
AB BackgroundChronic pain negatively affects sleep; it is unclear whether pain relief from acupuncture contributes to sleep quality improvements in cancer survivors. This study aimed to evaluate the effect of acupuncture versus usual care on sleep quality among cancer survivors with comorbid sleep disturbance and chronic musculoskeletal pain. MethodsSleep outcome data from the Personalized Electroacupuncture Versus Auricular Acupuncture Comparative Effectiveness (PEACE) randomized clinical trial were analyzed. Electroacupuncture or auricular acupuncture was compared with usual care for sleep quality improvement over 10 weeks of treatment among cancer survivors with clinically significant sleep disturbance and chronic musculoskeletal pain at baseline. Sleep quality was measured with the Pittsburgh Sleep Quality Index (PSQI) global score. ResultsAmong 268 participants (mean [standard deviation (SD)] age, 61.4 [12.6] years; 191 women [71.3%]; mean [SD] baseline PSQI global score, 10.3 [3.3] points), electroacupuncture and auricular acupuncture resulted in greater reductions in the PSQI global score from baseline to 10 weeks in comparison with usual care: 1.42 points (95% confidence interval [CI], 0.45-2.38; p = .004) and 1.59 points (95% CI, 0.62-2.55; p = .001), respectively. The improvement in sleep quality for the acupuncture groups was sustained for 24 weeks from randomization. Furthermore, a greater proportion of patients in the electroacupuncture and auricular acupuncture groups had clinically meaningful improvement in sleep quality compared to the usual care group (41.0% and 42.9% vs. 21.4%; p = .044). ConclusionsAmong cancer survivors with comorbid sleep disturbance and chronic pain, electroacupuncture and auricular acupuncture produced a clinically relevant and persistent improvement in sleep quality. These findings suggest that acupuncture may be an evidence-based nonpharmacologic intervention to improve sleep health for cancer survivors with pain. Plain Language Summary This study analyzed the sleep quality data from a published randomized clinical trial that evaluated the effect of electroacupuncture or auricular acupuncture versus usual care on pain relief among people who survived cancer.This analysis included a prespecified subgroup of 268 participants with co-occurring sleep disturbance and chronic musculoskeletal pain at baseline and found that patients who used acupuncture for pain relief demonstrated greater improvements in sleep quality compared with patients who received usual care.Sleep quality improvement by acupuncture was sustained after the treatment ended.
C1 [Yang, Mingxiao; Liou, Kevin T.; Li, Susan Q.; Mao, Jun J.] Mem Sloan Kettering Canc Ctr, Dept Med, Integrat Med Serv, New York, NY USA.
   [Baser, Raymond E.; Piulson, Lauren; Panageas, Katherine S.] Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, New York, NY USA.
C3 Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center
RP Mao, JJ (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Med, Integrat Med Serv, 321 East 61st St, New York, NY 10065 USA.
EM maoj@mskcc.org
FU National Institutes of Health/National Cancer Institute [R01CA240417]; US Department of Defense;  [P30 CA008748];  [W81XWH-15-1-0245]; National Cancer Institute [K08CA266927, R01CA240417, P30CA008748] Funding Source: NIH RePORTER
CR Akodu AK, 2021, J BODYW MOV THER, V26, P411, DOI 10.1016/j.jbmt.2020.09.008
   Babiloni AH, 2020, J NEURAL TRANSM, V127, P647, DOI 10.1007/s00702-019-02067-z
   BUYSSE DJ, 1989, PSYCHIAT RES, V28, P193, DOI 10.1002/smll.202408771
   Campbell CM, 2015, ARTHRIT CARE RES, V67, P1387, DOI 10.1002/acr.22609
   Cleeland CS, 1991, BRIEF PAIN INVENTORY, V0, P0
   Currie SR, 2000, J CONSULT CLIN PSYCH, V68, P407, DOI 10.1037//0022-006X.68.3.407
   De Groote S, 2019, NEUROIMAGE-CLIN, V24, P0, DOI 10.1016/j.nicl.2019.102087
   DORREPAAL KL, 1989, CANCER-AM CANCER SOC, V63, P593, DOI 10.1002/1097-0142(19890201)63:3<593::AID-CNCR2820630332>3.0.CO;2-5
   Eadie J, 2013, ARCH PHYS MED REHAB, V94, P2083, DOI 10.1016/j.apmr.2013.04.017
   Edinger JD, 2005, ARCH INTERN MED, V165, P2527, DOI 10.1001/archinte.165.21.2527
   Farrar JT, 2000, PAIN, V88, P287, DOI 10.1016/S0304-3959(00)00339-0
   Finan PH, 2014, SLEEP MED CLIN, V9, P261, DOI 10.1016/j.jsmc.2014.02.007
   Finan PH, 2013, J PAIN, V14, P1539, DOI 10.1016/j.jpain.2013.08.007
   Garland SN, 2019, JNCI-J NATL CANCER I, V111, P1323, DOI 10.1093/jnci/djz050
   Greenlee H, 2017, CA-CANCER J CLIN, V67, P195, DOI 10.3322/caac.21397
   Greenwald MK, 2021, TRANSL RES, V234, P58, DOI 10.1016/j.trsl.2021.03.006
   Grif SC, 2021, SLEEP MED, V86, P32, DOI 10.1016/j.sleep.2021.08.006
   Haack M, 2020, NEUROPSYCHOPHARMACOL, V45, P205, DOI 10.1038/s41386-019-0439-z
   He YH, 2020, JAMA ONCOL, V6, P271, DOI 10.1001/jamaoncol.2019.5233
   Höxtermann MD, 2021, CANCERS, V13, P0, DOI 10.3390/cancers13164082
   Howell D, 2014, ANN ONCOL, V25, P791, DOI 10.1093/annonc/mdt506
   Kirsch JL, 2020, PAIN MED, V21, P5, DOI 10.1093/pm/pny236
   Liou KT, 2020, MEDICINE, V99, P0, DOI 10.1097/MD.0000000000020085
   Liu GHF, 2009, STAT MED, V28, P2509, DOI 10.1002/sim.3639
   Lyman GH, 2018, J CLIN ONCOL, V36, P2647, DOI 10.1200/JCO.2018.79.2721
   Mao JJ, 2021, JAMA ONCOL, V7, P720, DOI 10.1001/jamaoncol.2021.0310
   Mao JJ, 2014, CANCER-AM CANCER SOC, V120, P3744, DOI 10.1002/cncr.28917
   McCrae CS, 2019, SLEEP, V42, P0, DOI 10.1093/sleep/zsy234
   Murphy CC, 2018, CANCER-AM CANCER SOC, V124, P2850, DOI 10.1002/cncr.31389
   Niemtzow RC, 2018, MED ACUPUNCT, V30, P57, DOI 10.1089/acu.2018.29077.rcn
   Palesh OG, 2010, J CLIN ONCOL, V28, P292, DOI 10.1200/JCO.2009.22.5011
   Perlis ML, 2005, PRINCIPLES PRACTICE, V4th, P714, DOI 10.1016/B0-72-160797-7/50067-7
   Raats MM, 1992, FOOD QUALITY AND PREFERENCE, V3, P89, DOI 10.1016/0950-3293(91)90028-D
   Robertson JA, 2016, ANAESTHESIA, V71, P1296, DOI 10.1111/anae.13601
   Savard J, 2001, J CLIN ONCOL, V19, P895, DOI 10.1200/JCO.2001.19.3.895
   Savard J, 2011, J CLIN ONCOL, V29, P3580, DOI 10.1200/JCO.2010.33.2247
   Savard J, 2009, J CLIN ONCOL, V27, P5233, DOI 10.1200/JCO.2008.21.6333
   Schennach R, 2019, J SLEEP RES, V28, P0, DOI 10.1111/jsr.12842
   Sharma N, 2012, PSYCHO-ONCOLOGY, V21, P1003, DOI 10.1002/pon.2004
   STRANG P, 1992, ACTA ONCOL, V31, P323, DOI 10.3109/02841869209108179
   Strollo SE, 2020, SLEEP MED, V65, P177, DOI 10.1016/j.sleep.2019.10.008
   Tang Nicole K Y, 2008, REV PAIN, V2, P2, DOI 10.1177/204946370800200102
   Troxel WM, 2013, J CLIN SLEEP MED, V9, P1281, DOI 10.5664/jcsm.3270
   Ulmer CS, 2011, J CLIN SLEEP MED, V7, P57
   Vitiello MV, 2014, PAIN, V155, P1547, DOI 10.1016/j.pain.2014.04.032
   Wang HX, 2020, PSYCHOTHER PSYCHOSOM, V89, P38, DOI 10.1159/000504609
   Yang MX, 2021, NPJ BREAST CANCER, V7, P0, DOI 10.1038/s41523-021-00355-0
   Yao ZW, 2021, SLEEP BREATH, V25, P1655, DOI 10.1007/s11325-020-02246-3
   Yin X, 2022, JAMA NETW OPEN, V5, P0, DOI 10.1001/jamanetworkopen.2022.20563
   Yin X, 2017, SLEEP MED, V37, P193, DOI 10.1016/j.sleep.2017.02.012
NR 50
TC 14
Z9 14
U1 2
U2 26
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0008-543X
EI 1097-0142
J9 CANCER-AM CANCER SOC
JI Cancer
PD JUL 1
PY 2023
VL 129
IS 13
BP 2084
EP 2094
DI 10.1002/cncr.34766
EA MAR 2023
PG 11
WC Oncology
SC Oncology
GA I9YJ4
UT WOS:000966652400001
PM 36989257
DA 2026-01-16
ER

PT J
AU Shan, Y
   Zhang, J
   Ma, Y
   Zhang, Y
AF Shan, Yunping
   Zhang, Juan
   Ma, Yinhua
   Zhang, Yiming
TI The effects of acupuncture combined with western medicine in the treatment of
SO American journal of translational research
LA English
DT Journal Article
DE Neck shoulder low back pain; acupuncture treatment; inflammatory factors; motor functions; symptom improvement
AB OBJECTIVE: To investigate the effect of Traditional Chinese Medicine (TCM)  acupuncture combined with western medicine in the treatment of neck, shoulder,  lumbar and leg pain and its influence on the degree of pain, motor functions and  inflammatory factor levels. METHODS: In this retrospective study, 86 patients  with neck, shoulder, lumbar and leg pain treated in Department of Orthopedics and  Traumatology, Hangzhou Fuyang Hospital of TCM from June 2019 to June 2022 were  selected as the study subjects. According to different treatment methods, these  patients were divided into an observation group (n=43) and a control group  (n=43). Patients from the control group were treated with conventional western  medicine, while those from the observation group were treated with combination of  traditional Chinese medicine acupuncture (Acupuncture + Fumigation with  Collaterals-Dredging Decoction) and western medicine. Patients in both groups  were treated for 4 weeks continuously. The treatment effect, visual analogue  scale (VAS) score, limb motor function scale (Fugl-Meyer) score, cervical  function score, daily living ability score, the levels of inflammatory factors  including interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α) and C-reactive  protein (CRP) were recorded and compared between two groups. RESULTS: The  effective rate of patients in the observation group was 93.02%, which was  significantly higher than 76.74% in the control group (P<0.05). There was no  significant difference in the term of Fugl-Meyer score, VAS score and levels of  inflammatory factors before treatment between two groups (all P>0.05). After  treatment, the VAS score and the levels of IL-6, TNF-α and CRP in both of groups  significantly decreased in contrast to before treatment. The Fugl-Meyer score  after treatment in both of groups was significantly increased in contrast to  before treatment. Compared with those after treatment in control group, the VAS  score and the levels of IL-6, TNF-α and CRP after treatment in the observation  group were obviously lower, while the Fugl-Meyer score in the observation group  was significantly higher (all P<0.05). CONCLUSION: TCM acupuncture combined with  western medicine has a good therapeutic effect on neck, shoulder, lumbar and leg  pains, which can effectively relieve the pain, improve motor function and reduce  the inflammatory reactions in patients. The combined treatment has clinical  application values and is worth promoting.
C1 Department of Pain Treatment, Hangzhou Fuyang Hospital of TCM Orthopedics and Traumatology Hangzhou, Zhejiang, China.
   Department of Pain Treatment, Zhejiang Provincial Hospital of TCM Hangzhou, Zhejiang, China.
   Department of Pain Treatment, Hangzhou Fuyang Hospital of TCM Orthopedics and Traumatology Hangzhou, Zhejiang, China.
   Orthopedics and Traumatology Department, Hangzhou Fuyang Hospital of TCM Orthopedics and Traumatology Hangzhou, Zhejiang, China.
NR 0
TC 0
SN 1943-814
EI 1943-814
J9 Am J Transl Res
PD JUL 12
PY 2023
VL 15
IS 6
BP 4246
EP 4254
DI 
PG 8
UT PubMed:37434859
PM 37434859
DA 2023-07-12
ER

PT J
AU Lee, B
   Kwon, CY
   Lee, HW
   Nielsen, A
   Wieland, LS
   Kim, TH
   Birch, S
   Alraek, T
   Lee, MS
AF Lee, Boram
   Kwon, Chan-Young
   Lee, Hye Won
   Nielsen, Arya
   Wieland, L Susan
   Kim, Tae-Hun
   Birch, Stephen
   Alraek, Terje
   Lee, Myeong Soo
TI Different Outcomes According to Needling Point Location Used in Sham Acupuncture
SO Cancers
LA English
DT Review
DE acupuncture therapy; cancer pain; cancer-related pain; placebo; sham acupuncture
AB Numerous acupuncture studies have been conducted on cancer-related pain; however,  its efficacy compared to sham acupuncture remains controversial. We confirmed  whether the outcome of acupuncture differs according to the needling points of  sham acupuncture for cancer-related pain. We searched 10 databases on 23 May 2023  to screen acupuncture trials using sham acupuncture or waiting list as controls  for cancer-related pain. Sham acupuncture was classified into two types,  depending on whether the needling was applied at the same locations as verum  acupuncture (SATV) or not (SATS). A network meta-analysis (NMA) was performed on  the basis of a frequentist approach to assess pain severity. Eight studies (n =  574 participants) were included in the review, seven of which (n = 527  participants) were included in the NMA. The pain severity was not significantly  different between SATV and verum acupuncture, but verum acupuncture significantly  improved pain severity compared to SATS. The risk of bias affecting the  comparisons between the verum and sham acupuncture was generally low. Previous  acupuncture trials for cancer-related pain showed differing outcomes of sham and  verum acupuncture, depending on the needling points of sham acupuncture. The  application of SATV cannot be considered a true placebo, which leads to an  underestimation of the efficacy of verum acupuncture.
C1 KM Science Research Division, Korea Institute of Oriental Medicine, Daejeon 34054, Republic of Korea.
   Department of Oriental Neuropsychiatry, Dong-Eui University College of Korean Medicine, Busan 47227, Republic of Korea.
   KM Convergence Research Division, Korea Institute of Oriental Medicine, Daejeon 34054, Republic of Korea.
   Department of Family Medicine & Community Health, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
   Center for Integrative Medicine, University of Maryland School of Medicine, Baltimore, MD 21201, USA.
   Korean Medicine Clinical Trial Center, Korean Medicine Hospital, Kyung Hee University, Seoul 02447, Republic of Korea.
   Kristiania University College, School of Health Sciences, 0317 Oslo, Norway.
   Kristiania University College, School of Health Sciences, 0317 Oslo, Norway.
   Department of Community Medicine, Faculty of Health Sciences, National Research 
   KM Science Research Division, Korea Institute of Oriental Medicine, Daejeon 34054, Republic of Korea.
NR 0
TC 0
SN 2072-669
EI 2072-669
J9 Cancers (Basel)
PD DEC 23
PY 2023
VL 15
IS 24
BP 
EP 
DI 10.3390/cancers15245875
PG 0
UT PubMed:38136419
PM 38136419
DA 2023-12-23
ER

PT J
AU Tao, SY
   Tang, J
   Wang, X
   Jiang, NN
   Li, Y
   Wu, P
AF Tao, Si-Yu
   Tang, Jie
   Wang, Xue
   Jiang, Nan-Nan
   Li, Yuan
   Wu, Ping
TI Moxibustion as an adjunctive treatment for rheumatoid arthritis and its effects
SO Zhongguo zhen jiu = Chinese acupuncture & moxibustion
LA chi
DT Journal Article
DE Wnt/β-catenin signaling pathway; bone metabolism; moxibustion; rheumatoid arthritis (RA); sclerostin (SOST); tumor necrosis factor-α (TNF-α); β-catenin
AB OBJECTIVES: To observe the clinical efficacy of moxibustion as an adjunctive  treatment for rheumatoid arthritis (RA) based on conventional medication and its  effects on serum sclerostin (SOST) and β-catenin levels, exploring the potential  mechanisms by which moxibustion may protect joint bones in RA patients. METHODS:  Seventy-six RA patients were randomly divided into an observation group (38  cases, 3 cases dropped out) and a control group (38 cases, 4 cases were  eliminated, 2 cases dropped out). The patients in the control group were treated  with conventional oral medication; based on the treatment of the control group,  the patients in the observation group were treated with moxibustion. The direct  moxibustion was applied at Zusanli (ST 36) on both sides and ashi points around  small joints, and indirect moxibustion was applied at Shenshu (BL 23) on both  sides and ashi points around large joints. The treatment was given three times a  week for a total of 5 weeks. The count of pain and swollen joint, morning  stiffness score, disease activity score of 28 joints (DAS28), visual analogue  scale (VAS) score, health assessment questionnaire (HAQ) score, and serum levels  of SOST, β-catenin, and tumor necrosis factor-α (TNF-α) were evaluated before and  after treatment in the two groups. RESULTS: Compared those before treatment,  after treatment, both groups showed a reduction in pain and swollen joint count  (P<0.01, P<0.05), morning stiffness, DAS28, VAS, and HAQ scores (P<0.01, P<0.05),  with the observation group having lower scores than the control group (P<0.01).  Serum levels of SOST, β-catenin, and TNF-α after treatment in the observation  group were lower than those in both before treatment and the control group  (P<0.01, P<0.05). There was a positive correlation between the difference in  serum β-catenin levels before and after treatment and the difference in serum  SOST (r=0.578, P<0.001) and TNF-α (r=0.403, P<0.05) levels in the observation  group. CONCLUSIONS: In addition to medication, moxibustion as an adjunctive  treatment could significantly alleviate joint pain and reduce disease activity in  RA patients, suggesting a potential role in joint protection. This mechanism may  be related to the inhibition of the inflammatory factor TNF-α, regulation of  β-catenin levels, and reduction in the production of the endogenous negative  regulator protein SOST within the Wnt/β-catenin signaling pathway.
C1 College of Acupuncture-Moxibustion and Tuina, Chengdu University of TCM, Chengdu 610075, Sichuan Province, China. 269402733@qq.com.
   College of Acupuncture-Moxibustion and Tuina, Chengdu University of TCM, Chengdu 610075, Sichuan Province, China.
   College of Acupuncture-Moxibustion and Tuina, Chengdu University of TCM, Chengdu 610075, Sichuan Province, China.
   College of Acupuncture-Moxibustion and Tuina, Chengdu University of TCM, Chengdu 610075, Sichuan Province, China.
   Department of Rheumatic Immunology, Hospital of Chengdu University of TCM/TCM Hospital of Sichuan Province.
   College of Acupuncture-Moxibustion and Tuina, Chengdu University of TCM, Chengdu 610075, Sichuan Province, China. wuping_33@163.com.
NR 0
TC 0
SN 
EI 0255-293
J9 Zhongguo Zhen Jiu
PD DEC 14
PY 2023
VL 43
IS 12
BP 1384
EP 1389
DI 10.13703/j.0255-2930.20230414-k0005
PG 5
WC Humans; Moxibustion; Tumor Necrosis Factor-alpha; beta Catenin; Acupuncture Points; Arthritis, Rheumatoid; therapy; Arthralgia; Adaptor Proteins, Signal Transducing
UT PubMed:38092536
PM 38092536
DA 2023-12-14
ER

PT J
AU Ding, YY
   Xu, F
   Wang, YF
   Han, LL
   Huang, SQ
   Zhao, S
   Ma, LL
   Zhang, TH
   Zhao, WJ
   Chen, XD
AF Ding, Yuan-yuan
   Xu, Feng
   Wang, Ya-feng
   Han, Lin-lin
   Huang, Shi-qian
   Zhao, Shuai
   Ma, Lu-lin
   Zhang, Tian-hao
   Zhao, Wen-jing
   Chen, Xiang-dong
TI Electroacupuncture alleviates postoperative pain through inhibiting neuroinflammation via stimulator of interferon genes/type-1 interferon pathway
SO JOURNAL OF INTEGRATIVE MEDICINE-JIM
LA English
DT Article
DE Electroacupuncture; Inflammation; Pain; Primary sensory neurons; Stimulator of interferon genes; Type -1 interferon
ID inflammatory pain; neuropathic pain; rat; injury; hypersensitivity; activation; mechanisms; laparotomy; allodynia; analgesia
AB Objective: This work explores the impact of electroacupuncture (EA) on acute postoperative pain (APP) and the role of stimulator of interferon genes/type-1 interferon (STING/IFN-1) signaling pathway modulation in the analgesic effect of EA in APP rats. Methods: The APP rat model was initiated through abdominal surgery and the animals received two 30 min sessions of EA at bilateral ST36 (Zusanli) and SP6 (Sanyinjiao) acupoints. Mechanical, thermal and cold sensitivity tests were performed to measure the pain threshold, and electroencephalograms were recorded in the primary somatosensory cortex to identify the effects of EA treatment on APP. Western blotting and immunofluorescence were used to examine the expression and distribution of proteins in the STING/IFN-1 pathway as well as neuroinflammation. A STING inhibitor (C-176) was administered intrathecally to verify its role in EA.Results: APP rats displayed mechanical and thermal hypersensitivities compared to the control group (P < 0.05). APP significantly reduced the amplitude of 0, a and c oscillations compared to their baseline values (P < 0.05). Interestingly, expression levels of proteins in the STING/IFN-1 pathway were downregulated after inducing APP (P < 0.05). Further, APP increased pro-inflammatory factors, including interleukin-6, tumor necrosis factor-a and inducible nitric oxide synthase, and downregulated antiinflammatory factors, including interleukin-10 and arginase-1 (P < 0.05). EA effectively attenuated APP-induced painful hypersensitivities (P < 0.05) and restored the 0, a and c power in APP rats (P < 0.05). Meanwhile, EA distinctly activated the STING/IFN-1 pathway and mitigated the neuroinflammatory response (P < 0.05). Furthermore, STING/IFN-1 was predominantly expressed in isolectin-B4- or calcitonin-gene-related-peptide-labeled dorsal root ganglion neurons and superficial laminae of the spinal dorsal horn. Inhibition of the STING/IFN-1 pathway by intrathecal injection of C-176 weakened the analgesic and anti-inflammatory effects of EA on APP (P < 0.05). Conclusion: EA can generate robust analgesic and anti-inflammatory effects on APP, and these effects may be linked to activating the STING/IFN-1 pathway, suggesting that STING/IFN-1 may be a target for relieving APP. Please cite this article as: Ding YY, Xu F, Wang YF, Han LL, Huang SQ, Zhao S, Ma LL, Zhang TH, Zhao WJ, Chen XD. Electroacupuncture alleviates postoperative pain through inhibiting neuroinflammation via stimulator of interferon genes/type-1 interferon pathway. J Integr Med. 2023; 21(5): 496-508.(c) 2023 Shanghai Yueyang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine. All rights reserved.
C1 [Ding, Yuan-yuan; Xu, Feng; Wang, Ya-feng; Han, Lin-lin; Huang, Shi-qian; Zhao, Shuai; Ma, Lu-lin; Zhang, Tian-hao; Zhao, Wen-jing; Chen, Xiang-dong] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Anesthesiol, Wuhan 430022, Hubei, Peoples R China.
C3 Huazhong University of Science & Technology
RP Chen, XD (corresponding author), Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Anesthesiol, Wuhan 430022, Hubei, Peoples R China.
EM xdchen@hust.edu.cn
FU National Natural Science Foundation of China [82071251]; National Key Research and Development Program of China [2018YFC2001802]; Hubei Province Key Research and Development Program [2021BCA145]
CR Barr MS, 2013, J NEUROIMMUNE PHARM, V8, P535, DOI 10.1007/s11481-012-9383-y
   Basbaum AI, 2009, CELL, V139, P267, DOI 10.1016/j.cell.2009.09.028
   Beaulieu P, 2021, PAIN, V162, P2309, DOI 10.1097/j.pain.0000000000002294
   Cavanaugh DJ, 2009, P NATL ACAD SCI USA, V106, P9075, DOI 10.1073/pnas.0901507106
   Chai WX, 2018, EVID-BASED COMPL ALT, V2018, P0, DOI 10.1155/2018/2598975
   Chang XY, 2022, NEURAL REGEN RES, V17, P2526, DOI 10.4103/1673-5374.339003
   CHAPLAN SR, 1994, J NEUROSCI METH, V53, P55, DOI 10.1016/0165-0270(94)90144-9
   Charlet A, 2011, J PAIN, V12, P246, DOI 10.1016/j.jpain.2010.07.005
   Chen J, 2013, NEUROSCIENCE IN THE 21ST CENTURY: FROM BASIC TO CLINICAL, V0, PP965, DOI 10.1007/978-1-4614-1997-6_32
   Cheng ZL, 2020, SIGNAL TRANSDUCT TAR, V5, P0, DOI 10.1038/s41392-020-0198-7
   Dan Y, 2004, J ACUPUNCT TUINA SCI, V2, P34, DOI 10.1007/BF02848398
   Deuis JR, 2017, FRONT MOL NEUROSCI, V10, P0, DOI 10.3389/fnmol.2017.00284
   Dobbs N, 2015, CELL HOST MICROBE, V18, P157, DOI 10.1016/j.chom.2015.07.001
   Donnelly CR, 2021, NATURE, V591, P275, DOI 10.1038/s41586-020-03151-1
   Donnelly CR, 2020, TRENDS NEUROSCI, V43, P822, DOI 10.1016/j.tins.2020.07.008
   Fairbanks CA, 2003, ADV DRUG DELIVER REV, V55, P1007, DOI 10.1016/S0169-409X(03)00101-7
   Feng L, 2021, NEURAL PLAST, V2021, P0, DOI 10.1155/2021/8537437
   Feng XM, 2012, BMC COMPLEM ALTERN M, V12, P0, DOI 10.1186/1472-6882-12-225
   Gao YH, 2017, PURINERG SIGNAL, V13, P215, DOI 10.1007/s11302-016-9552-1
   Gao Y, 2020, BRAIN BEHAV IMMUN, V88, P482, DOI 10.1016/j.bbi.2020.04.019
   Gao YH, 2013, NEUROCHEM RES, V38, P1467, DOI 10.1007/s11064-013-1047-7
   Gu N, 2016, CELL REP, V16, P605, DOI 10.1016/j.celrep.2016.06.018
   Hajat Z, 2017, ANAESTHESIA, V72, P38, DOI 10.1111/anae.13739
   Han LL, 2021, FRONT PHARMACOL, V12, P0, DOI 10.3389/fphar.2021.728300
   HARGREAVES K, 1988, PAIN, V32, P77, DOI 10.1016/0304-3959(88)90026-7
   He Lan, 2012, ZHONGGUO ZHEN JIU, V32, P107
   He YH, 2020, JAMA ONCOL, V6, P271, DOI 10.1001/jamaoncol.2019.5233
   Hou PP, 2021, CELL MOL IMMUNOL, V18, P2358, DOI 10.1038/s41423-021-00758-w
   Hu L, 2019, P NATL ACAD SCI USA, V116, P1782, DOI 10.1073/pnas.1812499116
   Ji RR, 2018, ANESTHESIOLOGY, V129, P343, DOI 10.1097/ALN.0000000000002130
   Ji RR, 2016, SCIENCE, V354, P572, DOI 10.1126/science.aaf8924
   Jiang QY, 2016, ACUPUNCT MED, V34, P223, DOI 10.1136/acupmed-2015-010951
   Kalso E, 2013, BRIT J ANAESTH, V111, P9, DOI 10.1093/bja/aet211
   Kim JH, 2004, BRAIN RES, V998, P230, DOI 10.1016/j.brainres.2003.11.045
   LeBlanc BW, 2016, PAIN, V157, P2330, DOI 10.1097/j.pain.0000000000000652
   Lee SH, 2012, MOL MED REP, V6, P157, DOI 10.3892/mmr.2012.879
   Li WW, 2020, SCI TRANSL MED, V12, P0, DOI 10.1126/scitranslmed.aay9013
   Li YY, 2019, INT J MOL SCI, V20, P0, DOI 10.3390/ijms20235917
   Liao HY, 2021, AM J CHINESE MED, V49, P1417, DOI 10.1142/S0192415X2150066X
   Lin JG, 2002, PAIN, V99, P509, DOI 10.1016/S0304-3959(02)00261-0
   Liu CC, 2016, SCI REP-UK, V6, P0, DOI 10.1038/srep34356
   Liu QY, 2021, PAIN THER, V10, P1755, DOI 10.1007/s40122-021-00283-8
   Liu SB, 2021, NATURE, V598, P641, DOI 10.1038/s41586-021-04001-4
   Lv ZT, 2019, ARTHRITIS RES THER, V21, P0, DOI 10.1186/s13075-019-1899-6
   Malver LP, 2014, BRIT J CLIN PHARMACO, V77, P72, DOI 10.1111/bcp.12137
   Martin TJ, 2004, ANESTHESIOLOGY, V101, P191, DOI 10.1097/00000542-200407000-00030
   McCoy ES, 2013, NEURON, V78, P138, DOI 10.1016/j.neuron.2013.01.030
   Meng XZ, 2011, BRAIN RES, V1414, P58, DOI 10.1016/j.brainres.2011.08.004
   Niwa F, 2019, ISCIENCE, V22, P453, DOI 10.1016/j.isci.2019.11.013
   Norcini M, 2016, FRONT MOL NEUROSCI, V9, P0, DOI 10.3389/fnmo1.2015.00100
   Peng XX, 2017, MOL PAIN, V13, P0, DOI 10.1177/1744806917697007
   Sideris-Lampretsas G, 2022, SCIENCE, V376, P33, DOI 10.1126/science.abo5592
   Simis M, 2022, PAIN MED, V23, P955, DOI 10.1093/pm/pnab124
   Small C, 2020, BJS-BRIT J SURG, V107, PE70, DOI 10.1002/bjs.11477
   Sun J, 2022, J NEUROIMMUNE PHARM, V17, P453, DOI 10.1007/s11481-021-10031-6
   Tan LL, 2021, TRENDS NEUROSCI, V44, P629, DOI 10.1016/j.tins.2021.05.003
   Wang KY, 2021, NAT COMMUN, V12, P0, DOI 10.1038/s41467-021-24867-2
   Wang XM, 2021, J CLIN ANESTH, V68, P0, DOI 10.1016/j.jclinane.2020.110071
   Wang YP, 2020, J NEUROINFLAMM, V17, P0, DOI 10.1186/s12974-020-01991-2
   Xiang XN, 2019, INT J MOL SCI, V20, P0, DOI 10.3390/ijms20133248
   Xing Guogang, 2003, BEIJING DA XUE XUE BAO YI XUE BAN, V35, P453
   Xu J, 2016, ANESTH ANALG, V122, P882, DOI 10.1213/ANE.0000000000001097
   Yang LY, 2022, FRONT IMMUNOL, V13, P0, DOI 10.3389/fimmu.2022.955581
   Zhong SB, 2009, EVID-BASED COMPL ALT, V6, P51, DOI 10.1093/ecam/nem062
   Zhu HM, 2019, FRONT PHYSIOL, V10, P0, DOI 10.3389/fphys.2019.00466
   Zhu YY, 2019, MOL CANCER, V18, P0, DOI 10.1186/s12943-019-1087-y
NR 66
TC 9
Z9 12
U1 3
U2 17
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 2095-4964
EI 
J9 J INTEGR MED-JIM
JI J. Integr. Med.-JIM
PD SEP 15
PY 2023
VL 21
IS 5
BP 496
EP 508
DI 10.1016/j.joim.2023.07.001
EA SEP 2023
PG 13
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA U1IC4
UT WOS:001082399600001
PM 37517892
DA 2026-01-16
ER

PT J
AU Wang, W
   Liu, Y
   Yang, X
   Sun, J
   Yue, Z
   Lu, D
   Zhou, K
   Sun, Y
   Hou, A
   Zang, Z
   Jin, X
   Liu, C
   Wang, Y
   Yu, J
   Zhu, L
   Liu, Z
AF Wang, Weiming
   Liu, Yan
   Yang, Xiaofang
   Sun, Jianhua
   Yue, Zenghui
   Lu, Dianrong
   Zhou, Kehua
   Sun, Yuanjie
   Hou, Aihua
   Zang, Zhiwei
   Jin, Xiaoqing
   Liu, Chao
   Wang, Yuhang
   Yu, Jinna
   Zhu, Lili
   Liu, Zhishun
TI Effects of Electroacupuncture for Opioid-Induced Constipation in Patients With
SO JAMA network open
LA English
DT Journal Article
AB IMPORTANCE: Opioid-induced constipation (OIC) is prevalent among patients treated  with opioids for cancer pain. Safe and effective therapies for OIC in patients  with cancer remain an unmet need. OBJECTIVE: To determine the efficacy of  electroacupuncture (EA) for OIC in patients with cancer. DESIGN, SETTING, AND  PARTICIPANTS: This randomized clinical trial was conducted at 6 tertiary  hospitals in China among 100 adult patients with cancer who were screened for OIC  and enrolled between May 1, 2019, and December 11, 2021. INTERVENTIONS: Patients  were randomized to receive 24 sessions of EA or sham electroacupuncture (SA) over  8 weeks and then were followed up for 8 weeks after treatment. MAIN OUTCOMES AND  MEASURES: The primary outcome was the proportion of overall responders, defined  as patients who had at least 3 spontaneous bowel movements (SBMs) per week and an  increase of at least 1 SBM from baseline in the same week for at least 6 of the 8  weeks of the treatment period. All statistical analyses were based on the  intention-to-treat principle. RESULTS: A total of 100 patients (mean [SD] age,  64.4 [10.5] years; 56 men [56.0%]) underwent randomization; 50 were randomly  assigned to each group. Among them, 44 of 50 patients (88.0%) in the EA group and  42 of 50 patients (84.0%) in the SA group received at least 20 (≥83.3%) sessions  of treatment. The proportion of overall responders at week 8 was 40.1% (95% CI,  26.1%-54.1%) in the EA group and 9.0% (95% CI, 0.5%-17.4%) in the SA group  (difference between groups, 31.1 percentage points [95% CI, 14.8-47.6 percentage  points]; P < .001). Compared with SA, EA provided greater relief for most OIC  symptoms and improved quality of life among patients with OIC. Electroacupuncture  had no effects on cancer pain and its opioid treatment dosage.  Electroacupuncture-related adverse events were rare, and, if any, all were mild  and transient. CONCLUSIONS AND RELEVANCE: This randomized clinical trial found  that 8-week EA treatment could increase weekly SBMs with a good safety profile  and improve quality of life for the treatment of OIC. Electroacupuncture thus  provided an alternative option for OIC in adult patients with cancer. TRIAL  REGISTRATION: ClinicalTrials.gov Identifier: NCT03797586.
C1 Department of Acupuncture and Moxibustion, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
   Key Laboratory of Chinese Internal Medicine of the Ministry of Education, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China.
   College of Acumox and Tuina, Guizhou University of Traditional Chinese Medicine, Guiyang, China.
   Department of Acupuncture Rehabilitation, the Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, China.
   College of Acupuncture and Tuina, Hunan University of Chinese Medicine, Changsha, Hunan, China.
   Department of Oncology, Wang Jing Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
   Department of Hospital Medicine, ThedaCare Regional Medical Center-Appleton, Appleton, Wisconsin.
   Department of Acupuncture and Moxibustion, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
   Department of Oncology, Yantai Hospital of Traditional Chinese Medicine, Yantai, China.
   Department of Acupuncture, Yantai Hospital of Traditional Chinese Medicine, Yantai, China.
   Department of Acupuncture, Zhejiang Hospital, Hangzhou, China.
   College of Acumox and Tuina, Guizhou University of Traditional Chinese Medicine, Guiyang, China.
   Department of Acupuncture Rehabilitation, the Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, China.
   Department of Acupuncture and Moxibustion, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
   Department of Acupuncture and Moxibustion, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
   Department of Acupuncture and Moxibustion, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
NR 0
TC 0
SN 2574-380
EI 
J9 JAMA Netw Open
PD FEB 23
PY 2023
VL 6
IS 2
BP e230310
EP e230310
DI 10.1001/jamanetworkopen.2023.0310
PG 1
WC Adult; Male; Humans; Middle Aged; Analgesics, Opioid; therapeutic use; Constipation; chemically induced; Electroacupuncture; Opioid-Induced Constipation; drug therapy; Cancer Pain; drug therapy; Quality of Life; Neoplasms; drug therapy; China
UT PubMed:36811861
PM 36811861
DA 2023-02-23
ER

PT J
AU Geagea, D
   Tyack, Z
   Kimble, R
   Polito, V
   Ayoub, B
   Terhune, DB
   Griffin, B
AF Geagea, Dali
   Tyack, Zephanie
   Kimble, Roy
   Polito, Vince
   Ayoub, Bassel
   Terhune, Devin B.
   Griffin, Bronwyn
TI Clinical Hypnosis for Procedural Pain and Distress in Children: A Scoping Review
SO PAIN MEDICINE
LA English
DT Review
DE Procedural Pain; Distress; Clinical Hypnosis; Children; Scoping Review
ID pediatric cancer-patients; systematic reviews; virtual-reality; self-hypnosis; burn pain; reduction; anxiety; adolescents; management; analgesia
AB Objective Pain and distress are common in children undergoing medical procedures, exposing them to acute and chronic biopsychosocial impairments if inadequately treated. Clinical hypnosis has emerged as a potentially beneficial treatment for children's procedural pain and distress due to evidence of effectiveness and potential superiority to other psychological interventions. However, systematic reviews of clinical hypnosis for children's procedural pain and distress have been predominantly conducted in children undergoing oncology and needle procedures and are lacking in broader pediatric contexts. This scoping review maps the evidence of clinical hypnosis for children's procedural pain and distress across broad pediatric contexts while highlighting knowledge gaps and areas requiring further investigation. Methods Published databases (PubMed, Cochrane Library, PsycINFO, Embase, CINAHL, Scopus, and Web of Science) and grey literature were searched in addition to hand-searching reference lists and key journals (up to May 2022). Two independent reviewers screened the titles and abstracts of search results followed by a full-text review against eligibility criteria. Articles were included if they involved a clinical hypnosis intervention comprising an induction followed by therapeutic suggestions for pain and distress in children undergoing medical procedures. This review followed the Arksey and O'Malley (2005) methodology and incorporated additional scoping review recommendations by the Joanna Briggs Institute and Preferred Reporting Items for Systematic Reviews and Meta-Analyses. Results A total of 38 eligible studies involving 2,205 children were included after 4,775 articles were screened. Research on clinical hypnosis for children's procedural pain and distress was marked by a lack of fidelity measures and qualitative data as well as by inadequate intervention reporting and high attrition rates. Evidence regarding the safety of clinical hypnosis, pain unpleasantness outcomes, factors influencing outcomes, as well as barriers and facilitators to implementing hypnosis and study procedures was also lacking. Clinical hypnosis has potential benefits for children's procedural pain and distress based on evidence of superiority to control conditions and nonpharmacological interventions (e.g., distraction, acupressure) with moderate to large effect sizes as reported in 76% of studies. However, heterogeneous interventions, contexts, study designs, and populations were identified, and the certainty of the evidence was not evaluated. Conclusions The review suggests potential benefits of clinical hypnosis for children's procedural pain and distress and thus provides a precursor for further systematic reviews and trials investigating the effectiveness of clinical hypnosis. The review also indicates the need to further explore the feasibility, acceptability, implementation, and safety of clinical hypnosis in children undergoing painful procedures. Based on the review, researchers implementing clinical hypnosis should adequately report interventions or use treatment manuals, follow recommended research guidelines, and assess the fidelity of intervention delivery to promote replicating and comparing interventions. The review also highlights common methodological shortcomings of published trials to avoid, such as the lack of implementation frameworks, small sample sizes, inadequate reporting of standard care or control conditions, and limited evidence on pain unpleasantness outcomes.
C1 [Geagea, Dali; Tyack, Zephanie] Univ Queensland, Child Hlth Res Ctr, Ctr Childrens Burns & Trauma Res, Brisbane, Australia.
   [Tyack, Zephanie] Queensland Univ Technol, Australian Ctr Hlth Serv Innovat, Brisbane, Australia.
   [Tyack, Zephanie] Queensland Univ Technol, Ctr Healthcare Transformat, Sch Publ Hlth & Social Work, Brisbane, Australia.
   [Kimble, Roy] Univ Queensland, Queensland Childrens Hosp, Ctr Childrens Burns & Trauma Res, Brisbane, Australia.
   [Polito, Vince] Macquarie Univ, Sch Psychol Sci, Sydney, Australia.
   [Ayoub, Bassel] Queensland Univ Technol, Fac Hlth, Brisbane, Australia.
   [Terhune, Devin B.] Goldsmiths Univ London, Dept Psychol, London, England.
   [Terhune, Devin B.] Kings Coll London, Inst Psychiat, Dept Psychol, Psychol & Neurosci, London, England.
   [Griffin, Bronwyn] Griffith Univ, Sch Nursing & Midwifery, Nathan, Qld, Australia.
   [Geagea, Dali] Ctr Childrens Hlth Res, Level 7,62 Graham St, South Brisbane, Qld 4101, Australia.
C3 University of Queensland; Queensland University of Technology (QUT); Queensland University of Technology (QUT); University of Queensland; Childrens Health Queensland Hospital & Health Service; Queensland Childrens Hospital; Macquarie University; Queensland University of Technology (QUT); University of London; Goldsmiths University London; University of London; King's College London; Griffith University
RP Geagea, D (corresponding author), Ctr Childrens Hlth Res, Level 7,62 Graham St, South Brisbane, Qld 4101, Australia.
EM d.geagea@uq.net.au
CR Accardi MC, 2009, J BEHAV MED, V32, P328, DOI 10.1007/s10865-009-9207-6
   AMBUEL B, 1992, J PEDIATR PSYCHOL, V17, P95, DOI 10.1093/jpepsy/17.1.95
   Arksey H, 2005, INT J SOC RES METHOD, V8, P19, DOI 10.1080/1364557032000119616
   Axelrad ABD, 2009, KAPLAN SADOCKS COMPR, V9th, P2804
   Baaleman DF, 2022, J NEUROGASTROENTEROL, V28, P312, DOI 10.5056/jnm20274
   Babineau J, 2014, J CAN HEALTH LIBRARI, V35, P68, DOI 10.5596/c14-016
   Barlow D H, 1988, ANXIETY AND ITS DISORDERS: THE NATURE AND TREATMENT OF ANXIETY PANIC, V0, P0
   Bayat A, 2010, EXPERT REV NEUROTHER, V10, P1747, DOI 10.1586/ern.10.158
   Birnie KA, 2014, J PEDIATR PSYCHOL, V39, P783, DOI 10.1093/jpepsy/jsu029
   Blount RL, 2009, HANDBOOK OF PEDIATRIC PSYCHOLOGY, V4th, P171
   Boggia B, 2020, HAEMOPHILIA, V26, P117
   Brennan F, 2007, ANESTH ANALG, V105, P205, DOI 10.1213/01.ane.0000268145.52345.55
   Brown EA, 2018, CLIN CHILD FAM PSYCH, V21, P224, DOI 10.1007/s10567-017-0252-3
   Brown NJ, 2014, BURNS, V40, P751, DOI 10.1016/j.burns.2013.09.027
   Brown NJ, 2014, BURNS, V40, P204, DOI 10.1016/j.burns.2013.11.024
   Brydges CR, 2019, INNOV AGING, V3, P0, DOI 10.1093/geroni/igz036
   Butler LD, 2005, PEDIATRICS, V115, PE77, DOI 10.1542/peds.2004-0818
   Calipel S, 2005, PEDIATR ANESTH, V15, P275, DOI 10.1111/j.1460-9592.2004.01514.x
   Centre for Musculoskeletal Outcomes Research (CMOR) Dunedin School of Medicine University of Otago , 2020, OBM INTEGRATIVE AND COMPLEMENTARY MEDICINE, V5, P0, DOI 10.21926/obm.icm.2001005
   Cheseaux N, 2014, INT J CLIN EXP HYP, V62, P399, DOI 10.1080/00207144.2014.931170
   Chester SJ, 2018, PAIN, V159, P1790, DOI 10.1097/j.pain.0000000000001276
   Christian LM, 2006, NEUROIMMUNOMODULAT, V13, P337, DOI 10.1159/000104862
   Cohen LL, 2008, J PEDIATR PSYCHOL, V33, P939, DOI 10.1093/jpepsy/jsm103
   Colquhoun HL, 2014, J CLIN EPIDEMIOL, V67, P1291, DOI 10.1016/j.jclinepi.2014.03.013
   Craig P, 2008, BMJ-BRIT MED J, V337, P0, DOI 10.1136/bmj.a1655
   CRAWFORD AH, 1976, ANESTH ANALG, V55, P42
   Duparc-Alegria N, 2018, J CLIN NURS, V27, P86, DOI 10.1111/jocn.13848
   Elkins G, 2005, PSYCHOTHERAPY, V42, P232, DOI 10.1037/0033-3204.42.2.232
   Elkins GR, 2015, INT J CLIN EXP HYP, V63, P1, DOI 10.1080/00207144.2014.961870
   ENQVIST B, 1995, STRESS MEDICINE, V11, P229, DOI 10.1002/smi.2460110138
   Erappa Umadevi, 2021, INT J CLIN PEDIATR DENT, V14, PS186, DOI 10.5005/jp-journals-10005-2113
   FRICTON JR, 1985, AM J CLIN HYPN, V27, P226, DOI 10.1080/00029157.1985.10402612
   Gagnier JJ, 2013, DTSCH ARZTEBL INT, V110, P603, DOI 10.1186/1752-1947-7-223
   Geagea D, 2021, PAIN MED, V22, P2818, DOI 10.1093/pm/pnab038
   Gillum M, 2022, J BURN CARE RES, V43, P368, DOI 10.1093/jbcr/irab167
   GOKLI MA, 1994, J DENT CHILD, V61, P272
   Goodenough B, 1999, EUR J PAIN, V3, P301, DOI 10.1016/S1090-3801(99)90012-5
   Gough D, 2012, SYST REV-LONDON, V1, P0, DOI 10.1186/2046-4053-1-28
   Hawkins PJ, 1998, CONT HYPNOSIS, V15, P199, DOI 10.1002/CH.135
   Hilgard ER, 1965, HYPNOTIC SUSCEPTIBILITY, V0, P0
   HILGARD JR, 1982, INT J CLIN EXP HYP, V30, P417, DOI 10.1080/00207148208407277
   Hodel TV, 1983, HYPNOSIS RELIEF PAIN, V0, P0
   Duedahl TH, 2007, PEDIATR ANESTH, V17, P756, DOI 10.1111/j.1460-9592.2007.02213.x
   Hoffmann TC, 2014, BMJ-BRIT MED J, V348, P0, DOI 10.1136/bmj.g1687
   Huet A, 2011, INT J CLIN EXP HYP, V59, P424, DOI 10.1080/00207144.2011.594740
   Iserson KV, 2014, J EMERG MED, V46, P588, DOI 10.1016/j.jemermed.2013.09.024
   Maria PPJ, 2021, CHILDREN-BASEL, V8, P0, DOI 10.3390/children8121195
   Kain ZN, 1996, ARCH PEDIAT ADOL MED, V150, P1238, DOI 10.1001/archpedi.1996.02170370016002
   Kashlak NL, 2012, THE ACCEPTABILITY OF IMAGERY-HYPNOSIS FOR MANAGEMENT OF PAIN, V0, P0
   KATZ ER, 1987, J PEDIATR PSYCHOL, V12, P379, DOI 10.1093/jpepsy/12.3.379
   Kekecs Z, 2022, INT J CLIN EXP HYP, V70, P104, DOI 10.1080/00207144.2022.2049446
   KELLERMAN J, 1983, J ADOLESCENT HEALTH, V4, P85, DOI 10.1016/S0197-0070(83)80024-2
   KOHEN DP, 1984, J DEV BEHAV PEDIATR, V5, P21
   Kohen DP, 2011, HYPNOSIS AND HYPNOTHERAPY WITH CHILDREN, V4th edition, P0
   KUTTNER L, 1988, J DEV BEHAV PEDIATR, V9, P374
   Kuttner L, 2012, PEDIATR ANESTH, V22, P573, DOI 10.1111/j.1460-9592.2012.03860.x
   Lambert SA, 1996, J DEV BEHAV PEDIATR, V17, P307, DOI 10.1097/00004703-199610000-00003
   Lee GY, 2014, PEDIATRICS, V133, P500, DOI 10.1542/peds.2013-2744
   LETHEM J, 1983, BEHAV RES THER, V21, P401, DOI 10.1016/0005-7967(83)90009-8
   Liossi C, 1999, INT J CLIN EXP HYP, V47, P104, DOI 10.1080/00207149908410025
   Liossi C, 2003, INT J CLIN EXP HYP, V51, P4, DOI 10.1076/iceh.51.1.4.14064
   Liossi C, 2006, HEALTH PSYCHOL, V25, P307, DOI 10.1037/0278-6133.25.3.307
   Liossi C, 2009, PAIN, V142, P255, DOI 10.1016/j.pain.2009.01.017
   Lobe TE, 2006, J LAPAROENDOSC ADV S, V16, P639, DOI 10.1089/lap.2006.16.639
   Loncar Z, 2006, COLLEGIUM ANTROPOL, V30, P319
   Mahood Q, 2014, RES SYNTH METHODS, V5, P221, DOI 10.1002/jrsm.1106
   Manworren RCB, 2015, JOURNAL OF PEDIATRIC SURGICAL NURSING, V4, P60, DOI 10.1097/jps.0000000000000061
   Manworren RCB, 2018, J LAPAROENDOSC ADV S, V28, P1234, DOI 10.1089/lap.2017.0699
   McGrath PJ, 1996, CLIN J PAIN, V12, P135, DOI 10.1097/00002508-199606000-00009
   McKittrick ML, 2022, PAIN MED, V23, P1015, DOI 10.1093/pm/pnab320
   Meller S T, 1994, DRUGS, V47 Suppl 5, P10, DOI 10.2165/00003495-199400475-00004
   Milling LS, 2000, INT J CLIN EXP HYP, V48, P113, DOI 10.1080/00207140008410044
   Moher D, 2009, J CLIN EPIDEMIOL, V62, P1006, DOI 10.1016/j.jclinepi.2009.06.005
   Montgomery GH, 2000, INT J CLIN EXP HYP, V48, P138, DOI 10.1080/00207140008410045
   MORGAN AH, 1973, INT J CLIN EXP HYP, V21, P78, DOI 10.1080/00207147308409308
   Munn Z, 2018, BMC MED RES METHODOL, V18, P0, DOI 10.1186/s12874-017-0468-4
   Nelson KL, 2010, ANESTH ANALG, V110, P754, DOI 10.1213/ANE.0b013e3181ca749c
   Nelson S, 2019, EUR J PAIN, V23, P421, DOI 10.1002/ejp.1319
   Oberoi J, 2016, PEDIATR DENT, V38, P112
   Ogez D, 2021, BRIT J PAIN, V15, P147, DOI 10.1177/2049463720932949
   Okur kavak EK, 2020, CRIT CARE, V24, P72, DOI 10.1186/s13054-020-2772-3
   Orne M T, 1996, INTRODUCING PSYCHOLOGICAL RESEARCH, V0, P0, DOI DOI 10.1007/978-1-349-24483-6_59
   Patterson DR, 2010, INT J CLIN EXP HYP, V58, P288, DOI 10.1080/00207141003760595
   Patterson DR, 2006, INT J CLIN EXP HYP, V54, P130, DOI 10.1080/00207140500528182
   Peters M, 2015, THE JOANNA BRIGGS INSTITUTE REVIEWERS MANUAL 2015, V0, PP3, DOI 10.1017/CBO9781107415324.004
   Polito V, 2014, J MIND-BODY REGUL, V2, P118
   Raja SN, 2020, PAIN, V161, P1976, DOI 10.1097/j.pain.0000000000001939
   Ramírez-Carrasco A, 2017, PAIN RES MANAG, V2017, P0, DOI 10.1155/2017/1434015
   Richardson J, 2006, J PAIN SYMPTOM MANAG, V31, P70, DOI 10.1016/j.jpainsymman.2005.06.010
   Rienhoff S, 2022, CHILDREN-BASEL, V9, P0, DOI 10.3390/children9050611
   Rocco TS, 2009, HUM RESOUR DEV REV, V8, P120, DOI 10.1177/1534484309332617
   Rycroft-Malone J, 2004, J NURS CARE QUAL, V19, P297, DOI 10.1097/00001786-200410000-00002
   Rycroft-Malone J, 2013, IMPLEMENT SCI, V8, P0, DOI 10.1186/1748-5908-8-28
   Sabherwal P, 2021, EUR ARCH PAEDIATR DE, V22, P823, DOI 10.1007/s40368-021-00619-0
   Saxe G, 2001, J AM ACAD CHILD PSY, V40, P915, DOI 10.1097/00004583-200108000-00013
   Schnee AD, 1995, PH.D. THESIS, V0, P0
   Schnur Julie B, 2008, CONTEMP HYPN, V25, P114, DOI 10.1002/ch.364
   Sheridan RL, 2014, J TRAUMA ACUTE CARE, V76, P828, DOI 10.1097/TA.0b013e3182ab111c
   Smith JT, 1996, J COUNS PSYCHOL, V43, P187, DOI 10.1037/0022-0167.43.2.187
   Stinson J, 2008, PAIN RES MANAG, V13, P51, DOI 10.1155/2008/465891
   Stoddard FJ, 2002, J BURN CARE REHABIL, V23, P135, DOI 10.1097/00004630-200203000-00012
   Terhune DB, 2016, AM J CLIN HYPN, V59, P155, DOI 10.1080/00029157.2016.1201454
   Thompson T, 2019, NEUROSCI BIOBEHAV R, V99, P298, DOI 10.1016/j.neubiorev.2019.02.013
   Tomé-Pires C, 2012, INT J CLIN EXP HYP, V60, P432, DOI 10.1080/00207144.2012.701092
   Tran LC, 2021, FRONT PEDIATR, V9, P0, DOI 10.3389/fped.2021.719626
   Tricco AC, 2018, ANN INTERN MED, V169, P467, DOI 10.7326/M18-0850
   Turk D, 2019, PAIN TERMS TAXONOMIE, V5th, P0
   Uman LS, 2006, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD005179.pub3
   Uman LS, 2008, J PEDIATR PSYCHOL, V33, P842, DOI 10.1093/jpepsy/jsn031
   Vanhaudenhuyse A, 2014, NEUROPHYSIOL CLIN, V44, P343, DOI 10.1016/j.neucli.2013.09.006
   WALL VJ, 1989, AM J CLIN HYPN, V31, P181, DOI 10.1080/00029157.1989.10402887
   Weisman SJ, 1998, ARCH PEDIAT ADOL MED, V152, P147
   Widgerow AD, 2012, BURNS, V38, P951, DOI 10.1016/j.burns.2012.05.024
   Wild MR, 2004, J DEV BEHAV PEDIATR, V25, P207, DOI 10.1097/00004703-200406000-00010
   Williams J, 2013, UNITED NATIONS CONVENTION ON THE RIGHTS OF THE CHILD IN WALES, V0, P1
   Yeh Vivian M, 2014, PSYCHOL CONSCIOUS (WASH D C), V1, P213
   Young KD, 2005, ANN EMERG MED, V45, P160, DOI 10.1016/j.annemergmed.2004.09.019
   ZELTZER L, 1982, J PEDIATR-US, V101, P1032
   ZELTZER LK, 1991, PEDIATRICS, V88, P34
   Zielinski J, 2020, ADV CLIN EXP MED, V29, P365, DOI 10.17219/acem/112600
NR 120
TC 21
Z9 21
U1 3
U2 26
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1526-2375
EI 1526-4637
J9 PAIN MED
JI Pain Med.
PD JUN 1
PY 2023
VL 24
IS 6
BP 661
EP 702
DI 10.1093/pm/pnac186
EA JAN 2023
PG 42
WC Anesthesiology; Medicine, General & Internal
SC Anesthesiology; General & Internal Medicine
GA H7AP5
UT WOS:000905659900001
PM 36448690
DA 2026-01-16
ER

PT J
AU Zhang, J
   Liu, L
   Zhu, M
   Zheng, X
   Liang, Y
   Zhong, Y
   Xu, J
   Yang, J
AF Zhang, Jingwen
   Liu, Liying
   Zhu, Manjia
   Zheng, Xiaoyan
   Liang, Yun
   Zhong, Ying
   Xu, Jing
   Yang, Jie
TI Research Status and Prospects of Acupuncture in Perioperative Medicine Over the
SO Journal of pain research
LA English
DT Review
DE CiteSpace; VOSviewer; acupuncture; mid-operative; perioperative medicine; post-operative
AB BACKGROUND: Over the past decade, acupuncture in the perioperative period has  attracted great interest, and a growing number of related literature has been  published. PURPOSE: To analyze the general information and identify the research  hotspots and trends of acupuncture in perioperative medicine in the last 10 years  by bibliometric analysis. METHODS: We searched the Web of Science Core Collection  for publications on acupuncture in perioperative medicine from 2013 to 2023. The  articles and reviews were collected with no language restriction. CiteSpace and  VOSviewer software were used for bibliometric and visual analysis of relevant  literature. RESULTS: A total of 814 bibliographic records were retrieved.  Overall, the annual number of publications showed an increasing trend. China and  its institutions were in a leading position regarding the publication number.  With comparatively more scientific collaboration with China, the USA ranked  second. Shanghai University of Traditional Chinese Medicine was the most prolific  institution. Ha, In-Hyuk had the most publications, and Han JS and Lee A were the  most cited authors. Medicine was the most popular journal and Journal of Clinical  Oncology had the highest impact factor. "Acupuncture", "electroacupuncture" and  "postoperative pain" were the top three keywords. The most popular topics were  postoperative pain, postoperative ileus, and postoperative nausea and vomiting  according to the keywords and references. And the clusters of postoperative  cognitive dysfunction, anxiety, and breast cancer attracted relatively more  attention recently. CONCLUSION: This study summarized the research status,  hotspots, and trends of acupuncture in perioperative medicine in the past decade,  which may aid researchers in better understanding this field. The research  hotspots primarily focused on postoperative pain management and postoperative  gastrointestinal function. The research of acupuncture for postoperative  cognitive dysfunction, cancer-related surgery, and psychological states were the  main frontiers topics and may be the focus in the future.
C1 Acupuncture and Tuina School, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, People's Republic of China.
   Acupuncture and Tuina School, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, People's Republic of China.
   Basic Medical College, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, People's Republic of China.
   Acupuncture and Tuina School, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, People's Republic of China.
   Sichuan Jinxin Xi'nan Women's and Children's Hospital, Chengdu, Sichuan, People's 
   Acupuncture and Tuina School, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, People's Republic of China.
   Sichuan Jinxin Xi'nan Women's and Children's Hospital, Chengdu, Sichuan, People's Republic of China.
   Acupuncture and Tuina School, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, People's Republic of China.
   Acupuncture and Tuina School, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, People's Republic of China.
   Sichuan Jinxin Xi'nan Women's and Children's Hospital, Chengdu, Sichuan, People's
NR 0
TC 0
SN 1178-709
EI 1178-709
J9 J Pain Res
PD JUL 3
PY 2023
VL 16
IS 
BP 2189
EP 2204
DI 10.2147/JPR.S415998
PG 15
UT PubMed:37397275
PM 37397275
DA 2023-07-03
ER

PT J
AU Papadopoulou, M
   Stamou, M
   Bakalidou, D
   Moschovos, C
   Zouvelou, V
   Zis, P
   Tzartos, J
   Chroni, E
   Michopoulos, I
   Tsivgoulis, G
AF Papadopoulou, Marianna
   Stamou, Magda
   Bakalidou, Daphne
   Moschovos, Christos
   Zouvelou, Vasiliki
   Zis, Panagiotis
   Tzartos, John
   Chroni, Elisabeth
   Michopoulos, Ioannis
   Tsivgoulis, Georgios
TI Non-pharmacological Interventions on Pain and Quality of Life in Chemotherapy
SO In vivo (Athens, Greece)
LA English
DT Journal Article
DE Chemotherapy-induced polyneuropathy; acupuncture; non-pharmacological interventions; pain; quality of life; review; yoga
AB BACKGROUND/AIM: Chemotherapy-induced peripheral neuropathy (CIPN) is a common  side effect of cancer treatment, resulting in pain, numbness, instability, and  thus affecting quality of life (QoL), occasionally leading to discontinuation of  chemotherapy. Pharmacological treatments are not sufficient. Non-pharmacological  interventions (NPIs) have also been tried. This study aimed to systematically  review the efficacy of NPIs on pain and QoL in patients suffering from CIPN.  MATERIALS AND METHODS: The databases searched were Pubmed, Cohrane, and Scopus  for randomized controlled trials (RCTs) published in the last 5 years  (2017-2022). Studies were considered eligible, if they assessed adult patients  suffering from CIPN because of any chemotherapeutic drug for any type and any  stage of cancer and if study protocols included non-pharmacological intervention  with a structured protocol. RESULTS: A total of 1,496 records were identified.  Finally, 10 RCTs including 495 patients (253 in the intervention group and 242 in  the control group) were included for meta-analysis. Intervention protocols  included acupuncture (n=6), exercise (n=3), and yoga (n=1). NPIs significantly  reduced neuropathic pain. However, the effect on QoL was not significant.  CONCLUSION: NPIs are beneficial in the treatment of pain in patients with CIPN  but their impact on QoL is not statistically supported. Larger sample sizes, more  homogenous in outcome measures and interventions are needed to further explore  NPIs' efficacy on CIPN symptoms.
C1 Department of Physiotherapy, University of West Attica, Athens, Greece
   marpapgr@yahoo.co.uk mpapad@uniwa.gr.
   Second Department of Neurology, Medical School, National and Kapodistrian 
   Department of Physiotherapy, University of West Attica, Athens, Greece.
   Department of Physiotherapy, University of West Attica, Athens, Greece.
   Second Department of Neurology, Medical School, National and Kapodistrian University of Athens, Attikon University General Hospital, Athens, Greece.
   First Department of Neurology, National and Kapodistrian University of Athens, School of Medicine, Eginition University Hospital, Athens, Greece.
   Second Department of Neurology, Medical School, National and Kapodistrian University of Athens, Attikon University General Hospital, Athens, Greece.
   Second Department of Neurology, Medical School, National and Kapodistrian University of Athens, Attikon University General Hospital, Athens, Greece.
   Department of Neurology, School of Medicine, University of Patras, Patras, Greece.
   Second Department of Psychiatry, Medical School, National and Kapodistrian University of Athens, Attikon University General Hospital, Athens, Greece.
   Second Department of Neurology, Medical School, National and Kapodistrian University of Athens, Attikon University General Hospital, Athens, Greece.
NR 0
TC 0
SN 1791-754
EI 0258-851
J9 In Vivo
PD JAN 3
PY 2023
VL 37
IS 1
BP 47
EP 56
DI 10.21873/invivo.13053
PG 9
WC Adult; Humans; Antineoplastic Agents; therapeutic use; Neoplasms; complications; Polyneuropathies; therapy; Neuralgia; chemically induced; Quality of Life
UT PubMed:36593011
PM 36593011
DA 2023-01-03
ER

PT J
AU Wang, P
   Xie, F
   Zhang, L
   Zhao, S
   Zhu, L
   Shen, S
   Li, D
   Chen, Z
   Xiao, R
   Lu, Y
   Lei, X
   Li, Y
   Zhang, G
   Zeng, W
   Wang, X
AF Wang, Peiru
   Xie, Fang
   Zhang, Linglin
   Zhao, Shuang
   Zhu, Lude
   Shen, Shuzhan
   Li, Dongsheng
   Chen, Zhou
   Xiao, Rong
   Lu, Yan
   Lei, Xia
   Li, Yan
   Zhang, Guolong
   Zeng, Weihui
   Wang, Xiuli
TI Plum-blossom needle tapping enhances the efficacy of ALA photodynamic therapy for
SO Photodiagnosis and photodynamic therapy
LA English
DT Journal Article
DE Actinic keratosis; Photodynamic therapy; Plum-blossom needle
AB BACKGROUND: Photodynamic therapy (PDT) with 5-aminolevulinic acid (ALA) is a  reliable treatment for actinic keratosis (AK), but its effect needs to be  enhanced in thick lesions. Plum-blossom needle is a traditional Chinese  cost-effective instrument for enhancing the transdermal delivery of ALA. However,  whether it could improve the efficacy of AK treatment has not yet been  investigated. OBJECTIVE: To compare the efficacy and safety of plum-blossom  needle-assisted PDT in facial AK in the Chinese population. METHODS: In this  multicenter, prospective study, a total of 142 patients with AKs (grades I-III)  were randomized into the plum-blossom needle-assisted PDT group (P-PDT) and  control PDT group (C-PDT). In the P-PDT group, each AK lesion was tapped  vertically by a plum-blossom needle before the application of 10% ALA cream. In  the C-PDT group, each lesion was only wiped with regular saline before ALA cream  incubation. Then, 3 hours later, all the lesions were irradiated with  light-emitting diode (LED) at a wavelength of 630 nm. PDT was performed once  every 2 weeks until all lesion patients achieved complete remission or completed  six sessions. The efficacy (lesion response) and safety (pain scale and adverse  events) in both groups were evaluated before each treatment and at every  follow-up visit at 3-month intervals until 12 months. RESULTS: In the P-PDT and  C-PDT groups, the clearance rates for all AK lesions after the first treatment  were 57.9% and 48.0%, respectively (P < 0.05). For grade I AK lesions, the  clearance rates were 56.5% and 50.4%, respectively (P = 0.34). For grade II AK  lesions, the clearance rates were 58.0% and 48.9%, respectively (P = 0.1). For  grade III AK lesions, the clearance rates were 59.0% and 44.2%, respectively (P <  0.05). Moreover, grade III AK lesions in the P-PDT group required fewer treatment  sessions (P < 0.05). There was no significant difference in the pain score  between the two groups (P = 0.752). CONCLUSION: Plum-blossom needle tapping may  enhance the efficacy of ALA-PDT by facilitating ALA delivery in the treatment of  AK.
C1 Shanghai Skin Disease Hospital, School of Medicine, Institute of Photomedicine, Tongji University, Shanghai, PR China.
   Department of Dermatology, The First Medical Center of Chinese PLA General Hospital, Beijing 100853, PR China.
   Shanghai Skin Disease Hospital, School of Medicine, Institute of Photomedicine, Tongji University, Shanghai, PR China.
   Xiangya Hospital Central South University, Changsha, PR China.
   Department of Dermatology, Changhai Hospital, Second Military Medical University, Shanghai, PR China.
   Shanghai Skin Disease Hospital, School of Medicine, Institute of Photomedicine, Tongji University, Shanghai, PR China.
   Wuhan No. 1 Hospital, Dermatology, Wuhan, PR China.
   Peking University People's Hospital, Beijing, PR China.
   Xiangya Hospital Central South University, Changsha, PR China.
   Department of Dermatology, First Affiliated Hospital of Nanjing Medical University, Nanjing, PR China.
   Department of Dermatology, Department of Dermatology, Daping Hospital, The Army Medical University, Chongqing, PR China.
   Department of Dermatology, Henan Provincial People's Hospital, Zhengzhou, PR China.
   Shanghai Skin Disease Hospital, School of Medicine, Institute of Photomedicine, Tongji University, Shanghai, PR China.
   Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, PR China. 
   Shanghai Skin Disease Hospital, School of Medicine, Institute of Photomedicine, Tongji University, Shanghai, PR China.
EM angxiuli_1400023@tongji.edu.cn
NR 0
TC 0
SN 1873-159
EI 
J9 Photodiagnosis Photodyn Ther
PD MAY 22
PY 2023
VL 42
IS 
BP 103611
EP 103611
DI 10.1016/j.pdpdt.2023.103611
PG 0
WC Humans; Aminolevulinic Acid; administration & dosage; East Asian People; Keratosis, Actinic; drug therapy; Pain; etiology; Photochemotherapy; methods; Photosensitizing Agents; administration & dosage; Prospective Studies; Treatment Outcome; Single-Blind Method; Administration, Cutaneous; Skin Cream; administration & dosage; Face; Dry Needling; instrumentation; Acupuncture Therapy; instrumentation
UT PubMed:37211296
PM 37211296
DA 2023-05-22
ER

PT J
AU Li, LL
   Jiang, X
   Wan, YX
   Qi, XW
   Huang, JC
AF Li, Li-Ling
   Jiang, Xin
   Wan, Yu-Xiang
   Qi, Xue-Wei
   Huang, Jin-Chang
TI [Exploration of the thinking and methods in treatment of cancer pain with
SO Zhongguo zhen jiu = Chinese acupuncture & moxibustion
LA chi
DT Journal Article
DE acupuncture-moxibustion therapy; cancer pain; fascial network; jingjin; myofascial chain
AB There is a commonality between jingjin (muscle region of meridian) and the  fascial network for coordinating the balance in the body. The occurrence and the  progression of tumor may disrupt the overall coordination between the fascial  network and jingjin directly or indirectly, thereby, the impairment of this  coordination may result in cancer pain. Rooted on the theory of overall balance  of the fascial network, and combined with understanding of pain in jingjin  theory, professor HUANG Jin-chang emphasizes the importance of "relaxing the  knot" in treatment of cancer pain. It is recommended to select the fascia  reaction point as the target point, in accordance with the principle of balance  adjustment and apply various acupuncture and moxibustion therapies, such as Fu's  subcutaneous needling, small-needle scalpel therapy, fire needling, and  moxibustion.
C1 Third Affiliated Hospital of Beijing University of CM, Beijing 100029, China.
   Oncology Department of Acupuncture and Minimally Invasive Treatment, Third Affiliated Hospital of Beijing University of CM, Beijing 100029.
   Oncology Department of Acupuncture and Minimally Invasive Treatment, Third Affiliated Hospital of Beijing University of CM, Beijing 100029
   Institute ofAcupuncture and Oncology, Beijing University of CM, Beijing 100029.
   Third Affiliated Hospital of Beijing University of CM, Beijing 100029, China.
   Oncology Department of Acupuncture and Minimally Invasive Treatment, Third Affiliated Hospital of Beijing University of CM, Beijing 100029
   Institute ofAcupuncture and Oncology, Beijing University of CM, Beijing 100029.
NR 0
TC 0
SN 
EI 0255-293
J9 Zhongguo Zhen Jiu
PD AUG 14
PY 2023
VL 43
IS 8
BP 894
EP 8
DI 10.13703/j.0255-2930.20230210-0004
PG -886
WC Humans; Moxibustion; Cancer Pain; Acupuncture Points; Acupuncture Therapy; Fascia; Neoplasms; complications
UT PubMed:37577884
PM 37577884
DA 2023-08-14
ER

PT J
AU Liao, CX
   Tao, SY
   Xiong, Y
   Dai, JY
   Bai, Y
   Wang, X
   Li, Y
   Wu, P
AF Liao, Chenxi
   Tao, Siyu
   Xiong, Yan
   Dai, Jingyang
   Bai, Yu
   Wang, Xue
   Li, Yuan
   Wu, Ping
TI The Effects and Potential Mechanisms of Moxibustion for Rheumatoid Arthritis-Related Pain: A Randomized, Controlled Trial
SO JOURNAL OF PAIN RESEARCH
LA English
DT Article
DE moxibustion; rheumatoid arthritis; pain; inflammatory factor
ID quality-of-life; american-college; acupuncture; definition; validation; activation; expression; management; cytokines; scores
AB Purpose: To investigate the effects of moxibustion in relieving pain, and other clinical symptoms for patients with rheumatoid arthritis (RA), and explore the potential mechanism of moxibustion treatment for RA.Patients and Methods: Seventy qualified RA patients were randomly assigned in a 1:1 ratio to the moxibustion group or the routine group. The routine group only took oral methotrexate tablets and folic acid tablets. The moxibustion group was treated with moxibustion based on oral pharmaceutical. Moxibustion was performed two times weekly for 8 weeks, a total of 16 sessions. Patients scored their pain on a visual analog scale (VAS). The American College of Rheumatology improvement criteria of 20%, 50% and 70% (ACR20, ACR50 and ACR70) after treatment were investigated. Clinical symptoms, a disease activity score using 28 joint counts (DAS28), simplified disease activity index (SDAI), clinical disease activity index (CDAI), health assessment questionnaire (HAQ), interleukin 1 beta (IL-1 beta), tumor necrosis factor-alpha (TNF-alpha), and vascular endothelial growth factor (VEGF) of RA patients were analyzed before and after treatment.Results: After treatment, the VAS scores, tender and swollen joint counts, morning stiffness scores, disease activity scores (DAS28, SDAI, CDAI), HAQ scores in the two groups were both improved, and the effects of moxibustion group were more obvious (P < 0.05). The ACR20 and ACR50 of the moxibustion group were greater than that of the routine group (P < 0.05), no significant difference of the ACR70 existed between the two groups (P > 0.05). In addition, the decreases of IL-1 beta, TNF-alpha, VEGF of the moxibustion group were better than that of the routine group (P < 0.05).Conclusion: Moxibustion could effectively relieve pain, ameliorate the clinical symptoms, and decrease the disease activity of RA. The potential mechanism may be the decrease in the level of serum inflammatory factors.
C1 [Liao, Chenxi; Tao, Siyu; Wang, Xue; Wu, Ping] Chengdu Univ Tradit Chinese Med, Acupuncture & Tuina Sch, Chengdu, Peoples R China.
   [Xiong, Yan] Sichuan Univ, Huaxi Hosp 4, Dept Osteoporosis, Chengdu, Peoples R China.
   [Dai, Jingyang] Chengdu Fifth Peoples Hosp, Dept Tradit Chinese Med, Chengdu, Peoples R China.
   [Bai, Yu] Chengdu Second Peoples Hosp, Dept Tradit Chinese Med, Chengdu, Peoples R China.
   [Li, Yuan] Chengdu Univ Tradit Chinese Med, Affiliated Hosp, Dept Rheumatol, Chengdu, Peoples R China.
C3 Chengdu University of Traditional Chinese Medicine; Sichuan University; Chengdu University of Traditional Chinese Medicine
RP Wu, P (corresponding author), Chengdu Univ Tradit Chinese Med, Acupuncture & Tuina Sch, Chengdu, Peoples R China.
EM wuping_33@163.com
FU National Natural Science Foundation of China [81373738]; Education Department of Sichuan Province [2017JY0016, 2022YFS0386]
CR Aletaha D, 2005, ARTHRITIS RES THER, V7, PR796, DOI 10.1186/ar1740
   Aletaha D, 2012, ANN RHEUM DIS, V71, P1190, DOI 10.1136/annrheumdis-2012-201491
   Aletaha D, 2010, ARTHRITIS RHEUM-US, V62, P2569, DOI 10.1002/art.27584
   Alshevskaya AA, 2015, MEDIAT INFLAMM, V2015, P0, DOI 10.1155/2015/948393
   Bruce B, 2003, J RHEUMATOL, V30, P167
   Chen Y, 2019, EVID-BASED COMPL ALT, V2019, P0, DOI 10.1155/2019/6436420
   Clavel G, 2007, CLIN IMMUNOL, V124, P158, DOI 10.1016/j.clim.2007.04.014
   Covic T, 2012, BMC PSYCHIATRY, V12, P0, DOI 10.1186/1471-244X-12-6
   Mitidieri AMD, 2020, PAIN PHYSICIAN, V23, P507, DOI 10.36076/ppj.2020/23/507
   Drosos AA, 2020, CURR RHEUMATOL REP, V22, P0, DOI 10.1007/s11926-020-00921-8
   FELSON DT, 1995, ARTHRITIS RHEUM, V38, P727, DOI 10.1002/art.1780380602
   Firestein GS, 2003, NATURE, V423, P356, DOI 10.1038/nature01661
   Fransen J, 2004, RHEUMATOLOGY, V43, P1252, DOI 10.1093/rheumatology/keh297
   Gao F, 2018, BRAIN BEHAV IMMUN, V67, P91, DOI 10.1016/j.bbi.2017.08.004
   [高秀花 Gao Xiuhua], 2015, 中国中医基础医学杂志 CHINESE JOURNAL OF BASIC MEDICINE IN TRADITIONAL CHINESE MEDICINE, V21, P1140
   Gong YY, 2019, PAIN RES MANAG, V2019, P0, DOI 10.1155/2019/4705247
   Hongwu Yu, 2016, ZHONGGUO ZHEN JIU, V36, P17
   Hwang YG, 2015, NEUROIMMUNOMODULAT, V22, P72, DOI 10.1159/000362727
   Jensen MP, 2003, J PAIN, V4, P407, DOI 10.1016/S1526-5900(03)00716-8
   Juarez M, 2012, SWISS MED WKLY, V142, P0, DOI 10.4414/smw.2012.13529
   Kaeley Nidhi, 2019, J FAMILY MED PRIM CARE, V8, P22, DOI 10.4103/jfmpc.jfmpc_260_18
   Katz J, 1999, SURG CLIN N AM, V79, P231, DOI 10.1016/S0039-6109(05)70381-9
   Kim HR, 2015, PLOS ONE, V10, P0, DOI 10.1371/journal.pone.0124909
   Koike T, 2014, J RHEUMATOL, V41, P15, DOI 10.3899/jrheum.130466
   Kwiatkowska B, 2019, PSYCHOL HEALTH MED, V24, P333, DOI 10.1080/13548506.2018.1529325
   [李兴 Li Xing], 2016, 中华疾病控制杂志 CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION, V20, P201
   Liu Zhidan, 2017, ZHONGGUO ZHEN JIU, V37, P1083, DOI 10.13703/j.0255-2930.2017.10.015
   Machin AR, 2020, CLIN RHEUMATOL, V39, P1471, DOI 10.1007/s10067-019-04900-y
   Moelants EAV, 2013, IMMUNOL CELL BIOL, V91, P393, DOI 10.1038/icb.2013.15
   Negrei C, 2016, EXP THER MED, V11, P1177, DOI 10.3892/etm.2016.3045
   Orange DE, 2020, ARTHRITIS RHEUMATOL, V72, P557, DOI 10.1002/art.41141
   Ovayolu N, 2011, CLIN RHEUMATOL, V30, P655, DOI 10.1007/s10067-010-1604-2
   Paradowska-Gorycka A, 2016, PLOS ONE, V11, P0, DOI 10.1371/journal.pone.0160769
   PREVOO MLL, 1995, ARTHRITIS RHEUM, V38, P44, DOI 10.1002/art.1780380107
   Rawla Prashanth, 2019, REUMATOLOGIA (WARSAW), V57, P27, DOI 10.5114/reum.2019.83236
   [任继刚 Ren Jigang], 2017, 时珍国医国药 LISHIZHEN MEDICINE AND MATERIA MEDICA RESEARCH, V28, P3048
   Scheiman JM, 2016, J CLIN GASTROENTEROL, V50, P5, DOI 10.1097/MCG.0000000000000432
   Shen BY, 2019, MEDICINE, V98, P0, DOI 10.1097/MD.0000000000016413
   Smolen JS, 2016, LANCET, V388, P2023, DOI 10.1016/S0140-6736(16)30173-8
   Smolen JS, 2017, ANN RHEUM DIS, V76, P960, DOI 10.1136/annrheumdis-2016-210715
   Smolen JS, 2003, RHEUMATOLOGY, V42, P244, DOI 10.1093/rheumatology/keg072
   Spagnolo P, 2018, ARTHRITIS RHEUMATOL, V70, P1544, DOI 10.1002/art.40574
   Su TF, 2012, EUR J PAIN, V16, P624, DOI 10.1002/j.1532-2149.2011.00055.x
   Takano S, 2018, BMC MUSCULOSKEL DIS, V19, P0, DOI 10.1186/s12891-018-2127-2
   Tedeschi SK, 2013, CLIN IMMUNOL, V149, P211, DOI 10.1016/j.clim.2013.03.003
   Uguz F, 2015, INT J PSYCHIAT MED, V49, P199, DOI 10.1177/0091217415582183
   Wan RH, 2022, FRONT IMMUNOL, V13, P0, DOI 10.3389/fimmu.2022.829409
   Wang Shunji, 2017, ZHONGGUO ZHEN JIU, V37, P1047, DOI 10.13703/j.0255-2930.2017.10.006
   Wei Jian-zi, 2007, ZHONGGUO ZHEN JIU, V27, P391
   Xie Xiao-Xia, 2008, ZHONGGUO ZHEN JIU, V28, P730
   Xu Sen-Lei, 2018, ZHEN CI YAN JIU, V43, P738, DOI 10.13702/j.1000-0607.170309
   Yang Han-Qi, 2013, ZHEN CI YAN JIU, V38, P134
   Yu XD, 2019, ACUPUNCT MED, V37, P312, DOI 10.1136/acupmed-2017-011536
   Zhang CY, 2009, J ACUPUNCT TUINA SCI, V7, P65, DOI 10.1007/s11726-009-0065-0
   Zhang Min, 2021, ZHONGGUO ZHEN JIU, V41, P489, DOI 10.13703/j.0255-2930.20200519-k0005
   Zheng YX, 2014, J IMMUNOL RES, V2014, P0, DOI 10.1155/2014/385352
   Zhong YM, 2020, EVID-BASED COMPL ALT, V2020, P0, DOI 10.1155/2020/6108619
NR 57
TC 4
Z9 7
U1 3
U2 21
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1178-7090
EI 
J9 J PAIN RES
JI J. Pain Res.
PD JUN 15
PY 2023
VL 16
IS 
BP 1739
EP 1749
DI 10.2147/JPR.S408814
PG 11
WC Clinical Neurology
SC Neurosciences & Neurology
GA I3YO8
UT WOS:001002171300001
PM 37261035
DA 2026-01-16
ER

PT J
AU Ling, F
   Qi, W
   Li, X
   Zhou, J
   Xiong, J
   Zhao, Y
   Zheng, Q
   Liang, F
AF Ling, Fayang
   Qi, Wenchuan
   Li, Xiao
   Zhou, Jun
   Xiong, Jian
   Zhao, Yi
   Zheng, Qianhua
   Liang, Fanrong
TI Bibliometric Analysis of Acupuncture Therapy for Cancer Pain Over the Past 10
SO Journal of pain research
LA English
DT Review
DE CiteSpace; acupuncture analgesia; bibliometric analysis; cancer; pain
AB PURPOSE: Cancer pain is a common symptom of cancer patients and greatly affects  quality of life. Acupuncture has certain curative effects on cancer pain. The aim  of this study was to analyze and visualize the current status and research trend  of acupuncture treatment for cancer pain over the last 10 years and provide  directions for future development. METHODS: A search of the Web of Science Core  Collection from 2012-01-01 to 2022-08-20 was performed to collect studies related  to acupuncture therapy for cancer pain. CiteSpace was used to conduct  bibliometric analysis and visualization from the perspective of the volume of  annual publications, journals, nations, institutions, authors, keywords, and  references. RESULTS: A total of 302 studies were included in the analysis. The  number of publications increased steadily with some fluctuations over the past  decade. Integrative Cancer Therapies was the journal with the most relevant  publications, and the Journal of Clinical Oncology was the most frequently cited  journal. China had the highest volume of publications, and the USA contributed  most to international collaboration. The most prolific institution was Memorial  Sloan Kettering Cancer Center. The most productive author was Mao JJ, and the  most influential author was Lu WD. "Acupuncture" was the top keyword in frequency  and centrality. The references with the highest frequency and centrality were  published by HE, Y, and Ting Bao, respectively. CONCLUSION: A stable development  trend has formed in this field. The overall collaborative network needs to be  strengthened. Breast cancer and multiple myeloma, electroacupuncture and bee  venom acupuncture, postoperative pain, peripheral neuropathic pain syndrome, and  aromatase inhibitors-associated arthralgia syndrome are research hotspots in this  field. Randomized controlled trials (RCTs), evidence-based evaluations and  mechanisms (cancer-induced bone pain) are research trends and frontiers.
C1 Acupuncture and Tuina School, Chengdu University of Traditional Chinese Medicine, Chengdu, People's Republic of China.
   Acupuncture and Tuina School, Chengdu University of Traditional Chinese Medicine, Chengdu, People's Republic of China.
   Acupuncture and Tuina School, Chengdu University of Traditional Chinese Medicine, Chengdu, People's Republic of China.
   Acupuncture and Tuina School, Chengdu University of Traditional Chinese Medicine, Chengdu, People's Republic of China.
   Acupuncture and Tuina School, Chengdu University of Traditional Chinese Medicine, Chengdu, People's Republic of China.
   Acupuncture and Tuina School, Chengdu University of Traditional Chinese Medicine, Chengdu, People's Republic of China.
   Acupuncture and Tuina School, Chengdu University of Traditional Chinese Medicine, Chengdu, People's Republic of China.
   Acupuncture and Tuina School, Chengdu University of Traditional Chinese Medicine/Clinical Research Center for Acupuncture and Moxibustion in SichuanProvince, Chengdu, People's Republic of China.
NR 0
TC 0
SN 1178-709
EI 1178-709
J9 J Pain Res
PD MAR 28
PY 2023
VL 16
IS 
BP 985
EP 1003
DI 10.2147/JPR.S395421
PG 18
UT PubMed:36968762
PM 36968762
DA 2023-03-28
ER

PT J
AU Yao, JL
   Yang, WX
   Wang, YC
   Jiao, LJ
   Shi, J
   Gong, YB
AF Yao, Jia-Lin
   Yang, Wen-Xiao
   Wang, Yi-Chao
   Jiao, Li-Jing
   Shi, Jun
   Gong, Ya-Bin
TI [Blade acupuncture combined with functional exercise for chronic pain after
SO Zhongguo zhen jiu = Chinese acupuncture & moxibustion
LA chi
DT Journal Article
DE blade acupuncture; functional exercise; non-small cell lung cancer; postoperative chronic pain; randomized controlled trial (RCT)
AB OBJECTIVE: To observe the clinical efficacy of blade acupuncture combined with  functional exercise for chronic pain after non-small cell lung cancer surgery.  METHODS: A total of 62 patients with chronic pain after surgery for non-small  cell lung cancer were randomly divided into an observation group and a control  group, 31 cases in each group. The patients in the control group were treated  with functional exercise. On the base of the treatment in the control group, the  patients in the observation group were treated with blade acupuncture at the  tendon nodes or painful points, once a week for 4 weeks. The visual analogue  scale (VAS) scores of pain before treatment and day 1, day 7, day 14, day 28 of  treatment and day 90, day 180 when follow up were compared between the two  groups; the brief pain inventory (BPI) scores before and after treatment were  compared between the two groups. RESULTS: The VAS score in the observation group  at each time point after treatment was lower than that before treatment (P<0.01),  and lower than that in the control group (P<0.01). Compared before treatment, the  daily life score, emotion score, walking ability score, sleep score and life  enjoyment score and total score of BPI in the observation group were reduced  after treatment (P<0.05), and the daily life score, emotion score, sleep score  and total score of BPI in the observation group were lower than those in the  control group (P<0.05). CONCLUSION: The blade acupuncture combined with  functional exercise could effectively alleviate the chronic pain after non-small  cell lung cancer surgery, improve the quality of life of patients, and the effect  is lasting and stable.
C1 Department of Oncology, Yueyang Hospital of Integrative Chinese and Western Medicine, Shanghai University of TCM, Shanghai 200437, China.
   Department of Oncology, Yueyang Hospital of Integrative Chinese and Western Medicine, Shanghai University of TCM, Shanghai 200437, China.
   Department of Oncology, Yueyang Hospital of Integrative Chinese and Western Medicine, Shanghai University of TCM, Shanghai 200437, China.
   Department of Oncology, Yueyang Hospital of Integrative Chinese and Western Medicine, Shanghai University of TCM, Shanghai 200437, China.
   Department of Oncology, Yueyang Hospital of Integrative Chinese and Western Medicine, Shanghai University of TCM, Shanghai 200437, China.
   Department of Oncology, Yueyang Hospital of Integrative Chinese and Western Medicine, Shanghai University of TCM, Shanghai 200437, China.
NR 0
TC 0
SN 
EI 0255-293
J9 Zhongguo Zhen Jiu
PD MAY 18
PY 2023
VL 42
IS 10
BP 1125
EP 8
DI 10.13703/j.0255-2930.20211203-k0001
PG -1117
WC Humans; Carcinoma, Non-Small-Cell Lung; complications; Chronic Pain; etiology; Quality of Life; Acupuncture Points; Lung Neoplasms; complications; Acupuncture Therapy; Treatment Outcome
UT PubMed:37199203
PM 37199203
DA 2023-05-18
ER

PT J
AU Cohen, SA
   Veleber, S
   Siman, J
   Guthrie, KA
   McMillen, K
   Heit, M
   Wadhera, S
   Daniels, J
   Hansen, K
   Jacoby, M
   Taromina, K
   Chin, S
   Romeo, M
   Langley, BO
   Coveler, AL
   Hannan, LM
   King, G
   Purcell, T
   Safyan, RA
   Shankaran, V
   Zhen, DB
   Chiorean, EG
   Greenlee, H
AF Cohen, Stacey A.
   Veleber, Susan
   Siman, Jonathan
   Guthrie, Katherine A.
   McMillen, Kerry
   Heit, Madilyn
   Wadhera, Sonia
   Daniels, Jonathan
   Hansen, Kjell
   Jacoby, Madeline
   Taromina, Katherine
   Chin, Samantha
   Romeo, Melissa
   Langley, Blake O.
   Coveler, Andrew L.
   Hannan, Lindsay M.
   King, Gentry
   Purcell, Tom
   Safyan, Rachael A.
   Shankaran, Veena
   Zhen, David B.
   Chiorean, E. Gabriela
   Greenlee, Heather
TI Use of acupuncture with acupressure in addition to standard-of-care cryotherapy to decrease chemotherapy-associated neuropathy in patients with gastrointestinal malignancies receiving oxaliplatin-based chemotherapy: Study protocol for a randomized, controlled pilot and feasibility study
SO CONTEMPORARY CLINICAL TRIALS
LA English
DT Article
DE Colorectal cancer; Pancreatic cancer; Oxaliplatin; Peripheral neuropathy
ID induced peripheral neuropathy; iii colon-cancer; prevention; survival; trial; electroacupuncture; gemcitabine; folfirinox
AB Background: Oxaliplatin is a key chemotherapeutic agent in the treatment of local and metastatic gastrointestinal (GI) malignancies. Dose density and treatment adherence can be limited by chemotherapy-induced peripheral neuropathy (CIPN). Early research suggests CIPN incidence and severity may be mitigated by acupuncture, but rigorous data in GI oncology patients is limited. Here, we describe the protocol of a randomized, waitlistcontrolled pilot study testing the use of preemptive of acupuncture plus acupressure to decrease CIPN and chemotherapy-related toxicities.Methods: Patients with a GI malignancy (n = 56) with planned 5-fluorouracil (5-FU) and oxaliplatin IV (FOLFOX, FOLFIRINOX) every 2 weeks are being recruited. Additional concurrent anti-neoplastic agents may be used. Enrolled patients are randomized 1:1 to a 3-month intervention of Arm A: acupuncture with acupressure and standard-of-care treatment, or Arm B: standard-of-care alone. In Arm A, on days 1 and 3 of each chemotherapy cycle a standardized acupuncture protocol is administered and patients are taught self-acupressure to perform daily between chemotherapy treatments. Patients in both arms are given standard-of-care oral and peripheral (hands/feet) ice chip cryotherapy during oxaliplatin administration. CIPN and other symptoms are assessed at baseline, 6 weeks, and 3 months from registration. The primary endpoint is CIPN severity at 3 months (EORTCCIPN 20). Additional endpoints evaluate CIPN incidence (CTCAE, Neuropen, tuning fork); incidence of pain, fatigue, nausea, oral dysesthesia, and anxiety; and feasibility (recruitment, retention, adherence, acceptability). If warranted, trial results will inform the design of a multi-center trial to expand testing of the intervention to a larger patient cohort.
C1 [Cohen, Stacey A.; McMillen, Kerry; Heit, Madilyn; Wadhera, Sonia; Daniels, Jonathan; Hansen, Kjell; Jacoby, Madeline; Coveler, Andrew L.; King, Gentry; Purcell, Tom; Safyan, Rachael A.; Shankaran, Veena; Zhen, David B.; Chiorean, E. Gabriela; Greenlee, Heather] Fred Hutchinson Canc Ctr, Clin Res Div, 825 Eastlake Ave E, Seattle, WA 98109 USA.
   [Cohen, Stacey A.; Heit, Madilyn; Wadhera, Sonia; Daniels, Jonathan; Hansen, Kjell; Jacoby, Madeline; Coveler, Andrew L.; Hannan, Lindsay M.; King, Gentry; Purcell, Tom; Safyan, Rachael A.; Shankaran, Veena; Zhen, David B.; Chiorean, E. Gabriela; Greenlee, Heather] Univ Washington, Sch Med, Div Med Oncol, Seattle, WA USA.
   [Veleber, Susan; Siman, Jonathan; Taromina, Katherine; Chin, Samantha; Romeo, Melissa; Langley, Blake O.; Greenlee, Heather] Fred Hutchinson Canc Ctr, Integrat Med Program, Div Support Care, Seattle, WA USA.
   [Veleber, Susan; Siman, Jonathan; Guthrie, Katherine A.; Langley, Blake O.; Greenlee, Heather] Fred Hutchinson Canc Ctr, Div Publ Hlth Sci, Seattle, WA USA.
   [Langley, Blake O.] Univ Washington, Dept Child Family & Populat Hlth Nursing, Seattle, WA 98195 USA.
   [Cohen, Stacey A.] 825 Eastlake Ave E,LG-465, Seattle, WA 98109 USA.
C3 Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle; Fred Hutchinson Cancer Center; Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle
RP Cohen, SA (corresponding author), 825 Eastlake Ave E,LG-465, Seattle, WA 98109 USA.
EM shiovitz@uw.edu
FU Safeway Albertsons Early Career Award in Cancer Research; National Center for Complementary and Integrative Health (NCCIH) [RT90AT00854]; National Center for Complementary and Integrative Health [T90AT008544] Funding Source: NIH RePORTER
CR Aghili M, 2023, J GASTROINTEST CANC, V54, P467, DOI 10.1007/s12029-022-00824-0
   Andersson V, 2020, SUPPORT CARE CANCER, V28, P3721, DOI 10.1007/s00520-019-05200-6
   André T, 2009, J CLIN ONCOL, V27, P3109, DOI 10.1200/JCO.2008.20.6771
   Bao T, 2020, JAMA NETW OPEN, V3, P0, DOI 10.1001/jamanetworkopen.2020.0681
   Bauman B, 1900, V17, V0, P0
   Beijers AJM, 2020, ANN ONCOL, V31, P131, DOI 10.1016/j.annonc.2019.09.006
   Breadner D, 2022, BMC CANCER, V22, P0, DOI 10.1186/s12885-022-10198-y
   Chien TJ, 2019, INTEGR CANCER THER, V18, P0, DOI 10.1177/1534735419886662
   Conroy T, 2018, NEW ENGL J MED, V379, P2395, DOI 10.1056/NEJMoa1809775
   Conroy T, 2011, NEW ENGL J MED, V364, P1817, DOI 10.1056/NEJMoa1011923
   Deadman P, 1998, MANUAL ACUPUNCTURE, V0, P256
   Derksen TME, 2017, EVID-BASED COMPL ALT, V2017, P0, DOI 10.1155/2017/7916031
   Gallois C, 2023, J CLIN ONCOL, V41, P803, DOI 10.1200/JCO.21.02726
   Greenlee H, 2016, BREAST CANCER RES TR, V156, P453, DOI 10.1007/s10549-016-3759-2
   Greenlee H, 2015, J ACUPUNCT MERIDIAN, V8, P152, DOI 10.1016/j.jams.2015.03.006
   Han XY, 2017, BMC CANCER, V17, P0, DOI 10.1186/s12885-016-3037-z
   He YH, 2020, JAMA ONCOL, V6, P271, DOI 10.1001/jamaoncol.2019.5233
   Hershman DL, 2014, J CLIN ONCOL, V32, P1941, DOI 10.1200/JCO.2013.54.0914
   Hsieh YL, 2016, ACUPUNCT MED, V34, P398, DOI 10.1136/acupmed-2016-011112
   Iravani S, 2020, PAIN RES MANAG, V2020, P0, DOI 10.1155/2020/2504674
   Li K, 2019, CURR ONCOL, V26, PE147, DOI 10.3747/co.26.4261
   Liang FX, 2012, EVID-BASED COMPL ALT, V2012, P0, DOI 10.1155/2012/792793
   Lin L, 2021, BMJ SUPPORT PALLIAT, V11, P32, DOI 10.1136/bmjspcare-2019-001937
   Litscher Gerhard, 2007, CRITICAL REVIEWS IN BIOMEDICAL ENGINEERING, V35, P1, DOI 10.1615/CritRevBiomedEng.v35.i1-2.10
   Loprinzi CL, 1900, V32, V0, P0
   Lu WD, 2020, ONCOLOGIST, V25, P310, DOI 10.1634/theoncologist.2019-0489
   Mao JJ, 2010, ALTERN THER HEALTH M, V16, P22
   Molassiotis A, 2019, INTEGR CANCER THER, V18, P0, DOI 10.1177/1534735419836501
   National Acupuncture Foundation, 2003, CLEAN NEEDL TECHN MA, V0, P0
   Peoples AR, 2019, SUPPORT CARE CANCER, V27, P4597, DOI 10.1007/s00520-019-04736-x
   Postma TJ, 2005, EUR J CANCER, V41, P1135, DOI 10.1016/j.ejca.2005.02.012
   Rostock M, 2013, EVID-BASED COMPL ALT, V2013, P0, DOI 10.1155/2013/349653
   Saif M Wasif, 2005, THER CLIN RISK MANAG, V1, P249
   Staff NP, 2019, J PERIPHER NERV SYST, V24, PS26, DOI 10.1111/jns.12335
   Tan AC, 2019, SUPPORT CARE CANCER, V27, P4771, DOI 10.1007/s00520-019-04781-6
   Venook AP, 2017, JAMA-J AM MED ASSOC, V317, P2392, DOI 10.1001/jama.2017.7105
   Yeh CH, 2019, PAIN MANAG NURS, V20, P623, DOI 10.1016/j.pmn.2019.04.004
   Zhang SQ, 2017, J TRADIT CHIN MED, V37, P179
   Zick SM, 2018, JNCI CANCER SPECT, V2, P0, DOI 10.1093/jncics/pky064
   Zok J, 2021, BMC CANCER, V21, P0, DOI 10.1186/s12885-021-08183-y
NR 42
TC 5
Z9 5
U1 3
U2 15
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1551-7144
EI 1559-2030
J9 CONTEMP CLIN TRIALS
JI Contemp. Clin. Trials
PD AUG 15
PY 2023
VL 131
IS 
BP 
EP 
DI 10.1016/j.cct.2023.107273
EA JUN 2023
PG 8
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA L9RC0
UT WOS:001026559400001
PM 37380021
DA 2026-01-16
ER

PT J
AU D'Souza, RS
   Alvarez, GAM
   Dombovy-Johnson, M
   Eller, J
   Abd-Elsayed, A
AF D'Souza, Ryan S
   Alvarez, Gabriel A Martinez
   Dombovy-Johnson, Marissa
   Eller, Jennifer
   Abd-Elsayed, Alaa
TI Evidence-Based Treatment of Pain in Chemotherapy-Induced Peripheral Neuropathy.
SO Current pain and headache reports
LA English
DT Journal Article
DE Cancer; Chemotherapy; Chronic pain; Neuromodulation; Peripheral neuropathy; Systematic review
AB PURPOSE OF REVIEW: Chemotherapy-induced peripheral neuropathy (CIPN) is a  debilitating and often painful condition that occurs after administration of  chemotherapeutic agents. The primary objective of this systematic review was to  appraise the literature on conservative, pharmacological, and interventional  treatment options for CIPN pain. RECENT FINDINGS: There is level I evidence  supporting modest to moderate improvement in CIPN pain from duloxetine treatment,  as well as short-term modest improvement from physical therapy and acupuncture.  Although opioid and cannabis administration may provide short-term modest  improvement, administration is commonly limited by side effects. Generally, most  studies reported no clinical benefit from yoga, topical neuropathic agents,  gabapentinoids, and tricyclic antidepressants. Evidence is currently equivocal  for scrambler therapy and transcutaneous electrical nerve stimulation. Finally,  evidence on neuromodulation options is limited to mostly case reports/series and  one observational study highlighting moderate improvement with auricular nerve  stimulation. This systematic review provides an overview of conservative,  pharmacologic, and interventional treatment modalities for CIPN pain.  Furthermore, it provides a level of evidence and degree of recommendation based  on the United States Preventive Services Task Force (USPSTF) criteria for each  specific treatment modality.
C1 Department of Anesthesiology and Perioperative Medicine, Mayo Clinic Hospital, Rochester, MN, USA.
   Department of Physical Medicine and Rehabilitation, Mayo Clinic Hospital, Rochester, MN, USA.
   Department of Physical Medicine and Rehabilitation, Mayo Clinic Hospital, Rochester, MN, USA.
   Department of Anesthesiology and Perioperative Medicine, Mayo Clinic Hospital, Rochester, MN, USA.
   Department of Anesthesiology, University of Wisconsin, Madison, WI, USA. abdelsayed@wisc.edu.
NR 0
TC 0
SN 1534-308
EI 
J9 Curr Pain Headache Rep
PD APR 15
PY 2023
VL 27
IS 5
BP 99
EP 116
DI 10.1007/s11916-023-01107-4
PG 17
WC Humans; Neuralgia; therapy; Neoplasms; chemically induced; Antineoplastic Agents; adverse effects; Pain Management; Transcutaneous Electric Nerve Stimulation; Observational Studies as Topic
UT PubMed:37058254
PM 37058254
DA 2023-04-15
ER

PT J
AU Narayanan, S
   Liu, W
   Lopez, G
   Fellman, B
   Reddy, A
   Subbiah, IM
   Cohen, L
   Bruera, E
AF Narayanan, Santhosshi
   Liu, Wenli
   Lopez, Gabriel
   Fellman, Bryan
   Reddy, Akhila
   Subbiah, Ishwaria M
   Cohen, Lorenzo
   Bruera, Eduardo
TI Practice Patterns on the Incorporation of Integrative Medicine Into the Oncologic
SO Integrative cancer therapies
LA English
DT Journal Article
DE cancer; complementary and alternative treatments; implementation research; integrative medicine; integrative oncology; patient reported outcomes
AB BACKGROUND: With rising interest in complementary approaches to symptom  management, awareness of real-world practice patterns in the incorporation of  integrative oncology (IO) into cancer care is limited. Therefore, we examined the  reasons for referral, symptom burdens, and clinical outcomes for cancer patients  who underwent initial IO consultations. METHODS: The records of adult patients  with cancer who underwent initial outpatient IO consultations at our cancer  center for a representative 10-day period at the start of each month for 12  months starting January 1, 2017, were reviewed retrospectively. Patient  demographic and medical characteristics and outpatient IO consultation details,  including patient-reported outcome measures of symptom burden, were extracted.  Descriptive summary statistics and logistic regression were used to analyze the  data. RESULTS: Among the 473 study patients, 71% were women, breast cancer (42%)  was the most common cancer type, and 31% had metastatic cancer. Referring  clinicians listed an integrative approach (57%) as the most common reason for  referral, followed by diet (26%), pain (19%), discussion of herbs and supplements  (18%), and stress (18%). In comparison, patients listed their primary concerns as  diet (16%), pain (15%), and an integrative approach to overall health (11%).  After the IO consultations, the highest likelihood of subsequent recommendations  were acupuncture for hot flashes (odds ratio [OR], P = .002) or peripheral  neuropathy (OR = 6.59, P < .001), oncology massage for pain (OR = 3.04,  P < .001), psychology referral for patient's self-reported anxiety (OR = 2.35,  P < .001), and mind-body therapies for stress (OR = 2.57, P < .001). CONCLUSION:  Cancer patients' top concerns regarding IO consultation may not always match  providers' reasons for referral. Longitudinal data analysis is needed to  determine the effect of integrative interventions on symptom burden.
C1 The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
   The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
   The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
   The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
   The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
   The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
   The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
   The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
NR 0
TC 0
SN 1552-695
EI 1534-735
J9 Integr Cancer Ther
PD NOV 18
PY 2023
VL 22
IS 
BP 15347354231213045
EP 15347354231213045
DI 10.1177/15347354231213045
PG 1
WC Adult; Humans; Female; Male; Integrative Medicine; Retrospective Studies; Medical Oncology; Breast Neoplasms; therapy; Pain
UT PubMed:37978821
PM 37978821
DA 2023-11-18
ER

PT J
AU Pérez, C
   Quintanar, T
   García, C
   Cuervo, MA
   Goberna, MJ
   Monleón, M
   González, AI
   Lizán, L
   Comellas, M
   Alvarez, M
   Peña, I
AF Perez, Concha
   Quintanar, Teresa
   Garcia, Carmen
   Cuervo, Miguel Angel
   Goberna, Maria Jesus
   Monleon, Manuela
   Gonzalez, Ana I.
   Lizan, Luis
   Comellas, Marta
   Alvarez, Maria
   Pena, Isaac
TI Cancer-Related Pain Management in Suitable Intrathecal Therapy Candidates: A Spanish Multidisciplinary Expert Consensus
SO CURRENT ONCOLOGY
LA English
DT Article
DE intrathecal; cancer; pain; Delphi technique; consensus
ID guidelines; analgesia
AB A consensus is needed among healthcare professionals involved in easing oncological pain in patients who are suitable candidates for intrathecal therapy. A Delphi consultation was conducted, guided by a multidisciplinary scientific committee. The 18-item study questionnaire was designed based on a literature review together with a discussion group. The first-round questionnaire assessed experts' opinion of the current general practice, as well as their recommendation and treatment feasibility in the near future (2-3-year period) using a 9-point Likert scale. Items for which consensus was not achieved were included in a second round. Consensus was defined as & GE;75% agreement (1-3 or 7-9). A total of 67 panelists (response rate: 63.2%) and 62 (92.5%) answered the first and second Delphi rounds, respectively. The participants were healthcare professionals from multiple medical disciplines who had an average of 17.6 (7.8) years of professional experience. A consensus was achieved on the recommendations (100%). The actions considered feasible to implement in the short term included effective multidisciplinary coordination, improvement in communication among the parties, and an assessment of patient satisfaction. Efforts should focus on overcoming the barriers identified, eventually leading to the provision of more comprehensive care and consideration of the patient's perspective.
C1 [Perez, Concha] Hosp Univ Princesa, Madrid 28006, Spain.
   [Quintanar, Teresa] Hosp Gen Univ Elche, Elche 03203, Spain.
   [Garcia, Carmen] Serv Madrileno Salud, Unidad Continu Asistencial, Madrid 28046, Spain.
   [Cuervo, Miguel Angel] Hosp Univ Badajoz, Badejoz 06080, Spain.
   [Goberna, Maria Jesus] Complejo Hosp Univ Vigo, Vigo 36204, Spain.
   [Monleon, Manuela] Equipo Soporte Atenc Domiciliaria Legazpi, Madrid 28045, Spain.
   [Gonzalez, Ana I.] Asociac Espanola Canc AECC, Madrid 28045, Spain.
   [Lizan, Luis; Comellas, Marta] Univ Jaume 1, Dept Med, Outcomes 10, Castellon de La Plana 12071, Spain.
   [Alvarez, Maria] Medtron Iber SA, Hlth Econ & Outcomes Res Unit, Madrid 28050, Spain.
   [Pena, Isaac] Hosp Univ Virgen Rocio, Seville 41013, Spain.
C3 Hospital de La Princesa; Complexo Hospitalario Universitario de Vigo; Universitat Jaume I; Virgen del Rocio University Hospital
RP Pérez, C (corresponding author), Hosp Univ Princesa, Madrid 28006, Spain.
EM concha.phte@gmail.com; teresaqv22@yahoo.es; cubero@salud.madrid.org; miguelangel.cuervop@gmail.com; maria.jesus.goberna.iglesias@sergas.es; manuela.monleon@salud.madrid.org; ana.gonzalez@contraelcancer.es; lizan@outcomes10.com; mcomellas@outcomes10.com; maria.alvarez.orozco@medtronic.com; isaacpv@gmail.com
FU Medtronic Iberica S.A
CR Adler JA, 2017, J PAIN RES, V10, P2565, DOI 10.2147/JPR.S142147
   Unknown -, 2018, WHO GUIDELINES FOR THE PHARMACOLOGICAL AND RADIOTHERAPEUTIC MANAGEMENT OF CANCER PAIN IN ADULTS AND ADOLESCENTS, V0, P0
   Bolash R, 2014, NEUROSURG CLIN N AM, V25, P735, DOI 10.1016/j.nec.2014.06.006
   Bruel BM, 2016, PAIN MED, V17, P2404, DOI 10.1093/pm/pnw060
   Cañete JD, 2020, J RHEUMATOL, V47, P1637, DOI 10.3899/jrheum.191056
   Carr D, 2002, EVID REP TECHNOL ASSESS (SUMM), V0, P1
   Casado E, 2021, ARCH OSTEOPOROS, V16, P0, DOI 10.1007/s11657-021-00878-w
   Deer TR, 2011, PAIN PHYSICIAN, V14, P0
   Escobar Y, 2022, SCI REP-UK, V12, P0, DOI 10.1038/s41598-022-26753-3
   FINK A, 1984, AM J PUBLIC HEALTH, V74, P979, DOI 10.2105/AJPH.74.9.979
   García-Mata J, 2018, CLIN TRANSL ONCOL, V20, P1061, DOI 10.1007/s12094-017-1826-8
   Gulati A, 2014, CURR PAIN HEADACHE R, V18, P0, DOI 10.1007/s11916-013-0391-2
   Hochberg U, 2020, PAIN PHYSICIAN, V23, PE451, DOI 10.36076/ppj.2020/23/e451
   Jara C, 2018, CLIN TRANSL ONCOL, V20, P97, DOI 10.1007/s12094-017-1791-2
   Kurita GP, 2019, CANCERS, V11, P0, DOI 10.3390/cancers11040443
   Liu HJ, 2017, AM J HOSP PALLIAT ME, V34, P148, DOI 10.1177/1049909115615110
   Mercadante S, 2019, CANCERS, V11, P0, DOI 10.3390/cancers11040565
   Nagel SJ, 2018, NEUROMODULATION, V21, P625, DOI 10.1111/ner.12693
   Olmos-Jiménez R, 2017, FARM HOSP, V41, P611, DOI 10.7399/fh.10762
   Perez C, 2017, GADO GUIA ABORDAJE I, V0, P0
   Porta-Sales J, 2015, J PALLIAT MED, V18, P923, DOI 10.1089/jpm.2015.29002.jps
   Samuelly-Leichtag G, 2019, RAMBAM MAIMONIDES ME, V10, P0, DOI 10.5041/RMMJ.10369
   Shah R, 2015, CURR PAIN HEADACHE R, V19, P0, DOI 10.1007/s11916-015-0488-x
   Shaparin N, 2015, J FAM PRACTICE, V64, P166
   Silverman JE, 2018, PAIN MANAG, V8, P389, DOI 10.2217/pmt-2018-0022
   Snijders RAH, 2023, CANCERS, V15, P0, DOI 10.3390/cancers15030591
   Wang NN, 2022, BMC HEALTH SERV RES, V22, P0, DOI 10.1186/s12913-022-08610-1
   Yin YN, 2020, MEDICINE, V99, P0, DOI 10.1097/MD.0000000000022448
NR 28
TC 1
Z9 2
U1 1
U2 5
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
SN 1198-0052
EI 1718-7729
J9 CURR ONCOL
JI Curr. Oncol.
PD AUG 15
PY 2023
VL 30
IS 8
BP 7303
EP 7314
DI 10.3390/curroncol30080530
PG 12
WC Oncology
SC Oncology
GA Q0PA3
UT WOS:001054608200001
PM 37623011
DA 2026-01-16
ER

PT J
AU Li, Y
   Hong, E
   Ye, W
   You, J
AF Li, Yan
   Hong, Ensi
   Ye, Wenguo
   You, Jianyu
TI Moxibustion as an Adjuvant Therapy for Cancer Pain: A Systematic Review and
SO Journal of pain research
LA English
DT Review
DE cancer pain; meta-analysis; moxibustion; systematic review
AB PURPOSE: Pain is one of the most common and feared symptoms among cancer  patients. Unrelieved pain denies patients comfort and greatly affects their  overall quality of life. Moxibustion is commonly used to manage chronic pain.  However, its efficacy on cancer pain remains inconclusive. This study aimed to  evaluate the efficacy of moxibustion for cancer pain. METHODS: We searched seven  databases to obtain articles about moxibustion combined with pharmacotherapy for  cancer pain published before November 2022. All data extraction was carried out  independently by two investigators. RevMan 5.4 software was used for data  analysis. RESULTS: A total of ten trials involving 999 cases were included. The  results of the meta-analysis revealed that moxibustion combined with  pharmacotherapy was significantly better than drug therapy alone in improving  pain relief rate (RR =1.16, 95% CI = [1.04, 1.30], P = 0.01), reducing pain  scores (SMD = -1.43, 95% CI = [-2.09, -0.77], P < 0.0001), Shortening the onset  of analgesia (MD = -12.07, 95% CI = [-12.91, -11.22], P < 0.00001), prolonging  the duration of analgesia (MD = 3.69, 95% CI = [3.21, 4.18], P < 0.00001), and  improving quality of life (SMD = 2.48, 95% CI = [0.67, 4.29], P = 0.007). In  addition, moxibustion combined with pharmacotherapy can effectively reduce  adverse reactions of drugs (RR =0.35, 95% CI = [0.21, 0.57], P < 0.0001).  CONCLUSION: The evidence in this review supports moxibustion as an effective  adjuvant therapy for cancer pain management. However, high-quality RCTs are  needed to further confirm these findings. REGISTRATION NUMBER: PROSPERO  CRD42022370942.
C1 Jiangxi University of Chinese Medicine, Nanchang, People's Republic of China.
   Jiangxi University of Chinese Medicine, Nanchang, People's Republic of China.
   The Affiliated Hospital of Jiangxi University of Chinese Medicine, Nanchang, 
   The Affiliated Hospital of Jiangxi University of Chinese Medicine, Nanchang, People's Republic of China.
   Jiangxi University of Chinese Medicine, Nanchang, People's Republic of China.
NR 0
TC 0
SN 1178-709
EI 1178-709
J9 J Pain Res
PD FEB 25
PY 2023
VL 16
IS 
BP 515
EP 525
DI 10.2147/JPR.S396696
PG 10
UT PubMed:36824500
PM 36824500
DA 2023-02-25
ER

PT J
AU Liao, CC
   Lin, CL
   Tsai, FJ
   Chien, CH
   Li, JM
AF Liao, Chung-Chih
   Lin, Cheng-Li
   Tsai, Fuu-Jen
   Chien, Chi-Hsien
   Li, Jung-Miao
TI Acupuncture's long-term impact on depression prevention in primary dysmenorrhea:
SO Journal of affective disorders
LA English
DT Journal Article
DE Acupuncture; Bioinformatics; Depression; Molecular mechanisms; Prevention; Primary dysmenorrhea
AB BACKGROUND: Primary dysmenorrhea (PD) is a common gynecological condition causing  depression. Acupuncture is an effective option for PD management but its effects  on PD-associated depression remain unclear. METHODS: A retrospective cohort study  involving 35,099 propensity score-matched pairs of acupuncture users and  non-users with PD was conducted using data from Taiwan's Longitudinal Generation  Tracking Database 2000. Cox proportional hazard models were used to estimate  depression risk, and bioinformatics analyses were performed to uncover underlying  molecular mechanisms. RESULTS: The risk of developing depression was reduced by  64 % in acupuncture users compared with non-acupuncture users during the 19-year  follow-up period. The decrease was dose-dependent. Bioinformatics analyses  identified 34 co-expressed targets for acupuncture, PD, and depression; and eight  hub genes (coding for interleukin 6 and 1B, tumor necrosis factor, albumin,  vascular endothelial growth factor A, C-reactive protein,  prostaglandin-endoperoxide synthase 2, and brain-derived neurotrophic factor)  potentially involved in the therapeutic effects of acupuncture. Several molecular  pathways were found to be involved, including cytokine-cytokine receptor  interaction, neuroactive ligand-receptor interaction, cyclic adenosine  3',5'-monophosphate signaling pathway, mitogen-activated protein kinase signaling  pathway, serotonergic synapse, and estrogen signaling pathway. LIMITATIONS: Bias  in the selection of participants could have been introduced as a consequence of  the retrospective nature of the study. Data were derived from a single national  database, and acupuncture treatment details were unavailable. CONCLUSION:  Acupuncture may protect against the development of depression in patients with  PD. This study provides insight into the potential molecular mechanisms  underlying the therapeutic effects of acupuncture in PD management and depression  prevention.
C1 Department of Post-Baccalaureate Veterinary Medicine, College of Medical and Health Science, Asia University, Taichung 41354, Taiwan
   Chuyuan Chinese MedicineClinic, Taichung 40455, Taiwan.
   Management Office for Health Data, China Medical University Hospital, Taichung 40459, Taiwan.
   School of Chinese Medicine, College of Chinese Medicine, China Medical University, Taichung 40402, Taiwan
   Department of Medical Research, China MedicalUniversity Hospital, Taichung 40402, Taiwan
   Division of Medical Genetics, ChinaMedical University Children's Hospital, Taichung 40447, Taiwan
   Department ofBiotechnology and Bioinformatics, Asia University, Taichung 41354, Taiwan.
   Department of Post-Baccalaureate Veterinary Medicine, College of Medical and Health Science, Asia University, Taichung 41354, Taiwan.
   School of Chinese Medicine, College of Chinese Medicine, China Medical University, Taichung 40402, Taiwan
   Department of Chinese Medicine, China MedicalUniversity Hospital, Taichung 40447 , Taiwan.
EM mli@mail.cmu.edu.tw
NR 0
TC 0
SN 1573-251
EI 
J9 J Affect Disord
PD OCT 11
PY 2023
VL 344
IS 
BP 48
EP 60
DI 10.1016/j.jad.2023.10.013
PG 12
WC Female; Humans; Retrospective Studies; Vascular Endothelial Growth Factor A; Depression; Follow-Up Studies; Dysmenorrhea; therapy; Taiwan; Acupuncture Therapy
UT PubMed:37816484
PM 37816484
DA 2023-10-11
ER

PT J
AU Wu, M
   Tang, Q
   Gao, W
   Zhu, L
AF Wu, Minmin
   Tang, Qiang
   Gao, Weibin
   Zhu, Luwen
TI Electroacupuncture for acute transverse myelitis following viral infection: A
SO Explore (New York, N.Y.)
LA English
DT Journal Article
DE Acute transverse myelitis; Case report; Electroacupuncture; Functional recovery
AB BACKGROUND: Electroacupuncture (EA) has a positive effect on neurological repair  and functional recovery following spinal cord disease. However, evidence of its  effectiveness in acute transverse myelitis (ATM) cases is limited. PATIENT  PRESENTATION: A 48-year-old woman experienced headache and fever for 5 days,  followed by a sudden onset of back pain, lower limb paralysis, and urinary and  bowel dysfunction. The patient received intravenous medications. However, she did  not experience improvement in clinical symptoms. She subsequently underwent  acupuncture treatment. She regained walking ability and experienced improved  bladder function and bowel control after 36 sessions of EA treatment. METHODS:  CARE guidelines informed the case study report. The MRC and ICIQ-UI-SF scores  were used to verify changes in lower-extremity muscle strength and urination  after EA treatment. Qualitative information was collected using feedback tables.  CONCLUSION: Pharmacological treatment for ATM lacks clear advantages because of  its complex pathophysiological mechanisms. Hence, EA could be recommended as a  promising treatment modality for ATM.
C1 Department of Rehabilitation Medicine, Heilongjiang University of Chinese Medicine, Harbin 150000, China.
   The Second Affiliated Hospital of Heilongjiang University of Chinese Medicine, 411 Guogeli Street, Nangan District, Harbin, Heilongjiang 150000, China.
   The Second Affiliated Hospital of Heilongjiang University of Chinese Medicine, 411 Guogeli Street, Nangan District, Harbin, Heilongjiang 150000, China.
   The Second Affiliated Hospital of Heilongjiang University of Chinese Medicine, 411 Guogeli Street, Nangan District, Harbin, Heilongjiang 150000, China.
EM zhuluwen1983@126.com
NR 0
TC 0
SN 1878-754
EI 
J9 Explore (NY)
PD DEC 2
PY 2023
VL 20
IS 4
BP 597
EP 601
DI 10.1016/j.explore.2023.11.012
PG 4
WC Humans; Female; Electroacupuncture; methods; Myelitis, Transverse; therapy; Middle Aged; Virus Diseases; therapy; Muscle Strength; Fever; therapy; Treatment Outcome; Back Pain; therapy
UT PubMed:38040618
PM 38040618
DA 2023-12-02
ER

PT J
AU Mao, QJ
   Huang, B
   Zhu, DC
   Wang, YQ
   Xu, SQ
   Wu, DS
   Huang, GM
   Li, ZR
   Chi, ZH
   Chen, RX
AF Mao, Qiangjian
   Huang, Biao
   Zhu, Daocheng
   Wang, Yuqing
   Xu, Shiqi
   Wu, Desheng
   Huang, Guomin
   Li, Ziru
   Chi, Zhenhai
   Chen, Rixin
TI A Bibliometric Analysis of Acupuncture Therapy in the Treatment of Musculoskeletal Pain from 2003 to 2022
SO JOURNAL OF PAIN RESEARCH
LA English
DT Review
DE musculoskeletal pain; acupuncture therapy; bibliometrics; CiteSpace
ID low-back-pain; breast-cancer patients; chronic knee pain; systematic reviews; trials; electroacupuncture; osteoarthritis; metaanalysis; multicenter; blind
AB Background: Acupuncture therapy has been widely used in the treatment of musculoskeletal pain (MP) in many countries around the world. However, there are no bibliometric studies on acupuncture therapy for MP. Therefore, the aim of this study was to analyze the current status, frontiers and hot spots in the use of acupuncture therapy for the treatment of MP.Methods: Literature on acupuncture therapy for MP was extracted from the Web of Science Core Collection database from 2003 to 2022. CiteSpace 6.2.R4 (64-bit) software was used to analyze the number and centrality of journals, countries, institutions, authors, references and keywords, and the functions of co-occurrence and clustering were applied to draw a visual knowledge map.Results: Over the past 20 years, the annual journal publications have been on a steady upward trend, with 438 articles published in 143 journals, including Acupuncture in Medicine Journal published the most (28, 6.39%), JAMA-Journal of the American Medical Association was the journal with the highest impact factor (IF = 120.7003), USA dominated with the most publications (140, 31.96%) among 44 countries, and among 196 research organizations Kyung Hee University was the most prolific (19, 4.34%) and Ha, In-Hyuk was the most published author (9, 2.05%). "Acupuncture" is the most popular and highly sought after keywords. "Low back pain" is the keyword with the highest centrality.Conclusion: This article provides the current situation of the use of acupuncture therapy in the treatment of MP in the past 20 years, and statistical analysis reveals that "low back pain", "knit osteoporosis" and "break cancer" are new research diseases related to acupuncture therapy for MP, and "myobasic trigger point" is a new research direction of acupuncture therapy for MP. Therefore, this study helps researchers grasp the research hotspots and provide certain references for in-depth research and future topic selection.
C1 [Mao, Qiangjian; Huang, Biao; Zhu, Daocheng; Wu, Desheng; Huang, Guomin; Li, Ziru; Chi, Zhenhai; Chen, Rixin] Jiangxi Univ Chinese Med, Affiliated Hosp, Nanchang, Jiangxi, Peoples R China.
   [Wang, Yuqing; Xu, Shiqi] Jiangxi Univ Chinese Med, Nanchang, Jiangxi, Peoples R China.
C3 Jiangxi University of Traditional Chinese Medicine; Jiangxi University of Traditional Chinese Medicine
RP Chi, ZH; Chen, RX (corresponding author), Jiangxi Univ Chinese Med, Affiliated Hosp, Nanchang, Jiangxi, Peoples R China.
EM 348916661@qq.com; chenrixin321@163.com
FU 2022 National Famous Elderly Chinese Medicine Experts Inheritance Workshop Construction Project [75]; National TCM Human Education Letter [75, 1]; 2022 National Famous Chinese Medicine Experts Inheritance Workshop Construction Project; Jiangxi Provincial Administration of Traditional Chinese Medicine [1]; Jiangxi Provincial Traditional Chinese Medicine Medical Thermal Acupuncture and Moxibustion Quality Control Centers; Gan Traditional Chinese Medicine Medical Policy Letter; Jiangxi Provincial Administration of Traditional Chinese Medicine Key Research Laboratory Construction Project of Pediatric Tuina [8]
CR Affaitati G, 2011, EUR J PAIN, V15, P61, DOI 10.1016/j.ejpain.2010.09.002
   Bao T, 2013, BREAST CANCER RES TR, V138, P167, DOI 10.1007/s10549-013-2427-z
   Barkin RL, 2015, AM J THER, V22, P388, DOI 10.1097/MJT.0b013e3182459abd
   Berman BM, 1999, J FAM PRACTICE, V48, P213
   Boyce D, 2020, INT J SPORTS PHYS TH, V15, P103, DOI 10.26603/ijspt20200103
   Brandt JS, 2019, JAMA NETW OPEN, V2, P0, DOI 10.1001/jamanetworkopen.2019.18007
   曹伯旭(译者), 2021, 中国疼痛医学杂志 CHINESE JOURNAL OF PAIN MEDICINE, V27, P2
   Chen CM, 2006, J AM SOC INF SCI TEC, V57, P359, DOI 10.1002/asi.20317
   Cherkin DC, 2001, ARCH INTERN MED, V161, P1081, DOI 10.1001/archinte.161.8.1081
   Chia KL, 2018, ACUPUNCT MED, V36, P183, DOI 10.1136/acupmed-2017-011547
   Chiu HY, 2017, EUR J CANCER CARE, V26, P0, DOI 10.1111/ecc.12457
   Chou R, 2017, ANN INTERN MED, V166, P493, DOI 10.7326/M16-2459
   Cieza A, 2020, LANCET, V396, P2006, DOI 10.1016/S0140-6736(20)32340-0
   Daniel O, 2022, PAIN THER, V11, P907, DOI 10.1007/s40122-022-00394-w
   Daniell JR, 2018, ASIAN SPINE J, V12, P372, DOI 10.4184/asj.2018.12.2.372
   Ding Y, 2016, J TRADIT CHIN MED, V36, P444, DOI 10.1016/s0254-6272(16)30060-7
   Dunning J, 2014, PHYS THER REV, V19, P252, DOI 10.1179/108331913X13844245102034
   El-Tallawy SN, 2021, PAIN THER, V10, P181, DOI 10.1007/s40122-021-00235-2
   Ezzo J, 2001, INT J TECHNOL ASSESS, V17, P457, DOI 10.1017/S0266462301107014
   Furlan AD, 2005, SPINE, V30, P944, DOI 10.1097/01.brs.0000158941.21571.01
   Furlan AD, 2005, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD001351.pub2
   Gadau M, 2014, BMC COMPLEM ALTERN M, V14, P0, DOI 10.1186/1472-6882-14-136
   Ge HY, 2009, PAIN, V147, P233, DOI 10.1016/j.pain.2009.09.019
   Geurts JW, 2017, HEALTH EXPECT, V20, P1201, DOI 10.1111/hex.12527
   Gich J, 2015, MULT SCLER J, V21, P1332, DOI 10.1177/1352458515572405
   Gore M, 2012, PAIN PRACT, V12, P550, DOI 10.1111/j.1533-2500.2012.00532.x
   Green S, 2005, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD005319
   Haake M, 2007, ARCH INTERN MED, V167, P1892, DOI 10.1001/archinte.167.17.1892
   He JJ, 2022, J MIDWIFERY WOM HEAL, V67, P478, DOI 10.1111/jmwh.13379
   He YH, 2020, JAMA ONCOL, V6, P271, DOI 10.1001/jamaoncol.2019.5233
   Hershman DL, 2018, JAMA-J AM MED ASSOC, V320, P167, DOI 10.1001/jama.2018.8907
   Hinman RS, 2014, JAMA-J AM MED ASSOC, V312, P1313, DOI 10.1001/jama.2014.12660
   Jan AL, 2017, EMERG MED AUSTRALAS, V29, P490, DOI 10.1111/1742-6723.12832
   Jo HR, 2022, MEDICINE, V101, P0, DOI 10.1097/MD.0000000000029656
   Kapural L, 2022, J PAIN RES, V15, P1623, DOI 10.2147/JPR.S353674
   Kawakita K, 2014, BIOPSYCHOSOC MED, V8, P0, DOI 10.1186/1751-0759-8-4
   Kietrys DM, 2013, J ORTHOP SPORT PHYS, V43, P620, DOI 10.2519/jospt.2013.4668
   Kuan TS, 2009, CURR PAIN HEADACHE R, V13, P365, DOI 10.1007/s11916-009-0059-0
   Liang CC, 2018, SAGE OPEN MED, V6, P0, DOI 10.1177/2050312118800199
   Liang YD, 2017, J PAIN RES, V10, P951, DOI 10.2147/JPR.S132808
   Lim Tiaw-Kee, 2018, MEDICINES (BASEL), V5, P0, DOI 10.3390/medicines5030063
   Linde K, 2007, PAIN, V128, P264, DOI 10.1016/j.pain.2006.12.006
   Luo HF, 2021, FRONT PSYCHOL, V12, P0, DOI 10.3389/fpsyg.2021.759347
   MacPherson H, 2013, PLOS ONE, V8, P0, DOI 10.1371/journal.pone.0077438
   Manheimer E, 2005, ANN INTERN MED, V142, P651, DOI 10.7326/0003-4819-142-8-200504190-00014
   Manheimer E, 2010, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD001977.pub2
   Mao JJ, 2021, JAMA ONCOL, V7, P720, DOI 10.1001/jamaoncol.2021.0310
   Mao JJ, 2014, CANCER-AM CANCER SOC, V120, P3744, DOI 10.1002/cncr.28917
   Molsberger AF, 2010, PAIN, V151, P146, DOI 10.1016/j.pain.2010.06.036
   Nahin Richard L, 2016, NATL HEALTH STAT REPORT, V0, P1
   Nakamura M, 2011, J ORTHOP SCI, V16, P424, DOI 10.1007/s00776-011-0102-y
   Paoloni JA, 2009, BRIT J SPORT MED, V43, P863, DOI 10.1136/bjsm.2009.059980
   Parsons S, 2007, FAM PRACT, V24, P308, DOI 10.1093/fampra/cmm027
   Puntillo F, 2021, THER ADV MUSCULOSKEL, V13, P0, DOI 10.1177/1759720X21995067
   Qaseem A, 2017, ANN INTERN MED, V166, P514, DOI 10.7326/M16-2367
   Schjerning AM, 2020, NAT REV CARDIOL, V17, P574, DOI 10.1038/s41569-020-0366-z
   Sjogren P, 2009, EUR J PAIN, V13, P287, DOI 10.1016/j.ejpain.2008.04.007
   Smith LA, 2000, PAIN, V86, P119, DOI 10.1016/S0304-3959(00)00234-7
   Srbely JZ, 2008, PAIN, V139, P260, DOI 10.1016/j.pain.2008.04.009
   Tough EA, 2009, EUR J PAIN, V13, P3, DOI 10.1016/j.ejpain.2008.02.006
   Tu JF, 2019, TRIALS, V20, P0, DOI 10.1186/s13063-018-3138-x
   van Tulder M, 2003, SPINE, V28, P1290, DOI 10.1097/00007632-200306150-00014
   Vickers AJ, 2018, J PAIN, V19, P455, DOI 10.1016/j.jpain.2017.11.005
   Vickers AJ, 2012, ARCH INTERN MED, V172, P1444, DOI 10.1001/archinternmed.2012.3654
   Wang YY, 2022, EVID-BASED COMPL ALT, V2022, P0, DOI 10.1155/2022/1989401
   White A, 2007, RHEUMATOLOGY, V46, P384, DOI 10.1093/rheumatology/kel413
   Wilson M, 2021, JAMA NETW OPEN, V4, P0, DOI 10.1001/jamanetworkopen.2021.5840
   Xiang HC, 2021, FRONT PSYCHOL, V12, P0, DOI 10.3389/fpsyg.2021.721872
   Yang Y, 2022, J HEALTHC ENG, V2022, P0, DOI 10.1155/2022/4903265
   Yuan QL, 2016, SCI REP-UK, V6, P0, DOI 10.1038/srep30675
   Zhang YP, 2020, COMPLEMENT THER MED, V50, P0, DOI 10.1016/j.ctim.2020.102392
   Zhang Y, 2020, ENVIRON SCI POLLUT R, V27, P15515, DOI 10.1007/s11356-020-07646-2
   Zhang YJ, 2020, CURR RHEUMATOL REP, V22, P0, DOI 10.1007/s11926-020-00954-z
   Zheng JQ, 2022, FRONT PUBLIC HEALTH, V10, P0, DOI 10.3389/fpubh.2022.904855
   Zhu DC, 2023, J PAIN RES, V16, P1647, DOI 10.2147/JPR.S409120
NR 76
TC 3
Z9 4
U1 6
U2 28
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1178-7090
EI 
J9 J PAIN RES
JI J. Pain Res.
PD JUN 15
PY 2023
VL 16
IS 
BP 3853
EP 3870
DI 10.2147/JPR.S431689
PG 18
WC Clinical Neurology
SC Neurosciences & Neurology
GA Y0QO6
UT WOS:001102403200001
PM 38026461
DA 2026-01-16
ER

PT J
AU Zhang, T
   Zhang, Q
   Zhu, P
   Sun, W
   Ding, Z
   Hu, L
AF Zhang, Teng
   Zhang, Qiang
   Zhu, Peiye
   Sun, Weidong
   Ding, Zaiqiao
   Hu, Lu
TI The Efficacy of Acupuncture in the Treatment of Chemotherapy-Induced Peripheral
SO Alternative therapies in health and medicine
LA English
DT Journal Article
AB BACKGROUND: Chemotherapy-induced peripheral neuropathy (CIPN), one of the most  common adverse events associated with chemotherapy, may affect efficacy because  of the interruption of chemotherapy or change of regimen in severe cases, and may  even increase cancer mortality. Relevant data supports the evidence that  acupuncture can treat pain and sensory abnormalities. However, choosing the most  effective acupuncture therapy is difficult because of the lack of evidence-based  medicine and comparisons between different acupuncture therapies for treating  CIPN. The aim of this study was to use a network meta-analysis (NMA) to evaluate  the efficacy of different acupuncture therapies for CIPN. METHODS: We searched  Embase, PubMed, Web of Science, The Cochrane Library, The Chinese Journal Full  Text Database, Chinese Biomedical Literature Database, and WanFang Database for  randomized controlled trials (RCTs) of acupuncture for CIPN. The search period  was from the creation of the relevant library to August 10, 2023. A total of 2  investigators independently performed literature screening, data extraction, and  risk for bias evaluation. Stata 14.0 software (StataCorp LLC, College Station,  Texas USA), was used for the NMA. RESULTS: A total of 13 eligible RCTs involving  746 patients and 6 acupuncture therapies were included in the study. The NMA  results showed that electroacupuncture was superior to moxibustion, manual  acupuncture, acupoint injection and Western medicine in improving the total  effective rate of treatment of CIPN; electroacupuncture + moxibustion was better  than manual acupuncture, acupoint injection, and Western medicine. Manual  acupuncture's total effective rate was better than Western medicine. However,  electroacupuncture was the most effective treatment for CIPN according to the  surface under the cumulative ranking curve (SUCRA) ranking. CONCLUSION: After a  comprehensive evaluation of 6 acupuncture therapies for treating CIPN based on  NMA, electroacupuncture may be the best option for treating CIPN. However, would  be more convincing to get evidence from more RCTs.
NR 0
TC 0
SN 
EI 1078-679
J9 Altern Ther Health Med
PD SEP 14
PY 2023
VL 29
IS 8
BP 898
EP 906
DI 
PG 8
WC Humans; Acupuncture Therapy; methods; Moxibustion; Peripheral Nervous System Diseases; chemically induced; Antineoplastic Agents; adverse effects
UT PubMed:37708563
PM 37708563
DA 2023-09-14
ER

PT J
AU Utli, H
   Dinç, M
   Utli, A
AF Utli, Hediye
   Dinc, Mahmut
   Utli, Adil
TI The effect of acupressure or reiki interventions on the levels of pain and fatigue of cancer patients receiving palliative care: A randomized controlled study
SO EXPLORE-THE JOURNAL OF SCIENCE AND HEALING
LA English
DT Article
DE Acupressure; Analgesic use; Cancer pain; Fatigue; Palliative care; Reiki
ID quality-of-life; therapy; management; oncology; chemotherapy; trial; women
AB Objective: Taking pain under control is important to calm the individual and reduce complications. This research was conducted with the aim of determining the effect of Acupressure or Reiki interventions on the levels of pain and fatigue of stage III and IV cancer patients receiving palliative care. Method: The research was a single-blind, repeated measures, randomized controlled study. Research data were collected between February and November 2022. The research sample consisted of Acupressure and Reiki intervention groups and a control group with 52 patients in each group for a total of 156 patients. Acupressure or Reiki was applied to their intervention groups for a total of eight sessions of 20 min each over four weeks, once a day on two days a week. Data were collected by means of a patient description form, an analgesic follow-up form, the Numeric Pain Rating Scale, and the Brief Fatigue Inventory. Results: In comparison with the control group, a significant reduction was seen over time in the levels of pain (p < 0.001), analgesic use (p < 0.001), and fatigue (p < 0.001) in the Acupressure or Reiki intervention groups. Conclusion: Acupressure or Reiki interventions were found to effective in reducing levels of pain, analgesic use, and fatigue. It was seen that in addition to their use in routine nursing care, both treatments can be accepted as effective nursing interventions that reduce pain and fatigue in stage III and IV cancer patients receiving palliative care.
C1 [Utli, Hediye] Mardin Artuklu Univ, Vocat Sch Hlth Serv, Dept Elderly Care, Mardin, Turkiye.
   [Dinc, Mahmut] Batman Univ, Fac Hlth Sci, Dept Nursing, Batman, Turkiye.
   [Utli, Adil] Eskisehir Osmangazi Fac Med, Dept Emergency Med, Eskisehir, Turkiye.
C3 Mardin Artuklu University; Batman University
RP Utli, H (corresponding author), Artuklu Campus,Box 47110, Mardin, Turkiye.
EM hediyeutli@artuklu.edu.tr
CR Abdulraheem S, 2018, EUR J ORTHODONT, V40, P475, DOI 10.1093/ejo/cjx089
   Alarcao Z, 2016, EUR J INTEGR MED, V8, P239, DOI 10.1016/j.eujim.2015.12.003
   Anderson Cancer Center, 2022, BRIEF FAT INV, V0, P0
   Unknown -, 2021, COMPLEMENTARY, V0, P0
   Unknown -, 2018, WHO GUIDELINES FOR THE PHARMACOLOGICAL AND RADIOTHERAPEUTIC MANAGEMENT OF CANCER PAIN IN ADULTS AND ADOLESCENTS, V0, P0
   Armstrong K, 2018, SUPPORT CARE CANCER, V26, P2267, DOI 10.1007/s00520-017-4007-y
   Bastani Farideh, 2015, IRAN J NURS MIDWIFERY RES, V20, P545, DOI 10.4103/1735-9066.164508
   Behzadmehr R, 2020, COMPLEMENT THER MED, V49, P0, DOI 10.1016/j.ctim.2020.102318
   Billot M, 2019, BMJ SUPPORT PALLIAT, V9, P434, DOI 10.1136/bmjspcare-2019-001775
   Birocco N, 2012, AM J HOSP PALLIAT ME, V29, P290, DOI 10.1177/1049909111420859
   Buyukbayram Z, 2021, EXPLORE-NY, V17, P22, DOI 10.1016/j.explore.2020.07.009
   Demir Melike, 2015, ASIAN PAC J CANCER PREV, V16, P4859, DOI 10.7314/apjcp.2015.16.12.4859
   Dyer NL, 2019, J ALTERN COMPLEM MED, V25, P1156, DOI 10.1089/acm.2019.0022
   Fleisher KA, 2014, INTEGR CANCER THER, V13, P62, DOI 10.1177/1534735413503547
   He YH, 2020, JAMA ONCOL, V6, P271, DOI 10.1001/jamaoncol.2019.5233
   Hong S, 2020, MED HYPOTHESES, V137, P0, DOI 10.1016/j.mehy.2020.109562
   Hsieh SH, 2021, CANCER NURS, V44, PE578, DOI 10.1097/NCC.0000000000000997
   Karaman S, 2021, CANCER NURS, V44, PE652, DOI 10.1097/NCC.0000000000000970
   Khanghah AG, 2019, J ACUPUNCT MERIDIAN, V12, P103
   Kirshbaum MN, 2016, INT J PALLIAT NURS, V22, P166, DOI 10.12968/ijpn.2016.22.4.166
   Lopes LC Jr, 2021, REV ESC ENFERM USP, V55, P0, DOI 10.1590/S1980-220X2020025103709
   Molassiotis A, 2014, J PAIN SYMPTOM MANAG, V47, P12, DOI 10.1016/j.jpainsymman.2013.03.007
   Nia HS, 2017, INT J NURS PRACT, V23, P0, DOI 10.1111/ijn.12513
   Olson K, 2003, J PAIN SYMPTOM MANAG, V26, P990, DOI 10.1016/S0885-3924(03)00334-8
   Orsak G, 2015, J EVID-BASED INTEGR, V20, P20, DOI 10.1177/2156587214556313
   Overcash J, 2018, ONCOL NURS FORUM, V45, P359, DOI 10.1188/18.ONF.359-371
   Ozdemir U, 2021, ALTERN THER HEALTH M, V0, P0
   Rizi MS, 2017, COMPLEMENT THER CLIN, V29, P136, DOI 10.1016/j.ctcp.2017.09.002
   Schulz KF, 2010, BMC MED, V8, P0, DOI 10.1186/1741-7015-8-18
   Serçe S, 2018, INTEGR CANCER THER, V17, P728, DOI 10.1177/1534735418769153
   Tang WR, 2014, COMPLEMENT THER MED, V22, P581, DOI 10.1016/j.ctim.2014.05.006
   Thrane SE, 2017, AM J HOSP PALLIAT ME, V34, P373, DOI 10.1177/1049909116630973
   Tsang KL, 2007, INTEGR CANCER THER, V6, P25, DOI 10.1177/1534735406298986
   Utli H, 2022, EXPLORE-NY, V18, P467, DOI 10.1016/j.explore.2021.07.004
   Willems AAJM, 2021, PAIN PRACT, V21, P871, DOI 10.1111/papr.13053
   Yang YL, 2021, SUPPORT CARE CANCER, V29, P7703, DOI 10.1007/s00520-021-06320-8
   Zick SM, 2016, JAMA ONCOL, V2, P1470, DOI 10.1001/jamaoncol.2016.1867
   Zick SM, 2011, EVID-BASED COMPL ALT, V2011, P0, DOI 10.1155/2011/142913
   Zick SM, 2018, JNCI CANCER SPECT, V2, P0, DOI 10.1093/jncics/pky064
   Zucchetti G, 2019, J PEDIATR ONCOL NURS, V36, P361, DOI 10.1177/1043454219845879
NR 41
TC 13
Z9 17
U1 3
U2 11
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1550-8307
EI 1878-7541
J9 EXPLORE-NY
JI Explore-J Sci. Heal.
PD JAN-FEB 15
PY 2023
VL 19
IS 1
BP 91
EP 99
DI 10.1016/j.explore.2022.11.007
EA JAN 2023
PG 9
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA 9Z7DH
UT WOS:000951296900001
PM 36476354
DA 2026-01-16
ER

PT J
AU Frenkel, M
   David, A
   Sapire, K
   Hausner, D
AF Frenkel, Moshe
   David, Adi
   Sapire, Kenneth
   Hausner, David
TI Complementary and Integrative Medicine in Pancreatic Cancer
SO CURRENT ONCOLOGY REPORTS
LA English
DT Review
DE Pancreatic cancer; Pancreatic ductal adenocarcinoma; Complementary medicine; Integrative medicine; Touch therapies; Nutrition; Nutritional supplements; Physical activity; Acupuncture; Reflexology; Homeopathy; Curcumin; Mind-body medicine; Dietary supplements
ID physical-activity; microbiome; management; risk; chemotherapy; oncology; survival; ahcc; pain
AB Purpose of Review Pancreatic cancer has high mortality and morbidity rates, associated with the issues of typically late diagnosis and the limited effectiveness of current treatments. Patients tend to experience multiple symptoms that can include anxiety, fear, depression, fatigue, weakness, peripheral neuropathy, and abdominal pain, which reduce quality of life (QoL) and may compromise the treatment continuum. Many of those symptoms are amenable to complementary and integrative medicine (CIM) therapies as a part of supportive and palliative care. This article reviews research findings on the beneficial effect of use of CIM modalities in regard to pancreatic cancer, with emphasis on pancreatic ductal adenocarcinoma (PDAC). Recent Findings Given the often-poor prognosis of the disease, patients with PDAC often seek integrative therapies to help manage the disease itself, to provide support through cancer treatment and its symptoms, and to provide emotional stress relief. Data is accumulating in the past few years on the potential benefits of CIM to the management of pancreatic cancer symptoms and treatment side effects, in order to augment supportive care. This data reveal that nutrition counselling; digestive enzyme therapy; microbiome support; dietary supplements; lifestyle interventions (physical activity and circadian health/sleep hygiene) appear to improve QoL of these patients through reduced symptom burden and meeting psychological needs, such as distress and fatigue. Acupuncture, mindfulness, yoga, reflexology, massage, and homeopathy may also contribute to symptom reduction, both physical and psychological, in all stages of the disease. Summary There is supporting evidence that some CIM modalities may alleviate side effects and symptoms related to pancreatic cancer and its treatment, suggesting that practitioners might consider integrating these modalities in certain situations encountered in the treatment of pancreatic cancer. Further investigation is needed to define the optimal integration of CIM into the treatment and supportive care of patients affected by pancreatic cancer.
C1 [Frenkel, Moshe] Rambam Hlth Care Campus, Complementary & Integrat Med Serv, Oncol Div, H_efa, Israel.
   [David, Adi; Hausner, David] Chaim Sheba Med Ctr, Inst Oncol, Tal Ctr Integrat Med, Ramat Gan, Israel.
   [Sapire, Kenneth] Univ Texas MD Anderson Canc Ctr, Dept Anesthesiol & Perioperat Med, Houston, TX USA.
   [Hausner, David] Chaim Sheba Med Ctr, Palliat Care Serv, Ramat Gan, Israel.
C3 Rambam Health Care Campus; Chaim Sheba Medical Center; Tel Aviv University; University of Texas System; UTMD Anderson Cancer Center; Chaim Sheba Medical Center; Tel Aviv University
RP Frenkel, M (corresponding author), Rambam Hlth Care Campus, Complementary & Integrat Med Serv, Oncol Div, H_efa, Israel.
EM frenkelm@netvision.net.il
CR Akce M, 2019, ONCOL HEMATOL REV US, V15, P27
   Unknown -, 2021, NCCN CLIN PRACTICE G, V0, P0
   Antunes F, 2018, CLINICS, V73, P0, DOI 10.6061/clinics/2018/e814s
   Arshad A, 2017, JPEN-PARENTER ENTER, V41, P398, DOI 10.1177/0148607115595221
   Ba DM, 2021, ADV NUTR, V12, P1691, DOI 10.1093/advances/nmab015
   Barnes AF, 2018, PANCREAS, V47, P1065, DOI 10.1097/MPA.0000000000001148
   Behrens G, 2015, EUR J EPIDEMIOL, V30, P279, DOI 10.1007/s10654-015-0014-9
   Bimonte S, 2016, NUTRIENTS, V8, P0, DOI 10.3390/nu8070433
   Block KI, 2018, J ALTERN COMPLEM MED, V24, P890, DOI 10.1089/acm.2018.0125
   Bonucci M, 2018, INTEGR CANCER THER, V17, P994, DOI 10.1177/1534735418755479
   Bouvard V, 2015, LANCET ONCOL, V16, P1599, DOI 10.1016/S1470-2045(15)00444-1
   Brennan GT, 2019, J PANCREAS, V20, P126
   Cereda E, 2019, CANCER MED-US, V8, P6923, DOI 10.1002/cam4.2517
   Chalhoub S, 2021, SLEEP DISORDERS, V4, P1
   Chen H, 2013, PANCREATOLOGY, V13, P594, DOI 10.1016/j.pan.2013.10.007
   Chen SM, 2020, SCI REP-UK, V10, P0, DOI 10.1038/s41598-020-77322-5
   Collins KP, 2017, SLEEP MED, V32, P208, DOI 10.1016/j.sleep.2016.06.041
   Coveler AL, 2021, ONCOLOGIST, V26, PE971, DOI 10.1002/onco.13796
   DOrta A, 2018, WORLD CANCER RES J, V5, P0
   David A, 2021, CURR ONCOL REP, V23, P0, DOI 10.1007/s11912-021-01135-6
   Di Marco Mariacristina, 2018, ACTA BIOMED, V89, P18, DOI 10.23750/abm.v89i4-S.7063
   Djalilova DM, 2019, BIOL RES NURS, V21, P198, DOI 10.1177/1099800418820162
   Ducreux M, 2015, ANN ONCOL, V26, PV56, DOI 10.1093/annonc/mdv295
   Eliaz I, 2019, NUTRIENTS, V11, P0, DOI 10.3390/nu11112619
   Epelbaum R, 2010, NUTR CANCER, V62, P1137, DOI 10.1080/01635581.2010.513802
   Falkensteiner Maria, 2011, ISRN NURS, V2011, P929868, DOI 10.5402/2011/929868
   Focan C, 2015, ANTICANCER RES, V35, P6311
   Frenkel M, 2022, CURR ONCOL REP, V24, P1557, DOI 10.1007/s11912-022-01308-x
   Frenkel M, 2015, CURR ONCOL REP, V17, P0, DOI 10.1007/s11912-015-0467-8
   Gaertner K, 2014, COMPLEMENT THER MED, V22, P320, DOI 10.1016/j.ctim.2013.12.014
   Gaertner S, 2015, GASTROINTEST TUMORS, V2, P195, DOI 10.1159/000442873
   García-Costela M, 2020, FRONT ENDOCRINOL, V11, P0, DOI 10.3389/fendo.2020.00638
   Gidron Y, 2018, J CLIN MED, V7, P0, DOI 10.3390/jcm7100371
   Giordano A, 2019, NUTRIENTS, V11, P0, DOI 10.3390/nu11102376
   González A, 2021, CANCERS, V13, P0, DOI 10.3390/cancers13133263
   Gumbs AA, 2021, SURGERIES-BASEL, V2, P216, DOI 10.3390/surgeries2020022
   Hashimoto D, 2021, SURG TODAY, V51, P1872, DOI 10.1007/s00595-021-02308-3
   He YH, 2020, JAMA ONCOL, V6, P271, DOI 10.1001/jamaoncol.2019.5233
   Huang XY, 2016, SCI REP-UK, V6, P0, DOI 10.1038/srep38936
   Isherwood J, 2020, ANN TRANSL MED, V8, P0, DOI 10.21037/atm.2020.02.02
   Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43
   Jentzsch V, 2020, CANCERS, V12, P0, DOI 10.3390/cancers12113096
   Kanai M, 2011, CANCER CHEMOTH PHARM, V68, P157, DOI 10.1007/s00280-010-1470-2
   Kazmierczak-Siedlecka K, 2021, EUR REV MED PHARMACO, V25, P7275, DOI 10.26355/eurrev_202112_27421
   Kita A, 2020, INT J ONCOL, V57, P721, DOI 10.3892/ijo.2020.5096
   Kleeff J, 2016, NAT REV DIS PRIMERS, V2, P0, DOI 10.1038/nrdp.2016.22
   Kobayashi T, 2011, CLIN EXP METASTAS, V28, P367, DOI 10.1007/s10585-011-9376-x
   Landers Amanda, 2019, PALLIAT CARE, V12, P1178224218825270, DOI 10.1177/1178224218825270
   Lewis AR, 2018, CURR PROB CANCER, V42, P26, DOI 10.1016/j.currproblcancer.2018.01.013
   Li LY, 2015, WORLD J SURG ONCOL, V13, P0, DOI 10.1186/s12957-015-0454-4
   Lissoni P, 2008, ANTICANCER RES, V28, P1377
   Liu Y, 2018, MEDICINE, V97, P0, DOI 10.1097/MD.0000000000010114
   Lu PY, 2017, NUTRIENTS, V9, P0, DOI 10.3390/nu9010038
   Luo H, 2021, PANCREAS, V50, P280, DOI 10.1097/MPA.0000000000001753
   Ma YJ, 2015, NUTR CANCER, V67, P112, DOI 10.1080/01635581.2015.976315
   Mach Claire M, 2008, J SOC INTEGR ONCOL, V6, P105
   Mansouri K, 2020, BMC CANCER, V20, P0, DOI 10.1186/s12885-020-07256-8
   Mao JJ, 2022, J CLIN ONCOL, V40, P3998, DOI 10.1200/JCO.22.01357
   Matsushita Y, 2018, BMC COMPLEM ALTERN M, V18, P0, DOI 10.1186/s12906-018-2385-4
   McQuade JL, 2019, LANCET ONCOL, V20, PE77, DOI 10.1016/S1470-2045(18)30952-5
   Mitchell T, 2019, HEALTHCARE-BASEL, V7, P0, DOI 10.3390/healthcare7030089
   Moffat GT, 2019, CANCER-AM CANCER SOC, V125, P3927, DOI 10.1002/cncr.32423
   Molina-Montes E, 2020, NUTRIENTS, V12, P0, DOI 10.3390/nu12072010
   Nangia-Makker P, 2018, GLYCOBIOLOGY, V28, P172, DOI 10.1093/glycob/cwy001
   National Comprehensive Cancer Network, 2022, NCCN GUID SUPP CAR, V0, P0
   Pedrosa LD, 2022, BIOMOLECULES, V12, P0, DOI 10.3390/biom12020289
   Pezzilli R, 2020, CANCERS, V12, P0, DOI 10.3390/cancers12020275
   Pushalkar S, 2018, CANCER DISCOV, V8, P403, DOI 10.1158/2159-8290.CD-17-1134
   Riquelme E, 2019, CELL, V178, P795, DOI 10.1016/j.cell.2019.07.008
   Samuels N, 2018, INTEGR CANCER THER, V17, P486, DOI 10.1177/1534735417736133
   Sluyter JD, 2021, JBMR PLUS, V5, P0, DOI 10.1002/jbm4.10420
   Sobocki BK, 2021, NUTRIENTS, V13, P0, DOI 10.3390/nu13124425
   Song SM, 2012, PLOS ONE, V7, P0, DOI 10.1371/journal.pone.0042699
   Sung H, 2021, CA-CANCER J CLIN, V71, P209, DOI 10.3322/caac.21660
   Talib WH, 2021, MOLECULES, V26, P0, DOI 10.3390/molecules26092506
   Tyagi Anupama, 2016, INT J YOGA, V9, P97, DOI 10.4103/0973-6131.183712
   Védie AL, 2019, PRESSE MED, V48, PE175, DOI 10.1016/j.lpm.2019.02.032
   Venturella G, 2021, INT J MOL SCI, V22, P0, DOI 10.3390/ijms22020634
   Vujasinovic M, 2017, NUTRIENTS, V9, P0, DOI 10.3390/nu9030183
   Wang Z, 2014, DIABETES RES CLIN PR, V106, P19, DOI 10.1016/j.diabres.2014.04.007
   Wei DY, 2021, CANCERS, V13, P0, DOI 10.3390/cancers13112716
   World Cancer Research Fund/American Institute for Cancer Research, 1900, NUTRITION, V0, Physical activity and colorectal cancer
   Xiao Q, 2021, CANCER RES, V81, P1616, DOI 10.1158/0008-5472.CAN-20-2256
   Xie FF, 2021, J SPORT HEALTH SCI, V10, P4, DOI 10.1016/j.jshs.2020.09.009
   Yanagimoto H, 2016, NUTR CANCER, V68, P234, DOI 10.1080/01635581.2016.1134597
   Zhang M, 2019, PROG MOL BIOL TRANSL, V163, P297, DOI 10.1016/bs.pmbts.2019.02.013
   Zhang ZQ, 2020, CANCER MED-US, V9, P6843, DOI 10.1002/cam4.3348
   Zhou DC, 2017, ONCOTARGET, V8, P62349, DOI 10.18632/oncotarget.17728
   Zoi V, 2021, BIOMEDICINES, V9, P0, DOI 10.3390/biomedicines9091086
NR 90
TC 8
Z9 12
U1 1
U2 17
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 1523-3790
EI 1534-6269
J9 CURR ONCOL REP
JI Curr. Oncol. Rep.
PD MAR 15
PY 2023
VL 25
IS 3
BP 231
EP 242
DI 10.1007/s11912-023-01370-z
EA FEB 2023
PG 12
WC Oncology
SC Oncology
GA 8Y4IV
UT WOS:000923574200001
PM 36735141
DA 2026-01-16
ER

PT J
AU McDonald, J
   Graca, S
   Citkovitz, C
   Taylor-Swanson, L
AF McDonald, John
   Graca, Sandro
   Citkovitz, Claudia
   Taylor-Swanson, Lisa
TI Turning Point: A Review of Key Research and Engagement in 2022
SO JOURNAL OF INTEGRATIVE AND COMPLEMENTARY MEDICINE
LA English
DT Review
ID sham acupuncture; pain; osteoarthritis; guidelines; management; symptoms; society; cancer
C1 [McDonald, John] Endeavour Coll Nat Hlth, Sch Chinese Med, Gold Coast, Qld, Australia.
   [Graca, Sandro] Northern Coll Acupuncture, Dept Res, York, England.
   [Citkovitz, Claudia] Massachusetts Coll Pharm & Hlth Sci, New England Sch Acupuncture, Worcester, MA USA.
   [Taylor-Swanson, Lisa] Univ Utah, Coll Nursing, Salt Lake City, UT USA.
   [Taylor-Swanson, Lisa] Univ Utah, Coll Nursing, Annette Cummings Bldg,10 South 2000 East, Salt Lake City, UT 84112 USA.
C3 Endeavour College of Natural Health; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah
RP Taylor-Swanson, L (corresponding author), Univ Utah, Coll Nursing, Annette Cummings Bldg,10 South 2000 East, Salt Lake City, UT 84112 USA.
EM lisa.taylor-swanson@nurs.utah.edu
CR Unknown -, 2021, NICE GUIDELINE NG193, V0, P0
   AWMF, 2021, GUID PROGR ONC GERM, V0, P0
   Bae K, 2023, CRIT REV ONCOL HEMAT, V181, P0, DOI 10.1016/j.critrevonc.2022.103898
   Baroncini A, 2022, J ORTHOP SURG RES, V17, P0, DOI 10.1186/s13018-022-03212-3
   Birch S, 2022, PERSPECTIVES ON INTEGRATIVE MEDICINE, V1, P3, DOI 10.56986/pim.2022.09.002
   Birch S, 2022, PHYTOMEDICINE, V104, P0, DOI 10.1016/j.phymed.2022.154297
   Birch S, 2022, INTEGR MED RES, V11, P0, DOI 10.1016/j.imr.2021.100725
   Birch S, 2021, EUR J INTEGR MED, V41, P0, DOI 10.1016/j.eujim.2020.101257
   Birch S, 2020, J ALTERN COMPLEM MED, V26, P784, DOI 10.1089/acm.2020.0032
   Birch S, 2018, J ALTERN COMPLEM MED, V24, P752, DOI 10.1089/acm.2018.0092
   Birch S, 2019, INTEGR MED RES, V8, P160, DOI 10.1016/j.imr.2019.05.002
   Birch S, 2019, INTEGR MED RES, V8, P33, DOI 10.1016/j.imr.2018.07.005
   Birch S, 2017, J ALTERN COMPLEM MED, V23, P242, DOI 10.1089/acm.2016.0385
   BMJ, 2022, CORONAVIRUS DISEASE 2019 (COVID-19), V0, P0
   Castellini G, 2022, J PHYSIOTHER, V68, P244, DOI 10.1016/j.jphys.2022.09.007
   Corbett MS, 2013, OSTEOARTHR CARTILAGE, V21, P1290, DOI 10.1016/j.joca.2013.05.007
   Cummings M, 2023, PERSPECTIVES ON INTEGRATIVE MEDICINE, V2, P3, DOI 10.56986/pim.2023.02.002
   Davis HE, 2023, NAT REV MICROBIOL, V21, P133, DOI 10.1038/s41579-022-00846-2
   de Valois B, 2022, SUPPORT CARE CANCER, V30, P5063, DOI 10.1007/s00520-022-06898-7
   Demarquay G, 2021, REV NEUROL-FRANCE, V177, P753, DOI 10.1016/j.neurol.2021.07.009
   Hershman DL, 2022, JAMA NETW OPEN, V5, P0, DOI 10.1001/jamanetworkopen.2022.41720
   Hershman DL, 2018, JAMA-J AM MED ASSOC, V320, P167, DOI 10.1001/jama.2018.8907
   Iwamura APD, 2021, REV MED VIROL, V31, P0, DOI 10.1002/rmv.2199
   Lam WC, 2021, AM J MED, V134, P1286, DOI 10.1016/j.amjmed.2021.05.002
   Langevin HM, 2011, EVID-BASED COMPL ALT, V2011, P0, DOI 10.1155/2011/180805
   Li HC, 2022, BMJ-BRIT MED J, V376, P0, DOI 10.1136/bmj-2021-067477
   Li M, 2022, ACUPUNCT MED, V40, P203, DOI 10.1177/09645284211041125
   Li Ruo-Qi, 2022, ZHONGGUO ZHEN JIU, V42, P1431, DOI 10.13703/j.0255-2930.20220513-0002
   Li RY, 2022, MEDICINE, V101, P0, DOI 10.1097/MD.0000000000032383
   Li YC, 2022, CELLS-BASEL, V11, P0, DOI 10.3390/cells11050860
   Lu LM, 2022, BMJ OPEN, V12, P0, DOI 10.1136/bmjopen-2021-056803
   Lu LM, 2022, BMJ-BRIT MED J, V376, P0, DOI 10.1136/bmj-2021-067475
   Luo D, 2022, FRONT MOL NEUROSCI, V15, P0, DOI 10.3389/fnmol.2022.817738
   Ma Y, 2016, PLOS ONE, V11, P0, DOI 10.1371/journal.pone.0168123
   Mao JJ, 2022, J CLIN ONCOL, V40, P3998, DOI 10.1200/JCO.22.01357
   Mao JJ, 2023, J INTEGR COMPLEMENT, V29, P209, DOI 10.1089/jicm.2023.0018
   Morita A, 2022, FRONT NEUROL, V13, P0, DOI 10.3389/fneur.2022.916944
   National Institute for Health and Care Excellence (NICE), 2020, NICE GUIDELINE, V0, P0
   NICE, 2021, HEAD 12S DIAGN MAN C, V0, P0
   NICE, 2022, OST 16S DIAGN MAN NI, V0, P0
   Oh JE, 2022, FRONT IMMUNOL, V12, P0, DOI 10.3389/fimmu.2021.813748
   Qaseem Amir, 2017, ANN INTERN MED, V166, P514, DOI 10.7326/M16-2367
   Shao TH, 2023, FRONT PUBLIC HEALTH, V10, P0, DOI 10.3389/fpubh.2022.1051581
   Trento MMS, 2021, PFLUG ARCH EUR J PHY, V473, P573, DOI 10.1007/s00424-020-02503-0
   Svenkerud S, 2018, ACUPUNCT MED, V36, P349, DOI 10.1136/acupmed-2017-011519
   Tang XR, 2022, BMJ OPEN, V12, P0, DOI 10.1136/bmjopen-2021-058834
   Vickers AJ, 2018, J PAIN, V19, P455, DOI 10.1016/j.jpain.2017.11.005
   Wan RH, 2022, FRONT IMMUNOL, V13, P0, DOI 10.3389/fimmu.2022.829409
   Wang L, 2023, APPL NURS RES, V70, P0, DOI 10.1016/j.apnr.2022.151651
   Wang XC, 2022, MEDICINE, V101, P0, DOI 10.1097/MD.0000000000031243
   Wu T, 2022, FRONT PUBLIC HEALTH, V10, P0, DOI 10.3389/fpubh.2022.1026971
   Yi T, 2022, FRONT NEUROL, V13, P0, DOI 10.3389/fneur.2022.885020
   Zhang YQ, 2022, BMJ-BRIT MED J, V376, P0, DOI 10.1136/bmj-2021-067476
   Zhang YQ, 2022, BMJ-BRIT MED J, V376, P0, DOI 10.1136/bmj-2022-070533
   Zheng H, 2022, NEUROLOGY, V99, PE1560, DOI 10.1212/WNL.0000000000200670
NR 58
TC 2
Z9 2
U1 1
U2 6
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 2768-3605
EI 2768-3613
J9 J INTEGR COMPLEMENT
JI J. Integr. Complement. Med.
PD AUG 1
PY 2023
VL 29
IS 8
BP 455
EP 461
DI 10.1089/jicm.2023.0283
EA JUL 2023
PG 7
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA P1PA4
UT WOS:001030624700001
PM 37462909
DA 2026-01-16
ER

